FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Thomas, TK Masaba, R Borkowf, CB Ndivo, R Zeh, C Misore, A Otieno, J Jamieson, D Thigpen, MC Bulterys, M Slutsker, L De Cock, KM Amornkul, PN Greenberg, AE Fowler, MG AF Thomas, Timothy K. Masaba, Rose Borkowf, Craig B. Ndivo, Richard Zeh, Clement Misore, Ambrose Otieno, Juliana Jamieson, Denise Thigpen, Michael C. Bulterys, Marc Slutsker, Laurence De Cock, Kevin M. Amornkul, Pauli N. Greenberg, Alan E. Fowler, Mary Glenn CA KiBS Study Team TI Triple-Antiretroviral Prophylaxis to Prevent Mother-To-Child HIV Transmission through Breastfeeding-The Kisumu Breastfeeding Study, Kenya: A Clinical Trial SO PLOS MEDICINE LA English DT Article ID SINGLE-DOSE NEVIRAPINE; PERINATAL HIV; ZIDOVUDINE; THERAPY; LAMIVUDINE; REGIMENS; TANZANIA; EFFICACY; RWANDA; INFANT AB Background: Effective strategies are needed for the prevention of mother-to-child HIV transmission (PMTCT) in resource-limited settings. The Kisumu Breastfeeding Study was a single-arm open label trial conducted between July 2003 and February 2009. The overall aim was to investigate whether a maternal triple-antiretroviral regimen that was designed to maximally suppress viral load in late pregnancy and the first 6 mo of lactation was a safe, well-tolerated, and effective PMTCT intervention. Methods and Findings: HIV-infected pregnant women took zidovudine, lamivudine, and either nevirapine or nelfinavir from 34-36 weeks' gestation to 6 mo post partum. Infants received single-dose nevirapine at birth. Women were advised to breastfeed exclusively and wean rapidly just before 6 mo. Using Kaplan-Meier methods we estimated HIV-transmission and death rates from delivery to 24 mo. We compared HIV-transmission rates among subgroups defined by maternal risk factors, including baseline CD4 cell count and viral load. Among 487 live-born, singleton, or first-born infants, cumulative HIV-transmission rates at birth, 6 weeks, and 6, 12, and 24 mo were 2.5%, 4.2%, 5.0%, 5.7%, and 7.0%, respectively. The 24-mo HIV-transmission rates stratified by baseline maternal CD4 cell count < 500 and >= 500 cells/ mm(3) were 8.4% (95% confidence interval [CI] 5.8%-12.0%) and 4.1% (1.8%-8.8%), respectively (p = 0.06); the corresponding rates stratified by baseline maternal viral load < 10,000 and > 10,000 copies/ml were 3.0% (1.1%-7.8%) and 8.7% (6.1%-12.3%), respectively (p = 0.01). None of the 12 maternal and 51 infant deaths (including two second-born infants) were attributed to antiretrovirals. The cumulative HIV-transmission or death rate at 24 mo was 15.7% (95% CI 12.7%-19.4%). Conclusions: This trial shows that a maternal triple-antiretroviral regimen from late pregnancy through 6 months of breastfeeding for PMTCT is safe and feasible in a resource-limited setting. These findings are consistent with those from other trials using maternal triple-antiretroviral regimens during breastfeeding in comparable settings. C1 [Thomas, Timothy K.; Borkowf, Craig B.; Zeh, Clement; Jamieson, Denise; Thigpen, Michael C.; De Cock, Kevin M.; Amornkul, Pauli N.; Greenberg, Alan E.; Fowler, Mary Glenn] US Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Thomas, Timothy K.; Zeh, Clement; Slutsker, Laurence; De Cock, Kevin M.; Amornkul, Pauli N.] KEMRI CDC, Kisumu, Kenya. [Misore, Ambrose] Minist Hlth, Prov Med Off Nyanza Prov, Kisumu, Kenya. [Otieno, Juliana] New Nyanza Prov Gen Hosp, Kisumu, Kenya. [Bulterys, Marc] CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Slutsker, Laurence] CDC, Div Parasit Dis, Atlanta, GA 30333 USA. RP Thomas, TK (reprint author), US Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM tft5@cdc.gov FU Kenya Medical Research Institute (KEMRI) through US Centers for Disease Control and Prevention (CDC) FX Funding for the study was provided by the Kenya Medical Research Institute (KEMRI) through a cooperative agreement with the US Centers for Disease Control and Prevention (CDC). Study drugs were provided by GlaxoSmithKline and Boehringer Ingelheim. The study design, data collection instruments, data collection, data analysis, decision to publish, and preparation of the manuscript were led by CDC and KEMRI staff based in Atlanta and at the KEMRI/CDC Field Station in Kisumu, Kenya. The companies that donated study drugs had an opportunity to review and comment on the manuscript, but otherwise did not have any role in the study. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the CDC. Use of trade names is for identification purposes only and does not constitute endorsement by the CDC or the Department of Health and Human Services. This publication has been approved by the Director of the Kenya Medical Research Institute. NR 35 TC 83 Z9 83 U1 0 U2 10 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD MAR PY 2011 VL 8 IS 3 AR e1001015 DI 10.1371/journal.pmed.1001015 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 742LN UT WOS:000288945200016 PM 21468300 ER PT J AU Zeh, C Weidle, PJ Nafisa, L Lwamba, HM Okonji, J Anyango, E Bondo, P Masaba, R Fowler, MG Nkengasong, JN Thigpen, MC Thomas, T AF Zeh, Clement Weidle, Paul J. Nafisa, Lillian Lwamba, Humphrey M. Okonji, Jully Anyango, Emily Bondo, Philip Masaba, Rose Fowler, Mary Glenn Nkengasong, John N. Thigpen, Michael C. Thomas, Timothy TI HIV-1 Drug Resistance Emergence among Breastfeeding Infants Born to HIV-Infected Mothers during a Single-Arm Trial of Triple-Antiretroviral Prophylaxis for Prevention of Mother-To-Child Transmission: A Secondary Analysis SO PLOS MEDICINE LA English DT Article ID RANDOMIZED-TRIAL; VERTICAL TRANSMISSION; PREGNANT-WOMEN; NEVIRAPINE; ZIDOVUDINE; INTRAPARTUM; HIVNET-012; THERAPY; MILK AB Background: Nevirapine and lamivudine given to mothers are transmitted to infants via breastfeeding in quantities sufficient to have biologic effects on the virus; this may lead to an increased risk of a breastfed infant's development of resistance to maternal antiretrovirals. The Kisumu Breastfeeding Study (KiBS), a single-arm open-label prevention of mother-to-child HIV transmission (PMTCT) trial, assessed the safety and efficacy of zidovudine, lamivudine, and either nevirapine or nelfinavir given to HIV-infected women from 34 wk gestation through 6 mo of breastfeeding. Here, we present findings from a KiBS trial secondary analysis that evaluated the emergence of maternal ARV-associated resistance among 32 HIV-infected breastfed infants. Methods and Findings: All infants in the cohort were tested for HIV infection using DNA PCR at multiple study visits during the 24 mo of the study, and plasma RNA viral load for all HIV-PCR-positive infants was evaluated retrospectively. Specimens from mothers and infants with viral load > 1,000 copies/ml were tested for HIV drug resistance mutations. Overall, 32 infants were HIV infected by 24 mo of age, and of this group, 24 (75%) infants were HIV infected by 6 mo of age. Of the 24 infants infected by 6 mo, nine were born to mothers on a nelfinavir-based regimen, whereas the remaining 15 were born to mothers on a nevirapine-based regimen. All infants were also given single-dose nevirapine within 48 hours of birth. We detected genotypic resistance mutations in none of eight infants who were HIV-PCR positive by 2 wk of age (specimens from six infants were not amplifiable), for 30% (6/20) at 6 wk, 63% (14/22) positive at 14 wk, and 67% (16/24) at 6 mo post partum. Among the 16 infants with resistance mutations by 6 mo post partum, the common mutations were M184V and K103N, conferring resistance to lamivudine and nevirapine, respectively. Genotypic resistance was detected among 9/9 (100%) and 7/15 (47%) infected infants whose mothers were on nelfinavir and nevirapine, respectively. No mutations were detected among the eight infants infected after the breastfeeding period (age 6 mo). Conclusions: Emergence of HIV drug resistance mutations in HIV-infected infants occurred between 2 wk and 6 mo post partum, most likely because of exposure to maternal ARV drugs through breast milk. Our findings may impact the choice of regimen for ARV treatment of HIV-infected breastfeeding mothers and their infected infants. C1 [Zeh, Clement; Thomas, Timothy] US Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Kisumu, Kenya. [Weidle, Paul J.; Thigpen, Michael C.; Thomas, Timothy] CDC, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Nafisa, Lillian; Lwamba, Humphrey M.; Okonji, Jully; Anyango, Emily; Bondo, Philip; Masaba, Rose] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Fowler, Mary Glenn] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA. [Nkengasong, John N.] CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Fowler, Mary Glenn] Makerere Univ, Johns Hopkins Univ Res Collaborat, Kampala, Uganda. RP Zeh, C (reprint author), US Ctr Dis Control & Prevent CDC, Div HIV AIDS Prevent, Kisumu, Kenya. EM czeh@ke.cdc.gov FU Kenya Medical Research Institute through US Centers for Disease Control and Prevention [5U19C1000323-05] FX This work was supported by the Kenya Medical Research Institute through a cooperative agreement with the US Centers for Disease Control and Prevention, Grant Award Number-5U19C1000323-05. Study drugs were provided by GlaxoSmithKline and Boehringer Ingelheim. Kenya Medical Research Institute and US Centers for Disease Control and Prevention investigators were involved with all aspects of study design, data collection, and analysis; interpretation of findings; report writing; and decision to submit the manuscript. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the US Centers for Disease Control and Prevention. Use of trade names is for identification purposes only and does not constitute endorsement by the US Centers for Disease Control and Prevention or the Department of Health and Human Services. NR 31 TC 53 Z9 53 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD MAR PY 2011 VL 8 IS 3 AR e1000430 DI 10.1371/journal.pmed.1000430 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 742LN UT WOS:000288945200010 PM 21468304 ER PT J AU Gase, LN Kuo, T Dunet, DO Simon, PA AF Gase, Lauren N. Kuo, Tony Dunet, Diane O. Simon, Paul A. TI Facilitators of and Barriers to Implementing a Local Policy to Reduce Sodium Consumption in the County of Los Angeles Government, California, 2009 SO PREVENTING CHRONIC DISEASE LA English DT Article ID SALT; HEALTH AB Introduction This qualitative study explores facilitators and barriers to a proposed food procurement policy that would require food purchasers, distributors, and vendors of food service in the County of Los Angeles government to meet specified nutrition standards, including limits on sodium content. Methods We conducted 30 key informant interviews. Interviewees represented 18 organizations from the County of Los Angeles government departments that purchased, distributed, or sold food; public and private non-County entities that had previously implemented food procurement policies in their organizations; and large organizations that catered food to the County. Results Study participants reported 3 key facilitators: their organization's authority to impose nutrition standards, their organization's desire to provide nutritious food, and the opportunity to build on existing nutrition policies. Eight key barriers were identified: 1) unique features among food service settings, 2) costs and unavailability of low-sodium foods, 3) complexity of food service arrangements, 4) lack of consumer demand for low-sodium foods, 5) undesirable taste of low-sodium foods, 6) preference for prepackaged products, 7) lack of knowledge and experience in operationalizing sodium standards, and 8) existing multiyear contracts that are difficult to change. Despite perceived barriers, several participants indicated that their organizations have successfully implemented nutritional standards that include limits on sodium. Conclusion Developing or changing policies for procuring food represents a potentially feasible strategy for reducing sodium consumption in food service venues controlled by the County of Los Angeles. The facilitators and barriers identified here can inform the formulation, adoption, implementation, and evaluation of sodium reduction policies in other jurisdictions. C1 [Kuo, Tony; Simon, Paul A.] Cty Los Angeles Dept Publ Hlth, Los Angeles, CA USA. RP Gase, LN (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,Mailstop K-47, Atlanta, GA 30341 USA. EM lgase@cdc.gov FU Division of Chronic Disease and Injury Prevention in the County of Los Angeles DPH FX We thank Mirna Ponce at the Division of Chronic Disease and Injury Prevention in the County of Los Angeles DPH and Centers for Disease Control and Promotion staff in the Division for Heart Disease and Stroke Prevention, including Michael Schooley and Janelle Peralez, for their support of and contributions to this article. NR 15 TC 7 Z9 8 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAR PY 2011 VL 8 IS 2 AR A33 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 874OM UT WOS:000298967900003 PM 21324247 ER PT J AU Duffy, J Sievert, D Rebmann, C Kainer, M Lynfield, R Smith, P Fridkin, S AF Duffy, Jonathan Sievert, Dawn Rebmann, Catherine Kainer, Marion Lynfield, Ruth Smith, Perry Fridkin, Scott TI Effective State-Based Surveillance for Multidrug-Resistant Organisms Related to Health Care-Associated Infections SO PUBLIC HEALTH REPORTS LA English DT Article ID STAPHYLOCOCCUS-AUREUS; SENTINEL SURVEILLANCE; COMMUNITY; DISEASE AB In September 2008, the Council of State and Territorial Epidemiologists and the Centers for Disease Control and Prevention sponsored a meeting of public health and infection-control professionals to address the implementation of surveillance for multidrug-resistant organisms (MDROs) particularly those related to health care-associated infections. The group discussed the role of health departments and defined goals for future surveillance activities. Participants identified the following main points: (1) surveillance should guide prevention and infection-control activities, (2) an MDRO surveillance system should be adaptable and not organism specific, (3) new systems should utilize and link existing systems, and (4) automated electronic laboratory reporting will be an important component of surveillance but will take time to develop. Current MDRO reporting mandates and surveillance methods vary across states and localities. Health departments that have not already done so should be proactive in determining what type of system, if any, will fit their needs. C1 [Duffy, Jonathan; Sievert, Dawn; Rebmann, Catherine; Fridkin, Scott] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Duffy, Jonathan] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Kainer, Marion; Lynfield, Ruth; Smith, Perry] Council State & Terr Epidemiologists, Atlanta, GA USA. [Kainer, Marion] Tennessee Dept Hlth, Nashville, TN USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Smith, Perry] New York State Dept Hlth, Albany, NY USA. RP Duffy, J (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. EM jduffy@cdc.gov NR 17 TC 2 Z9 2 U1 0 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2011 VL 126 IS 2 BP 176 EP 185 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 723ZX UT WOS:000287547000008 PM 21387947 ER PT J AU Boulet, SL Shin, M Kirby, RS Goodman, D Correa, A AF Boulet, Sheree L. Shin, Mikyong Kirby, Russell S. Goodman, David Correa, Adolfo TI Sensitivity of Birth Certificate Reports of Birth Defects in Atlanta, 1995-2005: Effects of Maternal, Infant, and Hospital Characteristics SO PUBLIC HEALTH REPORTS LA English DT Article ID CONGENITAL-MALFORMATIONS; DISCHARGE DATA; UNITED-STATES; NURSE-MIDWIFE; LIVE BIRTH; STANDARD; SURVEILLANCE; INFORMATION; PHYSICIAN; ACCURACY AB Objectives. We assessed variations in the sensitivity of birth defect diagnoses derived from birth certificate data by maternal, infant, and hospital characteristics. Methods. We compared birth certificate data for 1995-2005 births in Atlanta with data from the Metropolitan Atlanta Congenital Defects Program (MACDP). We calculated the sensitivity of birth certificates for reporting defects often discernable at birth (e.g., anencephaly, spina bifida, cleft lip, clubfoot, Down syndrome, and rectal atresia or stenosis). We used multivariable logistic regression models to examine associations with sociodemographic and hospital factors. Results. The overall sensitivity of birth certificates was 23% and ranged from 7% for rectal atresia/stenosis to 69% for anencephaly. Non-Hispanic black maternal race/ethnicity, less than a high school education, and preterm birth were independently associated with a lower probability of a birth defect diagnosis being reported on a birth certificate. Sensitivity also was lower for hospitals with > 1,000 births per year. Conclusions. The underreporting of birth defects on birth certificates is influenced by sociodemographic and hospital characteristics. Interpretation of birth defects prevalence estimates derived from birth certificate reports should take these issues into account. C1 [Boulet, Sheree L.; Shin, Mikyong; Correa, Adolfo] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Shin, Mikyong] RTI Int, Atlanta, GA USA. [Kirby, Russell S.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Med, Tampa, FL USA. [Goodman, David] Georgia Dept Community Hlth, Div Publ Hlth, Epidemiol & State Lab Program, Atlanta, GA USA. RP Boulet, SL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS-D02, Atlanta, GA 30333 USA. EM sboulet@cdc.gov NR 22 TC 17 Z9 17 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2011 VL 126 IS 2 BP 186 EP 194 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 723ZX UT WOS:000287547000009 PM 21387948 ER PT J AU Widdowson, MA Bulens, SN Beard, RS Lane, KM Monroe, SS Lance, S Bresee, JS Glass, RI AF Widdowson, Marc-Alain Bulens, Sandra N. Beard, R. Suzanne Lane, Kimberley M. Monroe, Stephen S. Lance, Susan Bresee, Joseph S. Glass, Roger I. TI Enhanced Surveillance of Norovirus Outbreaks of Gastroenteritis in Georgia SO PUBLIC HEALTH REPORTS LA English DT Article ID NORWALK-LIKE VIRUSES; ROUND-STRUCTURED VIRUSES; UNITED-STATES; VIRAL GASTROENTERITIS; FOODBORNE DISEASE; IDENTIFICATION; EPIDEMIOLOGY; TRANSMISSION; ILLNESS; TRENDS AB Objectives. The role of noroviruses in both foodborne and person-to-person outbreaks of acute gastroenteritis (AGE) has been difficult to determine in the U.S. because of lack of routine norovirus testing and of national reporting of person-to-person outbreaks. We conducted a prospective study in one state in which enhanced testing for noroviruses was performed to better understand the relative contribution of all gastroenteric pathogens. Methods. During the two-year period, 2000-2001, we took all fecal specimens from AGE outbreaks reported in Georgia that were negative for bacteria and tested these for norovirus. Results. We investigated 78 AGE outbreaks, from which suitable fecal samples were collected from 57 of them. Norovirus was identified in 25 (44%) outbreaks, bacteria in 20 (35%) outbreaks, and parasites in one (2%) outbreak. Forty-three (75%) of the outbreaks tested were foodborne, of which 17 (40%) were attributable to norovirus and 18 (42%) were attributable to bacteria. Adjusting for incomplete testing, we estimated that 53% of all AGE outbreaks were attributable to norovirus. A total of 2,674 people were reported ill in the 57 outbreaks, and norovirus infections accounted for 1,735 (65%) of these cases. Norovirus outbreaks tended to be larger than bacterial outbreaks, with a median number of 30 vs. 16 cases per outbreak, respectively (p=0.057). Conclusions. This study provides further evidence that noroviruses are, overall, the most common cause of AGE outbreaks in the U.S. Improved specimen collection, reporting person-to-person outbreaks, and access to molecular assays are needed to further understand the role of these viruses and methods for their prevention. C1 [Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30338 USA. [Bulens, Sandra N.; Glass, Roger I.] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Lane, Kimberley M.] Georgia Dept Human Resources, Notifiable Dis Epidemiol Sect, Atlanta, GA USA. [Beard, R. Suzanne; Monroe, Stephen S.; Lance, Susan] Purdue Univ, W Lafayette, IN 47907 USA. [Monroe, Stephen S.] Ctr Dis Control & Prevent, Natl Ctr Zoonot Vectorborne & Enter Dis, Atlanta, GA 30338 USA. [Glass, Roger I.] NIH, Fogarty Ctr, Bethesda, MD 20892 USA. RP Widdowson, MA (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS-A34, Atlanta, GA 30338 USA. EM mwiddowson@cdc.gov OI Monroe, Stephan/0000-0002-5424-716X NR 27 TC 1 Z9 1 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2011 VL 126 IS 2 BP 251 EP 258 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 723ZX UT WOS:000287547000016 PM 21387955 ER PT J AU Weiner, CP Dong, Y Zhou, H Abe, K Eggerman, R Ramsey, R Swaan, P AF Weiner, C. P. Dong, Y. Zhou, H. Abe, K. Eggerman, R. Ramsey, R. Swaan, P. TI Prediction of Preterm Birth (PTB) Using Maternal Plasma Cell Free RNA SO REPRODUCTIVE SCIENCES LA English DT Meeting Abstract C1 [Abe, K.] CDC, NCCDPHP, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 J9 REPROD SCI JI Reprod. Sci. PD MAR PY 2011 VL 18 IS 3 SU S MA O-102 BP 275A EP 275A PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 778RE UT WOS:000291721701277 ER PT J AU Weiner, CP Dong, Y Zhou, H Abe, K Eggerman, R Ramsey, R Swaan, P AF Weiner, C. P. Dong, Y. Zhou, H. Abe, K. Eggerman, R. Ramsey, R. Swaan, P. TI Prediction of Preterm Birth (PTB) Using Maternal Plasma Micro (mi) RNA SO REPRODUCTIVE SCIENCES LA English DT Meeting Abstract C1 [Abe, K.] CDC, NCCDPHP, Atlanta, GA 30333 USA. [Eggerman, R.; Ramsey, R.] Univ TN, Knoxville, TN USA. [Swaan, P.] Univ MD, College Pk, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1933-7191 J9 REPROD SCI JI Reprod. Sci. PD MAR PY 2011 VL 18 IS 3 SU S MA S-020 BP 300A EP 300A PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 778RE UT WOS:000291721701362 ER PT J AU de Garcia, BG Gaffney, C Chacon, S Gaffney, M AF de Garcia, Barbara Gerner Gaffney, Claudia Chacon, Susan Gaffney, Marcus TI Overview of newborn hearing screening activities in Latin America SO REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article DE Hearing loss; deafness; mass screening; Latin America ID DEVELOPING-COUNTRIES; IMPAIRMENT; CHILDREN; INFANTS; RESOURCES; LANGUAGE AB Objective. Ascertain the status of early hearing detection and intervention services in Latin America. Methods. Between June and November 2007, Gallaudet University, in collaboration with the U.S. Centers for Disease Control and Prevention Early Hearing Detection and Intervention Diversity Committee, disseminated a survey to 11 Latin American countries. It included questions about newborn hearing screening (NHS) procedures, the availability of intervention services for infants with hearing loss, and challenges in identifying infants with hearing loss. In addition, a literature review was conducted to help identify the status of NHS efforts in Latin America. Results. Six countries (Chile, Costa Rica, Guatemala, Mexico, Panama, and Uruguay) and one U.S. territory (Puerto Rico) responded to the survey. Responses indicated that efforts to identify infants with hearing loss vary within and across countries in Latin America. In some countries, activities have been implemented at a national level; in others, activities have been implemented at a single hospital or region within a country. Common barriers to implementation of NHS programs include a lack of funding, screening and diagnostic equipment, public awareness, and personnel qualified to work with infants and young children. Conclusions. In spite of several barriers, NHS programs have been implemented in at least some facilities and regions in Latin America. Additional efforts are needed to expand NHS activities in Latin America. C1 [de Garcia, Barbara Gerner] Gallaudet Univ, Washington, DC 20002 USA. [Gaffney, Claudia] McKing Consulting Corp, Atlanta, GA USA. [Chacon, Susan] New Mexico Dept Hlth, Childrens Med Serv, Santa Fe, NM USA. [Gaffney, Marcus] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP de Garcia, BG (reprint author), Gallaudet Univ, Washington, DC 20002 USA. EM barbara.gerner.de.garcia@gallaudet.edu NR 41 TC 10 Z9 12 U1 1 U2 5 PU PAN AMER HEALTH ORGANIZATION PI WASHINGTON PA 525 23RD ST NW, WASHINGTON, DC 20037 USA SN 1020-4989 J9 REV PANAM SALUD PUBL JI Rev. Panam. Salud Publica PD MAR PY 2011 VL 29 IS 3 BP 145 EP 152 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 748BD UT WOS:000289364100001 PM 21484013 ER PT J AU Martinez-Trujillo, MD Rocha-Castillo, J Clavel-Arcas, C Mack, KA AF de Lourdes Martinez-Trujillo, Maria Rocha-Castillo, Julio Clavel-Arcas, Carme Mack, Karin A. TI Fall-related injuries among youth under 20 years old who were treated in Nicaraguan emergency departments, 2004 SO SALUD PUBLICA DE MEXICO LA English DT Article DE accidental falls; youth; adolescents; Nicaragua ID CHILDHOOD FALLS; UNITED-STATES; CHILDREN; HOME AB Objective. To describe the circumstances of fall-related injuries among youth 0-19 years treated in emergency departments in Nicaragua; to estimate the incidence rates (IR) of falls; and, to identify areas for prevention efforts. Materials and Methods. All patients <20 years who were residents of Managua, Leon, Jinotepe, and Ciudad Sandino (6 593) were selected for analysis. Data were collected with the 2004 Injury Surveillance System. Results. In 2004, the IR of falls for youth <20 years old was 104.2 incidents per 10 000 persons. The IR for male youth was twice that of female youth. Overall, trees (23.3%) and beds (15.2%) were the main objects involved in falls. Fractures were the leading injuries sustained. Conclusions. This study identifies three areas that can be addressed: furniture, recreation, and physical environment. Interventions that may be most useful for caregivers and adolescents include changes in the home environment and recreation play areas, as well as educational programs. C1 [Mack, Karin A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [de Lourdes Martinez-Trujillo, Maria] UNAN, Fac Ciencias Med, Leon, Nicaragua. [Rocha-Castillo, Julio] Hosp Escuela Oscar Danilo Rosales HEODRA, Leon, Nicaragua. [Clavel-Arcas, Carme] Agencia Espanola Cooperac Int Desarrollo AECID, Managua, Nicaragua. RP Mack, KA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,F62, Atlanta, GA 30333 USA. EM kim9@cdc.gov NR 29 TC 0 Z9 0 U1 0 U2 4 PU INST NACIONAL SALUD PUBLICA PI CUERNAVACA PA AV UNIVERSIDAD 655, COL SANTA MARIA AHUACATITLAN, CUERNAVACA 62508, MORELOS, MEXICO SN 0036-3634 J9 SALUD PUBLICA MEXICO JI Salud Publica Mexico PD MAR-APR PY 2011 VL 53 IS 2 BP 116 EP 124 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 948HA UT WOS:000304493000004 ER PT J AU Owusu-Edusei, K Hoover, KW Tao, G AF Owusu-Edusei, Kwame, Jr. Hoover, Karen W. Tao, Guoyu TI Estimating the Direct Outpatient Medical Cost per Episode of Primary and Secondary Syphilis in the United States: Insured Population Perspective, 2003-2007 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED-DISEASES; PENICILLIN-G BENZATHINE; CONGENITAL-SYPHILIS; EVALUATING CEFTRIAXONE; ADMINISTRATIVE DATA; AZITHROMYCIN; HIV; INFECTIONS; CLINICS AB Background: No study has directly estimated the direct outpatient medical cost of care for primary and secondary (P&S) syphilis among the employer-sponsored commercially insured population in the United States. Methods: We used international classification of diseases, ninth revision (ICD-9) codes to identify outpatient claims for persons diagnosed with P&S syphilis for 2003 through 2007 from the MarketScan database. Diagnostic test costs were also analyzed using current procedural terminology codes for syphilis tests. We used healthcare common procedure coding system (HCPCS) codes to identify and analyze parenteral treatment costs for those diagnosed with P&S syphilis. Potential oral drug regimen was also investigated for those diagnosed using national drug codes. All costs were adjusted to 2007 US dollars. Overall costs estimates were categorized into males and females. Results: The overall average cost per episode of P&S syphilis on an outpatient basis was $194. Further analyses indicated that the estimated average cost per case of P&S syphilis diagnosed and treated parenterally on an outpatient basis was $229. We did not find any significant difference between the total average costs for males and females. However, the cost per parenteral treatment was significantly higher (P < 0.05) for males ($54) than those for females ($39). Conclusion: The estimate reported in this study represents a lower-bound estimate because it was based on direct medical cost only and does not include other associated costs such as pain and suffering nor lost productivity. C1 [Owusu-Edusei, Kwame, Jr.; Hoover, Karen W.; Tao, Guoyu] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Owusu-Edusei, K (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E 80, Atlanta, GA 30333 USA. EM Kowusuedusei@cdc.gov NR 45 TC 7 Z9 7 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2011 VL 38 IS 3 BP 175 EP 179 DI 10.1097/OLQ.0b013e3181f4207f PG 5 WC Infectious Diseases SC Infectious Diseases GA 719UV UT WOS:000287237500006 PM 20871492 ER PT J AU Brewer, NT Gottlieb, SL Reiter, PL Mcree, AL Liddon, N Markowitz, L Smith, JS AF Brewer, Noel T. Gottlieb, Sami L. Reiter, Paul L. McRee, Annie-Laurie Liddon, Nicole Markowitz, Lauri Smith, Jennifer S. TI Longitudinal Predictors of Human Papillomavirus Vaccine Initiation Among Adolescent Girls in a High-Risk Geographic Area SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID IMMUNIZATION PRACTICES ACIP; UNITED-STATES; ADVISORY-COMMITTEE; CERVICAL-CANCER; HPV VACCINE; INFLUENZA; PARENTS; RECOMMENDATIONS; ACCEPTABILITY; METAANALYSIS AB Background: Human papillomavirus (HPV) vaccine uptake is low among adolescent girls in the United States. We sought to identify longitudinal predictors of HPV vaccine initiation in populations at elevated risk for cervical cancer. Methods: We interviewed a population-based sample of parents of 10- to 18-year-old girls in areas of North Carolina with elevated cervical cancer rates. Baseline interviews occurred in summer 2007 and follow-up interviews in fall 2008. Measures included health belief model constructs. Results: Parents reported that 27% (149/567) of their daughters had initiated HPV vaccine between baseline and follow-up. Of parents who at baseline intended to get their daughters the vaccine in the next year, only 38% (126/348) had done so by follow-up. Of parents of daughters who remained unvaccinated at follow-up but had seen a doctor since baseline, only 37% (122/388) received an HPV vaccine recommendation. Rates of HPV vaccine initiation were higher among parents who at baseline perceived lower barriers to getting HPV vaccine, anticipated greater regret if their daughters got HPV because they were unvaccinated, did not report "needing more information" as the main reason they had not already vaccinated, intended to get their daughters the vaccine, or were not born-again Christians. Conclusions: Missed opportunities to increase HPV vaccine uptake included unrealized parent intentions and absent doctor recommendations. While several health belief model constructs identified in early acceptability studies (e.g., perceived risk, perceived vaccine effectiveness) were not longitudinally associated with HPV vaccine initiation, our findings suggest correlates of uptake (e.g., anticipated regret) that offer novel opportunities for intervention. C1 [Brewer, Noel T.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC 27599 USA. [Brewer, Noel T.; Reiter, Paul L.; Smith, Jennifer S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Gottlieb, Sami L.; Liddon, Nicole; Markowitz, Lauri] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Brewer, NT (reprint author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Behav & Hlth Educ, 325 Rosenau Hall CB 7440, Chapel Hill, NC 27599 USA. EM ntb1@unc.edu RI McRee, Annie/J-3077-2013 FU Centers for Disease Control and Prevention (CDC) [S3715-25/25]; American Cancer Society [MSRG-06-259-01-CPPB]; Lineberger Comprehensive Cancer Center [R25 CA57726]; Merck; GlaxoSmithKline FX Supported by the Centers for Disease Control and Prevention (CDC) (S3715-25/25), with additional support from the American Cancer Society (MSRG-06-259-01-CPPB) and from the Cancer Control Education Program at Lineberger Comprehensive Cancer Center (Grant No. R25 CA57726) (to P.L.R.). N. T. B. received a research grant from Merck for an unrelated study of men's attitudes toward HPV vaccination in 2008-2009, and J. S. S. received research grants, contracts, honoraria or consulting fees during the last 4 years from GlaxoSmithKline and Merck. NR 29 TC 107 Z9 107 U1 1 U2 14 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2011 VL 38 IS 3 BP 197 EP 204 DI 10.1097/OLQ.0b013e3181f12dbf PG 8 WC Infectious Diseases SC Infectious Diseases GA 719UV UT WOS:000287237500010 PM 20838362 ER PT J AU Tong, X Kuklina, EV Gillespie, C George, MG AF Tong, Xin Kuklina, Elena V. Gillespie, Cathleen George, Mary G. TI Trends of Acute Ischemic Stroke Hospitalizations by Age and Gender in the United States: 1994-2007 SO STROKE LA English DT Meeting Abstract CT International Stroke Conference CY FEB 08-10, 2011 CL Los Angeles, CA SP Amer Heart Assoc, Amer Stroke Assoc C1 [Tong, Xin; Kuklina, Elena V.; Gillespie, Cathleen; George, Mary G.] CDC, Atlanta, GA 30333 USA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0039-2499 J9 STROKE JI Stroke PD MAR PY 2011 VL 42 IS 3 BP E131 EP E131 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA 723AW UT WOS:000287479400293 ER PT J AU Simmons, G Glynn, SA Holmberg, JA Coffin, JM Hewlett, IK Lo, SC Mikovits, JA Switzer, WM Linnen, JM Busch, MP AF Simmons, Graham Glynn, Simone A. Holmberg, Jerry A. Coffin, John M. Hewlett, Indira K. Lo, Shyh-Ching Mikovits, Judy A. Switzer, William M. Linnen, Jeffrey M. Busch, Michael P. CA Blood XMRV Sci Res Working Grp TI The Blood Xenotropic Murine Leukemia Virus-Related Virus Scientific Research Working Group: mission, progress, and plans SO TRANSFUSION LA English DT Editorial Material ID CHRONIC-FATIGUE-SYNDROME; PROSTATE-CANCER; INFECTIOUS RETROVIRUS; MOUSE DNA; XMRV; DISEASE; CONTAMINATION; CELLS; RISK; SEQUENCES C1 [Simmons, Graham] Blood Syst Res Inst, San Francisco, CA 94118 USA. [Simmons, Graham] Univ Calif San Francisco, San Francisco, CA 94118 USA. [Glynn, Simone A.] NHLBI, Transfus Med & Cellular Therapeut Branch, Div Blood Dis & Resources, NIH, Bethesda, MD 20892 USA. Dept Hlth & Human Serv, Washington, DC USA. NCI, Bethesda, MD 20892 USA. Tufts Univ, Sch Med, Boston, MA 02111 USA. US FDA, Off Blood Res & Review, Silver Spring, MD USA. US FDA, Div Cellular & Gene Therapies Review, Silver Spring, MD USA. Univ Nevada, Reno, NV 89557 USA. Whittemore Peterson Inst, Reno, NV USA. Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. Gen Probe Inc, San Diego, CA USA. RP Simmons, G (reprint author), Blood Syst Res Inst, 270 Mason Ave, San Francisco, CA 94118 USA. EM gsimmons@bloodsystems.org; glynnsa@nhlbi.nih.gov RI Simmons, Graham/G-3523-2012 OI Simmons, Graham/0000-0002-9615-7023 FU NHLBI NIH HHS [N01HB-57181, N01HB57181, HHSN268200517181C]; PHS HHS [HHSN268200517181C] NR 40 TC 21 Z9 21 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD MAR PY 2011 VL 51 IS 3 BP 643 EP 653 DI 10.1111/j.1537-2995.2011.03063.x PG 11 WC Hematology SC Hematology GA 732DZ UT WOS:000288166200028 PM 21366602 ER PT J AU Javitz, HS Zbikowski, SM Deprey, M McAfee, TA McClure, JB Richards, J Catz, SL Jack, LM Swan, GE AF Javitz, Harold S. Zbikowski, Susan M. Deprey, Mona McAfee, Timothy A. McClure, Jennifer B. Richards, Julie Catz, Sheryl L. Jack, Lisa M. Swan, Gary E. TI Cost-effectiveness of varenicline and three different behavioral treatment formats for smoking cessation SO TRANSLATIONAL BEHAVIORAL MEDICINE LA English DT Article DE Smoking cessation; Varenicline; Cost-effectiveness; Quality-adjusted life-years saved; Behavioral intervention AB There is a lack of evidence of the relative cost-effectiveness of proactive telephone counseling (PTC) and Web-based delivery of smoking cessation services in conjunction with pharmacotherapy. We calculated the differential cost-effectiveness of three behavioral smoking cessation modalities with varenicline treatment in a randomized trial of current smokers from a large health system. Eligible participants were randomized to one of three smoking cessation interventions: Web-based counseling (n= 401), PTC (n= 402), or combined PTC-Web counseling (n= 399). All participants received a standard 12-week course of varenicline. The primary outcome was a 7-day point prevalent nonsmoking at the 6month follow-up. The Web intervention was the least expensive followed by the PTC and PTC-Web groups. Costs per additional 6-month nonsmoker and per additional lifetime quitter were $ 1,278 and $ 2,601 for Web, $ 1,472 and $ 2,995 for PTC, and $ 1,617 and $ 3,291 for PTC-Web. Cost per life-year (LY) and quality-adjusted life-year (QALY) saved were $ 1,148 and $ 1,136 for Web, $ 1,320 and $ 1,308 for PTC, and $ 1,450 and $ 1,437 for PTC-Web. Based on the cost per LY and QALY saved, these interventions are among the most cost-effective life-saving medical treatments. Web, PTC, and combined PTC-Web treatments were all highly cost-effective, with the Web treatment being marginally more cost-effective than the PTC or combined PTC-Web treatments. C1 [Javitz, Harold S.; Jack, Lisa M.; Swan, Gary E.] SRI Int, Ctr Hlth Sci, Menlo Pk, CA 94025 USA. [McClure, Jennifer B.; Richards, Julie; Catz, Sheryl L.] Grp Hlth Res Inst, Seattle, WA 98101 USA. [Zbikowski, Susan M.; Deprey, Mona] Free & Clear Inc, Seattle, WA 98104 USA. [McAfee, Timothy A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Javitz, HS (reprint author), SRI Int, Ctr Hlth Sci, 333 Ravenswood Ave, Menlo Pk, CA 94025 USA. EM harold.javitz@sri.com FU National Cancer Institute [R01CA071358]; Pfizer FX This study was funded by the National Cancer Institute (grant R01CA071358) and is registered at Clinicaltrials.gov (NCT00301145). Varenicline and nominal support for recruiting participants was provided by Pfizer, Inc. Neither entity had any role in the study design, the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the report for publication. In kind pharmacy support was provided by Group Health. Dr. Zbikowski and Ms. Deprey are employed by Free & Clear, Inc. which markets products similar to those in this study. Dr. Swan received financial support from Pfizer to attend a 1-day advisory meeting in 2008. The authors have no other potential conflicts of interest to report. NR 57 TC 9 Z9 9 U1 2 U2 3 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 1869-6716 EI 1613-9860 J9 TRANSL BEHAV MED JI Transl. Behav. Med. PD MAR PY 2011 VL 1 IS 1 BP 182 EP 190 DI 10.1007/s13142-010-0009-8 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V39LG UT WOS:000209411900026 PM 21731592 ER PT J AU Patton, TG Dietrich, G Gilmore, RD AF Patton, Toni G. Dietrich, Gabrielle Gilmore, Robert D., Jr. TI Detection of Borrelia burgdorferi DNA in Tick Feces Provides Evidence for Organism Shedding During Vector Feeding SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Borrelia burgdorferi; Ixodes ticks; Tick feces ID IXODES-RICINUS TICKS; TRANSMISSION; INFECTION; GENE AB Borrelia burgdorferi, the bacterium that causes Lyme disease, is transmitted to a susceptible host by Ixodes spp. tick bites. However, there is uncertainty whether B. burgdorferi are shed from ticks by the fecal route. In this study, B. burgdorferi-infected ticks were fed on mice while confined to a certain area of the skin by a capsule. During and after feeding, tick feces were collected and placed in Barbour-Stoenner-Kelley (BSK)-II media for cultivation and in sterile water for polymerase chain reaction (PCR) analysis. Although none of the tested samples were culture positive for B. burgdorferi, all but one of the fecal DNA samples from infected ticks were PCR positive. These results indicated that B. burgdorferi were shed from feeding ticks during defecation and suggest that the spirochetes did not remain viable once exposed to the outside environment. This finding has important ramifications for investigators interpreting B. burgdorferi-specific PCR results when conducting tick transmission experiments. C1 [Patton, Toni G.; Dietrich, Gabrielle; Gilmore, Robert D., Jr.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. RP Gilmore, RD (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM rbg9@cdc.gov NR 11 TC 3 Z9 3 U1 2 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD MAR PY 2011 VL 11 IS 3 BP 197 EP 200 DI 10.1089/vbz.2010.0149 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 741UZ UT WOS:000288892200001 PM 20925527 ER PT J AU Zhang, MT Fang, Y Brault, AC Reisen, WK AF Zhang, Miaotao Fang, Ying Brault, Aaron C. Reisen, William K. TI Variation in Western Equine Encephalomyelitis Viral Strain Growth in Mammalian, Avian, and Mosquito Cells Fails to Explain Temporal Changes in Enzootic and Epidemic Activity in California SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Cell culture; Real-time cell electronic sensing system; Western equine encephalomyelitis virus ID ENCEPHALITIS VIRUSES; VIRULENCE; PREVALENCE; ANTIBODIES; RESIDENTS; VALLEY; MOUSE AB The decrease in western equine encephalomyelitis virus (WEEV; Togaviridae, Alphavirus) activity in North America over the past 20-30 years has prompted research to determine if there have been concurrent declines in virulence. Six (WEEV) strains isolated from Culex tarsalis mosquitoes from California during each of the six preceding decades failed to show a consistent declining temporal trend in virus titer using mosquito (C6/36), avian (duck embryo fibroblast), or mammalian (Vero) cells, results similar to our recent in vivo studies using birds and mosquitoes. Titers measured by Vero cell plaque assay were consistently highest on mosquito cell culture, followed by avian and mammalian cell cultures. Similar to previous in vivo results in house sparrows and mice, titers for the IMP181 strain isolated in 2005 were significantly lower in both avian and mammalian cells. Real-time monitoring of changes in cell growth measured by electrical impedance showed consistent differences among cell types, but not WEEV strains. Collectively, these in vitro results failed to explain the decrease in WEEV enzootic and epidemic activity. Results with the IMP181 strain should be verified by additional sequencing, cell growth, and pathogenesis studies using concurrent or 2006 isolates of WEEV from California. C1 [Zhang, Miaotao; Fang, Ying; Brault, Aaron C.; Reisen, William K.] Univ Calif Davis, Sch Vet Med, Ctr Vectorborne Dis, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA. [Zhang, Miaotao] NW A&F Univ, Coll Vet Med, Yangling, Shaanxi, Peoples R China. [Brault, Aaron C.] Ctr Dis Control & Prevent, Ft Collins, CO USA. RP Reisen, WK (reprint author), Univ Calif Davis, Sch Vet Med, Ctr Vectorborne Dis, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA. EM wkreisen@ucdavis.edu FU China Scholar Council; National Institutes of Allergy and Infectious Diseases, NIH [R01 AI055607-06A2]; Science & Technology Directorate, Department of Homeland Security, and the Fogarty International Center, NIH FX M. Zhang was supported at the Center for Vectorborne Diseases by a grant from the China Scholar Council. This research was supported, in part, by grant R01 AI055607-06A2 from National Institutes of Allergy and Infectious Diseases, NIH. Funding for W. K. R. was provided, in part, from the RAPIDD program of the Science & Technology Directorate, Department of Homeland Security, and the Fogarty International Center, NIH. NR 22 TC 4 Z9 4 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD MAR PY 2011 VL 11 IS 3 BP 269 EP 275 DI 10.1089/vbz.2010.0078 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 741UZ UT WOS:000288892200010 PM 21395409 ER PT J AU Sipsma, HL Ickovics, JR Lewis, JB Ethier, KA Kershaw, TS AF Sipsma, Heather L. Ickovics, Jeannette R. Lewis, Jessica B. Ethier, Kathleen A. Kershaw, Trace S. TI Adolescent Pregnancy Desire and Pregnancy Incidence SO WOMENS HEALTH ISSUES LA English DT Article ID SEXUAL RISK BEHAVIOR; TEENAGE CHILDBEARING; FEMALE ADOLESCENTS; CONTRACEPTIVE USE; GIRLS; DISADVANTAGE; ATTITUDES AB Background: Research has suggested the importance of pregnancy desire in explaining pregnancy risk behavior among adolescent females. Much of the literature, however, uses cross-sectional study designs to examine this relationship. Because bias may strongly influence these results, more prospective studies are needed to confirm the relationship between pregnancy desire and pregnancy incidence over time. Methods: Nonpregnant adolescents aged 14- to 19 years (n = 208) completed baseline interviews and interviews every 6 months thereafter for 18 months. Logistic regression was used to examine demographic and psychosocial correlates of pregnancy desire. Cox regression analysis was used to determine whether pregnancy desire predicted pregnancy incidence over time after controlling for potential confounders. Results: Twenty-four percent of participants either desired pregnancy or were ambivalent toward pregnancy in the next year. Pregnancy desire was associated with older age, relationship duration of < 6 months, and greater perceived stress. After accounting for potential confounders, pregnancy desire doubled the risk of becoming pregnant over the 18-month follow-up period (relative risk, 2.00; 95% confidence interval [CI], 0.99-4.02). Additionally, a heightened risk for pregnancy was found among those who expressed some desire for pregnancy and who were not in school compared with those who expressed no desire for pregnancy and who were in school (relative risk, 4.84; 95% CI, 1.21-19.31). Conclusion: Our analysis reinforces the importance of evaluating pregnancy desire among sexually active adolescent females. Interventions should target young women in new romantic relationships and who are not in school to improve pregnancy prevention efforts. Additionally, improving coping abilities may help to reduce feelings of pregnancy desire among adolescent females. Copyright (c) 2011 by the Jacobs Institute of Women's Health. Published by Elsevier Inc. C1 [Sipsma, Heather L.; Ickovics, Jeannette R.; Lewis, Jessica B.; Kershaw, Trace S.] Yale Univ, Sch Publ Hlth, New Haven, CT 06510 USA. [Sipsma, Heather L.; Ickovics, Jeannette R.; Lewis, Jessica B.; Kershaw, Trace S.] Yale Ctr Interdisciplinary Res AIDS, New Haven, CT USA. [Ethier, Kathleen A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Sipsma, HL (reprint author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St, New Haven, CT 06510 USA. EM heather.sipsma@yale.edu FU NIMH NIH HHS [T32 MH020031, T32 MH020031-06A1] NR 31 TC 22 Z9 23 U1 2 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1049-3867 J9 WOMEN HEALTH ISS JI Womens Health Iss. PD MAR-APR PY 2011 VL 21 IS 2 BP 110 EP 116 DI 10.1016/j.whi.2010.09.004 PG 7 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA 735NH UT WOS:000288422100003 PM 21177123 ER PT J AU Rolka, HR AF Rolka, Henry R. TI Special Issue: 13th Biennial CDC & ATSDR Symposium on Statistical Methods Info-Fusion: Utilization of Multi-Source Data Preface SO STATISTICS IN MEDICINE LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Rolka, HR (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop E97, Atlanta, GA 30333 USA. EM hrr2@cdc.gov NR 0 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0277-6715 J9 STAT MED JI Stat. Med. PD FEB 28 PY 2011 VL 30 IS 5 SI SI BP 401 EP 402 DI 10.1002/sim.4149 PG 2 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 724YI UT WOS:000287612000001 PM 21312207 ER PT J AU Rolka, HR AF Rolka, Henry R. TI Comments on 'Some methodological issues in biosurveillance' SO STATISTICS IN MEDICINE LA English DT Article; Proceedings Paper CT 12th Biennial Symposium on Statistical Methods CY APR 06-08, 2009 CL Decatur, GA C1 Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Publ Hlth Surveillance Program Off, Atlanta, GA 30333 USA. RP Rolka, HR (reprint author), Ctr Dis Control & Prevent, Off Surveillance Epidemiol & Lab Serv, Publ Hlth Surveillance Program Off, 1600 Clifton Rd,MS E97, Atlanta, GA 30333 USA. EM HRolka@CDC.Gov NR 5 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD FEB 28 PY 2011 VL 30 IS 5 SI SI BP 416 EP 419 DI 10.1002/sim.4112 PG 4 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 724YI UT WOS:000287612000003 PM 21312209 ER PT J AU Molinari, NM Wolter, KM Skalland, B Montgomery, R Khare, M Smith, PJ Barron, ML Copeland, K Santos, K Singleton, JA AF Molinari, NoelleAngelique M. Wolter, Kirk M. Skalland, Benjamin Montgomery, Robert Khare, Meena Smith, Philip J. Barron, Martin L. Copeland, Kennon Santos, Kathleen Singleton, James A. TI Quantifying bias in a health survey: Modeling total survey error in the National Immunization Survey SO STATISTICS IN MEDICINE LA English DT Article; Proceedings Paper CT 12th Biennial Symposium on Statistical Methods CY APR 06-08, 2009 CL Decatur, GA DE total survey error; Monte Carlo simulation; nonresponse bias; noncoverage bias; survey methodology ID OBSERVATIONAL DATA; SYSTEMATIC-ERRORS; RATES AB Random-digit-dial telephone surveys are experiencing both declining response rates and increasing under-coverage due to the prevalence of households that substitute a wireless telephone for their residential landline telephone. These changes increase the potential for bias in survey estimates and heighten the need for survey researchers to evaluate the sources and magnitudes of potential bias. We apply a Monte Carlo simulation-based approach to assess bias in the NIS, a land-line telephone survey of 19-35 month-old children used to obtain national vaccination coverage estimates. We develop a model describing the survey stages at which component nonsampling error may be introduced due to nonresponse and under-coverage. We use that model and components of error estimated in special studies to quantify the extent to which noncoverage and nonresponse may bias the vaccination coverage estimates obtained from the NIS and present a distribution of the total survey error. Results indicated that the total error followed a normal distribution with mean of 1.72 per cent (95 per cent CI: 1.71, 1.74 per cent) and final adjusted survey weights corrected for this error. Although small, the largest contributor to error in terms of magnitude was nonresponse of immunization providers. The total error was most sensitive to declines in coverage due to cell phone only households. These results indicate that, while response rates and coverage may be declining, total survey error is quite small. Since response rates have historically been used to proxy for total survey error, the finding that these rates do not accurately reflect bias is important for evaluation of survey data. Published in 2011 by John Wiley & Sons, Ltd. C1 [Molinari, NoelleAngelique M.; Smith, Philip J.; Singleton, James A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Wolter, Kirk M.; Skalland, Benjamin; Montgomery, Robert; Barron, Martin L.; Copeland, Kennon; Santos, Kathleen] Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA. [Khare, Meena] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Molinari, NM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Mail Stop E-03, Atlanta, GA 30333 USA. EM nmolinari@cdc.gov NR 24 TC 10 Z9 11 U1 2 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD FEB 28 PY 2011 VL 30 IS 5 SI SI BP 505 EP 514 DI 10.1002/sim.3911 PG 10 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 724YI UT WOS:000287612000014 PM 21294147 ER PT J AU Caudill, SP AF Caudill, Samuel P. TI Important issues related to using pooled samples for environmental chemical biomonitoring SO STATISTICS IN MEDICINE LA English DT Article; Proceedings Paper CT 12th Biennial Symposium on Statistical Methods CY APR 06-08, 2009 CL Decatur, GA DE lognormal; perfluoroalkyl compounds; pooled samples AB Pooling samples for analysis was first proposed in the 1940s to reduce analytical measurement costs associated with screening World War II recruits for syphilis. Later, it progressed to more complex screening strategies, to population prevalence estimation for discrete quantities, and to population mean estimation for continuous quantities. Recently, pooled samples have also been used to provide efficient alternatives for gene microarray analyses, epidemiologic studies of biomarkers of exposure, and characterization of populations regarding environmental chemical exposures. In this study, we address estimation and bias issues related to using pooled-sample variance information from an auxiliary source to augment pooled-sample variance estimates from the study of interest. The findings are illustrated by using pooled samples from the National Health and Nutrition Examination Survey 2001-2002 to assess exposures to perfluorooctanesulfonate and other polyfluoroalkyl compounds in the U.S. population. Published in 2011 by John Wiley & Sons, Ltd. C1 Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Publ Hlth Serv,US Dept HHS, Atlanta, GA 30341 USA. RP Caudill, SP (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Publ Hlth Serv,US Dept HHS, 4770 Buford Highway NE,MS F25, Atlanta, GA 30341 USA. EM spc1@cdc.gov NR 8 TC 4 Z9 4 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD FEB 28 PY 2011 VL 30 IS 5 SI SI BP 515 EP 521 DI 10.1002/sim.3885 PG 7 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 724YI UT WOS:000287612000015 PM 21312217 ER PT J AU Zhao, Z AF Zhao, Zhen TI Power of tests for comparing trend curves with application to national immunization survey (NIS) SO STATISTICS IN MEDICINE LA English DT Article; Proceedings Paper CT 12th Biennial Symposium on Statistical Methods CY APR 06-08, 2009 CL Decatur, GA DE trend curves; test power; interaction; parallel; vaccination coverage ID UNITED-STATES; TUBERCULOSIS AB To develop statistical tests for comparing trend curves of study outcomes between two socio-demographic strata across consecutive time points, and compare statistical power of the proposed tests under different trend curves data, three statistical tests were proposed. For large sample size with independent normal assumption among strata and across consecutive time points, the Z and Chi-square test statistics were developed, which are functions of outcome estimates and the standard errors at each of the study time points for the two strata. For small sample size with independent normal assumption, the F-test statistic was generated, which is a function of sample size of the two strata and estimated parameters across study period. If two trend curves are approximately parallel, the power of Z-test is consistently higher than that of both Chi-square and F-test. If two trend curves cross at low interaction, the power of Z-test is higher than or equal to the power of both Chi-square and F-test; however, at high interaction, the powers of Chi-square and F-test are higher than that of Z-test. The measurement of interaction of two trend curves was defined. These tests were applied to the comparison of trend curves of vaccination coverage estimates of standard vaccine series with National Immunization Survey (NIS) 2000-2007 data. Copyright (C) 2011 John Wiley & Sons, Ltd. C1 [Zhao, Zhen] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Zhao, Z (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS E62, Atlanta, GA 30333 USA. EM zaz0@cdc.gov NR 22 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD FEB 28 PY 2011 VL 30 IS 5 SI SI BP 531 EP 540 DI 10.1002/sim.3898 PG 10 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 724YI UT WOS:000287612000017 PM 21287587 ER PT J AU Barker, LK Griffin, SO Jeon, S Gray, SK Vidakovic, B AF Barker, Laurie K. Griffin, Susan O. Jeon, Seonghye Gray, Shellie Kolavic Vidakovic, Brani TI Ecological-type inference in matched-pair studies with fixed marginal totals SO STATISTICS IN MEDICINE LA English DT Article; Proceedings Paper CT 12th Biennial Symposium on Statistical Methods CY APR 06-08, 2009 CL Decatur, GA DE matched-pair study; Bayesian inference; hierarchical model; ecological inference; Markov chain Monte Carlo; dental sealants meta-analysis ID CONTINGENCY-TABLES; DISTRIBUTIONS; RETENTION; TRIALS; MODELS AB This paper applies a Bayesian approach to ecological-type inference in matched-pair studies because traditional methods that assume parallel tables are not directly applicable. The proposed procedure is based on a hierarchical Bayes structure which models information about the within-pair association. The proposed algorithm relies on Markov chain Monte Carlo simulation, recovers the full table, and reports its accuracy in terms of credible sets for the cell counts. This methodology is motivated and illustrated with examples from split-mouth designs assessing the effectiveness of dental sealant materials and cross-over trials comparing two forms of insulin. Published in 2011 by John Wiley & Sons, Ltd. C1 [Barker, Laurie K.] Ctr Dis Control & Prevent, Math Statistician Surveillance Invest & Res Team, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Jeon, Seonghye; Vidakovic, Brani] Georgia Inst Technol, Atlanta, GA 30332 USA. [Gray, Shellie Kolavic] Northrop Grumman Corp, Atlanta, GA USA. RP Barker, LK (reprint author), Ctr Dis Control & Prevent, Math Statistician Surveillance Invest & Res Team, Div Oral Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F-10, Atlanta, GA 30341 USA. EM LBarker@cdc.gov FU NSF at Georgia Institute of Technology [0724524]; Department of Energy; NCCDPHP FX This project was supported in part by an appointment to the Research Participation Program for the Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, administered by the Oak Ridge Institute for Science and Education through an agreement between the Department of Energy and NCCDPHP. The authors also acknowledge the Oak Ridge Institute for Science and Research and Northrop Grumman - Information Systems, CIO-SP2i Brani Vidakovic was partially supported by NSF Grant 0724524 at Georgia Institute of Technology. The authors are thankful to Adrian Dobra, Steve Fienberg, Xiaoli Meng, and Jon Wakefield for very useful discussions and direction to key publications in the area. NR 20 TC 2 Z9 2 U1 2 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD FEB 28 PY 2011 VL 30 IS 5 SI SI BP 541 EP 548 DI 10.1002/sim.3919 PG 8 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 724YI UT WOS:000287612000018 PM 21312218 ER PT J AU Ferdinands, JM Belongia, EA Nwasike, C Shay, DK AF Ferdinands, Jill M. Belongia, Edward A. Nwasike, Chinyelu Shay, David K. TI Influenza vaccination status is not associated with influenza testing among children: Implications for observational studies of vaccine effectiveness SO VACCINE LA English DT Article DE Influenza; Influenza vaccines; Bias (epidemiology) ID SEASON; HOSPITALIZATIONS; DIAGNOSIS; EFFICACY; DESIGNS AB Estimates of influenza vaccine effectiveness from observational studies that rely on physician-ordered influenza tests may be biased if physician testing behavior is influenced by patient vaccination status. To assess the potential for differential diagnostic testing of children by vaccine status, we examined the association between receipt of a commercial influenza diagnostic test and influenza vaccination among children aged 6-59 months who sought care at the Marshfield Clinic for acute respiratory or febrile illnesses during the 2004-05 through 2007-08 influenza seasons. There was no significant association between prior influenza vaccination and receipt of a diagnostic test for influenza. These findings suggest that estimates of vaccine effectiveness derived from observational studies among children are unlikely to be biased due to differential diagnostic testing. (C) 2011 Published by Elsevier Ltd. C1 [Ferdinands, Jill M.; Shay, David K.] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Belongia, Edward A.] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. [Nwasike, Chinyelu] Univ Massachusetts, Sch Publ Hlth, Amherst, MA 01003 USA. RP Ferdinands, JM (reprint author), US Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30333 USA. EM jferdinands@cdc.gov OI Shay, David/0000-0001-9619-4820 NR 27 TC 5 Z9 5 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 24 PY 2011 VL 29 IS 10 BP 1935 EP 1940 DI 10.1016/j.vaccine.2010.12.098 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 739PP UT WOS:000288730500012 PM 21219986 ER PT J AU Inoue, K Kabeya, H Hagiya, K Kosoy, MY Une, Y Yoshikawa, Y Maruyama, S AF Inoue, Kai Kabeya, Hidenori Hagiya, Keiko Kosoy, Michael Y. Une, Yumi Yoshikawa, Yasuhiro Maruyama, Soichi TI Multi-locus sequence analysis reveals host specific association between Bartonella washoensis and squirrels SO VETERINARY MICROBIOLOGY LA English DT Article DE Bartonella washoensis; Genetic diversity; Multi-locus sequence analysis (MLSA); Phylogenetic relationship; Sciuridae; Squirrel ID PHYLOGENETIC ANALYSIS; GENE; DIFFERENTIATION; CLASSIFICATION; SUBSTITUTION; CONFIDENCE; INFERENCE; STRAINS; MRBAYES; TREES AB To clarify phylogenetic relationships and genetic diversity among Bartonella washoensis strains obtained from squirrels, multi-locus sequence analysis (MLSA) with the 16S rRNA, ftsZ, gltA, groEL, ribC, and rpoB genes was applied for 20 strains of B. washoensis isolated from five genera of squirrels (Tamias, Tamiasciurus, Glaucomys, Sciurus, and Spermophilus) within the family Sciuridae. Sequence similarities in the concatenated sequences of B. washoensis strains from squirrels of different genera ranged from 94.7% (Sciurus vs. Spermophilus) to 98.4% (Tamiasciurus vs. Glaucomys). Phylogenetic trees based on the concatenated sequences revealed that B. washoensis strains formed five distinct clades and each clade correlated with the genus of squirrel from which the strains were originally obtained. The discrimination was supported by 100% bootstrap values and posterior probabilities, respectively. These results suggest that B. washoensis strains may have co-speciated with their squirrel hosts and provide new insights into the application of the MLSA to identify sources of B. washoensis infection with accuracy. (C) 2010 Elsevier B.V. All rights reserved. C1 [Inoue, Kai; Kabeya, Hidenori; Hagiya, Keiko; Maruyama, Soichi] Nihon Univ, Coll Bioresource Sci, Dept Vet Med, Lab Vet Publ Hlth, Kanagawa 2528510, Japan. [Kosoy, Michael Y.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Bartonella Lab, Ft Collins, CO USA. [Une, Yumi] Azabu Univ, Sch Vet Med, Lab Vet Pathol, Kanagawa, Japan. [Yoshikawa, Yasuhiro] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biomed Sci, Tokyo, Japan. RP Maruyama, S (reprint author), Nihon Univ, Coll Bioresource Sci, Dept Vet Med, Lab Vet Publ Hlth, 1866 Kameino, Kanagawa 2528510, Japan. EM maruyama.soichi@nihon-u.ac.jp OI Une, Yumi/0000-0002-2112-1894 FU Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labor and Welfare, Japan FX This work was supported in part by a Grant for Strategic Research Base Development Program, international research on epidemiology of zoonoses and training for young researchers, from the Ministry of Education, Culture, Sports, Science and Technology, and also supported in part by a Grant-in-Aid from the Ministry of Health, Labor and Welfare, Japan. NR 25 TC 10 Z9 10 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1135 EI 1873-2542 J9 VET MICROBIOL JI Vet. Microbiol. PD FEB 24 PY 2011 VL 148 IS 1 BP 60 EP 65 DI 10.1016/j.vetmic.2010.08.007 PG 6 WC Microbiology; Veterinary Sciences SC Microbiology; Veterinary Sciences GA 727WQ UT WOS:000287834000008 PM 20884133 ER PT J AU Mody, RK Greene, SA Gaul, L Sever, A Pichette, S Zambrana, I Dang, T Gass, A Wood, R Herman, K Cantwell, LB Falkenhorst, G Wannemuehler, K Hoekstra, RM McCullum, I Cone, A Franklin, L Austin, J Delea, K Behravesh, CB Sodha, SV Yee, JC Emanuel, B Al-Khaldi, SF Jefferson, V Williams, IT Griffin, PM Swerdlow, DL AF Mody, Rajal K. Greene, Sharon A. Gaul, Linda Sever, Adrianne Pichette, Sarah Zambrana, Ingrid Dang, Thi Gass, Angie Wood, Rene Herman, Karen Cantwell, Laura B. Falkenhorst, Gerhard Wannemuehler, Kathleen Hoekstra, Robert M. McCullum, Isaac Cone, Amy Franklin, Lou Austin, Jana Delea, Kristin Behravesh, Casey Barton Sodha, Samir V. Yee, J. Christopher Emanuel, Brian Al-Khaldi, Sufian F. Jefferson, Val Williams, Ian T. Griffin, Patricia M. Swerdlow, David L. TI National Outbreak of Salmonella Serotype Saintpaul Infections: Importance of Texas Restaurant Investigations in Implicating Jalapeno Peppers SO PLOS ONE LA English DT Article ID INTERNATIONAL OUTBREAK; FRESH PRODUCE; UNITED-STATES; MULTISTATE OUTBREAK; CONSUMPTION; TOMATOES; GROWTH AB Background: In May 2008, PulseNet detected a multistate outbreak of Salmonella enterica serotype Saintpaul infections. Initial investigations identified an epidemiologic association between illness and consumption of raw tomatoes, yet cases continued. In mid-June, we investigated two clusters of outbreak strain infections in Texas among patrons of Restaurant A and two establishments of Restaurant Chain B to determine the outbreak's source. Methodology/Principal Findings: We conducted independent case-control studies of Restaurant A and B patrons. Patients were matched to well controls by meal date. We conducted restaurant environmental investigations and traced the origin of implicated products. Forty-seven case-patients and 40 controls were enrolled in the Restaurant A study. Thirty case-patients and 31 controls were enrolled in the Restaurant Chain B study. In both studies, illness was independently associated with only one menu item, fresh salsa (Restaurant A: matched odds ratio [mOR], 37; 95% confidence interval [CI], 7.2-386; Restaurant B: mOR, 13; 95% CI 1.3-infinity). The only ingredient in common between the two salsas was raw jalapeno peppers. Cultures of jalapeno peppers collected from an importer that supplied Restaurant Chain B and serrano peppers and irrigation water from a Mexican farm that supplied that importer with jalapeno and serrano peppers grew the outbreak strain. Conclusions/Significance: Jalapeno peppers, contaminated before arrival at the restaurants and served in uncooked fresh salsas, were the source of these infections. Our investigations, critical in understanding the broader multistate outbreak, exemplify an effective approach to investigating large foodborne outbreaks. Additional measures are needed to reduce produce contamination. C1 [Mody, Rajal K.; Sever, Adrianne] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Mody, Rajal K.; Greene, Sharon A.; Herman, Karen; Cantwell, Laura B.; Falkenhorst, Gerhard; Wannemuehler, Kathleen; Hoekstra, Robert M.; McCullum, Isaac; Austin, Jana; Behravesh, Casey Barton; Sodha, Samir V.; Williams, Ian T.; Griffin, Patricia M.; Swerdlow, David L.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Gaul, Linda; Dang, Thi] Texas Dept State Hlth Serv, Austin, TX USA. [Pichette, Sarah; Zambrana, Ingrid; Yee, J. Christopher; Emanuel, Brian; Al-Khaldi, Sufian F.; Jefferson, Val] US FDA, Silver Spring, MD USA. [Gass, Angie; Wood, Rene; Cone, Amy; Franklin, Lou] Wichita Falls Wichita Cty Publ Hlth Dist, Wichita Falls, TX USA. [Delea, Kristin] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Mody, RK (reprint author), Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM rmody@cdc.gov FU core government FX This work was supported by core government funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 24 TC 29 Z9 29 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 23 PY 2011 VL 6 IS 2 AR e16579 DI 10.1371/journal.pone.0016579 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 725PJ UT WOS:000287657500012 PM 21373185 ER PT J AU Pour, AM Allensworth, CD Clark, TA Liang, JL Bonner, PC Messonnier, ML Asay, GRB AF Pour, A. M. Allensworth, C. D. Clark, T. A. Liang, J. L. Bonner, P. Cullison Messonnier, M. L. Asay, G. R. Beeler TI Local Health Department Costs Associated With Response to a School-Based Pertussis Outbreak-Omaha, Nebraska, September-November 2008 (Reprinted from MMWR, vol 60, pg 5-9, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID MORBIDITY C1 [Pour, A. M.; Allensworth, C. D.] Douglas Cty Hlth Dept, Omaha, NE 68183 USA. [Clark, T. A.; Liang, J. L.; Bonner, P. Cullison] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Messonnier, M. L.; Asay, G. R. Beeler] CDC, Immunizat Svcs Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Pour, AM (reprint author), Douglas Cty Hlth Dept, Omaha, NE 68183 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 23 PY 2011 VL 305 IS 8 BP 771 EP 773 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 724RQ UT WOS:000287594300009 ER PT J AU Jue, S Hardee, R Overman, M Mays, E Bowen, A Whichard, J Greene, K Pecic, G Taylor, T AF Jue, S. Hardee, R. Overman, M. Mays, E. Bowen, A. Whichard, J. Greene, K. Pecic, G. Taylor, T. TI Emergence of Shigella flexneri 2a Resistant to Ceftriaxone and Ciprofloxacin-South Carolina, October 2010 (Reprinted from MMWR, vol 59, pg 1619, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Jue, S.] Greenville Hosp Syst, Univ Med Ctr, Greenville, SC 29605 USA. [Hardee, R.; Overman, M.; Mays, E.] S Carolina Dept Hlth & Environm Control, Columbia, SC 29201 USA. [Bowen, A.; Whichard, J.; Greene, K.; Pecic, G.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Taylor, T.] CDC, EIS, Atlanta, GA 30333 USA. RP Jue, S (reprint author), Greenville Hosp Syst, Univ Med Ctr, Greenville, SC 29605 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 23 PY 2011 VL 305 IS 8 BP 776 EP 776 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 724RQ UT WOS:000287594300011 ER PT J AU De, P Ellison, LF Barr, RD Semenciw, R Marrett, LD Weir, HK Dryer, D Grunfeld, E AF De, Prithwish Ellison, Larry F. Barr, Ronald D. Semenciw, Robert Marrett, Loraine D. Weir, Hannah K. Dryer, Dagny Grunfeld, Eva CA Steering Comm Canadian Canc Stat TI Canadian adolescents and young adults with cancer: opportunity to improve coordination and level of care SO CANADIAN MEDICAL ASSOCIATION JOURNAL LA English DT Article ID CLINICAL-TRIALS; PERIOD ANALYSIS; EMPIRICAL-EVALUATION; OLDER ADOLESCENTS; HEALTH-CARE; SURVIVAL; CHILDREN; ONCOLOGY; REGISTRY; ENGLAND C1 [De, Prithwish] Canadian Canc Soc, Toronto, ON M4V 3B1, Canada. [Ellison, Larry F.] STAT Canada, Hlth Stat Div, Ottawa, ON, Canada. [Barr, Ronald D.] McMaster Univ, Hamilton, ON, Canada. [Barr, Ronald D.] McMaster Childrens Hosp, Hamilton, ON, Canada. [Semenciw, Robert] Publ Hlth Agcy Canada, Ctr Chron Dis Prevent & Control, Ottawa, ON, Canada. [Marrett, Loraine D.] Canc Care Ontario, Surveillance & Populat Studies, Toronto, ON, Canada. [Weir, Hannah K.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Dryer, Dagny] PEI Canc Treatment Ctr, Charlottetown, PE, Canada. [Grunfeld, Eva] Ontario Inst Canc Res, Toronto, ON, Canada. RP De, P (reprint author), Canadian Canc Soc, 10 Alcorn Ave,Ste 200, Toronto, ON M4V 3B1, Canada. EM pde@cancer.ca FU Public Health Agency of Canada FX Ronald Barr has received grants from the Public Health Agency of Canada, has received royalties from Springer-Verlag for for coediting a book and has received reimbursement for travel expenses from the Teenage Cancer Trust (UK) and the Canadian Adolescent and Young Adult Task Force. None declared for all other authors. NR 51 TC 17 Z9 17 U1 0 U2 4 PU CMA-CANADIAN MEDICAL ASSOC PI OTTAWA PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA SN 0820-3946 J9 CAN MED ASSOC J JI Can. Med. Assoc. J. PD FEB 22 PY 2011 VL 183 IS 3 BP E187 EP E194 DI 10.1503/cmaj.100800 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 723LB UT WOS:000287506900034 PM 21115674 ER PT J AU Satterfield, BC Garcia, RA Jia, HW Tang, SH Zheng, HQ Switzer, WM AF Satterfield, Brent C. Garcia, Rebecca A. Jia, Hongwei Tang, Shaohua Zheng, HaoQiang Switzer, William M. TI Serologic and PCR testing of persons with chronic fatigue syndrome in the United States shows no association with xenotropic or polytropic murine leukemia virus-related viruses SO RETROVIROLOGY LA English DT Article ID PROSTATE-CANCER; RETROVIRUS XMRV; MOUSE DNA; CONTAMINATION; SEQUENCES; PREVALENCE; INFECTION; FAILURE; ABSENCE; DISEASE AB In 2009, a newly discovered human retrovirus, xenotropic murine leukemia virus (MuLV)-related virus (XMRV), was reported by Lombardi et al. in 67% of persons from the US with chronic fatigue syndrome (CFS) by PCR detection of gag sequences. Although six subsequent studies have been negative for XMRV, CFS was defined more broadly using only the CDC or Oxford criteria and samples from the US were limited in geographic diversity, both potentially reducing the chances of identifying XMRV positive CFS cases. A seventh study recently found polytropic MuLV sequences, but not XMRV, in a high proportion of persons with CFS. Here we tested blood specimens from 45 CFS cases and 42 persons without CFS from over 20 states in the United States for both XMRV and MuLV. The CFS patients all had a minimum of 6 months of post-exertional malaise and a high degree of disability, the same key symptoms described in the Lombardi et al. study. Using highly sensitive and generic DNA and RNA PCR tests, and a new Western blot assay employing purified whole XMRV as antigen, we found no evidence of XMRV or MuLV in all 45 CFS cases and in the 42 persons without CFS. Our findings, together with previous negative reports, do not suggest an association of XMRV or MuLV in the majority of CFS cases. C1 [Satterfield, Brent C.; Garcia, Rebecca A.] Cooperat Diagnost LLC, Greenwood, SC 29646 USA. [Jia, Hongwei; Tang, Shaohua; Zheng, HaoQiang; Switzer, William M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Satterfield, BC (reprint author), Cooperat Diagnost LLC, Greenwood, SC 29646 USA. EM brent@codiagnostics.com FU Cooperative Diagnostics FX This study was sponsored by Cooperative Diagnostics in order to help CFS patients. The authors thank Dr. Robert Silverman at the Cleveland Clinic for the VP62 XMRV plasmid and C7 cell line and Dr. John Hackett at Abbott Diagnostics, Chicago, IL for the XMRV-infected macaque sera. Use of trade names is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services, the Public Health Service, or the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease control and Prevention. NR 24 TC 38 Z9 39 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4690 J9 RETROVIROLOGY JI Retrovirology PD FEB 22 PY 2011 VL 8 AR 12 DI 10.1186/1742-4690-8-12 PG 7 WC Virology SC Virology GA 758ZT UT WOS:000290209100001 PM 21342521 ER PT J AU Meng, SL Sun, Y Wu, XF Tang, JR Xu, GL Lei, YL Wu, J Yan, JX Yang, XM Rupprecht, CE AF Meng, Shengli Sun, Yan Wu, Xianfu Tang, Jianrong Xu, Gelin Lei, Yongliang Wu, Jie Yan, Jiaxin Yang, Xiaoming Rupprecht, Charles E. TI Evolutionary dynamics of rabies viruses highlights the importance of China rabies transmission in Asia SO VIROLOGY LA English DT Article DE Rabies virus; Temporal-spatial dynamic; N gene ID REPUBLIC-OF-CHINA; PHYLOGENETIC ANALYSIS; SEQUENCES; PHYLOGEOGRAPHY; HISTORY; AFRICA; INDIA; GENE AB Rabies in Asia is emerging as a serious public health issue. To explore the possible origin, phylogenetic relationships, and evolutionary dynamics of Asian Rabies viruses (RABV), we examined 200 complete nucleoprotein (N) gene sequences from RABV isolates in the region. Phylogeny supported the classification of Asian RABVs into five distinct clusters in lyssavirus genotype 1. Our geospatial and temporal analyses demonstrated that China appears to be the prime source of Asian RABVs. Understanding of rabies transmission and associated human activities, such as dog translocation, can help rabies control and elimination in Asia through collaborative efforts or programs. (C) 2010 Elsevier Inc. All rights reserved. C1 [Meng, Shengli; Xu, Gelin; Wu, Jie; Yan, Jiaxin; Yang, Xiaoming] Wuhan Inst Biol Prod, Wuhan 430060, Peoples R China. [Sun, Yan] S Cent Univ Nationalities, Wuhan Inst Neurosci & Neuroengn, Wuhan 430074, Peoples R China. [Wu, Xianfu; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Tang, Jianrong] Natl Inst Control Pharmaceut & Biol Prod, Beijing 100050, Peoples R China. [Lei, Yongliang] Lishui Ctr Dis Control & Prevent, Lishui 323000, Peoples R China. RP Meng, SL (reprint author), Wuhan Inst Biol Prod, Wuhan 430060, Peoples R China. EM msl3459@yahoo.com.cn; sunyan198112@yahoo.com.cn; xaw6@cdc.gov; tangjr60429@l63.com; xugelin@yahoo.com.cn; ls2123365@tom.com; wu.jie1964@163.com; yanjx45@163.com; xmyang@wibp.com.cn; cyr5@cdc.gov FU 863 Program [2007AA022402] FX This work was supported by 863 Program (2007AA022402). We thank Dr. Todd Smith (Rabies/PRB, CDC) for critical reading of the manuscript. NR 28 TC 20 Z9 22 U1 0 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD FEB 20 PY 2011 VL 410 IS 2 BP 403 EP 409 DI 10.1016/j.virol.2010.12.011 PG 7 WC Virology SC Virology GA 719DQ UT WOS:000287180400015 PM 21195445 ER PT J AU Mei, JV Li, LX Rasmussen, SA Collier, S Frias, JL Honein, MA Shaw, GM Lorey, F Meyer, R Chaing, S Canfield, MA Jones, J Hannon, WH AF Mei, Joanne V. Li, LiXia Rasmussen, Sonja A. Collier, Sarah Frias, Jaime L. Honein, Margaret A. Shaw, Gary M. Lorey, Fred Meyer, Robert Chaing, Shu Canfield, Mark A. Jones, Jeffrey Hannon, W. Harry TI Effect of specimen storage conditions on newborn dried blood spots used to assess Toxoplasma gondii immunoglobulin M (IgM) SO CLINICA CHIMICA ACTA LA English DT Article DE Dried blood spots; Storage conditions; Toxoplasma gondii IgM; Congenital hydrocephalus; Newborn screening ID FILTER-PAPER; SAMPLES; FEASIBILITY; ANTIBODIES; STABILITY; INFANTS; PROGRAM; BANKS; ASSAY AB Background: Newborn screening programs store under varying conditions residual dried blood spots (DBS). Residual DBS were used to investigate the contribution of congenital infection with Toxoplasma gondii to the etiology of hydrocephalus and as a key step, we assessed the effect of storage conditions on the stability of newborn screening biomarkers. Methods: Infants with hydrocephalus (410 cases) were identified using population-based birth defects surveillance systems in California, North Carolina, and Texas. Infants without birth defects (448 controls) were randomly selected from the same geographic areas and time periods. California stores DBS with controlled temperature, while North Carolina and Texas store DBS under ambient conditions. After removal of personal identifiers. DBS were tested for Toxo-specific immunoglobulin-M (Toxo-IgM). Because of poor elution of DBS stored in ambient conditions, additional biomarkers were tested on a specimen subset. Results: Among 858 DBS tested, Toxo-IgM was found in 3 cases and no controls from California (N=515) and in no specimens from North Carolina or Texas (N=343). Among the 98 specimens tested for selected biomarkers, statistically significant differences were found for California vs. combined North Carolina and Texas DBS (thyroid stimulating hormone, phenylalanine, methionine, leucine and citrulline p<0.0001; tyrosine and valine p<0.001). Conclusions: Storage conditions for residual DBS had an effect on the ability to extract, recover, and accurately measure Toxo-IgM and other biomarkers from the filter paper matrix. Published by Elsevier B.V. C1 [Mei, Joanne V.; Li, LiXia; Hannon, W. Harry] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Newborn Screening Qual Assurance Program, Atlanta, GA 30341 USA. [Rasmussen, Sonja A.; Frias, Jaime L.; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. [Collier, Sarah; Jones, Jeffrey] Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Div Parasit Dis, Atlanta, GA 30341 USA. [Frias, Jaime L.; Hannon, W. Harry] McKing Consulting Corp, Fairfax, VA USA. [Shaw, Gary M.] Stanford Univ, Palo Alto, CA 94304 USA. [Lorey, Fred] Calif Dept Publ Hlth, Richmond, CA USA. [Meyer, Robert; Chaing, Shu] N Carolina Div Publ Hlth, Raleigh, NC USA. [Canfield, Mark A.] Texas Dept State Hlth Serv, Austin, TX USA. RP Mei, JV (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Newborn Screening Qual Assurance Program, Mail Stop F-19,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM jmei@cdc.gov NR 28 TC 5 Z9 6 U1 0 U2 5 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD FEB 20 PY 2011 VL 412 IS 5-6 BP 455 EP 459 DI 10.1016/j.cca.2010.11.028 PG 5 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 713CY UT WOS:000286713800009 PM 21114968 ER PT J AU Thamthitiwat, S Marin, N Baggett, HC Peruski, LF Kiatkulwiwat, W Panumatrasmee, V Varma, JK Nateniyom, S Akarasewi, P Maloney, SA AF Thamthitiwat, Somsak Marin, Nongnush Baggett, Henry C. Peruski, Leonard F. Kiatkulwiwat, Wannachai Panumatrasmee, Veerachai Varma, Jay K. Nateniyom, Sriprapa Akarasewi, Pasakorn Maloney, Susan A. TI Mycobacterium bovis (Bacille Calmette-Guerin) bacteremia in immunocompetent neonates following vaccination SO VACCINE LA English DT Article DE BCG; Mycobacterium bovis; Bacteremia; Neonates ID INDUCED DISEASE; BCG INFECTION; GUINEA-PIG; CHILDREN; IMMUNODEFICIENCY; DISPERSION AB We describe four cases of Mycobacterium tuberculosis complex bacteremia diagnosed in immunocompetent neonates, who presented with high fever and/or jaundice within 72 h after Bacille Calmette-Guerin (BCG) vaccination. All neonates were hospitalized, and none received anti-mycobacterial therapy. All recovered completely and remain healthy 2-3.5 years later. Genotyping of one available isolate identified the pathogen as Mycobacterium bovis BCG. The similar clinical presentations and close temporal association between BCG vaccination and illness suggest that all four neonates likely had BCG bacteremia. BCG bacteremia shortly following vaccination among healthy neonates has not been previously described and merits further study to determine its frequency and clinical significance. Published by Elsevier Ltd. C1 [Thamthitiwat, Somsak; Baggett, Henry C.; Peruski, Leonard F.; Maloney, Susan A.] US Ctr Dis Control & Prevent CDC Collaborat, Thailand Minist Publ Hlth MOPH, Nonthaburi 10110, Thailand. [Marin, Nongnush] Mae Sai Hosp, Thailand MOPH, Chiang Rai Prov Hlth Off, Chiang Rai, Thailand. [Panumatrasmee, Veerachai] Aranyaprathet Hosp, Thailand MOPH, Sa Kaeo Prov Hlth Off, Aranyaprathet, Thailand. [Varma, Jay K.] China US Collaborat Program Emerging & Reemerging, Beijing, Peoples R China. [Nateniyom, Sriprapa] MOPH, Bur TB, Nonthaburi, Thailand. [Akarasewi, Pasakorn] MOPH, Bur Epidemiol, Nonthaburi, Thailand. [Baggett, Henry C.; Peruski, Leonard F.; Varma, Jay K.; Maloney, Susan A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Thamthitiwat, S (reprint author), US Ctr Dis Control & Prevent CDC Collaborat, Thailand Minist Publ Hlth MOPH, Nonthaburi 10110, Thailand. EM somsakt@th.cdc.gov NR 17 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 17 PY 2011 VL 29 IS 9 BP 1727 EP 1730 DI 10.1016/j.vaccine.2010.12.089 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 730TV UT WOS:000288058500001 PM 21215347 ER PT J AU Freed, GL Clark, SJ Cowan, AE Coleman, MS AF Freed, Gary L. Clark, Sarah J. Cowan, Anne E. Coleman, Margaret S. TI Primary care physician perspectives on providing adult vaccines SO VACCINE LA English DT Article DE Immunization; Vaccine; Adult ID IMMUNIZATION; DISPARITIES AB Recently, several new vaccines have been recommended for adults. Little is known regarding the immunization purchase and stocking practices of adult primary care physicians. To determine the proportion of family practice and internal medicine physicians who routinely stock specific adult vaccines and their rationale for those decisions, we conducted a cross-sectional survey in 2009 of a national random sample of 993 family physicians (FPs) and 997 general internists (IMs) in the US. Of the 1109 respondents, 886 reported that they provide primary care to adults aged 19-64 years and 96% of these physicians stock at least one vaccine recommended for adults. Of those. 2% plan to stop and 12% plan to increase vaccine purchases; the rest plan to maintain status quo. Of the respondents, 27% (31% FPs vs 20% IMs) stocked all adult vaccines. We conclude that many primary care physicians who provide care to adults do not stock all recommended immunizations. Efforts to improve adult immunization rates must address this fundamental issue. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Freed, Gary L.; Clark, Sarah J.; Cowan, Anne E.] Univ Michigan Hlth Syst, Dept Pediat & Communicable Dis, Div Gen Pediat, Ann Arbor, MI USA. [Freed, Gary L.; Clark, Sarah J.; Cowan, Anne E.] Univ Michigan, Child Hlth Evaluat & Res CHEAR Unit, Ann Arbor, MI 48109 USA. [Freed, Gary L.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA. [Coleman, Margaret S.] Ctr Dis Control & Prevent, Hlth Serv Res & Evaluat Branch, Atlanta, GA USA. RP Freed, GL (reprint author), Univ Michigan Hlth Syst, Dept Pediat & Communicable Dis, Div Gen Pediat, Ann Arbor, MI USA. EM gfreed@med.umich.edu; saclark@med.umich.edu; cowana@med.umich.edu; zby5@cdc.gov FU US Centers for Disease Control and Prevention FX This work was funded by the US Centers for Disease Control and Prevention. NR 18 TC 23 Z9 23 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 17 PY 2011 VL 29 IS 9 BP 1850 EP 1854 DI 10.1016/j.vaccine.2010.12.097 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 730TV UT WOS:000288058500017 PM 21216314 ER PT J AU Lima, JC Jiang, J Rodrigues-da-Silva, RN Banic, DM Tran, TM Ribeiro, RY Meyer, VSE De-Simone, SG Santos, F Moreno, A Barnwell, JW Galinski, MR Oliveira-Ferreira, J AF Lima-Junior, J. C. Jiang, J. Rodrigues-da-Silva, R. N. Banic, D. M. Tran, T. M. Ribeiro, R. Y. Meyer, V. S. E. De-Simone, S. G. Santos, F. Moreno, A. Barnwell, J. W. Galinski, M. R. Oliveira-Ferreira, J. TI B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax Merozoite Surface Protein-3 alpha (PvMSP-3 alpha) in malaria exposed individuals from Brazilian Amazon SO VACCINE LA English DT Article DE Plasmodium vivax; Merozoite surface protein; B cell epitope; Vaccine; Malaria; Immunity ID HUMORAL IMMUNE-RESPONSES; C-TERMINAL REGIONS; PAPUA-NEW-GUINEA; PROTEIN MSP-3-ALPHA; KNOWLESI MALARIA; PEPTIDE ARRAYS; SPOT SYNTHESIS; FALCIPARUM; PROTECTION; ANTIGEN AB The Plasmodium vivax Merozoite Surface Protein-3 alpha (PvMSP-3 alpha) is considered as a potential vaccine candidate. However, the detailed investigations of the type of immune responses induced in naturally exposed populations are necessary. Therefore, we aim to characterize the naturally induced antibody to PvMSP-3 alpha in 282 individuals with different levels of exposure to malaria infections residents in Brazilian Amazon. PvMSP3 specific antibodies (IgA, IgG and IgG subclass) to five recombinant proteins and the epitope mapping by Spot-synthesis technique to full-protein sequence of amino acids (15aa sequence with overlapping sequence of 9aa) were performed. Our results indicates that PvMSP3 is highly immunogenic in naturally exposed populations, where 78% of studied individuals present IgG immune response against the full-length recombinant protein (PVMSP3-FL) and IgG subclass profile was similar to all five recombinant proteins studied with a high predominance of IgG1 and IgG3. We also observe that IgG and subclass levels against PvMSP3 are associated with malaria exposure. The PvMSP3 epitope mapping by Spot-synthesis shows a natural recognition of at least 15 antigenic determinants, located mainly in the two blocks of repeats, confirming the high immunogenicity of this region. In conclusion, PvMSP-3 alpha is immunogenic in naturally exposed individuals to malaria infections and that antibodies to PvMSP3 are induced to several B cell epitopes. The presence of PvMSP3 cytophilic antibodies (IgG1 and IgG3), suggests that this mechanism could also occur in P. vivax. (C) 2011 Elsevier Ltd. All rights reserved. C1 [Lima-Junior, J. C.; Rodrigues-da-Silva, R. N.; Ribeiro, R. Y.; Oliveira-Ferreira, J.] Fiocruz MS, Inst Oswaldo Cruz, Lab lmmunoparasitol, BR-21045900 Rio De Janeiro, Brazil. [Jiang, J.; Meyer, V. S. E.; Moreno, A.; Galinski, M. R.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Banic, D. M.] Fiocruz MS, Inst Oswaldo Cruz, Malaria Res Lab, BR-21045900 Rio De Janeiro, Brazil. [Tran, T. M.; De-Simone, S. G.] Fiocruz MS, Inst Oswaldo Cruz, Lab Biochem Prot & Peptides, BR-21045900 Rio De Janeiro, Brazil. [Tran, T. M.; De-Simone, S. G.] Univ Fed Fluminense, Dept Biochem & Cell Biol, Rio De Janeiro, Brazil. [Santos, F.] LACEN, Dept Entomol, Porto Velho, RO, Brazil. [Barnwell, J. W.] CDC, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA. [Moreno, A.; Galinski, M. R.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. RP Oliveira-Ferreira, J (reprint author), Fiocruz MS, Inst Oswaldo Cruz, Lab lmmunoparasitol, 4th Floor,Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil. EM lila@ioc.fiocruz.br RI Lima-Junior, Josue /B-1361-2014; Oliveira-Ferreira, Joseli/E-7942-2014; OI Lima-Junior, Josue /0000-0002-5848-404X; Oliveira-Ferreira, Joseli/0000-0002-6063-465X; De-Simone, Salvatore/0000-0002-2172-656X FU Brazilian National Research Council; CNPq/PAPES, Fiocruz; National Institute of Health; National Center for Research Resources of the National Institutes of Health [RR00165]; NIH [RO1 AI0555994]; FAPERJ FX This work was supported by Brazilian National Research Council - CNPq/PAPES, Fiocruz, National Institute of Health, the Yerkes National Primate Research Center Base Grant # RR00165 awarded by the National Center for Research Resources of the National Institutes of Health, and NIH Grant #RO1 AI0555994 (MRG). Josue da Costa Lima Junior was the recipient of a FAPERJ Fellowship. We are grateful to all individuals that participate in this study for their cooperation and generous donation of blood, which made this study possible. We thank Eileen Farnon and Jennie Larson for the assistance during the sample collection and Paloma Napoleao Pego for the Spot-synthesis technique. We thank the Secretary of Health of Rondonia State and the Laboratorio Central - LACEN of Rondonia for providing fieldwork support. NR 67 TC 23 Z9 23 U1 2 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD FEB 17 PY 2011 VL 29 IS 9 BP 1801 EP 1811 DI 10.1016/j.vaccine.2010.12.099 PG 11 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 730TV UT WOS:000288058500011 PM 21215342 ER PT J AU Robertson, JS Nicolson, C Harvey, R Johnson, R Major, D Guilfoyle, K Roseby, S Newman, R Collin, R Wallis, C Engelhardt, OG Wood, JM Le, JH Manojkumar, R Pokorny, BA Silverman, J Devis, R Bucher, D Verity, E Agius, C Camuglia, S Ong, C Rockman, S Curtis, A Schoofs, P Zoueva, O Xie, H Li, X Lin, ZS Ye, ZP Chen, LM O'Neill, E Balishe, A Lipatov, AS Guo, Z Isakova, I Davis, CT Rivailler, P Gustin, KM Belser, JA Maines, TR Tumpey, TM Xu, XY Katz, JM Klimov, A Cox, NJ Donis, RO AF Robertson, James S. Nicolson, Carolyn Harvey, Ruth Johnson, Rachel Major, Diane Guilfoyle, Kate Roseby, Sarah Newman, Robert Collin, Rebecca Wallis, Chantal Engelhardt, Othmar G. Wood, John M. Le, Jianhua Manojkumar, Ramanunninair Pokorny, Barbara A. Silverman, Jeanmarie Devis, Rene Bucher, Doris Verity, Erin Agius, Catherine Camuglia, Sarina Ong, Chi Rockman, Steven Curtis, Anne Schoofs, Peter Zoueva, Olga Xie, Hang Li, Xing Lin, Zhengshi Ye, Zhiping Chen, Li-Mei O'Neill, Eduardo Balishe, Amanda Lipatov, Aleksandr S. Guo, Zhu Isakova, Irina Davis, Charles T. Rivailler, Pierre Gustin, Kortney M. Belser, Jessica A. Maines, Taronna R. Tumpey, Terrence M. Xu, Xiyan Katz, Jacqueline M. Klimov, Alexander Cox, Nancy J. Donis, Ruben O. TI The development of vaccine viruses against pandemic A(H1N1) influenza SO VACCINE LA English DT Article DE Influenza vaccines; Candidate vaccine viruses; Reverse genetics; High growth reassortants; HA antigen yield ID A VIRUS; REVERSE GENETICS; GENERATION; RECOMBINANTS; SYSTEM; EGG; DNA AB Wild type human influenza viruses do not usually grow well in embryonated hens' eggs, the substrate of choice for the production of inactivated influenza vaccine, and vaccine viruses need to be developed specifically for this purpose. In the event of a pandemic of influenza, vaccine viruses need to be created with utmost speed. At the onset of the current A(H1N1) pandemic in April 2009, a network of laboratories began a race against time to develop suitable candidate vaccine viruses. Two approaches were followed, the classical reassortment approach and the more recent reverse genetics approach. This report describes the development and the characteristics of current pandemic H1N1 candidate vaccine viruses. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Robertson, James S.; Nicolson, Carolyn; Harvey, Ruth; Johnson, Rachel; Major, Diane; Guilfoyle, Kate; Roseby, Sarah; Newman, Robert; Collin, Rebecca; Wallis, Chantal; Engelhardt, Othmar G.; Wood, John M.] Natl Inst Biol Stand & Controls, Div Virol, Potters Bar EN6 3QG, Herts, England. [Le, Jianhua; Manojkumar, Ramanunninair; Pokorny, Barbara A.; Silverman, Jeanmarie; Devis, Rene; Bucher, Doris] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA. [Zoueva, Olga; Xie, Hang; Li, Xing; Lin, Zhengshi; Ye, Zhiping] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA. [Chen, Li-Mei; O'Neill, Eduardo; Balishe, Amanda; Lipatov, Aleksandr S.; Guo, Zhu; Isakova, Irina; Davis, Charles T.; Rivailler, Pierre; Gustin, Kortney M.; Belser, Jessica A.; Maines, Taronna R.; Tumpey, Terrence M.; Xu, Xiyan; Katz, Jacqueline M.; Klimov, Alexander; Cox, Nancy J.; Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Robertson, JS (reprint author), Natl Inst Biol Stand & Controls, Div Virol, Blanche Lane, Potters Bar EN6 3QG, Herts, England. EM jim.robertson@nibsc.hpa.org.uk RI Isakova-Sivak, Irina/C-1034-2014 OI Isakova-Sivak, Irina/0000-0002-2801-1508 NR 28 TC 49 Z9 53 U1 2 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 17 PY 2011 VL 29 IS 9 BP 1836 EP 1843 DI 10.1016/j.vaccine.2010.12.044 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 730TV UT WOS:000288058500015 PM 21199698 ER PT J AU Hotz, G Ginzburg, E Wurm, G DeGennaro, V Andrews, D Basavaraju, S Coronado, V Xu, L Dulski, T Moffett, D Tappero, J Selent, M AF Hotz, G. Ginzburg, E. Wurm, G. DeGennaro, V. Andrews, D. Basavaraju, S. Coronado, V. Xu, L. Dulski, T. Moffett, D. Tappero, J. Selent, M. TI Post-Earthquake Injuries Treated at a Field Hospital-Haiti, 2010 (Reprinted from MMWR, vol 59, pg 1673-1677, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID EARTHQUAKE C1 [Hotz, G.; Ginzburg, E.; Wurm, G.; DeGennaro, V.; Andrews, D.] Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA. [Selent, M.] CDC, EIS, Atlanta, GA 30333 USA. RP Hotz, G (reprint author), Univ Miami, Miller Sch Med, Coral Gables, FL 33124 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 16 PY 2011 VL 305 IS 7 BP 664 EP 666 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 721NH UT WOS:000287361100009 ER PT J AU Bynum, L Griffin, T Ridings, DL Wynkoop, KS Anda, RF Edwards, VJ Strine, TW Liu, Y McKnight-Eily, LR Croft, JB AF Bynum, L. Griffin, T. Ridings, D. L. Wynkoop, K. S. Anda, R. F. Edwards, V. J. Strine, T. W. Liu, Y. McKnight-Eily, L. R. Croft, J. B. TI Adverse Childhood Experiences Reported by Adults-Five States, 2009 (Reprinted from MMWR, vol 59, pg 1609-1613, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Bynum, L.] Arkansas Dept Hlth, Little Rock, AR 72205 USA. [Anda, R. F.] Carter Consulting Inc, Atlanta, GA USA. [Edwards, V. J.; Strine, T. W.; Liu, Y.; McKnight-Eily, L. R.; Croft, J. B.] CDC, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Bynum, L (reprint author), Arkansas Dept Hlth, Little Rock, AR 72205 USA. NR 1 TC 0 Z9 0 U1 1 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 16 PY 2011 VL 305 IS 7 BP 666 EP 668 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 721NH UT WOS:000287361100010 ER PT J AU Ahluwalia, IB Jamieson, DJ D'Angelo, DV Singleton, JA Santibanez, T Euler, G Weinbaum, C AF Ahluwalia, I. B. Jamieson, D. J. D'Angelo, D. V. Singleton, J. A. Santibanez, T. Euler, G. Weinbaum, C. TI Seasonal Influenza and 2009 H1N1 Influenza Vaccination Coverage Among Pregnant Women-10 States, 2009-10 Influenza Season (Reprinted from MMWR, vol 59, pg 1541-1545, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID UNITED-STATES C1 [Singleton, J. A.; Santibanez, T.; Euler, G.; Weinbaum, C.] CDC, Immunizat Svcs Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 16 PY 2011 VL 305 IS 7 BP 668 EP 670 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 721NH UT WOS:000287361100011 ER PT J AU Kattan, JA Sosa, LE Bohnwagner, HD Hadler, JL AF Kattan, Jessica A. Sosa, Lynn E. Bohnwagner, Heather D. Hadler, James L. TI Impact of 2-Dose Vaccination on Varicella Epidemiology: Connecticut-2005-2008 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; MORTALITY AB In 2006, the Advisory Committee on Immunization Practices recommended that children routinely receive 2 varicella vaccine doses in place of the 1 dose previously recommended. This recommendation's initial impact on varicella epidemiology in Connecticut was assessed. Reported incidence and case-specific data were compared for 2005 and 2008. Varicella incidence decreased from 48.7 cases/100,000 persons in 2005 to 24.5 in 2008. Age-specific incidence decreased significantly (P < .05) among children aged 1-14 years. Reported varicella incidence has declined in Connecticut after implementation of routine 2-dose varicella vaccination for children. Continued surveillance is needed to determine the recommendation's full impact. C1 [Kattan, Jessica A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Kattan, Jessica A.; Sosa, Lynn E.; Bohnwagner, Heather D.] Connecticut Dept Publ Hlth & Addict Serv, Hartford, CT 06106 USA. [Hadler, James L.] Connecticut Emerging Infect Program, Hartford, CT USA. RP Kattan, JA (reprint author), 410 Capitol Ave,MS 11FDS,POB 340308, Hartford, CT 06134 USA. EM jessica.kattan@ct.gov FU Centers for Disease Control and Prevention, Immunization and Vaccines [5H23IP122525-08] FX This work was supported by the Centers for Disease Control and Prevention, Immunization and Vaccines for Children Grants (grant 5H23IP122525-08). NR 15 TC 28 Z9 34 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 15 PY 2011 VL 203 IS 4 BP 509 EP 512 DI 10.1093/infdis/jiq081 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 709VE UT WOS:000286468700011 PM 21199882 ER PT J AU Cauchemez, S Bhattarai, A Marchbanks, TL Fagan, RP Ostroff, S Ferguson, NM Swerdlow, D AF Cauchemez, Simon Bhattarai, Achuyt Marchbanks, Tiffany L. Fagan, Ryan P. Ostroff, Stephen Ferguson, Neil M. Swerdlow, David CA Penn H1N1 Working Grp TI Role of social networks in shaping disease transmission during a community outbreak of 2009 H1N1 pandemic influenza SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE epidemiology; infectious diseases; Bayesian statistics; data augmentation; mathematical modelling ID BAYESIAN-MCMC APPROACH; MONTE-CARLO METHODS; A H1N1; UNITED-STATES; HOUSEHOLD; SCHOOL; INFECTIONS; PARAMETERS; INFERENCE; VIRUS AB Evaluating the impact of different social networks on the spread of respiratory diseases has been limited by a lack of detailed data on transmission outside the household setting as well as appropriate statistical methods. Here, from data collected during a H1N1 pandemic (pdm) influenza outbreak that started in an elementary school and spread in a semirural community in Pennsylvania, we quantify how transmission of influenza is affected by social networks. We set up a transmission model for which parameters are estimated from the data via Markov chain Monte Carlo sampling. Sitting next to a case or being the playmate of a case did not significantly increase the risk of infection; but the structuring of the school into classes and grades strongly affected spread. There was evidence that boys were more likely to transmit influenza to other boys than to girls (and vice versa), which mimicked the observed assortative mixing among playmates. We also investigated the presence of abnormally high transmission occurring on specific days of the outbreak. Late closure of the school (i.e., when 27% of students already had symptoms) had no significant impact on spread. School-aged individuals (6-18 y) facilitated the introduction and spread of influenza in households, but only about one in five cases aged >18 y was infected by a school-aged household member. This analysis shows the extent to which clearly defined social networks affect influenza transmission, revealing strong between-place interactions with back-and-forth waves of transmission between the school, the community, and the household. C1 [Cauchemez, Simon; Ferguson, Neil M.] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Infect Dis Epidemiol, Med Res Council Ctr Outbreak Anal & Modelling, London W2 1PG, England. [Bhattarai, Achuyt; Fagan, Ryan P.; Swerdlow, David] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Marchbanks, Tiffany L.; Ostroff, Stephen; Penn H1N1 Working Grp] Penn Dept Hlth, Harrisburg, PA 17120 USA. RP Cauchemez, S (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Infect Dis Epidemiol, Med Res Council Ctr Outbreak Anal & Modelling, London W2 1PG, England. EM s.cauchemez@imperial.ac.uk RI Ferguson, Neil/B-8578-2008; Bhattarai, Achuyt/B-8760-2008 OI Ferguson, Neil/0000-0002-1154-8093; Bhattarai, Achuyt/0000-0002-0514-4850 FU Medical Research Council; Bill and Melinda Gates Foundation; National Institute of General Medical Sciences Models of Infectious Disease Agent Study initiative; European Union; Research Councils United Kingdom; Centers for Disease Control and Prevention Cooperative Agreement [U60/CCU007277] FX We thank Drs. Bob Kirkcaldy, Deborah Dowell, Alexandra Oster, and Christina Dorell at the Centers for Disease Control and Prevention for their inputs on data collection for social network analysis during field investigation. S.C. and N.M.F. thank the Medical Research Council, the Bill and Melinda Gates Foundation, the National Institute of General Medical Sciences Models of Infectious Disease Agent Study initiative, the European Union FP7 FluModCont project, and Research Councils United Kingdom for research funding. This study/report was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists and funded by the Centers for Disease Control and Prevention Cooperative Agreement U60/CCU007277. NR 33 TC 110 Z9 114 U1 5 U2 45 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 15 PY 2011 VL 108 IS 7 BP 2825 EP 2830 DI 10.1073/pnas.1008895108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 721TB UT WOS:000287377000040 PM 21282645 ER PT J AU Lin, WH Griffin, DE Rota, PA Papania, M Cape, SP Bennett, D Quinn, B Sievers, RE Shermer, C Powell, K Adams, RJ Godin, S Winston, S AF Lin, Wen-Hsuan Griffin, Diane E. Rota, Paul A. Papania, Mark Cape, Stephen P. Bennett, David Quinn, Brian Sievers, Robert E. Shermer, Charles Powell, Kenneth Adams, Robert J. Godin, Steven Winston, Scott TI Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE aerosol delivery; protective immunity; multifunctional T cells; antibody avidity ID AEROSOLIZED MEASLES; HUMORAL IMMUNITY; SUBCUTANEOUS ROUTE; CLINICAL SPECIMENS; RAPID ELIMINATION; IMMUNOGENICITY; RESPONSES; PROTECTION; INFECTION; CHILDREN AB Measles remains an important cause of childhood mortality worldwide. Sustained high vaccination coverage is the key to preventing measles deaths. Because measles vaccine is delivered by injection, hurdles to high coverage include the need for trained medical personnel and a cold chain, waste of vaccine in multidose vials and risks associated with needle use and disposal. Respiratory vaccine delivery could lower these barriers and facilitate sustained high coverage. We developed a novel single unit dose, dry powder live-attenuated measles vaccine (MVDP) for respiratory delivery without reconstitution. We tested the immunogenicity and protective efficacy in rhesus macaques of one dose of MVDP delivered either with a mask or directly intranasal with two dry powder inhalers, PuffHaler and BD Solovent. MVDP induced robust measles virus (MeV)-specific humoral and T-cell responses, without adverse effects, which completely protected the macaques from infection with wild-type MeV more than one year later. Respiratory delivery of MVDP was safe and effective and could aid in measles control. C1 [Lin, Wen-Hsuan; Griffin, Diane E.] Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA. [Rota, Paul A.; Papania, Mark] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Cape, Stephen P.] Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA. [Bennett, David; Quinn, Brian; Sievers, Robert E.; Winston, Scott] Aktiv Dry LLC, Boulder, CO 80301 USA. [Sievers, Robert E.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA. [Shermer, Charles; Powell, Kenneth] BD Technol, Res Triangle Pk, NC 27709 USA. [Adams, Robert J.] Johns Hopkins Univ, Sch Med, Dept Comparat & Mol Pathol, Baltimore, MD 21205 USA. [Godin, Steven] AVANZA Labs, Gaithersburg, MD 20878 USA. RP Griffin, DE (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA. EM dgriffin@jhsph.edu FU Bill and Melinda Gates Foundation [RG3522]; Foundation for the National Institutes of Health [1077]; Marjorie Gilbert Scholarship FX We thank Ravindra Muley, Vivek Vaidya, and Rajeev Dhere (Serum Institute of India Ltd.); Brandyn Lau, Debra Hauer, and Annie Tsay (The Johns Hopkins University); Marcus Collins, Sun Bae Sowers, and Laura Walls (Centers for Disease Control); Lia Rebits, David Krank, Jim Searles, Pankaj Pathak, and Pradnya Bhagwat (Aktiv-Dry LLC); Jessica Burger, David McAdams, Lowry Lindsay, and Mark Hernandez (University of Colorado); and Vince Sullivan (BD Technologies) for expert technical assistance. This work was funded by Bill and Melinda Gates Foundation Grant RG3522 (to D. E. G.) and the Foundation for the National Institutes of Health Grant 1077 (to R. E. S.). W.-H. L. was partially supported by the Marjorie Gilbert Scholarship Fund. NR 45 TC 41 Z9 42 U1 0 U2 4 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 15 PY 2011 VL 108 IS 7 BP 2987 EP 2992 DI 10.1073/pnas.1017334108 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 721TB UT WOS:000287377000067 PM 21282608 ER PT J AU Jennes, W Verheyden, S Demanet, C Menten, J Vuylsteke, B Nkengasong, JN Kestens, L AF Jennes, Wim Verheyden, Sonja Demanet, Christian Menten, Joris Vuylsteke, Bea Nkengasong, John N. Kestens, Luc TI Low CD4+T Cell Counts among African HIV-1 Infected Subjects with Group B KIR Haplotypes in the Absence of Specific Inhibitory KIR Ligands SO PLOS ONE LA English DT Article ID MHC CLASS-I; NATURAL-KILLER-CELLS; VIRUS TYPE-1 INFECTION; HLA CLASS-I; EXPOSED UNINFECTED INDIVIDUALS; IMMUNOGLOBULIN-LIKE RECEPTORS; HIV-1 INFECTION; NK CELLS; CUTTING EDGE; DISEASE PROGRESSION AB Natural killer (NK) cells are regulated by interactions between polymorphic killer immunoglobulin-like receptors (KIR) and human leukocyte antigens (HLA). Genotypic combinations of KIR3DS1/L1 and HLA Bw4-80I were previously shown to influence HIV-1 disease progression, however other KIR genes have not been well studied. In this study, we analyzed the influence of all activating and inhibitory KIR, in association with the known HLA inhibitory KIR ligands, on markers of disease progression in a West African population of therapy-naive HIV-1 infected subjects. We observed a significant association between carriage of a group B KIR haplotype and lower CD4+ T cell counts, with an additional effect for KIR3DS1 within the frame of this haplotype. In contrast, we found that individuals carrying genes for the inhibitory KIR ligands HLA-Bw4 as well as HLA-C1 showed significantly higher CD4+ T cell counts. These associations were independent from the viral load and from individual HIV-1 protective HLA alleles. Our data suggest that group B KIR haplotypes and lack of specific inhibitory KIR ligand genes, genotypes considered to favor NK cell activation, are predictive of HIV-1 disease progression. C1 [Jennes, Wim; Vuylsteke, Bea; Kestens, Luc] Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium. [Verheyden, Sonja; Demanet, Christian] Univ Ziekenhuis Brussel, HLA, Brussels, Belgium. [Verheyden, Sonja; Demanet, Christian] Univ Ziekenhuis Brussel, Mol Hematol Lab, Brussels, Belgium. [Menten, Joris] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium. [Vuylsteke, Bea; Nkengasong, John N.] Projet RETRO CI, Abidjan, Cote Ivoire. [Nkengasong, John N.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. RP Jennes, W (reprint author), Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium. EM wjennes@itg.be RI Jennes, Wim/M-2523-2013 OI Jennes, Wim/0000-0002-3125-6389 FU Belgian Fund for Scientific Research (FWO-Vlaanderen) [G.0660.06] FX This work was supported by the Belgian Fund for Scientific Research (FWO-Vlaanderen), grant number G.0660.06. Website: www.fwo.be. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 55 TC 14 Z9 14 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 14 PY 2011 VL 6 IS 2 AR e17043 DI 10.1371/journal.pone.0017043 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 721PR UT WOS:000287367600033 PM 21347267 ER PT J AU Williams, IT Bell, BP Kuhnert, W Alter, MJ AF Williams, Ian T. Bell, Beth P. Kuhnert, Wendi Alter, Miriam J. TI Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006 SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID INJECTION-DRUG USERS; NON-B HEPATITIS; NEW-YORK-CITY; VIRUS-INFECTION; RISK-FACTORS; BLOOD-DONORS; NON-A; HUMAN-IMMUNODEFICIENCY; LIVER-DISEASE; PREVALENCE AB Background: Monitoring disease incidence and transmission patterns is important to characterize groups at risk for hepatitis C virus (HCV) infection. Clinical cases generally represent about 20% to 30% of all newly acquired infections. Methods: We used sentinel surveillance to determine incidence and transmission patterns for acute hepatitis C in the United States using data from 25 years of population-based surveillance in the general community. Acute cases of hepatitis C were identified from 1982 through 2006 by a stimulated passive surveillance system in 4 to 6 US counties. Cases were defined by a discrete onset of symptoms, alanine aminotransferase (ALT) levels greater than 2.5 times the upper limit of normal (X ULN), negative findings for serologic markers for acute hepatitis A and B, and positive findings for antibody to HCV or HCV RNA. Incidence and frequency of reported risk factors were the main outcome measures. Results: Of 2075 patients identified, the median age was 31 years, 91.5% had ALT values greater than 7 X ULN, 77.3% were jaundiced, 22.5% were hospitalized, and 1.2% died. Incidence averaged 7.4 per 100 000 individuals (95% confidence interval [CI], 6.4-8.5 per 100 000) during 1982 to 1989 then declined averaging 0.7 per 100 000 (95% CI, 0.5-1.0 per 100 000) during 1994 to 2006. Among 1748 patients interviewed (84.2%), injection drug use (IDU) was the most commonly reported risk factor. The average number of IDU-related cases declined paralleling the decline in incidence, but the proportion of IDU-related cases rose from 31.8% (402 of 1266) during 1982 to 1989 to 45.6% (103 of 226) during 1994 to 2006. Among IDU-related cases reported during 1994 to 2006, 56 of 61 individuals (91.8%) had been in a drug treatment program and/or incarcerated. Conclusions: The incidence of acute HCV declined substantially over the 25 years of population-based surveillance. Despite declines, IDU is the most common risk factor for new HCV infection. C1 [Williams, Ian T.; Bell, Beth P.; Kuhnert, Wendi; Alter, Miriam J.] Ctr Dis Control & Prevent CDC, Div Viral Hepatitis, Atlanta, GA USA. RP Williams, IT (reprint author), Ctr Dis Control & Prevent, Outbreak Response & Prevent Branch, Div Foodborne Waterborne & Environm Dis, MS A-38,1600 Clifton Rd, Atlanta, GA 30333 USA. EM IWilliams@cdc.gov NR 29 TC 66 Z9 69 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD FEB 14 PY 2011 VL 171 IS 3 BP 242 EP 248 DI 10.1001/archinternmed.2010.511 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 721CI UT WOS:000287328700011 PM 21325115 ER PT J AU Goulart, C Darrieux, M Rodriguez, D Pimenta, FC Brandileone, MCC de Andrade, ALSS Leite, LCC AF Goulart, Cibelly Darrieux, Michelle Rodriguez, Dunia Pimenta, Fabiana C. Brandileone, Maria Cristina C. de Andrade, Ana Lucia S. S. Leite, Luciana C. C. TI Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells SO VACCINE LA English DT Article DE Streptococcus pneumoniae; Complement; PspA; Opsonophagocytosis ID PNEUMOCOCCAL CONJUGATE VACCINE; PROTEIN-A PSPA; STREPTOCOCCUS-PNEUMONIAE; HETEROLOGOUS PSPA; CHILDREN YOUNGER; ANTIBODIES; SURFACE; AGE; IMMUNIZATION; PROTECTION AB PspA is one of the most well studied pneumococcal proteins and a promising candidate for a future protein-based anti-pneumococcal vaccine. Nevertheless, its structural and serological variability suggests the inclusion of more than one PspA molecule in order to broaden protection. Since different PspAs exhibit variable levels of cross-reactivity, the selection of the protein combination with the highest coverage potential is an essential step for PspA-based vaccine development. This work investigated the level of cross-reactivity within family 1 PspAs, and established a complement based antibody mediated opsonophagocytic assay for measuring the level of cross-protection. Among a panel of ten family 1 PspA molecules, two of them, one belonging to clade 1 and another from clade 2, induced antibodies capable of enhancing complement deposition and mediating the phagocytic killing by mouse peritoneal macrophages of all pneumococci bearing PspA family 1 strains tested, regardless of their serotype. Therefore, we suggest the inclusion of either one in a PspA-based vaccine, as a representative of family 1. Furthermore, our results suggest that opsonophagocytosis by mouse peritoneal cells can be an efficient means of evaluating the induction of protective immune responses in mice across a large number of strains. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Darrieux, Michelle] Univ Sao Francisco, Lab Biol Mol Microrganismos, BR-12916900 Sao Paulo, Brazil. [Goulart, Cibelly; Leite, Luciana C. C.] Programa Posgrad Interunidades Biotecnol USP IPT, Sao Paulo, Brazil. [Goulart, Cibelly; Rodriguez, Dunia; Leite, Luciana C. C.] Inst Butantan, Ctr Biotecnol, Sao Paulo, Brazil. [Pimenta, Fabiana C.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. [Brandileone, Maria Cristina C.] Inst Adolfo Lutz Registro, Bacteriol Lab, Sao Paulo, Brazil. [de Andrade, Ana Lucia S. S.] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil. RP Darrieux, M (reprint author), Univ Sao Francisco, Lab Biol Mol Microrganismos, Av Sao Francisco de Assis 218, BR-12916900 Sao Paulo, Brazil. EM michelle.bertoncini@saofrancisco.edu.br RI Leite, Luciana/D-1353-2012; Goulart, Cibelly/F-4265-2014; Rodriguez Soto, Dunia Del Carmen/J-4305-2014; Goulart, Cibelly/B-6666-2014; Andrade, Ana Lucia/L-5751-2013 OI Rodriguez Soto, Dunia Del Carmen/0000-0001-6449-3359; FU FAPESP; Fundacao Butantan; SES-SP/FUNDAP FX This project was supported by FAPESP, Fundacao Butantan and SES-SP/FUNDAP. NR 32 TC 22 Z9 22 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 11 PY 2011 VL 29 IS 8 BP 1634 EP 1642 DI 10.1016/j.vaccine.2010.12.074 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 732MC UT WOS:000288188400018 PM 21211592 ER PT J AU Schenker, N Borrud, LG Burt, VL Curtin, LR Flegal, KM Hughes, J Johnson, CL Looker, AC Mirel, L AF Schenker, Nathaniel Borrud, Lori G. Burt, Vicki L. Curtin, Lester R. Flegal, Katherine M. Hughes, Jeffery Johnson, Clifford L. Looker, Anne C. Mirel, Lisa TI Multiple imputation of missing dual-energy X-ray absorptiometry data in the National Health and Nutrition Examination Survey SO STATISTICS IN MEDICINE LA English DT Article DE body composition; body fat; body mass index; bone mineral density; missing at random; sequential regression multivariate imputation ID FULLY CONDITIONAL SPECIFICATION AB In 1999, dual-energy x-ray absorptiometry (DXA) scans were added to the National Health and Nutrition Examination Survey (NHANES) to provide information on soft tissue composition and bone mineral content. However, in 1999-2004, DXA data were missing in whole or in part for about 21 per cent of the NHANES participants eligible for the DXA examination; and the missingness is associated with important characteristics such as body mass index and age. To handle this missing-data problem, multiple imputation of the missing DXA data was performed. Several features made the project interesting and challenging statistically, including the relationship between missingness on the DXA measures and the values of other variables; the highly multivariate nature of the variables being imputed; the need to transform the DXA variables during the imputation process; the desire to use a large number of non-DXA predictors, many of which had small amounts of missing data themselves, in the imputation models; the use of lower bounds in the imputation procedure; and relationships between the DXA variables and other variables, which helped both in creating and evaluating the imputations. This paper describes the imputation models, methods, and evaluations for this publicly available data resource and demonstrates properties of the imputations via examples of analyses of the data. The analyses suggest that imputation helps to correct biases that occur in estimates based on the data without imputation, and that it helps to increase the precision of estimates as well. Moreover, multiple imputation usually yields larger estimated standard errors than those obtained with single imputation. Published in 2010 by John Wiley & Sons, Ltd. C1 [Schenker, Nathaniel; Borrud, Lori G.; Burt, Vicki L.; Curtin, Lester R.; Flegal, Katherine M.; Hughes, Jeffery; Johnson, Clifford L.; Looker, Anne C.; Mirel, Lisa] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Schenker, N (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 3209, Hyattsville, MD 20782 USA. EM nschenker@cdc.gov RI Flegal, Katherine/A-4608-2013; OI Flegal, Katherine/0000-0002-0838-469X NR 52 TC 20 Z9 20 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD FEB 10 PY 2011 VL 30 IS 3 BP 260 EP 276 DI 10.1002/sim.4080 PG 17 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 715ST UT WOS:000286908500006 PM 21213343 ER PT J AU Jenkins, PH Montejano, HJ Abbasi, MJ Crowley, MS O'Brien, MG Conte, V Etienne, M Rico, E Rea, DG Baker, RM Burden, EA Gillis, LD Hamilton, JJ Hopkins, RS Kite-Powell, AC Merlo, E AF Jenkins, P. H. Montejano, H. J. Abbasi, M. J. Crowley, M. S. O'Brien, M. G. Conte, V. Etienne, M. Rico, E. Rea, D. G. Baker, R. M. Burden, E. A. Gillis, L. D. Hamilton, J. J. Hopkins, R. S. Kite-Powell, A. C. Merlo, E. TI Update on Cholera-Haiti, Dominican Republic, and Florida, 2010 (Reprinted from MMWR, vol 59, pg 1637-1641, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Baker, R. M.; Burden, E. A.; Gillis, L. D.; Hamilton, J. J.; Hopkins, R. S.; Kite-Powell, A. C.; Merlo, E.] CDC, Pan Amer Hlth Org, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 2 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 9 PY 2011 VL 305 IS 6 BP 554 EP 556 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 717XI UT WOS:000287080500010 ER PT J AU Kruger, K Miller, T Feist, M Keller, S Carlson, B Klockmann, R Schwabenlander, S Scheftel, J Rupprecht, C Cope, JR Petersen, B AF Kruger, K. Miller, T. Feist, M. Keller, S. Carlson, B. Klockmann, R. Schwabenlander, S. Scheftel, J. Rupprecht, C. Cope, J. R. Petersen, B. TI Public Health Response to a Rabid Dog in an Animal Shelter-North Dakota and Minnesota, 2010 (Reprinted from MMWR, vol 59, pg 1678-1680, 2011) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Keller, S.; Carlson, B.] N Dakota State Board Anim Hlth, Fargo, ND USA. [Scheftel, J.] Minnesota Dept Hlth, Minneapolis, MN 55414 USA. [Cope, J. R.; Petersen, B.] CDC, EIS, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 9 PY 2011 VL 305 IS 6 BP 561 EP 562 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 717XI UT WOS:000287080500012 ER PT J AU Beck, EJ Mandalia, S Harling, G Santas, XM Mosure, D Delay, PR AF Beck, Eduard J. Mandalia, Sundhiya Harling, Guy Santas, Xenophon M. Mosure, Debra Delay, Paul R. TI Protecting HIV information in countries scaling up HIV services: a baseline study SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Article ID STIGMA AB Background: Individual-level data are needed to optimize clinical care and monitor and evaluate HIV services. Confidentiality and security of such data must be safeguarded to avoid stigmatization and discrimination of people living with HIV. We set out to assess the extent that countries scaling up HIV services have developed and implemented guidelines to protect the confidentiality and security of HIV information. Methods: Questionnaires were sent to UNAIDS field staff in 98 middle-and lower-income countries, some reportedly with guidelines (G-countries) and others intending to develop them (NG-countries). Responses were scored, aggregated and weighted to produce standard scores for six categories: information governance, country policies, data collection, data storage, data transfer and data access. Responses were analyzed using regression analyses for associations with national HIV prevalence, gross national income per capita, OECD income, receiving US PEPFAR funding, and being a G- or NG-country. Differences between G-and NG-countries were investigated using non-parametric methods. Results: Higher information governance scores were observed for G-countries compared with NG-countries; no differences were observed between country policies or data collection categories. However, for data storage, data transfer and data access, G-countries had lower scores compared with NG-countries. No significant associations were observed between country score and HIV prevalence, per capita gross national income, OECD economic category, and whether countries had received PEPFAR funding. Conclusions: Few countries, including G-countries, had developed comprehensive guidelines on protecting the confidentiality and security of HIV information. Countries must develop their own guidelines, using established frameworks to guide their efforts, and may require assistance in adapting, adopting and implementing them. C1 [Beck, Eduard J.; Harling, Guy; Delay, Paul R.] UNAIDS, Programme Branch, Geneva, Switzerland. [Mandalia, Sundhiya] Univ London Imperial Coll Sci Technol & Med, HIV GUM Dept, London SW7 2AZ, England. [Santas, Xenophon M.; Mosure, Debra] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. RP Beck, EJ (reprint author), UNAIDS, Programme Branch, Geneva, Switzerland. EM becke@unaids.org RI Harling, Guy/R-6442-2016; OI Harling, Guy/0000-0001-6604-491X NR 18 TC 2 Z9 2 U1 0 U2 2 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD FEB 6 PY 2011 VL 14 AR 6 DI 10.1186/1758-2652-14-6 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 839EV UT WOS:000296349100001 PM 21294916 ER PT J AU Calvert, AE Kalantarov, GF Chang, GJJ Trakht, I Blair, CD Roehrig, JT AF Calvert, Amanda E. Kalantarov, Gavreel F. Chang, Gwong-Jen J. Trakht, Ilya Blair, Carol D. Roehrig, John T. TI Human monoclonal antibodies to West Nile virus identify epitopes on the prM protein SO VIROLOGY LA English DT Article DE West Nile virus; Flavivirus; Pre-membrane protein; Human monoclonal antibodies ID NONINFECTIOUS RECOMBINANT ANTIGEN; JAPANESE ENCEPHALITIS-VIRUS; CROSS-REACTIVE EPITOPES; DENGUE VIRUS; ENVELOPE PROTEIN; IMMUNE-RESPONSE; FLAVIVIRUS; INFECTION; MICE; CHALLENGE AB Hybridoma cell lines (2E8, 8G8 and 5G12) producing fully human monoclonal antibodies (hMAbs) specific for the pre-membrane (prM) protein of West Nile virus (WNV) were prepared using a human fusion partner cell line, MFP-2, and human peripheral blood lymphocytes from a blood donor diagnosed with WNV fever in 2004. Using site-directed mutagenesis of a WNV-like particle (VLP) we identified 4 amino acid residues in the prM protein unique to WNV and important in the binding of these hMAbs to the VLP. Residues V19 and 133 are important epitopes for the binding of all three hMAbs. Mutations at residue, T20 and T24 affected the binding of hMAbs, 8G8 and 5G12 only. These hMAbs did not significantly protect AG129 interferon-deficient mice or Swiss Webster outbred mice from WNV infection. Published by Elsevier Inc. C1 [Calvert, Amanda E.; Chang, Gwong-Jen J.; Roehrig, John T.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Infect Dis, Publ Hlth Serv,US Dept Hlth & Human Serv, Ft Collins, CO 80521 USA. [Kalantarov, Gavreel F.; Trakht, Ilya] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA. [Blair, Carol D.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. RP Calvert, AE (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Infect Dis, Publ Hlth Serv,US Dept Hlth & Human Serv, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM zpz0@cdc.gov OI Roehrig, John/0000-0001-7581-0479 NR 44 TC 11 Z9 11 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD FEB 5 PY 2011 VL 410 IS 1 BP 30 EP 37 DI 10.1016/j.virol.2010.10.033 PG 8 WC Virology SC Virology GA 709BT UT WOS:000286411000004 PM 21084104 ER PT J AU Hsieh, SC Zou, G Tsai, WY Qing, M Chang, GJ Shi, PY Wang, WK AF Hsieh, Szu-Chia Zou, Gang Tsai, Wen-Yang Qing, Min Chang, Gwong-Jen Shi, Pei-Yong Wang, Wei-Kung TI The C-terminal helical domain of dengue virus precursor membrane protein is involved in virus assembly and entry SO VIROLOGY LA English DT Article DE Dengue virus; Precursor membrane; Virus-like particles; Assembly; Entry ID TICK-BORNE ENCEPHALITIS; WEST-NILE-VIRUS; RECOMBINANT SUBVIRAL PARTICLES; FLAVIVIRUS ENVELOPE GLYCOPROTEIN; STEM-ANCHOR REGION; PR-M JUNCTION; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE REGION; PREMEMBRANE PROTEIN; CELL-CULTURES AB The role of the alpha-helical domain (MH) of dengue virus (DENV) precursor membrane protein in replication was investigated by site-directed mutagenesis. Proline substitutions of three residues (120, 123 and 127) at the C-terminus, but not those at the N-terminus of MH domain, reduced the virus-like particles of DENV1, DENV2 and DENV4 detected in supernatants. In a DENV2 replicon trans-packaging system, these three mutations suppressed particles detected; two of them (I123P and V127P) also affected viral entry. In the context of DENV2 genome-length RNA. all three mutations reduced virion assembly and virus spreading in cell culture. Analysis of revertants showed that mutation A120P could partially support viral infection cycle; in contrast, mutations I123P and V127P were lethal, and adaptations of I123P -> I123L and V127P -> V127L were required to restore the viral infection cycle. These findings demonstrate that the C-terminus of the MH domain is involved in both assembly and entry of DENV. (C) 2010 Elsevier Inc. All rights reserved. C1 [Zou, Gang; Qing, Min; Shi, Pei-Yong] Novartis Inst Trop Dis, Singapore 138670, Singapore. [Hsieh, Szu-Chia; Tsai, Wen-Yang; Wang, Wei-Kung] Natl Taiwan Univ, Coll Med, Inst Microbiol, Taipei 10764, Taiwan. [Hsieh, Szu-Chia; Tsai, Wen-Yang; Wang, Wei-Kung] Univ Hawaii, John A Burns Sch Med, Dept Trop Med Med Microbiol & Pharmacol, Honolulu, HI 96813 USA. [Chang, Gwong-Jen] Ctr Dis Control & Prevent, Div Vector Borne Dis, Publ Hlth Serv, US Dept HHS, Ft Collins, CO USA. RP Shi, PY (reprint author), Novartis Inst Trop Dis, 10 Biopolis Rd,Chromos Bldg, Singapore 138670, Singapore. EM pei_yong.shi@novartis.com; wangwk@hawaii.edu RI Zou, Gang/J-1833-2014 OI Zou, Gang/0000-0001-9607-7827 FU National Science Council Taiwan [NSC95-2320-B-002- 084-MY3]; JABSOM; National Center for Research Resources of the National Institutes of Health [2P20RR018727-06A1] FX This work was supported by the National Science Council Taiwan (NSC95-2320-B-002- 084-MY3), start-up fund from JABSOM, and grant 2P20RR018727-06A1 from the National Center for Research Resources of the National Institutes of Health. NR 64 TC 18 Z9 18 U1 2 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD FEB 5 PY 2011 VL 410 IS 1 BP 170 EP 180 DI 10.1016/j.virol.2010.11.006 PG 11 WC Virology SC Virology GA 709BT UT WOS:000286411000018 PM 21129763 ER PT J AU de Carvalho, CX Kipnis, A Thorn, L de Andrade, JG Pimenta, F Brandileone, MCD Zanella, RC Flannery, B Sgambatti, S Andrade, AL AF de Carvalho, Camila Xavier Kipnis, Andre Thoern, Licia de Andrade, Joao Guimaraes Pimenta, Fabiana de Cunto Brandileone, Maria Cristina Zanella, Rosemeire Cobo Flannery, Brendan Sgambatti, Sabrina Andrade, Ana Lucia TI Carriage of Haemophilus influenzae among Brazilian children attending day care centers in the era of widespread Hib vaccination SO VACCINE LA English DT Article DE H. influenzae carriage; Hib vaccination; Nontypeable H. influenzae ID ACUTE OTITIS-MEDIA; B CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; BETA-LACTAMASES; EPIDEMIOLOGIC CHARACTERISTICS; NASOPHARYNGEAL COLONIZATION; CHANGING EPIDEMIOLOGY; INVASIVE DISEASE; PROTEIN-D; PATHOGENS AB Haemophilus influenzae type b vaccine was introduced into the Immunization Program of Brazil in 1999 and no study has evaluated the impact of Hib vaccination in H. influenzae carriage so far. In June 2010, Brazil introduced the 10-valent pneumococcal nontypeable H. influenzae (NTHi) conjugate vaccine (PHiD-CV). We investigated the prevalence of encapsulated H. influenzae and NTHi isolates in nasopharyngeal samples of 1192 children attending day-care centers in Goiania, central Brazil. H. influenzae carriage rate was 32.1% and 38.4% of them carried beta-lactamase TEM-1 gene. Serotype f (4.6%) was the most frequent encapsulated isolate, type b was recovered in only 0.7% and carriage rate of NTHi was 23.3%. Recurrent acute otitis media and NTHi were independently associated with colonization by beta-lactamase producing H. influenzae. Changes in frequency of H. influenzae carriage isolates should be carefully monitored to assess the impact of the PHiD-CV on NTHi carriage in young children. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Andrade, Ana Lucia] Univ Fed Goias, Dept Community Hlth, Inst Trop Pathol & Publ Hlth, BR-74605050 Goiania, Go, Brazil. [de Carvalho, Camila Xavier; Kipnis, Andre] Univ Fed Goias, Lab Mol Bacteriol, Inst Trop Pathol & Publ Hlth, BR-74605050 Goiania, Go, Brazil. [Thoern, Licia] Secretary Hlth Goiania, Div Epidemiol, Goiania, Go, Brazil. [de Andrade, Joao Guimaraes] Univ Fed Goias, Dept Trop Med & Dermatol, Inst Trop Pathol & Publ Hlth, BR-74605050 Goiania, Go, Brazil. [Pimenta, Fabiana] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Atlanta, GA USA. [de Cunto Brandileone, Maria Cristina; Zanella, Rosemeire Cobo] Secretary Hlth State Sao Paulo, Inst Adolfo Lutz, Bacteriol Branch, Sao Paulo, Brazil. [Flannery, Brendan] Pan Amer Hlth Org, Brasilia, DF, Brazil. [Sgambatti, Sabrina] Catolica Univ Goias, Dept Med, Goiania, Go, Brazil. RP Andrade, AL (reprint author), Univ Fed Goias, Dept Saude Colet, Inst Trop Pathol & Publ Hlth, Rua 235,Esq Com 1 Ave,Setor Leste Univ, BR-74605050 Goiania, Go, Brazil. EM camilamicrobiol@hotmail.com; akipnis@iptsp.ufg.br; liciakamila@gmail.com; jguima0@hotmail.com; gzy7@cdc.gov; brandi@ial.sp.gov.br; cobo@ial.sp.gov.br; flanneryb@bra.ops-oms.org; sasgambatti@gmail.com; ana@iptsp.ufg.br RI Iats, Inct/K-2300-2013; Andrade, Ana Lucia/L-5751-2013 FU National Council for Scientific and Technological Development/CNPq [47187/2004-3, 482646/2007-1]; Secretariat of Health of Goiania Municipality; National Institute of Science and Technology for Health Technology Assessment/IATS (CNPq); CNPq [309196/2007-8, 301198/2009-8, 301340/2007-2, 301594/2007-4]; Pfizer FX This investigation was sponsored by The National Council for Scientific and Technological Development/CNPq (Research Grants no. 47187/2004-3, 482646/2007-1) and the Secretariat of Health of Goiania Municipality. The investigation was supported by the National Institute of Science and Technology for Health Technology Assessment/IATS (CNPq). AL Andrade (grant no. 309196/2007-8), A. Kipnis (grant no. 301198/2009-8), MC Brandileone (grant no. 301340/2007-2) and R Zanella (grant no. 301594/2007-4) are fellowships of CNPq.; In the last 24 months, AL Andrade has received a research grant from Pfizer to conduct the LEAP Study (Latin American Epidemiologic Assessment of Pneumococcus), and has served as an advisor/consultant for Pfizer. NR 45 TC 10 Z9 10 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 4 PY 2011 VL 29 IS 7 BP 1438 EP 1442 DI 10.1016/j.vaccine.2010.12.045 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 727DJ UT WOS:000287777500013 PM 21199703 ER PT J AU Eko, FO Ekong, E He, Q Black, CM Igietseme, JU AF Eko, F. O. Ekong, E. He, Q. Black, C. M. Igietseme, J. U. TI Induction of immune memory by a multisubunit chlamydial vaccine SO VACCINE LA English DT Article DE Chlamydia; Vaccine; Delivery; Immunity ID OUTER-MEMBRANE PROTEIN; GENITAL-TRACT INFECTION; VIBRIO-CHOLERAE GHOSTS; CELL-DEFICIENT MICE; T-CELLS; PROTECTIVE IMMUNITY; TRACHOMATIS; CHALLENGE; IMMUNIZATION; REINFECTION AB We tested the hypothesis that intramuscular immunization with a multisubunit chlamydial vaccine candidate will induce long lasting immune responses in mice. Accordingly, groups of female C57BL/6 mice were immunized intramuscularly with Vibrio cholerae ghosts (VCG) expressing the Poring B and polymorphic membrane protein-D proteins of Chlamydia trachomatis or a control antigen. Humoral and cell-mediated immune responses were evaluated following immunization and after live chlamydial infection. Immunization induced an anamnestic response characterized by chlamydial-specific IgG2a and IgA antibodies in sera and vaginal lavage as well as specific genital and splenic T cell responses. The results also revealed that the local mucosal and systemic cellular and humoral immune effectors induced in mice following immunization with the vaccine candidate are long lasting. Vaccinated mice cleared intravaginal challenge with 10(5) chlamydial inclusion forming units within 12 days compared to control mice, which shed up to 2 x 10(3) IFUs at this time point. Moreover, rechallenge of mice 98 days after resolution of the primary infection resulted in the recall and retention of a relatively high frequency of chlamydial-specific Th1 cells and IgG2a in the genital mucosa. These results provide the first evidence that a VCG-based multisubunit chlamydial vaccine is capable of effectively stimulating anamnestic systemic and mucosal immune responses in mice. The data support further vaccine evaluation and testing for induction of long-term protective immunity. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Eko, F. O.] Morehouse Sch Med, Dept Microbiol Immunol & Biochem, Atlanta, GA 30310 USA. [Black, C. M.; Igietseme, J. U.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Eko, FO (reprint author), Morehouse Sch Med, Dept Microbiol Immunol & Biochem, 720 W View Dr SW, Atlanta, GA 30310 USA. EM feko@msm.edu FU National Institutes of Health [AI41231]; National Center for Research Resources, National Institutes of Health [1 C06 RR18386] FX This work was supported by a Public Health Service grant AI41231 from the National Institutes of Health. The investigation was conducted in a facility constructed with support from Research Facilities Improvement Grant #1 C06 RR18386 from the National Center for Research Resources, National Institutes of Health. NR 55 TC 10 Z9 10 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 4 PY 2011 VL 29 IS 7 BP 1472 EP 1480 DI 10.1016/j.vaccine.2010.12.024 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 727DJ UT WOS:000287777500018 PM 21184858 ER PT J AU Ramos, M Orozovich, P Moser, K Phares, CR Stauffer, W Mitchell, T AF Ramos, M. Orozovich, P. Moser, K. Phares, C. R. Stauffer, W. Mitchell, T. TI Health of Resettled Iraqi Refugees-San Diego County, California, October 2007-September 2009 (Reprinted from MMWR, vol 59, pg 1614-1618, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID UNITED-STATES; TUBERCULOSIS C1 [Moser, K.] San Diego Cty Dept Publ Health, San Diego, CA USA. [Mitchell, T.] CDC, EIS, Atlanta, GA 30333 USA. NR 11 TC 1 Z9 1 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 2 PY 2011 VL 305 IS 5 BP 459 EP 461 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 714LI UT WOS:000286810700009 ER PT J AU Villarruel, GR Langley, GE Oberste, MS Pallansch, M AF Villarruel, G. R. Langley, G. E. Oberste, M. S. Pallansch, M. TI Nonpolio Enterovirus and Human Parechovirus Surveillance-United States, 2006-2008 (Reprinted from MMWR, vol 59, pg 1577-1580, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID DISEASE; INFECTION C1 [Villarruel, G. R.; Langley, G. E.; Oberste, M. S.; Pallansch, M.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Villarruel, GR (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 2 PY 2011 VL 305 IS 5 BP 461 EP 463 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 714LI UT WOS:000286810700010 ER PT J AU Rittenour, WR Adhikari, A Reponen, T Beezhold, DH Green, BJ AF Rittenour, W. R. Adhikari, A. Reponen, T. Beezhold, D. H. Green, B. J. TI Fungal rRNA Sequencing of Indoor and Occupational Air Samples SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting CY MAR 18-22, 2011 CL San Francisco, CA SP Amer Acad Allergy Asthma & Immunol C1 [Rittenour, W. R.; Beezhold, D. H.; Green, B. J.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. [Adhikari, A.; Reponen, T.] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA. NR 0 TC 1 Z9 1 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2011 VL 127 IS 2 SU S BP AB96 EP AB96 DI 10.1016/j.jaci.2010.12.386 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 832YI UT WOS:000295846400369 ER PT J AU Hertz, MF David-Ferdon, C AF Hertz, Marci Feldman David-Ferdon, Corinne TI Online Aggression: A Reflection of In-Person Victimization or a Unique Phenomenon? SO JOURNAL OF ADOLESCENT HEALTH LA English DT Editorial Material ID BULLYING PREVENTION PROGRAM; CONTROLLED-TRIAL; SCHOOL; INTERVENTION; HARASSMENT; PREVALENCE; VIOLENCE; YOUTH C1 [Hertz, Marci Feldman] Ctr Dis Control & Prevent, Div Adolescent, Atlanta, GA 30333 USA. [Hertz, Marci Feldman] Ctr Dis Control & Prevent, Sch Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [David-Ferdon, Corinne] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Hertz, MF (reprint author), Ctr Dis Control & Prevent, Div Adolescent, Atlanta, GA 30333 USA. NR 19 TC 3 Z9 3 U1 1 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2011 VL 48 IS 2 BP 119 EP 120 DI 10.1016/j.jadohealth.2010.11.255 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 709PW UT WOS:000286454000002 PM 21257108 ER PT J AU Guarner, J Liu, L Bhatnagar, J Jones, T Patel, M DeLeon-Carnes, M Zaki, SR AF Guarner, J. Liu, L. Bhatnagar, J. Jones, T. Patel, M. DeLeon-Carnes, M. Zaki, S. R. TI Fatal Acute Meningitis: Pathology and Etiologic Diagnosis SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Emory Univ, Atlanta, GA 30322 USA. Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RI Guarner, Jeannette/B-8273-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1426 BP 336A EP 336A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001082 ER PT J AU Shieh, WJ Bhatnagar, J Paddock, CD Zaki, SR AF Shieh, W-J Bhatnagar, J. Paddock, C. D. Zaki, S. R. TI Pathologic Studies of Fatal Enterovirus 71 Encephalitis in the United States SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 [Shieh, W-J; Bhatnagar, J.; Paddock, C. D.; Zaki, S. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1436 BP 338A EP 338A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001092 ER PT J AU Boland, JM Vaszar, LT Jones, JL Wilkins, P Rovzar, MA Colby, TV Leslie, KO Tazelaar, HD AF Boland, J. M. Vaszar, L. T. Jones, J. L. Wilkins, P. Rovzar, M. A. Colby, T. V. Leslie, K. O. Tazelaar, H. D. TI Pleuropulmonary Infection by Paragonimus westermani in the United States: A Clinicopathologic Analysis of Four Cases with Identification of a Unique Risk Factor. SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 100th Annual Meeting of the United States and Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP Canadian Acad Pathol C1 Mayo Clin, Rochester, MN USA. Mayo Clin, Scottsdale, AZ USA. Ctr Dis Control & Prevent, Atlanta, GA USA. Miss Reg Med Ctr, Mission Viejo, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2011 VL 91 SU 1 MA 1724 BP 405A EP 405A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 773CQ UT WOS:000291285001380 ER PT J AU Guarner, J Liu, L Bhatnagar, J Jones, T Patel, M DeLeon-Carnes, M Zaki, SR AF Guarner, J. Liu, L. Bhatnagar, J. Jones, T. Patel, M. DeLeon-Carnes, M. Zaki, S. R. TI Fatal Acute Meningitis: Pathology and Etiologic Diagnosis SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Emory Univ, Atlanta, GA 30322 USA. Ctr Dis Control & Prevent CDC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1426 BP 336A EP 336A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301581 ER PT J AU Boland, JM Vaszar, LT Jones, JL Wilkins, P Rovzar, MA Colby, TV Leslie, KO Tazelaar, HD AF Boland, J. M. Vaszar, L. T. Jones, J. L. Wilkins, P. Rovzar, M. A. Colby, T. V. Leslie, K. O. Tazelaar, H. D. TI Pleuropulmonary Infection by Paragonimus westermani in the United States: A Clinicopathologic Analysis of Four Cases with Identification of a Unique Risk Factor SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 Mayo Clin, Rochester, MN USA. Mayo Clin, Scottsdale, AZ USA. Ctr Dis Control & Prevent, Atlanta, GA USA. Mission Reg Med Ctr, Mission Viejo, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1724 BP 405A EP 405A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282302170 ER PT J AU Burton, DC Flannery, B Onyango, B Larson, C Alaii, J Zhang, XY Hamel, MJ Breiman, RF Feikin, DR AF Burton, Deron C. Flannery, Brendan Onyango, Bernard Larson, Charles Alaii, Jane Zhang, Xingyou Hamel, Mary J. Breiman, Robert F. Feikin, Daniel R. TI Healthcare-seeking Behaviour for Common Infectious Disease-related Illnesses in Rural Kenya: A Community-based House-to-house Survey SO JOURNAL OF HEALTH POPULATION AND NUTRITION LA English DT Article DE Community health services; Delivery of healthcare; Diarrhoea; Fever; Healthcare-seeking behaviour; Pneumonia; Rural health; Rural health services; Kenya ID INTEGRATED MANAGEMENT; CHILDHOOD ILLNESS; WESTERN KENYA; CHILDREN; PNEUMONIA; TANZANIA; SURVEILLANCE; MORTALITY; DISTRICT; WORKERS AB Community surveys of healthcare-use determine the proportion of illness episodes not captured by health facility-based surveillance, the methodology used most commonly to estimate the burden of disease in Africa. A cross-sectional survey of households with children aged less than five years was conducted in 35 of 686 census enumeration areas in rural Bondo district, western Kenya. Healthcare sought for acute episodes of diarrhoea or fever in the past two weeks or pneumonia in the past year was evaluated. Factors associated with healthcare-seeking were analyzed by logistic regression accounting for sample design. In total, 6,223 residents of 981 households were interviewed. Of 1,679 children aged less than five years, 233 (14%) had diarrhoea, and 736 (44%) had fever during the past two weeks; care at health facilities was sought for one-third of these episodes. Pneumonia in the past year was reported for 64 (4%) children aged less than five years; 88% sought healthcare at any health facility and 48% at hospitals. Seeking healthcare at health facilities was more likely for children from households with higher socioeconomic status and with more symptoms of severe illness. Health facility and hospital-based surveillance would underestimate the burden of disease substantially in rural western Kenya. Seeking healthcare at health facilities and hospitals varied by syndrome, severity of illness, and characteristics of the patient. C1 [Burton, Deron C.; Flannery, Brendan; Zhang, Xingyou] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Onyango, Bernard; Hamel, Mary J.] CDC Res & Publ Hlth Collaborat, Kenya Med Res Inst, Kisumu, Kenya. [Larson, Charles] McGill Med Sch, Montreal, PQ, Canada. [Breiman, Robert F.; Feikin, Daniel R.] CDC Int Emerging Infect Program, Nairobi, Kenya. [Zhang, Xingyou] McKing Consulting Corp, Atlanta, GA 30341 USA. RP Burton, DC (reprint author), KEMRI CDC Res & Publ Hlth Collaborat, POB 1578, Kisumu, Kenya. EM DBurton@ke.cdc.gov FU NICHD NIH HHS [R24 HD041020, T32 HD007338] NR 31 TC 52 Z9 52 U1 0 U2 7 PU ICDDR B PI DHAKA PA MOHAKHALI, 1212 DHAKA, BANGLADESH SN 1606-0997 EI 2072-1315 J9 J HEALTH POPUL NUTR JI J. Heatlh Popul. Nutr. PD FEB PY 2011 VL 29 IS 1 BP 61 EP 70 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 749TB UT WOS:000289491700008 PM 21528791 ER PT J AU Asfaw, A Pana-Cryan, R Rosa, R AF Asfaw, Abay Pana-Cryan, Regina Rosa, Roger TI The business cycle and the incidence of workplace injuries: Evidence from the USA SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE The business cycle; Workplace injury; Industry; Labor utilization effect; Physical capital utilization effect; Time series ID RECESSIONS GOOD; RATES; UNEMPLOYMENT; REDUNDANCY; WORK; ACCIDENTS; THREAT AB Introduction: The current study explored the association between the business cycle and the incidence of workplace injuries to identify cyclically sensitive industries and the relative contribution of physical capital and labor utilization within industries. Method: Bureau of Labor Statistics nonfatal injury rates from 1976 through 2007 were examined across five industry sectors with respect to several macroeconomic indicators. Within industries, injury associations with utilization of labor and physical capital over time were tested using time series regression methods. Results: Pro-cyclical associations between business cycle indicators and injury incidence were observed in mining, construction, and manufacturing but not in agriculture or trade. Physical capital utilization was the highest potential contributor to injuries in mining while labor utilization was the highest potential contributor in construction. In manufacturing each effect had a similar association with injuries. Conclusion: The incidence of workplace injury is associated with the business cycle. However, the degree of association and the mechanisms through with the business cycle affects the incidence of workplace injuries was not the same across industries. Impact on Industry: The results suggest that firms in the construction, manufacturing, and mining industries should take additional precautionary safety measures during cyclical upturns. Potential differences among industries in the mechanisms through which the business cycle affects injury incidence suggest different protective strategies for those industries. For example, in construction, additional efforts might be undertaken to ensure workers are adequately trained and not excessively fatigued, while safety procedures continue to be followed even during boom times. National Safety Council and Elsevier Ltd. All rights reserved. C1 [Asfaw, Abay; Pana-Cryan, Regina; Rosa, Roger] NIOSH, Ctr Dis Control & Prevent CDC, Off Director, Washington, DC 20201 USA. [Pana-Cryan, Regina] NIOSH, Econ Program, Washington, DC USA. RP Asfaw, A (reprint author), NIOSH, Ctr Dis Control & Prevent CDC, Off Director, Washington, DC 20201 USA. NR 27 TC 11 Z9 12 U1 2 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PD FEB PY 2011 VL 42 IS 1 BP 1 EP 8 DI 10.1016/j.jsr.2010.10.008 PG 8 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 743MB UT WOS:000289021300001 PM 21392623 ER PT J AU Piercefield, E Wendling, T Archer, P Mallonee, S AF Piercefield, Emily Wendling, Tracy Archer, Pam Mallonee, Sue TI Winter storm-related injuries in Oklahoma, January 2007 SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE Environmental medicine; Injury surveillance; Wounds; Fractures; Falls; Traffic collisions ID ICE STORM; FRACTURES AB Introduction: A January 2007 ice storm occurred in Oklahoma, causing power outages and hazardous travel conditions. The objective of this investigation was to describe the nature of winter storm-related injuries among Oklahoma residents, to determine populations at risk, and to inform prevention-planning personnel. Methods: Winter storm-related injuries were a temporarily reportable condition; all acute-care hospitals and the state medical examiner logged storm-related injuries and deaths during January 12 - 30, 2007. Medical records were retrospectively abstracted. Risk of injury was described by demographic group, injury type, and mechanism. Results: Among 6,047 persons experiencing winter storm-related injuries, 74% were injured in falls, 13% in motor-vehicle collisions (MVCs), 8% while sledding, 1% by unintentional carbon monoxide poisoning, 1% in cleanup activities, and 3% by other mechanisms. Median age of injured persons was 39 years. Persons aged >= 40 years were 1.4 times more likely to experience falls as the cause of injury than those aged <40 years, and falls were twice as likely as other mechanisms to cause fractures among persons aged >= 40 years. Injured persons aged <40 years were 2.2 times more likely to experience MVC-related injuries, and 19 times more likely to experience sledding-related injuries than persons aged >= 40 years. Conclusions: Younger persons were more likely injured in MVCs and sledding incidents, whereas older persons were more likely to experience falls and fractures. Impact on industry: Prevention messages for winter storm-related injuries should target winter-driving safety tips to younger adults and precautions regarding falls to older adults. National Safety Council and Elsevier Ltd. All rights reserved. C1 [Piercefield, Emily] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Oklahoma State Dept Hlth, OSELS SEPDPO PMR, Atlanta, GA 30333 USA. [Piercefield, Emily; Wendling, Tracy; Archer, Pam] Oklahoma Dept Hlth, Injury Prevent Serv, Oklahoma City, OK 73117 USA. RP Piercefield, E (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Oklahoma State Dept Hlth, OSELS SEPDPO PMR, 1600 Clifton Rd NE,Mailstop E-92, Atlanta, GA 30333 USA. EM epiercefield@cdc.gov; TracyLM@health.ok.gov; PamA@health.ok.gov NR 14 TC 1 Z9 1 U1 0 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PD FEB PY 2011 VL 42 IS 1 BP 27 EP 32 DI 10.1016/j.jsr.2010.11.004 PG 6 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 743MB UT WOS:000289021300004 PM 21392626 ER PT J AU Martel, LD Mueller, CW AF Martel, Lise D. Mueller, Charles W. TI The Effect of Anticipated Service Interruptions on Disaster Preparedness Intentions SO JOURNAL OF APPLIED SOCIAL PSYCHOLOGY LA English DT Article ID NEGATIVE THREAT APPEALS; SEISMIC HAZARD ADJUSTMENTS; TORNADO PREPAREDNESS; EARTHQUAKE PREPAREDNESS; PRE MODEL; RISK; EVACUATION; INFORMATION; ADOPTION; RESPONSIBILITY AB This study examined the effects of anticipated service interruptions on natural disaster preparedness intentions. In a 3 x 2 x 2 factorial experiment, students were exposed to scenarios with varied levels of anticipated basic service interruption (no mention, low, high), and person-relative-to event (PrE) factors shown to affect preparedness (low, high), across 2 types of disaster (earthquake, flood). Results indicated no main or interaction effects related to type of natural disasters, significant main effects for levels of PrE and service interruption, and a significant PrE x Service Interruption interaction. Anticipated service interruption affected preparedness, regardless of level of PrE. Bringing service interruption into awareness increases willingness to prepare, suggesting that public-health efforts should include messages regarding potential interruption of services. C1 [Martel, Lise D.; Mueller, Charles W.] Univ Hawaii Manoa, Honolulu, HI 96822 USA. RP Martel, LD (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Int Emergency & Refugee Hlth Branch, 4770 Buford Highway,MS F-60, Atlanta, GA 30341 USA. EM lmartel@cdc.gov RI Mueller, Charles/F-8426-2013 NR 49 TC 1 Z9 1 U1 1 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9029 EI 1559-1816 J9 J APPL SOC PSYCHOL JI J. Appl. Soc. Psychol. PD FEB PY 2011 VL 41 IS 2 BP 298 EP 311 DI 10.1111/j.1559-1816.2010.00714.x PG 14 WC Psychology, Social SC Psychology GA 724PK UT WOS:000287588500004 ER PT J AU Krahn, G Terdal, L AF Krahn, Gloria Terdal, Leif TI Ann Magaret Garner (1916-2010) OBITUARY SO AMERICAN PSYCHOLOGIST LA English DT Biographical-Item C1 [Krahn, Gloria] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Terdal, Leif] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Krahn, G (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0003-066X J9 AM PSYCHOL JI Am. Psychol. PD FEB-MAR PY 2011 VL 66 IS 2 SI SI BP 142 EP 142 DI 10.1037/a0022498 PG 1 WC Psychology, Multidisciplinary SC Psychology GA 721EE UT WOS:000287335600006 ER PT J AU Parks, SE Mirchandani, G Rodriguez, S Hellsten, J AF Parks, Sharyn E. Mirchandani, Gita Rodriguez, Susan Hellsten, John TI History of maltreatment among unintentional injury deaths: analyses of Texas child fatality review data, 2005-2007 SO INJURY PREVENTION LA English DT Review ID UNITED-STATES; ABUSE AB Objective This report examines unintentional injury deaths among children with and without a history of child maltreatment. Methods Data are from reviews of 1192 unintentional injury deaths occurring among children in Texas during 2005-2007. The study examined differences in child demographic characteristics, injury mechanism, and supervisor status at time of death between children with and without maltreatment history by using descriptive statistics and chi(2) tests. Separate analyses compared characteristics of asphyxia, drowning, and poisoning deaths. Results In 10% of the unintentional injury deaths that were reviewed, the child had a history of maltreatment. The prevalence of a history of maltreatment was highest among black decedents and lowest among white decedents. Prevalence of a history of maltreatment was highest among infant decedents and lowest among youth decedents, ages 10-14 years. Among deaths where there was no maltreatment history, 54% were due to motor vehicle related incidents, whereas 51% of deaths among children with maltreatment history were caused by drowning, asphyxia, and poisoning. Supervisors of child decedents with a history of maltreatment were significantly more likely to have been alcohol impaired (6.9% vs 1.6%; p<0.0005), or asleep (12.1% vs 6.6%; p=0.03) at the time of death. Differences between child decedents with and without maltreatment history were observed in infant sleep surface in suffocation deaths, location and barrier type in drowning deaths, and substance type in poisoning deaths. Conclusions These data show that the mechanisms and circumstances surrounding unintentional injury deaths among children with a history of maltreatment differ from those without a history of maltreatment. This underscores the need for appropriate interventions to prevent unintentional and intentional injuries in families with a history of maltreatment. C1 [Parks, Sharyn E.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Mirchandani, Gita; Rodriguez, Susan; Hellsten, John] Texas Dept State Hlth Serv, Austin, TX USA. RP Parks, SE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS-F64, Atlanta, GA 30341 USA. EM Svp2@cdc.gov NR 7 TC 1 Z9 1 U1 1 U2 4 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 J9 INJURY PREV JI Inj. Prev. PD FEB PY 2011 VL 17 SU 1 BP 14 EP 18 DI 10.1136/ip.2010.026336 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 725WV UT WOS:000287678500004 ER PT J AU Espitia-Hardeman, V Borse, NN Dellinger, AM Betancourt, CE Villareal, AN Caicedo, LD Portillo, C AF Espitia-Hardeman, Victoria Borse, Nagesh N. Dellinger, Ann M. Elena Betancourt, Carmen Nelly Villareal, Alba Diana Caicedo, Luz Portillo, Carlos TI The burden of childhood injuries and evidence based strategies developed using the injury surveillance system in Pasto, Colombia SO INJURY PREVENTION LA English DT Article ID VIOLENCE AB Objective This article characterises the burden of childhood injuries and provides examples of evidence-based injury prevention strategies developed using a citywide injury surveillance system in Pasto, Colombia. Methods Fatal (2003-2007) and non-fatal (2006-2007) childhood injury data were analysed by age, sex, cause, intent, place of occurrence, and disposition. Results Boys accounted for 71.5% of fatal and 64.9% of non-fatal injuries. The overall fatality rate for all injuries was 170.8 per 100,000 and the non-fatal injury rate was 4,053 per 100,000. Unintentional injuries were the leading causes of fatal injuries for all age groups, except for those 15-19 years whose top four leading causes were violence-related. Among non-fatal injuries, falls was the leading mechanism in the group 0-14 years. Interpersonal violence with a sharp object was the most important cause for boys aged 15-19 years. Home was the most frequent place of occurrence for both fatal and non-fatal injuries for young children 0-4 years old. Home, school and public places became an important place for injuries for boys in the age group 5-15 years. The highest case-fatality rate was for self-inflicted injuries (8.9%). Conclusions Although some interventions have been implemented in Pasto to reduce injuries, it is necessary to further explore risk factors to better focus prevention strategies and their evaluation. We discuss three evidence-based strategies developed to prevent firework-related injuries during festival, self-inflicted injuries, and road traffic-related injuries, designed and implemented based on the injury surveillance data. C1 [Espitia-Hardeman, Victoria] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Borse, Nagesh N.] Ctr Dis Control & Prevent, Off Workforce & Career Dev, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. [Dellinger, Ann M.] Ctr Dis Control & Prevent, Motor Vehicle Team Leader, Natl Ctr Injury Prevent & Control, Div Unintent Injury, Atlanta, GA 30341 USA. [Elena Betancourt, Carmen; Nelly Villareal, Alba; Diana Caicedo, Luz; Portillo, Carlos] Observ Delito, Pasto, Colombia. RP Espitia-Hardeman, V (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE, Atlanta, GA 30341 USA. EM vbe2@cdc.gov NR 23 TC 4 Z9 4 U1 0 U2 6 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 J9 INJURY PREV JI Inj. Prev. PD FEB PY 2011 VL 17 SU 1 BP 38 EP 44 DI 10.1136/ip.2009.026112 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 725WV UT WOS:000287678500009 ER PT J AU Flegal, KM AF Flegal, Katherine M. TI Commentary: Is there a best index of weight for height? SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Editorial Material ID BODY-MASS INDEX; CHILDREN; GROWTH; ADIPOSITY; INDICES; BLACKS; WHITES C1 Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Flegal, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM kmf2@cdc.gov RI Flegal, Katherine/A-4608-2013; OI Flegal, Katherine/0000-0002-0838-469X NR 17 TC 2 Z9 2 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD FEB PY 2011 VL 40 IS 1 BP 44 EP 46 DI 10.1093/ije/dyq266 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 739MC UT WOS:000288720900009 PM 21252213 ER PT J AU Moser, BD Klenk, HP Schumann, P Potter, G Lasker, BA Steigerwalt, AG Hinrikson, HP Brown, JM AF Moser, Benjamin D. Klenk, Hans-Peter Schumann, Peter Poetter, Gabriele Lasker, Brent A. Steigerwalt, Arnold G. Hinrikson, Hans P. Brown, June M. TI Nocardia niwae sp. nov., isolated from human pulmonary sources SO INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY LA English DT Article ID AD-HOC-COMMITTEE; ACID; GENE; CLASSIFICATION; IDENTIFICATION; ASTEROIDES; EXTRACTION AB Members of the genus Nocardia are responsible for cutaneous, pulmonary and disseminated human infections. From 2003 to 2008, four nocardioform strains (W8027, W8681, W9071 and W9241(T)) were isolated from patients in the state of Florida, USA. Ribosomal gene sequencing analysis suggested that a novel species of the genus Nocardia had been isolated. These strains were subjected to a taxonomic analysis using a polyphasic approach. Phenotypic analyses included morphological examination, biochemical profiling and antimicrobial susceptibility testing. Molecular studies included 16S rRNA and DNA gyrase B subunit (gyrB) gene sequence analyses and DNA DNA hybridization. Phylogenetic neighbours were determined through 16S rRNA and gyrB gene sequence analyses. Phenotypic characteristics that differentiated the novel isolates from phylogenetically related species were growth at 45 degrees C, and three of the four novel strains utilized L-rhamnose. The antimicrobial profiles could not reliably distinguish the novel species from related nocardiae. Analysis showed that the 16S rRNA gene sequences of the four novel isolates were identical. The BLAST analysis of the near full-length 16S rRNA gene showed 99.2% sequence similarity to Nocardia araoensis DSM 44729(T), Nocardia arthritidis DSM 44731(T) and Nocardia beijingensis JCM 10666(T), 98.7% to Nocardia amamiensis DSM 45066(T), 98.2% to Nocardia pneumoniae JCM 12119(T) and 97.8% to Nocardia takedensis JCM 13313(T). Analysis of partial gyrB gene sequences showed that the novel isolates had 95.4% similarity to N. arthritidis DSM 44731(T), 95.3% to Nocardia gamkensis DSM 44956(T), 944% to N. pneumoniae JCM 12119(T), 93.8% to Nocardia asiatica DSM 44668(T), 93.5% to N. amamiensis DSM 45066(T), 93.4% to N. beijingensis JCM 10666(T) and 93.2 % to N. araoensis DSM 44729(T). The DNA DNA relatedness values between the four novel strains were 86-89 %; the relatedness value for strain W9241(T) compared with N. beijingensis JCM 10666(T) was 47% and 46% with N. araoensis DSM 44729(T), 44% with N. arthritidis DSM 44731(T), 32% with N. amamiensis DSM 45066T and 20 % with N. asiatica DSM 44668(T). The results of the taxonomic analysis suggested that the new isolates represent a novel species of the genus Nocardia for which the name Nocardia niwae sp. nov. is proposed. The type strain is W9241(T) (=DSM 45340(T)=CCUG 57756(T)). C1 [Moser, Benjamin D.; Lasker, Brent A.; Steigerwalt, Arnold G.; Hinrikson, Hans P.; Brown, June M.] Ctr Dis Control & Prevent, Bacterial Zoonoses Branch, Div Foodborne Bacterial & Mycot Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. [Klenk, Hans-Peter; Schumann, Peter; Poetter, Gabriele] German Collect Microorganisms & Cell Cultures, Braunschweig, Germany. RP Moser, BD (reprint author), Ctr Dis Control & Prevent, Bacterial Zoonoses Branch, Div Foodborne Bacterial & Mycot Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. EM ghn5@cdc.gov NR 26 TC 7 Z9 7 U1 0 U2 1 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1466-5026 J9 INT J SYST EVOL MICR JI Int. J. Syst. Evol. Microbiol. PD FEB PY 2011 VL 61 BP 438 EP 442 DI 10.1099/ijs.0.020370-0 PN 2 PG 5 WC Microbiology SC Microbiology GA 736DS UT WOS:000288471300040 PM 20348315 ER PT J AU Fowler, BA AF Fowler, Bruce A. TI Symp XIVa Molecular Markers for Metal and Metalloid Toxicity SO INTERNATIONAL JOURNAL OF TOXICOLOGY LA English DT Meeting Abstract CT 31st Annual Meeting of the American-College-of-Toxicology CY NOV 07-10, 2010 CL Baltimore, MD SP Amer Coll Toxicol C1 [Fowler, Bruce A.] Agcy Tox Subst & Dis Registry, Div Toxicol & Environm Med, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1091-5818 J9 INT J TOXICOL JI Int. J. Toxicol. PD FEB PY 2011 VL 30 IS 1 BP 132 EP 132 PG 1 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 733RJ UT WOS:000288280200129 ER PT J AU Miller, KS Forehand, R Wiegand, R Fasula, AM Armistead, L Long, N Wyckoff, SC AF Miller, Kim S. Forehand, Rex Wiegand, Ryan Fasula, Amy M. Armistead, Lisa Long, Nicholas Wyckoff, Sarah C. TI MAKING HIV PREVENTION PROGRAMMING COUNT: IDENTIFYING PREDICTORS OF SUCCESS IN A PARENT-BASED HIV PREVENTION PROGRAM FOR YOUTH SO AIDS EDUCATION AND PREVENTION LA English DT Article ID RISK; COMMUNICATION; ADOLESCENTS; BEHAVIORS AB Predictors of change in the number of sexual topics parents discussed and responsiveness during sex communication with their preadolescent after participating in a five-session sexual risk reduction intervention for parents were examined. Data were from 339 African American parents of preadolescents enrolled in the intervention arm of a randomized-controlled trial of the Parents' Matter! Program (PMP). Four categories of predictors of success were examined: time and resource constraints, personal characteristics, the parent-child relationship, and parent perceptions of child readiness for sex communication. There were only sporadic associations between success and time and resource constraints for either outcome. Parent perception of child readiness for sex communication was positively associated with discussions of sex topics (b = 1.11, confidence interval [CI]: 0.24-1.97) and parental responsiveness (b = .68, CI:0.22-1.15). Although parents face time and resource constraints, most attended at least four sessions, and demo-graphics such as income had limited effects on program success. C1 [Miller, Kim S.; Wiegand, Ryan; Fasula, Amy M.; Wyckoff, Sarah C.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Forehand, Rex] Univ Vermont, Burlington, VT 05405 USA. [Armistead, Lisa] Georgia State Univ, Dept Psychol, Atlanta, GA 30303 USA. [Long, Nicholas] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA. RP Miller, KS (reprint author), 1600 Clifton Rd NE,Mailstop E-04, Atlanta, GA 30333 USA. EM kmiller@cdc.gov NR 29 TC 4 Z9 4 U1 2 U2 5 PU GUILFORD PUBLICATIONS INC PI NEW YORK PA 72 SPRING STREET, NEW YORK, NY 10012 USA SN 0899-9546 J9 AIDS EDUC PREV JI Aids Educ. Prev. PD FEB PY 2011 VL 23 IS 1 BP 38 EP 53 PG 16 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA 716YE UT WOS:000287008600004 PM 21341959 ER PT J AU Haverkamp, D Perdue, DG Espey, D Cobb, N AF Haverkamp, Donald Perdue, David G. Espey, David Cobb, Nathaniel TI A Survey of Indian Health Service and Tribal Health Providers' Colorectal Cancer Screening Knowledge, Perceptions, and Practices SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE American Indians and Alaska Natives; colorectal cancer; screening; providers ID PRIMARY-CARE PHYSICIANS; FECAL OCCULT BLOOD; AMERICAN-INDIANS; ALASKA-NATIVES; NATIONAL-SURVEY; TASK-FORCE; RECOMMENDATION; SURVEILLANCE; GUIDELINES; RATIONALE AB Background. Provider recommendation is critical for colorectal cancer (CRC) screening participation, yet few data exist on practices of providers serving American Indians and Alaska Natives. We examined Indian Health Service (IHS) and tribal provider practices, beliefs about screening efficacy, and perceptions of barriers. Methods. We developed a Web-based questionnaire and recruited respondents via electronic distribution lists. We generated descriptive statistics by region, provider type, and workplace setting. Results. Most respondents (77%) recommend starting CRC screening of average-risk patients at age 50; however, 22% recommend flexible sigmoidoscopy and 43% colonoscopy at intervals inconsistent with national guidelines. Of those recommending fecal occult blood test (FOBT), 23% use a single, in-office FOBT card as their only FOBT method. Respondents reported barriers to screening to include underutilized reminder systems and inadequate resources. Conclusions. Indian Health Service/tribal providers are knowledgeable about when to begin CRC screening; however, education about the appropriate use and frequency of CRC tests is needed. C1 [Haverkamp, Donald; Cobb, Nathaniel] Indian Hlth Serv, Div Epidemiol & Dis Prevent, Chron Dis Branch, Albuquerque, NM 87110 USA. [Haverkamp, Donald; Espey, David] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Perdue, David G.] Minnesota Gastroenterol PA, Minneapolis, MN USA. [Perdue, David G.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA. RP Haverkamp, D (reprint author), Indian Hlth Serv, Div Epidemiol & Dis Prevent, Chron Dis Branch, 5300 Homestead Rd NE, Albuquerque, NM 87110 USA. EM donald.haverkamp@ihs.gov NR 30 TC 7 Z9 7 U1 0 U2 1 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2011 VL 22 IS 1 BP 243 EP 257 PG 15 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 718ZK UT WOS:000287165100019 PM 21317519 ER PT J AU Laffoon, B Crutchfield, A Levi, M Bower, WA Kuehnert, M Brooks, JT Selik, RM Switzer, WM Heneine, W Shankar, A Iuliano, AD AF Laffoon, B. Crutchfield, A. Levi, M. Bower, W. A. Kuehnert, M. Brooks, J. T. Selik, R. M. Switzer, W. M. Heneine, W. Shankar, A. Iuliano, A. D. TI HIV Transmission Through Transfusion-Missouri and Colorado, 2008 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; SCREENED BLOOD; UNITED-STATES; NAT; PREVALENCE; DONOR; RISK C1 [Levi, M.] Univ Colorado, Denver, CO 80202 USA. [Brooks, J. T.; Selik, R. M.; Switzer, W. M.; Heneine, W.; Shankar, A.; Iuliano, A. D.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. NR 10 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD FEB PY 2011 VL 11 IS 2 BP 403 EP 406 DI 10.1111/j.1600-6143.2010.03428.x PG 4 WC Surgery; Transplantation SC Surgery; Transplantation GA 711XZ UT WOS:000286626700030 ER PT J AU McQuiston, JR Waters, RJ Dinsmore, BA Mikoleit, ML Fields, PI AF McQuiston, John R. Waters, R. Jordan Dinsmore, Blake A. Mikoleit, Matthew L. Fields, Patricia I. TI Molecular Determination of H Antigens of Salmonella by Use of a Microsphere-Based Liquid Array SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID MULTIPLEX PCR; FLAGELLAR ANTIGENS; COVALENT STRUCTURE; ENTERICA SEROVAR; GENETIC-ANALYSIS; PHASE VARIATION; TYPHI; ELECTROPHORESIS; RECOMBINATION; NOMENCLATURE AB Serotyping of Salmonella has been an invaluable subtyping method for epidemiologic studies for more than 70 years. The technical difficulties of serotyping, primarily in antiserum production and quality control, can be overcome with modern molecular methods. We developed a DNA-based assay targeting the genes encoding the flagellar antigens ( fliC and fljB) of the Kauffmann-White serotyping scheme. Fifteen H antigens ( H: a, -b, -c, -d, -d/j, -e, h, -i, -k, -r, -y, -z, -z(10), -z(29), -z(35), and -z(6)), 5 complex major antigens ( H: G, -EN, -Z4, -1, and -L) and 16 complex secondary antigens ( H: 2, -5, -6, -7, -f, -m/g, m, -m/m, t, -p, -s, -t/m, t, -v, -x, -z(15), -z(24), -z(28), and -z(51)) were targeted in the assay. DNA probes targeting these antigens were designed and evaluated on 500 isolates tested in parallel with traditional serotyping methods. The assay correctly identified 461 (92.2%) isolates based on the 36 antigens detected in the assay. Among the isolates considered correctly identified, 47 (9.4%) were partially serotyped because probes corresponding to some antigens in the strains were not in the assay, and 13 (2.6%) were monophasic or nonmotile strains that possessed flagellar antigen genes that were not expressed but were detected in the assay. The 39 (7.8%) strains that were not correctly identified possessed an antigen that should have been detected by the assay but was not. Apparent false-negative results may be attributed to allelic divergence. The molecular assay provided results that paralleled traditional methods with a much greater throughput, while maintaining the integrity of the Kauffmann-White serotyping scheme, thus providing backwards-compatible epidemiologic data. This assay should greatly enhance the ability of clinical and public health laboratories to serotype Salmonella. C1 [McQuiston, John R.] Ctr Dis Control & Prevent, Natl Salmonella Reference Lab, Div Foodborne Waterborne & Environm Dis, Enter Dis Lab Branch, Atlanta, GA 30333 USA. RP McQuiston, JR (reprint author), Ctr Dis Control & Prevent, Natl Salmonella Reference Lab, Div Foodborne Waterborne & Environm Dis, Enter Dis Lab Branch, MS-C03,1600 Clifton Rd, Atlanta, GA 30333 USA. EM zje8@cdc.gov OI Mikoleit, Matthew/0000-0002-4582-6733 NR 36 TC 27 Z9 29 U1 1 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2011 VL 49 IS 2 BP 565 EP 573 DI 10.1128/JCM.01323-10 PG 9 WC Microbiology SC Microbiology GA 716NE UT WOS:000286977500014 PM 21159932 ER PT J AU Cohen, AL Feikin, DR Levine, OS Whitney, CG AF Cohen, Adam L. Feikin, Daniel R. Levine, Orin S. Whitney, Cynthia G. TI Untitled Response SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Letter ID STREPTOCOCCUS-PNEUMONIAE; DISEASE; CHILDREN; VACCINE; TIME C1 [Cohen, Adam L.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Feikin, Daniel R.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Emerging Zoonoses & Infect Dis, Atlanta, GA USA. [Feikin, Daniel R.; Levine, Orin S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Int Vaccine Access Ctr, Baltimore, MD USA. RP Cohen, AL (reprint author), Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM dvjl@cdc.gov NR 9 TC 1 Z9 1 U1 0 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2011 VL 84 IS 2 BP 357 EP 358 DI 10.4269/ajtmh.2011.10-0584a PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 716WJ UT WOS:000287003900033 PM 21292914 ER PT J AU Browne, ML Hoyt, AT Feldkamp, ML Rasmussen, SA Marshall, EG Druschel, CM Romitti, PA AF Browne, Marilyn L. Hoyt, Adrienne T. Feldkamp, Marcia L. Rasmussen, Sonja A. Marshall, Elizabeth G. Druschel, Charlotte M. Romitti, Paul A. TI Maternal Caffeine Intake and Risk of Selected Birth Defects in the National Birth Defects Prevention Study SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE caffeine; coffee; tea; soft drinks; congenital abnormalities; birth defects ID NEURAL-TUBE DEFECTS; CONGENITAL-ABNORMALITIES; PREGNANCY; CONSUMPTION; EXPOSURE; COFFEE; GASTROSCHISIS; PATTERNS; NAUSEA AB BACKGROUND: Caffeine intake is common during pregnancy, yet few epidemiologic studies have examined the association between maternal caffeine consumption and birth defects. Using data from the National Birth Defects Prevention Study (NBDPS), we examined the association between maternal caffeine consumption and anotia/microtia, esophageal atresia, small intestinal atresia, craniosynostosis, diaphragmatic hernia, omphalocele, and gastroschisis. METHODS: The NBDPS is a multi-site population-based case-control study. The present analysis included 3,346 case infants and 6,642 control infants born from October 1997 through December 2005. Maternal telephone interview reports of demographic characteristics and conditions and exposures before and during pregnancy were collected. Odds ratios and 95% confidence intervals, adjusted for relevant covariates, were calculated to estimate the associations between maternal dietary caffeine intake (coffee, tea, soda, and chocolate) and maternal use of caffeine-containing medications and each defect. RESULTS: We observed small, statistically significant elevations in adjusted odds ratios ranging from 1.3 to 1.8 for total maternal dietary caffeine intake or specific types of caffeinated beverages and anotia/microtia, esophageal atresia, small intestinal atresia, and craniosynostosis; however, dose-response patterns were absent. Periconceptional use of caffeine-containing medications was infrequent and estimates were imprecise. CONCLUSIONS: We did not find convincing evidence of an association between maternal caffeine intake and the birth defects included in this study. The increasing popularity of caffeine-containing energy drinks and other caffeinated products may result in higher caffeine intake among women of childbearing age. Future studies should consider more detailed evaluation of such products. Birth Defects Research (Part A) 91:93-101, 2011. (C) 2011 Wiley-Liss, Inc. C1 [Browne, Marilyn L.; Hoyt, Adrienne T.; Druschel, Charlotte M.] New York State Dept Hlth, Congenital Malformat Registry, Troy, NY USA. [Feldkamp, Marcia L.] Univ Utah, Hlth Sci Ctr, Dept Pediat, Div Med Genet, Salt Lake City, UT USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Marshall, Elizabeth G.] UMDNJ Sch Publ Hlth, Dept Epidemiol, Piscataway, NJ USA. [Romitti, Paul A.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA. RP Browne, ML (reprint author), 547 River St,Room 200, Troy, NY 12180 USA. EM mlb10@health.state.ny.us RI Publications, NBDPS/B-7692-2013 FU Centers for Disease Control and Prevention, Centers of Excellence [U01/DD00048702] FX This study was supported by a cooperative agreement from the Centers for Disease Control and Prevention, Centers of Excellence Award No. U01/DD00048702. Coding of drug information in the NBDPS used the Slone Epidemiology Center Drug Dictionary, under license from the Slone Epidemiology Center at Boston University. We thank Sandra Richardson for additional replication of our statistical analyses. We would also like to thank all the scientists and staff of the National Birth Defects Prevention Study and the families who participated in the study. NR 29 TC 14 Z9 15 U1 3 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD FEB PY 2011 VL 91 IS 2 BP 93 EP 101 DI 10.1002/bdra.20752 PG 9 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 730LU UT WOS:000288035600004 PM 21254365 ER PT J AU Carter, TC Olney, RS Mitchell, AA Romitti, PA Bell, EM Druschel, CM AF Carter, Tonia C. Olney, Richard S. Mitchell, Allen A. Romitti, Paul A. Bell, Erin M. Druschel, Charlotte M. CA Natl Birth Defects Prevention Stud TI Maternal Self-Reported Genital Tract Infections During Pregnancy and the Risk of Selected Birth Defects SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article; Proceedings Paper CT 50th Annual Meeting of the Teratology-Society CY JUN 26-30, 2010 CL Louisville, KY SP Teratol Soc DE Chlamydia; congenital abnormalities; female genital diseases; gonorrhea; herpes genitalis ID HERPES-SIMPLEX-VIRUS; CHLAMYDIA-TRACHOMATIS INFECTION; PELVIC-INFLAMMATORY-DISEASE; NEURAL-TUBE DEFECTS; CONGENITAL-ABNORMALITIES; BACTERIAL VAGINOSIS; PRETERM DELIVERY; HUMAN-PAPILLOMAVIRUS; NO ASSOCIATION; WOMEN AB BACKGROUND: Genital tract infections are common during pregnancy and can result in adverse outcomes including preterm birth and neonatal infection. This hypothesis-generating study examined whether these infections are associated with selected birth defects. METHODS: We conducted a case-control study of 5913 children identified as controls and 12,158 cases with birth defects from the National Birth Defects Prevention Study (1997-2004). Maternal interviews provided data on genital tract infections that occurred from one month before pregnancy through the end of the first trimester. Infections were either grouped together as a single overall exposure or were considered as a subgroup that included chlamydia/gonorrhea/pelvic inflammatory disease. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using unconditional logistic regression with adjustment for potential confounders. RESULTS: Genital tract infections were associated with bilateral renal agenesis/hypoplasia (OR, 2.89; 95% CI, 1.11-7.50), cleft lip with or without cleft palate (OR, 1.46; 95% CI, 1.03-2.06), and transverse limb deficiency (OR, 1.84; 95% CI, 1.04-3.26). Chlamydia/gonorrhea/pelvic inflammatory disease was associated with cleft lip only (OR, 2.81; 95% CI, 1.39-5.69). These findings were not statistically significant after adjustment for multiple comparisons. CONCLUSIONS: Caution is needed in interpreting these findings due to the possible misclassification of infection, the limited sample size that constrained consideration of the effects of treatment, and the possibility of chance associations. Although these data do not provide strong evidence for an association between genital tract infections and birth defects, additional research on the possible effects of these relatively common infections is needed. Birth Defects Research (Part A) 91:108-116, 2011. (C) 2010 Wiley-Liss, Inc. C1 [Carter, Tonia C.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, Natl Inst Hlth, Dept Hlth & Human Serv, Bethesda, MD USA. [Olney, Richard S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Mitchell, Allen A.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Romitti, Paul A.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. [Bell, Erin M.; Druschel, Charlotte M.] SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, Albany, NY USA. [Druschel, Charlotte M.] New York State Dept Hlth, Congenital Malformat Registry, Troy, NY USA. RP Carter, TC (reprint author), 6100 Execut Blvd,Room 7B03, Bethesda, MD 20892 USA. EM carterto@mail.nih.gov RI Publications, NBDPS/B-7692-2013; OI Mitchell, Allen/0000-0003-0950-6799 FU Intramural NIH HHS; NCBDD CDC HHS [U01 DD000492]; PHS HHS [U50/CCU223184] NR 53 TC 7 Z9 9 U1 0 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD FEB PY 2011 VL 91 IS 2 BP 108 EP 116 DI 10.1002/bdra.20749 PG 9 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 730LU UT WOS:000288035600006 PM 21319278 ER PT J AU den Baumen, TSI Khoury, MJ AF den Baumen, Tobias Schulte In Khoury, Muin J. TI Genome-based knowledge and public health: the vision of tomorrow and the challenge of today SO EUROPEAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material ID CANCER GENOME C1 [den Baumen, Tobias Schulte In] Maastricht Univ, IPHG, Sch Publ Hlth & Primary Care CAPHRI, Maastricht, Netherlands. [Khoury, Muin J.] CDC, Off Publ Hlth Genom, Atlanta, GA 30333 USA. RP den Baumen, TSI (reprint author), Maastricht Univ, IPHG, Sch Publ Hlth & Primary Care CAPHRI, Maastricht, Netherlands. EM t.sidb@maastrichtuniversity.nl NR 5 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1101-1262 J9 EUR J PUBLIC HEALTH JI Eur. J. Public Health PD FEB PY 2011 VL 21 IS 1 BP 4 EP 5 DI 10.1093/eurpub/ckq201 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 709TA UT WOS:000286463100003 ER PT J AU Meeker, D Joyce, GF Malkin, J Teutsch, SM Haddix, AC Goldman, DP AF Meeker, Daniella Joyce, Geoffrey F. Malkin, Jesse Teutsch, Steven M. Haddix, Anne C. Goldman, Dana P. TI Coverage and Preventive Screening SO HEALTH SERVICES RESEARCH LA English DT Article DE Health care financing; insurance; premiums; evaluation design research; health care costs ID HEALTH-INSURANCE COVERAGE; CONTROLLED-TRIAL; OFFICE VISIT; CANCER; MAMMOGRAPHY; CARE; SERVICES; PLANS AB Context Preventive care has been shown as a high-value health care service. Many employers now offer expanded coverage of preventive care to encourage utilization. Objective To determine whether expanding coverage is an effective means to encourage utilization. Design Comparison of screening rates before and after introduction of deductible-free coverage. Setting People insured through large corporations between 2002 and 2006. Patients or Other Participants Preferred Provider Organization (PPO) enrollees from an employer introducing deductible-free coverage, and a control group enrolled in a PPO from a second employer with no policy change. Main Outcome Measures Adjusted probability of endoscopy, fecal occult blood test (FOBT), lipid screens, mammography, and Papanicolaou (pap) smears. Intervention Introduction of first-dollar coverage (FDC) of preventive services in 2003. Results After adjusting for demographics and secular trends, there were between 23 and 78 additional uses per 1,000 eligible patients of covered preventive screens (lipid screens, pap smears, mammograms, and FOBT), with no significant changes in the control group or in a service without FDC (endoscopy). Conclusions FDC improves utilization modestly among healthy individuals, particularly those in lower deductible plans. Compliance with guidelines can be encouraged by lowering out-of-pocket costs, but patients' predisposing characteristics merit attention. C1 [Meeker, Daniella; Joyce, Geoffrey F.; Malkin, Jesse; Goldman, Dana P.] RAND Corp, Santa Monica, CA 90407 USA. [Joyce, Geoffrey F.] Univ So Calif, Sch Pharm, Los Angeles, CA USA. [Teutsch, Steven M.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Haddix, Anne C.] Ctr Dis Control & Prevent, Off Associate Director Policy, Atlanta, GA USA. [Goldman, Dana P.] Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA USA. RP Meeker, D (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90407 USA. EM dmeeker@rand.org OI Meeker, Daniella/0000-0002-1034-7628 FU National Institute on Aging [NIA-R01AG029514]; Centers for Disease Control and Prevention [CDC-200-2004-07601-0008]; Bing Center for Health Economics; Merck Co., Inc. [MERCK-08.23.07] FX This research was sponsored by the National Institute on Aging (NIA-R01AG029514: Improving Pharmacy Benefit Design), the Centers for Disease Control and Prevention (CDC-200-2004-07601-0008: High-Deductible Health Plans and Use of Preventive Services), the Bing Center for Health Economics, and Merck & Co., Inc. (MERCK-08.23.07: The Impact of High-Deductible Health Plans on Use of Preventive Services and Prescription Drugs). We thank Mark Totten (RAND) for programming assistance, and Faruque Ahmed (CDC) and Jim Murray (Merck) for helpful discussions. NR 20 TC 11 Z9 11 U1 1 U2 5 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0017-9124 J9 HEALTH SERV RES JI Health Serv. Res. PD FEB PY 2011 VL 46 IS 1 BP 173 EP 184 DI 10.1111/j.1475-6773.2010.01188.x PN 1 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 701OZ UT WOS:000285831600010 PM 21029084 ER PT J AU Alwan, S Reefhuis, J Rasmussen, SA Friedman, JM AF Alwan, Sura Reefhuis, Jennita Rasmussen, Sonja A. Friedman, Jan M. CA Natl Birth Defects Prevention Stud TI Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population SO JOURNAL OF CLINICAL PHARMACOLOGY LA English DT Article DE Antidepressants; selective serotonin-reuptake inhibitors; pregnancy ID SEROTONIN-REUPTAKE INHIBITORS; PERSISTENT PULMONARY-HYPERTENSION; CONGENITAL-MALFORMATIONS; MATERNAL DEPRESSION; BIRTH-DEFECTS; NEONATAL OUTCOMES; PRENATAL EXPOSURE; GESTATIONAL-AGE; HEALTH DATA; RISK AB This article describes the pattern of reported antidepressant use around the time of pregnancy in a population-based sample of women who delivered live-born babies without birth defects. Data were used from the National Birth Defects Prevention Study, an ongoing case-control study of risk factors for birth defects covering 10 US states. Mothers of live-born infants without birth defects (controls) born between 1998 and 2005 were randomly selected from each site. Information on the mother's characteristics and exposure to antidepressants was collected via a standardized telephone interview. Among 6582 mothers included in the study, 298 (4.5%) reported use of an antidepressant in the period of 3 months before through the end of pregnancy. Use of selective serotonin-reuptake inhibitors was reported most often (3.8%), followed by bupropion (0.7%). A statistically significant decline was observed, from 3.1% to 2.3% (P < .001), in reported use of antidepressants between the first and second month after conception. The frequency of reported antidepressant use at any time during pregnancy increased from 2.5% in 1998 to 8.1% in 2005 (P < .001) in 4 states. The findings show an increase in reported antidepressant use over a 9-year period and a substantial decrease in use around the usual time of pregnancy recognition. C1 [Reefhuis, Jennita; Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Alwan, Sura; Friedman, Jan M.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. [Alwan, Sura; Friedman, Jan M.] Child & Family Res Inst, Vancouver, BC, Canada. RP Reefhuis, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM JReefhuis@cdc.gov RI Reefhuis, Jennita/E-1793-2011; Publications, NBDPS/B-7692-2013; OI Reefhuis, Jennita/0000-0002-4747-4831; Friedman, Jan/0000-0002-7482-9570 FU US Centers for Disease Control and Prevention FX The NBDPS is funded by the US Centers for Disease Control and Prevention. NR 46 TC 68 Z9 69 U1 0 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0091-2700 J9 J CLIN PHARMACOL JI J. Clin. Pharmacol. PD FEB PY 2011 VL 51 IS 2 BP 264 EP 270 DI 10.1177/0091270010373928 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 710XZ UT WOS:000286551600015 PM 20663997 ER PT J AU Gould, LH Jordan, JG Dunn, J Apostol, M Griffin, PM AF Gould, L. Hannah Jordan, John G. Dunn, John Apostol, Mirasol Griffin, Patricia M. CA Emerging Infect Program FoodNet Wo TI POSTDIARRHEAL HEMOLYTIC UREMIC SYNDROME IN PERSONS AGED 65 AND OLDER IN FOODNET SITES, 2000-2006 SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Letter ID INFECTIONS C1 [Gould, L. Hannah; Griffin, Patricia M.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA 30333 USA. [Jordan, John G.] Univ S Carolina, Dept Family & Prevent Med, Columbia, SC 29208 USA. [Dunn, John] Tennessee Dept Hlth, Nashville, TN USA. [Apostol, Mirasol] Calif Emerging Infect Program, Richmond, CA USA. RP Gould, LH (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA 30333 USA. NR 9 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2011 VL 59 IS 2 BP 366 EP 368 DI 10.1111/j.1532-5415.2011.03269.x PG 3 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 719VX UT WOS:000287240700026 PM 21314655 ER PT J AU Caixeta, A Stone, GW Mehran, R Lee, EA McLaurin, BT Cox, DA Bertrand, ME Lincoff, AM Moses, JW White, HD Ohman, EM Palmerini, T Syros, G Kittas, C Fahy, M Hooper, WC Lansky, AJ Dangas, GD AF Caixeta, Adriano Stone, Gregg W. Mehran, Roxana Lee, Edwin A. McLaurin, Brent T. Cox, David A. Bertrand, Michel E. Lincoff, A. Michael Moses, Jeffrey W. White, Harvey D. Ohman, E. Magnus Palmerini, Tullio Syros, George Kittas, Christos Fahy, Martin Hooper, W. Craig Lansky, Alexandra J. Dangas, George D. TI Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Article DE C-reactive protein; Acute coronary syndrome; Invasive strategy; Long-term mortality ID ACUTE MYOCARDIAL-INFARCTION; LONG-TERM MORTALITY; UNSTABLE ANGINA; PROGNOSTIC VALUE; CARDIOVASCULAR-DISEASE; ARTERY-DISEASE; TROPONIN-T; INFLAMMATION; RISK; OUTCOMES AB We sought to evaluate the association between C-reactive protein (CRP) sampled on admission and short- and long-term mortality in patients with acute coronary syndromes (ACS) undergoing early invasive treatment. Baseline levels of CRP were determined in 2,974 patients with moderate and high-risk ACS undergoing an early invasive treatment strategy in the large-scale randomized ACUITY trial. The relationship of CRP to 30-day and 1-year clinical outcomes were assessed according to quartiles of CRP values. Patients with CRP levels in the fourth quartile compared to the first quartile had significantly higher 30-day mortality (2.3 vs. 0.3%, P = 0.0004) and 1-year mortality (5.5 vs. 2.8%, P = 0.0003). CRP level as a continuous variable was associated with 30-day mortality (OR [95% CI] for one unit increase in logarithmically transformed CRP level = 1.42 [1.08-1.89], P = 0.01) and 1-year mortality (OR [95% CI] = 1.24, [1.04-1.47], P = 0.02). By multivariable analysis, higher baseline CRP levels independently predicted 30-day and 1-year mortality, a relationship that was particularly strong for patients with the highest quartile of CRP (OR [95% CI] = 5.19 [1.14-23.68], P = 0.009). In troponin-positive patients, increasing quartiles of CRP were associated with a trend for 30-day mortality (P (trend) = 0.08) and a significant increase in 1-year mortality (P (trend) = 0.02); this relationship was not present in troponin-negative patients. Baseline CRP level is a powerful independent predictor of both early and late mortality in patients with ACS being treated with an early invasive strategy, especially in troponin positive patients. C1 [Mehran, Roxana; Dangas, George D.] Mt Sinai Med Ctr, Cardiovasc Res Fdn, Cardiovasc Inst, New York, NY 10029 USA. [Caixeta, Adriano; Stone, Gregg W.; Lee, Edwin A.; Moses, Jeffrey W.; Fahy, Martin] Columbia Univ, Med Ctr, New York, NY USA. [Caixeta, Adriano; Stone, Gregg W.; Lee, Edwin A.; Moses, Jeffrey W.; Fahy, Martin] Cardiovasc Res Fdn, New York, NY USA. [McLaurin, Brent T.] AnMed Hlth, Anderson, SC USA. [Cox, David A.] Mid Carolina Cardiol, Charlotte, NC USA. [Bertrand, Michel E.] Hop Cardiol, F-59037 Lille, France. [Lincoff, A. Michael] Cleveland Clin, Cleveland, OH 44106 USA. [White, Harvey D.] Auckland City Hosp, Auckland, New Zealand. [Ohman, E. Magnus] Duke Univ, Med Ctr, Durham, NC USA. [Palmerini, Tullio] Univ Bologna, Bologna, Italy. [Syros, George] St Elizabeth Hosp, Boston, MA USA. [Kittas, Christos] Univ Athens, Athens, Greece. [Lansky, Alexandra J.] Yale Univ, Med Ctr, New Haven, CT USA. [Hooper, W. Craig] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. RP Dangas, GD (reprint author), Mt Sinai Med Ctr, Cardiovasc Res Fdn, Cardiovasc Inst, Box 1030,1 Gustave L Levy Pl, New York, NY 10029 USA. EM george.dangas@mssm.edu RI Caixeta, Adriano/K-7977-2013; OI Caixeta, Adriano/0000-0002-6287-5414 FU The Medicines Co (Parsippany, NJ); Nycomed (Roskilde, Denmark); The Medicines Co; Boston Scientific; Abbott Vascular; Eli Lilly; Astra Zeneca; Cordis; Medtronic; Abbott; Schering-Plough; Eli Lilly Co; Merck Sharpe and Dohme; National Institutes of Health; Pfizer; Roche; Johnson Johnson; AstraZeneca; Liposcience; Inovise Medical; Response Biomedical; Datascope; Abiomed; Bristol-Myers Squibb; Sanofi-Aventis; Millennium Pharmaceuticals; Daiichi Sankyo FX The ACUITY trial was sponsored and funded by The Medicines Co (Parsippany, NJ) and Nycomed (Roskilde, Denmark).; Dr. Stone has received research support from The Medicines Co, Boston Scientific, and Abbott Vascular and honoraria from Eli Lilly. Dr. Mehran and Dr. Dangas have received consulting fees from Eli Lilly and Astra Zeneca and speaker honoraria from Sanofi Aventis, Cordis, Boston Scientific, and The Medicines Co. Dr. Lansky has received research grants from The Medicines Co, Cordis, Boston Scientific, Medtronic, and Abbott. Dr. Moses has received consulting fees from Cordis and is on the speakers' bureau for AstraZeneca. Dr White has received grant support from The Medicines Co, Sanofi-Aventis, Schering-Plough, Eli Lilly Co, Merck Sharpe and Dohme, National Institutes of Health, Pfizer, Roche, Johnson & Johnson, and AstraZeneca. Dr. Ohman has received consulting fees from The Medicines Co, Liposcience, Inovise Medical, Response Biomedical, Datascope, and Abiomed; equity interests in Medtronic and Savacor; lecture fees from Schering-Plough, Bristol-Myers Squibb, and Datascope; and grant support from The Medicines Co, Schering-Plough, Bristol-Myers Squibb, Sanofi-Aventis, Millennium Pharmaceuticals, Eli Lilly, and Daiichi Sankyo. Dr Ohman is on the speakers' bureau for CV Therapeutics and The Medicines Co. The other authors report no conflicts. NR 25 TC 10 Z9 12 U1 0 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD FEB PY 2011 VL 31 IS 2 BP 154 EP 164 DI 10.1007/s11239-010-0516-y PG 11 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 709UR UT WOS:000286467400004 PM 20953817 ER PT J AU Zhang, LQ Ashley, DL Watson, CH AF Zhang, Liqin Ashley, David L. Watson, Clifford H. TI Quantitative Analysis of Six Heterocyclic Aromatic Amines in Mainstream Cigarette Smoke Condensate Using Isotope Dilution Liquid Chromatography-Electrospray Ionization Tandem Mass Spectrometry SO NICOTINE & TOBACCO RESEARCH LA English DT Article ID ALPHA-CARBOLINES; PYROLYSIS PRODUCTS; BETA-CARBOLINES; MUTAGENS; NORHARMAN; MUTAGENS/CARCINOGENS; CARCINOGEN; HARMAN; FOODS AB Heterocyclic aromatic amines (HAAs) represent an important class of carcinogens in mainstream cigarette smoke. Accurate HAA quantification is challenging because of their relative low abundances and numerous chemical interferences that arise naturally from thousands of the constituents present in cigarette smoke. We have developed and validated a straightforward high-throughput method to quantify HAA levels in mainstream cigarette smoke and demonstrated the applicability by analyzing select research and domestic cigarette brands. Machine-smoked cigarette condensate collected under both standard and intensive smoking regimens was examined. Mainstream smoke particulate from individual cigarettes trapped on a glass fiber filter pad was spiked with an appropriate internal standard solution and subsequently solvent extracted. The extract was quantitatively analyzed by high-performance liquid chromatography and tandem mass spectrometry. Method validation data showed excellent accuracy, reproducibility and high throughput; it is suitable for the routine analysis of HAAs in cigarette smoke condensate delivered under a wide of differing smoking conditions. The smoking machine deliveries of HAAs are strongly influenced by cigarettes' physical design, filler blend, and smoking regimen. A quick and accurate method has been developed for the analysis of 6 HAAs in mainstream cigarette smoke condensate. Results provided a good mean to access the ranges of HAAs in commercial products and evaluate the relative contribution of cigarette design, filler blend, and smoking regimen on delivery. Such data are vital in helping provide exposure ranges for potential human exposure estimates. C1 [Zhang, Liqin; Ashley, David L.; Watson, Clifford H.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Emergency Response & Air Toxicants Branch, Atlanta, GA 30341 USA. RP Watson, CH (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Emergency Response & Air Toxicants Branch, 4770 Buford Highway NE,Mailstop F-47, Atlanta, GA 30341 USA. EM cwatson@cdc.gov FU National Center for Chronic Disease Prevention and Health Promotion; Office of Smoking and Health of the Centers for Disease Control and Prevention FX This project was financial supported by the National Center for Chronic Disease Prevention and Health Promotion and the Office of Smoking and Health of the Centers for Disease Control and Prevention. NR 22 TC 20 Z9 22 U1 0 U2 7 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD FEB PY 2011 VL 13 IS 2 BP 120 EP 126 DI 10.1093/ntr/ntq219 PG 7 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA 712ME UT WOS:000286670100009 PM 21173043 ER PT J AU Wright, MO Hebden, JN Allen-Bridson, K Morrell, GC Horan, T AF Wright, Marc-Oliver Hebden, Joan N. Allen-Bridson, Kathy Morrell, Gloria C. Horan, Teresa TI Health care-associated infections studies project: Case 4 SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article C1 [Wright, Marc-Oliver] N Shore Univ Hlth Syst, Dept Infect Control, Evanston, IL 60201 USA. [Hebden, Joan N.] Univ Maryland, Med Ctr, Dept Infect Control, Baltimore, MD 21201 USA. [Allen-Bridson, Kathy; Morrell, Gloria C.; Horan, Teresa] Ctr Dis Control & Prevent, Natl Healthcare Safety Network, Div Healthcare Qual Promot, Atlanta, GA USA. RP Wright, MO (reprint author), N Shore Univ Hlth Syst, Dept Infect Control, 2650 Ridge Ave,Burch 124, Evanston, IL 60201 USA. EM MWright@northshore.org NR 0 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB PY 2011 VL 39 IS 1 BP 64 EP 65 DI 10.1016/j.ajic.2010.12.001 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 714JP UT WOS:000286806200011 ER PT J AU Moro, PL Broder, K Zheteyeva, Y Walton, K Rohan, P Sutherland, A Guh, A Haber, P DeStefano, F Vellozzi, C AF Moro, Pedro L. Broder, Karen Zheteyeva, Yenlik Walton, Kimp Rohan, Patricia Sutherland, Andrea Guh, Alice Haber, Penina DeStefano, Frank Vellozzi, Claudia TI Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE pregnancy; seasonal influenza vaccine; surveillance; vaccine safety ID BELLS-PALSY; PANDEMIC INFLUENZA; SAFETY; IMMUNIZATION; GUIDELINES; HEALTH; IMPACT; RATES AB OBJECTIVE: The objective of the study was to characterize reports to the Vaccine Adverse Event Reporting System (VAERS) in pregnant women who received seasonal influenza vaccines to assess for potential vaccine safety concerns. STUDY DESIGN: We searched VAERS for reports of adverse events (AEs) in pregnant women who received trivalent inactivated influenza vaccine (TIV) from July 1, 1990 through June 30, 2009, or live attenuated influenza vaccine (LAIV) from July 1, 2003, through June 30, 2009. RESULTS: A total of 148 reports after TIV and 27 reports after LAIV were identified. Twenty TIV (13.5%) and 1 LAIV (4%) reports were classified as serious. No specific AEs were reported in 30 TIV (20.3%) and 16 LAIV (59%) reports. The most common pregnancy-specific AE was spontaneous abortion: 17 after TIV (11.5%) and 3 after LAIV (11%). The reporting rate of spontaneous abortion was 1.9 per million pregnant women vaccinated. CONCLUSION: No unusual patterns of pregnancy complications or fetal outcomes were observed in the VAERS reports of pregnant women after the administration of TIV or LAIV. C1 [Moro, Pedro L.; Broder, Karen; Zheteyeva, Yenlik; Walton, Kimp; Guh, Alice; Haber, Penina; DeStefano, Frank; Vellozzi, Claudia] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Rohan, Patricia; Sutherland, Andrea] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Silver Spring, MD USA. RP Moro, PL (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS D26, Atlanta, GA 30333 USA. NR 30 TC 29 Z9 30 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD FEB PY 2011 VL 204 IS 2 AR 146.e1 DI 10.1016/j.ajog.2010.08.050 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 715HV UT WOS:000286874900022 PM 20965490 ER PT J AU Warren, CW Sinha, DN Lee, J Lea, V Jones, NR AF Warren, Charles W. Sinha, Dhirendra N. Lee, Juliette Lea, Veronica Jones, Nathan R. TI Tobacco use, exposure to secondhand smoke, and cessation counseling among medical students: cross-country data from the Global Health Professions Student Survey (GHPSS), 2005-2008 SO BMC PUBLIC HEALTH LA English DT Article ID INTERVENTION AB Background: GHPSS is a school-based survey that collects self-administered data from students in regular classroom settings. GHPSS produces representative data at the national or city level in each country. This study aims to investigate the prevalence of tobacco use, exposure to secondhand smoke, and cessation counseling among medical students using the GHPSS data. Methods: The Global Health Professions Student Survey (GHPSS) was conducted among 3(rd) year medical students in 47 countries and the Gaza Strip/West Bank from 2005-2008 to determine the prevalence of tobacco use and amount of formal training in cessation counseling. Results: In 26 of the 48 sites, over 20% of the students currently smoked cigarettes, with males having higher rates than females in 37 sites. Over 70% of students reported having been exposed to secondhand smoke in public places in 29 of 48 sites. The majority of students recognized that they are role models in society (over 80% in 42 of 48 sites), believed they should receive training on counseling patients to quit using tobacco (over 80% in 41 of 48 sites), but few reported receiving formal training (less than 40% in 46 of 48 sites). Conclusion: Tobacco control efforts must discourage tobacco use among health professionals, promote smoke free workplaces, and implement programs that train medical students in effective cessation-counseling techniques. C1 [Warren, Charles W.; Lee, Juliette; Lea, Veronica] US Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. [Sinha, Dhirendra N.] WHO, Tobacco Free Initiat, SE Asia Reg, Delhi, India. [Jones, Nathan R.] Univ Wisconsin, Paul P Carbone Comprehens Canc Ctr, Madison, WI USA. RP Warren, CW (reprint author), US Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA USA. EM wcw1@cdc.gov NR 24 TC 26 Z9 27 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD FEB 1 PY 2011 VL 11 AR 72 DI 10.1186/1471-2458-11-72 PG 16 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 723UW UT WOS:000287533800001 PM 21284864 ER PT J AU Yong, LC Petersen, MR AF Yong, Lee C. Petersen, Martin R. TI High dietary niacin intake is associated with decreased chromosome translocation frequency in airline pilots SO BRITISH JOURNAL OF NUTRITION LA English DT Article DE Niacin; Vitamin B; Chromosome translocations; Airline pilots; Radiation exposure ID FOLATE-DEFICIENCY; IONIZING-RADIATION; HUMAN-LYMPHOCYTES; GENETIC-DAMAGE; FREE-RADICALS; DNA; HEALTH; NICOTINAMIDE; VALIDITY; CANCER AB Experimental studies suggest that B vitamins such as niacin, folate, riboflavin, vitamin B(6) and vitamin B(12) may protect against DNA damage induced by ionising radiation (IR). However, to date, data from IR-exposed human populations are not available. We examined the intakes of these B vitamins and their food sources in relation to the frequency of chromosome translocations as a biomarker of cumulative DNA damage, in eighty-two male airline pilots. Dietary intakes were estimated by using a self-administered semi-quantitative FFQ. Translocations in peripheral blood lymphocytes were scored by using fluorescence in situ hybridisation whole-chromosome painting. Negative binomial regression was used to estimate rate ratios and 95% CI, adjusted for age and occupational and lifestyle factors. We observed a significant inverse association between translocation frequency and dietary intake of niacin (P=0.02): adjusted rate ratio for subjects in the highest tertile compared with the lowest tertile was 0.58 (95% CI 0.40, 0.83). Translocation frequency was not associated with total niacin intake from food and supplements as well as dietary or total intake of folate, riboflavin or vitamin B(6) or B(12). However, the adjusted rate ratios were significant for subjects with >= median compared with, median intake of whole grains (P=0.03) and red and processed meat (P=0.01): 0.69 (95% CI 0.50, 0.96) and 1.56 (95% CI 1.13, 2.16), respectively. Our data suggest that a high intake of niacin from food or a diet high in whole grains but low in red and processed meat may protect against cumulative DNA damage in IR-exposed persons. C1 [Yong, Lee C.; Petersen, Martin R.] NIOSH, CDC, Cincinnati, OH 45226 USA. [Yong, Lee C.] NIOSH, Industrywide Studies Branch, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. RP Yong, LC (reprint author), NIOSH, CDC, Cincinnati, OH 45226 USA. EM lay7@cdc.gov FU National Institute for Occupational Safety and Health; National Cancer Institute [Y1CP802904]; Division of Cancer Epidemiology and Genetics, National Cancer Institute FX We thank the airline pilots, whose participation made the present study possible; the staff of Battelle Centers for Public Health Research and Evaluation (particularly Louise Glezen, Katrina Spencer and James Kerrigan) for data collection; Lian Luo (SRA International Inc) for assistance with data programming; Laura A. Sampson (Harvard School of Public Health) for assistance with dietary assessment; and Teresa T. Fung (Simmons College) for consultation on the categorisation of the FFQ food items. The authors' responsibilities were as follows: L. C. Y. developed the study concept and design as well as the statistical analysis plan, performed the analysis, wrote the first draft of the manuscript and obtained funding; and M. R. P. provided the statistical expertise and advice. All the authors contributed to the interpretation of data and writing and approval of the final manuscript. None of the authors had a conflict of interest to declare. The present research was supported in part by an interagency agreement between the National Institute for Occupational Safety and Health and the National Cancer Institute (contract Y1CP802904) and by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 40 TC 1 Z9 2 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0007-1145 J9 BRIT J NUTR JI Br. J. Nutr. PD FEB PY 2011 VL 105 IS 4 BP 496 EP 505 DI 10.1017/S000711451000379X PG 10 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 724VY UT WOS:000287605500002 PM 20932352 ER PT J AU Rouphael, NG Satola, S Farley, MM Rudolph, K Schmidt, DS Gomez-de-Leon, P Robbins, JB Schneerson, R Carlone, GM Romero-Steiner, S AF Rouphael, Nadine G. Satola, Sarah Farley, Monica M. Rudolph, Karen Schmidt, Daniel S. Gomez-de-Leon, Patricia Robbins, John B. Schneerson, Rachel Carlone, George M. Romero-Steiner, Sandra TI Evaluation of Serum Bactericidal Antibody Assays for Haemophilus influenzae Serotype a SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID CAPSULAR POLYSACCHARIDE; INVASIVE INFECTIONS; A DISEASE; VIRULENCE; EPIDEMIOLOGY; CHILDREN; VACCINE AB Haemophilus influenzae type a (Hia) is an important pathogen for some American Indian, Alaskan native, and Northern Canada aboriginal populations. Assays to measure serum bactericidal activity (SBA) to Hia have not been developed or validated. Here, we describe two methods for the measurement of SBA: SBA with a viability endpoint (CFU counts) and SBA with a fluorometric endpoint using alamarBlue as the metabolic indicator. Both SBA assays measure Hia-specific functional antibody and correlate with anti-Hia IgG enzyme-linked immunosorbent assay (ELISA) concentration of naturally acquired antibodies. C1 [Romero-Steiner, Sandra] Ctr Dis Control & Prevent, Vaccinol Lab, Div Bacterial Dis, Atlanta, GA 30333 USA. [Rouphael, Nadine G.; Satola, Sarah; Farley, Monica M.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30303 USA. [Rudolph, Karen] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK 99508 USA. [Satola, Sarah; Farley, Monica M.] Atlanta Vet Affairs Med Ctr, Decatur, GA 30033 USA. [Gomez-de-Leon, Patricia] Univ Nacl Autonoma Mexico, Fac Med, Dept Salud Publ, Mexico City 04510, DF, Mexico. [Robbins, John B.; Schneerson, Rachel] NICHHD, NIH, Bethesda, MD 20892 USA. RP Romero-Steiner, S (reprint author), Ctr Dis Control & Prevent, Vaccinol Lab, Div Bacterial Dis, Bldg 18,Room B-105,Mailstop A-36,CDC,1600 Clifton, Atlanta, GA 30333 USA. EM SSteiner@cdc.gov OI Romero-Steiner, Sandra/0000-0003-4128-7768 NR 19 TC 5 Z9 5 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD FEB PY 2011 VL 18 IS 2 BP 243 EP 247 DI 10.1128/CVI.00219-10 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 712GJ UT WOS:000286653900008 PM 21177919 ER PT J AU Spencer, JS Kim, HJ Wheat, WH Chatterjee, D Balagon, MV Cellona, RV Tan, EV Gelber, R Saunderson, P Duthie, MS Reece, ST Burman, W Belknap, R Mac Kenzie, WR Geluk, A Oskam, L Dockrell, HM Brennan, PJ AF Spencer, John S. Kim, Hee Jin Wheat, William H. Chatterjee, Delphi Balagon, Marivic V. Cellona, Roland V. Tan, Esterlina V. Gelber, Robert Saunderson, Paul Duthie, Malcolm S. Reece, Stephen T. Burman, William Belknap, Robert Mac Kenzie, William R. Geluk, Annemieke Oskam, Linda Dockrell, Hazel M. Brennan, Patrick J. CA IDEAL Consortium TI Analysis of Antibody Responses to Mycobacterium leprae Phenolic Glycolipid I, Lipoarabinomannan, and Recombinant Proteins To Define Disease Subtype-Specific Antigenic Profiles in Leprosy SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID TUBERCULOSIS INFECTION; POSTGENOMIC APPROACH; CELL; IDENTIFICATION; DIAGNOSIS; SERODIAGNOSIS; PEPTIDES; BACILLUS; ASSAY AB A simple serodiagnostic test based on the Mycobacterium leprae-specific phenolic glycolipid I(PGL-I), for individuals with leprosy is nearly universally positive in leprosy patients with high bacillary loads but cannot be used as a stand-alone diagnostic test for the entire spectrum of the disease process. For patients with early infection with no detectable acid-fast bacilli in lesions or with low or no antibody titer to PGL-I, as in those at the tuberculoid end of the disease spectrum, this diagnostic approach has limited usefulness. To identify additional M. leprae antigens that might enhance the serological detection of these individuals, we have examined the reactivity patterns of patient sera to PGL-I, lipoarabinomannan (LAM), and six recombinant M. leprae proteins (ML1877, ML0841, ML2028, ML2038, ML0380, and ML0050) by Western blot analysis and enzyme-linked immunosorbent assay (ELISA). Overall, the responses to ML2028 (Ag85B) and ML2038 (bacterioferritin) were consistently high in both multibacillary and paucibacillary groups and weak or absent in endemic controls, while responses to other antigens showed considerable variability, from strongly positive to completely negative. This analysis has given a clearer understanding of some of the differences in the antibody responses between individuals at opposite ends of the disease spectrum, as well as illustrating the heterogeneity of antibody responses toward protein, carbohydrate, and glycolipid antigens within a clinical group. Correlating these response patterns with a particular disease state could allow for a more critical assessment of the form of disease within the leprosy spectrum and could lead to better patient management. C1 [Spencer, John S.; Kim, Hee Jin; Wheat, William H.; Chatterjee, Delphi; Brennan, Patrick J.] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Balagon, Marivic V.; Cellona, Roland V.; Tan, Esterlina V.; Gelber, Robert; Saunderson, Paul] Leonard Wood Mem Leprosy Res Ctr, Cebu, Philippines. [Duthie, Malcolm S.; Reece, Stephen T.] Infect Dis Res Inst, Seattle, WA USA. [Burman, William; Belknap, Robert] Denver Hlth, Denver, CO USA. [Mac Kenzie, William R.] Ctr Dis Control, Atlanta, GA 30333 USA. [Geluk, Annemieke] Leiden Univ, Med Ctr, Dept Infect Dis, Leiden, Netherlands. [Oskam, Linda] KIT Biomed Res, Amsterdam, Netherlands. [Dockrell, Hazel M.] London Sch Hyg & Trop Med, Dept Immunol & Infect, London WC1, England. RP Spencer, JS (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Campus Delivery 1682, Ft Collins, CO 80523 USA. EM John.Spencer@colostate.edu RI Mac Kenzie, William /F-1528-2013; Chiang, Vincent, Ming-Hsien/D-4312-2016; OI Mac Kenzie, William /0000-0001-7723-0339; Chiang, Vincent, Ming-Hsien/0000-0002-2029-7863; Dockrell, Hazel/0000-0003-1869-9107 FU NIH/NIAID [N01 AI-25469, R01 AI-47197]; Colorado State University; Order of Malta Grants for Leprosy Research; Netherlands Leprosy Relief [ILEP: 7.01.02.48]; Turing Foundation as part of the IDEAL; (Initiative for Diagnosis and Epidemiological Assays for Leprosy) Consortium.; Damien-Dutton Award FX This work was supported by NIH/NIAID contract N01 AI-25469 and NIH/NIAID grant R01 AI-47197, by a College Research Council grant from Colorado State University (to J.S.S.), by a grant from the Order of Malta Grants for Leprosy Research (MAGRALEPRE; to A. G. and J.S.S.), and by a grant from the Netherlands Leprosy Relief (ILEP: 7.01.02.48) and the Turing Foundation as part of the IDEAL (Initiative for Diagnosis and Epidemiological Assays for Leprosy) Consortium.; We thank the investigators and study coordinators of the Tuberculosis Trials Consortium Study 22 who collected and stored the sera and data from active TB patients, as well as James zumBrunnen of the Department of Statistics at Colorado State University for assistance with statistical analysis of the data. Special thanks to Roland V. Cellona (London), recipient of the 2007 Damien-Dutton Award, for his many years of dedicated service to leprosy research and to members of the clinical staff at the Cebu Skin Clinic in Cebu, Philippines. NR 38 TC 30 Z9 30 U1 1 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD FEB PY 2011 VL 18 IS 2 BP 260 EP 267 DI 10.1128/CVI.00472-10 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 712GJ UT WOS:000286653900011 PM 21177913 ER PT J AU Sumner, S Brown, LG Frick, R Stone, C Carpenter, LR Bushnell, L Nicholas, D Mack, J Blade, H Tobin-D'Angelo, M Everstine, K AF Sumner, Steven Brown, Laura Green Frick, Roberta Stone, Carmily Carpenter, L. Rand Bushnell, Lisa Nicholas, Dave Mack, James Blade, Henry Tobin-D'Angelo, Melissa Everstine, Karen CA Environm Hlth Specialists Network TI Factors Associated with Food Workers Working while Experiencing Vomiting or Diarrhea SO JOURNAL OF FOOD PROTECTION LA English DT Article ID HAND HYGIENE PRACTICES; UNITED-STATES; FOODBORNE-DISEASE; METAANALYSIS; OUTBREAKS AB This study sought to determine the frequency with which food workers said they had worked while experiencing vomiting or diarrhea, and to identify restaurant and worker characteristics associated with this behavior. We conducted interviews with food workers (n = 491) and their managers (n = 387) in the nine states that participate in the Centers for Disease Control and Prevention's Environmental Health Specialists Network. Restaurant and worker characteristics associated with repeatedly working while experiencing vomiting or diarrhea were analyzed via multivariable regression. Fifty-eight (11.9%) workers said they had worked while suffering vomiting or diarrhea on two or more shifts in the previous year. Factors associated with workers having worked while experiencing vomiting or diarrhea were (i) high volume of meals served, (ii) lack of policies requiring workers to report illness to managers, (iii) lack of on-call workers, (iv) lack of manager experience, and (v) workers of the male gender. Our findings suggest that policies that encourage workers to tell managers when they are ill and that help mitigate pressures to work while ill could reduce the number of food workers who work while experiencing vomiting or diarrhea. C1 [Brown, Laura Green; Environm Hlth Specialists Network] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Sumner, Steven] Duke Univ Hosp, Durham, NC 27710 USA. [Frick, Roberta] Calif Dept Publ Hlth, Food & Drug Branch, Richmond, CA 94808 USA. [Stone, Carmily] Bur Environm Hlth Serv, Iowa Dept Publ Hlth, Des Moines, IA 50319 USA. [Carpenter, L. Rand] Tennessee Dept Hlth, Nashville, TN 37243 USA. [Bushnell, Lisa] Connecticut Dept Publ Hlth, Food Protect Program, Div Environm Hlth, Hartford, CT 06134 USA. [Nicholas, Dave] Bur Community Environm Hlth & Food Protect, New York State Dept Hlth, Troy, NY 12180 USA. [Mack, James] Wisconsin Dept Hlth Serv, Madison, WI 53702 USA. [Blade, Henry] Rhode Isl Dept Hlth, Off Food Protect, Providence, RI 02908 USA. [Tobin-D'Angelo, Melissa] Dept Human Resources, Georgia Div Publ Hlth, Atlanta, GA 30303 USA. [Everstine, Karen] Minnesota Dept Hlth, St Paul, MN 55164 USA. RP Brown, LG (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, MS F60,4770 Buford Highway, Atlanta, GA 30341 USA. EM lrg0@cdc.gov FU CDC [CDC-RFA-EH05-013] FX This study was conducted by states receiving CDC grant awards funded under CDC-RFA-EH05-013. This publication is based on data collected and provided by the EHS-Net. The contents of this study are solely the responsibility of the authors and do not necessarily represent the official views of CDC. NR 18 TC 19 Z9 19 U1 0 U2 4 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X J9 J FOOD PROTECT JI J. Food Prot. PD FEB PY 2011 VL 74 IS 2 BP 215 EP 220 DI 10.4315/0362-028X.JFP-10-108 PG 6 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 719SD UT WOS:000287228400006 PM 21333140 ER PT J AU Reidy, DE Zeichner, A Seibert, LA AF Reidy, Dennis E. Zeichner, Amos Seibert, L. Alana TI Unprovoked Aggression: Effects of Psychopathic Traits and Sadism SO JOURNAL OF PERSONALITY LA English DT Article ID LABORATORY AGGRESSION; TAXOMETRIC ANALYSIS; BEHAVIOR; PERSONALITY; OFFENDERS; VIOLENT; WOMEN; PROVOCATION; PERSPECTIVE; PERFORMANCE AB Psychopathic individuals engage in the most violent and cold-blooded acts of aggression. In the laboratory, psychopathy traits have been linked to the commission of unprovoked aggression. The purpose of this study was to assess affective motives that may underlie the relationship between psychopathy and unprovoked aggression. One hundred thirty-seven men viewed a series of photographs depicting violent imagery, completed a lexical decision task designed to assess state affect, and competed in a laboratory-based aggression paradigm. Results indicated that participants who responded faster to happiness words after viewing violent imagery (i.e., sadistic) were significantly more likely to engage in unprovoked aggression. Additionally, Factor 1 psychopathy (emotional detachment) predicted increased probability of unprovoked aggression; however, this relationship was not mediated by sadism. Rather, Factor 1 and sadism each independently predicted unprovoked aggression. The implications of the present data suggest that the type of violence evinced may inform the risk for perpetration of future acts. That is, the individual who demonstrates unprovoked violence may be more likely to employ aggressive tactics across situational contexts than the individual who demonstrates only impulsive acts of hostile/reactive aggression. C1 [Reidy, Dennis E.; Zeichner, Amos; Seibert, L. Alana] Univ Georgia, Athens, GA 30602 USA. RP Reidy, DE (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. EM dreidy@cdc.gov NR 79 TC 18 Z9 18 U1 3 U2 8 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-3506 J9 J PERS JI J. Pers. PD FEB PY 2011 VL 79 IS 1 BP 75 EP 100 DI 10.1111/j.1467-6494.2010.00691.x PG 26 WC Psychology, Social SC Psychology GA 705EF UT WOS:000286111000004 PM 21223265 ER PT J AU Dye, BA Vargas, CM Lee, JJ Magder, L Tinanoff, N AF Dye, Bruce A. Vargas, Clemencia M. Lee, Jessica J. Magder, Laurence Tinanoff, Norman TI Assessing the relationship between children's oral health status and that of their mothers SO JOURNAL OF THE AMERICAN DENTAL ASSOCIATION LA English DT Article; Proceedings Paper CT 87th General Session and Exhibition of the International-Association-for-Dental-Research CY APR, 2009 CL Miami, FL SP Int Assoc Dental Res DE Third National Health and Nutrition Examination Survey; oral health; pediatric dentistry; caries risk; epidemiology ID EARLY-CHILDHOOD CARIES; PEDIATRIC DENTAL-CARIES; UNITED-STATES; MUTANS STREPTOCOCCI; INITIAL ACQUISITION; NATIONAL-HEALTH; INFANTS; CARE; PREVALENCE; PREVENTION AB Background. The authors conducted a study to describe the relationship between the oral health of young children and that of their mothers. Methods. Using data from the Third National Health and Nutrition Examination Survey and a related birth certificate linked file, the authors compiled a sample of 1,184 mother/child pairs for children aged 2 through 6 years. The authors performed logistic and cumulative logistic regression analyses by using children's caries experience and untreated caries status as dependent variables. They evaluated the mothers' untreated caries status and tooth loss status along with other covariates, including age, race/ethnicity and poverty status. Results. Children of mothers who had high levels of untreated caries were more than three times as likely (odds ratio [OR] 3.5; 95 percent confidence interval [CI], 2.0-6.2) to have higher levels of caries experience (treated or untreated dental caries) compared with children whose mothers had no untreated caries. A similar relationship was observed between mothers' tooth loss and caries experience among their children. The children of mothers with high levels of tooth loss were more than three times as likely (OR, 3.3; 95 percent CI, 1.8-6.4) to have higher levels of caries experience compared with children of mothers with no tooth loss; for mothers with moderate tooth loss, the OR was 2.3 (95 percent CI, 1.5-3.5). Conclusions. Mothers' oral health status is a strong predictor of the oral health status of their children. Practice Implications. Preventive plans for children should be based on a caries risk assessment. The results of this study demonstrate that basic information obtained from the child's mother regarding her oral health status is valuable in helping the dentist determine the child's caries risk. C1 [Dye, Bruce A.] Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Dye, Bruce A.] Univ Maryland, Sch Dent, Ctr Dis Control & Prevent, Baltimore, MD 21201 USA. [Vargas, Clemencia M.; Tinanoff, Norman] Univ Maryland, Sch Dent, Dept Hlth Promot & Policy, Baltimore, MD 21201 USA. [Magder, Laurence] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA. RP Dye, BA (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4416, Hyattsville, MD 20782 USA. EM bfd1@cdc.gov FU NIDCR NIH HHS [5R03DE17123-2] NR 49 TC 29 Z9 30 U1 2 U2 10 PU AMER DENTAL ASSOC PI CHICAGO PA 211 E CHICAGO AVE, CHICAGO, IL 60611 USA SN 0002-8177 J9 J AM DENT ASSOC JI J. Am. Dent. Assoc. PD FEB PY 2011 VL 142 IS 2 BP 173 EP 183 PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA 716UU UT WOS:000286999800020 PM 21282684 ER PT J AU Wright, JD Wang, CY AF Wright, Jacqueline D. Wang, Chia-Yih TI Awareness of Federal Dietary Guidance in Persons Aged 16 Years and Older: Results from the National Health and Nutrition Examination Survey 2005-2006 SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION LA English DT Article ID USDA FOOD GUIDE; EATING PLAN; TRIAL; RISK; BEHAVIOR AB The National Health and Nutrition Examination Survey 2005-2006 included questions on awareness of the Dietary Guidelines for Americans (DGA), the Food Guide Pyramid, and the 5 A Day for Better Health Program. Prevalence of awareness of federal dietary guidance was estimated and differences were tested across demographic traits, health characteristics, and diet-related attitudes and behavior. The continuous National Health and Nutrition Examination Survey uses a nationally representative cross-sectional sample design. The analytic sample consisted of 5,499 persons aged 16 years and older with complete data. Among persons aged 16 years and older, 83.8% had heard of at least one of the initiatives: 49.2% had heard of the DGA, 80.6% had heard of the Food Guide Pyramid, and 51.2% had heard of the 5 A Day program. There was a linear trend of decreasing awareness of at least one of the guidance efforts with increasing age. Differences by sex, race/ethnicity, education, and income were also observed. Differences by body mass index were not statistically significant; however, significant differences were seen with fatalistic beliefs about body weight. Differences by smoking, self-assessed diet quality, and eating out frequency were not statistically significant after adjustment for sex, age, race/ethnicity, education, and income. These results may be useful in promotion of the upcoming edition of the DGA and to suggest population groups that may benefit from strengthened and more innovative education efforts at the public health program level and at the clinic level. J Am Diet Assoc. 2011;111:295-300. C1 [Wright, Jacqueline D.] NHLBI, Epidemiol Branch, Div Cardiovasc Sci, NIH,Rockledge Ctr 2, Bethesda, MD 20892 USA. [Wright, Jacqueline D.; Wang, Chia-Yih] Ctr Dis Control & Prevent, Div Natl Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Wright, JD (reprint author), NHLBI, Epidemiol Branch, Div Cardiovasc Sci, NIH,Rockledge Ctr 2, Suite 10018,6701 Rockledge Dr MSC 7936, Bethesda, MD 20892 USA. EM jacqueline.wright@nih.gov NR 23 TC 11 Z9 11 U1 0 U2 3 PU AMER DIETETIC ASSOC PI CHICAGO PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA SN 0002-8223 J9 J AM DIET ASSOC JI J. Am. Diet. Assoc. PD FEB PY 2011 VL 111 IS 2 BP 295 EP 300 DI 10.1016/j.jada.2010.10.049 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 717UV UT WOS:000287073800019 PM 21272706 ER PT J AU Henkle, E Steinhoff, MC Omer, SB Roy, E Arifeen, SE Raqib, R McNeal, M Breiman, RF Moss, WJ Zaman, K AF Henkle, Emily Steinhoff, Mark C. Omer, Saad B. Roy, Eliza Arifeen, Shams E. Raqib, Rubhana McNeal, Monica Breiman, Robert F. Moss, William J. Zaman, K. TI INCIDENCE OF INFLUENZA VIRUS INFECTION IN EARLY INFANCY A PROSPECTIVE STUDY IN SOUTH ASIA SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE influenza; infants ID IMMUNIZATION; ANTIBODY; PREGNANCY; CHILDREN; MOTHERS AB We evaluated infant sera from an immunization trial in Bangladesh to assess influenza hemagglutination inhibition antibody titer increases in 131 unimmunized infants from birth to 6 months. We detected 31 serologically defined infections. Combined with 10 additional rapid test-proven influenza cases, the minimal estimated incidence was 31 of 100 infants (95% CI: 24-41). These data suggest a high burden of influenza in young infants in tropical South Asia. C1 [Henkle, Emily; Steinhoff, Mark C.; Moss, William J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Steinhoff, Mark C.; McNeal, Monica] Cincinnati Childrens Hosp Med Ctr, Global Hlth Ctr, Cincinnati, OH 45229 USA. [Omer, Saad B.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Roy, Eliza; Arifeen, Shams E.; Raqib, Rubhana; Zaman, K.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Breiman, Robert F.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Steinhoff, MC (reprint author), Cincinnati Childrens Hosp Med Ctr, Childrens Global Hlth Ctr, 3333 Burnet Ave,MLC 2048, Cincinnati, OH 45229 USA. EM mark.steinhoff@cchmc.org RI Omer, Saad/K-1182-2012; OI Omer, Saad/0000-0002-5383-3474; Raqib, Rubhana/0000-0002-8116-4511 FU Bill and Melinda Gates Foundation; United States Agency for International Development [HRN-A-0096-90006-00]; Wyeth Pharmaceuticals Inc; Thrasher Research Fund; Aventis Pasteur; ICDDR,B; Bloomberg School of Public Health at Johns Hopkins University; Department of Health and Human Services, National Institutes of Health, National Eye Institute [EY 07127]; Merck; USAID; Thrasher Fund; Wyeth; GlaxoSmithKline; Sanofi-Aventis FX The Mother's Gift project was supported by the Bill and Melinda Gates Foundation, United States Agency for International Development cooperative agreement HRN-A-0096-90006-00; Wyeth Pharmaceuticals Inc, the Thrasher Research Fund, Aventis Pasteur, ICDDR,B, and the Bloomberg School of Public Health at Johns Hopkins University. ICDDR, B, acknowledges with gratitude the commitment of donors to the Centre's research efforts. Ms. Henkle was supported by the Department of Health and Human Services, National Institutes of Health, National Eye Institute Training Grant Number EY 07127 Clinical Trials Training Program in Vision Research.; Research support from Merck, the Bill and Melinda Gates Foundation, and USAID (to R. F. B); research support from the Bill and Melinda Gates Foundation, USAID, the Thrasher Fund, Wyeth, Glaxo Smith-Kline, Sanofi-Aventis, and Merck, and lecture fees from GlaxoSmithKline and Sanofi-Aventis (to M. C. S.). No other potential conflict of interest relevant to this article was reported. NR 10 TC 11 Z9 12 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2011 VL 30 IS 2 BP 170 EP 173 DI 10.1097/INF.0b013e3181f63c39 PG 4 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 707TG UT WOS:000286310400021 PM 20856162 ER PT J AU Delgado, S Neyra, RC Machaca, VRQ Juarez, JA Chu, LC Verastegui, MR Apaza, GMM Bocangel, CD Tustin, AW Sterling, CR Comrie, AC Naquira, C del Carpio, JGC Gilman, RH Bern, C Levy, MZ AF Delgado, Stephen Neyra, Ricardo Castillo Quispe Machaca, Victor R. Ancca Juarez, Jenny Chou Chu, Lily Renee Verastegui, Manuela Moscoso Apaza, Giovanna M. Bocangel, Cesar D. Tustin, Aaron W. Sterling, Charles R. Comrie, Andrew C. Naquira, Cesar Cornejo del Carpio, Juan G. Gilman, Robert H. Bern, Caryn Levy, Michael Z. TI A History of Chagas Disease Transmission, Control, and Re-Emergence in Peri-Rural La Joya, Peru SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID TRYPANOSOMA-CRUZI INFECTION; TRIATOMA-INFESTANS POPULATIONS; 2ND-ORDER ANALYSIS; COMMUNITIES; ARGENTINA; CHALLENGES; PREVALENCE; PATTERNS; AREQUIPA; REGION AB Background: The history of Chagas disease control in Peru and many other nations is marked by scattered and poorly documented vector control campaigns. The complexities of human migration and sporadic control campaigns complicate evaluation of the burden of Chagas disease and dynamics of Trypanosoma cruzi transmission. Methodology/Principal Findings: We conducted a cross-sectional serological and entomological study to evaluate temporal and spatial patterns of T. cruzi transmission in a peri-rural region of La Joya, Peru. We use a multivariate catalytic model and Bayesian methods to estimate incidence of infection over time and thereby elucidate the complex history of transmission in the area. Of 1,333 study participants, 101 (7.6%; 95% CI: 6.2-9.0%) were confirmed T. cruzi seropositive. Spatial clustering of parasitic infection was found in vector insects, but not in human cases. Expanded catalytic models suggest that transmission was interrupted in the study area in 1996 (95% credible interval: 1991-2000), with a resultant decline in the average annual incidence of infection from 0.9% (95% credible interval: 0.6-1.3%) to 0.1% (95% credible interval: 0.005-0.3%). Through a search of archival newspaper reports, we uncovered documentation of a 1995 vector control campaign, and thereby independently validated the model estimates. Conclusions/Significance: High levels of T. cruzi transmission had been ongoing in peri-rural La Joya prior to interruption of parasite transmission through a little-documented vector control campaign in 1995. Despite the efficacy of the 1995 control campaign, T. cruzi was rapidly reemerging in vector populations in La Joya, emphasizing the need for continuing surveillance and control at the rural-urban interface. C1 [Delgado, Stephen; Comrie, Andrew C.] Univ Arizona, Sch Geog & Dev, Tucson, AZ 85721 USA. [Delgado, Stephen] Univ Arizona, Div Epidemiol & Biostat, Tucson, AZ USA. [Neyra, Ricardo Castillo; Gilman, Robert H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Quispe Machaca, Victor R.; Ancca Juarez, Jenny; Chou Chu, Lily; Renee Verastegui, Manuela; Moscoso Apaza, Giovanna M.; Bocangel, Cesar D.; Naquira, Cesar; Gilman, Robert H.] Univ Peruana Cayetano Heredia, Lima, Peru. [Tustin, Aaron W.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Sterling, Charles R.] Univ Arizona, Dept Vet Sci & Microbiol, Tucson, AZ USA. [Cornejo del Carpio, Juan G.] Gerencia Reg Salud Arequipa, Arequipa, Peru. [Bern, Caryn] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Levy, Michael Z.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. RP Delgado, S (reprint author), Univ Arizona, Sch Geog & Dev, Tucson, AZ 85721 USA. EM mzlevy@mail.med.upenn.edu FU National Institutes of Health [5P50 AI074285-03, 5P50 AI074285-04, 3K01AI079162-02S1, 5T37 MD001427]; National Institute of Allergy and Infectious Diseases [1K01AI079162-03]; American Society of Tropical Medicine and Hygiene FX This work was supported by the National Institutes of Health (http://nih.gov/; 5P50 AI074285-03 and 04, 3K01AI079162-02S1 to M.Z.L., 5T37 MD001427 to S.D.), the National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov/; 1K01AI079162-03 to M.Z.L.) and the American Society of Tropical Medicine and Hygiene (http://www.astmh.org; Benjamin Kean Fellowship to A. W. T.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this publication are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 37 TC 15 Z9 15 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2727 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2011 VL 5 IS 2 AR e970 DI 10.1371/journal.pntd.0000970 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 726CQ UT WOS:000287696700017 PM 21364970 ER PT J AU Blanchard, JF Aral, SO AF Blanchard, James F. Aral, Sevgi O. TI Program Science: an initiative to improve the planning, implementation and evaluation of HIV/sexually transmitted infection prevention programmes SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Editorial Material ID HIV PREVENTION C1 [Blanchard, James F.] Univ Manitoba, Dept Community Hlth Sci, Ctr Global Publ Hlth, Winnipeg, MB R3E 0T6, Canada. [Aral, Sevgi O.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Blanchard, JF (reprint author), Univ Manitoba, Dept Community Hlth Sci, Ctr Global Publ Hlth, R070 Med Rehab Bldg,771 McDermot Ave, Winnipeg, MB R3E 0T6, Canada. EM james_blanchard@umanitoba.ca NR 10 TC 12 Z9 12 U1 2 U2 7 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD FEB PY 2011 VL 87 IS 1 BP 2 EP 3 DI 10.1136/sti.2010.047555 PG 2 WC Infectious Diseases SC Infectious Diseases GA 706MZ UT WOS:000286223800002 PM 21126962 ER PT J AU Sejvar, JJ Lindsey, NP Campbell, GL AF Sejvar, James J. Lindsey, Nicole P. Campbell, Grant L. TI Primary Causes of Death in Reported Cases of Fatal West Nile Fever, United States, 2002-2006 SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Flavivirus; Survival; West Nile; Fever ID VIRUS ACTIVITY AB Morbidity and mortality associated with human West Nile virus (WNV) infection is generally attributable to severe neurologic disease; most illness with WNV, however, is characterized by febrile illness. Although generally considered to be a benign, self-limited syndrome, some cases of West Nile Fever (WNF) have been reported as resulting in fatal outcome. We reviewed cause-of-death information for 35 cases of WNF reported as fatal to the Centers for Disease Control and Prevention between 2002 and 2006, to determine underlying primary causes of death and identify groups at highest risk for fatal WNF. Fifteen were determined to be misclassified neuroinvasive disease cases; one death was medically unrelated to WNV infection. Among the remaining 23 cases, the median age was 78 years (range: 54-92), and 78% were >70 years old; the median age for all 13,482 reported cases of WNF during this time period was 47 years (range: 1 month-97 years). Cardiac (8 cases, 35%) and pulmonary complications (6 cases, 25%) were the most common primary causes of death. Underlying medical conditions among fatal WNF cases included cardiovascular disease (13; 76%), hypertension (8; 47%), and diabetes mellitus (6; 35%). Our study suggests that in some individuals, especially persons of advanced age and those with underlying medical conditions, WNF may precipitate death. The elderly are at increased risk of death from both West Nile neuroinvasive disease and WNF, which emphasizes the importance of primary prevention of WNV infection and close monitoring for cardiac and pulmonary complications in elderly patients hospitalized for WNV disease. C1 [Sejvar, James J.; Lindsey, Nicole P.; Campbell, Grant L.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vectorborne & Enter Dis, Ft Collins, CO USA. [Sejvar, James J.] CDC, Div Viral & Rickettsial Dis, NCZVED, Atlanta, GA 30333 USA. RP Sejvar, JJ (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vectorborne & Enter Dis, 1600 Clifton Rd,Mailstop A-39, Atlanta, GA 30333 USA. EM zea3@cdc.gov NR 13 TC 14 Z9 15 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2011 VL 11 IS 2 BP 161 EP 164 DI 10.1089/vbz.2009.0086 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 715GX UT WOS:000286871900010 PM 20687860 ER PT J AU Kahler, AM Cromeans, TL Roberts, JM Hill, VR AF Kahler, Amy M. Cromeans, Theresa L. Roberts, Jacquelin M. Hill, Vincent R. TI Source water quality effects on monochloramine inactivation of adenovirus, coxsackievirus, echovirus, and murine norovirus SO WATER RESEARCH LA English DT Article DE Disinfection; Monochloramine; Water; Virus ID HEPATITIS-A VIRUS; FREE CHLORINE; VIRUCIDAL EFFECTIVENESS; FELINE CALICIVIRUS; ENTERIC VIRUSES; DRINKING-WATER; UV-LIGHT; DISINFECTION; POTENTIATION; KINETICS AB There is a need for more information regarding monochloramine disinfection efficacy for viruses in water. In this study, monochloramine disinfection efficacy was investigated for coxsackievirus B5 (CVB5), echovirus 11 (E11), murine norovirus (MNV), and human adenovirus 2 (HAdV2) in one untreated ground water and two partially treated surface waters. Duplicate disinfection experiments were completed at pH 7 and 8 in source water at concentrations of 1 and 3 mg/L monochloramine at 5 and 15 degrees C. The Efficiency Factor Horn (EFH) model was used to calculate CT values (mg-min/L) required to achieve 2-, 3-, and 4-log(10) reductions in viral titers. In all water types, monochloramine disinfection was most effective for MNV, with 3-log(10) CT values at 5 degrees C ranging from 27 to 110. Monochloramine disinfection was least effective for HAdV2 and Ell, depending on water type, with 3-log(10) CT values at 5 degrees C ranging from 1200 to 3300 and 810 to 2300, respectively. Overall, disinfection proceeded faster at 15 degrees C and pH 7 for all water types. Inactivation of the study viruses was significantly different between water types, but there was no indication that overall disinfection efficacy was enhanced or inhibited in any one water type. CT values for HAdV2 in two types of source water exceeded federal CT value recommendations in the US. The results of this study demonstrate that water quality impacts the inactivation of viruses and should be considered when developing chloramination plans. Published by Elsevier Ltd. C1 [Kahler, Amy M.; Hill, Vincent R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. [Cromeans, Theresa L.] Atlanta Res & Educ Fdn, Decatur, GA USA. [Cromeans, Theresa L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30329 USA. [Roberts, Jacquelin M.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. RP Kahler, AM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd,Mail Stop D-66, Atlanta, GA 30329 USA. EM akahler@cdc.gov RI Hill, Vincent/G-1789-2012 OI Hill, Vincent/0000-0001-7069-7737 FU Water Research Foundation [3134]; Centers for Disease Control and Prevention; Atlanta Research and Education Foundation FX The authors thank Dr. Charles Humphrey (CDC) for electron microscopy analysis of virus preparations and Bonnie Mull and Carmela Smith (Atlanta Research and Education Foundation) for assistance with experiment preparation and virus plaque assays. The use of trade names and names of commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. The findings and conclusions in this presentation are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention. Funding for this project was provided by the Water Research Foundation (Project #3134, Contaminant Candidate List Viruses: Evaluation of Disinfection Efficacy), the Centers for Disease Control and Prevention, and the Atlanta Research and Education Foundation. NR 29 TC 8 Z9 8 U1 1 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0043-1354 J9 WATER RES JI Water Res. PD FEB PY 2011 VL 45 IS 4 BP 1745 EP 1751 DI 10.1016/j.watres.2010.11.026 PG 7 WC Engineering, Environmental; Environmental Sciences; Water Resources SC Engineering; Environmental Sciences & Ecology; Water Resources GA 716SY UT WOS:000286995000024 PM 21145573 ER PT J AU Eick, AA Uyeki, TM Klimov, A Hall, H Reid, R Santosham, M O'Brien, KL AF Eick, Angelia A. Uyeki, Timothy M. Klimov, Alexander Hall, Henrietta Reid, Raymond Santosham, Mathuram O'Brien, Katherine L. TI Maternal Influenza Vaccination and Effect on Influenza Virus Infection in Young Infants SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID ALASKA NATIVE CHILDREN; UNITED-STATES; RESPIRATORY ILLNESS; OUTPATIENT VISITS; PREGNANT-WOMEN; HOSPITALIZATIONS; IMMUNIZATION; ANTIBODY; RECOMMENDATIONS; SURVEILLANCE AB Objective: To assess the effect of seasonal influenza vaccination during pregnancy on laboratory-confirmed influenza in infants to 6 months of age. Design: Nonrandomized, prospective, observational cohort study. Setting: Navajo and White Mountain Apache Indian reservations, including 6 hospitals on the Navajo reservation and 1 on the White Mountain Apache reservation. Participants: A total of 1169 mother-infant pairs with mothers who delivered an infant during 1 of 3 influenza seasons. Main Exposure: Maternal seasonal influenza vaccination. Main Outcome Measures: In infants, laboratory-confirmed influenza, influenzalike illness (ILI), ILI hospitalization, and influenza hemagglutinin inhibition antibody titers. Results: A total of 1160 mother-infant pairs had serum collected and were included in the analysis. Among infants, 193 (17%) had an ILI hospitalization, 412 (36%) had only an ILI outpatient visit, and 555 (48%) had no ILI episodes. The ILI incidence rate was 7.2 and 6.7 per 1000 person-days for infants born to unvaccinated and vaccinated women, respectively. There was a 41% reduction in the risk of laboratory-confirmed influenza virus infection (relative risk, 0.59; 95% confidence interval, 0.37-0.93) and a 39% reduction in the risk of ILI hospitalization (relative risk, 0.61; 95% confidence interval, 0.45-0.84) for infants born to influenza-vaccinated women compared with infants born to unvaccinated mothers. Infants born to influenza-vaccinated women had significantly higher hemagglutinin inhibition antibody titers at birth and at 2 to 3 months of age than infants of unvaccinated mothers for all 8 influenza virus strains investigated. Conclusions: Maternal influenza vaccination was significantly associated with reduced risk of influenza virus infection and hospitalization for an ILI up to 6 months of age and increased influenza antibody titers in infants through 2 to 3 months of age. C1 [Eick, Angelia A.; Reid, Raymond; Santosham, Mathuram; O'Brien, Katherine L.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Amer Indian Hlth, Baltimore, MD 21205 USA. [Uyeki, Timothy M.; Klimov, Alexander; Hall, Henrietta] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP O'Brien, KL (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Amer Indian Hlth, 621 N Washington St, Baltimore, MD 21205 USA. EM klobrien@jhsph.edu FU Med-Immune; Pfizer; National Vaccine Program Office, Department of Health and Human Services; Office of Minority Women's Health, Centers for Disease Control and Prevention; Aventis-Pasteur; Evans-Powderject; Uyeki; O'Brien FX Obtained funding: Uyeki and O'Brien.; Dr O'Brien reports receiving grants for research projects unrelated to this article from Med-Immune and Pfizer and serving on expert advisory committees for pneumococcal vaccines from Sanofi-Pasteur; all 3 manufacture influenza vaccine.; The study was funded by the National Vaccine Program Office, Department of Health and Human Services, the Office of Minority Women's Health, Centers for Disease Control and Prevention, Aventis-Pasteur, and Evans-Powderject. NR 27 TC 131 Z9 135 U1 2 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD FEB PY 2011 VL 165 IS 2 BP 104 EP 111 DI 10.1001/archpediatrics.2010.192 PG 8 WC Pediatrics SC Pediatrics GA 717KH UT WOS:000287042100002 PM 20921345 ER PT J AU Zelenka, MP Barr, DB Nicolich, MJ Lewis, RJ Bird, MG Letinski, DJ Metcalf, SW O'Lone, RB AF Zelenka, Michael P. Barr, Dana Boyd Nicolich, Mark J. Lewis, R. Jeffrey Bird, Michael G. Letinski, Daniel J. Metcalf, Susan W. O'Lone, Raegan B. TI A weight of evidence approach for selecting exposure biomarkers for biomonitoring SO BIOMARKERS LA English DT Article DE Biological monitoring; biomarker of exposure; weight of evidence calculator; benzene ID BENZENE AB Context: It is known that there are usually several biomarkers and/or medium combinations that can be applied to answer a specific exposure question. To help determine an appropriate combination for the specific question, we have developed a weight-of-evidence Framework that provides a relative appropriateness score for competing combinations. Methods: The Framework is based on an expert assessor's evaluation of the relevance and suitability of the biomarker and medium for the question based on a set of criteria. We provide a computer based modeling tool to guide the researcher through the process. Results: We present an example with six biomarkers of benzene exposure in one matrix; the six are either the most commonly used biomarkers and/or have recent widespread usage. The example clearly demonstrates the usefulness of the Framework for scoring the choices, as well as the transparency of the method that provides the basis for discussion. Conclusions: The Framework provides for the first time a method to transparently document the rationale behind selecting, from among a set of alternatives, the most scientifically supportable exposure biomarker to address a specific biomonitoring question, thus providing a reproducible account of expert opinions on the suitability of a biomarker. C1 [Zelenka, Michael P.; Lewis, R. Jeffrey; Bird, Michael G.; Letinski, Daniel J.] ExxonMobil Biomed Sci Inc, Annandale, NJ 08801 USA. [Barr, Dana Boyd] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Nicolich, Mark J.] COGIMET, Lambertville, NJ USA. [Metcalf, Susan W.] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. [O'Lone, Raegan B.] ILSI Hlth & Environm Sci Inst, Washington, DC USA. RP Zelenka, MP (reprint author), ExxonMobil Biomed Sci Inc, 1545 US Highway 22 E,Room LA388, Annandale, NJ 08801 USA. EM michael.p.zelenka@exxonmobil.com RI Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013 FU ILSI-HESI FX The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the Agency for Toxic Substances and Disease Registry. This publication stems from a subgroup of the HESI Integration of Biomonitoring Exposure Data into the Risk Assessment Process Technical Committee, whose work is funded through ILSI-HESI. NR 17 TC 4 Z9 4 U1 0 U2 4 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1354-750X J9 BIOMARKERS JI Biomarkers PD FEB PY 2011 VL 16 IS 1 BP 65 EP 73 DI 10.3109/1354750X.2010.533283 PG 9 WC Biotechnology & Applied Microbiology; Toxicology SC Biotechnology & Applied Microbiology; Toxicology GA 722RG UT WOS:000287451400009 PM 21250852 ER PT J AU Farr, SL Curtis, KM Robbins, CL Zapata, LB Dietz, PM AF Farr, Sherry L. Curtis, Kathryn M. Robbins, Cheryl L. Zapata, Lauren B. Dietz, Patricia M. TI Use of contraception among US women with frequent mental distress SO CONTRACEPTION LA English DT Article DE Mental health; Contraception; Mental disorder; Stress; Psychological ID UNITED-STATES; UNINTENDED PREGNANCY; DEPRESSION; BEHAVIORS AB Background: This study examines whether a woman's mental health is associated with use of contraception. Study Design: We used national data from 2004 and 2006 to calculate the prevalence of contraceptive use among women with frequent mental distress. We examined associations among mental distress and permanent contraception and any highly or moderately effective, reversible contraceptive method. Results: Women with (86%) and without (87%) frequent mental distress reported using contraception, but contraceptive type varied by mental distress and income. Among women who use contraception, those with frequent mental distress had 1.4 times higher odds (95% CI: 1.2-1.6) of using permanent contraception. Among lower income women who use reversible contraception, those with frequent mental distress had lower odds of using highly [adjusted odds ratio (aOR)=0.5, 95% CI: 0.4-0.8] and moderately (aOR=0.6, 95% CI: 0.4-0.9) effective methods than less effective methods. Conclusion: Contraceptive providers should consider mental health when providing counseling about contraception. Published by Elsevier Inc. C1 [Farr, Sherry L.; Curtis, Kathryn M.; Robbins, Cheryl L.; Zapata, Lauren B.; Dietz, Patricia M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. RP Farr, SL (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. EM SFarr@cdc.gov NR 30 TC 11 Z9 11 U1 4 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0010-7824 J9 CONTRACEPTION JI Contraception PD FEB PY 2011 VL 83 IS 2 BP 127 EP 133 DI 10.1016/j.contraception.2010.07.005 PG 7 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 716WI UT WOS:000287003800006 PM 21237337 ER PT J AU Harris, JR Blaney, DD Lindsley, MD Zaki, SR Paddock, CD Drew, CP Johnson, AJ Landau, D Vanderbush, J Baker, R AF Harris, Julie R. Blaney, David D. Lindsley, Mark D. Zaki, Sherif R. Paddock, Christopher D. Drew, Clifton P. Johnson, April J. Landau, Douglas Vanderbush, Joel Baker, Robert TI Blastomycosis in Man after Kinkajou Bite SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INOCULATION BLASTOMYCOSIS; POTOS-FLAVUS; ONTARIO AB We report transmission of Blastomyces dermatitidis fungal infection from a pet kinkajou to a man. When treating a patient with a recalcitrant infection and a history of an animal bite, early and complete animal necropsy and consideration of nonbacterial etiologies are needed. C1 [Harris, Julie R.] Ctr Dis Control & Prevent, Mycot Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Johnson, April J.] Purdue Univ, Sch Vet Med, W Lafayette, IN 47907 USA. [Landau, Douglas] Indiana State Dept Hlth Labs, Indianapolis, IN USA. [Vanderbush, Joel] Animalia Inc, Indianapolis, IN USA. [Baker, Robert] Community Hlth Network, Indianapolis, IN USA. RP Harris, JR (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30333 USA. EM ggt5@cdc.gov NR 15 TC 6 Z9 6 U1 0 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2011 VL 17 IS 2 BP 268 EP 270 DI 10.3201/eid1702.101046 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 722MM UT WOS:000287436400020 PM 21291603 ER PT J AU Pornruangwong, S Hendriksen, RS Pulsrikarn, C Bangstrakulnonth, A Mikoleit, M Davies, RH Aarestrup, FM Garcia-Migura, L AF Pornruangwong, Srirat Hendriksen, Rene S. Pulsrikarn, Chaiwat Bangstrakulnonth, Aroon Mikoleit, Matthew Davies, Rob H. Aarestrup, Frank M. Garcia-Migura, Lourdes TI Epidemiological Investigation of Salmonella enterica Serovar Kedougou in Thailand SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID MOLECULAR CHARACTERIZATION; ANTIMICROBIAL RESISTANCE; ESCHERICHIA-COLI; BETA-LACTAMASES; FOOD-PRODUCTS; DENMARK; PREVALENCE; INFECTION; POULTRY; SWINE AB Objective: Salmonella enterica serovar Kedougou is among the top 10 serovars reported in northern Thailand. The objective of this study was to identify risk factors associated with Salmonella Kedougou infection in Thailand and to compare the molecular types and antimicrobial resistance with Salmonella Kedougou isolates of human origin from United States and of animal origin from the United Kingdom. Methods: Data from 13,976 Salmonella infections of which 253 were Salmonella Kedougou collected in Thailand between 2002 and 2008 were analyzed by logistic regression. Antimicrobial susceptibility testing and pulsed-field gel electrophoresis (PFGE) were performed on selected Salmonella Kedougou strains causing infections in Thailand (n = 66), and compared to isolates from the United States (n = 5) and the United Kingdom (n = 20). Results: Logistic analysis revealed season (hot/dry; p = 0.023), region (northern Thailand; p < 0.001), and specimen (stool; p < 0.001) as significant risk factors associated with Salmonella Kedougou infection compared to other nontyphoid Salmonella. Of the Salmonella Kedougou isolates of human origin, 84% exhibited resistance to at least three antimicrobial classes. Three strains recovered from human stool in Thailand were resistant to third-generation cephalosporins: two harbored bla(CTX-M-63) and one bla(CMY-2). PFGE revealed 45 unique clusters. Isolates obtained from humans in Thailand and the United States presented identical PFGE profiles suggesting a travel association, whereas the majority of the animal isolates from United Kingdom clustered separately. Conclusions: This study reveals Salmonella Kedougou as a major cause of human infections in northern Thailand especially during the hot period and suggests a global spread probably due to travel. The clonal types causing infections in humans differed from those observed in animals in United Kingdom, which suggests the absence of an epidemiological link and could suggest differences in virulence. The high frequency of antimicrobial resistance, including emergence of resistance to fluoroquinolones and third-generation cephalosporins, might pose problems for treatment of infections. C1 [Garcia-Migura, Lourdes] Tech Univ Denmark, Natl Food Inst, Antimicrobial Resistance Unit, WHO Collaborating Ctr Antimicrobial Resistance Fo, DK-2800 Lyngby, Denmark. [Hendriksen, Rene S.; Aarestrup, Frank M.; Garcia-Migura, Lourdes] Tech Univ Denmark, Natl Food Inst, European Union Reference Lab Antimicrobial Resist, DK-2800 Lyngby, Denmark. [Pornruangwong, Srirat; Pulsrikarn, Chaiwat] Natl Inst Hlth, Dept Med Sci, Minist Publ Hlth, WHO Int Salmonella & Shigella Ctr, Bangkok, Thailand. [Bangstrakulnonth, Aroon] SS&A Reagents Lab Ltd, Bangkok, Thailand. [Mikoleit, Matthew] Ctr Dis Control & Prevent, WHO Collaborating Ctr Surveillance Epidemiol & Co, Enter Dis Epidemiol Branch, Atlanta, GA USA. [Davies, Rob H.] Vet Labs Agencies, Dept Food & Environm Safety, Addlestone, Surrey, England. RP Garcia-Migura, L (reprint author), Tech Univ Denmark, Natl Food Inst, Antimicrobial Resistance Unit, WHO Collaborating Ctr Antimicrobial Resistance Fo, Bldg 204, DK-2800 Lyngby, Denmark. EM lgmi@food.dtu.dk RI Davies, Robert/F-1055-2010; APHA, Staff publications/E-6082-2010; Migura-Garcia, Lourdes/E-3560-2016; OI Migura-Garcia, Lourdes/0000-0003-2935-928X; Mikoleit, Matthew/0000-0002-4582-6733 FU World Health Organization Global Foodborne Infections Network (GFN) FX The authors gratefully acknowledge Mrs. Christina Aaby Svendsen at the National Food Institute for her technical support. This work was supported by the World Health Organization Global Foodborne Infections Network (GFN), www.who.int/gfn/en/. NR 33 TC 4 Z9 4 U1 1 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD FEB PY 2011 VL 8 IS 2 BP 203 EP 211 DI 10.1089/fpd.2010.0626 PG 9 WC Food Science & Technology SC Food Science & Technology GA 713HA UT WOS:000286724900004 PM 21034262 ER PT J AU Krueger, AL Folster, J Medalla, F Joyce, K Perri, MB Johnson, L Zervos, M Whichard, JM Barzilay, EJ AF Krueger, Amy L. Folster, Jason Medalla, Felicita Joyce, Kevin Perri, Mary Beth Johnson, Laura Zervos, Marcus Whichard, Jean M. Barzilay, Ezra J. TI Commensal Escherichia coli Isolate Resistant to Eight Classes of Antimicrobial Agents in the United States SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID SEROVAR TYPHIMURIUM DT104; URINARY-TRACT-INFECTIONS; RISK-FACTORS; PLASMIDS; ANTIBIOTICS; ANIMALS; HUMANS AB To increase understanding of community-acquired resistance, stool samples from 477 nonhospitalized persons in Maryland and Michigan, from 2004 to 2008, were screened for ceftriaxone resistance. Seven (1.5%) yielded ceftriaxone-resistant Escherichia coli; one isolate was resistant to all eight antimicrobial classes routinely tested: aminoglycosides, beta-lactam/beta-lactamase inhibitor combinations, cephems, penicillins, folate pathway inhibitors, phenicols, quinolones, and tetracyclines. The extensively resistant isolate was from a 50-year-old woman who denied antimicrobial use, hospitalization, or international travel within 6 months. Meat (beef, chicken, and pork) and eggs were consumed within 1 month before stool collection. Further studies are warranted to understand potential sources, including the food supply, of resistant E. coli. C1 [Krueger, Amy L.; Folster, Jason; Medalla, Felicita; Joyce, Kevin; Whichard, Jean M.; Barzilay, Ezra J.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Enter Zoonot & Infect Dis, Atlanta, GA 30333 USA. [Folster, Jason] Int Hlth Resource Consulting, Atlanta, GA USA. [Perri, Mary Beth; Johnson, Laura; Zervos, Marcus] Henry Ford Hosp & Med Ctr, Dept Internal Med, Div Infect Dis & Hosp Epidemiol, Detroit, MI 48202 USA. RP Krueger, AL (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Enter Zoonot & Infect Dis, 1600 Clifton Rd,MS D-63, Atlanta, GA 30333 USA. EM frf7@cdc.gov; fhm1@cdc.gov FU U.S. Food and Drug Administration Center for Veterinary Medicine FX We thank the Henry Ford Medical Centers in Detroit, Michigan, for their assistance with the Enterococci/E. coli Resistance Study. Michigan's participation in the E. coli resistance study was supported through the Epidemiology and Laboratory Capacity (ELC) cooperative agreement, which was partially funded by the U.S. Food and Drug Administration Center for Veterinary Medicine. NR 22 TC 2 Z9 2 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD FEB PY 2011 VL 8 IS 2 BP 329 EP 332 DI 10.1089/fpd.2010.0619 PG 4 WC Food Science & Technology SC Food Science & Technology GA 713HA UT WOS:000286724900020 PM 20973731 ER PT J AU Zeidler-Erdely, PC Battelli, LA Stone, S Chen, BT Frazer, DG Young, SH Erdely, A Kashon, ML Andrews, R Antonini, JM AF Zeidler-Erdely, Patti C. Battelli, Lori A. Stone, Sam Chen, Bean T. Frazer, David G. Young, Shih-Houng Erdely, Aaron Kashon, Michael L. Andrews, Ronnee Antonini, James M. TI Short-term inhalation of stainless steel welding fume causes sustained lung toxicity but no tumorigenesis in lung tumor susceptible A/J mice SO INHALATION TOXICOLOGY LA English DT Article DE welding; chromium; lung cancer; strain A mice; bronchoalveolar lavage ID INTRATRACHEAL INSTILLATION; PULMONARY RESPONSE; DEFENSE RESPONSES; TITANIUM-DIOXIDE; MILD-STEEL; II CELL; INFLAMMATION; EXPOSURE; INJURY; RATS AB Debate exists as to whether welding fume is carcinogenic, but epidemiological evidence suggests that welders are an at-risk population for development of lung cancer. Our objective was to expose, by inhalation, lung tumor susceptible (A/J) and resistant C57BL/6J (B6) mice to stainless steel (SS) welding fume containing carcinogenic metals and characterize the lung-inflammatory and tumorigenic response. Male mice were exposed to air or gas metal arc (GMA)-SS welding fume at 40 mg/m= 35 years with CHD and to determine factors associated with not receiving recommended diabetes screenings. Methods: The Behavioral Risk Factor Surveillance System (BRFSS) is an annual state-based telephone survey of non-institutionalized U. S. adults. Information on prediabetes prevalence was collected for 33 states in 2008; data analysis was conducted in 2009. The prevalence of diabetes and prediabetes among adults aged >= 35 years with CHD (n = 20,618) and prevalence of diabetes screening among nondiabetic adults with CHD (n = 14,335) were assessed. Multivariate logistic regression was used to calculate the odds of not being screened for diabetes in the past 3 years while controlling for other factors. Results: Among adults with CHD, 30.7% (95% CI = 29.4%, 32.1%) reported being diagnosed with diabetes and 10.0% (95% CI = 9.2%, 10.8%) reported prediabetes. Among nondiabetic adults with CHD, 25.4% (95% CI = 23.9%, 26.9%) reported not being screened for diabetes in the past 3 years. Those with no recent routine checkup and those with no health insurance had the highest odds of no recent diabetes screening. Conclusions: The prevalence of diabetes and prediabetes is substantial among adults with CHD and likely underestimated because of suboptimal screening. One of four nondiabetic adults with CHD reported not being screened for diabetes in the past 3 years. (Am J Prev Med 2011;40(2):159-165) (c) 2011 American Journal of Preventive Medicine C1 [Kilmer, Greta] RTI Int, Behav Hlth & Criminal Justice Res Div, Atlanta, GA 30341 USA. [Hughes, Elizabeth] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Zhang, Xuanping] CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Elam-Evans, Laurie] CDC, Div Behav Surveillance, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Kilmer, G (reprint author), RTI Int, Behav Hlth & Criminal Justice Res Div, 2951 Flowers Rd, Atlanta, GA 30341 USA. EM gkilmer@rti.org NR 24 TC 6 Z9 6 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2011 VL 40 IS 2 BP 159 EP 165 DI 10.1016/j.amepre.2010.09.021 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 706AP UT WOS:000286184100009 PM 21238864 ER PT J AU Farfan, EB Gaschak, SP Maksymenko, AM Jannik, GT Marra, JC Bondarkov, MD Donnelly, EH AF Farfan, Eduardo B. Gaschak, Sergii P. Maksymenko, Andriy M. Jannik, G. Tim Marra, James C. Bondarkov, Mikhail D. Donnelly, Elizabeth H. TI ASSESSMENT OF BETA PARTICLE FLUX FROM SURFACE CONTAMINATION AS A RELATIVE INDICATOR FOR RADIONUCLIDE DISTRIBUTION ON EXTERNAL SURFACES OF A MULTISTORY BUILDING IN PRIPYAT SO HEALTH PHYSICS LA English DT Article DE Chernobyl; decontamination; environmental impact; nuclear power plant ID MODELS AB Several issues should be considered when assessing the feasibility of remediation following the detonation of a radiological dispersion device (e.g., dirty bomb) or improvised nuclear device in a large city. These issues include the levels and characteristics of the radioactive contamination, the availability of resources required for decontamination, and the planned future use of the city's structures and buildings. Presently, little is known about the distribution, redistribution, and migration of radionuclides in an urban environment. However, Pripyat, a city substantially contaminated by the Chernobyl Nuclear Power Plant accident in April 1986, may provide some answers. The main objective of this study was to determine the radionuclide distribution on a Pripyat multistory building that had not been decontaminated and, therefore, could reflect the initial fallout and its further natural redistribution on external surfaces over 23 y. The seven-story building selected was surveyed from the ground floor to the roof on horizontal and vertical surfaces along seven ground-to-roof transections. Some results from this study indicate that the upper floors of the building had higher contamination levels than the lower floors. Consequently, the authors recommend that thorough decontamination should be considered for all the floors of tall buildings (not just lower floors). Health Phys. 100(2):221-227; 2011 C1 [Farfan, Eduardo B.] Savannah River Nucl Solut LLC, Savannah River Natl Lab, Environm Sci & Biotechnol, Environm Dosimetry Grp, Aiken, SC 29808 USA. [Gaschak, Sergii P.; Maksymenko, Andriy M.; Bondarkov, Mikhail D.] Int Radioecol Lab, Chernobyl Ctr Nucl Safety, UA-07100 Slavutych, Ukraine. [Donnelly, Elizabeth H.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Farfan, EB (reprint author), Savannah River Nucl Solut LLC, Savannah River Natl Lab, Environm Sci & Biotechnol, Environm Dosimetry Grp, Bldg 773-42A,Room 236, Aiken, SC 29808 USA. EM Eduardo.Farfan@srnl.doe.gov FU U.S. Department of Energy Office of Environmental Management; SRNL; U.S. Department of Energy [DE-AC09-08SR22470]; IRL FX The authors would like to thank Mr. Kurt Gerdes and Ms. Ana Han for their support of the U.S. Department of Energy Office of Environmental Management's international cooperative program with IRL. The authors would also like to thank Mr. Jason Davis (SRNL Records and Document Control) for his help with the development of graphical representations and Dr. Tatyana Albert (Thomas E. Albert and Associates, Inc.) for translating documents and reports prepared at IRL. This research was supported by the SRNL's Laboratory Directed Research and Development program in conjunction with work accomplished under contract No. DE-AC09-08SR22470 with the U.S. Department of Energy. NR 12 TC 4 Z9 4 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0017-9078 EI 1538-5159 J9 HEALTH PHYS JI Health Phys. PD FEB PY 2011 VL 100 IS 2 BP 221 EP 227 DI 10.1097/HP.0b013e3181ee31ac PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging GA 700BR UT WOS:000285707600012 PM 21399438 ER PT J AU Wei, XR Youngpairoj, AS Garrido, C Zahonero, N Corral, A de Mendoza, C Heneine, W Johnson, JA Garcia-Lerma, G AF Wei, Xierong Youngpairoj, Ae S. Garrido, Carolina Zahonero, Natalia Corral, Angelica de Mendoza, Carmen Heneine, Walid Johnson, Jeffrey A. Garcia-Lerma, Gerardo TI Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance SO JOURNAL OF CLINICAL VIROLOGY LA English DT Article DE Antiretroviral therapy; Dried blood spots; Archived drug resistance; Minority resistance mutations; Real-time PCR; Cost-effective specimen ID SENSITIVE GENOTYPING ASSAY; VIRUS TYPE-1 RNA; ANTIRETROVIRAL TREATMENT; TRANSMITTED HIV; SUBTYPE-B; SURVEILLANCE; PLASMA; QUANTIFICATION; TANZANIA; SAMPLES AB Background: Dried blood spots (DBS) could serve as an attractive, cost-effective alternative to plasma for HIV drug resistance testing. Objectives: To assess the utility and potential gain in genotypic information with sensitive testing of DBS compared to conventional bulk plasma genotyping, and examine the correlation of majority and minority-level resistance mutations in DBS with treatment history. Study design: Evaluate nucleic acids from the DBS of 33 antiretroviral-experienced subtype B-infected subjects for minority M41L, K65R, K70R, K103N, Y181C, M184V, and T215Y/F mutations by real-time PCR. Compare minority resistance mutations in DBS with bulk genotypes from the same DBS cards and available plasma specimens. Results: All but one (50/51, 98%) mutation from the original plasma bulk sequencing were still detectable in the DBS after three years of storage. The one mutation not identified in DBS was also no longer detectable by bulk sequencing. Furthermore, sensitive testing found 12 additional drug resistance mutations at minority levels in the DBS of 11 (33%) patients. Six minority mutations were in the RNA compartment and six were detected only in the DNA compartment. Resistance was detected in the DBS RNA compartment only in cases where the associated drug was in use within one year of sample collection. Conclusions: Our ability to identify majority and additional minority-level resistance mutations demonstrated that DBS, if stored properly, is a high-integrity specimen type for conventional and sensitive drug resistance testing. Our data further support the global utility of DBS for drug resistance surveillance and clinical monitoring. Published by Elsevier B.V. C1 [Wei, Xierong; Youngpairoj, Ae S.; Heneine, Walid; Johnson, Jeffrey A.; Garcia-Lerma, Gerardo] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Branch Lab, Atlanta, GA 30333 USA. [Garrido, Carolina; Zahonero, Natalia; Corral, Angelica; de Mendoza, Carmen] Hosp Carlos III, Dept Infect Dis, Madrid, Spain. RP Johnson, JA (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Branch Lab, 1600 Clifton Rd NE,MS G45, Atlanta, GA 30333 USA. EM jjohnson1@cdc.gov; jng5@cdc.gov FU Fondo de Investigacion Sanitaria (FIS) [CP06/284, PI06/1826] FX This work was entirely supported intramurally by CDC with original sample collection funded by grants from the Fondo de Investigacion Sanitaria (FIS, CP06/284 and PI06/1826). NR 22 TC 8 Z9 8 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1386-6532 J9 J CLIN VIROL JI J. Clin. Virol. PD FEB PY 2011 VL 50 IS 2 BP 148 EP 152 DI 10.1016/j.jcv.2010.11.006 PG 5 WC Virology SC Virology GA 711KP UT WOS:000286590600012 PM 21130027 ER PT J AU Brener, ND Pejavara, A McManus, T AF Brener, Nancy D. Pejavara, Anu McManus, Tim TI Applying the School Health Index to a Nationally Representative Sample of Schools: Update for 2006 SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE school health; health education; physical education; nutrition ID POLICIES; PROGRAMS AB METHODS: SHPPS 2006 data were collected through computer-assisted personal interviews with faculty and staff in a nationally representative sample of schools. The data were then matched to SHI items to calculate the percentage of schools meeting the recommendations in 4 areas: school health and safety policies and environment, health education, physical education and other physical activity programs, and nutrition services. RESULTS: In accordance with the earlier findings, the present analysis indicated that schools nationwide were focusing their efforts on a few policies and programs rather than addressing the entire set of recommendations in the SHI. The percentage of items related to nutrition that schools met remained high, and an increase occurred in the percentage of items that schools met related to school health and safety policies and environment. CONCLUSIONS: More work needs to be done to assist schools in implementing school health policies and practices; this analysis helps identify specific areas where improvement is needed. C1 [Brener, Nancy D.] Ctr Dis Control & Prevent, Surveillance Res Team, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. RP Brener, ND (reprint author), Ctr Dis Control & Prevent, Surveillance Res Team, Div Adolescent & Sch Hlth, 4770 Buford Hwy NE,MSK 33, Atlanta, GA 30341 USA. EM nbrener@cdc.gov; apejavara@cdc.gov; tsm9@cdc.gov NR 23 TC 2 Z9 2 U1 1 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD FEB PY 2011 VL 81 IS 2 BP 81 EP 90 DI 10.1111/j.1746-1561.2010.00564.x PG 10 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 705NX UT WOS:000286144300006 PM 21223275 ER PT J AU Hankin, A Hertz, M Simon, T AF Hankin, Abigail Hertz, Marci Simon, Thomas TI Impacts of Metal Detector Use in Schools: Insights From 15 Years of Research SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE violence; injury prevention; public health ID VIOLENCE; PREVALENCE AB METHODS: We conducted an extensive literature search, including databases for the medical, public health, sociology, and political science literature. Of 128 papers that met our search criteria, 7 studies met inclusion criteria for the literature review. RESULTS: Each of the papers reviewed utilized data that originated from self-report surveys. Four of the studies consisted of secondary analyses of national databases, with the other 3 utilizing local surveys. The studies varied as to the outcome, ranging from student/staff perceptions of safety at school to student self-reports of weapon carrying and/or victimization, and showed mixed results. Several studies suggested potential detrimental effects of metal detectors on student perceptions of safety. One study showed a significant beneficial effect, linking metal detector use to a decrease in the likelihood that students reported carrying a weapon while in school (7.8% vs 13.8%), without a change in weapon carrying in other settings or a decline in participation in physical fights. CONCLUSION: There is insufficient data in the literature to determine whether the presence of metal detectors in schools reduces the risk of violent behavior among students, and some research suggests that the presence of metal detectors may detrimentally impact student perceptions of safety. C1 [Hankin, Abigail] Emory Univ, Atlanta, GA 30303 USA. [Hertz, Marci] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. [Simon, Thomas] Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Hankin, A (reprint author), Emory Univ, 49 Jesse Hill Dr, Atlanta, GA 30303 USA. EM ahankin@emory.edu; mvf4@cdc.gov; tgs9@cdc.gov NR 22 TC 8 Z9 8 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD FEB PY 2011 VL 81 IS 2 BP 100 EP 106 DI 10.1111/j.1746-1561.2010.00566.x PG 7 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 705NX UT WOS:000286144300008 PM 21223277 ER PT J AU McConley, RL Mrug, S Gilliland, MJ Lowry, R Elliott, MN Schuster, MA Bogart, LM Franzini, L Escobar-Chaves, SL Franklin, FA AF McConley, Regina L. Mrug, Sylvie Gilliland, M. Janice Lowry, Richard Elliott, Marc N. Schuster, Mark A. Bogart, Laura M. Franzini, Luisa Escobar-Chaves, Soledad L. Franklin, Frank A. TI Mediators of Maternal Depression and Family Structure on Child BMI: Parenting Quality and Risk Factors for Child Overweight SO OBESITY LA English DT Article ID OBESE CHILDREN; OBESIGENIC FAMILIES; PHYSICAL-ACTIVITY; ADOLESCENTS; WEIGHT; ASSOCIATION; BEHAVIORS; CONTEXT; ENVIRONMENT; ADJUSTMENT AB Risk factors for child obesity may be influenced by family environment, including maternal depression, family structure, and parenting quality. We tested a path model in which maternal depression and single parent status are associated with parenting quality, which relates to three risk factors for child obesity: diet, leisure, and sedentary behavior. Participants included 4,601 5th-grade children and their primary caregivers who participated in the Healthy Passages study. Results showed that associations of maternal depression and single parenthood with child BMI are mediated by parenting quality and its relation to children's leisure activity and sedentary behavior. Interventions for child obesity may be more successful if they target family environment, particularly parenting quality and its impact on children's active and sedentary behaviors. C1 [McConley, Regina L.; Mrug, Sylvie; Franklin, Frank A.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA. [McConley, Regina L.; Mrug, Sylvie; Franklin, Frank A.] Univ Alabama Birmingham, Dept Hlth Behav, Birmingham, AL 35294 USA. [Gilliland, M. Janice] Univ Utah, Dept Pediat, Salt Lake City, UT USA. [Lowry, Richard] Ctr Dis Control & Prevent, Atlanta, GA USA. [Elliott, Marc N.; Schuster, Mark A.; Bogart, Laura M.] RAND Corp, Santa Monica, CA USA. [Schuster, Mark A.; Bogart, Laura M.] Harvard Univ, Sch Med, Dept Med, Childrens Hosp Boston, Boston, MA USA. [Franzini, Luisa; Escobar-Chaves, Soledad L.] Univ Texas Hlth Sci Ctr Houston, Ctr Hlth Promot & Prevent Res, Houston, TX USA. RP Mrug, S (reprint author), Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA. EM smrug@uab.edu FU Centers for Disease Control and Prevention [U48DP000046, U48DP000057, U48DP000056] FX This research was supported by Cooperative Agreement Numbers U48DP000046, U48DP000057, and U48DP000056 from the Centers for Disease Control and Prevention. The contents of this report are solely the responsibility of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. S.M. has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. NR 60 TC 24 Z9 24 U1 1 U2 19 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1930-7381 J9 OBESITY JI Obesity PD FEB PY 2011 VL 19 IS 2 BP 345 EP 352 DI 10.1038/oby.2010.177 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 712FW UT WOS:000286651400018 PM 20798670 ER PT J AU Peytchev, A Carley-Baxter, LR Black, MC AF Peytchev, Andy Carley-Baxter, Lisa R. Black, Michele C. TI Multiple Sources of Nonobservation Error in Telephone Surveys: Coverage and Nonresponse SO SOCIOLOGICAL METHODS & RESEARCH LA English DT Article DE nonresponse bias; coverage bias; dual frame; two phase; cell phone; weighting adjustments ID BIAS; PHONE; RATES; CELL AB Random digit dialed telephone surveys are facing two serious problems undermining probability-based inference and creating a potential for bias in survey estimates: declining response rates and declining coverage of the landline telephone frame. Optimum survey designs need to focus reduction techniques on errors that cannot be addressed through statistical adjustment. This requires (a) separating and estimating the relative magnitude of different error sources and (b) evaluating the degree to which each error source can be statistically adjusted. In this study, the authors found significant differences in means both for nonrespondents and for the eligible population excluded from the landline frame, which are also in opposite directions. Differences were also found for element variances and associations, which can affect survey results but are rarely examined. Adjustments were somewhat effective in decreasing both sources of bias, although addressing at least one through data collection led to less bias in the adjusted estimates. C1 [Peytchev, Andy] RTI Int, Program Res Survey Methodol, Res Triangle Pk, NC 27709 USA. [Black, Michele C.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Peytchev, A (reprint author), RTI Int, Program Res Survey Methodol, 3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA. EM andrey@umich.edu NR 37 TC 6 Z9 6 U1 0 U2 5 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0049-1241 J9 SOCIOL METHOD RES JI Sociol. Methods. Res. PD FEB PY 2011 VL 40 IS 1 BP 138 EP 168 DI 10.1177/0049124110392547 PG 31 WC Social Sciences, Mathematical Methods; Sociology SC Mathematical Methods In Social Sciences; Sociology GA 705BP UT WOS:000286103900007 ER PT J AU Lopiano, KK Young, LJ Gotway, CA AF Lopiano, Kenneth K. Young, Linda J. Gotway, Carol A. TI A comparison of errors in variables methods for use in regression models with spatially misaligned data SO STATISTICAL METHODS IN MEDICAL RESEARCH LA English DT Article; Proceedings Paper CT Biannual GEOMED Conference CY NOV, 2009 CL Med Univ, Charleston, SC HO Med Univ ID AIR-POLLUTION; EXPOSURES; CITIES AB When a response variable Y is measured on one set of points and a spatially varying predictor variable X is measured on a different set of points, X and Y have different supports and thus are spatially misaligned. To draw inference about the association between X and Y , X is commonly predicted at the points for which Y is observed, and Y is regressed on the predicted X. If X is predicted using kriging or some other smoothing approach, use of the predicted instead of the true (unobserved) X values in the regression results in unbiased estimates of the regression parameters. However, the naive standard errors of these parameters tend to be too small. In this article, two simulation studies are used to compare methods for providing appropriate standard errors in this spatial setting. Three of the methods are extended to the change-of-support case where X is observed at points, but Y is observed for areal units, and these approaches are also compared via simulation. C1 [Lopiano, Kenneth K.; Young, Linda J.] Univ Florida, Dept Stat, Gainesville, FL 32611 USA. [Gotway, Carol A.] Ctr Dis Control, Atlanta, GA 30333 USA. RP Lopiano, KK (reprint author), Univ Florida, Dept Stat, Gainesville, FL 32611 USA. EM klopiano@ufl.edu FU NCEH CDC HHS [5 U38 EH000177-02] NR 20 TC 10 Z9 10 U1 0 U2 7 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0962-2802 J9 STAT METHODS MED RES JI Stat. Methods Med. Res. PD FEB PY 2011 VL 20 IS 1 SI SI BP 29 EP 47 DI 10.1177/0962280210370266 PG 19 WC Health Care Sciences & Services; Mathematical & Computational Biology; Medical Informatics; Statistics & Probability SC Health Care Sciences & Services; Mathematical & Computational Biology; Medical Informatics; Mathematics GA 710ON UT WOS:000286521200003 PM 20519258 ER PT J AU Clough, A Wagman, J Rollins, C Barnes, J Connor-Smith, J Holditch-Niolon, P McDowell, S Martinez-Bell, E Bloom, T Baker, C Glass, N AF Clough, Amber Wagman, Jennifer Rollins, Chiquita Barnes, Jamie Connor-Smith, Jennifer Holditch-Niolon, Phyllis McDowell, Sarah Martinez-Bell, Erminia Bloom, Tina Baker, Charlene Glass, Nancy TI The SHARE Project: Maximizing Participant Retention in a Longitudinal Study with Victims of Intimate Partner Violence SO FIELD METHODS LA English DT Article DE retention; intimate partner violence; research methods; safety needs; longitudinal studies ID BATTERED WOMEN; RECRUITMENT; STRATEGIES; RISK AB Retaining victims of intimate partner violence (IPV) in longitudinal research is challenging, as abused women often face safety concerns, housing and employment instability, poverty, and major life transitions, making it difficult to locate and retain participants at follow-up time points. This article builds on past research to describe individualized, technology-based retention strategies for hard-to-reach populations, which minimize participant loss while maintaining participant safety. These techniques have resulted in retention rates of 94% at 6-, 12-, and 18-month follow-up interviews in a sample of 278 women experiencing both IPV and housing instability. The authors discuss the ethical use of appropriate technology for maximizing retention of participants as well as the importance of adjusting retention activities to meet the individual safety needs of each participant. C1 [Clough, Amber; Rollins, Chiquita; Barnes, Jamie; Martinez-Bell, Erminia] Multnomah Cty Domest Violence Coordinators Off, Portland, OR USA. [Wagman, Jennifer; Glass, Nancy] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD 21205 USA. [Connor-Smith, Jennifer] Portland State Univ, Dept Criminol & Criminal Justice, Portland, OR 97207 USA. [Holditch-Niolon, Phyllis] Ctr Dis Control & Prevent, Prevent Dev & Evaluat Branch, Div Violence Prevent, Atlanta, GA USA. [McDowell, Sarah] United Way, Portland, OR USA. [Bloom, Tina] Univ Missouri, Sch Nursing, Sinclair Sch Nursing S326, Columbia, MO USA. [Baker, Charlene] Univ Hawaii, Dept Psychol, Honolulu, HI 96822 USA. RP Glass, N (reprint author), Johns Hopkins Univ, Sch Nursing, 525 N Wolfe St,Rm 439, Baltimore, MD 21205 USA. EM nglass1@son.jhmi.edu OI Wagman, Jennifer/0000-0002-9957-1932; Bloom, Tina/0000-0002-5581-1228 NR 16 TC 4 Z9 4 U1 2 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1525-822X J9 FIELD METHOD JI Field Methods PD FEB PY 2011 VL 23 IS 1 BP 86 EP 101 DI 10.1177/1525822X10384446 PG 16 WC Anthropology; Social Sciences, Interdisciplinary SC Anthropology; Social Sciences - Other Topics GA 699TJ UT WOS:000285685400006 ER PT J AU Lantagne, D Preston, K Blanton, E Kotlarz, N Gezagehn, H van Dusen, E Berens, J Jellison, K AF Lantagne, D. Preston, K. Blanton, E. Kotlarz, N. Gezagehn, H. van Dusen, E. Berens, J. Jellison, K. TI Hypochlorite Solution Expiration and Stability in Household Water Treatment in Developing Countries SO JOURNAL OF ENVIRONMENTAL ENGINEERING-ASCE LA English DT Article DE Developing countries; Expiration; Household water treatment; Safe water system; Sodium hypochlorite; Stability ID RANDOMIZED CONTROLLED-TRIAL; FLOCCULANT-DISINFECTANT; DIARRHEA PREVENTION; DRINKING-WATER; CHILDHOOD DIARRHEA; SAFE STORAGE; COMMUNITY; CHILDREN AB Household water treatment with dilute hypochlorite solution has been shown to improve microbiological water quality and reduce diarrheal disease in developing countries. One concern raised by governmental agencies, implementers, and nongovernmental organizations is whether the hypochlorite solution remains stable during distribution and after the bottle is opened and usage begins. In this study, laboratory and field research was conducted to determine the expiration date and stability in the home of hypochlorite solution. Expiration-date testing found that pH-stabilized similar to 1.25% hypochlorite solution made using various production techniques in Ethiopia, Guinea, and Nigeria was stable for a minimum of 12 months in temperatures less than 35 C. Stability testing during laboratory simulated normal usage showed no degradation, and 77-91% of bottles collected from households tested met standards. Hypochlorite solution concentration drops rapidly when pH is not stabilized, when pH levels fall, and when solution is exposed to direct sunlight. C1 [Lantagne, D.; Blanton, E.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA 30333 USA. [Preston, K.; Kotlarz, N.; Jellison, K.] Lehigh Univ, Dept Civil & Environm Engn, Bethlehem, PA 18015 USA. [Gezagehn, H.] Populat Serv Int, Addis Ababa, Ethiopia. [van Dusen, E.] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Berens, J.] Innovat Poverty Act, Kisumu, Kenya. RP Lantagne, D (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, 1600 Clifton Rd,MS-A38, Atlanta, GA 30333 USA. EM dlantagne@cdc.gov FU National Science Foundation [0545687]; U.S. Agency for International Development, Population Services International; Jolivert Safe Water for Families; Innovations for Poverty Action FX The writers would like to thank Clorox Cooperation for their assistance, as well as Prime Enterprises, PSI staff in Nigeria and Guinea, and JSWF staff in Haiti. The Lehigh University work was partially supported by a National Science Foundation CAREER grant to cowriter Jellison (Award No. 0545687). The in-country work was partially supported by the U.S. Agency for International Development, Population Services International, the Jolivert Safe Water for Families project, and Innovations for Poverty Action. NR 17 TC 3 Z9 3 U1 1 U2 18 PU ASCE-AMER SOC CIVIL ENGINEERS PI RESTON PA 1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA SN 0733-9372 J9 J ENVIRON ENG-ASCE JI J. Environ. Eng.-ASCE PD FEB PY 2011 VL 137 IS 2 BP 131 EP 136 DI 10.1061/(ASCE)EE.1943-7870.0000299 PG 6 WC Engineering, Environmental; Engineering, Civil; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 706LN UT WOS:000286220000004 ER PT J AU Siegel, BR Baughman, W Ahlquist, AM Ladson, J Lockhart, SR Chiller, T Farley, MM AF Siegel, B. R. Baughman, W. Ahlquist, A. M. Ladson, J. Lockhart, S. R. Chiller, T. Farley, M. M. TI CANDIDEMIA IN METROPOLITAN ATLANTA, GEORGIA, 2008-09: EPIDEMIOLOGIC CHARACTERISTICS AND SELECTED OUTCOMES SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract CT Southern Regional Meeting of the American-Federation-for-Medical-Research 2011 CY FEB 17-19, 2011 CL New Orleans, LA SP Amer Federation Med Res Southern Region C1 [Siegel, B. R.; Farley, M. M.] Emory Univ, Atlanta, GA 30322 USA. [Baughman, W.; Farley, M. M.] Atlanta VAMC, Decatur, GA USA. [Ahlquist, A. M.; Lockhart, S. R.; Chiller, T.] CDC, Atlanta, GA 30333 USA. [Ladson, J.] Atl Res & Educ Fdn, Decatur, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD FEB PY 2011 VL 59 IS 2 MA 416 BP 489 EP 489 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 709SK UT WOS:000286461500426 ER PT J AU Looker, AC Dawson-Hughes, B Tosteson, ANA Johansson, H Kanis, JA Melton, LJ AF Looker, A. C. Dawson-Hughes, B. Tosteson, A. N. A. Johansson, H. Kanis, J. A. Melton, L. J., III TI Hip fracture risk in older US adults by treatment eligibility status based on new National Osteoporosis Foundation guidance SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Incident hip fracture; National Osteoporosis Foundation Clinician's Guide; Population study; Treatment eligibility ID TRAUMA FRACTURES; UNITED-STATES; ELDERLY WOMEN; WHITE WOMEN; MEN; BMD; PROBABILITY; THRESHOLDS; PREVALENCE; GUIDELINES AB This analysis of National Health and Nutrition Examination Survey III data found a significant risk of incident hip fracture in adults aged 65 years and older who are candidates for treatment to lower fracture risk, according to the new National Osteoporosis Foundation Clinician's Guide. The relationship between treatment eligibility by the new National Osteoporosis Foundation (NOF) Guide to the Prevention and Treatment of Osteoporosis and the risk of subsequent hip fracture is unknown. The study sample consisted of 3,208 men and women ages 65 years and older who were examined in the third National Health and Nutrition Examination Survey (NHANES III, 1988-1994), a nationally representative survey. Risk factors used to define treatment eligibility at baseline were measured in NHANES III or were simulated using World Health Organization study cohorts. Incident hip fractures were ascertained using linked mortality and Medicare records that were obtained for NHANES III participants through December 31, 2000. Cox proportional hazards models were used to estimate the relative risk (RR) of hip fracture by treatment eligibility status. The RR for subsequent hip fracture was 4.9 (95% CI 3.30, 7.94) in treatment-eligible vs treatment-ineligible persons. The increased risk for treatment-eligible persons remained statistically significant when examined by sex or age: RR(men) = 5.5 (2.6, 11.4) and RR(women) = 4.3 (2.2, 8.4); RR(65-79 y) = 4.8 (2.6, 8.7) and RR(80+ y) = 4.6 (2.1, 10.1). Treatment-eligible persons were about five times more likely to experience a subsequent hip fracture than the non-eligible persons. The new NOF guidelines appear to predict future hip fracture risk equally in men as in women, and fracture risk prediction did not appear to diminish with age. C1 [Looker, A. C.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Dawson-Hughes, B.] Tufts Univ, Human Nutr Res Ctr Aging, Jean Mayer USDA, Boston, MA 02111 USA. [Tosteson, A. N. A.] Dartmouth Med Sch, Multidisciplinary Clin Res Ctr Musculoskeletal Di, Lebanon, NH USA. [Tosteson, A. N. A.] Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA. [Johansson, H.; Kanis, J. A.] Univ Sheffield, Sch Med, WHO Collaborating Ctr Metab Bone Dis, Sheffield, S Yorkshire, England. [Melton, L. J., III] Mayo Clin, Coll Med, Div Epidemiol, Rochester, MN USA. RP Looker, AC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Rm 4310,3311 Toledo Rd, Hyattsville, MD 20782 USA. EM ALooker@cdc.gov NR 35 TC 8 Z9 9 U1 0 U2 1 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD FEB PY 2011 VL 22 IS 2 BP 541 EP 549 DI 10.1007/s00198-010-1288-0 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 706HC UT WOS:000286207800014 PM 20480142 ER PT J AU Plantinga, LC Johansen, K Crews, DC Shahinian, VB Robinson, BM Saran, R Burrows, NR Williams, DE Powe, NR AF Plantinga, Laura C. Johansen, Kirsten Crews, Deidra C. Shahinian, Vahakn B. Robinson, Bruce M. Saran, Rajiv Burrows, Nilka Rios Williams, Desmond E. Powe, Neil R. CA CDC CKD Surveillance Team TI Association of CKD With Disability in the United States SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Chronic kidney disease; disability; activities of daily living; limitations; employment; physical functioning; cognitive functioning ID CHRONIC KIDNEY-DISEASE; CHRONIC RENAL-INSUFFICIENCY; GLOMERULAR-FILTRATION-RATE; COGNITIVE FUNCTION; SERUM CREATININE; NATIONAL-HEALTH; DIALYSIS; EQUATION; FRAILTY AB Background: Little is known about disability in early-stage chronic kidney disease (CKD). Study Design: Cross-sectional national survey (National Health and Nutrition Examination Survey 19992006). Setting & Participants: Community-based survey of 16,011 noninstitutionalized US civilian adults (aged >20 years). Predictor: CKD, categorized as no CKD, stages 1 and 2 (albuminuria and estimated glomerular filtration rate [eGFR] >= 60 mL/min/1.73 m(2)), and stages 3 and 4 (eGFR, 15-59 mL/min/1.73 m(2)). Outcome: Self-reported disability, defined by limitations in working, walking, and cognition and difficulties in activities of daily living (ADL), instrumental ADL, leisure and social activities, lower-extremity mobility, and general physical activity. Measurements: Albuminuria and eGFR assessed from urine and blood samples; disability, demographics, access to care, and comorbid conditions assessed using a standardized questionnaire. Results: Age-adjusted prevalence of reported limitations generally was significantly greater with CKD: for example, difficulty with ADL was reported by 17.6%, 24.7%, and 23.9% of older (>= 65 years) and 6.8%, 11.9%, and 11.0% of younger (20-64 years) adults with no CKD, stages 1 and 2, and stages 3 and 4, respectively. CKD also was associated with greater reported limitations and difficulty in other activities after age adjustment, including instrumental ADL, leisure and social activities, lower-extremity mobility, and general physical activity. Other demographics, socioeconomic status, and access to care generally only slightly attenuated the observed associations, particularly in older individuals; adjustment for cardiovascular disease, arthritis, and cancer attenuated most associations such that statistical significance no longer was achieved. Limitations: Inability to establish causality and possible unmeasured confounding. Conclusion: CKD is associated with a higher prevalence of disability in the United States. Age and other comorbid conditions account for most, but not all, of this association. Am J Kidney Dis. 57(2):212-227. (C) 2011 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Plantinga, Laura C.; Powe, Neil R.] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. [Plantinga, Laura C.; Johansen, Kirsten; Powe, Neil R.] Univ Calif San Francisco, San Francisco, CA 94110 USA. [Johansen, Kirsten] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA. [Crews, Deidra C.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Shahinian, Vahakn B.; Saran, Rajiv] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Robinson, Bruce M.; Saran, Rajiv] Arbor Res Collaborat Hlth, Ann Arbor, MI USA. [Burrows, Nilka Rios; Williams, Desmond E.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. RP Plantinga, LC (reprint author), San Francisco Gen Hosp, Dept Med, 1001 Potrero Ave,Bldg 10,Fl 3, San Francisco, CA 94110 USA. EM plantingal@medsfgh.ucsf.edu FU Centers for Disease Control and Prevention (CDC) through the Association of American Medical Colleges (AAMC) [U36/CCU319276, MM-0997-07/07, MM-1143-10/10]; Robert Wood Johnson Foundation; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD [K24DK02643] FX This project was supported under a cooperative agreement from the Centers for Disease Control and Prevention (CDC) through the Association of American Medical Colleges (AAMC), grant number U36/CCU319276, AAMC ID numbers MM-0997-07/07 and MM-1143-10/10. Report contents are solely the responsibility of the authors and do not necessarily represent the official views of the AAMC or CDC. Dr Crews is supported by the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. Dr Powe is partially supported by grant K24DK02643 from the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. NR 26 TC 24 Z9 24 U1 1 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD FEB PY 2011 VL 57 IS 2 BP 212 EP 227 DI 10.1053/j.ajkd.2010.08.016 PG 16 WC Urology & Nephrology SC Urology & Nephrology GA 708OK UT WOS:000286372700008 PM 21036441 ER PT J AU Louie, JK Jamieson, DJ Rasmussen, SA AF Louie, Janice K. Jamieson, Denise J. Rasmussen, Sonja A. TI 2009 pandemic influenza A (H1N1) virus infection in postpartum women in California SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE influenza; pandemic; postpartum; pregnancy; swine; 2009 pandemic influenza A ID PREGNANT-WOMEN; ASIAN INFLUENZA; UNITED-STATES; ILLNESS; IMPACT; TESTS AB OBJECTIVE: The objective of the study was to characterize severe illness because of the 2009 pandemic influenza A (H1N1) infection in postpartum women. STUDY DESIGN: We reviewed case reports of infected hospitalized postpartum (<= 6 months from delivery) women identified through state-wide surveillance in California. From April 23 through August 11, 2009, all hospitalizations and/or deaths were reported. After August 11, reporting was limited to cases requiring intensive care or deaths. RESULTS: From April 23 to December 31, 2009, 15 cases were reported; 11 (73%) had symptom onset within 7 days postpartum. Of 10 hospitalized cases reported through August 11, 4 required intensive care, 3 required mechanical ventilation, and 2 died. Of 5 cases requiring intensive care reported after August 11, all required mechanical ventilation and 1 died. Overall, 6 (43%) received antivirals within 48 hours of symptom onset. CONCLUSION: The 2009 H1N1 can cause severe illness in postpartum women, especially in the first week following delivery. C1 [Louie, Janice K.] Calif Dept Publ Hlth, Richmond, CA 94804 USA. [Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Louie, JK (reprint author), Calif Dept Publ Hlth, 850 Marina Bay Pkwy, Richmond, CA 94804 USA. EM janice.louie@cdph.ca.gov FU California Department of Public Health FX We are grateful for the support of Meileen Acosta, Cynthia Jean, Shilpa Gavali, Nina Huynh, Christopher Anderson, Daniel Zhuang, Samuel Yang, Melinee Stewart, Miguel Ramos, Bela Matyas, and Gilberto Chavez. Many thanks go to all dedicated staff at the CDPH, epidemiologists and laboratorians alike, who contributed to surveillance and laboratory investigation of the 2009 (H1N1) influenza cases. In addition, although we cannot name them all, we gratefully acknowledge the contributions of the clinicians throughout California and all the staff at California local health departments who diligently worked to help acquire the epidemiologic and clinical information and ensured that these cases were reported to the CDPH. None of the authors has any conflict of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the article) relevant to the subject of this article. Dr Louie had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the article was fully sponsored by the California Department of Public Health. NR 27 TC 0 Z9 0 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD FEB PY 2011 VL 204 IS 2 AR 144.e1 DI 10.1016/j.ajog.2010.08.057 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 715HV UT WOS:000286874900021 PM 21074132 ER PT J AU Zimmerman, RK Albert, SM Nowalk, MP Yonas, MA Ahmed, F AF Zimmerman, Richard K. Albert, Steven M. Nowalk, Mary Patricia Yonas, Michael A. Ahmed, Faruque TI Use of Standing Orders for Adult Influenza Vaccination A National Survey of Primary Care Physicians SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID MISSED OPPORTUNITIES; RATES AB Background: Influenza vaccination of adults remains below recommended levels. Standing orders programs (SOPs) that allow nonphysician medical staff to assess eligibility and administer vaccines without an individualized physician's order are a proven method to increase vaccination rates. However, recent data on their use are not available. Purpose: Investigators surveyed primary care physicians nationwide in 2009 to assess factors related to awareness and use of SOPs. Methods: Using the AMA Master List, a stratified random sample of U. S. family physicians (n = 820) and general internists (n = 820) was selected to receive a mailed questionnaire. The inclusion criterion was providing primary care to adults in an office-based practice. The primary outcome measure, analyzed in 2010, was consistent use of SOPs. Results: The survey response rate was 67% (1015/1517). Forty-two percent of respondents who immunized adults in their practices reported consistent use of SOPs. Those physicians differed in several dimensions, including awareness of recommendations and regulations regarding SOPs for vaccines, size and type of practice, number and level of training of clinical staff, attributes of the staff. The two variables in logistic regression models that were associated with the highest likelihood of using SOPs were awareness of recommendations to use them (OR = 3.0; 95% CI = 2.2, 4.1) and agreement with their effectiveness (OR = 2.7, 95% CI = 1.9, 3.8). Conclusions: Fewer than half of physicians report using SOPs for influenza vaccination, a number that is not much higher than it was about a decade ago. Approaches to increase use of SOPs are needed. (Am J Prev Med 2011;40(2):144-148) (c) 2011 American Journal of Preventive Medicine C1 [Zimmerman, Richard K.; Nowalk, Mary Patricia; Yonas, Michael A.] Univ Pittsburgh, Dept Family Med & Clin Epidemiol, Sch Med, Pittsburgh, PA 15261 USA. [Zimmerman, Richard K.; Albert, Steven M.] Univ Pittsburgh, Dept Behav & Community Hlth Sci, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Ahmed, Faruque] CDC, Atlanta, GA 30333 USA. RP Nowalk, MP (reprint author), Univ Pittsburgh, Dept Family Med & Clin Epidemiol, Sch Med, 3518 5th Ave, Pittsburgh, PA 15261 USA. EM tnowalk@pitt.edu OI Zimmerman, Richard/0000-0001-5941-6092; Albert, Steven/0000-0001-6786-9956 FU Association for Prevention Teaching and Research (APTR) [5U50CD300860, TS-1432]; Merck Co, Inc.; MedImmune; LLC FX This publication was made possible through the CDC and the Association for Prevention Teaching and Research (APTR) Cooperative Agreement, No. 5U50CD300860, Project TS-1432. The findings and conclusions in this publication are those of the authors and do not necessarily represent the views of the CDC or the Association for Prevention Teaching and Research.; RKZ has received research support from and is a consultant for Merck & Co, Inc. and has received research support from MedImmune, LLC. MPN has received research support from MedImmune, LLC. NR 19 TC 13 Z9 13 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2011 VL 40 IS 2 BP 144 EP 148 DI 10.1016/j.amepre.2010.10.027 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 706AP UT WOS:000286184100007 PM 21238862 ER PT J AU Lu, PJ Euler, GL Harpaz, R AF Lu, Peng-jun Euler, Gary L. Harpaz, Rafael TI Herpes Zoster Vaccination Among Adults Aged 60 Years and Older, in the US, 2008 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID UNITED-STATES; POSTHERPETIC NEURALGIA; COVERAGE AB Background: Shingles (herpes zoster [HZ]) is a localized, generally painful and debilitating disease that occurs most frequently among older adults. It is caused by reactivation of varicella-zoster virus. HZ causes substantial morbidity, especially among older adults. The vaccine to prevent HZ was approved by Food and Drug Administration and recommended by the Advisory Committee for Immunization Practices for people aged >= 60 years in 2006 (these recommendations were published in 2008). Purpose: To examine HZ vaccination among people aged >= 60 years in the U.S. in 2008. Methods: Data from the 2008 National Health Interview Survey among people aged >= 60 years were analyzed in 2010. Multivariable logistic regression and predictive marginal analyses were conducted to identify factors independently associated with HZ vaccination. Potential missed opportunities also were assessed. Results: By 2008, only 6.7% (95% CI = 5.9%, 7.6%) of adults aged >= 60 years reported having had HZ vaccination. The level of HZ vaccination coverage was lower (4.7%) among people aged 60-64 years compared to people aged 65-74 years (7.4%); 75-84 years (7.6%); and >= 85 years (8.2%). Coverage was statistically higher for non-Hispanic whites (7.6%) compared with non-Hispanic blacks (2.5%) and Hispanics (2.1%). Among people aged >= 60 years who reported never receiving HZ vaccination, 95.1% reported at least one missed opportunity to be vaccinated. People more likely to report ever having been vaccinated were older, female, non-Hispanic white, married, more educated, and reporting received influenza vaccination in the past year. Conclusions: By 2008, HZ vaccination coverage was 6.7%. The coverage level was low among all groups, but it was lowest among minority groups. Increased efforts are needed to remove barriers and to enable HZ vaccination among all adults aged >= 60 years. (Am J Prev Med 2011;40(2):e1-e6) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Lu, Peng-jun; Euler, Gary L.] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. [Harpaz, Rafael] CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. RP Lu, PJ (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, 1600 Clifton Rd NE,Mail Stop E 62, Atlanta, GA 30333 USA. EM plu@cdc.gov NR 30 TC 29 Z9 29 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2011 VL 40 IS 2 BP E1 EP E6 DI 10.1016/j.amepre.2010.10.012 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 706AP UT WOS:000286184100001 PM 21238856 ER PT J AU Murtagh, L Moulton, AD AF Murtagh, Lindsey Moulton, Anthony D. TI Strategies to Protect Vulnerable Populations Working Mothers, Breastfeeding, and the Law SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; MATERNAL EMPLOYMENT; DURATION; INITIATION; WORKPLACE; FRAMEWORK; BARRIERS; IMPACT; LEAVE; WOMEN C1 [Murtagh, Lindsey] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Moulton, Anthony D.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Murtagh, L (reprint author), Care of Blewett L, Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA. EM lmurtagh@jd09.law.harvard.edu NR 32 TC 27 Z9 27 U1 1 U2 9 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2011 VL 101 IS 2 BP 217 EP 223 DI 10.2105/AJPH.2009.185280 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 707QH UT WOS:000286300600010 PM 21164100 ER PT J AU Strickland, BB van Dyck, PC Kogan, MD Lauver, C Blumberg, SJ Bethell, CD Newacheck, PW AF Strickland, Bonnie B. van Dyck, Peter C. Kogan, Michael D. Lauver, Cassie Blumberg, Stephen J. Bethell, Christina D. Newacheck, Paul W. TI Assessing and Ensuring a Comprehensive System of Services for Children With Special Health Care Needs: A Public Health Approach SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article C1 [Strickland, Bonnie B.; van Dyck, Peter C.; Kogan, Michael D.; Lauver, Cassie] Maternal & Child Hlth Bur, US Hlth Resources & Serv Adm, Rockville, MD USA. [Blumberg, Stephen J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Bethell, Christina D.] Oregon Hlth & Sci Univ, Portland, OR USA. [Newacheck, Paul W.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA. [Newacheck, Paul W.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. RP Strickland, BB (reprint author), 5600 Fishers Lane,Room 18A27,Parklawn Bldg, Rockville, MD 20587 USA. EM bstrickland@hrsa.gov NR 19 TC 15 Z9 15 U1 1 U2 11 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2011 VL 101 IS 2 BP 224 EP 231 DI 10.2105/AJPH.2009.177915 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 707QH UT WOS:000286300600011 PM 21228285 ER PT J AU Beeler, E Abramowicz, KF Zambrano, ML Sturgeon, MM Khalaf, N Hu, R Dasch, GA Eremeeva, ME AF Beeler, Emily Abramowicz, Kyle F. Zambrano, Maria L. Sturgeon, Michele M. Khalaf, Nada Hu, Renjie Dasch, Gregory A. Eremeeva, Marina E. TI A Focus of Dogs and Rickettsia massiliae-Infected Rhipicephalus sanguineus in California SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID FEVER GROUP RICKETTSIAE; MOUNTAIN-SPOTTED-FEVER; CONORII INFECTION; HUMAN PARASITISM; R-MASSILIAE; TICKS; IDENTIFICATION; IXODIDAE; ACARI; SPAIN AB A recurrent focus of Rhipicephalus sanguineus infestation was investigated in a suburban area of southern California after reports of suspected Rocky Mountain spotted fever in two dogs on the same property. Abundant quantities of Rh. sanguineus were collected on the property and repeatedly from each dog, and Rickettsia massiliae DNA was detected by polymerase chain reaction (PCR). Whole blood and serum samples from four dogs were tested by using PCR and microimmunofluorescent assay for antibodies against spotted fever group rickettsiae. Serum samples from all four dogs contained antibodies reactive with R. massiliae, R. rhipicephali, R. rickettsii, and 364D Rickettsia but no rickettsial DNA was detected by PCR of blood samples. Serum cross-absorption and Western blot assays implicated R. massiliae as the most likely spotted fever group rickettsiae responsible for seropositivity. To our knowledge, this is the first detection of R. massiliae in ticks in California. C1 [Abramowicz, Kyle F.; Zambrano, Maria L.; Sturgeon, Michele M.; Dasch, Gregory A.; Eremeeva, Marina E.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Beeler, Emily] Los Angeles Cty Dept Publ Hlth, Vet Publ Hlth & Rabies Control Program, Los Angeles, CA USA. [Hu, Renjie] Ctr Infect Dis, Vector Borne Dis Sect, Calif Dept Publ Hlth, Ontario, CA USA. [Khalaf, Nada] VCA McClave Anim Hosp, Reseda, CA USA. RP Eremeeva, ME (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Natl Ctr Emerging & Zoonot Infect Dis, Mailstop G13,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM ebeeler@ph.lacounty.gov; kabramowicz@cdc.gov; mzambrano@cdc.gov; msturgeon@cdc.gov; nada.khalaf@vca-hospitals.com; renjie.hu@cdph.ca.gov; gdasch@cdc.gov; meremeeva@cdc.gov OI Dasch, Gregory/0000-0001-6090-1810 NR 50 TC 22 Z9 22 U1 0 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2011 VL 84 IS 2 BP 244 EP 249 DI 10.4269/ajtmh.2011.10-0355 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 716WJ UT WOS:000287003900012 PM 21292893 ER PT J AU Baker, CJ Pickering, LK Chilton, L Cieslak, P Coyne-Beasley, T Duchin, J Ehresmann, KR Englund, J Friedman, C Jenkins, R Judson, FN Keitel, WA Marcy, MS Meissner, CH Rosenbaum, S Sawyer, MH Temte, J AF Baker, Carol J. Pickering, Larry K. Chilton, Lance Cieslak, Paul Coyne-Beasley, Tamera Duchin, Jeffrey Ehresmann, Kristen R. Englund, Janet Friedman, Carol Jenkins, Renee Judson, Franklyn N. Keitel, Wendy A. Marcy, Michael S. Meissner, Cody H. Rosenbaum, Sarah Sawyer, Mark H. Temte, Jonathan CA Advisory Comm Immunization Practic TI Recommended Adult Immunization Schedule: United States, 2011 SO ANNALS OF INTERNAL MEDICINE LA English DT Article C1 [Pickering, Larry K.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Chilton, Lance] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA. [Cieslak, Paul] Oregon Publ Hlth Div, Portland, OR USA. [Coyne-Beasley, Tamera] Univ N Carolina, Chapel Hill, NC USA. [Duchin, Jeffrey] Univ Washington, Seattle, WA 98195 USA. [Ehresmann, Kristen R.] Minnesota Dept Hlth, St Paul, MN USA. [Englund, Janet] Childrens Hosp, Seattle, WA USA. [Englund, Janet] Reg Med Ctr, Seattle, WA USA. [Friedman, Carol] Ctr Dis Control & Prevent, ACIP Adult Immunizat Working Grp, Atlanta, GA USA. [Jenkins, Renee] Howard Univ, Coll Med, Washington, DC USA. [Judson, Franklyn N.] Univ Colorado, Denver, CO 80202 USA. [Marcy, Michael S.] So Calif Permanente Med Grp, Los Angeles, CA 90027 USA. [Meissner, Cody H.] Tufts Med Ctr, Boston, MA USA. [Rosenbaum, Sarah] George Washington Univ, Washington, DC USA. [Sawyer, Mark H.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Temte, Jonathan] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. RP Baker, CJ (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop E52, Atlanta, GA 30333 USA. EM ams7@cdc.gov FU Centers for Disease Control and Prevention; Novartis; Medimmune; ADMA; National Institutes of Health; Bill AMP; Melinda Gates Foundation; Exxon Mobil Research Club; Protein Sciences FX To assure the integrity of the ACIP, the U. S. Department of Health and Human Services has taken steps to assure that there is technical compliance with ethics statutes and regulations regarding financial conflicts of interest. Concerns regarding the potential for the appearance of a conflict are addressed, or avoided altogether, through both pre- and postappointment considerations. Individuals with particular vaccine-related interests will not be considered for appointment to the committee. Potential nominees are screened for conflicts of interest and, if any are found, they are asked to divest or forgo certain vaccine-related activities. In addition, at the beginning of each ACIP meeting, each member is asked to declare his or her conflicts. Members with conflicts are not permitted to vote if the conflict involves the vaccine or biologic being voted upon. Members of the ACIP have disclosed the following: Dr. Chilton: Support to travel to meetings for the study or other purposes: Centers for Disease Control and Prevention. Dr. Coyne-Beasley: Consultancy: sanofi-pasteur; Payment for lectures including service on speakers bureaus: sanofi-pasteur. Dr. Ehresmann: Consulting fee or honorarium (money to institution): Centers for Disease Control and Prevention; Support to travel to meetings for the study or other purposes (money to institution): Centers for Disease Control and Prevention. Dr. Englund: Support to travel to meetings for the study or other purposes: Centers for Disease Control and Prevention; Grants/grants pending (money to institution): Novartis, Medimmune, ADMA; Other (money to institution): National Institutes of Health, Bill & Melinda Gates Foundation. Dr. Keitel: Consulting fee or honorarium: Centers for Disease Control and Prevention; Support to travel to meetings for the study or other purposes: Centers for Disease Control and Prevention; Grants/grants pending: Exxon Mobil Research Club; Grants/grants pending (money to institution): Novartis, Protein Sciences; Stock/stock options: Pfizer (since divested), Schering-Plough (since divested). Dr. Marcy: Consultancy: ACIP; Consultancy (money to institution): ACIP; Payment for development of educational presentations: Medical Education Speakers' Network, National Foundation for Infectious Diseases, Rady Children's Hospital San Diego, Phoenix Children's Hospital, Symposia Medicus. Dr. Rosenbaum: Consulting fee or honorarium: Centers for Disease Control and Prevention; Support to travel to meetings for the study or other purposes: Centers for Disease Control and Prevention. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-278 9. NR 0 TC 11 Z9 11 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 1 PY 2011 VL 154 IS 3 BP 168 EP + DI 10.7326/0003-4819-154-3-201102010-00006 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 713HY UT WOS:000286729200004 ER PT J AU Kalb, SR Baudys, J Egan, C Smith, TJ Smith, LA Pirkle, JL Barr, JR AF Kalb, Suzanne R. Baudys, Jakub Egan, Christina Smith, Theresa J. Smith, Leonard A. Pirkle, James L. Barr, John R. TI Different Substrate Recognition Requirements for Cleavage of Synaptobrevin-2 by Clostridium baratii and Clostridium botulinum Type F Neurotoxins SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID SEROTYPE-A; NEUROTRANSMITTER RELEASE; B NEUROTOXIN; MASS-SPECTROMETRY; UNITED-STATES; ENDOPEP-MS; TOXIN; SNAP-25; VAMP/SYNAPTOBREVIN; IDENTIFICATION AB Botulinum neurotoxins (BoNTs) cause botulism, which can be fatal if it is untreated. BoNTs cleave proteins necessary for nerve transmission, resulting in paralysis. The in vivo protein target has been reported for all seven serotypes of BoNT, i.e., serotypes A to G. Knowledge of the cleavage sites has led to the development of several assays to detect BoNT based on its ability to cleave a peptide substrate derived from its in vivo protein target. Most serotypes of BoNT can be subdivided into subtypes, and previously, we demonstrated that three of the currently known subtypes of BoNT/F cleave a peptide substrate, a shortened version of synaptobrevin-2, between Q58 and K59. However, our research indicated that Clostridium baratii type F toxin did not cleave this peptide. In this study, we detail experiments demonstrating that Clostridium baratii type F toxin cleaves recombinant synaptobrevin-2 in the same location as that cleaved by proteolytic F toxin. In addition, we demonstrate that Clostridium baratii type F toxin can cleave a peptide substrate based on the sequence of synaptobrevin-2. This peptide substrate is an N-terminal extension of the original peptide substrate used for detection of other BoNT/F toxins and can be used to detect four of the currently known BoNT/F subtypes by mass spectrometry. C1 [Kalb, Suzanne R.; Pirkle, James L.; Barr, John R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. [Baudys, Jakub] Ctr Dis Control & Prevent, Battelle Mem Inst, Atlanta, GA 30341 USA. [Egan, Christina] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12208 USA. [Smith, Theresa J.; Smith, Leonard A.] USA, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA. RP Barr, JR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM jbarr@cdc.gov OI Kalb, Suzanne/0000-0002-8067-136X NR 46 TC 13 Z9 13 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD FEB PY 2011 VL 77 IS 4 BP 1301 EP 1308 DI 10.1128/AEM.01662-10 PG 8 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 717WM UT WOS:000287078100018 PM 21169446 ER PT J AU Prosser, LA Meltzer, MI Fiore, A Epperson, S Bridges, CB Hinrichsen, V Lieu, TA AF Prosser, Lisa A. Meltzer, Martin I. Fiore, Anthony Epperson, Scott Bridges, Carolyn B. Hinrichsen, Virginia Lieu, Tracy A. TI Effects of Adverse Events on the Projected Population Benefits and Cost-effectiveness of Using Live Attenuated Influenza Vaccine in Children Aged 6 Months to 4 Years SO ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE LA English DT Article ID YOUNG-CHILDREN; UNITED-STATES; VIRUS INFECTIONS; EFFICACY; ILLNESS; HOSPITALIZATIONS; FAMILIES; INFANTS; ASTHMA; ENCEPHALOPATHY AB Objective: To evaluate the effect of adverse events associated with live attenuated influenza vaccine (LAIV) in children younger than 5 years on the cost-effectiveness of influenza vaccination. Design: A decision analytic model was developed to predict costs and health effects of no vaccination, vaccination with LAIV, and vaccination with inactivated influenza vaccine (IIV). Probabilities, costs, and quality adjustments for uncomplicated influenza, outpatient visits, hospitalizations, deaths, vaccination, and vaccine adverse events were based on primary and published data. The analysis included the possible increased incidence of adverse events following vaccination with LAIV for children younger than 5 years, including fever, wheezing, and hospitalization. A societal perspective was used. Sensitivity analyses, including probabilistic sensitivity analysis, were conducted. Setting: Vaccination in the physician office setting in the United States. Participants: Hypothetical cohorts of healthy children aged 6 months to 4 years. Intervention: Vaccination with LAIV or IIV. Main Outcome Measure: Incremental cost-effectiveness ratio in dollars per quality-adjusted life-year (QALY). Results: Cost-effectiveness ratios ranged from $20 000/ QALY (age 6-23 months) to $33 000/QALY (age 3-4 years) for LAIV and from $21 000/QALY to $37 000/QALY for IIV for healthy children aged 6 months to 4 years. Inclusion of possible new adverse events for LAIV had varying effects on cost-effectiveness results. Results were not sensitive to the inclusion of wheezing as an adverse event but were sensitive to a possible increase in the probability of hospitalization. Conclusion: Live attenuated influenza vaccine had comparable cost-effectiveness compared with IIV for children younger than 5 years under a wide range of assumptions about the incidence of adverse events. C1 [Prosser, Lisa A.] Univ Michigan Hlth Syst, Child Hlth Evaluat & Res Unit, Div Pediat, Ann Arbor, MI 48109 USA. [Prosser, Lisa A.; Hinrichsen, Virginia; Lieu, Tracy A.] Harvard Univ, Sch Med, Ctr Child Hlth Care Studies, Dept Populat Med, Boston, MA USA. Harvard Pilgrim Hlth Care, Boston, MA USA. [Meltzer, Martin I.] Ctr Dis Control & Prevent, Div Emerging Infect & Surveillance Serv, Natl Ctr Preparedness Detect & Control Infect Dis, Atlanta, GA USA. [Meltzer, Martin I.] Ctr Dis Control & Prevent, Coordinating Ctr Infect Dis, Atlanta, GA USA. [Fiore, Anthony; Epperson, Scott; Bridges, Carolyn B.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Prosser, LA (reprint author), Univ Michigan Hlth Syst, Div Gen Pediat, 300 N Ingalls St,Room 6E14,SPC 5456, Ann Arbor, MI 48109 USA. EM lisapros@med.umich.edu FU Centers for Disease Control and Prevention (CDC); Prosser; Fiore; Bridges; Lieu FX Obtained funding: Prosser, Fiore, Bridges, and Lieu.; Funding for this study was provided by the Centers for Disease Control and Prevention (CDC) through the Harvard/CDC Joint Initiative in Vaccine Economics. NR 39 TC 9 Z9 9 U1 1 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 1072-4710 J9 ARCH PEDIAT ADOL MED JI Arch. Pediatr. Adolesc. Med. PD FEB PY 2011 VL 165 IS 2 BP 112 EP 118 DI 10.1001/archpediatrics.2010.182 PG 7 WC Pediatrics SC Pediatrics GA 717KH UT WOS:000287042100003 PM 20921341 ER PT J AU Kuklina, EV Callaghan, WM AF Kuklina, E. V. Callaghan, W. M. TI Chronic heart disease and severe obstetric morbidity among hospitalisations for pregnancy in the USA: 1995-2006 SO BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY LA English DT Article DE Epidemiology; heart diseases; pregnancy ID UNITED-STATES; MATERNAL MORBIDITY; DISORDERS; MORTALITY; RISK AB Objectives To describe changes in characteristics of delivery and postpartum hospitalisations with chronic heart disease from 1995 to 2006. Design Cross-sectional study. Setting USA, nationwide hospital discharge data. Population A total of 47 882 817 delivery hospitalisations and 660 038 postpartum hospitalisations. Methods Adjusted odds ratios describing the associations between chronic maternal heart disease and severe obstetric complications were obtained from multivariable logistic models. The contribution of chronic heart disease to severe morbidity was estimated using adjusted population-attributable fractions. Main outcome measures Prevalence and trends in chronic heart disease, rate and risk of severe obstetric complications. Results In 2004-2006, about 1.4% of delivery hospitalisations were complicated with chronic heart disease. No substantial changes in the overall prevalence of chronic heart disease among hospitalisations for delivery were observed from 1995-1997 to 2004-2006. Even so, a linear increase was found for specific congenital heart disease, cardiac dysrhythmias, and cardiomyopathy and congestive heart failure (P < 0.01). During this same period the rate of postpartum hospitalisations with chronic heart disease tripled (P < 0.01). Severe complications during hospitalisations for delivery among women with chronic heart disease were more common in 2004-2006 than in 1995-1997. In 2004-2006, 64.5% of the cases of acute myocardial infarction, 57.5% of the instances of cardiac arrest/ventricular fibrillation, 27.8% of in-hospital mortality and 26.0% of the cases of adult respiratory distress syndrome were associated with hospitalisations with chronic heart disease. Conclusions In the USA chronic heart disease among women hospitalised during pregnancy may have increased in severity from 1995 to 2006. C1 [Kuklina, E. V.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA 30341 USA. [Callaghan, W. M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Kuklina, EV (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, 4770 Buford Highway NE,Mailstop K-37, Atlanta, GA 30341 USA. EM ekuklina@cdc.gov NR 29 TC 42 Z9 42 U1 0 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1470-0328 J9 BJOG-INT J OBSTET GY JI BJOG PD FEB PY 2011 VL 118 IS 3 BP 345 EP 352 DI 10.1111/j.1471-0528.2010.02743.x PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 705PL UT WOS:000286148300011 PM 21091604 ER PT J AU Liu, C Bayer, A Cosgrove, SE Daum, RS Fridkin, SK Gorwitz, RJ Kaplan, SL Karchmer, AW Levine, DP Murray, BE Rybak, MJ Talan, DA Chambers, HF AF Liu, Catherine Bayer, Arnold Cosgrove, Sara E. Daum, Robert S. Fridkin, Scott K. Gorwitz, Rachel J. Kaplan, Sheldon L. Karchmer, Adolf W. Levine, Donald P. Murray, Barbara E. Rybak, Michael J. Talan, David A. Chambers, Henry F. TI Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children: Executive Summary SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; UNITED-STATES; NECROTIZING FASCIITIS; VENOUS THROMBOSIS; OSTEOMYELITIS; INFLUENZA; MANIFESTATIONS; HOSPITALS AB Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures. C1 [Liu, Catherine; Chambers, Henry F.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94102 USA. [Chambers, Henry F.] San Francisco Gen Hosp, Div Infect Dis, San Francisco, CA 94110 USA. [Bayer, Arnold] Harbor UCLA Med Ctr, Div Infect Dis, Torrance, CA 90509 USA. [Talan, David A.] Olive View UCLA Med Ctr, Div Emergency Med, Sylmar, CA 91342 USA. [Talan, David A.] Olive View UCLA Med Ctr, Div Infect Dis, Sylmar, CA 91342 USA. [Bayer, Arnold; Talan, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Cosgrove, Sara E.] Johns Hopkins Med Inst, Div Infect Dis, Baltimore, MD 21205 USA. [Daum, Robert S.] Univ Chicago, Dept Pediat, Infect Dis Sect, Chicago, IL 60637 USA. [Fridkin, Scott K.; Gorwitz, Rachel J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Kaplan, Sheldon L.] Baylor Coll Med, Dept Pediat, Infect Dis Sect, Houston, TX 77030 USA. [Karchmer, Adolf W.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Infect Dis, Boston, MA 02215 USA. [Levine, Donald P.; Rybak, Michael J.] Wayne State Univ, Dept Med, Div Infect Dis, Detroit Receiving Hosp, Detroit, MI 48202 USA. [Levine, Donald P.; Rybak, Michael J.] Univ Hlth Ctr, Detroit, MI USA. [Rybak, Michael J.] Wayne State Univ, Dept Pharm Practice, Detroit, MI USA. [Murray, Barbara E.] Univ Texas Med Sch, Div Infect Dis, Houston, TX USA. [Murray, Barbara E.] Univ Texas Med Sch, Ctr Study Emerging & Reemerging Pathogens, Houston, TX USA. RP Liu, C (reprint author), Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94102 USA. EM catherine.liu@ucsf.edu FU Cubist; Ortho-McNeil; Pfizer; Theravance; Targanta; Astellas; AdvanDx; Clorox; Sanofi Pasteur; Sage; GeneOhm; Cubist Pharmaceuticals; Merck; Wyeth; Johnson Johnson; Sanofi-Aventis; Vicuron Pharmaceuticals; Wyeth-Ayerst; Theravance/Astellas FX H.F.C. has received honoraria and research grants and has served as a consultant to Cubist, Ortho-McNeil, Pfizer, Theravance, and Targanta. S.E.C. has received honoraria from Forest and RibX, has served as a consultant for Merck and has received research support from Astellas, Cubist and AdvanDx. R.D. has received research funding from Pfizer, Clorox, Sanofi Pasteur, Sage, and GeneOhm. S.L.K. has received grant funding from Pfizer, has served as MRSA Leadership Advisor to Pfizer, and is participating in a pediatric daptomycin study. A.W.K. has received honoraria and grants from Cubist Pharmaceuticals, Merck, Wyeth, and Pfizer and has served as a consultant for Cubist Pharmaceuticals, Theravance, Astellas, Pfizer, Merck, and Ortho-McNeil and has owned stock from Cubist Pharmaceutical, Pfizer, and Johnson and Johnson. D.P.L. has received research support from Cubist, Johnson & Johnson, and Theravance and has served as a speaker for Cubist. B.E.M. has served as a consultant and received research support from Johnson & Johnson, Astellas, Pfizer, Cubist, Theravance, Targanta, Sanofi-Aventis, Vicuron Pharmaceuticals, and Wyeth-Ayerst. M.R. has received grants and or has served as a consultant speaker for the Pfizer, Cubist, Theravance/Astellas, Targanta, and Johnson & Johnson. D.A.T. has served on the advisory board to Pfizer, Ortho-McNeil, Astellas, Schering-Plough, and Replidyne. All other authors: no conflicts. NR 27 TC 480 Z9 525 U1 4 U2 33 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2011 VL 52 IS 3 BP 285 EP 292 DI 10.1093/cid/cir034 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706KD UT WOS:000286216400002 PM 21217178 ER PT J AU Leung, J Harpaz, R Molinari, NA Jumaan, A Zhou, FJ AF Leung, Jessica Harpaz, Rafael Molinari, Noelle-Angelique Jumaan, Aisha Zhou, Fangjun TI Herpes Zoster Incidence Among Insured Persons in the United States, 1993-2006: Evaluation of Impact of Varicella Vaccination SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID POSTHERPETIC NEURALGIA; RISK-FACTOR; OLDER-ADULTS; EPIDEMIOLOGY; SHINGLES; CHILDREN; EXPOSURE; KINGDOM; GENDER; VIRUS AB Background. Herpes zoster (HZ) is caused by reactivation of latent varicella zoster virus and is often associated with substantial pain and disability. Baseline incidence of HZ prior to introduction of HZ vaccine is not well described, and it is unclear whether introduction of the varicella vaccination program in 1995 has altered the epidemiology of HZ. We examined trends in the incidence of HZ and impact of varicella vaccination on HZ trends using a large medical claims database. Methods. Medical claims data from the MarketScan (R) databases were obtained for 1993-2006. We calculated HZ incidence using all persons with a first outpatient service associated with a 053.xx code (HZ ICD-9 code) as the numerator, and total MarketScan enrollment as the denominator; HZ incidence was stratified by age and sex. We used statewide varicella vaccination coverage in children aged 19-35 months to explore the impact of varicella vaccination on HZ incidence. Results. HZ incidence increased for the entire study period and for all age groups, with greater rates of increase 1993-1996 (P<.001). HZ rates were higher for females than males throughout the study period (P<.001) and for all age groups (P<.001). HZ incidence did not vary by state varicella vaccination coverage. Conclusions. HZ incidence has been increasing from 1993-2006. We found no evidence to attribute the increase to the varicella vaccine program. C1 [Leung, Jessica; Harpaz, Rafael; Molinari, Noelle-Angelique; Jumaan, Aisha; Zhou, Fangjun] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Jumaan, Aisha] Program Appropriate Technol Hlth, HPV Vaccines Project, Seattle, WA USA. RP Leung, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A-47, Atlanta, GA 30333 USA. EM jleung@cdc.gov NR 40 TC 81 Z9 84 U1 2 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2011 VL 52 IS 3 BP 332 EP 340 DI 10.1093/cid/ciq077 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706KD UT WOS:000286216400008 PM 21217180 ER PT J AU Kugeler, KJ Griffith, KS Gould, LH Kochanek, K Delorey, MJ Biggerstaff, BJ Mead, PS AF Kugeler, Kiersten J. Griffith, Kevin S. Gould, L. Hannah Kochanek, Ken Delorey, Mark J. Biggerstaff, Brad J. Mead, Paul S. TI A Review of Death Certificates Listing Lyme Disease as a Cause of Death in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Review ID PATIENT AB Lyme disease was listed as an underlying or multiple cause of death on 114 death records during 1999-2003. Upon review, only 1 record was consistent with clinical manifestations of Lyme disease. This analysis indicates that Lyme disease is rare as a cause of death in the United States. C1 [Kugeler, Kiersten J.; Griffith, Kevin S.; Gould, L. Hannah; Delorey, Mark J.; Biggerstaff, Brad J.; Mead, Paul S.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Ft Collins, CO USA. [Kochanek, Ken] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Griffith, KS (reprint author), 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM kkg8@cdc.gov FU CDC FX Financial support was provided by CDC. NR 9 TC 7 Z9 8 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2011 VL 52 IS 3 BP 364 EP 367 DI 10.1093/cid/ciq157 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706KD UT WOS:000286216400013 PM 21189272 ER PT J AU Mondy, KE Gottdiener, J Overton, ET Henry, K Bush, T Conley, L Hammer, J Carpenter, CC Kojic, E Patel, P Brooks, JT AF Mondy, Kristin E. Gottdiener, John Overton, E. Turner Henry, Keith Bush, Tim Conley, Lois Hammer, John Carpenter, Charles C. Kojic, Erna Patel, Pragna Brooks, John T. CA SUN Study Investigators TI High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; C-REACTIVE PROTEIN; REVERSE-TRANSCRIPTASE INHIBITORS; PULMONARY ARTERIAL-HYPERTENSION; ACUTE MYOCARDIAL-INFARCTION; CORONARY-HEART-DISEASE; LEFT-VENTRICULAR MASS; CLINICAL-TRIALS GROUP; DILATED CARDIOMYOPATHY; STANDARDS COMMITTEE AB Background. In the era of highly active antiretroviral therapy (HAART), human immunodeficiency virus (HIV)-infected persons have higher cardiovascular disease risk. Little is known about asymptomatic abnormalities in cardiac structure and function in this population. Methods. The Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) is a prospective, observational, multi-site cohort of 656 HIV-infected participants who underwent baseline echocardiography during 2004-2006. We examined prevalence of and factors associated with left ventricular systolic dysfunction (LVSD), diastolic dysfunction (DD), pulmonary hypertension (PHTN), left ventricular hypertrophy (LVH), and left atrial enlargement (LAE). Results. Participant characteristics were as follows: median age, 41 years; 24% women; 29% non-Hispanic black; 73% receiving HAART; and median CD4+ cell count, 462 cells/mu L. Among evaluable participants, 18% had LVSD, 26% had DD, 57% had PHTN (right ventricular pressure >30 mm Hg), 6.5% had LVH, and 40% had LAE. In multivariate analyses, significant factors (P < .05) associated with LVSD were history of MI, elevated highly sensitive C-reactive protein (hsCRP) level, and current tobacco smoking; for DD, elevated hsCRP level and hypertension; for PHTN, current use of ritonavir; for LVH, hypertension, diabetes, non-white race, female sex with elevated body mass index, calculated as the weight in kilograms divided by the square of height in meters, of >= 25, elevated hsCRP level, and current use of abacavir; for LAE, hypertension and recent marijuana use. Conclusions. In this large contemporary HIV cohort, the prevalence of subclinical functional and structural cardiac abnormalities was greater than expected for age. Abnormalities were mostly associated with expected and often modifiable risks. Lifestyle modification should become a greater priority in the management of chronic HIV disease. C1 [Mondy, Kristin E.; Overton, E. Turner] Washington Univ, Sch Med, St Louis, MO USA. [Mondy, Kristin E.] Univ Texas SW, Austin Program, Austin, TX USA. [Gottdiener, John] Univ Maryland, Baltimore, MD 21201 USA. [Henry, Keith] Hennepin Cty Med Ctr, Minneapolis, MN USA. [Bush, Tim; Conley, Lois; Patel, Pragna; Brooks, John T.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Hammer, John] Denver Infect Dis Consultants, Denver, CO USA. [Carpenter, Charles C.; Kojic, Erna] Miriam Hosp, Providence, RI 02906 USA. RP Mondy, KE (reprint author), Univ Med Ctr Brackenridge, 601 E 15th St,Brackenridge Annex Bldg, Austin, TX 78701 USA. EM kristinmd@swbell.net FU Centers for Disease Control and Prevention [200-2002-00610/00611/00612/00613, 200-2007-3633/23634/23635/23636] FX The Centers for Disease Control and Prevention (contract nos. 200-2002-00610/00611/00612/00613; 200-2007-3633/23634/23635/23636). NR 53 TC 60 Z9 61 U1 0 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2011 VL 52 IS 3 BP 378 EP 386 DI 10.1093/cid/ciq066 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706KD UT WOS:000286216400016 PM 21217185 ER PT J AU Dao, CN Patel, P Overton, ET Rhame, F Pals, SL Johnson, C Bush, T Brooks, JT AF Dao, Christine N. Patel, Pragna Overton, E. Turner Rhame, Frank Pals, Sherri L. Johnson, Christopher Bush, Timothy Brooks, John T. CA Study Understand Nat Hist HIV AID TI Low Vitamin D among HIV-Infected Adults: Prevalence of and Risk Factors for Low Vitamin D Levels in a Cohort of HIV-Infected Adults and Comparison to Prevalence among Adults in the US General Population SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID IMMUNODEFICIENCY-VIRUS-INFECTION; D DEFICIENCY; ANTIRETROVIRAL THERAPY; D INSUFFICIENCY; UNITED-STATES; 25-HYDROXYVITAMIN-D; EFAVIRENZ; TENOFOVIR; HEALTH; DYSFUNCTION AB Background. We explored serum 25-hydroxyvitamin D (25[OH]D) levels and associated factors for insufficiency or deficiency in an adult human immunodeficiency virus (HIV) cohort and compared 25(OH)D levels with those in the general US population. Methods. Using baseline data from the Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN), a prospective, observational cohort study of HIV-infected adults enrolled at 7 HIV specialty clinics in 4 US cities from March 2004 to June 2006, we estimated the prevalence of vitamin D insufficiency or deficiency (defined as 25(OH) D levels <30 ng/mL), standardized by age, race, and sex. Using multiple logistic regression, we examined risk factors for vitamin D insufficiency or deficiency. Results. Among 672 SUN participants with baseline serum 25(OH)D determinations who were not receiving vitamin D supplements, 70.3% (95% confidence interval [CI], 68.1%-74.9%) were vitamin D insufficient or deficient, compared with 79.1%(95% CI, 76.7-81.3) of US adults. Factors associated with vitamin D insufficiency or deficiency included black race (adjusted odds ratio [aOR], 4.51; 95% CI, 2.59-7.85), Hispanic ethnicity (aOR, 2.78; 95% CI, 1.31-5.90), higher body mass index (aOR, 1.04; 95% CI, 1.00-1.09), hypertension (aOR, 1.88; 95% CI, 1.10-3.22), lack of exercise (aOR, 3.14; 95% CI, 1.80-5.47), exposure to efavirenz (aOR, 1.98; 95% CI, 1.18-3.34), higher exposure to ultraviolet light (aOR, .78; 95% CI, .71-.86), renal insufficiency (aOR, .55; 95% CI, .36-.83), and exposure to ritonavir (aOR, .56; 95% CI, .35-0.89). Conclusions. Similar to findings in US adults generally, vitamin D insufficiency or deficiency is highly prevalent among HIV-infected adults and is associated with known risk factors. Observed associations of vitamin D levels with renal insufficiency and with use of ritonavir-and efavirenz-containing regimens are consistent with both HIV-related and therapy-mediated alterations in vitamin D metabolism. Clinicians should consider screening all patients for vitamin D insufficiency or deficiency. C1 [Dao, Christine N.; Patel, Pragna; Pals, Sherri L.; Johnson, Christopher; Bush, Timothy; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Overton, E. Turner] Washington Univ, Sch Med, Dept Infect Dis, St Louis, MO USA. [Rhame, Frank] Abbott NW Hosp, Dept Infect Dis, Minneapolis, MN 55407 USA. RP Patel, P (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-45, Atlanta, GA 30333 USA. EM plp3@cdc.gov FU CDC [200-2002-00610, 200-2002-00611, 200-2002-00612, 200-2002-00613, 200-2007-23633, 200-2007-23634, 200-2007-23635, 200-200723636] FX This work was supported by the CDC (contract numbers 200-2002-00610, 200-2002-00611, 200-2002-00612, 200-2002-00613, 200-2007-23633, 200-2007-23634, 200-2007-23635, and 200-200723636). NR 48 TC 120 Z9 120 U1 0 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2011 VL 52 IS 3 BP 396 EP 405 DI 10.1093/cid/ciq158 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706KD UT WOS:000286216400018 PM 21217186 ER PT J AU Yu, HJ Feng, ZJ Uyeki, TM Liao, QH Zhou, L Feng, LZ Ye, M Xiang, NJ Huai, Y Yuan, YA Jiang, H Zheng, YD Gargiullo, P Peng, ZB Feng, YX Zheng, JD Xu, CL Zhang, YP Shu, YL Gao, ZC Yang, WZ Wang, Y AF Yu, Hongjie Feng, Zijian Uyeki, Timothy M. Liao, Qiaohong Zhou, Lei Feng, Luzhao Ye, Min Xiang, Nijuan Huai, Yang Yuan, Yuan Jiang, Hui Zheng, Yingdong Gargiullo, Paul Peng, Zhibin Feng, Yunxia Zheng, Jiandong Xu, Cuiling Zhang, Yanping Shu, Yuelong Gao, Zhancheng Yang, Weizhong Wang, Yu TI Risk Factors for Severe Illness with 2009 Pandemic Influenza A (H1N1) Virus Infection in China SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID CRITICALLY-ILL PATIENTS; PREGNANT-WOMEN; A(H1N1) INFECTION; UNITED-STATES; HOSPITALIZATION; PREVALENCE; CALIFORNIA; OUTCOMES; CANADA; MEXICO AB Background. Data on risk factors for severe outcomes from 2009 pandemic influenza A (H1N1) virus infection are limited outside of developed countries. Methods. We reviewed medical charts to collect data from patients hospitalized with laboratory-confirmed 2009 H1N1 infection who were identified across China during the period from September 2009 through February 2010, and we analyzed potential risk factors associated with severe illness (defined as illness requiring intensive care unit admission or resulting in death). Results. Among 9966 case patients, the prevalence of chronic medical conditions (33% vs 14%), pregnancy (15% vs 7%), or obesity (19% vs 14%) was significantly higher in those patients with severe illness than it was in those with less severe disease. In multivariable analyses, among nonpregnant case patients aged >= 2 years, having a chronic medical condition significantly increased the risk of severe outcome among all age groups, and obesity was a risk factor among those < 60 years of age. The risk of severe illness among pregnant case patients was significantly higher for those in the second and third trimesters. The risk of severe illness was increased when oseltamivir treatment was initiated >= 5 days after illness onset (odds ratio, 1.42; 95% confidence interval, 1.20-1.67). For persons < 60 years of age, the prevalence of obesity among case patients with severe illness was significantly greater than it was among those without severe illness or among the general population. Conclusions. Risk factors for severe 2009 H1N1 illness in China were similar to those observed in developed countries, but there was a lower prevalence of chronic medical conditions and a lower prevalence of obesity. Obesity was a risk factor among case patients < 60 years of age. Early initiation of oseltamivir treatment was most beneficial, and there was an increased risk of severe disease when treatment was started >= 5 days after illness onset. C1 [Yu, Hongjie; Feng, Zijian; Liao, Qiaohong; Zhou, Lei; Feng, Luzhao; Ye, Min; Xiang, Nijuan; Huai, Yang; Jiang, Hui; Peng, Zhibin; Feng, Yunxia; Zheng, Jiandong; Yang, Weizhong; Wang, Yu] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing 102206, Peoples R China. [Xu, Cuiling; Zhang, Yanping; Shu, Yuelong] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing 102206, Peoples R China. [Yuan, Yuan; Gao, Zhancheng] Peking Univ Hlth Sci Ctr, Peking Univ Peoples Hosp, Beijing, Peoples R China. [Zheng, Yingdong] Peking Univ Hlth Sci Ctr, Sch Publ Hlth, Beijing, Peoples R China. [Uyeki, Timothy M.; Gargiullo, Paul] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Wang, Y (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Off Dis Control & Emergency Response, 155 Changbai Rd, Beijing 102206, Peoples R China. EM wangyu@chinacdc.cn OI Zhou, Lei/0000-0002-6640-0774 FU Ministry of Health, China; US National Institutes of Health [U19 AI51915]; China-U.S. Collaborative Program on Emerging and Re-emerging Infectious Diseases FX We thank the participating hospitals, local health departments and Centers for Disease Control and Prevention in China for assistance in coordinating data collection, and the Ministry of Health, China for supporting this study. The views expressed are those of the authors and do not necessarily represent the policy of the China CDC or the U.S. Centers for Disease Control and Prevention.; US National Institutes of Health (Comprehensive International Program for Research on AIDS grant U19 AI51915) and the China-U.S. Collaborative Program on Emerging and Re-emerging Infectious Diseases. NR 37 TC 80 Z9 91 U1 1 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB PY 2011 VL 52 IS 4 BP 457 EP 465 DI 10.1093/cid/ciq144 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 712PD UT WOS:000286677800009 PM 21220768 ER PT J AU Lopman, BA Hall, AJ Curns, AT Parashar, UD AF Lopman, Ben A. Hall, Aron J. Curns, Aaron T. Parashar, Umesh D. TI Increasing Rates of Gastroenteritis Hospital Discharges in US Adults and the Contribution of Norovirus, 1996-2007 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID INFECTIOUS INTESTINAL DISEASE; UNITED-STATES; ROTAVIRUS VACCINATION; CHILD-MORTALITY; ENGLAND; BURDEN; EPIDEMIOLOGY; SURVEILLANCE; COMMUNITY; OUTBREAKS AB Background. Diarrhea remains an important cause of morbidity, but until the mid 1990s, hospital admissions for diarrhea in the US adult population were declining. We aimed to describe recent trends in gastroenteritis hospitalizations and to determine the contribution of norovirus. Methods. We analyzed all gastroenteritis-associated hospital discharges during 1996-2007 from a nationally representative data set of hospital inpatient stays. Annual rates of discharges by age were calculated. Time-series regression models were fitted using cause-specified discharges as explanatory variables; model residuals were analyzed to estimate norovirus- and rotavirus-associated discharges. We then calculated the annual hospital charges for norovirus-associated discharges. Results. Sixty-nine percent of all gastroenteritis discharges were cause-unspecified and rates increased by >= 50% in all adult and elderly age groups (>= 18 years of age) from 1996 through 2007. We estimate an annual mean of 71,000 norovirus-associated hospitalizations, costing $493 million per year, with surges to nearly 110,000 hospitalizations per year in epidemic seasons. We also estimate 24,000 rotavirus hospitalizations annually among individuals aged >= 5 years. Conclusions. Gastroenteritis hospitalizations are increasing, and we estimate that norovirus is the cause of 10% of cause-unspecified and 7% of all-cause gastroenteritis discharges. Norovirus should be routinely considered as a cause of gastroenteritis hospitalization. C1 [Lopman, Ben A.; Hall, Aron J.; Curns, Aaron T.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Lopman, BA (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM blopman@cdc.gov NR 40 TC 90 Z9 91 U1 0 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB PY 2011 VL 52 IS 4 BP 466 EP 474 DI 10.1093/cid/ciq163 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 712PD UT WOS:000286677800010 PM 21258098 ER PT J AU Pronovost, PJ Cardo, DM Goeschel, CA Berenholtz, SM Saint, S Jernigan, JA AF Pronovost, Peter J. Cardo, Denise M. Goeschel, Christine A. Berenholtz, Sean M. Saint, Sanjay Jernigan, John A. TI A Research Framework for Reducing Preventable Patient Harm SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID BLOOD-STREAM INFECTIONS; URINARY-TRACT-INFECTION; INTENSIVE-CARE UNITS; CATHETER-RELATED INFECTION; POVIDONE-IODINE; HEALTH-CARE; CHLORHEXIDINE GLUCONATE; RANDOMIZED TRIAL; SITE CARE; SAFETY AB Programs to reduce central line-associated bloodstream infections (CLABSIs) have improved the safety of hospitalized patients. Efforts are underway to disseminate these successes broadly to reduce other types of hospital-acquired infectious and noninfectious preventable harms. Unfortunately, the ability to broadly measure and prevent other types of preventable harms, especially infectious harms, needs enhancement. Moreover, an overarching research framework for creating and integrating evidence will help expedite the development of national prevention programs. This article outlines a 5-phase translational (T) framework to develop robust research programs that reduce preventable harm, as follows: phase T0, discover opportunities and approaches to prevent adverse health care events; phase T1, use T0 discoveries to develop and test interventions on a small scale; phase T2, broaden and strengthen the evidence base for promising interventions to develop evidence-based guidelines; phase T3, translate guidelines into clinical practice; and phase T4, implement and evaluate T3 work on a national and international scale. Policy makers should use this framework to fill in the knowledge gaps, coordinate efforts among federal agencies, and prioritize research funding. C1 [Pronovost, Peter J.; Goeschel, Christine A.; Berenholtz, Sean M.] Johns Hopkins Univ, Qual & Safety Res Grp, Dept Anesthesiol & Crit Care, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21231 USA. [Pronovost, Peter J.; Berenholtz, Sean M.] Johns Hopkins Univ, Sch Med, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21231 USA. [Pronovost, Peter J.; Goeschel, Christine A.; Berenholtz, Sean M.] Johns Hopkins Univ, Dept Hlth Policy & Management, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21231 USA. [Pronovost, Peter J.; Goeschel, Christine A.] Johns Hopkins Univ, Sch Nursing, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21231 USA. [Cardo, Denise M.; Jernigan, John A.] Ctr Dis Control & Prevent, Prevent & Response Branch, Div Healthcare Qual Promot, Atlanta, GA USA. [Saint, Sanjay] Univ Michigan Hlth Syst, Ann Arbor VA Med Ctr, Dept Internal Med, Ann Arbor, MI USA. [Saint, Sanjay] Univ Michigan, Ann Arbor VA Med Ctr, Patient Safety Enhancement Program, Ann Arbor, MI 48109 USA. RP Pronovost, PJ (reprint author), Johns Hopkins Univ, Qual & Safety Res Grp, Dept Anesthesiol & Crit Care, Johns Hopkins Bloomberg Sch Publ Hlth, 1909 Thames St,2nd Floor, Baltimore, MD 21231 USA. EM ppronovo@jhmi.edu FU Agency for Healthcare Research and Quality (AHRQ); National Institutes of Health (NIH); National Patient Safety Agency (NPSA); Robert Wood Johnson Foundation (RWJF); Commonwealth Fund; World Health Organization; Michigan Health and Hospital Association; Department of Veterans Affairs; Institute for Healthcare Improvement FX P.J.P. receives grant or contract support from the Agency for Healthcare Research and Quality (AHRQ), the National Institutes of Health (NIH), the National Patient Safety Agency (NPSA), the Robert Wood Johnson Foundation (RWJF), and the Commonwealth Fund; has received a gift from private philanthropy for work on another study; has received honoraria from various hospitals, health systems, and the Leigh Speakers Bureau to speak about patient safety and quality-related issues; is a consultant for the Association for Professionals in Infection Control and Epidemiology; and receives royalties for his book, Safe Patients, Smart Hospitals. C.A.G. receives grant support from AHRQ and honoraria from various not-for-profit health care organizations and is an unpaid senior advisor to the World Health Organization, Patient Safety Program. S.M.B. receives grant or contract support from AHRQ, NPSA, World Health Organization, Michigan Health and Hospital Association, NIH, and RWJF; receives honoraria from the Speakers Bureau; and holds equity ownership in DocuSys. S.S. receives grant support from the NIH, Department of Veterans Affairs, the RWJF, and receives honoraria or speaking fees from various hospitals, academic medical centers, medical societies, and non-profit foundations (e.g., Michigan Health and Hospital Association, Institute for Healthcare Improvement). All other authors: no conflicts. NR 56 TC 16 Z9 16 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB PY 2011 VL 52 IS 4 BP 507 EP 513 DI 10.1093/cid/ciq172 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 712PD UT WOS:000286677800017 PM 21258104 ER PT J AU Baddley, JW Schain, DC Gupte, AA Lodhi, SA Kayler, LK Frade, JP Lockhart, SR Chiller, T Bynon, JS Bower, WA AF Baddley, John W. Schain, Denise C. Gupte, Asmita A. Lodhi, Sundus A. Kayler, Liise K. Frade, Joao P. Lockhart, Shawn R. Chiller, Tom Bynon, J. Steve, Jr. Bower, William A. TI Transmission of Cryptococcus neoformans by Organ Transplantation SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID CORNEAL TRANSPLANTATION; FUNGAL-INFECTIONS; RECIPIENTS; DONOR; PATIENT AB Background. This article describes transmission of Cryptococcus neoformans by solid organ transplantation. Methods. We reviewed medical records and performed molecular genotyping of isolates to determine potential for donor transmission of Cryptococcus. Results. Cryptococcosis was diagnosed in 3 recipients of organs from a common donor with an undifferentiated neurologic condition at the time of death. Cryptococcal meningoencephalitis was later diagnosed in the donor at autopsy. The liver and 1 kidney recipient developed cryptococcemia and pneumonia and the other kidney recipient developed cryptococcemia and meningitis; 2 patients recovered with prolonged antifungal therapy. We tested 4 recipient isolates with multilocus sequence typing and found they had identical alleles. Conclusions. Our investigation documents the transmission of Cryptococcus neoformans by organ transplantation. Evaluation for cryptococcosis in donors with unexplained neurologic symptoms should be strongly considered. C1 [Baddley, John W.] Univ Alabama, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Schain, Denise C.; Gupte, Asmita A.; Lodhi, Sundus A.; Kayler, Liise K.] Univ Florida, Dept Med, Sch Med, Gainesville, FL USA. [Frade, Joao P.; Lockhart, Shawn R.; Chiller, Tom; Bower, William A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Baddley, JW (reprint author), Univ Alabama, Dept Med, Div Infect Dis, 1900 Univ Blvd,229 Tinsley Harrison Tower, Birmingham, AL 35294 USA. EM jbad-dley@uab.edu FU Pfizer FX J.W.B. is an advisory board member at Merck and Co., a consultant for Pfizer, and a Pfizer research grant recipient. All other authors: no conflicts. NR 26 TC 25 Z9 25 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB PY 2011 VL 52 IS 4 BP E94 EP E98 DI 10.1093/cid/ciq216 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 712PD UT WOS:000286677800002 PM 21220771 ER PT J AU Liu, C Bayer, A Cosgrove, SE Daum, RS Fridkin, SK Gorwitz, RJ Kaplan, SL Karchmer, AW Levine, DP Murray, BE Rybak, MJ Talan, DA Chambers, HF AF Liu, Catherine Bayer, Arnold Cosgrove, Sara E. Daum, Robert S. Fridkin, Scott K. Gorwitz, Rachel J. Kaplan, Sheldon L. Karchmer, Adolf W. Levine, Donald P. Murray, Barbara E. Rybak, Michael J. Talan, David A. Chambers, Henry F. TI Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID SOFT-TISSUE INFECTIONS; SKIN-STRUCTURE INFECTIONS; SIMULATED ENDOCARDIAL VEGETATIONS; VITRO PHARMACODYNAMIC MODEL; VENTILATOR-ASSOCIATED PNEUMONIA; PANTON-VALENTINE LEUKOCIDIN; GRAM-POSITIVE INFECTIONS; CRITICALLY-ILL PATIENTS; PROSTHETIC VALVE ENDOCARDITIS; RANDOMIZED CONTROLLED-TRIAL AB Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures. C1 [Liu, Catherine; Chambers, Henry F.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94102 USA. [Chambers, Henry F.] San Francisco Gen Hosp, Div Infect Dis, San Francisco, CA 94110 USA. [Bayer, Arnold] Harbor UCLA Med Ctr, Div Infect Dis, Torrance, CA 90509 USA. [Talan, David A.] Olive View UCLA Med Ctr, Div Emergency Med, Sylmar, CA 91342 USA. [Talan, David A.] Olive View UCLA Med Ctr, Div Infect Dis, Sylmar, CA 91342 USA. [Bayer, Arnold; Talan, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Cosgrove, Sara E.] Johns Hopkins Med Inst, Div Infect Dis, Baltimore, MD 21205 USA. [Daum, Robert S.] Univ Chicago, Dept Pediat, Infect Dis Sect, Chicago, IL 60637 USA. [Fridkin, Scott K.; Gorwitz, Rachel J.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Kaplan, Sheldon L.] Baylor Coll Med, Dept Pediat, Infect Dis Sect, Houston, TX 77030 USA. [Karchmer, Adolf W.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Infect Dis, Sch Med, Boston, MA 02215 USA. [Levine, Donald P.; Rybak, Michael J.] Wayne State Univ, Dept Med, Div Infect Dis, Detroit Receiving Hosp, Detroit, MI 48202 USA. [Levine, Donald P.; Rybak, Michael J.] Univ Hlth Ctr, Detroit, MI USA. [Rybak, Michael J.] Wayne State Univ, Dept Pharm Practice, Detroit, MI USA. [Murray, Barbara E.] Univ Texas Med Sch, Div Infect Dis, Houston, TX USA. [Murray, Barbara E.] Univ Texas Med Sch, Ctr Study Emerging & Reemerging Pathogens, Houston, TX USA. RP Liu, C (reprint author), Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94102 USA. EM catherine.liu@ucsf.edu FU Cubist; Ortho-McNeil; Pfizer; Theravance; Targanta; Astellas; AdvanDx; Clorox; Sanofi Pasteur; Sage; GeneOhm; Cubist Pharmaceuticals; Merck; Wyeth; Johnson Johnson; Sanofi-Aventis; Vicuron Pharmaceuticals; Wyeth-Ayerst; Theravance/Astellas FX H.F.C. has received honoraria and research grants and has served as a consultant to Cubist, Ortho-McNeil, Pfizer, Theravance, and Targanta. S.E.C. has received honoraria from Forest and RibX, has served as a consultant for Merck and has received research support from Astellas, Cubist and AdvanDx. R.D. has received research funding from Pfizer, Clorox, Sanofi Pasteur, Sage, and GeneOhm. S.L.K. has received grant funding from Pfizer, has served as MRSA Leadership Advisor to Pfizer, and is participating in a pediatric daptomycin study. A.W.K. has received honoraria and grants from Cubist Pharmaceuticals, Merck, Wyeth, and Pfizer and has served as a consultant for Cubist Pharmaceuticals, Theravance, Astellas, Pfizer, Merck, and Ortho-McNeil and has owned stock from Cubist Pharmaceutical, Pfizer, and Johnson and Johnson. D.P.L. has received research support from Cubist, Johnson & Johnson, and Theravance and has served as a speaker for Cubist. B.E.M. has served as a consultant and received research support from Johnson & Johnson, Astellas, Pfizer, Cubist, Theravance, Targanta, Sanofi-Aventis, Vicuron Pharmaceuticals, and Wyeth-Ayerst. M.R. has received grants and or has served as a consultant speaker for the Pfizer, Cubist, Theravance/Astellas, Targanta, and Johnson & Johnson. D.A.T. has served on the advisory board to Pfizer, Ortho-McNeil, Astellas, Schering-Plough, and Replidyne. All other authors: no conflicts. NR 373 TC 634 Z9 698 U1 9 U2 68 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2011 VL 52 IS 3 BP E18 EP E55 DI 10.1093/cid/ciq146 PG 38 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706KD UT WOS:000286216400001 PM 21208910 ER PT J AU Shen, AK Mead, PS Beard, CB AF Shen, Angela K. Mead, Paul S. Beard, Charles B. TI The Lyme Disease Vaccine-A Public Health Perspective SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; PREVENTION AB Lyme disease, which is caused by the spirochetal agent Borrelia burgdoferi, is the most common vector-borne illness in the United States. In 1998, the US Food and Drug Administration approved a recombinant Lyme disease vaccine that was later voluntarily withdrawn from the market by the manufacturer. Current Lyme disease prevention efforts focus on a combination of methods and approaches, including area acaricides, landscape management, host-targeted interventions, management of deer populations, and personal protective measures, such as the use of insect repellant and tick checks. Although these methods are generally safe and relatively inexpensive, the primary limitations of these methods are that their effectiveness has been difficult to demonstrate conclusively and that rates of compliance are generally poor. An effective human Lyme disease vaccine that has been adequately evaluated in the highest-risk population groups could be very beneficial in preventing Lyme disease; however, it would need to meet high standards regarding safety, efficacy, cost, and public acceptance. C1 [Mead, Paul S.; Beard, Charles B.] Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80526 USA. [Shen, Angela K.] Natl Vaccine Program Off, Dept Hlth & Human Serv, Washington, DC USA. RP Beard, CB (reprint author), Ctr Dis Control & Prevent, Bacterial Dis Branch, Div Vector Borne Infect Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80526 USA. EM cbeard@cdc.gov FU Baxter Laboratories and Centers for Disease Control, Fort Collins, CO FX This article was published as part of a supplement entitled "The Need for a New Lyme Disease Vaccine Sponsor" sponsored by Baxter Laboratories and Centers for Disease Control, Fort Collins, CO, and Stanley Plotkin. NR 21 TC 17 Z9 18 U1 0 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2011 VL 52 SU 3 BP S247 EP S252 DI 10.1093/cid/ciq115 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706KG UT WOS:000286216700001 PM 21217171 ER PT J AU Rand, CM Schaffer, SJ Humiston, SG Albertin, CS Shone, LP Heintz, EV Blumkin, AK Stokley, S Szilagyi, PG AF Rand, Cynthia M. Schaffer, Stanley J. Humiston, Sharon G. Albertin, Christina S. Shone, Laura P. Heintz, Eric V. Blumkin, Aaron K. Stokley, Shannon Szilagyi, Peter G. TI Patient-Provider Communication and Human Papillomavirus Vaccine Acceptance SO CLINICAL PEDIATRICS LA English DT Article DE immunization; adolescent; preventive care; communication ID TRANSMITTED INFECTION VACCINATION; AGED 13-17 YEARS; HPV VACCINE; UNITED-STATES; PRIMARY-CARE; REMINDER/RECALL INTERVENTIONS; PARENTAL SATISFACTION; ADOLESCENT CHILDREN; IMMUNIZATION RATES; ACCEPTABILITY AB The authors performed telephone interviews of parents of adolescents (n = 430) and their older adolescents (n = 208) in Monroe County, New York to measure parent and adolescent acceptance of human papillomavirus (HPV) vaccine, its association with ratings of provider communication, and vaccine-related topics discussed with the adolescent's provider. More than half of adolescent girls had already received an HPV vaccination, with fewer than one quarter refusing. Parent and teen ratings of provider communication was high, and not related to HPV vaccine refusal. Parents were more likely to refuse if they were Hispanic (odds ratio [OR] = 5.88, P = .05) or did not consider vaccines "very safe" (OR = 2.76, P = .04). Most parents of boys (85%) believed males should be given HPV vaccine if recommended. Few parents and teens recalled discussing that vaccination does not preclude future Pap smear testing. Providers should address cultural and vaccine safety concerns in discussions about HPV vaccine. C1 [Rand, Cynthia M.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. [Stokley, Shannon] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Rand, CM (reprint author), Univ Rochester, Sch Med & Dent, Dept Pediat, 601 Elmwood Ave,Box 777, Rochester, NY 14642 USA. EM cynthia_rand@urmc.rochester.edu OI Schaffer, Stanley/0000-0001-7993-1374 FU Centers for Disease Control and Prevention [U01 IP000040] FX This work was supported by Cooperative Agreement U01 IP000040 with the Centers for Disease Control and Prevention. NR 49 TC 28 Z9 28 U1 2 U2 15 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0009-9228 J9 CLIN PEDIATR JI Clin. Pediatr. PD FEB PY 2011 VL 50 IS 2 BP 106 EP 113 DI 10.1177/0009922810379907 PG 8 WC Pediatrics SC Pediatrics GA 706RI UT WOS:000286235100003 PM 20837607 ER PT J AU Schelonka, RL Maheshwari, A Carlo, WA Taylor, S Hansen, NI Schendel, DE Thorsen, P Skogstrand, K Hougaard, DM Higgins, RD AF Schelonka, Robert L. Maheshwari, Akhil Carlo, Waldemar A. Taylor, Sarah Hansen, Nellie I. Schendel, Diana E. Thorsen, Poul Skogstrand, Kristin Hougaard, David M. Higgins, Rosemary D. CA NICHD Neonatal Res Network TI T cell cytokines and the risk of blood stream infection in extremely low birth weight infants SO CYTOKINE LA English DT Article DE Cytokine; Infection; Sepsis; Neonate ID ONSET NEONATAL SEPSIS; DIAGNOSTIC MARKERS; INTERLEUKIN-6; DIVERSITY; IMMUNITY; RECEPTOR; NETWORK; INNATE; HELPER AB Cytokines mediate the host immune response to infectious micro-organisms. The objective of this study was to determine whether immune regulatory interleukins (IL-4, IL-5, IL-6, and IL-10) and inflammatory cytokines (Interferon-gamma [INF-gamma], tumor necrosis factor-beta [TNF-beta], IL-2, and IL-17) are associated with an increased risk of developing blood stream bacterial/fungal infection (BSI) in extremely low birth weight (ELBW) infants. ELBW infants from 17 NICHD Neonatal Research Network centers without early onset sepsis were studied. Cytokines were measured from blood on days 1, 3, 7, 14, and 21 after birth. 996 ELBW infants contributed a minimum of 4080 unique measurements for each cytokine during the five sampling periods. Infants with BSI had lower levels of the inflammatory cytokines IL-17 (p = 0.01), and higher levels of the regulatory cytokines, IL-6 (p = 0.01) and IL-10 (p < 0.001). Higher levels of regulatory cytokines relative to pro-inflammatory cytokines were associated with increased risk of BSI even after adjusting for confounding variables. In ELBW infants, the ratio of immune regulatory cytokines to inflammatory cytokines was associated with development of BSI. Altered maturation of regulatory and inflammatory cytokines may increase the risk of serious infection in this population. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Schelonka, Robert L.; Maheshwari, Akhil; Carlo, Waldemar A.] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA. [Taylor, Sarah; Hansen, Nellie I.] RTI Int, Stat & Epidemiol Unit, Res Triangle Pk, NC USA. [Schendel, Diana E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Thorsen, Poul] Lillebaelt Hosp, Dept Obstet & Gynecol, Kolding, Denmark. [Skogstrand, Kristin; Hougaard, David M.] Statens Serum Inst, Dept Clin Biochem & Immunol, Sect Neonatal Screening & Hormones, DK-2300 Copenhagen, Denmark. [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. RP Schelonka, RL (reprint author), Oregon Hlth & Sci Univ, Mail Code CDRCP,707 SW Gaines St, Portland, OR 97239 USA. EM schelonk@ohsu.edu OI Skogstrand, Kristin/0000-0002-0026-3711 FU National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Centers for Disease Control and Prevention [Y1-HD-5000-01] FX The National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the Centers for Disease Control and Prevention (via an Interagency Agreement Y1-HD-5000-01) provided grant support for recruitment during 1999-2001 and data analysis for the Neonatal Research Network's Cytokines Study. The funding agencies provided overall oversight for study conduct, but all data analyses and interpretation were independent of the funding agencies. We are indebted to our medical and nursing colleagues and the infants and their parents who agreed to take part in this study. NR 30 TC 21 Z9 22 U1 0 U2 6 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 1043-4666 J9 CYTOKINE JI Cytokine PD FEB PY 2011 VL 53 IS 2 BP 249 EP 255 DI 10.1016/j.cyto.2010.11.003 PG 7 WC Biochemistry & Molecular Biology; Cell Biology; Immunology SC Biochemistry & Molecular Biology; Cell Biology; Immunology GA 720HX UT WOS:000287272700020 PM 21145756 ER PT J AU James, C Bullard, KM Rolka, DB Geiss, LS Williams, DE Cowie, CC Albright, A Gregg, EW AF James, Cherie Bullard, Kai McKeever Rolka, Deborah B. Geiss, Linda S. Williams, Desmond E. Cowie, Catherine C. Albright, Ann Gregg, Edward W. TI Implications of Alternative Definitions of Prediabetes for Prevalence in US Adults SO DIABETES CARE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; INCIDENT CARDIOVASCULAR EVENTS; DIABETES PREVENTION PROGRAM; LIFE-STYLE; GLYCATED HEMOGLOBIN; FASTING GLYCEMIA; RISK; DIAGNOSIS; MELLITUS; IMPACT AB OBJECTIVE-To compare the prevalence of prediabetes using A1C, fasting plasma glucose (FPG), and oral glucose tolerance test (OGTT) criteria, and to examine the degree of agreement between the measures. RESEARCH DESIGN AND METHODS-We used the 2005-2008 National Health and Nutrition Examination Surveys to classify 3,627 adults aged >= 18 years without diabetes according to their prediabetes status using A1C, FPG, and OGTT. We compared the prevalence of prediabetes according to different measures and used conditional probabilities to examine agreement between measures. RESULTS-In 2005-2008, the crude prevalence of prediabetes in adults >= 18 aged years was 14.2% for A1C 5.7-6.4% (A1C5.7), 26.2% for FPG 100-125 mg/dL (IFG100), 7.0% for FPG 110-125 mg/dL (IFG110), and 13.7% for OGTT 140-199 mg/dL (IGT). Prediabetes prevalence varied by age, sex, and race/ethnicity, and there was considerable discordance between measures of prediabetes. Among those with IGT, 58.2, 23.4, and 32.3% had IFG100, IFG110, and A1C5.7, respectively, and 67.1% had the combination of either A1C5.7 or IFG100. CONCLUSIONS-The prevalence of prediabetes varied by the indicator used to measure risk; there was considerable discordance between indicators and the characteristics of individuals with prediabetes. Programs to prevent diabetes may need to consider issues of equity, resources, need, and efficiency in targeting their efforts. C1 [Bullard, Kai McKeever; Rolka, Deborah B.; Geiss, Linda S.; Williams, Desmond E.; Albright, Ann; Gregg, Edward W.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA. [James, Cherie] RTI Int, Atlanta Reg Off, Atlanta, GA USA. [Cowie, Catherine C.] NIDDK, NIH, Bethesda, MD USA. RP Geiss, LS (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA 30333 USA. EM lgeiss@cdc.gov NR 24 TC 49 Z9 50 U1 0 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2011 VL 34 IS 2 BP 387 EP 391 DI 10.2337/dc10-1314 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 722LO UT WOS:000287433900026 PM 21270196 ER PT J AU Gong, Q Gregg, EW Wang, J An, Y Zhang, P Yang, W Li, H Li, H Jiang, Y Shuai, Y Zhang, B Zhang, J Gerzoff, RB Roglic, G Hu, Y Li, G Bennett, PH AF Gong, Q. Gregg, E. W. Wang, J. An, Y. Zhang, P. Yang, W. Li, H. Li, H. Jiang, Y. Shuai, Y. Zhang, B. Zhang, J. Gerzoff, R. B. Roglic, G. Hu, Y. Li, G. Bennett, P. H. TI Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study SO DIABETOLOGIA LA English DT Article DE Diabetic retinopathy; Impaired glucose tolerance; Lifestyle intervention; Nephropathy; Neuropathy ID PIMA-INDIANS; VASCULAR-DISEASE; FOLLOW-UP; PREVALENCE; RETINOPATHY; MORTALITY; MELLITUS; PROGRAM; AGE; IGT AB We determined the effects of 6 years of lifestyle intervention in persons with impaired glucose tolerance (IGT) on the development of retinopathy, nephropathy and neuropathy over a 20 year period. In 1986, 577 adults with IGT from 33 clinics in Da Qing, China were randomly assigned by clinic to a control group or one of three lifestyle intervention groups (diet, exercise, and diet plus exercise). Active intervention was carried out from 1986 to 1992. In 2006 we conducted a 20 year follow-up study of the original participants to compare the incidence of microvascular complications in the combined intervention group vs the control group. Follow-up information was obtained on 542 (94%) of the 577 original participants. The cumulative incidence of severe retinopathy was 9.2% in the combined intervention group and 16.2% in the control group (p = 0.03, log-rank test). After adjusting for clinic and age, the incidence of severe retinopathy was 47% lower in the intervention group than the control group (hazard rate ratio 0.53, 95% CI 0.29-0.99, p = 0.048). No significant differences were found in the incidence of severe nephropathy (hazard rate ratio 1.05, 95% CI 0.16-7.05, intervention vs control, p = 0.96) or in the prevalence of neuropathy (8.6% vs 9.1%, p = 0.89) among the 20 year survivors. Lifestyle intervention for 6 years in IGT was associated with a 47% reduction in the incidence of severe, vision-threatening retinopathy over a 20 year interval, primarily due to the reduced incidence of diabetes in the intervention group. However, similar benefits were not seen for nephropathy or neuropathy. C1 [Gong, Q.; An, Y.; Yang, W.; Shuai, Y.; Zhang, B.; Li, G.] China Japan Friendship Hosp, Dept Endocrinol, Beijing 100029, Peoples R China. [Gregg, E. W.; Zhang, P.; Gerzoff, R. B.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Wang, J.; Jiang, Y.; Zhang, J.; Hu, Y.] Da Qing First Hosp, Dept Cardiol, Da Qing, Peoples R China. [Roglic, G.] World Hlth Org, Dept Chron Dis & Hlth Promot, Geneva, Switzerland. [Gong, Q.; Bennett, P. H.] NIDDKD, Diabet Epidemiol & Clin Res Sect, NIH, Phoenix, AZ USA. RP Li, G (reprint author), China Japan Friendship Hosp, Dept Endocrinol, Beijing 100029, Peoples R China. EM guangwei_li@medmail.com.cn FU CDC/WHO [U58/CCU424123-01-02]; China-Japan Friendship Hospital; Da Qing First Hospital; American Diabetes Association; National Institute of Diabetes and Digestive and Kidney Diseases FX We thank the participants in the original Da Qing Diabetes Prevention Study and the Da Qing Diabetes Prevention Outcome Study. We thank L. Zhang and H. Zhang of the China-Japan Friendship Hospital for grading the fundus photographs. We thank M. M. Engelgau for assistance in acquiring funding and B.V. Howard for help in the design of the original study. We also acknowledge L. Kong, the China Ministry of Health, the leadership of the China-Japan Friendship Hospital, Da Qing First Hospital, the Da Qing City Health Bureau and the Beijing and West Pacific Regional Office of WHO for their general support. We thank W.C. Knowler, C.C. Mason, R.G. Nelson and S. Kobes of the Diabetes Epidemiology and Clinical Research Section, NIDDK, for statistical assistance. Special thanks are due to the late Professor X. Pan as this study would not have been possible without his leadership in the original Da Qing Diabetes Prevention Study. This study was supported by CDC/WHO Cooperative Agreement No. U58/CCU424123-01-02, China-Japan Friendship Hospital and Da Qing First Hospital. Q. Gong received a Mentor-based Postdoctoral Research Fellowship from the American Diabetes Association and partial support from Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases. The sponsors had no role in any aspect of the study design, in the collection, analysis and interpretation of data, or in the development of the manuscript. NR 27 TC 92 Z9 100 U1 1 U2 20 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X J9 DIABETOLOGIA JI Diabetologia PD FEB PY 2011 VL 54 IS 2 BP 300 EP 307 DI 10.1007/s00125-010-1948-9 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 703SO UT WOS:000286001800014 PM 21046360 ER PT J AU Engelthaler, DM Chiller, T Schupp, JA Colvin, J Beckstrom-Sternberg, SM Driebe, EM Moses, T Tembe, W Sinari, S Beckstrom-Sternberg, JS Christoforides, A Pearson, JV Carpten, J Keim, P Peterson, A Terashita, D Balajee, SA AF Engelthaler, David M. Chiller, Tom Schupp, James A. Colvin, Joshua Beckstrom-Sternberg, Stephen M. Driebe, Elizabeth M. Moses, Tracy Tembe, Waibhav Sinari, Shripad Beckstrom-Sternberg, James S. Christoforides, Alexis Pearson, John V. Carpten, John Keim, Paul Peterson, Ashley Terashita, Dawn Balajee, S. Arunmozhi TI Next-Generation Sequencing of Coccidioides immitis Isolated during Cluster Investigation SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SOFTWARE; GENOMES AB Next-generation sequencing enables use of whole-genome sequence typing (WGST) as a viable and discriminatory tool for genotyping and molecular epidemiologic analysis. We used WGST to confirm the linkage of a cluster of Coccidioides immitis isolates from 3 patients who received organ transplants from a single donor who later had positive test results for coccidioidomycosis. Isolates from the 3 patients were nearly genetically identical (a total of 3 single-nucleotide polymorphisms identified among them), thereby demonstrating direct descent of the 3 isolates from an original isolate. We used WGST to demonstrate the genotypic relatedness of C. immitis isolates that were also epidemiologically linked. Thus, WGST offers unique benefits to public health for investigation of clusters considered to be linked to a single source. C1 [Chiller, Tom; Balajee, S. Arunmozhi] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Engelthaler, David M.; Schupp, James A.; Colvin, Joshua; Beckstrom-Sternberg, Stephen M.; Driebe, Elizabeth M.; Moses, Tracy; Tembe, Waibhav; Sinari, Shripad; Christoforides, Alexis; Pearson, John V.; Carpten, John; Keim, Paul] Translat Genom Res Inst, Phoenix, AZ USA. [Beckstrom-Sternberg, Stephen M.; Beckstrom-Sternberg, James S.; Keim, Paul] No Arizona Univ, Flagstaff, AZ 86011 USA. [Peterson, Ashley; Terashita, Dawn] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. RP Balajee, SA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G11, Atlanta, GA 30333 USA. EM fir3@cdc.gov RI Keim, Paul/A-2269-2010; Pearson, John/F-2249-2011 OI Pearson, John/0000-0003-0904-4598 FU Arizona Biomedical Research Commission [0816]; National Institutes of Health [1S10RR25056-01, 1S10RR023390-01] FX Laboratory work for this study was funded in part by the Arizona Biomedical Research Commission (no. 0816). Bioinformatic analyses were conducted on the Translational Genomics Research Institute's (TGen's) High-Performance Bio-Computing resources funded by the National Institutes of Health grant nos. 1S10RR25056-01 and 1S10RR023390-01. NR 27 TC 23 Z9 23 U1 0 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2011 VL 17 IS 2 BP 227 EP 232 DI 10.3201/eid1702.100620 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 722MM UT WOS:000287436400010 PM 21291593 ER PT J AU Graitcer, SB Gubareva, L Kamimoto, L Doshi, S Vandermeer, M Louie, J Waters, C Moore, Z Sleeman, K Okomo-Adhiambo, M Marshall, SA George, KS Pan, CY LaPlante, JM Klimov, A Fry, AM AF Graitcer, Samuel B. Gubareva, Larisa Kamimoto, Laurie Doshi, Saumil Vandermeer, Meredith Louie, Janice Waters, Christine Moore, Zack Sleeman, Katrina Okomo-Adhiambo, Margaret Marshall, Steven A. George, Kirsten St. Pan, Chao-Yang LaPlante, Jennifer M. Klimov, Alexander Fry, Alicia M. TI Characteristics of Patients with Oseltamivir-Resistant Pandemic (H1N1) 2009, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFLUENZA-A; VIRUS-INFECTION AB During April 2009 June 2010, thirty-seven (0.5%) of 6,740 pandemic (H1N1) 2009 viruses submitted to a US surveillance system were oseltamivir resistant. Most patients with oseltamivir-resistant infections were severely immunocompromised (76%) and had received oseltamivir before specimen collection (89%). No evidence was found for community circulation of resistant viruses; only 4 (unlinked) patients had no oseltamivir exposure. C1 [Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Vandermeer, Meredith] Oregon Dept Human Serv, Portland, OR USA. [Louie, Janice; Pan, Chao-Yang] Calif Dept Hlth, Sacramento, CA USA. [Waters, Christine; George, Kirsten St.; LaPlante, Jennifer M.] New York State Dept Hlth, Albany, NY USA. [Moore, Zack] N Carolina Dept Hlth & Human Serv, Raleigh, NC USA. [Marshall, Steven A.] Wisconsin Dept Hlth, Madison, WI USA. RP Fry, AM (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,Mailstop A34, Atlanta, GA 30333 USA. EM afry@cdc.gov NR 10 TC 42 Z9 45 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2011 VL 17 IS 2 BP 255 EP 257 DI 10.3201/eid1702.101724 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 722MM UT WOS:000287436400016 PM 21291599 ER PT J AU Shakoor, S Beg, MA Mahmood, SF Bandea, R Sriram, R Noman, F Ali, F Visvesvara, GS Zafar, A AF Shakoor, Sadia Beg, Mohammad Asim Mahmood, Syed Faisal Bandea, Rebecca Sriram, Rama Noman, Fatima Ali, Farheen Visvesvara, Govinda S. Zafar, Afia TI Primary Amebic Meningoencephalitis Caused by Naegleria fowleri, Karachi, Pakistan SO EMERGING INFECTIOUS DISEASES LA English DT Article ID WATER AB We report 13 cases of Naegleria fowleri primary amebic meningoencephalitis in persons in Karachi, Pakistan, who had no history of aquatic activities. Infection likely occurred through ablution with tap water. An increase in primary amebic meningoencephalitis cases may be attributed to rising temperatures, reduced levels of chlorine in potable water, or deteriorating water distribution systems. C1 [Mahmood, Syed Faisal] Aga Khan Univ Hosp, Dept Med, Karachi 75800, Pakistan. [Bandea, Rebecca; Sriram, Rama; Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Noman, Fatima] Liaquat Natl Hosp, Karachi, Pakistan. RP Mahmood, SF (reprint author), Aga Khan Univ Hosp, Dept Med, Karachi 75800, Pakistan. EM faisal.mahmood@aku.edu FU Deanery, Aga Khan University Hospital, Karachi FX Financial support for shipping materials to the Centers for Disease Control and Prevention was provided by the Deanery, Aga Khan University Hospital, Karachi. NR 14 TC 32 Z9 33 U1 1 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2011 VL 17 IS 2 BP 258 EP 261 DI 10.3201/eid1702.100442 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 722MM UT WOS:000287436400017 PM 21291600 ER PT J AU Silva, N Eremeeva, ME Rozental, T Ribeiro, GS Paddock, CD Ramos, EAG Favacho, ARM Reis, MG Dasch, GA de Lemos, ERS Ko, AI AF Silva, Nanci Eremeeva, Marina E. Rozental, Tatiana Ribeiro, Guilherme S. Paddock, Christopher D. Ramos, Eduardo Antonio G. Favacho, Alexsandra R. M. Reis, Mitermayer G. Dasch, Gregory A. de Lemos, Elba R. S. Ko, Albert I. TI Eschar-associated Spotted Fever Rickettsiosis, Bahia, Brazil SO EMERGING INFECTIOUS DISEASES LA English DT Article ID RHIPICEPHALUS-SANGUINEUS TICKS; ENDEMIC AREA; SAO-PAULO; MASSILIAE; STATE AB In Brazil, Brazilian spotted fever was once considered the only tick-borne rickettsial disease. We report eschar-associated rickettsial disease that occurred after a tick bite. The etiologic agent is most related to Rickettsia parkeri, R. africae, and R. sibirica and probably widely distributed from Sao Paulo to Bahia in the Atlantic Forest. C1 [Ko, Albert I.] Yale Univ, Sch Publ Hlth, Epidemiol Microbial Dis Div, New Haven, CT 06520 USA. [Silva, Nanci] Med & Publ Hlth Sch Bahia, Salvador, BA, Brazil. [Eremeeva, Marina E.; Paddock, Christopher D.; Dasch, Gregory A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rozental, Tatiana; Favacho, Alexsandra R. M.; de Lemos, Elba R. S.] Inst Oswaldo Cruz, BR-20001 Rio De Janeiro, Brazil. [Ribeiro, Guilherme S.; Ramos, Eduardo Antonio G.; Reis, Mitermayer G.; Ko, Albert I.] Inst Oswaldo Cruz, Salvador, BA, Brazil. [Ribeiro, Guilherme S.] Univ Fed Bahia, Salvador, BA, Brazil. RP Ko, AI (reprint author), Yale Univ, Sch Publ Hlth, Epidemiol Microbial Dis Div, 60 Coll St,POB 208034, New Haven, CT 06520 USA. EM albert.ko@yale.edu RI Rozental, Tatiana/B-6270-2014; Ko, Albert/P-2343-2015; OI Rozental, Tatiana/0000-0002-8360-8876; Dasch, Gregory/0000-0001-6090-1810 NR 16 TC 49 Z9 53 U1 0 U2 11 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2011 VL 17 IS 2 BP 275 EP 278 DI 10.3201/eid1702.100859 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 722MM UT WOS:000287436400022 PM 21291605 ER PT J AU Ramirez-Gonzalez, JE Gonzalez-Duran, E Alcantara-Perez, P Wong-Arambula, C Olivera-Diaz, H Cortez-Ortiz, I Barrera-Badillo, G Nguyen, H Gubareva, L Lopez-Martinez, I Diaz-Quinonez, JA Lezana-Fernandez, MA Gatell-Ramirez, HL Villalobos, JAC Hernandez-Avila, M Alpuche-Aranda, C AF Ernesto Ramirez-Gonzalez, Jose Gonzalez-Duran, Elizabeth Alcantara-Perez, Patricia Wong-Arambula, Claudia Olivera-Diaz, Hiram Cortez-Ortiz, Iliana Barrera-Badillo, Gisela Nguyen, Ha Gubareva, Larisa Lopez-Martinez, Irma Alberto Diaz-Quinonez, Jose Angel Lezana-Fernandez, Miguel Lopez Gatell-Ramirez, Hugo Cordova Villalobos, Jose Angel Hernandez-Avila, Mauricio Alpuche-Aranda, Celia TI Oseltamivir-Resistant Pandemic (H1N1) 2009 Virus, Mexico SO EMERGING INFECTIOUS DISEASES LA English DT Article ID HUMAN INFLUENZA-A AB During May 2009 April 2010, we analyzed 692 samples of pandemic (H1N1) 2009 virus from patients in Mexico. We detected the H275Y substitution of the neuraminidase gene in a specimen from an infant with pandemic (H1N1) 2009 who was treated with oseltamivir. This virus was susceptible to zanamivir and resistant to adamantanes and oseltamivir. C1 [Ernesto Ramirez-Gonzalez, Jose; Gonzalez-Duran, Elizabeth; Alcantara-Perez, Patricia; Wong-Arambula, Claudia; Olivera-Diaz, Hiram; Cortez-Ortiz, Iliana; Barrera-Badillo, Gisela; Lopez-Martinez, Irma; Alberto Diaz-Quinonez, Jose; Angel Lezana-Fernandez, Miguel; Lopez Gatell-Ramirez, Hugo; Cordova Villalobos, Jose Angel; Hernandez-Avila, Mauricio; Alpuche-Aranda, Celia] Inst Diagnost & Referencia Epidemiol, Mexico City, DF, Mexico. [Ernesto Ramirez-Gonzalez, Jose; Gonzalez-Duran, Elizabeth; Alcantara-Perez, Patricia; Wong-Arambula, Claudia; Olivera-Diaz, Hiram; Cortez-Ortiz, Iliana; Barrera-Badillo, Gisela; Lopez-Martinez, Irma; Alberto Diaz-Quinonez, Jose; Angel Lezana-Fernandez, Miguel; Lopez Gatell-Ramirez, Hugo; Cordova Villalobos, Jose Angel; Hernandez-Avila, Mauricio; Alpuche-Aranda, Celia] Secretaria Salud Mexico, Mexico City, DF, Mexico. [Nguyen, Ha; Gubareva, Larisa] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Alpuche-Aranda, C (reprint author), InDRE SSA, Carpio 470, Colonia Santo Tomas 11340, Mexico. EM celia.alpuche@salud.gob.mx OI Diaz-Quinonez, Jose Alberto/0000-0002-3503-7079 FU Institute of Epidemiologic Diagnosis and Reference of the Ministry of Health, Mexico FX This study was supported by the Institute of Epidemiologic Diagnosis and Reference of the Ministry of Health, Mexico. NR 15 TC 14 Z9 15 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2011 VL 17 IS 2 BP 283 EP 286 DI 10.3201/eid1702.100897 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 722MM UT WOS:000287436400024 PM 21291607 ER PT J AU Kuhar, DT Henderson, DK AF Kuhar, David T. Henderson, David K. TI Pandemic (H1N1) 2009 and HIV Co-infection SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 [Kuhar, David T.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Henderson, David K.] NIH, Bethesda, MD 20892 USA. RP Kuhar, DT (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A31, Atlanta, GA 30333 USA. EM dkuhar@cdc.gov NR 4 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2011 VL 17 IS 2 BP 328 EP 328 DI 10.3201/eid1702.101775 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 722MM UT WOS:000287436400045 PM 21291627 ER PT J AU Potter, P AF Potter, Polyxeni TI The Icy Realm of the Rime SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, EID Journal, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, EID Journal, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM PMP1@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2011 VL 17 IS 2 BP 331 EP 332 DI 10.3201/eid1702.AC1702 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 722MM UT WOS:000287436400047 ER PT J AU Ko, JH Chang, SI Kim, M Holt, JB Seong, JC AF Ko, Joon Hee Chang, Seo Il Kim, Minho Holt, James B. Seong, Jeong C. TI Transportation noise and exposed population of an urban area in the Republic of Korea SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Transportation noise; Noise prediction models; Exposed population; Youngdeungpo-gu; Republic of Korea ID ROAD TRAFFIC NOISE; ENVIRONMENTAL NOISE; COMMUNITY NOISE; HEALTH; ANNOYANCE; STRESS AB Using noise prediction models, we explored the transportation noise levels of Youngdeungpo-gu, an urbanized area of Seoul Metropolitan City in the Republic of Korea. In addition, we estimated the population exposed to transportation noise levels and determined how many people are vulnerable to noise levels that would cause serious annoyance and sleep disturbance. Compared with the World Health Organization [WHO] recommended levels, the daytime and nighttime transportation noise levels were still high enough to have the two psychosocial effects on people when considering the recommended levels of the World Health Organization (WHO; 55 decibels [dB[A]] and 40 db[A] for daytime and nighttime, respectively). Particularly, nighttime transportation noise was discovered to be harmful to a wider area and more people than daytime noise. Approximately 91% of the Youngdeungpo-gu area experienced nighttime transportation noise levels exceeding those recommended by WHO. It was estimated that as much as 80% of the people in the study area were exposed to transportation noise levels >40 dB[A] during nighttime. Taking this into account, there is an urgent need to control and reduce transportation noise levels in Seoul, to protect residents against the potential ill health effects caused by urban transportation. (c) 2010 Elsevier Ltd. All rights reserved. C1 [Ko, Joon Hee; Chang, Seo Il] Univ Seoul, Dept Environm Engn, Seoul 130743, South Korea. [Kim, Minho; Holt, James B.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Seong, Jeong C.] Univ W Georgia, Dept Geosci, Carrollton, GA 30118 USA. RP Chang, SI (reprint author), Univ Seoul, Dept Environm Engn, Seoul 130743, South Korea. EM schang@uos.ac.kr FU Youngdeungpo-gu Government; Ministry of Environment, Republic of Korea FX This work was financially supported by the Youngdeungpo-gu Government and the Ministry of Environment, Republic of Korea. We acknowledge that the findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention. NR 32 TC 18 Z9 19 U1 1 U2 7 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD FEB PY 2011 VL 37 IS 2 BP 328 EP 334 DI 10.1016/j.envint.2010.10.001 PG 7 WC Environmental Sciences SC Environmental Sciences & Ecology GA 725BL UT WOS:000287620100004 PM 21056472 ER PT J AU Meeker, JD Yang, T Ye, XY Calafat, AM Hauser, R AF Meeker, John D. Yang, Tiffany Ye, Xiaoyun Calafat, Antonia M. Hauser, Russ TI Urinary Concentrations of Parabens and Serum Hormone Levels, Semen Quality Parameters, and Sperm DNA Damage SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE biomarker; endocrine; epidemiology; exposure; fertility; reproduction; thyroid ID MALE REPRODUCTIVE-SYSTEM; P-HYDROXYBENZOIC ACID; COMET ASSAY; HUMAN-SPERMATOZOA; TEMPORAL VARIABILITY; BUTYL PARABEN; CHO-K1 CELLS; HUMAN HEALTH; ESTERS; MEN AB BACKGROUND: Parabens are commonly used as antimicrobial preservatives in cosmetics, pharmaceuticals, and food and beverage processing. Widespread human exposure to parabens has been recently documented, and some parabens have demonstrated adverse effects on male reproduction in animal studies. However, human epidemiologic studies are lacking. OBJECTIVE: We investigated relationships between urinary concentrations of parabens and markers of male reproductive health in an ongoing reproductive epidemiology study. Methods: Urine samples collected from male partners attending an infertility clinic were analyzed for methyl paraben (MP), propyl paraben (PP), butyl paraben (BP), and bisphenol A (BPA). Associations with serum hormone levels (n = 167), semen quality parameters (n = 190), and sperm DNA damage measures (n = 132) were assessed using multivariable linear regression. RESULTS: Detection rates in urine were 100% for MP, 92% for PP, and 32% for BP. We observed no statistically significant associations between MP or PP and the outcome measures. Categories of urinary BP concentration were not associated with hormone levels or conventional semen quality parameters, but they were positively associated with sperm DNA damage (p for trend = 0.03). When urinary BPA quartiles were added to the model, BP and BPA were both positively associated with sperm DNA damage (p for trend = 0.03). Assessment of paraben concentrations measured on repeated urine samples from a subset of the men (n = 78) revealed substantial temporal variability. CONCLUSIONS: We found no evidence for a relationship between urinary parabens and hormone levels or semen quality, although intraindividual variability in exposure and a modest sample size could have limited our ability to detect subtle relationships. Our observation of a relationship between BP and sperm DNA damage warrants further investigation. C1 [Meeker, John D.; Yang, Tiffany] Univ Michigan, Dept Environm Hlth Sci, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Ye, Xiaoyun; Calafat, Antonia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Boston, MA 02114 USA. RP Meeker, JD (reprint author), Univ Michigan, Dept Environm Hlth Sci, Sch Publ Hlth, 6635 SPH Tower,109 S Observ St, Ann Arbor, MI 48109 USA. EM meekerj@umich.edu OI Meeker, John/0000-0001-8357-5085 FU National Institute of Environmental Health Sciences, National Institutes of Health [ES009718, ES00002] FX This work was supported by grants ES009718 and ES00002 from the National Institute of Environmental Health Sciences, National Institutes of Health. NR 46 TC 89 Z9 91 U1 4 U2 49 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD FEB PY 2011 VL 119 IS 2 BP 252 EP 257 DI 10.1289/ehp.1002238 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 714IP UT WOS:000286803400029 PM 20876036 ER PT J AU Needham, LL Grandjean, P Heinzow, B Jorgensen, PJ Nielsen, F Patterson, DG Sjodin, A Turner, WE Weihe, P AF Needham, Larry L. Grandjean, Philippe Heinzow, Birger Jorgensen, Poul J. Nielsen, Flemming Patterson, Donald G., Jr. Sjoedin, Andreas Turner, Wayman E. Weihe, Pal TI Partition of Environmental Chemicals between Maternal and Fetal Blood and Tissues SO ENVIRONMENTAL SCIENCE & TECHNOLOGY LA English DT Article ID POLYBROMINATED BIPHENYLS PBBS; POLYCHLORINATED-BIPHENYLS; BREAST-MILK; CORD BLOOD; PRENATAL EXPOSURE; ADIPOSE-TISSUE; UMBILICAL-CORD; POSTNATAL EXPOSURE; DIPHENYL ETHERS; IN-UTERO AB Passage of environmental chemicals across the placenta has important toxicological consequences, as well as for choosing samples for analysis and for interpreting the results. To obtain systematic data, we collected in 2000 maternal and cord blood, cord tissue, placenta, and milk in connection with births in the Faroe Islands, where exposures to marine contaminants is increased. In 15 sample sets, we measured a total of 87 environmental chemicals, almost all of which were detected both in maternal and fetal tissues. The maternal serum lipid-based concentrations of organohalogen compounds averaged 1.7 times those of cord serum, 2.8 times those of cord tissue and placenta, and 0.7 those of milk. For organohalogen compounds detectable in all matrices, a high degree of correlation between concentrations in maternal serum and the other tissues investigated was generally observed (r(2) > 0.5). Greater degree of chlorination resulted in lower transfer from maternal serum into milk. Concentrations of pentachlor-benzene, gamma-hexachlorocyclohexane, and several polychlorinated biphenyl congeners with low chlorination were higher in fetal samples and showed poor correlation with maternal levels. Perfluorinated compounds occurred in lower concentrations in cord serum than in maternal serum. Cadmium, lead, mercury, and selenium were all detected in fetal samples, but only mercury showed close correlations among concentrations in different matrices. Although the environmental chemicals examined pass through the placenta and are excreted into milk, partitions between maternal and fetal samples are not uniform. C1 [Grandjean, Philippe] Harvard Univ, Dept Environm Hlth, Sch Publ Hlth, Landmark Ctr, Boston, MA 02215 USA. [Needham, Larry L.; Patterson, Donald G., Jr.; Sjoedin, Andreas; Turner, Wayman E.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Grandjean, Philippe; Nielsen, Flemming; Weihe, Pal] Univ So Denmark, Inst Publ Hlth, Odense, Denmark. [Heinzow, Birger] State Agcy Social Serv Schleswig Holstein, Kiel, Germany. [Jorgensen, Poul J.] Odense Univ Hosp, Dept Biochem & Clin Pharmacol, DK-5000 Odense, Denmark. RP Grandjean, P (reprint author), Harvard Univ, Dept Environm Hlth, Sch Publ Hlth, Landmark Ctr, 3-102E,401 Pk Dr, Boston, MA 02215 USA. EM Pgrand@hsph.harvard.edu RI Needham, Larry/E-4930-2011; Sjodin, Andreas/F-2464-2010; OI Grandjean, Philippe/0000-0003-4046-9658 FU U.S. National Institute of Environmental Health Sciences [ES012199]; Danish Environmental Protection Agency; Danish Council for Strategic Research FX This study was supported by grants from the U.S. National Institute of Environmental Health Sciences (ES012199), the Danish Environmental Protection Agency as part of the environmental support program DANCEA (Danish Cooperation for Environment in the Arctic), and the Danish Council for Strategic Research. The authors are solely responsible for the contents of this paper, which do not necessarily represent the official views of the Centers for Disease Control and Prevention, the NIEHS, NIH, or any other funding agency. The funding sources had no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript. We thank Anna Sofia Veyhe for help with sample collection and preparation; Antonia Calafat and her colleagues for measuring the concentrations of PFCs in the milk samples; and Mette L. Eriksen for help with the data management. NR 40 TC 109 Z9 112 U1 3 U2 41 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0013-936X J9 ENVIRON SCI TECHNOL JI Environ. Sci. Technol. PD FEB 1 PY 2011 VL 45 IS 3 BP 1121 EP 1126 DI 10.1021/es1019614 PG 6 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 711HG UT WOS:000286577100043 PM 21166449 ER PT J AU Rosenthal, NA Lee, LE Vermeulen, BAJ Hedberg, K Keene, WE Widdowson, MA Cieslak, PR Vinje, J AF Rosenthal, N. A. Lee, L. E. Vermeulen, B. A. J. Hedberg, K. Keene, W. E. Widdowson, M. -A. Cieslak, P. R. Vinje, J. TI Epidemiological and genetic characteristics of norovirus outbreaks in long-term care facilities, 2003-2006 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Epidemiology; genetics; long-term care facility; norovirus; outbreak ID NORWALK-LIKE VIRUSES; REVERSE TRANSCRIPTION-PCR; ACUTE GASTROENTERITIS; UNITED-STATES; NURSING-HOMES; INFECTION; NETHERLANDS; IMMUNITY; CALICIVIRUSES; EMERGENCE AB To identify the epidemiological and genetic characteristics of norovirus (NoV) outbreaks and estimate the impact of NoV infections in an older population, we analysed epidemiological and laboratory data collected using standardized methods from long-term care facilities (LTCFs) during 2003-2006. Faecal specimens were tested for NoV by real-time reverse transcriptase-polymerase chain reaction. NoV strains were genotyped by sequencing. Of the 234 acute gastroenteritis (AGE) outbreaks reported, 163 (70%) were caused by NoV. The annual attack rate of outbreak-associated NoV infection in LTCF residents was 4%, with a case-hospitalization rate of 3.1% and a case-fatality rate of 0.5%. GII. 4 strains accounted for 84% of NoV outbreaks. Median duration of illness was longer for GII. 4 infections than non-GII. 4 infections (33 vs. 24 h, P<0.001). Emerging GII. 4 strains (Hunter/2004, Minerva/2006b, Terneuzen/2006a) gradually replaced the previously dominant strain (Farmington Hills/2002) during 2004-2006. NoV GII. 4 strains are now associated with the majority of AGE outbreaks in LTCFs and prolonged illness in Oregon. C1 [Rosenthal, N. A.; Lee, L. E.; Hedberg, K.; Keene, W. E.; Cieslak, P. R.] Oregon Publ Hlth Div, Portland, OR 97232 USA. [Vermeulen, B. A. J.; Widdowson, M. -A.; Vinje, J.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Rosenthal, N. A.] Ctr Dis Control & Prevent, Oregon Publ Hlth Div, Epidem Intelligence Serv Assigned, Atlanta, GA USA. RP Lee, LE (reprint author), Oregon Publ Hlth Div, 800 NE Oregon St,Suite 772, Portland, OR 97232 USA. EM lore.e.lee@state.or.us OI Widdowson, Marc-Alain/0000-0002-0682-6933; Vinje, Jan/0000-0002-1530-3675 FU Centers for Disease Control and Prevention FX The authors thank Tasha M. Poissant and John Rodakowski for their assistance with data management; Christianne Biggs, LaDonna Grenz, and Marjorie Yungclas at the Oregon State Public Health Laboratory and Kara Williams at CDC for technical assistance; Elaine Young at the Oregon Department of Human Services, Division of Services for Seniors and the Disabled, for providing information regarding long-term care facility regulations; and the communicable disease nurses and environmental health specialists at the Oregon local health departments who investigated NoV outbreaks and provided data for this report. We also thank Dr Sheryl Lyss at CDC for her helpful comments and suggestions. Thanks are also due to the Emerging Infectious Disease programme at the Centers for Disease Control and Prevention for their funding to Oregon. NR 42 TC 21 Z9 23 U1 0 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD FEB PY 2011 VL 139 IS 2 BP 286 EP 294 DI 10.1017/S095026881000083X PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 703WU UT WOS:000286012800015 PM 20412611 ER PT J AU Sodha, SV Lynch, M Wannemuehler, K Leeper, M Malavet, M Schaffzin, J Chen, T Langer, A Glenshaw, M Hoefer, D Dumas, N Lind, L Iwamoto, M Ayers, T Nguyen, T Biggerstaff, M Olson, C Sheth, A Braden, C AF Sodha, S. V. Lynch, M. Wannemuehler, K. Leeper, M. Malavet, M. Schaffzin, J. Chen, T. Langer, A. Glenshaw, M. Hoefer, D. Dumas, N. Lind, L. Iwamoto, M. Ayers, T. Nguyen, T. Biggerstaff, M. Olson, C. Sheth, A. Braden, C. TI Multistate outbreak of Escherichia coli O157:H7 infections associated with a national fast-food chain, 2006: a study incorporating epidemiological and food source traceback results SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Diarrhoea; Escherichia coli O157; lettuce; outbreak ID UNITED-STATES; O157-H7; LETTUCE; CONSUMPTION; EFFICACY; WATER AB A multistate outbreak of Escherichia coli O157:H7 infections occurred in the USA in November-December 2006 in patrons of restaurant chain A. We identified 77 cases with chain A exposure in four states - Delaware, New Jersey, New York, and Pennsylvania. Fifty-one (66%) patients were hospitalized, and seven (9%) developed haemolytic uraemic syndrome; none died. In a matched analysis controlling for age in 31 cases and 55 controls, illness was associated with consumption of shredded iceberg lettuce [matched odds ratio (mOR) 8.0, 95% confidence interval (CI) 1.1-348.1] and shredded cheddar cheese (mOR 6.2, CI 1.7-33.7). Lettuce, an uncooked ingredient, was more commonly consumed (97% of patients) than cheddar cheese (84%) and a single source supplied all affected restaurants. A single source of cheese could not explain the regional distribution of outbreak cases. The outbreak highlights challenges in conducting rapid multistate investigations and the importance of incorporating epidemiological study results with other investigative findings. C1 [Sodha, S. V.; Lynch, M.; Wannemuehler, K.; Leeper, M.; Schaffzin, J.; Chen, T.; Langer, A.; Glenshaw, M.; Iwamoto, M.; Ayers, T.; Nguyen, T.; Biggerstaff, M.; Olson, C.; Sheth, A.; Braden, C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Malavet, M.; Langer, A.; Glenshaw, M.] New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA. [Schaffzin, J.; Hoefer, D.; Dumas, N.] New York State Dept Hlth, Albany, NY USA. [Chen, T.; Lind, L.] Penn Dept Hlth, Harrisburg, PA 17108 USA. RP Sodha, SV (reprint author), 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA. EM ssodha@cdc.gov OI Ayers, Tracy/0000-0003-4140-3263 NR 16 TC 22 Z9 23 U1 0 U2 9 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD FEB PY 2011 VL 139 IS 2 BP 309 EP 316 DI 10.1017/S0950268810000920 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 703WU UT WOS:000286012800018 PM 20429971 ER PT J AU Moonesinghe, R Khoury, MJ Liu, T Janssens, ACJW AF Moonesinghe, Ramal Khoury, Muin J. Liu, Tiebin Janssens, A. Cecile J. W. TI Discriminative accuracy of genomic profiling comparing multiplicative and additive risk models SO EUROPEAN JOURNAL OF HUMAN GENETICS LA English DT Article DE discriminative accuracy; genomic profiles; sensitivity; specificity; additive models ID BREAST-CANCER; DISTRIBUTIONS; POLYMORPHISMS; ASSOCIATION; METHODOLOGY AB Genetic prediction of common diseases is based on testing multiple genetic variants with weak effect sizes. Standard logistic regression and Cox Proportional Hazard models that assess the combined effect of multiple variants on disease risk assume multiplicative joint effects of the variants, but this assumption may not be correct. The risk model chosen may affect the predictive accuracy of genomic profiling. We investigated the discriminative accuracy of genomic profiling by comparing additive and multiplicative risk models. We examined genomic profiles of 40 variants with genotype frequencies varying from 0.1 to 0.4 and relative risks varying from 1.1 to 1.5 in separate scenarios assuming a disease risk of 10%. The discriminative accuracy was evaluated by the area under the receiver operating characteristic curve. Predicted risks were more extreme at the lower and higher risks for the multiplicative risk model compared with the additive model. The discriminative accuracy was consistently higher for multiplicative risk models than for additive risk models. The differences in discriminative accuracy were negligible when the effect sizes were small (<1.2), but were substantial when risk genotypes were common or when they had stronger effects. Unraveling the exact mode of biological interaction is important when effect sizes of genetic variants are moderate at the least, to prevent the incorrect estimation of risks. European Journal of Human Genetics (2011) 19, 180-185; doi:10.1038/ejhg.2010.165; published online 17 November 2010 C1 [Moonesinghe, Ramal] Ctr Dis Control & Prevent, Off Minor Hlth & Hlth Dispar, Atlanta, GA 30341 USA. [Khoury, Muin J.; Liu, Tiebin] Ctr Dis Control & Prevent, Coordinating Ctr Hlth Promot, Off Publ Hlth Genom, Atlanta, GA 30341 USA. [Janssens, A. Cecile J. W.] Erasmus MC Univ Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands. [Janssens, A. Cecile J. W.] Erasmus MC Univ Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. RP Moonesinghe, R (reprint author), Ctr Dis Control & Prevent, Off Minor Hlth & Hlth Dispar, 4770 Buford Highway,Mailstop E-67, Atlanta, GA 30341 USA. EM rmoonesinghe@cdc.gov OI Janssens, A Cecile/0000-0002-6153-4976 FU Centre for Medical Systems Biology (CMSB); Netherlands Organisation for Scientific Research (NWO) FX This study was supported by the Centre for Medical Systems Biology (CMSB) in the framework of The Netherlands Genomics Initiative (NGI). ACJW Janssens was sponsored by the VIDI Grant of The Netherlands Organisation for Scientific Research (NWO). NR 18 TC 7 Z9 7 U1 0 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1018-4813 J9 EUR J HUM GENET JI Eur. J. Hum. Genet. PD FEB PY 2011 VL 19 IS 2 BP 180 EP 185 DI 10.1038/ejhg.2010.165 PG 6 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA 705YK UT WOS:000286176500012 PM 21081969 ER PT J AU Gwinn, M Grossniklaus, DA Yu, W Melillo, S Wulf, A Flome, J Dotson, WD Khoury, MJ AF Gwinn, Marta Grossniklaus, Daurice A. Yu, Wei Melillo, Stephanie Wulf, Anja Flome, Jennifer Dotson, W. David Khoury, Muin J. TI Horizon scanning for new genomic tests SO GENETICS IN MEDICINE LA English DT Article DE genetic test; genomic test; horizon scanning; surveillance; database AB Purpose: The development of health-related genomic tests is decentralized and dynamic, involving government, academic, and commercial entities. Consequently, it is not easy to determine which tests are in development, currently available, or discontinued. We developed and assessed the usefulness of a systematic approach to identifying new genomic tests on the Internet. Methods: We devised targeted queries of Web pages, newspaper articles, and blogs (Google Alerts) to identify new genomic tests. We finalized search and review procedures during a pilot phase that ended in March 2010. Queries continue to run daily and are compiled weekly; selected data are indexed in an online database, the Genomic Applications in Practice and Prevention Finder. Results: After the pilot phase, our scan detected approximately two to three new genomic tests per week. Nearly two thirds of all tests (122/188, 65%) were related to cancer; only 6% were related to hereditary disorders. Although 88 (47%) of the tests, including 2 marketed directly to consumers, were commercially available, only 12 (6%) claimed United States Food and Drug Administration licensure. Conclusion: Systematic surveillance of the Internet provides information about genomic tests that can be used in combination with other resources to evaluate genomic tests. The Genomic Applications in Practice and Prevention Finder makes this information accessible to a wide group of stakeholders. Genet Med 2011:13(2):161-165. C1 [Grossniklaus, Daurice A.; Yu, Wei; Melillo, Stephanie; Dotson, W. David; Khoury, Muin J.] CDC, OPHG, OSELS, Atlanta, GA 30333 USA. [Gwinn, Marta; Flome, Jennifer] McKing Consulting Corp, Atlanta, GA USA. [Wulf, Anja] Cadence Grp, Atlanta, GA USA. RP Gwinn, M (reprint author), CDC, OPHG, OSELS, 1600 Clifton Rd,Mail Stop E-61, Atlanta, GA 30333 USA. EM mgwinn@cdc.gov OI Dotson, William David/0000-0002-9606-6594 NR 13 TC 24 Z9 26 U1 0 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD FEB PY 2011 VL 13 IS 2 BP 161 EP 165 DI 10.1097/GIM.0b013e3182011661 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA 716LY UT WOS:000286971500012 PM 21233720 ER PT J AU Asfaw, A AF Asfaw, Abay TI DOES CONSUMPTION OF PROCESSED FOODS EXPLAIN DISPARITIES IN THE BODY WEIGHT OF INDIVIDUALS? THE CASE OF GUATEMALA SO HEALTH ECONOMICS LA English DT Article DE partially processed foods; highly processed foods; overweight; obesity; BMI; nutrition transition; Guatemala ID NUTRITION TRANSITION; EMPIRICAL-EVIDENCE; OBESITY; SUPERMARKETS; AFRICA; CARBOHYDRATE; HOUSEHOLDS; COSTS; CHINA; WOMEN AB Overweight/obesity, caused by the 'nutrition transition', is identified as one of the leading risk factors for non-communicable mortality. The nutrition transition in developing countries is associated with a major shift from the consumption of staple crops and whole grains to highly and partially processed foods. This study examines the contribution of processed foods consumption to the prevalence of overweight/obesity in Guatemala using generalized methods of moments (GMM) regression. The results show that all other things remaining constant, a 10% point increase in the share of partially processed foods from the total household food expenditure increases the BMI of family members (aged 10 years and above) by 3.95%. The impact of highly processed foods is much stronger. A 10% point increase in the share of highly processed food items increases the BMI of individuals by 4.25%, ceteris paribus. The results are robust when body weight is measured by overweight/obesity indicators. These findings suggest that increasing shares of partially and highly processed foods from the total consumption expenditure could be one of the major risk factors for the high prevalence of overweight/obesity in the country. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 NIOSH, Ctr Dis Control & Prevent CDC, Off Director, Washington, DC 20201 USA. RP Asfaw, A (reprint author), NIOSH, Ctr Dis Control & Prevent CDC, Off Director, 395 E St SW, Washington, DC 20201 USA. EM hqp0@cdc.gov RI Sriwisit, Sukhumaphorn/G-1405-2011 NR 42 TC 27 Z9 28 U1 3 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9230 J9 HEALTH ECON JI Health Econ. PD FEB PY 2011 VL 20 IS 2 BP 184 EP 195 DI 10.1002/hec.1579 PG 12 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 714XN UT WOS:000286845100004 PM 20029821 ER PT J AU Reefhuis, J Honein, MA Schieve, LA Rasmussen, SA AF Reefhuis, J. Honein, M. A. Schieve, L. A. Rasmussen, S. A. CA Natl Birth Defects Prevention Stud TI Use of clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997-2005 SO HUMAN REPRODUCTION LA English DT Article DE clomiphene citrate; ovulation stimulation; birth defects; congenital malformations ID NEURAL-TUBE DEFECTS; METROPOLITAN ATLANTA; OVULATION INDUCTION; RISK; POPULATION; FERTILITY; ANOMALIES; FETAL; CRANIOSYNOSTOSIS; SUBFERTILITY AB BACKGROUND: Clomiphene citrate (CC) is the first line drug for subfertility treatment. Studies assessing the association between CC and birth defects have been inconclusive. METHODS: We used data from the National Birth Defects Prevention Study, a population-based, multi-site case-control study of major birth defects. Women from 10 US regions with deliveries affected by at least one of > 30 birth defects (cases) and mothers of live born infants without a major birth defect (controls) who delivered October 1997-December 2005 were interviewed. The exposure of interest was reported CC use in the period from 2 months before conception through the first month of pregnancy. Women who conceived using assisted reproductive technology were excluded. Thirty-six birth defect categories with at least three exposed cases were studied. Multiple logistic regression was used to control for potential confounders. RESULTS: CC use was reported by 1.4% of control mothers (94/6500). Among 36 case-groups assessed, increased adjusted odds ratios (aOR) were found [all: aOR, 95% confidence interval (CI)] for anencephaly (2.3, 1.1-4.7), Dandy-Walker malformation (4.4, 1.7-11.6), septal heart defects (1.6, 1.1-2.2), muscular ventricular septal defect (4.9, 1.4-16.8), coarctation of aorta (1.8, 1.1-3.0), esophageal atresia (2.3, 1.3-4.0), cloacal exstrophy (5.4, 1.6-19.3), craniosynostosis (1.9, 1.2-3.0) and omphalocele (2.2, 1.1-4.5). CONCLUSIONS: Several associations between CC use and birth defects were observed. However, because of the small number of cases, inconsistency of some findings with previous reports, and the fact that we cannot assess the CC effect separately from that of the subfertility, these associations should be interpreted cautiously. C1 [Reefhuis, J.; Honein, M. A.; Schieve, L. A.; Rasmussen, S. A.; Natl Birth Defects Prevention Stud] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Reefhuis, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS E-86, Atlanta, GA 30333 USA. EM nzr5@cdc.gov RI Publications, NBDPS/B-7692-2013 FU Centers for Disease Control and Prevention FX The Centers for Disease Control and Prevention provided funding for the National Birth Defects Prevention Study and for the analysis of data from this study. NR 33 TC 44 Z9 45 U1 0 U2 11 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 J9 HUM REPROD JI Hum. Reprod. PD FEB PY 2011 VL 26 IS 2 BP 451 EP 457 DI 10.1093/humrep/deq313 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 709VW UT WOS:000286470500024 PM 21112952 ER PT J AU Reiter, PL McRee, AL Gottlieb, SL Markowitz, LE Brewer, NT AF Reiter, Paul L. McRee, Annie-Laurie Gottlieb, Sami L. Markowitz, Lauri E. Brewer, Noel T. TI Uptake of 2009 H1N1 vaccine among adolescent females SO HUMAN VACCINES LA English DT Article DE influenza; vaccination; pandemic; H1N1; adolescents; infectious disease; health behavior ID INFLUENZA VACCINATION; UNITED-STATES; COVERAGE; CHILDREN AB Background: The public health response to the threat of pandemic influenza A (H1N1) virus during the 2009-2010 influenza season was extensive. To better understand the lower than expected vaccine uptake, we aimed to characterize correlates of 2009 H1N1 vaccination among adolescent females in the US and examine accessibility of the vaccine to parents. Results: Overall, 22% (221/944) of mothers indicated their daughters had received 2009 H1N1 vaccine. H1N1 vaccination was higher among daughters who had received 2009 seasonal influenza vaccine (49% vs. 11%, OR = 7.00, 95% CI: 4.18-11.73) or whose mothers expressed higher trust in their daughters' healthcare providers (26% vs. 11%, OR = 2.28, 95% CI: 1.10-4.73). Among mothers of unvaccinated daughters, 20% (150/723) indicated they wanted to get their daughters 2009 H1N1 vaccine but were unable to. Vaccination among daughters and accessibility of the vaccine to parents did not differ by race, socioeconomic status or health insurance status. Discussion: One explanation for the lower than expected uptake of 2009 H1N1 vaccine is that many parents were unable to get their daughters the vaccine despite wanting to do so. Concomitant administration with seasonal influenza vaccine may increase uptake of novel influenza vaccines. Methods: We collected data from a national sample of mothers of adolescent females ages 11-14 years (n = 944) during December 2009 using an online survey. C1 [Reiter, Paul L.; McRee, Annie-Laurie; Brewer, Noel T.] UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. [Reiter, Paul L.; Brewer, Noel T.] Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Gottlieb, Sami L.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Reiter, PL (reprint author), UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. EM preiter@email.unc.edu; ntb1@unc.edu RI McRee, Annie/J-3077-2013 FU Centers for Disease Control and Prevention (CDC) [02577-10]; Merck Co., Inc.; GlaxoSmithKline FX This study was primarily funded by a grant from the Centers for Disease Control and Prevention (CDC, 02577-10) with additional support for project staff from the American Cancer Society (MSRG-06-259-01-CPPB) and the Cancer Control Education Program at Lineberger Comprehensive Cancer Center (R25 CA57726). Members of the CDC were involved in conducting the study and in preparing and submitting this article. None of the other funding sources had a role in the design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript. Although we do not believe we have any conflicts of interest, we wish to share the following information in the interest of full disclosure. Authors have received research grants from Merck & Co., Inc., (N.B., P.R.) and GlaxoSmithKline (N.B.), but neither has received honoraria or consulting fees from these companies. These funds were not used to support this research study. NR 21 TC 1 Z9 1 U1 1 U2 2 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8600 J9 HUM VACCINES JI Hum. Vaccines PD FEB PY 2011 VL 7 IS 2 BP 191 EP 196 DI 10.4161/hv.7.2.13847 PG 6 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA 743BQ UT WOS:000288990900008 PM 21307658 ER PT J AU Nayak, AP Green, BJ Janotka, E Blachere, FM Vesper, SJ Beezhold, DH Schmechel, D AF Nayak, Ajay P. Green, Brett J. Janotka, Erika Blachere, Francoise M. Vesper, Stephen J. Beezhold, Donald H. Schmechel, Detlef TI Production and Characterization of IgM Monoclonal Antibodies Against Hyphal Antigens of Stachybotrys Species SO HYBRIDOMA LA English DT Article ID MACROCYCLIC TRICHOTHECENE MYCOTOXINS; WATER-DAMAGED BUILDINGS; ASPERGILLUS-VERSICOLOR; PULMONARY HEMORRHAGE; CHARTARUM STRAINS; STACHYRASE-A; INDOOR MOLD; STACHYHEMOLYSIN; STACHYLYSIN; HEMOLYSIN AB Stachybotrys is a hydrophilic fungal genus that is well known for its ability to colonize water-damaged building materials in indoor environments. Personal exposure to Stachybotrys chartarum allergens, mycotoxins, cytolytic peptides, and other immunostimulatory macromolecules has been proposed to exacerbate respiratory morbidity. To date, advances in Stachybotrys detection have focused on the identification of unique biomarkers that can be detected in human serum; however, the availability of immunodiagnostic reagents to Stachybotrys species have been limited. In this study, we report the initial characterization of monoclonal antibodies (MAbs) against a semi-purified cytolytic S. chlorohalonata preparation (cScp) derived from hyphae. BALB/c mice were immunized with cScp and hybridomas were screened against the cScp using an antigen-mediated indirect ELISA. Eight immunoglobulin M MAbs were produced and four were specifically identified in the capture ELISA to react with the cScp. Cross-reactivity of the MAbs was tested against crude hyphal extracts derived from 15 Stachybotrys isolates representing nine Stachybotrys species as well as 39 other environmentally abundant fungi using a capture ELISA. MAb reactivity to spore and hyphal antigens was also tested by a capture ELISA and by fluorescent halogen immunoassay (fHIA). ELISA analysis demonstrated that all MAbs strongly reacted with extracts of S. chartarum but not with extracts of 39 other fungi. However, four MAbs showed cross-reactivity to the phylogenetically related genus Memnoniella. fHIA analysis confirmed that greatest MAb reactivity was ultrastructurally localized in hyphae and phialides. The results of this study further demonstrate the feasibility of specific MAb-based immunoassays for the detection of S. chartarum. C1 [Nayak, Ajay P.; Green, Brett J.; Janotka, Erika; Blachere, Francoise M.; Beezhold, Donald H.; Schmechel, Detlef] NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Nayak, Ajay P.] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Sch Med, Morgantown, WV 26506 USA. [Vesper, Stephen J.] US EPA, Natl Exposure Res Lab, Cincinnati, OH 45268 USA. RP Beezhold, DH (reprint author), NIOSH, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd,M-S L-4020, Morgantown, WV 26505 USA. EM zec1@cdc.gov FU InterAgency agreement with the National Institute of Environmental Health Sciences [Y1-ES0001-06] FX The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. This work was supported in part by an InterAgency agreement with the National Institute of Environmental Health Sciences (Y1-ES0001-06). NR 34 TC 3 Z9 3 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1554-0014 J9 HYBRIDOMA JI Hybridoma PD FEB PY 2011 VL 30 IS 1 BP 29 EP 36 DI 10.1089/hyb.2010.0071 PG 8 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Immunology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Immunology GA 726NF UT WOS:000287728900004 PM 21466283 ER PT J AU Santiago, HC Bennuru, S Boyd, A Eberhard, M Nutman, TB AF Santiago, Helton C. Bennuru, Sasisekhar Boyd, Alexis Eberhard, Mark Nutman, Thomas B. TI Structural and immunologic cross-reactivity among filarial and mite tropomyosin: Implications for the hygiene hypothesis SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Allergy; antibody cross-reactivity; Dermatophagoides pteronyssinus; filariasis; hygiene hypothesis; tropomyosin ID IMMUNOGLOBULIN-E ANTIBODY; FC-GAMMA-RIIB; HELMINTH INFECTIONS; ASCARIS-LUMBRICOIDES; BLOCKING ANTIBODIES; PARASITE INFECTION; IGE BINDING; SERUM-IGE; T-CELLS; B-CELLS AB Background: The hygiene hypothesis suggests that parasitic infection modulates host immune responses and decreases atopy. Other data suggest parasitic infections may induce allergic responsiveness. Objective: To assess the structural and immunologic relationships between the known Dermatophagoides pteronyssinus (Der p 10) tropomyosin allergen and filarial tropomyosin of Onchocerca volvulus (OvTrop). Methods: The molecular, structural, and immunologic relationships between OvTrop and Der p 10 were compared. Levels of OvTrop-specific and Der p 10-specific IgE, IgG, and IgG(4) in sera of filaria-infected and filarial-uninfected D pteronyssinus-atopic individuals were compared, as were the responses in nonhuman primates infected with the filarial parasite Loa loa. Cross-reactivity was compared by antigen-mediated depletion assays and functionality by passive basophil sensitization. Results: Filarial and mite tropomyosins were very similar, with 72% identity at the amino acid level, and overlapping predicted 3-dimensional structures. The prevalence of IgE and IgG to Der p 10 was increased in filaria-infected individuals compared with uninfected subjects. There was a strong correlation between serum levels of Ov- and Der p 10-tropomyosin-specific IgE, IgG, and IgG4 (P < .0001; r > 0.79). Preincubation of sera from anti-Der p 10-positive subjects with OvTrop completely depleted IgE, IgG, and IgG4 anti-Der p 10. Basophils sensitized with sera from individuals allergic to Der p 10 released histamine similarly when triggered with OvTrop or Der p 10. Primates experimentally infected with L loa developed IgE that cross-reacted with Der p 10. Conclusion: Filarial infection induces strong cross-reactive antitropomyosin antibody responses that may affect sensitization and regulation of allergic reactivity. (J Allergy Clin Immunol 2011;127:479-86.) C1 [Santiago, Helton C.; Bennuru, Sasisekhar; Boyd, Alexis; Nutman, Thomas B.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA. [Boyd, Alexis] George Washington Univ, Washington, DC USA. [Eberhard, Mark] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. RP Nutman, TB (reprint author), NIAID, Parasit Dis Lab, NIH, 4 Ctr Dr,Bldg 4,Room B105, Bethesda, MD 20892 USA. EM tnutman@niaid.nih.gov RI Santiago, Helton/F-8704-2012; Vacinas, Inct/J-9431-2013 OI Santiago, Helton/0000-0002-5695-8256; FU Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health FX Supported by the Intramural Research Program, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. NR 50 TC 30 Z9 30 U1 1 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2011 VL 127 IS 2 BP 479 EP 486 DI 10.1016/j.jaci.2010.11.007 PG 8 WC Allergy; Immunology SC Allergy; Immunology GA 714KH UT WOS:000286808000023 PM 21185070 ER PT J AU Anderson, SE Franko, J Beezhold, D Meade, BJ AF Anderson, S. E. Franko, J. Beezhold, D. Meade, B. J. TI Environmental Chemical Exposure May Augment Occupational Asthma SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting CY MAR 18-22, 2011 CL San Francisco, CA SP Amer Acad Allergy Asthma & Immunol C1 [Anderson, S. E.; Franko, J.; Beezhold, D.; Meade, B. J.] NIOSH, CDC, Morgantown, WV USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2011 VL 127 IS 2 SU S BP AB177 EP AB177 DI 10.1016/j.jaci.2010.12.705 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 832YI UT WOS:000295846400687 ER PT J AU Green, BJ Rittenour, WR Hettick, JM Janotka, E Beezhold, DH AF Green, B. J. Rittenour, W. R. Hettick, J. M. Janotka, E. Beezhold, D. H. TI Characterization of Paecilomyces variotii Allergens SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT American-Academy-of-Allergy-Asthma-and-Immunology Annual Meeting CY MAR 18-22, 2011 CL San Francisco, CA SP Amer Acad Allergy Asthma & Immunol C1 [Green, B. J.; Rittenour, W. R.; Hettick, J. M.; Janotka, E.; Beezhold, D. H.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. RI Hettick, Justin/E-9955-2010 NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2011 VL 127 IS 2 SU S BP AB264 EP AB264 DI 10.1016/j.jaci.2010.12.1051 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 832YI UT WOS:000295846401165 ER PT J AU Avchen, RN Wiggins, LD Devine, O Braun, KV Rice, C Hobson, NC Schendel, D Yeargin-Allsopp, M AF Avchen, Rachel Nonkin Wiggins, Lisa D. Devine, Owen Braun, Kim Van Naarden Rice, Catherine Hobson, Nancy C. Schendel, Diana Yeargin-Allsopp, Marshalyn TI Evaluation of a Records-Review Surveillance System Used to Determine the Prevalence of Autism Spectrum Disorders SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Autism; Surveillance; Sensitivity; Specificity; Prevalence ID SCREENING QUESTIONNAIRE; TOTAL POPULATION; UNITED-STATES; CHILDREN; DIAGNOSIS; IDENTIFICATION AB We conducted the first study that estimates the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of a population-based autism spectrum disorders (ASD) surveillance system developed at the Centers for Disease Control and Prevention. The system employs a records-review methodology that yields ASD classification (case versus non-ASD case) and was compared with classification based on clinical examination. The study enrolled 177 children. Estimated specificity (0.96, [CI(.95) = 0.94, 0.99]), PPV (0.79 [CI(.95) = 0.66, 0.93]), and NPV (0.91 [CI(.95) = 0.87, 0.96]) were high. Sensitivity was lower (0.60 [CI(.95) = 0.45, 0.75]). Given diagnostic heterogeneity, and the broad array of ASD in the population, identifying children with ASD is challenging. Records-based surveillance yields a population-based estimate of ASD that is likely conservative. C1 [Avchen, Rachel Nonkin; Wiggins, Lisa D.; Devine, Owen; Braun, Kim Van Naarden; Rice, Catherine; Schendel, Diana; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Dev Disabil Branch, Atlanta, GA 30333 USA. [Hobson, Nancy C.] Res Triangle Inst, Atlanta, GA USA. RP Avchen, RN (reprint author), Ctr Dis Control & Prevent, Dev Disabil Branch, 1600 Clifton Rd,MS E-92, Atlanta, GA 30333 USA. EM ravchen@cdc.gov RI Rice, Catherine/D-6305-2016 NR 31 TC 23 Z9 23 U1 2 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD FEB PY 2011 VL 41 IS 2 BP 227 EP 236 DI 10.1007/s10803-010-1050-7 PG 10 WC Psychology, Developmental SC Psychology GA 708WH UT WOS:000286394500009 PM 20568003 ER PT J AU Nolte, FS Rogers, BB Tang, YW Oberste, MS Robinson, CC Kehl, KS Rand, KA Rotbart, HA Romero, JR Nyquist, AC Persing, DH AF Nolte, Frederick S. Rogers, Beverly B. Tang, Yi-Wei Oberste, M. Steven Robinson, Christine C. Kehl, K. Sue Rand, Kenneth A. Rotbart, Harley A. Romero, Jose R. Nyquist, Ann-Christine Persing, David H. TI Evaluation of a Rapid and Completely Automated Real-Time Reverse Transcriptase PCR Assay for Diagnosis of Enteroviral Meningitis SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID POLYMERASE-CHAIN-REACTION; CEREBROSPINAL-FLUID; CLINICAL UTILITY; MANAGEMENT; INFECTIONS; IMPACT; AMPLIFICATION AB Nucleic acid amplification tests (NAATs) for enterovirus RNA in cerebrospinal fluid (CSF) have emerged as the new gold standard for diagnosis of enteroviral meningitis, and their use can improve the management and decrease the costs for caring for children with enteroviral meningitis. The Xpert EV assay (Cepheid, Sunnyvale, CA) is a rapid, fully automated real-time PCR test for the detection of enterovirus RNA that was approved by the U. S. Food and Drug Administration for in vitro diagnostic use in March 2007. In this multicenter trial we established the clinical performance characteristics of the Xpert EV assay in patients presenting with meningitis symptoms relative to clinical truth. Clinical truth for enteroviral meningitis was defined as clinical evidence of meningitis, the absence of another detectable pathogen in CSF, and detection of enterovirus in CSF either by two reference NAATs or by viral culture. A total of 199 prospectively and 235 retrospectively collected specimens were eligible for inclusion in this study. The overall prevalence of enteroviral meningitis was 26.04%. The Xpert EV assay had a sensitivity of 94.69% (90% confidence interval [CI] = 89.79 to 97.66%), specificity of 100% (90% CI = 99.07 to 100%), positive predictive value of 100%, negative predictive value of 98.17, and an accuracy of 98.62% relative to clinical truth. The Xpert EV assay demonstrated a high degree of accuracy for diagnosis of enteroviral meningitis. The simplicity and on-demand capability of the Xpert EV assay should prove to be a valuable adjunct to the evaluation of suspected meningitis cases. C1 [Nolte, Frederick S.] Emory Univ, Sch Med, Atlanta, GA USA. [Rogers, Beverly B.] Childrens Med Ctr, Dallas, TX 75235 USA. [Tang, Yi-Wei] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Oberste, M. Steven] Ctr Dis Control & Prevent, Atlanta, GA USA. [Robinson, Christine C.; Rotbart, Harley A.; Nyquist, Ann-Christine] Childrens Hosp, Aurora, CO USA. [Kehl, K. Sue] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Rand, Kenneth A.] Univ Florida, Coll Med, Gainesville, FL USA. [Robinson, Christine C.; Rotbart, Harley A.; Nyquist, Ann-Christine] Univ Colorado Denver, Hlth Sci Ctr, Aurora, CO USA. [Romero, Jose R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Persing, David H.] Cepheid, Sunnyvale, CA USA. RP Nolte, FS (reprint author), Med Univ S Carolina, Dept Pathol & Lab Med, 165 Ashley Ave, Charleston, SC 29425 USA. EM nolte@musc.edu FU Cepheid FX Financial support for this study was provided by Cepheid. NR 23 TC 13 Z9 13 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2011 VL 49 IS 2 BP 528 EP 533 DI 10.1128/JCM.01570-10 PG 6 WC Microbiology SC Microbiology GA 716NE UT WOS:000286977500009 PM 21159942 ER PT J AU Chaffin, M Funderburk, B Bard, D Valle, LA Gurwitch, R AF Chaffin, Mark Funderburk, Beverly Bard, David Valle, Linda Anne Gurwitch, Robin TI A Combined Motivation and Parent-Child Interaction Therapy Package Reduces Child Welfare Recidivism in a Randomized Dismantling Field Trial SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY LA English DT Article DE parenting; PCIT; child abuse; child neglect ID ABUSE POTENTIAL INVENTORY; MULTIPLE-IMPUTATION; CLINICAL-TRIALS; MODEL; RISK AB Objective: A package of parent child interaction therapy (PCIT) combined with a self-motivational (SM) orientation previously was found in a laboratory trial to reduce child abuse recidivism compared with services as usual (SAU). Objectives of the present study were to test effectiveness in a field agency rather than in a laboratory setting and to dismantle the SM versus SAU orientation and PCIT versus SAU parenting component effects. Method: Participants were 192 parents in child welfare with an average of 6 prior referrals and most with all of their children removed. Following a 2 X 2 sequentially randomized experimental design, parents were randomized first to orientation condition (SM vs. SAU) and then subsequently randomized to a parenting condition (PCIT vs. SAU). Cases were followed for child welfare recidivism for a median of 904 days. An imputation-based approach was used to estimate recidivism survival complicated by significant treatment-related differences in timing and frequency of children returned home. Results: A significant orientation condition by parenting condition interaction favoring the SM + PCIT combination was found for reducing future child welfare reports, and this effect was stronger when children were returned to the home sooner rather than later. Conclusions: Findings demonstrate that previous laboratory results can be replicated in a field implementation setting and among parents with chronic and severe child welfare histories, supporting a synergistic SM + PCIT benefit. Methodological considerations for analyzing child welfare event history data complicated by differential risk deprivation are also emphasized. C1 [Chaffin, Mark; Funderburk, Beverly; Bard, David] Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, Oklahoma City, OK 73126 USA. [Valle, Linda Anne] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gurwitch, Robin] Cincinnati Childrens Hosp Med Center, Cincinnati, OH USA. RP Chaffin, M (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Pediat, POB 26901, Oklahoma City, OK 73126 USA. EM mark-chaffin@ouhsc.edu RI Bard, David/I-6629-2012; OI Chaffin, Mark/0000-0002-3620-6583 FU NCIPC CDC HHS [R49CE622338, R49 CE622338] NR 42 TC 64 Z9 64 U1 1 U2 19 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0022-006X EI 1939-2117 J9 J CONSULT CLIN PSYCH JI J. Consult. Clin. Psychol. PD FEB PY 2011 VL 79 IS 1 BP 84 EP 95 DI 10.1037/a0021227 PG 12 WC Psychology, Clinical SC Psychology GA 714ZD UT WOS:000286849300009 PM 21171738 ER PT J AU Darney, S Fowler, B Grandjean, P Heindel, J Mattison, D Slikker, W AF Darney, Sally Fowler, Bruce Grandjean, Philippe Heindel, Jerrold Mattison, Donald Slikker, William, Jr. TI Prenatal Programming and Toxicity II (PPTOX II): Role of Environmental Stressors in the Developmental Origins of Disease SO JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE LA English DT Editorial Material C1 [Fowler, Bruce] Ctr Dis Control, Div Toxicol & Environm Med, ATSDR, Atlanta, GA 30333 USA. [Grandjean, Philippe] Univ So Denmark, Odense, Denmark. [Heindel, Jerrold] NIEHS, Organs & Syst Pathobiol Branch, Res Triangle Pk, NC USA. [Mattison, Donald] NICHD, Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, HHS, Bethesda, MD USA. [Slikker, William, Jr.] US FDA, Natl Ctr Toxicol Res, Rockville, MD 20857 USA. OI Mattison, Donald/0000-0001-5623-0874 NR 2 TC 0 Z9 0 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 2040-1744 J9 J DEV ORIG HLTH DIS JI J. Dev. Orig. Health Dis. PD FEB PY 2011 VL 2 IS 1 BP 2 EP 2 DI 10.1017/S2040174411000109 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 755LW UT WOS:000289933800001 ER PT J AU Schulte, I Hitziger, T Giugliano, S Timm, J Gold, H Heinemann, FM Khudyakov, Y Strasser, M Konig, C Castermans, E Mok, JY van Esch, WJE Bertoletti, A Schumacher, TN Roggendorf, M AF Schulte, I. Hitziger, T. Giugliano, S. Timm, J. Gold, H. Heinemann, F. M. Khudyakov, Y. Strasser, M. Koenig, C. Castermans, E. Mok, J. Y. van Esch, W. J. E. Bertoletti, A. Schumacher, T. N. Roggendorf, M. TI Characterization of CD8+T-cell response in acute and resolved hepatitis A virus infection SO JOURNAL OF HEPATOLOGY LA English DT Article DE Hepatitis A virus; Cellular immune response; Epitope characterization ID CLASS-I LIGANDS; BETA-INTERFERON; ACTIVATION; INDUCTION; COMPLEXES; OUTBREAK; EXCHANGE; CELLS AB Background & Aims: In contrast to the infection with other hepatotropic viruses, hepatitis A virus (HAV) always causes acute self-limited hepatitis, although the role for virus-specific CD8 T cells in viral containment is unclear. Herein, we analyzed the T cell response in patients with acute hepatitis by utilizing a set of overlapping peptides and predicted HLA-A2 binders from the polyprotein. Methods: A set of 11 predicted peptides from the HAV polyprotein, identified as potential binders, were synthesized. Peripheral blood mononuclear cells (PBMCs) from patients were tested for IFN gamma secretion after stimulation with these peptides and ex vivo with HLA-A2 tetramers. Phenotyping was carried out by staining with the activation marker CD38 and the memory marker CD127. Results: Eight out of 11 predicted HLA-A2 binders showed a high binding affinity and five of them were recognized by CD8+ T cells from patients with hepatitis A. There were significant differences in the magnitude of the responses to these five peptides. One was reproducibly immunodominant and the only one detectable ex vivo by tetramer staining of CD8+ T cells. These cells have an activated phenotype (CD38hi CD127lo) during acute infection. Three additional epitopes were identified in HLA-A2 negative patients, most likely representing epitopes restricted by other HLA-class 1-alleles (HLA-A11, B35, B40). Conclusions: Patients with acute hepatitis A have a strong multispecific T cell response detected by ICS. With the tetramer carrying the dominant HLA-A2 epitope, HAV-specific and activated CD8+ T cells could be detected ex vivo. This first description of the HAV specific CTL-epitopes will allow future studies on strength, breadth, and kinetics of the T-cell response in hepatitis A. (C) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 [Schulte, I.; Hitziger, T.; Giugliano, S.; Timm, J.; Roggendorf, M.] Univ Duisburg Essen, Inst Virol, D-45147 Essen, Germany. [Gold, H.] Referat Gesundheit & Umwelt, D-80335 Munich, Germany. [Heinemann, F. M.] Univ Duisburg Essen, Inst Transfus Med, D-45147 Essen, Germany. [Khudyakov, Y.] Ctr Dis Control, Atlanta, GA 30333 USA. [Strasser, M.] Paracelsus Private Med Univ, A-5020 Salzburg, Austria. [Koenig, C.] Publ Hlth Author, A-5020 Salzburg, Austria. [Castermans, E.; Schumacher, T. N.] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands. [Mok, J. Y.; van Esch, W. J. E.] Sanquin, NL-1066 CX Amsterdam, Netherlands. [Bertoletti, A.] ASTAR, Singapore Inst Clin Sci, Singapore, Singapore. RP Roggendorf, M (reprint author), Univ Duisburg Essen, Dept Virol, D-45122 Essen, Germany. EM michael.roggendorf@uni-due.de OI Bertoletti, Antonio/0000-0002-2942-0485 FU Deutsche Forschungsgemeinschaft [GK 1045] FX This work was supported by the Deutsche Forschungsgemeinschaft (GK 1045). We thank Inga Moller for her technical assistance. NR 21 TC 5 Z9 5 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 J9 J HEPATOL JI J. Hepatol. PD FEB PY 2011 VL 54 IS 2 BP 201 EP 208 DI 10.1016/j.jhep.2010.07.010 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 717TN UT WOS:000287070400005 PM 21056495 ER PT J AU Pahud, BA Glaser, CA Dekker, CL Arvin, AM Schmid, DS AF Pahud, Barbara A. Glaser, Carol A. Dekker, Cornelia L. Arvin, Ann M. Schmid, D. Scott TI Varicella Zoster Disease of the Central Nervous System: Epidemiological, Clinical, and Laboratory Features 10 Years after the Introduction of the Varicella Vaccine SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID IMMUNIZATION SAFETY DATA; VIRUS-VACCINE; HERPES-ZOSTER; ENCEPHALITIS; IDENTIFICATION; INFECTIONS; GENOTYPES; STRAINS; MENINGITIS; COLLECTION AB Background. Since the introduction of live attenuated varicella zoster virus (VZV) vaccine in 1995 there has been a significant reduction in varicella incidence and its associated complications, but the impact on VZV-associated central nervous system (CNS) disease has not been assessed. Methods. In this descriptive study we evaluated patients referred to the California Encephalitis Project from 1998 to 2009 with VZV PCR-positive cerebrospinal fluid (CSF). Epidemiological, clinical, and laboratory data were collected using a standardized case form. Specimens were genotyped using multi-single nucleotide polymorphism (SNP) analysis. Results. Twenty-six specimens were genotyped from patients 12-85 years of age (median, 46 years). Clinical presentations included meningitis (50%), encephalitis (42%), and acute disseminated encephalomyelitis (ADEM) (8%). Only 11 patients (42%) had a concomitant herpes zoster rash. Genotype analysis identified 20 European Group (Clade1, Clade 3) strains; 4 Asian (Clade 2) strains, and 2 Mosaic Group (Clade 4, Clade VI) strains. One specimen was recognized as vaccine strain by identifying vaccine-associated SNPs. Conclusions. VZV continues to be associated with CNS disease, with meningitis being the most frequent clinical presentation. CNS VZV disease often presented without accompanying zoster rash. Sequencing data revealed multiple genotypes, including 1 vaccine strain detected in the CSF of a young patient with meningitis. C1 [Pahud, Barbara A.] Stanford Univ, Sch Med, Stanford LPCH Vaccine Program, Div Pediat Infect Dis, Stanford, CA 94305 USA. [Pahud, Barbara A.] Univ Calif San Francisco, Div Pediat Infect Dis, San Francisco, CA 94143 USA. [Glaser, Carol A.] Calif Dept Publ Hlth, Viral & Rickettsial Dis Lab, Richmond, CA USA. [Schmid, D. Scott] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP Pahud, BA (reprint author), Stanford Univ, Sch Med, Stanford LPCH Vaccine Program, Div Pediat Infect Dis, 300 Pasteur Dr,Room G322, Stanford, CA 94305 USA. EM bpahud@stanford.edu FU Centers for Disease Control and Prevention (CDC) for the Clinical Immunization Safety Assessment Network [200-2002-00732]; CDC Emerging Infections Program [U50/CCU015546-09] FX This study was funded through a subcontract with America's Health Insurance Plans (AHIP) under contract 200-2002-00732 from the Centers for Disease Control and Prevention (CDC) for the Clinical Immunization Safety Assessment Network and under CDC Emerging Infections Program (U50/CCU015546-09). NR 38 TC 52 Z9 53 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2011 VL 203 IS 3 BP 316 EP 323 DI 10.1093/infdis/jiq066 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 711SN UT WOS:000286611800006 PM 21177308 ER PT J AU Gibney, KB Lanciotti, RS Sejvar, JJ Nugent, CT Linnen, JM Delorey, MJ Lehman, JA Boswell, EN Staples, JE Fischer, M AF Gibney, Katherine B. Lanciotti, Robert S. Sejvar, James J. Nugent, C. Thomas Linnen, Jeffrey M. Delorey, Mark J. Lehman, Jennifer A. Boswell, Erin N. Staples, J. Erin Fischer, Marc TI West Nile Virus RNA Not Detected in Urine of 40 People Tested 6 Years After Acute West Nile Virus Disease SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID INFECTION; HAMSTERS; ASSAY AB West Nile virus (WNV) causes an acute infection that is usually cleared by an effective immune response after several days of viremia. However, a recent study detected WNV RNA in the urine of 5 of 25 persons (20%) tested several years after their initial acute WNV disease. We evaluated an established cohort of 40 persons >6 years after initial infection with WNV. Urine collected from all participants tested negative for WNV RNA by reverse-transcription polymerase chain reaction and transcription-mediated amplification. Prospective studies are needed to determine if and for how long WNV persists in urine following WNV disease. C1 [Gibney, Katherine B.; Lanciotti, Robert S.; Sejvar, James J.; Delorey, Mark J.; Lehman, Jennifer A.; Boswell, Erin N.; Staples, J. Erin; Fischer, Marc] Ctr Dis Control & Prevent, Arboviral Dis Branch, Ft Collins, CO 80521 USA. [Gibney, Katherine B.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Off, Atlanta, GA USA. [Nugent, C. Thomas; Linnen, Jeffrey M.] Gen Probe Inc, San Diego, CA USA. RP Fischer, M (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM mfischer@cdc.gov OI Gibney, Katherine/0000-0001-5851-5339 FU Centers for Disease Control and Prevention FX This work was supported by the the Centers for Disease Control and Prevention. NR 15 TC 28 Z9 28 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2011 VL 203 IS 3 BP 344 EP 347 DI 10.1093/infdis/jiq057 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 711SN UT WOS:000286611800011 PM 21208926 ER PT J AU Mladenova, Z Iturriza-Gomara, M Esona, MD Gray, J Korsun, N AF Mladenova, Zornitsa Iturriza-Gomara, Miren Esona, Mathew D. Gray, James Korsun, Neli TI Genetic Characterization of Bulgarian Rotavirus Isolates and Detection of Rotavirus Variants: Challenges for the Rotavirus Vaccine Program? SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE rotavirus; genotype; mutant; rotavirus vaccine ID GROUP-A ROTAVIRUS; POLYMERASE CHAIN-REACTION; P TYPES; STRAINS; DIVERSITY; REASSORTMENT; GASTROENTERITIS; CHILDREN; SEQUENCE; DIARRHEA AB Annually 20-70% of all hospital admissions and 20% of fatal diarrhea cases among children less than 5 years of age occur due to severe rotavirus diarrhea. Universal immunization is the major strategy aimed at controlling rotavirus infection. The main objective of the present study was to elucidate the evolutionary relationships of the most common rotavirus strains co-circulating in Bulgaria. The sequence and phylogenetic analysis revealed strain diversity and circulation of different rotavirus variants belonging to a single genotype. A mutated G4P[8] strain with the insertion of an asparagine residue in position 76; G2, G9, and G1 variants with amino acid substitutions in the antigenic regions A, B, and/or C were all identified in this study in the absence of an immunization program. Rotavirus strain surveillance in both the pre- and post-vaccine eras is of increasing importance in order to assess the effectiveness of the rotavirus vaccines for protection against disease associated with a diverse population of rotavirus strains. J. Med. Virol. 83:348-356, 2011. (C) 2010 Wiley-Liss, Inc. C1 [Mladenova, Zornitsa; Korsun, Neli] Natl Ctr Infect & Parasit Dis, Natl Reference Lab Enteroviruses, Dept Virol, Sofia 1233, Bulgaria. [Iturriza-Gomara, Miren] Hlth Protect Agcy, Ctr Infect, Enter Virus Unit, Virus Reference Dept, London, England. [Esona, Mathew D.] CDC, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, NCIRD, Alberta, GA USA. [Gray, James] Norfolk & Norwich Univ Hosp, Specialist Virol Ctr, Norwich, Norfolk, England. RP Mladenova, Z (reprint author), Natl Ctr Infect & Parasit Dis, Natl Reference Lab Enteroviruses, Dept Virol, 44A Stoletov Blvd, Sofia 1233, Bulgaria. EM zornitsavmbg@yahoo.com RI Iturriza Gomara, Miren/B-4351-2013 OI Iturriza Gomara, Miren/0000-0001-5816-6423 NR 33 TC 5 Z9 5 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0146-6615 J9 J MED VIROL JI J. Med. Virol. PD FEB PY 2011 VL 83 IS 2 BP 348 EP 356 DI 10.1002/jmv.21919 PG 9 WC Virology SC Virology GA 699QS UT WOS:000285678500023 PM 21181933 ER PT J AU Bailey, RL Gahche, JJ Lentino, CV Dwyer, JT Engel, JS Thomas, PR Betz, JM Sempos, CT Picciano, MF AF Bailey, Regan L. Gahche, Jaime J. Lentino, Cindy V. Dwyer, Johanna T. Engel, Jody S. Thomas, Paul R. Betz, Joseph M. Sempos, Christopher T. Picciano, Mary Frances TI Dietary Supplement Use in the United States, 2003-2006 SO JOURNAL OF NUTRITION LA English DT Article ID MULTIVITAMIN-MULTIMINERAL SUPPLEMENTS; INTERNATIONAL INTERFACE STANDARD; NUTRITION EXAMINATION SURVEY; NATIONAL-HEALTH; IRON-DEFICIENCY; FOOD DATABASES; CHILDREN; ADULTS AB Dietary supplement use has steadily increased over time since the 1970s; however, no current data exist for the U.S. population. Therefore, the purpose of this analysis was to estimate dietary supplement use using the NHANES 2003-2006, a nationally representative, cross-sectional survey. Dietary supplement use was analyzed for the U.S. population (>= 1y of age) by the DRI age groupings. Supplement use was measured through a questionnaire and was reported by 49% of the U.S. population (44% of males, 53% of females). Multivitamin-multimineral use was the most frequently reported dietary supplement (33%). The majority of people reported taking only 1 dietary supplement and did so on a daily basis. Dietary supplement use was lowest in obese adults and highest among non-Hispanic whites, older adults, and those with more than a high-school education. Between 28 and 30% reported using dietary supplements containing vitamins B-6, B-12, C, A, and E; 18-19% reported using iron, selenium, and chromium; and 26-27% reported using zinc- and magnesium-containing supplements. Botanical supplement use was more common in older than in younger age groups and was lowest in those aged 1-13 y but was reported by similar to 20% of adults. About one-half of the U.S. population and 70% of adults >= 71 y use dietary supplements; one-third use multivitamin-multimineral dietary supplements. Given the widespread use of supplements, data should be included with nutrient intakes from foods to correctly determine total nutrient exposure. J. Nutr. 141: 261-266,2011. C1 [Bailey, Regan L.; Lentino, Cindy V.; Dwyer, Johanna T.; Engel, Jody S.; Thomas, Paul R.; Betz, Joseph M.; Sempos, Christopher T.; Picciano, Mary Frances] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Gahche, Jaime J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Bailey, RL (reprint author), NIH, Off Dietary Supplements, Bldg 10, Bethesda, MD 20892 USA. EM baileyr@mail.nih.gov OI Dwyer, Johanna/0000-0002-0783-1769 NR 24 TC 257 Z9 262 U1 9 U2 53 PU AMER SOC NUTRITIONAL SCIENCE PI BETHESDA PA 9650 ROCKVILLE PIKE, RM L-2407A, BETHESDA, MD 20814 USA SN 0022-3166 J9 J NUTR JI J. Nutr. PD FEB PY 2011 VL 141 IS 2 BP 261 EP 266 DI 10.3945/jn.110.133025 PG 6 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 712XU UT WOS:000286700400015 PM 21178089 ER PT J AU Li, CY Ford, ES McBride, PE Kwiterovich, PO McCrindle, BW Gidding, SS AF Li, Chaoyang Ford, Earl S. McBride, Patrick E. Kwiterovich, Peter O. McCrindle, Brian W. Gidding, Samuel S. TI Non-High-Density Lipoprotein Cholesterol Concentration is Associated with the Metabolic Syndrome among US Youth Aged 12-19 Years SO JOURNAL OF PEDIATRICS LA English DT Article ID HEART-DISEASE RISK; PATHOBIOLOGICAL DETERMINANTS; CARDIOVASCULAR-DISEASE; CONSENSUS STATEMENT; DIABETES-MELLITUS; YOUNG-ADULTS; A-I; ADOLESCENTS; CHILDREN; ATHEROSCLEROSIS AB Objective To test the hypothesis that the concentration of non-high-density lipoprotein cholesterol (non-HDL-C) is associated with the metabolic syndrome (MetS) in youth. Study design Data on children and adolescents aged 12-19 years (n = 2734) from the cross-sectional National Health and Nutrition Examination Survey 1999-2004 were analyzed. Results Depending on the definition of MetS used, the mean non-HDL-C concentration among youth with MetS ranged from 144.2 to 155.8 mg/dL, compared with 108.8-109.1 mg/dL in those without MetS (all P < .001). The MetS prevalence ranged from 6.9% to 11.7% in youth with a non-HDL-C concentration of 120-144 mg/dL and from 21.5% to 23.4% in those with a concentration >= 145 mg/dL-both significantly higher than the prevalence of 1.9%-3.4% in youth with a concentration < 120 mg/dL (all P < .001). After adjustment for potential confounders, youth with a non-HDL-C concentration >= 120 mg/dL or >= 145 mg/dL were about 3 or 4 times more likely to have MetS compared with those with a non-HDL-C < 120 mg/dL or < 145 mg/dL (all P < .001). Conclusions Fasting non-HDL-C concentration was strongly associated with MetS in US youth. Our results support the use of non-HDL-C thresholds of 120 mg/dL and 145 mg/dL to indicate borderline and high MetS risk, respectively. (J Pediatr 2011; 158:201-7). C1 [Li, Chaoyang; Ford, Earl S.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [McBride, Patrick E.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [McBride, Patrick E.] Univ Wisconsin, Dept Family Med, Sch Med & Publ Hlth, Madison, WI USA. [Kwiterovich, Peter O.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA. [McCrindle, Brian W.] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Gidding, Samuel S.] Alfred I DuPont Hosp Children, Nemours Cardiac Ctr, Wilmington, DE USA. RP Li, CY (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 1600 Clifton Rd NE,MSE-90, Atlanta, GA 30333 USA. EM cli@cdc.gov NR 34 TC 27 Z9 31 U1 0 U2 5 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD FEB PY 2011 VL 158 IS 2 BP 201 EP 207 DI 10.1016/j.jpeds.2010.07.050 PG 7 WC Pediatrics SC Pediatrics GA 706DC UT WOS:000286196300008 PM 20828715 ER PT J AU Naumann, RB Dellinger, AM Kresnow, MJ AF Naumann, Rebecca B. Dellinger, Ann M. Kresnow, Marcie-jo TI Driving self-restriction in high-risk conditions: How do older drivers compare to others? SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE Motor vehicle; Self-restriction; Older adult ID 2ND INJURY CONTROL; AVOIDANCE; BEHAVIOR; ADULTS; TRAVEL AB Introduction: Many older drivers self-restrict or avoid driving under high-risk conditions. Little is known about the onset of driving self-restrictions or how widespread self-restrictions are among drivers of all ages. Methods: The Second Injury Control and Risk Survey (ICARIS-2) was a nationwide cross-sectional, list-assisted random-digit-dial telephone survey from 2001 to 2003. National prevalence estimates and weighted percentages of those reporting driving self-restrictions were calculated. Multivariable logistic regression was used to explore associations between specific self-restrictions and age group, adjusting for other personal characteristics. Results: More than half of all drivers reported at least one driving self-restriction. The most commonly reported restriction was avoidance of driving in bad weather (47.5%), followed by at night (27.9%) and on highways or high-speed roads (19%). A greater percentage of young adult women (18-24 years) reported self-restricting in bad weather compared to women in other age groups, and the percentage of drivers self-restricting at night, in bad weather, and on highways or high-speed roads increased steeply after age 64. We found that women, those in low income groups, and those who had driven low annual mileage were more likely to self-restrict. Conclusions: In addition to assessing self-restrictions among older drivers, a new finding from our study is that self-restrictions are also quite prevalent among younger age groups. Driving self-restrictions may be better understood as a spectrum across ages in which drivers' reasons for restriction change. Impact on industry: Future research on the ability of driving self-restrictions to reduce actual crash risk and prevent injuries is needed. National Safety Council and Elsevier Ltd. All rights reserved. C1 [Naumann, Rebecca B.; Dellinger, Ann M.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Kresnow, Marcie-jo] Ctr Dis Control & Prevent, Off Stat & Programming, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Naumann, RB (reprint author), CDC NCIPC, 4770 Buford Hwy,MS F-62, Atlanta, GA 30341 USA. EM RNaumann@cdc.gov NR 21 TC 19 Z9 19 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PD FEB PY 2011 VL 42 IS 1 BP 67 EP 71 DI 10.1016/j.jsr.2010.12.001 PG 5 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 743MB UT WOS:000289021300010 PM 21392632 ER PT J AU Campbell, CL Steinhubl, SR Hooper, WC Jozic, J Smyth, SS Bernstein, D De Staercke, C Syros, G Negus, BH Stuckey, T Stone, GW Mehran, R Dangas, G AF Campbell, Charles L. Steinhubl, Steven R. Hooper, William C. Jozic, Joseph Smyth, Susan S. Bernstein, Debra De Staercke, Christine Syros, George Negus, Brian H. Stuckey, Thomas Stone, Gregg W. Mehran, Roxana Dangas, George TI Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Article DE Acute coronary syndromes; Bleeding events; Highly sensitive C-reactive protein; Interleukin-1 ID ACUTE MYOCARDIAL-INFARCTION; NF-KAPPA B; BLOOD-TRANSFUSION; ACUTE CATHETERIZATION; ARTERY-DISEASE; TERM MORTALITY; HEMORRHAGE; BIVALIRUDIN; STRATEGIES; INFLUENZA AB Bleeding events have been associated with adverse early and late outcomes in virtually all clinical settings. The mechanism behind this observation remains poorly understood. We sought to determine if the reason might be the provocation of an inflammatory response by bleeding events. In a formal substudy of the ACUITY trial, plasma samples of a range of biomarkers were collected at baseline, discharge, 30 days, and 1 year from 192 patients with acute coronary syndromes (ACS) and were analyzed in a central core laboratory. Temporal changes in biomarker levels were assessed in patients who experienced in-hospital hemorrhagic events, recurrent ischemic events, or neither. Sixteen patients were excluded from the study (7 with incomplete samples, 5 undergoing coronary artery bypass grafting (CABG) during index hospitalization; 1 had both bleeding and ischemic events). Median high sensitivity C-reactive protein (hs-CRP) levels (mg/l) increased significantly more from admission to discharge among the 9 patients who experienced an in-hospital major bleed compared to either the 9 patients who had a recurrent ischemic event (+6.0 vs. +0.70, P = 0.04) or the 151 patients who had no event (+6.0 vs. +0.60, P = 0.003). Compared to patients with no in-hospital events, median interleukin-6 (IL-6) levels (pg/ml) increased from admission to hospital discharge non-significantly in those with a bleeding event (+0.92 vs. +2.46, P = 0.55) and in those who experienced an in-hospital recurrent ischemic event (+0.92 vs. +3.60, P = 0.09). These data suggest that major bleeding is associated with development of a pro-inflammatory state. If confirmed, this mechanism may in part explain the poor prognosis of patients experiencing an acute hemorrhagic event. C1 [Dangas, George] Mt Sinai Hosp, Cardiovasc Inst, New York, NY 10029 USA. [Campbell, Charles L.; Smyth, Susan S.] Univ Kentucky, Gill Heart Inst, Lexington, KY 40536 USA. [Campbell, Charles L.; Smyth, Susan S.] Lexington VA Med Ctr, Lexington, KY USA. [Steinhubl, Steven R.] Geisinger Med Ctr, Danville, PA 17822 USA. [Bernstein, Debra] Medicines Co, Parsippany, NJ USA. [Hooper, William C.; De Staercke, Christine] Ctr Dis Control, Atlanta, GA 30333 USA. [Jozic, Joseph] Univ Hosp Case Med Ctr, Harrington McLaughlin Heart & Vasc Inst, Cleveland, OH USA. [Syros, George; Stone, Gregg W.] Columbia Univ Med Ctr, New York, NY USA. [Syros, George; Stone, Gregg W.] Cardiovasc Res Fdn, New York, NY USA. [Negus, Brian H.] Chattanooga Heart Inst, Chattanooga, TN USA. [Stuckey, Thomas] LeBauer Cardiovasc Res Fdn, Greensboro, NC USA. [Mehran, Roxana] Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA. RP Dangas, G (reprint author), Mt Sinai Hosp, Cardiovasc Inst, Box 1030,1 G Levy Pl, New York, NY 10029 USA. EM clcampbell@uky.edu; George.Dangas@mssn.edu FU The Medicines Company; Nycomed FX The ACUITY trial was sponsored by The Medicines Company and Nycomed. NR 35 TC 8 Z9 9 U1 0 U2 2 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD FEB PY 2011 VL 31 IS 2 BP 139 EP 145 DI 10.1007/s11239-010-0513-1 PG 7 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA 709UR UT WOS:000286467400002 PM 20872045 ER PT J AU Brown, AS Disler, S Burns, L Carlson, A Davis, A Kurian, C Weems, D Wilson, K AF Brown, Amanda Savage Disler, Sheri Burns, Laura Carlson, Angie Davis, Adam Kurian, Cizely Weems, Dolores Wilson, Kristen TI Family and Home Asthma Services across the Controlling Asthma in American Cities Project SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Home visit; Asthma; Trigger reduction; Self-management; Home education; Home remediation; Cross site; Social factors ID INNER-CITY CHILDREN; ENVIRONMENTAL INTERVENTION; RACIAL/ETHNIC DISPARITIES; PSYCHOSOCIAL FACTORS; EDUCATION; ISSUES; INCOME AB Asthma is among the most common chronic childhood diseases, affecting 6.8 million children nationwide. The highest rates of morbidity and mortality associated with the disease occur among those living in the inner city. Because asthma is a complex disease affected by physiological, social, environmental, and behavioral factors, interventions to reduce its morbidity burden need to address multiple determinants of health. In response to this need, the Centers for Disease Control and Prevention developed a multisite cooperative agreement for the Controlling Asthma in American Cities Project (CAAC), with the primary goal of developing innovative, effective community-based interventions. All CAAC sites found a need for family and home asthma services (FHAS) and developed multicomponent (e. g., asthma self-management, social services, coordinated care) and multitrigger environmental interventions. This paper presents a synthesis of key program variables and process indicators for six CAAC FHAS interventions for consideration by communities, coalitions, or programs planning to implement similar activities. C1 [Brown, Amanda Savage; Disler, Sheri] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Atlanta, GA 30333 USA. [Burns, Laura] Chesterfield Cty Hlth Dept, Virginia Dept Hlth, Chesterfield, VA USA. [Carlson, Angie] Data Intelligence LLC, Eden Prairie, MN USA. [Davis, Adam] Childrens Hosp, Oakland, CA USA. [Davis, Adam] Res Ctr, Oakland, CA USA. [Kurian, Cizely] Merck Sharp & Dohme Corp, Philadelphia, PA USA. [Weems, Dolores] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Wilson, Kristen] St Louis Univ, Sch Publ Hlth, St Louis, MO 63103 USA. RP Brown, AS (reprint author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Atlanta, GA 30333 USA. EM abrown2@cdc.gov NR 29 TC 7 Z9 7 U1 2 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD FEB PY 2011 VL 88 SU 1 BP S100 EP S112 DI 10.1007/s11524-010-9472-2 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 724PL UT WOS:000287588600011 PM 21337056 ER PT J AU Davis, A Herman, E AF Davis, Adam Herman, Elizabeth TI Considerations and Challenges for Planning a Public Health Approach to Asthma SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Morbidity; Community; Public health; Population; Population-level; Intervention; Large scale ID EMERGENCY-DEPARTMENT UTILIZATION; QUALITY-OF-LIFE; DISEASE MANAGEMENT; CARE UTILIZATION; PROGRAM; INTERVENTIONS; SURVEILLANCE; MORBIDITY; SERVICES AB Addressing asthma from a public health perspective is a relatively new concept for which the literature provides little guidance. A public health approach seeks to decrease the burden of asthma and improve health outcomes at the population level, such as communities, cities, or states, by reaching large numbers of individuals with effective interventions and at reasonable cost. Projects designed to achieve a measureable impact at the population level are fundamentally different from projects or interventions designed to improve outcomes among individuals. This paper uses the experience of the Controlling Asthma in American Cities Project and a review of the relevant literature to explore some of the unique questions and considerations that are implicit when planning large-scale asthma projects intended to improve population outcomes. The paper is intended to inform decision making by local and state government agencies, managed care organizations, health systems, community coalitions, and funders. Analysis of asthma and other chronic disease projects aiming to achieve population-level impact is an area for continued public health research. C1 [Davis, Adam] Amer Lung Assoc Calif, Oakland, CA USA. [Herman, Elizabeth] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Davis, A (reprint author), Amer Lung Assoc Calif, Oakland, CA USA. EM adavis@alaebay.org FU Centers for Disease Control and Prevention, US Department of Health and Human Services [03030] FX The authors gratefully acknowledge Jeanne Moorman, survey statistician with the Centers for Disease Control and Prevention, for her assistance with the calculations in the section on scaling intervention, and for providing Tables 1 and 2. This project was supported through a cooperative agreement with the Centers for Disease Control and Prevention, US Department of Health and Human Services, under program announcement 03030. NR 42 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD FEB PY 2011 VL 88 SU 1 BP S16 EP S29 DI 10.1007/s11524-010-9515-8 PG 14 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 724PL UT WOS:000287588600003 PM 21286828 ER PT J AU Findley, SE Thomas, G Madera-Reese, R McLeod, N Kintala, S Martinez, RA Ortiz, B Herman, E AF Findley, Sally E. Thomas, Gloria Madera-Reese, Rosa McLeod, Natasha Kintala, Sreelata Martinez, Raquel Andres Ortiz, Benjamin Herman, Elizabeth TI A Community-Based Strategy for Improving Asthma Management and Outcomes for Preschoolers SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Early childhood centers; Asthma; Self-management training; Indoor trigger reduction; Community-based interventions ID LOW-INCOME CHILDREN; HEAD-START; SELF-MANAGEMENT; YOUNG-CHILDREN; RISK-FACTORS; EDUCATION; INTERVENTION; PARENTS; PROGRAM; POPULATION AB Although almost one in ten (8.6%) preschool children has been diagnosed with asthma, few asthma management programs are designed for parents of preschool children. The Asthma Basics for Children program addressed this need in 2003-2008 by implementing a multi-layered approach that offered educational activities to center staff, parents, and children and PACE training to physicians in 31 Northern Manhattan daycare centers. Following program participation, 85% of parents reported reducing their child's triggers, 89% said it was easier to talk to their child's physician, and 80% were confident in their ability to manage their child's asthma. Children's any daytime symptoms dropped from 78% to 42%, any nighttime symptoms from 81% to 49%, any daycare absences from 56% to 38%, any asthma-related emergency department (ED) visits from 74% to 47%, and any asthma-related hospitalizations from 24% to 11% (p<.001 for all differences). Outcomes varied by level of exposure. In the Center-Only group (no parent participation), the only reduction was from 19% to 10% (McNemar=3.77, p=.052) in hospitalizations. Children whose parents participated in the program had significant reductions in daycare absences (62% to 38%, McNemar=11.1, p<.001), ED visits (72% to 43%, McNemar=19.2, p<.001), and hospitalizations (24% to 11%, McNemar=5.54, p=.018). Children whose parents and healthcare provider participated had the greatest improvements with asthma-related daycare absences dropping from 62% to 32% (McNemar=9.8, p=.001), ED visits from 72% to 37% (McNemar=14.4, p<.001), and hospitalizations from 35% to 15% (McNemar=8.33, p=.003). This study demonstrates that a multi-layered approach can improve asthma outcomes among preschoolers with a combination of parent and provider education having the greatest impact. C1 [Findley, Sally E.; Thomas, Gloria; Madera-Reese, Rosa; McLeod, Natasha; Kintala, Sreelata] Columbia Univ, Mailman Sch Publ Hlth, Heilbrunn Dept Populat & Family Hlth, New York, NY 10032 USA. [Martinez, Raquel Andres; Ortiz, Benjamin] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Herman, Elizabeth] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Atlanta, GA USA. RP Findley, SE (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Heilbrunn Dept Populat & Family Hlth, 60 Haven Ave,B 2, New York, NY 10032 USA. EM sef5@columbia.edu NR 28 TC 16 Z9 16 U1 5 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD FEB PY 2011 VL 88 SU 1 BP S85 EP S99 DI 10.1007/s11524-010-9479-8 PG 15 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 724PL UT WOS:000287588600010 PM 21337055 ER PT J AU Herman, EJ Garbe, PL McGeehin, MA AF Herman, Elizabeth J. Garbe, Paul L. McGeehin, Michael A. TI Assessing Community-Based Approaches to Asthma Control: The Controlling Asthma in American Cities Project SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Editorial Material ID EDUCATION; CHILDREN C1 [Herman, Elizabeth J.; Garbe, Paul L.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [McGeehin, Michael A.] Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Herman, EJ (reprint author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM ehh9@cdc.gov NR 13 TC 3 Z9 3 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD FEB PY 2011 VL 88 SU 1 BP S1 EP S6 DI 10.1007/s11524-010-9480-2 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 724PL UT WOS:000287588600001 PM 21337047 ER PT J AU Herman, EJ Keller, A Davis, A Ehrensberger, R Telleen, S Kurz, R Nesvold, JH Findley, S Bryant-Stephens, T Benson, M Fierro, L AF Herman, Elizabeth Jane Keller, Adrienne Davis, Adam Ehrensberger, Ryan Telleen, Sharon Kurz, Richard Nesvold, Jill Heins Findley, Sally Bryant-Stephens, Tyra Benson, Mindy Fierro, Leslie TI A Model-Driven Approach to Qualitatively Assessing the Added Value of Community Coalitions SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Asthma; Coalitions; Community interventions; Socio-ecological model of influence ID HEALTH-PROMOTION; PREVENTION; SYSTEM AB Community-based coalitions are commonly formed to plan and to carry out public health interventions. The literature includes evaluations of coalition structure, composition, and functioning; evaluations of community-level changes achieved through coalition activities; and the association between coalition characteristics and various indicators of success. Little information is available on the comparative advantage or "added value" of conducting public health interventions through coalitions as opposed to less structured collaborative mechanisms. This paper describes a qualitative, iterative process carried out with site representatives of the Controlling Asthma in American Cities Project (CAACP) to identify outcomes directly attributable to coalitions. The process yielded 2 complementary sets of results. The first were criteria that articulated and limited the concept of "added value of coalitions". The criteria included consensus definitions, an organizing figure, a logic model, and inclusion/exclusion criteria. The second set of results identified site-specific activities that met the definitional criteria and were, by agreement, examples of CAACP coalitions' added value. Beyond the specific findings relevant to the added value of coalitions in this project, the use of a social ecological model to identify the components of added value and the placement of those components within a logic model specific to coalitions should provide useful tools for those planning and assessing coalition-based projects. C1 [Herman, Elizabeth Jane] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Keller, Adrienne] Univ Virginia, Charlottesville, VA USA. [Davis, Adam] Amer Lung Assoc, Oakland, CA USA. [Ehrensberger, Ryan] Bon Secours Richmond Hlth Syst, Richmond, VA USA. [Telleen, Sharon] Univ Illinois, Chicago, IL USA. [Kurz, Richard] Univ N Texas, Sch Publ Hlth, Dallas, TX USA. [Nesvold, Jill Heins] Amer Lung Assoc, St Paul, MN USA. [Findley, Sally] Columbia Univ, New York, NY USA. [Bryant-Stephens, Tyra] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Benson, Mindy] Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA. [Fierro, Leslie] Claremont Grad Sch, Claremont, CA 91711 USA. RP Herman, EJ (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM ehh9@cdc.gov FU Centers for Disease Control and Prevention, US Department of Health and Human Services [03030] FX This project was supported through a cooperative agreement with the Centers for Disease Control and Prevention, US Department of Health and Human Services, under program announcement 03030. The findings and conclusions of this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention NR 22 TC 2 Z9 2 U1 2 U2 9 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD FEB PY 2011 VL 88 SU 1 BP S130 EP S143 DI 10.1007/s11524-010-9520-y PG 14 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 724PL UT WOS:000287588600014 PM 21337059 ER PT J AU Herman, EJ AF Herman, Elizabeth Jane TI Conceptual Framework of the Controlling Asthma in American Cities Project SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Community health partnerships; Coalitions; Asthma; Inner-city; Program theory; Ecological model of behavior change ID INNER-CITY CHILDREN; HEALTH PROMOTION; INTERVENTION; PREVENTION; TRIAL AB The Controlling Asthma in American Cities Project (CAACP) was designed to improve the control of asthma in inner-city populations of children with a disparate burden of symptoms and adverse outcomes. As with many chronic diseases, asthma is the manifestation of multiple biologic, environmental, and social determinants. In addition to appropriate medical management, individuals with asthma must have logistical, financial, and cultural access to environments that allow avoidance of asthma triggers and encourage good asthma management practices. In recognition of this complexity, the CAACP required the seven project sites to coordinate and synchronize multiple interventions (education, healthcare access, medical management, trigger reduction) at multiple levels (individual, home, school, community, and policy) through the collaboration of relevant groups, institutions, and individuals. This paper describes the "program theory" of the CAACP project-the assumptions about how the project worked, how the components were linked, and what outcomes were anticipated. It relates the subsequent papers in the supplement to the program theory and describes how the papers can inform and guide other community-based interventions, and advance the translation of scientific knowledge to effective interventions in communities of need. C1 Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Herman, EJ (reprint author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, 4770 Buford Highway MS F58, Atlanta, GA 30341 USA. EM ehh9@cdc.gov FU Centers for Disease Control and Prevention, US Department of Health and Human Services [03030] FX This project was supported through a cooperative agreement with the Centers for Disease Control and Prevention, US Department of Health and Human Services, under program announcement 03030. NR 29 TC 3 Z9 3 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 J9 J URBAN HEALTH JI J. Urban Health PD FEB PY 2011 VL 88 SU 1 BP S7 EP S15 DI 10.1007/s11524-010-9473-1 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 724PL UT WOS:000287588600002 PM 21337048 ER PT J AU Belser, JA Gustin, KM Maines, TR Blau, DM Zaki, SR Katz, JM Tumpey, TM AF Belser, Jessica A. Gustin, Kortney M. Maines, Taronna R. Blau, Dianna M. Zaki, Sherif R. Katz, Jacqueline M. Tumpey, Terrence M. TI Pathogenesis and Transmission of Triple-Reassortant Swine H1N1 Influenza Viruses Isolated before the 2009 H1N1 Pandemic SO JOURNAL OF VIROLOGY LA English DT Article ID A H5N1 VIRUS; UNITED-STATES; INFECTION; FERRETS; HUMANS; MAMMALS; DISEASE AB The 2009 H1N1 pandemic influenza virus represents the greatest incidence of human infection with an influenza virus of swine origin to date. Moreover, triple-reassortant swine (TRS) H1N1 viruses, which share similar host and lineage origins with 2009 H1N1 viruses, have been responsible for sporadic human cases since 2005. Similar to 2009 H1N1 viruses, TRS viruses are capable of causing severe disease in previously healthy individuals and frequently manifest with gastrointestinal symptoms; however, their ability to cause severe disease has not been extensively studied. Here, we evaluated the pathogenicity and transmissibility of two TRS viruses associated with disease in humans in the ferret model. TRS and 2009 H1N1 viruses exhibited comparable viral titers and histopathologies following virus infection and were similarly unable to transmit efficiently via respiratory droplets in the ferret model. Utilizing TRS and 2009 H1N1 viruses, we conducted extensive hematologic and blood serum analyses on infected ferrets to identify lymphohematopoietic parameters associated with mild to severe influenza virus infection. Following H1N1 or H5N1 influenza virus infection, ferrets were found to recapitulate several laboratory abnormalities previously documented with human disease, furthering the utility of the ferret model for the assessment of influenza virus pathogenicity. C1 [Belser, Jessica A.; Gustin, Kortney M.; Maines, Taronna R.; Katz, Jacqueline M.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Blau, Dianna M.; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Tumpey, TM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Mail Stop G-16,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM tft9@cdc.gov RI Wei, Jianjian/F-7788-2011 OI Wei, Jianjian/0000-0001-8859-8462 NR 35 TC 40 Z9 40 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD FEB PY 2011 VL 85 IS 4 BP 1563 EP 1572 DI 10.1128/JVI.02231-10 PG 10 WC Virology SC Virology GA 709EP UT WOS:000286420900014 PM 21123386 ER PT J AU Broussard, DL Sappenfield, WB Fussman, C Kroelinger, CD Grigorescu, V AF Broussard, Danielle L. Sappenfield, William B. Fussman, Chris Kroelinger, Charlan D. Grigorescu, Violanda TI Core State Preconception Health Indicators: A Voluntary, Multi-state Selection Process SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Health indicators; Preconception health; Public health surveillance; Reproductive health; Women's health ID UNITED-STATES; WOMENS HEALTH; CONGENITAL-ANOMALIES; DIABETES-MELLITUS; CHRONIC DISEASE; CARE; PREGNANCY; BIRTH; RISK; POLICY AB This report describes the consensus-based selection process undertaken by a voluntary committee of policy/program leaders and epidemiologists from seven states to identify core state indicators to monitor the health of reproductive age women (aged 18-44 years). Domains of preconception health were established based on priority areas within maternal and child health and women's health. Measures (i.e., potential indicators) addressing the domains were identified from population-based, state level data systems. Each indicator was evaluated on five criteria: public health importance, policy/program importance, data availability, data quality, and the complexity of calculating the indicator. Evaluations served as the basis for iterative voting, which was continued until unanimous consent or a super majority to retain or exclude each indicator was achieved. Eleven domains of preconception health were identified: general health status and life satisfaction; social determinants of health; health care; reproductive health and family planning; tobacco, alcohol and substance use; nutrition and physical activity; mental health; emotional and social support; chronic conditions; infections; and genetics/epigenetics. Ninety-six possible indicators were identified from which 45 core indicators were selected. The scope of preconception care and the public health components to address preconception health are still under development. Despite this challenge and other measurement limitations, preconception health and health care indicators are urgently needed. The proposed core indicators are a set of measures that all states can use to evaluate their preconception health efforts. Furthermore, the indicators serve as a basis for improving the surveillance of the health of reproductive age women. C1 [Broussard, Danielle L.; Sappenfield, William B.] Bur Family & Community Hlth, Maternal & Child Hlth Practice & Anal Unit, Div Family Hlth Serv, Florida Dept Hlth, Tallahassee, FL USA. [Broussard, Danielle L.] Ctr Dis Control & Prevent, Council State & Terr Epidemiologists, Appl Epidemiol Fellowship Program, Atlanta, GA USA. [Fussman, Chris; Grigorescu, Violanda] Michigan Dept Community Hlth, Div Genom Perinatal Hlth & Chron Dis Epidemiol, Lansing, MI USA. [Kroelinger, Charlan D.] Delaware Dept Hlth & Social Serv, Ctr Family Hlth Res & Epidemiol, Div Publ Hlth, Wilmington, DE USA. RP Broussard, DL (reprint author), Bur Family & Community Hlth, Maternal & Child Hlth Practice & Anal Unit, Div Family Hlth Serv, Florida Dept Hlth, Tallahassee, FL USA. EM Danielle_Broussard@doh.state.fl.us; Bill_Sappenfield@doh.state.fl.us; FussmanC@michigan.gov; dwz8@cdc.gov; GrigorescuV@michigan.gov NR 67 TC 18 Z9 18 U1 1 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD FEB PY 2011 VL 15 IS 2 BP 158 EP 168 DI 10.1007/s10995-010-0575-x PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 711PM UT WOS:000286603900003 PM 20225127 ER PT J AU Shieh, WJ Bhatnagar, J Paddock, CD Zaki, SR AF Shieh, W-J Bhatnagar, J. Paddock, C. D. Zaki, S. R. TI Pathologic Studies of Fatal Enterovirus 71 Encephalitis in the United States SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 100th Annual Meeting United States-and-Canadian-Academy-of-Pathology CY FEB 26-MAR 04, 2011 CL San Antonio, TX SP United States Canadian Acad Pathol C1 [Shieh, W-J; Bhatnagar, J.; Paddock, C. D.; Zaki, S. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2011 VL 24 SU 1 MA 1436 BP 338A EP 338A PG 1 WC Pathology SC Pathology GA 720LN UT WOS:000287282301591 ER PT J AU McCarthy, BJ Rankin, KM Aldape, K Bondy, ML Brannstrom, T Broholm, H Feychting, M Il'yasova, D Inskip, PD Johansen, C Mellin, BS Ruder, AM Butler, MA Scheurer, ME Schuz, J Schwartzbaum, JA Wrensch, MR Davis, FG AF McCarthy, Bridget J. Rankin, Kristin M. Aldape, Ken Bondy, Melissa L. Brannstrom, Thomas Broholm, Helle Feychting, Maria Il'yasova, Dora Inskip, Peter D. Johansen, Christoffer Mellin, Beatrice S. Ruder, Avima M. Butler, Mary Ann Scheurer, Michael E. Schuz, Joachim Schwartzbaum, Judith A. Wrensch, Margaret R. Davis, Faith G. TI Risk factors for oligodendroglial tumors: A pooled international study SO NEURO-ONCOLOGY LA English DT Article DE anaplastic oligodendroglioma; epidemiology; mixed glioma; oligodendroglioma; risk factors ID NERVOUS-SYSTEM; BRAIN-TUMORS; REPRODUCTIVE FACTORS; ADULT GLIOMA; ARMS 1P; 19Q; SURVIVAL; ASSOCIATION; HISTORY; SUSCEPTIBILITY AB Oligodendroglial tumors are rare subtypes of brain tumors and are often combined with other glial tumors in epidemiological analyses. However, different demographic associations and clinical characteristics suggest potentially different risk factors. The purpose of this study was to investigate possible risk factors for oligodendroglial tumors (including oligodendroglioma, anaplastic oligodendroglioma, and mixed glioma). Data from 7 case control studies (5 US and 2 Scandinavian) were pooled. Unconditional logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs), adjusted for age group, gender, and study site. Data on 617 cases and 1260 controls were available for analyses. Using data from all 7 studies, history of allergies and/or asthma was associated with a decreased risk of anaplastic oligodendroglioma (OR = 0.6; 95% CI: 0.4-0.9), and history of asthma only was associated with a decreased risk of oligodendroglioma (OR = 0.5; 95% CI: 0.3-0.9) and anaplastic oligodendroglioma (OR = 0.3; 95% CI: 0.1-0.9). A family history of brain tumors was associated with an increased risk of anaplastic oligodendroglioma (OR = 2.2; 95% CI: 1.1-4.5). Having had chicken pox was associated with a decreased risk of oligodendroglioma (OR = 0.6; 95% CI: 0.4-0.9) and anaplastic oligodendroglioma (OR = 0.5; 95% CI: 0.3-0.9) in the US studies. Although there is some overlap in risk factors between oligodendroglial tumors and gliomas as a group, it is likely that additional factors specific to oligodendroglial tumors have yet to be identified. Large, multi-institution international studies will be necessary to better characterize these etiological risk factors. C1 [McCarthy, Bridget J.] Univ Illinois, Sch Publ Hlth, Dept Epidemiol Biostat, Div Epidemiol, Chicago, IL 60612 USA. [Aldape, Ken] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA. [Bondy, Melissa L.] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA. [Brannstrom, Thomas] Umea Univ, Dept Med Biosci, Umea, Sweden. [Mellin, Beatrice S.] Umea Univ, Dept Radiat Sci, Umea, Sweden. [Broholm, Helle] Copenhagen Univ Hosp, Dept Pathol, Ctr Diagnost Invest, Rigshosp, Copenhagen, Denmark. [Feychting, Maria] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden. [Il'yasova, Dora] Duke Univ, Preston Robert Tisch Brain Tumor Ctr Duke, Med Ctr, Durham, NC USA. [Il'yasova, Dora] Duke Univ, Dept Community & Family Med, Med Ctr, Div Prevent Res, Durham, NC USA. [Inskip, Peter D.] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Johansen, Christoffer; Schuz, Joachim] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark. [Ruder, Avima M.; Butler, Mary Ann] Ctr Dis Control & Prevent, Dept Hlth & Human Serv, NIOSH, Cincinnati, OH USA. [Scheurer, Michael E.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Scheurer, Michael E.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Schwartzbaum, Judith A.] Ohio State Univ, Div Epidemiol, Sch Publ Hlth, Columbus, OH 43210 USA. [Wrensch, Margaret R.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA. RP McCarthy, BJ (reprint author), Univ Illinois, Sch Publ Hlth, Dept Epidemiol Biostat, Div Epidemiol, 1603 W Taylor St,M-C 923, Chicago, IL 60612 USA. EM bjm3@uic.edu RI Ruder, Avima/I-4155-2012; OI Ruder, Avima/0000-0003-0419-6664; Scheurer, Michael/0000-0002-8379-6088 FU National Brain Tumor Foundation (NBTF); National Cancer Institute [R01CA070917, R01 CA52689, N01-CO-12400, R01CA122163]; National Institutes of Health [P20CA96890, P50CA108786, P50CA097257]; National Cancer Institute, National Institutes of Health, Department of Health and Human Services; National Institute for Occupational Safety and Health Initiative for Cancer Control; Centers for Disease Control/National Institute for Occupational Safety and Health; College of Medicine, Ohio State University; Swedish Research Council; Swedish Cancer Society; Northern Sweden Cancer Society; European Union [QLK4-CT-1999-01563]; International Union against Cancer (UICC); Mobile Manufacturers' Forum and GSM Association; Acta Oncologica through the Swedish Royal Academy of Science; Danish Cancer Society FX An epidemiology grant from the National Brain Tumor Foundation (NBTF) to B.J.M. has funded this research. Research for the US studies was supported by extramural [National Cancer Institute (R01CA070917 to M.L.B., K.A., M.E.S.; R01 CA52689 to M.R.W.; N01-CO-12400 to P.I.D.); National Institutes of Health Specialized Program of Research Excellence (P20CA96890 and P50CA108786 to F.G.D., K.R.M., D.I., B.J.M.; P50CA097257 to M.R.W.) and intramural funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services to P.D.I., and the National Institute for Occupational Safety and Health Initiative for Cancer Control Projects for Farmers, and Centers for Disease Control/National Institute for Occupational Safety and Health operating funds to A.M.R. and M.A.B. Funding support for J.A.S. was provided by The Neurosciences Signature Program, College of Medicine, Ohio State University and the National Cancer Institute, R01CA122163. Funding support for the Swedish Interphone Study to B.S.M., M.F., J.S., and T.B. included the Swedish Research Council, the Swedish Cancer Society, the Northern Sweden Cancer Society, European Union Fifth Framework Program (contract number QLK4-CT-1999-01563), and the International Union against Cancer (UICC); the UICC received funds for this purpose from the Mobile Manufacturers' Forum and GSM Association. Provision of funds to the INTERPHONE study investigators via the UICC was governed by agreements that guaranteed INTERPHONE's complete scientific independence. The terms of these agreements are publicly available at http://www.iarc.fr/en/research-groups/RAD/RCAd.html; Acta Oncologica sponsored the Research Fellowship of B.S.M. through the Swedish Royal Academy of Science. Funding for the Danish Interphone Study to C.J., H.B., and J.S. included European Union Fifth Framework Program (contract number QLK4-CT-1999-01563), the International Union against Cancer (UICC), under the same conditions as stated above, and the Danish Cancer Society. NR 44 TC 9 Z9 9 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD FEB PY 2011 VL 13 IS 2 BP 242 EP 250 DI 10.1093/neuonc/noq173 PG 9 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA 716VX UT WOS:000287002700010 PM 21149253 ER PT J AU Blumenthal, DT Shacham-Shmueli, E Bokstein, F Schmid, DS Cohrs, RJ Nagel, MA Mahalingam, R Gilden, D AF Blumenthal, D. T. Shacham-Shmueli, E. Bokstein, F. Schmid, D. S. Cohrs, R. J. Nagel, M. A. Mahalingam, R. Gilden, D. TI ZOSTER SINE HERPETE: VIROLOGIC VERIFICATION BY DETECTION OF ANTI-VZV IgG ANTIBODY IN CSF SO NEUROLOGY LA English DT Editorial Material C1 [Cohrs, R. J.; Nagel, M. A.; Mahalingam, R.; Gilden, D.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO 80045 USA. [Gilden, D.] Univ Colorado, Sch Med, Dept Microbiol, Aurora, CO 80045 USA. [Schmid, D. S.] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA. [Blumenthal, D. T.; Shacham-Shmueli, E.; Bokstein, F.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Div Oncol, IL-69978 Tel Aviv, Israel. RP Gilden, D (reprint author), Univ Colorado, Sch Med, Dept Neurol, 12700 E 19th Ave,Mail Stop B182, Aurora, CO 80045 USA. EM don.gilden@ucdenver.edu FU NIA NIH HHS [R01 AG006127, AG006127, AG032958]; NINDS NIH HHS [NS067070] NR 7 TC 17 Z9 18 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD FEB 1 PY 2011 VL 76 IS 5 BP 484 EP 485 DI 10.1212/WNL.0b013e31820a0d28 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA 717BP UT WOS:000287017500014 PM 21282595 ER PT J AU Louie, JK Wadford, DA Norman, A Jamieson, DJ AF Louie, Janice K. Wadford, Debra A. Norman, Agnes Jamieson, Denise J. TI 2009 Pandemic Influenza A (H1N1) and Vaccine Failure in Pregnancy SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID IMMUNIZATION; ANTIBODY; INFANTS; MOTHERS; WOMEN AB BACKGROUND: Emerging data suggest that pregnancy conveys high risk for severe complications from the 2009 pandemic influenza A virus (2009 H1N1) infection. CASE: We describe an infected pregnant woman with critical illness owing to acute respiratory distress syndrome despite previous vaccination. Early serologic testing indicated absent immunity, followed 11 days later by a robust immune response. The patient required mechanical ventilation for 11 days, but ultimately improved, and was discharged home on hospital day 14. CONCLUSION: With the expectation that 2009 H1N1 will continue to cause disease in the immediate future, the virus has been included as a component of the 2010-2011 seasonal influenza vaccine. Vaccination of pregnant women is strongly encouraged. However, regardless of vaccination history, clinicians should remain vigilant for 2009 H1N1 infection when the virus is in circulation, and should not delay antiviral treatment of pregnant women with suspected influenza. (Obstet Gynecol 2011; 117: 470-2) DOI: 10.1097/AOG.0b013e3181fd2e38 C1 [Louie, Janice K.] Calif Dept Publ Hlth, Richmond, CA 94804 USA. Sacramento Cty Dept Hlth & Human Serv, Sacramento, CA USA. Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. RP Louie, JK (reprint author), Calif Dept Publ Hlth, 850 Marina Bay Pkwy, Richmond, CA 94804 USA. EM Janice.louie@cdph.ca.gov NR 8 TC 3 Z9 3 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD FEB PY 2011 VL 117 IS 2 SU S BP 470 EP 472 DI 10.1097/AOG.0b013e3181fd2e38 PN 2 PG 4 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 714KQ UT WOS:000286808900017 PM 21252793 ER PT J AU Breiding, MJ Ziembroski, JS AF Breiding, Matthew J. Ziembroski, Jessica S. TI The relationship between intimate partner violence and children's asthma in 10 US states/territories SO PEDIATRIC ALLERGY AND IMMUNOLOGY LA English DT Article DE asthma; domestic violence; intimate partner violence; Behavioral Risk Factor Surveillance System ID MATERNAL STRESS; HEALTH AB P>Intimate partner violence (IPV) has been shown to negatively impact the health of both the adults who experience IPV and the children who are exposed to IPV. Although IPV experienced by women has been linked to children's asthma, this study is the first to examine this question among both women and men, and the first study in the United States to examine this question as part of a population-based data set. In 2005, ten US states/territories administered an IPV module and a children's asthma module within the Behavioral Risk Factor Surveillance System (BRFSS). Lifetime IPV was assessed by four questions that asked about threatened, attempted, or completed physical violence, as well as unwanted sex, by a current or former intimate partner. The children's asthma module asked respondents to report whether a randomly selected child in their household had ever been diagnosed with asthma and whether the same child currently had asthma. Women who experienced lifetime IPV, in contrast to women who never experienced IPV, were significantly more likely to report that their children had ever had asthma and currently have asthma. Among men, significant differences were not found when comparing men who reported lifetime IPV to those that did not report lifetime IPV. The results highlight the importance of primary prevention of IPV, as reducing the occurrence of IPV could improve not only the long-term health of those who experience IPV but also the health of their children. C1 [Breiding, Matthew J.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Ziembroski, Jessica S.] Gainesville State Coll, Gainesville, GA USA. RP Breiding, MJ (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop F-64, Atlanta, GA 30341 USA. EM dvi8@cdc.gov NR 19 TC 8 Z9 8 U1 1 U2 1 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0905-6157 J9 PEDIAT ALLERG IMM-UK JI Pediatr. Allergy Immunol. PD FEB PY 2011 VL 22 IS 1 BP e95 EP e100 DI 10.1111/j.1399-3038.2010.01087.x PN 2 PG 6 WC Allergy; Immunology; Pediatrics SC Allergy; Immunology; Pediatrics GA 725RC UT WOS:000287662600002 PM 20735803 ER PT J AU Korzeniewski, SJ Young, WI Hawkins, HC Cavanagh, K Nasr, SZ Langbo, C TenEyck, KR Grosse, SD Kleyn, M Grigorescu, V AF Korzeniewski, Steven J. Young, William I. Hawkins, Harry C. Cavanagh, Kevin Nasr, Samya Z. Langbo, Carrie TenEyck, Kelly R. Grosse, Scott D. Kleyn, Mary Grigorescu, Violanda TI Variation in Immunoreactive Trypsinogen Concentrations Among Michigan Newborns and Implications for Cystic Fibrosis Newborn Screening SO PEDIATRIC PULMONOLOGY LA English DT Article DE cystic fibrosis; newborn screening; immunoreactive trypsinogen ID ETHNICALLY DIVERSE POPULATION; EXPERIENCE; WISCONSIN; INFANTS AB Objective: To investigate variation in immunoreactive trypsinogen (IRT) concentrations by race, sex, birth weight, and gestational age and their implications for the use of percentile-based cutoffs for cystic fibrosis (CF) newborn screening (NBS) programs. Patients and Methods: This cross-sectional population-based study of resident infants screened in Michigan investigates associations between demographic and perinatal variables and I RI concentrations after controlling for covariates. This study also analyzed how 96th and 99.8th IRT concentration percentiles values calculated by Michigan NBS vary by demographic and perinatal factors. Characteristics of infants having high (>= 99.8th percentile) IRT concentrations and negative DNA tests are also explored. Results: IRT mean concentrations and percentiles vary significantly by race, birth weight, gestational age, and to a lesser degree by sex. The greatest variation in mean IRT concentrations was observed among racial categories; black infants had an adjusted mean concentration of 36 ng/ml and Asian/Pacific Islander infants had a mean concentration of 25 ng/ml compared to an average concentration of 28 ng/ml in white infants and infants of other races. Conclusions: Variation in IRT concentrations resulted in the over-representation of certain groups referred for secondary testing, particularly referrals for sweat testing based on very high (>= 99.8th percentile) concentrations alone, which is no longer recommended in Michigan. Further research may be warranted to evaluate initial IRT cutoffs used for CF NBS. Pediatr Pulmonol. 2011; 46:125-130. (C) 2011 Wiley-Liss, Inc. C1 [Langbo, Carrie] Perinatal Hlth & Chron Dis Epidemiol Bur Epidemio, Div Genom, Michigan Dept Community Hlth, Lansing, MI 48906 USA. [Nasr, Samya Z.] Univ Michigan, Ann Arbor, MI 48109 USA. [Grosse, Scott D.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Langbo, C (reprint author), Perinatal Hlth & Chron Dis Epidemiol Bur Epidemio, Div Genom, Michigan Dept Community Hlth, 201 Capital View 4-012, Lansing, MI 48906 USA. EM langboc@michigan.gov FU Michigan Cystic Fibrosis Newborn Screening Research Subcommittee FX We would like to acknowledge the Michigan Cystic Fibrosis Newborn Screening Research Subcommittee for their support of this project. The lead author now works for MPRO in Farmington Hills, Michigan. NR 18 TC 7 Z9 7 U1 0 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PD FEB PY 2011 VL 46 IS 2 BP 125 EP 130 DI 10.1002/ppul.21330 PG 6 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 717SS UT WOS:000287068300004 PM 20848586 ER PT J AU Lopez, AS Zhang, J Brown, C Bialek, S AF Lopez, Adriana S. Zhang, John Brown, Cedric Bialek, Stephanie TI Varicella-Related Hospitalizations in the United States, 2000-2006: The 1-Dose Varicella Vaccination Era SO PEDIATRICS LA English DT Article DE varicella-related hospitalizations; varicella vaccination; varicella-related hospitalization rates; United States; 1-dose varicella vaccination era ID CHILDREN; COMPLICATIONS; IMMUNIZATION; EPIDEMIOLOGY; DECLINE; PREVENTION; IMPACT AB OBJECTIVE: To describe the effect of the mature 1-dose varicella vaccination program on varicella morbidity, we analyzed 2 national data-bases for varicella-related hospitalizations in the United States since implementation of the varicella vaccination program in 1995. PATIENTS AND METHODS: Data from the National Hospital Discharge Survey and Nationwide Inpatient Sample were analyzed to describe trends in varicella-related hospitalizations during the 1-dose vaccination era (2000-2006) compared with those in the prevaccination era (1988-1995). Varicella-related hospitalizations were defined by using International Classification of Diseases, Ninth Revision codes. Results were extrapolated to represent national estimates. RESULTS: Using National Hospital Discharge Survey data, 24 488 varicella-related hospitalizations were estimated to occur in the United States during the 1-dose vaccination era. The varicella-related hospitalization rate was 0.12 per 10 000 population during the 1-dose vaccination era versus 0.42 per 10 000 population in the prevaccination era (P < .01). During the 1-dose vaccination era, the estimated annual average number of varicella-related hospitalizations was significantly lower and decreased by >= 65% in all age groups compared with those in the prevaccination era (P < .001 in all age groups). The varicella-related hospitalization rate during the 1-dose vaccination era estimated from the Nationwide Inpatient Sample was 0.09 per 10 000 population. CONCLUSIONS: Varicella-related hospitalization numbers and rates declined significantly during the 1-dose varicella vaccination era. Assuming declines in varicella-related hospitalizations are due, mainly, to the routine childhood varicella vaccination program, these data suggest that varicella vaccination prevented similar to 50 000 varicella-related hospitalizations in the United States from 2000 to 2006. Pediatrics 2011; 127:238-245 C1 [Lopez, Adriana S.; Zhang, John; Brown, Cedric; Bialek, Stephanie] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Lopez, AS (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mail Stop A-47, Atlanta, GA 30333 USA. EM alopez@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 35 Z9 39 U1 0 U2 0 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD FEB PY 2011 VL 127 IS 2 BP 238 EP 245 DI 10.1542/peds.2010-0962 PG 8 WC Pediatrics SC Pediatrics GA 714JF UT WOS:000286805200039 PM 21199857 ER PT J AU Berman, SM Satterwhite, CL AF Berman, Stuart M. Satterwhite, Catherine L. TI A Paradox: Overscreening of Older Women for Chlamydia While Too Few Younger Women Are Being Tested SO SEXUALLY TRANSMITTED DISEASES LA English DT Editorial Material ID SEXUALLY-TRANSMITTED-DISEASE; ALCOHOL-CONSUMPTION; UNITED-STATES C1 [Berman, Stuart M.; Satterwhite, Catherine L.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Berman, SM (reprint author), 1600 Clifton Rd,Mailstop E07, Atlanta, GA 30333 USA. EM smb1@cdc.gov NR 21 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2011 VL 38 IS 2 BP 130 EP 132 DI 10.1097/OLQ.0b013e3182027e00 PG 3 WC Infectious Diseases SC Infectious Diseases GA 705YJ UT WOS:000286176400013 PM 21173722 ER PT J AU Neumann, MS O'Donnell, L Doval, AS Schillinger, J Blank, S Ortiz-Rios, E Garcia, T O'Donnell, CR AF Neumann, Mary Spink O'Donnell, Lydia Doval, Alexi San Schillinger, Julia Blank, Susan Ortiz-Rios, Elizabeth Garcia, Trinidad O'Donnell, Carl R. TI Effectiveness of the VOICES/VOCES Sexually Transmitted Disease/Human Immunodeficiency Virus Prevention Intervention When Administered by Health Department Staff: Does It Work in the "Real World"? SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID STD CLINIC PATIENTS; HIV PREVENTION; CONDOM ACQUISITION; PATIENT EDUCATION; BEHAVIORAL INTERVENTIONS; TECHNICAL ASSISTANCE; IMPLEMENTATION; ADAPTATION; DIFFUSION; ATTITUDES AB Background: Prevention providers wonder whether benefits achieved in the original, researcher-led, efficacy trials of interventions are replicated when the intervention is delivered in real-world settings by their agency's staff. Methods: A replication study was conducted at 2 public sexually transmitted disease (STD) clinics (New York City and San Juan, PR). Using a controlled trial design, intervention (VOICES/VOCES) and comparison conditions (regular clinic services) were assigned in alternating 4-week blocks. Trained agency staff delivered the intervention. Effectiveness was assessed for incident STDs, redemption of coupons for condoms at neighborhood location after the visit, and improved knowledge and attitudes about STDs and condoms. Results: A total of 3365 patients were recruited, completed the protocol, and followed through STD surveillance systems for an average of 17 months. Of 397 with an incident infection, 226 (13.4%) were among those enrolled during comparison blocks; 171 were among those in the intervention condition (10.2%). Controlling for site and gender, participants enrolled during intervention blocks were significantly less likely to have an incident STD reported to the surveillance system (hazard ratio, 0.78; 95% confidence interval, 0.64-0.96). Intervention block participants scored higher on scales of STD knowledge (4.89 vs. 3.87, P < 0.001) and condom knowledge, attitude, and efficacy (10.98 vs. 9.16, P < 0.001). More of those exposed to VOICES/VOCES redeemed condoms (P < 0.05). Positive effects were more consistent in New York, which may be related to fidelity of implementation. Conclusions: A packaged human immunodeficiency virus prevention intervention can be delivered by agencies, with benefits similar to those achieved in the research setting. C1 [Neumann, Mary Spink] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [O'Donnell, Lydia; Doval, Alexi San; O'Donnell, Carl R.] Educ Dev Ctr, Newton, MA USA. [Schillinger, Julia; Blank, Susan; Garcia, Trinidad] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Schillinger, Julia; Blank, Susan] NYC Dept Hlth & Mental Hyg, Bur STD, New York, NY USA. [Ortiz-Rios, Elizabeth] US Hlth Resources & Serv Adm, Div Transplantat, Healthcare Syst Bur, Rockville, MD 20857 USA. RP Neumann, MS (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS E37, Atlanta, GA 30333 USA. EM MNeumann@cdc.gov FU Centers for Disease Control and Prevention [200-2201-00132] FX Supported by Centers for Disease Control and Prevention, contract 200-2201-00132. NR 21 TC 18 Z9 18 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2011 VL 38 IS 2 BP 133 EP 139 DI 10.1097/OLQ.0b013e3181f0c051 PG 7 WC Infectious Diseases SC Infectious Diseases GA 705YJ UT WOS:000286176400014 PM 20729794 ER PT J AU Howard, EJ Xu, FJ Taylor, SN Stoner, BP Mena, L Nsuami, MJ Powell, S Lillis, R Martin, DH AF Howard, Elizabeth J. Xu, Fujie Taylor, Stephanie N. Stoner, Bradley P. Mena, Leandro Nsuami, M. Jacques Powell, Suzanne Lillis, Rebecca Martin, David H. TI Patient Preference for Patient-Delivered Partner Therapy: Exploratory Findings From Three Sexually Transmitted Disease Clinics SO SEXUALLY TRANSMITTED DISEASES LA English DT Letter ID CHLAMYDIA-TRACHOMATIS INFECTION; CONTROLLED-TRIAL; DETERMINANTS; PERSISTENT; RECURRENT; WOMEN C1 [Howard, Elizabeth J.; Taylor, Stephanie N.; Nsuami, M. Jacques; Lillis, Rebecca; Martin, David H.] Louisiana State Univ, Infect Dis Sect, Sch Med, Hlth Sci Ctr, New Orleans, LA 70126 USA. [Xu, Fujie; Powell, Suzanne] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Stoner, Bradley P.] Washington Univ, Dept Anthropol, St Louis, MO 63130 USA. [Stoner, Bradley P.] Washington Univ, Dept Internal Med, St Louis, MO USA. [Mena, Leandro] Univ Mississippi, Med Ctr, Crossroads Clin, Mississippi State Dept Hlth, Jackson, MS 39216 USA. RP Howard, EJ (reprint author), Louisiana State Univ, Infect Dis Sect, Sch Med, Hlth Sci Ctr, New Orleans, LA 70126 USA. NR 10 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2011 VL 38 IS 2 BP 148 EP 149 DI 10.1097/OLQ.0b013e3182036d45 PG 2 WC Infectious Diseases SC Infectious Diseases GA 705YJ UT WOS:000286176400016 PM 21209597 ER PT J AU Kachur, R Adelson, S Firenze, K Herrera, M AF Kachur, Rachel Adelson, Stephan Firenze, Kelly Herrera, Marcella TI Reaching Patients and Their Partners Through Mobile: Text Messaging for Case Management and Partner Notification SO SEXUALLY TRANSMITTED DISEASES LA English DT Letter C1 [Kachur, Rachel] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. [Adelson, Stephan] Adelson Consulting Inc, Boston, MA USA. [Firenze, Kelly] New York State Dept Hlth, Syracuse, NY USA. [Herrera, Marcella] Calif Dept Publ Hlth, Richmond, CA USA. RP Kachur, R (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. NR 11 TC 10 Z9 10 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2011 VL 38 IS 2 BP 149 EP 150 DI 10.1097/OLQ.0b013e3182036bab PG 2 WC Infectious Diseases SC Infectious Diseases GA 705YJ UT WOS:000286176400017 PM 21173721 ER PT J AU Hubbs, AF Mercer, RR Benkovic, SA Harkema, J Sriram, K Schwegler-Berry, D Goravanahally, MP Nurkiewicz, TR Castranova, V Sargent, LM AF Hubbs, Ann F. Mercer, Robert R. Benkovic, Stanley A. Harkema, Jack Sriram, Krishnan Schwegler-Berry, Diane Goravanahally, Madhusudan P. Nurkiewicz, Timothy R. Castranova, Vincent Sargent, Linda M. TI Nanotoxicology-A Pathologist's Perspective SO TOXICOLOGIC PATHOLOGY LA English DT Review DE nanotoxicology; nanopathology; nanotechnology; nano; particulates; pathology; toxicology ID WALLED-CARBON-NANOTUBES; TITANIUM-DIOXIDE PARTICLES; CHRONIC BERYLLIUM DISEASE; BLOOD-BRAIN-BARRIER; CELLS IN-VITRO; SYSTEMIC MICROVASCULAR DYSFUNCTION; POTENTIAL INHALATION EXPOSURE; INSTILLED ULTRAFINE PARTICLES; SCANNING-ELECTRON-MICROSCOPY; PARTICULATE AIR-POLLUTION AB Advances in chemistry and engineering have created a new technology, nanotechnology, involving the tiniest known manufactured products. These products have a rapidly increasing market share and appear poised to revolutionize engineering, cosmetics, and medicine. Unfortunately, nanotoxicology, the study of nanoparticulate health effects, lags behind advances in nanotechnology. Over the past decade, existing literature on ultrafine particles and respirable durable fibers has been supplemented by studies of first-generation nanotechnology products. These studies suggest that nanosizing increases the toxicity of many particulates. First, as size decreases, surface area increases, thereby speeding up dissolution of soluble particulates and exposing more of the reactive surface of durable but reactive particulates. Second, nanosizing facilitates movement of particulates across cellular and intracellular barriers. Third, nanosizing allows particulates to interact with, and sometimes even hybridize with, subcellular structures, including in some cases microtubules and DNA. Finally, nanosizing of some particulates, increases pathologic and physiologic responses, including inflammation, fibrosis, allergic responses, genotoxicity, and carcinogenicity, and may alter cardiovascular and lymphatic function. Knowing how the size and physiochemical properties of nanoparticulates affect bioactivity is important in assuring that the exciting new products of nanotechnology are used safely. This review provides an introduction to the pathology and toxicology of nanoparticulates. C1 [Hubbs, Ann F.; Mercer, Robert R.; Benkovic, Stanley A.; Sriram, Krishnan; Schwegler-Berry, Diane; Goravanahally, Madhusudan P.; Castranova, Vincent; Sargent, Linda M.] Ctr Dis Control & Prevent, Hlth Effects Lab Div, NIOSH, Morgantown, WV 26505 USA. [Harkema, Jack] Michigan State Univ, E Lansing, MI 48824 USA. [Nurkiewicz, Timothy R.] W Virginia Univ, Ctr Cardiovasc & Resp Sci, Sch Med, Morgantown, WV 26506 USA. RP Hubbs, AF (reprint author), Ctr Dis Control & Prevent, Hlth Effects Lab Div, NIOSH, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM ahubbs@cdc.gov FU NIH [RO1ES015022, RC1 ES018274] FX The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. Timothy R. Nurkiewicz's contribution was supported by NIH RO1ES015022 and RC1 ES018274. NR 246 TC 61 Z9 65 U1 8 U2 54 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0192-6233 EI 1533-1601 J9 TOXICOL PATHOL JI Toxicol. Pathol. PD FEB PY 2011 VL 39 IS 2 BP 301 EP 324 DI 10.1177/0192623310390705 PG 24 WC Pathology; Toxicology SC Pathology; Toxicology GA 800QW UT WOS:000293380000001 PM 21422259 ER PT J AU Kimani, D Mwangi, J Mwangi, M Bunnell, R Kellogg, TA Oluoch, T Gichangi, A Kaiser, R Mugo, N Odongo, T Oduor, M Marum, L AF Kimani, D. Mwangi, J. Mwangi, M. Bunnell, R. Kellogg, T. A. Oluoch, T. Gichangi, A. Kaiser, R. Mugo, N. Odongo, T. Oduor, M. Marum, L. CA KAIS Study Grp TI Blood donors in Kenya: a comparison of voluntary and family replacement donors based on a population-based survey SO VOX SANGUINIS LA English DT Article DE blood transfusion; family replacement donor; kenya; population-based survey; voluntary donor ID VIRAL MARKERS; SOUTH-AFRICAN; TRANSFUSION; EXPERIENCE; DONATION; SAFETY AB Background and Objectives Blood safety and sufficiency are major challenges in Kenya and other sub-Saharan African countries forcing many countries to rely on family replacement donors (FRD). We analysed data from a national AIDS indicator survey to describe blood donors in Kenya and potential risks of transfusion transmissible infections (TTI) comparing voluntary donors and FRD. Materials and Methods A population-based, cross-sectional survey was conducted in 2007 among 15- to 64- year-olds. Consenting participants were interviewed about blood donation history and were tested for HIV, HSV-2 and syphilis. Results Of the 17 940 people surveyed, 445 (2 center dot 3%) reported donating blood in the prior 12 months. Sixty-four per cent were voluntary donors, and the rest were FRD. Compared to FRD, the majority of voluntary donors were < 25 years old (59% versus 18%), from the highest wealth quintile (57% versus 42%) and single (64% versus 23%). In addition, voluntary donors were less likely to have been sexually active than replacement donors (43% versus 13%). HIV prevalence was lower among voluntary donors than among FRD (2 center dot 6% versus 7 center dot 4%, P-value = 0 center dot 07). Conclusions The majority of blood donors in Kenya are voluntary with lower potential risk of TTI. C1 [Kimani, D.; Mwangi, J.; Mwangi, M.; Oluoch, T.; Gichangi, A.; Kaiser, R.] Ctr Dis Control & Prevent, Global AIDS Program, Nairobi 00621, Kenya. [Bunnell, R.] CDC, Div STD Prevent, Atlanta, GA 30333 USA. [Kellogg, T. A.] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Mugo, N.] Kenyatta Natl Hosp, Nairobi, Kenya. [Odongo, T.; Oduor, M.] Natl Blood Transfus Serv, Nairobi, Kenya. [Marum, L.] Ctr Dis Control & Prevent, Lusaka, Zambia. RP Kimani, D (reprint author), Ctr Dis Control & Prevent, Global AIDS Program, POB 606,Mbagathi Rd, Nairobi 00621, Kenya. EM dkimani@ke.cdc.gov RI Mermin, Jonathan/J-9847-2012; OI Oluoch, Tom/0000-0001-9621-5900 FU US President's Emergency Plan for AIDS Relief, through CDC/HHS FX We express gratitude and acknowledgement to the contributions of Professor George Rutherford, Dr. Willy McFarland and the KAIS Study Group. Supported by the US President's Emergency Plan for AIDS Relief, through CDC/HHS. NR 19 TC 8 Z9 9 U1 1 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0042-9007 J9 VOX SANG JI Vox Sang. PD FEB PY 2011 VL 100 IS 2 BP 212 EP 218 DI 10.1111/j.1423-0410.2010.01376.x PG 7 WC Hematology SC Hematology GA 705OR UT WOS:000286146300006 PM 20738836 ER PT J AU Slade, BA Gee, J Broder, KR Vellozzi, C AF Slade, Barbara A. Gee, Julianne Broder, Karen R. Vellozzi, Claudia TI Comment on the contribution by Souayah et al., "Guillain-Barre syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006-2009" SO VACCINE LA English DT Letter ID UNITED-STATES; SAFETY; SURVEILLANCE; VAERS C1 [Slade, Barbara A.; Gee, Julianne; Broder, Karen R.; Vellozzi, Claudia] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual & Promot, Immunizat Safety Off,Off Infect, Atlanta, GA 30333 USA. RP Slade, BA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Healthcare Qual & Promot, Immunizat Safety Off,Off Infect, 1600 Clifton Rd NE,Mailstop D-26, Atlanta, GA 30333 USA. EM BSlade@cdc.gov NR 13 TC 8 Z9 8 U1 1 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 29 PY 2011 VL 29 IS 5 BP 865 EP 866 DI 10.1016/j.vaccine.2010.11.031 PG 2 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 720QS UT WOS:000287295800001 PM 21111783 ER PT J AU Wong, CA Saraiya, M Hariri, S Eckert, L Howlett, RI Markowitz, LE Brotherton, JML Sinka, K Martinez-Montanez, OG Kjaer, SK Dunne, EF AF Wong, Charlene A. Saraiya, Mona Hariri, Susan Eckert, Linda Howlett, Roberta I. Markowitz, Lauri E. Brotherton, Julia M. L. Sinka, Katy Martinez-Montanez, Olga G. Kjaer, Susanne K. Dunne, Eileen F. TI Approaches to monitoring biological outcomes for HPV vaccination: Challenges of early adopter countries SO VACCINE LA English DT Review DE HPV vaccine; Post marketing product surveillance; Cervical cancer ID RECURRENT RESPIRATORY PAPILLOMATOSIS; HUMAN-PAPILLOMAVIRUS VACCINATION; CERVICAL-CANCER PREVENTION; PARTICLE VACCINE; FOLLOW-UP; QUADRIVALENT VACCINE; SUSTAINED EFFICACY; UNITED-STATES; YOUNG-WOMEN; INFECTION AB In this review, we describe plans to monitor the impact of human papillomavirus (HPV) vaccine on biologic outcomes in selected international areas (Australia, Canada, Mexico, the Nordic countries, Scotland, and the United States) that have adopted this vaccine. This summary of monitoring plans provides a background for discussing the challenges of vaccine monitoring in settings where resources and capacity may vary. A variety of approaches that depend on existing infrastructure and resources are planned or underway for monitoring HPV vaccine impact. Monitoring HPV vaccine impact on biologic outcomes is a complex and challenging task, but also plays an important role in documenting the benefit of vaccination, monitoring the progress of vaccination programs, and providing data to inform vaccination and disease prevention policies. Published by Elsevier Ltd. C1 [Wong, Charlene A.; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Hariri, Susan; Markowitz, Lauri E.; Dunne, Eileen F.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. [Eckert, Linda] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA. [Howlett, Roberta I.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Brotherton, Julia M. L.] Victorian Cytol Serv, Melbourne, Vic, Australia. [Sinka, Katy] Hlth Protect Scotland, Immunisat & Resp Sect, Glasgow, Lanark, Scotland. [Martinez-Montanez, Olga G.] Natl Ctr Reprod Hlth & Gender Equ, Minist Hlth, Mexico City, DF, Mexico. [Kjaer, Susanne K.] Univ Copenhagen, Rigshosp, Gynecol Clin, DK-2100 Copenhagen, Denmark. RP Saraiya, M (reprint author), 4770 Buford Highway,Mailstop K-55, Atlanta, GA 30341 USA. EM MSaraiya@cdc.gov OI Kjaer, Susanne/0000-0002-8347-1398 FU External Medical Affairs, Pfizer Inc.; CDC FX We would like to thank Dr. Eduardo Franco and Dr. Elizabeth Unger for sharing their presentations from the CDC-sponsored satellite symposium at the 2009 IPV conference. Charlene Wong completed this project during her one-year fellowship The CDC Experience, a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer Inc. NR 82 TC 22 Z9 22 U1 0 U2 13 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 29 PY 2011 VL 29 IS 5 BP 878 EP 885 DI 10.1016/j.vaccine.2010.10.018 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 720QS UT WOS:000287295800004 PM 20971113 ER PT J AU Sobel, HL Mantaring, JB Cuevas, F Ducusin, JV Thorley, M Hennessey, KA Nyunt-U, S AF Sobel, Howard L. Mantaring, Jacinto Blas, III Cuevas, Francisca Ducusin, Joyce V. Thorley, Margaret Hennessey, Karen A. Nyunt-U, Soe TI Implementing a national policy for hepatitis B birth dose vaccination in Philippines: Lessons for improved delivery SO VACCINE LA English DT Article DE Hepatitis B vaccination; Immunization; Birth dose; Perinatal transmission ID DISEASE BURDEN AB Background: An estimated seven million Filipinos (10-12% of the population) are chronically infected with hepatitis B virus (HBV). Achieving high birth dose coverage with hepatitis B vaccine is critical for achieving the World Health Organization's Western Pacific Regional goal of reducing the prevalence of chronic HBV among children 5 years of age to <2% by 2012. Methods: Seven months after the Philippines adopted a hepatitis B vaccine birth dose policy, hospitals with the highest number of deliveries were invited to participate in an assessment of implementation of the birth dose policy. Additionally, in metro Manila birth dose coverage was estimated before and after conducting a training workshop and supervisory follow-up for practitioners conducting home deliveries or deliveries at lying-in clinics. Results: Of the country's largest 150 hospitals in terms of authorized bed capacity, 85(56%) were included in this assessment. These hospitals had 55,719 deliveries during July-September 2007. Of these, 54% infants had a documented birth dose; however, only 22% were vaccinated within 24 h of delivery. Having a copy of the hepatitis B vaccine vaccination policy (prevalence odds ratio [pOR] = 4.7, 95% confidence interval [CI] = 1.2-18.0), having standing orders pOR = 4.8, 95% Cl = 1.3-18.1 and providing training pOR = 18.9, 95% CI = 5.3-67.0 were associated with >50% birth dose coverage in a hospital. In metro-Manila, regardless of place of birth, the training workshop and supervisory follow-up significantly improved hepatitis B vaccine administration within 24h after birth, increasing from 19% before to 74% after the training workshop and follow-up. Conclusions: Experience in the Philippines showed that actions by national, regional and health facility policy makers such as establishing national policies, distributing detailed and specific guidelines, conducting effective training and supervision, and having hospital standing orders substantially increased hepatitis B vaccine birth dose coverage. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Sobel, Howard L.; Nyunt-U, Soe] WHO, Philippines Country Off, Manila, Philippines. [Mantaring, Jacinto Blas, III] Philippine Gen Hosp, Dept Pediat, Manila, Philippines. [Cuevas, Francisca] Metro Manila, Municipal Pateros, Manila, Philippines. [Ducusin, Joyce V.] Natl Expanded Program Immunizat, Dept Hlth, Manila, Philippines. [Thorley, Margaret; Hennessey, Karen A.] US Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. RP Sobel, HL (reprint author), WHO Representat Off Philippines, POB 2932, Manila 1000, Philippines. EM sobelh@wpro.who.int FU World Health Organization FX The evaluations were funded by World Health Organization. NR 13 TC 6 Z9 6 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 29 PY 2011 VL 29 IS 5 BP 941 EP 945 DI 10.1016/j.vaccine.2010.11.047 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 720QS UT WOS:000287295800012 PM 21115051 ER PT J AU Gidudu, J Sack, DA Pina, M Hudson, MJ Kohl, KS Bishop, P Chatterjee, A Chiappini, E Compingbutra, A da Costa, C Fernandopulle, R Fischer, TK Haber, P Masana, W de Menezes, MR Kang, G Khuri-Bulos, N Killion, LA Nair, C Poerschke, G Rath, B Salazar-Lindo, E Setse, R Wenger, P Wong, VCN Zaman, K AF Gidudu, J. Sack, D. A. Pina, M. Hudson, M. J. Kohl, K. S. Bishop, P. Chatterjee, A. Chiappini, E. Compingbutra, A. da Costa, C. Fernandopulle, R. Fischer, T. K. Haber, P. Masana, W. de Menezes, Martins R. Kang, G. Khuri-Bulos, N. Killion, L. A. Nair, C. Poerschke, G. Rath, B. Salazar-Lindo, E. Setse, R. Wenger, P. Wong, V. C. N. Zaman, K. CA Brighton Collaboration Diarrhea Wo TI Diarrhea: Case definition and guidelines for collection, analysis, and presentation of immunization safety data SO VACCINE LA English DT Article DE Diarrhea; Adverse event; Immunization; Guidelines; Case definition ID EVENT FOLLOWING IMMUNIZATION; ANTIBIOTIC-ASSOCIATED DIARRHEA; REASSORTANT ROTAVIRUS VACCINE; ESCHERICHIA-COLI; CONTROLLED-TRIAL; INFECTIOUS DIARRHEA; CHILDREN; GASTROENTERITIS; INFANTS; DISEASE C1 [Gidudu, J.; Kohl, K. S.; Compingbutra, A.; Haber, P.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Sack, D. A.; Setse, R.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Pina, M.] Sanofi Pasteur MSD GmbH, Walldorf, Germany. [Hudson, M. J.] Hlth Protect Agcy, Salisbury, Wilts, England. [Bishop, P.] Univ Mississippi, Med Ctr, Jackson, MS USA. [Chatterjee, A.] Panacea Biotec, New Delhi, India. [Chiappini, E.] Univ Florence, Florence, Italy. [da Costa, C.] GlaxoSmithKline Biol, Rixensart, Belgium. [Fernandopulle, R.] Univ Colombo, Fac Med, Colombo, Sri Lanka. [Fischer, T. K.] Statens Serum Inst, DK-2300 Copenhagen, Denmark. [Masana, W.] Minist Hlth Buenos Aires Providence, Buenos Aires, DF, Argentina. [de Menezes, Martins R.] Biomanguinhos FIOCRUZ Manguinhos Rio de Janeiro, Rio De Janeiro, Brazil. [Kang, G.] Christian Med Coll & Hosp, Vellore 632004, Tamil Nadu, India. [Khuri-Bulos, N.] Jordan Univ Hosp Amman, Amman, Jordan. [Killion, L. A.] Wyeth Pharmaceut, Collegeville, PA USA. [Nair, C.] GlaxoSmithKline Biol, Bangalore, Karnataka, India. [Poerschke, G.] Merck Sharp & Dohme Asia Ltd, Hong Kong, Hong Kong, Peoples R China. [Rath, B.] Univ Childrens Hosp Basel, Basel, Switzerland. [Salazar-Lindo, E.] DS Consult, Lima, Peru. [Wenger, P.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA. [Wong, V. C. N.] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China. [Zaman, K.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. RP Gidudu, J (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM contact@brightoncollaboration.org RI Martins, Reinaldo/I-3413-2015; Chiappini, Elena/D-1118-2012; OI Martins, Reinaldo/0000-0002-0667-532X; Chiappini, Elena/0000-0002-1476-4752; Fischer, Thea Kolsen/0000-0003-4812-980X NR 92 TC 8 Z9 8 U1 0 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JAN 29 PY 2011 VL 29 IS 5 BP 1053 EP 1071 DI 10.1016/j.vaccine.2010.11.065 PG 19 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 720QS UT WOS:000287295800029 PM 21130754 ER PT J AU Croucher, NJ Harris, SR Fraser, C Quail, MA Burton, J van der Linden, M Mcgee, L von Gottberg, A Song, JH Ko, KS Pichon, B Baker, S Parry, CM Lambertsen, LM Shahinas, D Pillai, DR Mitchell, TJ Dougan, G Tomasz, A Klugman, KP Parkhill, J Hanage, WP Bentley, SD AF Croucher, Nicholas J. Harris, Simon R. Fraser, Christophe Quail, Michael A. Burton, John van der Linden, Mark McGee, Lesley von Gottberg, Anne Song, Jae Hoon Ko, Kwan Soo Pichon, Bruno Baker, Stephen Parry, Christopher M. Lambertsen, Lotte M. Shahinas, Dea Pillai, Dylan R. Mitchell, Timothy J. Dougan, Gordon Tomasz, Alexander Klugman, Keith P. Parkhill, Julian Hanage, William P. Bentley, Stephen D. TI Rapid Pneumococcal Evolution in Response to Clinical Interventions SO SCIENCE LA English DT Article ID RESISTANT STREPTOCOCCUS-PNEUMONIAE; ANTIBIOTIC-RESISTANCE; INTERCONTINENTAL SPREAD; UNITED-STATES; SEROTYPE 19A; 23F CLONE; EMERGENCE; DISEASE; TRANSFORMATION; SEQUENCE AB Epidemiological studies of the naturally transformable bacterial pathogen Streptococcus pneumoniae have previously been confounded by high rates of recombination. Sequencing 240 isolates of the PMEN1 (Spain(23F)-1) multidrug-resistant lineage enabled base substitutions to be distinguished from polymorphisms arising through horizontal sequence transfer. More than 700 recombinations were detected, with genes encoding major antigens frequently affected. Among these were 10 capsule-switching events, one of which accompanied a population shift as vaccine-escape serotype 19A isolates emerged in the USA after the introduction of the conjugate polysaccharide vaccine. The evolution of resistance to fluoroquinolones, rifampicin, and macrolides was observed to occur on multiple occasions. This study details how genomic plasticity within lineages of recombinogenic bacteria can permit adaptation to clinical interventions over remarkably short time scales. C1 [Croucher, Nicholas J.; Harris, Simon R.; Quail, Michael A.; Burton, John; Dougan, Gordon; Parkhill, Julian; Bentley, Stephen D.] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England. [Fraser, Christophe; Hanage, William P.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London W2 1PG, England. [van der Linden, Mark] Rhein Westfal TH Aachen, Univ Hosp, Inst Med Microbiol, Natl Reference Ctr Streptococci, D-52074 Aachen, Germany. [McGee, Lesley; Klugman, Keith P.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. [von Gottberg, Anne; Klugman, Keith P.] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Resp & Meningeal Pathogens Res Unit, ZA-2000 Johannesburg, South Africa. [von Gottberg, Anne; Klugman, Keith P.] Univ Witwatersrand, ZA-2000 Johannesburg, South Africa. [Song, Jae Hoon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea. [Song, Jae Hoon] Asia Pacific Fdn Infect Dis, Seoul, South Korea. [Ko, Kwan Soo] Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Suwon 440746, South Korea. [Pichon, Bruno] Hlth Protect Agcy Ctr Infect, Resp & Syst Infect Lab, London NW9 5HT, England. [Baker, Stephen; Parry, Christopher M.] Oxford Univ Clin Res Unit, Wellcome Trust Major Overseas Programme, Hosp Trop Dis, Ho Chi Minh City, Vietnam. [Lambertsen, Lotte M.] Statens Serum Inst, Dept Microbiol Surveillance & Res, DK-2300 Copenhagen S, Denmark. [Shahinas, Dea; Pillai, Dylan R.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1V2, Canada. [Shahinas, Dea; Pillai, Dylan R.] Ontario Agcy Hlth Protect & Promot, Toronto, ON M5G 1V2, Canada. [Mitchell, Timothy J.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, Scotland. [Tomasz, Alexander] Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA. [Klugman, Keith P.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Klugman, Keith P.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA. [Hanage, William P.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. RP Bentley, SD (reprint author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England. EM sdb@sanger.ac.uk RI Fraser, Christophe/A-8109-2008; van der Linden, Mark/B-9305-2009; Tomasz, Alexander/B-9939-2011; Song, Jae Hoon/C-9602-2011; Parkhill, Julian/G-4703-2011; Harris, Simon/K-1318-2013 OI Fraser, Christophe/0000-0003-2399-9657; van der Linden, Mark/0000-0002-6574-4313; Lambertsen, Lotte/0000-0001-6409-6337; Mitchell, Timothy/0000-0002-8309-5556; Tomasz, Alexander/0000-0003-1520-1983; Ko, Kwan Soo/0000-0002-0978-1937; Parkhill, Julian/0000-0002-7069-5958; Harris, Simon/0000-0003-1512-6194 FU Wellcome Trust FX We thank the participating surveillance networks, listed in table S1, and the core informatics, library-making, and sequencing teams at the Wellcome Trust Sanger Institute. Attending authors were grateful for the opportunity to discuss this project at the Permafrost conference. Sequence accession codes are given in tables S1 and S2. This work was funded by the Wellcome Trust. NR 31 TC 410 Z9 419 U1 13 U2 92 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 0036-8075 EI 1095-9203 J9 SCIENCE JI Science PD JAN 28 PY 2011 VL 331 IS 6016 BP 430 EP 434 DI 10.1126/science.1198545 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 712BB UT WOS:000286635900044 PM 21273480 ER PT J AU Wesolowski, LG Delaney, KP Lampe, MA Nesheim, SR AF Wesolowski, Laura G. Delaney, Kevin P. Lampe, Margaret A. Nesheim, Steven R. TI False-Positive Human Immunodeficiency Virus Enzyme Immunoassay Results in Pregnant Women SO PLOS ONE LA English DT Article ID UNITED-STATES; WESTERN BLOTS; HIV; TESTS; RISK; POPULATION; INFECTION; DELIVERY; ADULTS; LABOR AB Objective: Examine whether false-positive HIV enzyme immunoassay (EIA) test results occur more frequently among pregnant women than among women who are not pregnant and men (others). Design: To obtain a large number of pregnant women and others tested for HIV, we identified specimens tested at a national laboratory using Genetic Systems HIV-1/HIV-2 Plus O EIA from July 2007 to June 2008. Methods: Specimens with EIA repeatedly reactive and Western blot-negative or indeterminate results were considered EIA false-positive. We compared the false-positive rate among uninfected pregnant women and others, adjusting for HIV prevalence. Among all reactive EIAs, we evaluated the proportion of false-positives, positive predictive value (PPV), and Western blot bands among indeterminates, by pregnancy status. Results: HIV prevalence was 0.06% among 921,438 pregnant women and 1.34% among 1,103,961 others. The false-positive rate was lower for pregnant women than others (0.14% vs. 0.21%, odds ratio 0.65 [95% confidence interval 0.61, 0.70]). Pregnant women with reactive EIAs were more likely than others (p < 0.01) to have Western blot-negative (52.9% vs. 9.8%) and indeterminate results (17.0% vs. 3.7%) and lower PPV (30% vs. 87%). The p24 band was detected more often among pregnant women (p < 0.01). Conclusions: False-positive HIV EIA results were rare and occurred less frequently among pregnant women than others. Pregnant women with reactive EIAs were more likely to have negative and indeterminate Western blot results due to lower HIV prevalence and higher p24 reactivity, respectively. Indeterminate results may complicate clinical management during pregnancy. Alternative methods are needed to rule out infection in persons with reactive EIAs from low prevalence populations. C1 [Wesolowski, Laura G.; Delaney, Kevin P.; Lampe, Margaret A.; Nesheim, Steven R.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Wesolowski, LG (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM lig7@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX Funding for this project was provided by the Centers for Disease Control and Prevention (CDC). CDC staff designed the analysis, decided to publish the data, and prepared the manuscript. The study was based on existing laboratory data collected at a commercial laboratory. NR 23 TC 7 Z9 7 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 27 PY 2011 VL 6 IS 1 AR e16538 DI 10.1371/journal.pone.0016538 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 712JV UT WOS:000286663900065 PM 21304592 ER PT J AU Dowell, SF Tappero, JW Frieden, TR AF Dowell, Scott F. Tappero, Jordan W. Frieden, Thomas R. TI Public Health in Haiti - Challenges and Progress SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material C1 [Dowell, Scott F.] Ctr Dis Control & Prevent, Div Global Dis Detect & Emergency Response, Atlanta, GA 30333 USA. [Tappero, Jordan W.] Ctr Dis Control & Prevent, Hlth Syst Reconstruct Off, Atlanta, GA USA. RP Dowell, SF (reprint author), Ctr Dis Control & Prevent, Div Global Dis Detect & Emergency Response, Atlanta, GA 30333 USA. NR 5 TC 23 Z9 23 U1 0 U2 7 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 27 PY 2011 VL 364 IS 4 BP 300 EP 301 DI 10.1056/NEJMp1100118 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 711LH UT WOS:000286592600004 PM 21219131 ER PT J AU Sitienei, J Kipruto, H Nganga, L Ackers, M Odhiambo, J Laserson, K Nakashima, AK Modi, S AF Sitienei, J. Kipruto, H. Nganga, L. Ackers, M. Odhiambo, J. Laserson, K. Nakashima, A. K. Modi, S. TI HIV Testing and Treatment Among Tuberculosis Patients-Kenya, 2006-2009 (Reprinted from MMWR, vol 59, pg 1514-1517, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID CARE C1 [Nakashima, A. K.] Global AIDS Program Atlanta, Atlanta, GA USA. [Modi, S.] CDC, EIS, Atlanta, GA 30333 USA. NR 11 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 26 PY 2011 VL 305 IS 4 BP 351 EP 353 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 711MH UT WOS:000286595200010 ER PT J AU Fox, JB Richards, CL AF Fox, J. B. Richards, C. L. TI Vital Signs: Health Insurance Coverage and Health Care Utilization-United States, 2006-2009 and January-March 2010 (Reprinted from MMWR, vol 59, pg 1448-1454, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Fox, J. B.; Richards, C. L.] CDC, Off Prevent Healthcare, Off Associate Director Policy, Atlanta, GA 30333 USA. RP Fox, JB (reprint author), CDC, Off Prevent Healthcare, Off Associate Director Policy, Atlanta, GA 30333 USA. NR 1 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 26 PY 2011 VL 305 IS 4 BP 353 EP 355 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 711MH UT WOS:000286595200011 ER PT J AU Lee, DH Steffes, MW Sjodin, A Jones, RS Needham, LL Jacobs, DR AF Lee, Duk-Hee Steffes, Michael W. Sjoedin, Andreas Jones, Richard S. Needham, Larry L. Jacobs, David R., Jr. TI Low Dose Organochlorine Pesticides and Polychlorinated Biphenyls Predict Obesity, Dyslipidemia, and Insulin Resistance among People Free of Diabetes SO PLOS ONE LA English DT Article ID PERSISTENT ORGANIC POLLUTANTS; ENDOCRINE-DISRUPTING CHEMICALS; SERUM CONCENTRATIONS; NONDIABETIC ADULTS; NATIONAL-HEALTH; ASSOCIATION; MECHANISMS AB Background: There is emerging evidence that background exposure to persistent organic pollutants (POPs) are important in the development of conditions predisposing to diabetes as well as of type 2 diabetes itself. We recently reported that low dose POPs predicted incident type 2 diabetes in a nested case-control study. The current study examined if low dose POPs predicted future adiposity, dyslipidemia, and insulin resistance among controls without diabetes in that study. Methodology/Principal Findings: The 90 controls were diabetes-free during 20 years follow-up. They were a stratified random sample, enriched with overweight and obese persons. POPs measured in 1987-88 (year 2) sera included 8 organochlorine (OC) pesticides, 22 polychlorinated biphenyls (PCBs), and 1 polybrominated biphenyl (PBB). Body mass index (BMI), triglycerides, HDL-cholesterol, LDL-cholesterol, and homeostasis model assessment value for insulin resistance (HOMA-IR) were study outcomes at 2005-06 (year 20). The evolution of study outcomes during 18 years by categories of serum concentrations of POPs at year 2 was evaluated by adjusting for the baseline values of outcomes plus potential confounders. Parallel to prediction of type 2 diabetes, many statistically significant associations of POPs with dysmetabolic conditions appeared at low dose, forming inverted U-shaped dose-response relations. Among OC pesticides, p,p'-DDE most consistently predicted higher BMI, triglycerides, and HOMA-IR and lower HDL-cholesterol at year 20 after adjusting for baseline values. Oxychlordane, trans-nonachlor, and hexachlorobenzene also significantly predicted higher triglycerides. Persistent PCBs with >= 7 chlorides predicted higher BMI, triglycerides, and HOMA-IR and lower HDL-cholesterol at year 20 with similar dose-response curves. Conclusions/Significance: Simultaneous exposure to various POPs in the general population may contribute to development of obesity, dyslipidemia, and insulin resistance, common precursors of type 2 diabetes and cardiovascular diseases. Although obesity is a primary cause of these metabolic abnormalities, POPs exposure may contribute to excess adiposity and other features of dysmetabolism. C1 [Lee, Duk-Hee] Kyungpook Natl Univ, Sch Med, Dept Preventat Med, Taegu, South Korea. [Steffes, Michael W.] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Sjoedin, Andreas; Jones, Richard S.; Needham, Larry L.] Ctr Dis Control & Prevent, Organ Analyt Toxicol Branch OAT, DLS, NCEH, Atlanta, GA USA. [Jacobs, David R., Jr.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA. [Jacobs, David R., Jr.] Univ Oslo, Dept Nutr, Oslo, Norway. RP Lee, DH (reprint author), Kyungpook Natl Univ, Sch Med, Dept Preventat Med, Taegu, South Korea. EM jacob004@umn.edu RI Needham, Larry/E-4930-2011; Sjodin, Andreas/F-2464-2010 FU National Heart, Lung, and Blood Institute (CARDIA field centers), (CARDIA Coordinating Center) [N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050, N01-HC-95095]; YALTA [R01-HL-53560] FX Supported by National Heart, Lung, and Blood Institute contracts N01-HC-48047, N01-HC-48048, N01-HC-48049, N01-HC-48050 (CARDIA field centers), N01-HC-95095 (CARDIA Coordinating Center), and grant R01-HL-53560 (YALTA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 23 TC 144 Z9 155 U1 8 U2 53 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 26 PY 2011 VL 6 IS 1 AR e15977 DI 10.1371/journal.pone.0015977 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 712JL UT WOS:000286662800014 PM 21298090 ER PT J AU Welsh, JA Sharma, A Cunningham, SA Vos, MB AF Welsh, Jean A. Sharma, Andrea Cunningham, Solveig A. Vos, Miriam B. TI Consumption of Added Sugars and Indicators of Cardiovascular Disease Risk Among US Adolescents SO CIRCULATION LA English DT Article DE Sugars; cardiovascular diseases; risk factors; lipids; triglycerides; diabetes mellitus ID DIETARY FRUCTOSE; ENERGY-INTAKE; TASK-FORCE; INSULIN; GLUCOSE; HEALTH; WOMEN; FOODS; DYSLIPIDEMIA; HOMEOSTASIS AB Background-Whereas increased carbohydrate and sugar consumption has been associated with higher cardiovascular disease risk among adults, little is known about the impact of high consumption of added sugars (caloric sweeteners) among US adolescents. Methods and Results-In a cross-sectional study of 2157 US adolescents in the National Health and Nutrition Examination Survey (NHANES) 1999 to 2004, dietary data from one 24-hour recall were merged with added sugar content data from the US Department of Agriculture MyPyramid Equivalents databases. Measures of cardiovascular disease risk were estimated by added sugar consumption level (<10%, 10 to <15%, 15 to <20%, 20 to <25%, 25 to <30%, and >= 30% of total energy). Multivariable means were weighted to be representative of US adolescents and variances adjusted for the complex sampling methods. Daily consumption of added sugars averaged 21.4% of total energy. Added sugars intake was inversely correlated with mean high-density lipoprotein cholesterol levels (mmol/L) which were 1.40 (95% confidence interval [CI] 1.36 to 1.44) among the lowest consumers and 1.28 (95% CI 1.23 to 1.33) among the highest (P trend = 0.001). Added sugars were positively correlated with low-density lipoproteins (P trend = 0.01) and geometric mean triglycerides (P trend = 0.05). Among the lowest and highest consumers, respectively, low-density lipoproteins (mmol/L) were 2.24 (95% CI 2.12 to 2.37) and 2.44 (95% CI 2.34 to 2.53), and triglycerides (mmol/L) were 0.81 (95% CI 0.74, 0.88) and 0.89 (95% CI 0.83 to 0.96). Among those overweight/obese (>= 85th percentile body-mass-index), added sugars were positively correlated with the homeostasis model assessment (P linear trend = 0.004). Conclusion-Consumption of added sugars among US adolescents is positively associated with multiple measures known to increase cardiovascular disease risk. (Circulation. 2011; 123: 249-257.) C1 [Welsh, Jean A.; Sharma, Andrea; Vos, Miriam B.] Emory Univ, Nutr & Hlth Sci Program, Atlanta, GA 30322 USA. [Vos, Miriam B.] Emory Univ, Sch Med, Dept Pediat Gastroenterol Hepatol & Nutr, Atlanta, GA USA. [Cunningham, Solveig A.] Emory Univ, Rollins Schools Publ Hlth, Grad Div Biol & Med Sci, Atlanta, GA 30322 USA. [Cunningham, Solveig A.] Emory Univ, Rollins Schools Publ Hlth, Dept Global Hlth, Atlanta, GA 30322 USA. [Welsh, Jean A.; Vos, Miriam B.] Childrens Healthcare Atlanta, Atlanta, GA USA. [Sharma, Andrea] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. RP Welsh, JA (reprint author), 2015 Uppergate Dr NE, Atlanta, GA 30322 USA. EM jwelsh1@emory.edu RI Cunningham, Solveig/K-6760-2012; OI Cunningham, Solveig/0000-0002-2354-1526; Sharma, Andrea/0000-0003-0385-0011 FU National Institutes of Diabetes and Digestive and Kidney Diseases [K23DK080953]; Children's Digestive Health and Nutrition Foundation FX Dr Vos is supported in part by a career award from the National Institutes of Diabetes and Digestive and Kidney Diseases (K23DK080953) and by the Children's Digestive Health and Nutrition Foundation. NR 51 TC 75 Z9 79 U1 3 U2 20 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0009-7322 J9 CIRCULATION JI Circulation PD JAN 25 PY 2011 VL 123 IS 3 BP 249 EP 257 DI 10.1161/CIRCULATIONAHA.110.972166 PG 9 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 710JM UT WOS:000286507800011 PM 21220734 ER PT J AU Thaipadunpanit, J Chierakul, W Wuthiekanun, V Limmathurotsakul, D Amornchai, P Boonslip, S Smythe, LD Limpaiboon, R Hoffmaster, AR Day, NPJ Peacock, SJ AF Thaipadunpanit, Janjira Chierakul, Wirongrong Wuthiekanun, Vanaporn Limmathurotsakul, Direk Amornchai, Premjit Boonslip, Siriphan Smythe, Lee D. Limpaiboon, Roongrueng Hoffmaster, Alex R. Day, Nicholas P. J. Peacock, Sharon J. TI Diagnostic Accuracy of Real-Time PCR Assays Targeting 16S rRNA and lipl32 Genes for Human Leptospirosis in Thailand: A Case-Control Study SO PLOS ONE LA English DT Article ID POLYMERASE-CHAIN-REACTION; PATHOGENIC LEPTOSPIRES; QUANTITATIVE PCR; TAQMAN ASSAY; CULTURE AB Background: Rapid PCR-based tests for the diagnosis of leptospirosis can provide information that contributes towards early patient management, but these have not been adopted in Thailand. Here, we compare the diagnostic sensitivity and specificity of two real-time PCR assays targeting rrs or lipL32 for the diagnosis of leptospirosis in northeast Thailand. Methods/Principal Findings: A case-control study of 266 patients (133 cases of leptospirosis and 133 controls) was constructed to evaluate the diagnostic sensitivity and specificity (DSe & DSp) of both PCR assays. The median duration of illness prior to admission of cases was 4 days (IQR 2-5 days; range 1-12 days). DSe and DSp were determined using positive culture and/or microscopic agglutination test (MAT) as the gold standard. The DSe was higher for the rrs assay than the lipL32 assay (56%, (95% CI 47-64%) versus 43%, (95% CI 34-52%), p < 0.001). No cases were positive for the lipL32 assay alone. There was borderline evidence to suggest that the DSp of the rrs assay was lower than the lipL32 assay (90% (95% CI 83-94%) versus 93%, (95% CI 88-97%), p = 0.06). Nine controls gave positive reactions for both assays and 5 controls gave a positive reaction for the rrs assay alone. The DSe of the rrs and lipL32 assays were high in the subgroup of 39 patients who were culture positive for Leptospira spp. (95% and 87%, respectively, p = 0.25). Conclusions/Significance: Early detection of Leptospira using PCR is possible for more than half of patients presenting with leptospirosis and could contribute to individual patient care. C1 [Thaipadunpanit, Janjira; Chierakul, Wirongrong; Wuthiekanun, Vanaporn; Limmathurotsakul, Direk; Amornchai, Premjit; Boonslip, Siriphan; Day, Nicholas P. J.; Peacock, Sharon J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand. [Thaipadunpanit, Janjira] Siriraj Hosp, Med Prote Unit, Off Res & Dev, Fac Med, Bangkok, Thailand. [Chierakul, Wirongrong] Mahidol Univ, Fac Trop Med, Dept Clin Trop Med, Bangkok, Thailand. [Limmathurotsakul, Direk] Mahidol Univ, Fac Trop Med, Dept Trop Hyg, Bangkok, Thailand. [Peacock, Sharon J.] Mahidol Univ, Fac Trop Med, Dept Microbiol & Immunol, Bangkok, Thailand. [Smythe, Lee D.] Queensland Hlth Forens & Sci Serv, Communicable Dis Unit, WHO FAO OIE Collaborating Ctr Reference & Res Lep, Brisbane, Qld, Australia. [Limpaiboon, Roongrueng] Udon Thani Reg Hosp, Udon Thani, Thailand. [Hoffmaster, Alex R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Day, Nicholas P. J.] Univ Oxford, Nuffield Dept Clin Med, Ctr Clin Vaccinol & Trop Med, Churchill Hosp, Oxford, England. [Peacock, Sharon J.] Univ Cambridge, Dept Med, Addenbrookes Hosp, Cambridge CB2 2QQ, England. RP Thaipadunpanit, J (reprint author), Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand. EM janjira@tropmedres.ac FU Wellcome Trust FX The Wellcome Trust (http://www.wellcome.ac.uk) funded the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 24 TC 38 Z9 42 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 24 PY 2011 VL 6 IS 1 AR e16236 DI 10.1371/journal.pone.0016236 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 710PJ UT WOS:000286523400027 PM 21283633 ER PT J AU Van Kerkhove, MD Mumford, E Mounts, AW Bresee, J Ly, S Bridges, CB Otte, J AF Van Kerkhove, Maria D. Mumford, Elizabeth Mounts, Anthony W. Bresee, Joseph Ly, Sowath Bridges, Carolyn B. Otte, Joachim TI Highly Pathogenic Avian Influenza (H5N1): Pathways of Exposure at the Animal-Human Interface, a Systematic Review SO PLOS ONE LA English DT Review ID HEALTH-CARE WORKERS; TO-PERSON TRANSMISSION; A H5N1; RISK-FACTORS; POULTRY WORKERS; VIRUS-INFECTION; HONG-KONG; ANTI-H5 ANTIBODY; LOW-FREQUENCY; CHINA AB Background: The threat posed by highly pathogenic avian influenza A H5N1 viruses to humans remains significant, given the continued occurrence of sporadic human cases (499 human cases in 15 countries) with a high case fatality rate (approximately 60%), the endemicity in poultry populations in several countries, and the potential for reassortment with the newly emerging 2009 H1N1 pandemic strain. Therefore, we review risk factors for H5N1 infection in humans. Methods and Findings: Several epidemiologic studies have evaluated the risk factors associated with increased risk of H5N1 infection among humans who were exposed to H5N1 viruses. Our review shows that most H5N1 cases are attributed to exposure to sick poultry. Most cases are sporadic, while occasional limited human-to-human transmission occurs. The most commonly identified factors associated with H5N1 virus infection included exposure through contact with infected blood or bodily fluids of infected poultry via food preparation practices; touching and caring for infected poultry; consuming uncooked poultry products; exposure to H5N1 via swimming or bathing in potentially virus laden ponds; and exposure to H5N1 at live bird markets. Conclusions: Research has demonstrated that despite frequent and widespread contact with poultry, transmission of the H5N1 virus from poultry to humans is rare. Available research has identified several risk factors that may be associated with infection including close direct contact with poultry and transmission via the environment. However, several important data gaps remain that limit our understanding of the epidemiology of H5N1 in humans. Although infection in humans with H5N1 remains rare, human cases continue to be reported and H5N1 is now considered endemic among poultry in parts of Asia and in Egypt, providing opportunities for additional human infections and for the acquisition of virus mutations that may lead to more efficient spread among humans and other mammalian species. Collaboration between human and animal health sectors for surveillance, case investigation, virus sharing, and risk assessment is essential to monitor for potential changes in circulating H5N1 viruses and in the epidemiology of H5N1 in order to provide the best possible chance for effective mitigation of the impact of H5N1 in both poultry and humans. Disclaimer: The opinions expressed in this article are those of the authors and do not necessarily reflect those of the institutions or organizations with which they are affiliated. C1 [Van Kerkhove, Maria D.] Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Modelling, London, England. [Mumford, Elizabeth; Mounts, Anthony W.] WHO, Global Influenza Programme, CH-1211 Geneva, Switzerland. [Bresee, Joseph; Bridges, Carolyn B.] Ctr Dis Control & Prevent, Influenza Div, NCIRD, Atlanta, GA USA. [Ly, Sowath] Inst Pasteur Cambodge, Phnom Penh, Cambodia. [Otte, Joachim] Food & Agr Org United Nations, Anim Prod & Hlth Div, Rome, Italy. RP Van Kerkhove, MD (reprint author), Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Modelling, London, England. EM m.vankerkhove@imperial.ac.uk OI Mumford, Elizabeth/0000-0002-9548-9675 FU United Kingdom Department for International Development (DFID) [GCP/INT/804/UK]; Medical Research Council; Bill and Melinda Gates Foundation FX The work was supported by the United Kingdom Department for International Development (DFID), funders of the HPAI research project (GCP/INT/804/UK); the Medical Research Council (MVK); and the Bill and Melinda Gates Foundation (MVK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 67 TC 66 Z9 67 U1 6 U2 58 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 24 PY 2011 VL 6 IS 1 AR e14582 DI 10.1371/journal.pone.0014582 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 710PJ UT WOS:000286523400004 PM 21283678 ER PT J AU O'Brien, VA Moore, AT Young, GR Komar, N Reisen, WK Brown, CR AF O'Brien, Valerie A. Moore, Amy T. Young, Ginger R. Komar, Nicholas Reisen, William K. Brown, Charles R. TI An enzootic vector-borne virus is amplified at epizootic levels by an invasive avian host SO PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES LA English DT Article DE arbovirus; Buggy Creek virus; cliff swallow; house sparrow; pathogen transmission; virus ecology ID BUGGY-CREEK-VIRUS; WEST-NILE-VIRUS; VICARIUS HEMIPTERA CIMICIDAE; PASSER-DOMESTICUS L; FORT-MORGAN VIRUS; HOUSE SPARROWS; OECIACUS-VICARIUS; ENCEPHALITIS-VIRUS; CLIFF SWALLOWS; TOGAVIRIDAE ALPHAVIRUS AB Determining the effect of an invasive species on enzootic pathogen dynamics is critical for understanding both human epidemics and wildlife epizootics. Theoretical models suggest that when a naive species enters an established host-parasite system, the new host may either reduce ('dilute') or increase ('spillback') pathogen transmission to native hosts. There are few empirical data to evaluate these possibilities, especially for animal pathogens. Buggy Creek virus (BCRV) is an arthropod-borne alphavirus that is enzootically transmitted by the swallow bug (Oeciacus vicarius) to colonially nesting cliff swallows (Petrochelidon pyrrhonota). In western Nebraska, introduced house sparrows (Passer domesticus) invaded cliff swallow colonies approximately 40 years ago and were exposed to BCRV. We evaluated how the addition of house sparrows to this host-parasite system affected the prevalence and amplification of a bird-associated BCRV lineage. The infection prevalence in house sparrows was eight times that of cliff swallows. Nestling house sparrows in mixed-species colonies were significantly less likely to be infected than sparrows in single-species colonies. Infected house sparrows circulated BCRV at higher viraemia titres than cliff swallows. BCRV detected in bug vectors at a site was positively associated with virus prevalence in house sparrows but not with virus prevalence in cliff swallows. The addition of a highly susceptible invasive host species has led to perennial BCRV epizootics at cliff swallow colony sites. The native cliff swallow host confers a dilution advantage to invasive sparrow hosts in mixed colonies, while at the same sites house sparrows may increase the likelihood that swallows become infected. C1 [O'Brien, Valerie A.; Moore, Amy T.; Brown, Charles R.] Univ Tulsa, Dept Biol Sci, Tulsa, OK 74104 USA. [Young, Ginger R.; Komar, Nicholas] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO 80522 USA. [Reisen, William K.] Univ Calif Davis, Sch Vet Med, Ctr Vectorborne Dis, Davis, CA 95616 USA. RP O'Brien, VA (reprint author), Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA. EM valerie.obrien@okstate.edu FU National Institutes of Health [AI057569]; National Science Foundation [DEB-0514824]; American Ornithologists' Union FX We thank Jillian Blackwell, Ananda Ellis, Ying Fang, Sandra Garcia, Allison Johnson, Sarah Knutie, Kristen Lear and Sara Robinson for field or laboratory assistance, and Martin Pfeffer and two anonymous reviewers for comments on the manuscript. The University of Nebraska-Lincoln allowed us to use the facilities of the Cedar Point Biological Station. This work was funded by the National Institutes of Health (AI057569), the National Science Foundation (DEB-0514824) and the American Ornithologists' Union. NR 68 TC 22 Z9 22 U1 1 U2 20 PU ROYAL SOC PI LONDON PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND SN 0962-8452 EI 1471-2954 J9 P ROY SOC B-BIOL SCI JI Proc. R. Soc. B-Biol. Sci. PD JAN 22 PY 2011 VL 278 IS 1703 BP 239 EP 246 DI 10.1098/rspb.2010.1098 PG 8 WC Biology; Ecology; Evolutionary Biology SC Life Sciences & Biomedicine - Other Topics; Environmental Sciences & Ecology; Evolutionary Biology GA 691MS UT WOS:000285085600011 PM 20685711 ER PT J AU Solomon, A Newman, M AF Solomon, Amy Newman, Matthew TI Decadal predictability of tropical Indo-Pacific Ocean temperature trends due to anthropogenic forcing in a coupled climate model SO GEOPHYSICAL RESEARCH LETTERS LA English DT Article ID EL-NINO; VARIABILITY; CCSM3 AB This study quantifies the impact of ENSO on the decadal predictability of tropical Indo-Pacific Ocean trends in a very large ensemble of NCAR CCSM3 anthropogenically-forced (A1B scenario) simulations, by decomposing upper ocean temperatures into "ENSO" and "non-ENSO" variability. On decadal time scales, the ENSO pattern primarily contributes to the ensemble spread and has a trend whose amplitude is not predictable. However, the non-ENSO component of the trend has much smaller spread and is predictable after 10 years, much sooner than the total trend, which is predictable after 25 years. The non-ENSO component of the trend explains 96% of the total trend and has a structure that is distinct from ENSO, including cooling in the South Pacific due to increased southeast trades, warming of the warm pool, and strengthening of the equatorial Pacific near-surface temperature gradient superimposed upon a uniform warming. Citation: Solomon, A., and M. Newman (2011), Decadal predictability of tropical Indo-Pacific Ocean temperature trends due to anthropogenic forcing in a coupled climate model, Geophys. Res. Lett., 38, L02703, doi: 10.1029/2010GL045978. C1 [Solomon, Amy; Newman, Matthew] NOAA, PSD, ESRL, Boulder, CO USA. [Solomon, Amy; Newman, Matthew] Univ Colorado, CDC, CIRES, Boulder, CO 80305 USA. RP Solomon, A (reprint author), NOAA, PSD, ESRL, Boulder, CO USA. RI Newman, Matthew /F-8336-2010; Solomon, Amy/L-8988-2013 OI Newman, Matthew /0000-0001-5348-2312; FU NOAA OAR FX The authors thank the NCAR CCR section for executing the simulations and two anonymous reviewers, M. Alexander, G. Compo, C. Deser, P. Gent, J. Perlwitz, and P. Sardeshmukh for helpful comments. This work was supported by grants from NOAA OAR CVP Program. NR 19 TC 9 Z9 9 U1 1 U2 5 PU AMER GEOPHYSICAL UNION PI WASHINGTON PA 2000 FLORIDA AVE NW, WASHINGTON, DC 20009 USA SN 0094-8276 J9 GEOPHYS RES LETT JI Geophys. Res. Lett. PD JAN 21 PY 2011 VL 38 AR L02703 DI 10.1029/2010GL045978 PG 6 WC Geosciences, Multidisciplinary SC Geology GA 710MY UT WOS:000286517100006 ER PT J AU Martellini, JA Cole, AL Svoboda, P Stuchlik, O Chen, LM Chai, KX Gangrade, BK Sorensen, OE Pohl, J Cole, AM AF Martellini, Julie A. Cole, Amy L. Svoboda, Pavel Stuchlik, Olga Chen, Li-Mei Chai, Karl X. Gangrade, Bhushan K. Sorensen, Ole E. Pohl, Jan Cole, Alexander M. TI HIV-1 Enhancing Effect of Prostatic Acid Phosphatase Peptides Is Reduced in Human Seminal Plasma SO PLOS ONE LA English DT Article ID SEMEN-MEDIATED ENHANCEMENT; ANTIMICROBIAL PEPTIDES; SEMENOGELIN-I; INFECTION; DEFENSINS; ANTIGEN; INHIBITOR; SUBSTRATE; FLUID; SEVI AB We recently reported that HIV-1 infection can be inhibited by innate antimicrobial components of human seminal plasma (SP). Conversely, naturally occurring peptidic fragments from the SP-derived prostatic acid phosphatase ( PAP) have been reported to form amyloid fibrils called "SEVI'' and enhance HIV-1 infection in vitro. In order to understand the biological consequence of this proviral effect, we extended these studies in the presence of human SP. PAP-derived peptides were agitated to form SEVI and incubated in the presence or absence of SP. While PAP-derived peptides and SEVI alone were proviral, the presence of 1% SP ablated their proviral activity in several different anti-HIV-1 assays. The anti-HIV-1 activity of SP was concentration dependent and was reduced following filtration. Supraphysiological concentrations of PAP peptides and SEVI incubated with diluted SP were degraded within hours, with SP exhibiting proteolytic activity at dilutions as high as 1:200. Sub-physiological concentrations of two prominent proteases of SP, prostate-specific antigen (PSA) and matriptase, could degrade physiological and supraphysiological concentrations of PAP peptides and SEVI. While human SP is a complex biological fluid, containing both antiviral and proviral factors, our results suggest that PAP peptides and SEVI may be subject to naturally occurring proteolytic components capable of reducing their proviral activity. C1 [Martellini, Julie A.; Cole, Amy L.; Chen, Li-Mei; Chai, Karl X.; Cole, Alexander M.] Univ Cent Florida, Coll Med, Dept Mol Biol & Microbiol, Biomol Sci Ctr,Burnett Sch Biomed Sci, Orlando, FL 32816 USA. [Svoboda, Pavel; Pohl, Jan] Emory Univ, Microchem & Prote Facil, Atlanta, GA 30322 USA. [Svoboda, Pavel; Stuchlik, Olga; Pohl, Jan] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Div Safety Res, Atlanta, GA USA. [Gangrade, Bhushan K.] Ctr Reprod Med, Orlando, FL USA. [Sorensen, Ole E.] Lund Univ, Dept Clin Sci, Div Infect Med, Lund, Sweden. RP Martellini, JA (reprint author), Univ Cent Florida, Coll Med, Dept Mol Biol & Microbiol, Biomol Sci Ctr,Burnett Sch Biomed Sci, Orlando, FL 32816 USA. EM acole@mail.ucf.edu OI Sorensen, Ole E./0000-0001-8681-6921 FU National Institutes of Health [R01 AI052017, U19 AI065430] FX Research was supported by the National Institutes of Health: Grants R01 AI052017; and, U19 AI065430 (Project 2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 35 TC 12 Z9 12 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 20 PY 2011 VL 6 IS 1 AR e16285 DI 10.1371/journal.pone.0016285 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 710OX UT WOS:000286522200047 PM 21283773 ER PT J AU Dimitrov, NB Goll, S Hupert, N Pourbohloul, B Meyers, LA AF Dimitrov, Nedialko B. Goll, Sebastian Hupert, Nathaniel Pourbohloul, Babak Meyers, Lauren Ancel TI Optimizing Tactics for Use of the US Antiviral Strategic National Stockpile for Pandemic Influenza SO PLOS ONE LA English DT Article ID MULTIARMED BANDIT PROBLEM; A H1N1 VIRUS; UNITED-STATES; OSELTAMIVIR; TRANSMISSIBILITY; INFECTION; OUTBREAKS AB In 2009, public health agencies across the globe worked to mitigate the impact of the swine-origin influenza A (pH1N1) virus. These efforts included intensified surveillance, social distancing, hygiene measures, and the targeted use of antiviral medications to prevent infection (prophylaxis). In addition, aggressive antiviral treatment was recommended for certain patient subgroups to reduce the severity and duration of symptoms. To assist States and other localities meet these needs, the U.S. Government distributed a quarter of the antiviral medications in the Strategic National Stockpile within weeks of the pandemic's start. However, there are no quantitative models guiding the geo-temporal distribution of the remainder of the Stockpile in relation to pandemic spread or severity. We present a tactical optimization model for distributing this stockpile for treatment of infected cases during the early stages of a pandemic like 2009 pH1N1, prior to the wide availability of a strain-specific vaccine. Our optimization method efficiently searches large sets of intervention strategies applied to a stochastic network model of pandemic influenza transmission within and among U.S. cities. The resulting optimized strategies depend on the transmissability of the virus and postulated rates of antiviral uptake and wastage (through misallocation or loss). Our results suggest that an aggressive community-based antiviral treatment strategy involving early, widespread, pro-rata distribution of antivirals to States can contribute to slowing the transmission of mildly transmissible strains, like pH1N1. For more highly transmissible strains, outcomes of antiviral use are more heavily impacted by choice of distribution intervals, quantities per shipment, and timing of shipments in relation to pandemic spread. This study supports previous modeling results suggesting that appropriate antiviral treatment may be an effective mitigation strategy during the early stages of future influenza pandemics, increasing the need for systematic efforts to optimize distribution strategies and provide tactical guidance for public health policy-makers. C1 [Dimitrov, Nedialko B.] Univ Texas Austin, ORIE Program, Austin, TX 78712 USA. [Hupert, Nathaniel] US Ctr Dis Control & Prevent, Preparedness Modeling Unit, Atlanta, GA USA. [Hupert, Nathaniel] Weill Cornell Med Coll, New York, NY USA. [Pourbohloul, Babak] British Columbia Ctr Dis Control, Vancouver, BC, Canada. [Meyers, Lauren Ancel] Santa Fe Inst, Santa Fe, NM 87501 USA. RP Dimitrov, NB (reprint author), Univ Texas Austin, ORIE Program, Austin, TX 78712 USA. EM ned@alumni.cs.utexas.edu FU NIGMS NIH HHS [U01-GM087719-01] NR 48 TC 14 Z9 14 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 19 PY 2011 VL 6 IS 1 AR e16094 DI 10.1371/journal.pone.0016094 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 710OH UT WOS:000286520600021 PM 21283514 ER PT J AU Johnson, AS Heitgerd, J Koenig, LJ Van Handel, M Branson, BM Connelly, E Aff, MP Hall, HI Valleroy, LA AF Johnson, A. Satcher Heitgerd, J. Koenig, L. J. Van Handel, M. Branson, B. M. Connelly, E. Aff, M. P. Hall, H. I. Valleroy, L. A. TI Vital Signs: HIV Testing and Diagnosis Among Adults-United States, 2001-2009 (Reprinted from MMWR, vol 59, pg 1550-1555, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Johnson, A. Satcher; Heitgerd, J.; Koenig, L. J.; Van Handel, M.; Branson, B. M.; Connelly, E.; Aff, M. P.; Hall, H. I.; Valleroy, L. A.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Johnson, AS (reprint author), CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. NR 1 TC 1 Z9 1 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 19 PY 2011 VL 305 IS 3 BP 244 EP 246 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 707YY UT WOS:000286328700010 ER PT J AU Gilchrist, J Haileyesus, T Murphy, M Comstock, RD Collins, C McIlvain, N Yard, E AF Gilchrist, J. Haileyesus, T. Murphy, M. Comstock, R. D. Collins, C. McIlvain, N. Yard, E. TI Heat Illness Among High School Athletes-United States, 2005-2009 (Reprinted from MMWR, vol 59, pg 1009-1013, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Murphy, M.] CDC, Hlth Studies Br, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Comstock, R. D.] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Columbus, OH USA. [Comstock, R. D.] Ohio State Univ, Columbus, OH 43210 USA. [McIlvain, N.] Nationwide Childrens Hosp, Ctr Injury Res & Policy, Columbus, OH USA. [Yard, E.] CDC, EIS, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 19 PY 2011 VL 305 IS 3 BP 246 EP 249 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 707YY UT WOS:000286328700011 ER PT J AU Mbaeyi, C AF Mbaeyi, C. CA Ctr Global Hlth TI Notes From the Field: Transplant-Transmitted Balamuthia mandrillaris-Arizona, 2010 (Reprinted from MMWR, vol 59, pg 1182, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Mbaeyi, C.] CDC, Atlanta, GA 30333 USA. RP Mbaeyi, C (reprint author), CDC, Atlanta, GA 30333 USA. NR 4 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 19 PY 2011 VL 305 IS 3 BP 249 EP 249 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 707YY UT WOS:000286328700012 ER PT J AU Sserwanga, A Harris, JC Kigozi, R Menon, M Bukirwa, H Gasasira, A Kakeeto, S Kizito, F Quinto, E Rubahika, D Nasr, S Filler, S Kamya, MR Dorsey, G AF Sserwanga, Asadu Harris, Jamal C. Kigozi, Ruth Menon, Manoj Bukirwa, Hasifa Gasasira, Anne Kakeeto, Stella Kizito, Fred Quinto, Ebony Rubahika, Denis Nasr, Sussann Filler, Scott Kamya, Moses R. Dorsey, Grant TI Improved Malaria Case Management through the Implementation of a Health Facility-Based Sentinel Site Surveillance System in Uganda SO PLOS ONE LA English DT Article ID COMBINATION THERAPY; COST-EFFECTIVENESS; MICROSCOPY; TRANSMISSION; TANZANIA; AFRICA; ZAMBIA; KENYA; ERA AB Background: Heath facility-based sentinel site surveillance has been proposed as a means of monitoring trends in malaria morbidity but may also provide an opportunity to improve malaria case management. Here we described the impact of a sentinel site malaria surveillance system on promoting laboratory testing and rational antimalarial drug use. Methodology/Principal Findings: Sentinel site malaria surveillance was established at six health facilities in Uganda between September 2006 and January 2007. Data were collected from all patients presenting to the outpatient departments including demographics, laboratory results, diagnoses, and treatments prescribed. Between the start of surveillance and March 2010, a total 424,701 patients were seen of which 229,375 (54%) were suspected of having malaria. Comparing the first three months with the last three months of surveillance, the proportion of patients with suspected malaria who underwent diagnostic testing increased from 39% to 97% (p<0.001). The proportion of patients with an appropriate decision to prescribe antimalarial therapy (positive test result prescribed, negative test result not prescribed) increased from 64% to 95% (p<0.001). The proportion of patients appropriately prescribed antimalarial therapy who were prescribed the recommended first-line regimen artemether-lumefantrine increased from 48% to 69% (p<0.001). Conclusions/Significance: The establishment of a sentinel site malaria surveillance system in Uganda achieved almost universal utilization of diagnostic testing in patients with suspected malaria and appropriate decisions to prescribed antimalarial based on test results. Less success was achieved in promoting prescribing practice for the recommended first-line therapy. This system could provide a model for improving malaria case management in other health facilities in Africa. C1 [Sserwanga, Asadu; Kigozi, Ruth; Bukirwa, Hasifa; Gasasira, Anne; Kakeeto, Stella; Kizito, Fred] Uganda Malaria Surveillance Project, Kampala, Uganda. [Harris, Jamal C.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA. [Menon, Manoj; Nasr, Sussann; Filler, Scott] Ctr Dis Control & Prevent, Atlanta, GA USA. [Quinto, Ebony; Rubahika, Denis] Uganda Minist Hlth, Kampala, Uganda. [Kamya, Moses R.] Makerere Univ, Sch Med, Dept Med, Kampala, Uganda. [Dorsey, Grant] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. RP Sserwanga, A (reprint author), Uganda Malaria Surveillance Project, Kampala, Uganda. EM gdorsey@medsfgh.ucsf.edu FU President's Malaria Initiative; Centers for Disease Control and Prevention [U50/CCU925122]; National Institute of Mental Health [T32MH019105] FX This study received financial support from the President's Malaria Initiative through a cooperative agreement with the Centers for Disease Control and Prevention (U50/CCU925122). JH was supported in part by an Institutional Research Training Grant (T32MH019105) from the National Institute of Mental Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. The funding agencies had no role in the design and conduct of the study; collection, management, and analysis of the data. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. Members of the Centers for Disease Control and Prevention (MM, SN, and SF) were involved in the preparation, review, and approval of the manuscript. NR 19 TC 32 Z9 33 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 19 PY 2011 VL 6 IS 1 AR e16316 DI 10.1371/journal.pone.0016316 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 710OH UT WOS:000286520600040 PM 21283815 ER PT J AU Perucca, P Jacoby, A Marson, AG Baker, GA Lane, S Benn, EKT Thurman, DJ Hauser, WA Gilliam, FG Hesdorffer, DC AF Perucca, P. Jacoby, A. Marson, A. G. Baker, G. A. Lane, S. Benn, E. K. T. Thurman, D. J. Hauser, W. A. Gilliam, F. G. Hesdorffer, D. C. TI Adverse antiepileptic drug effects in new-onset seizures A case-control study SO NEUROLOGY LA English DT Article ID QUALITY-OF-LIFE; NEWLY-DIAGNOSED EPILEPSY; TEMPORAL-LOBE EPILEPSY; SINGLE SEIZURES; DEPRESSION; COMMUNITY; TRIALS; IMMEDIATE; FREQUENCY; OUTCOMES AB Objective: Adverse effects (AEs) are a major concern when starting antiepileptic drug (AED) treatment. This study quantified the extent to which AE reporting in people with new-onset seizures started on AEDs is attributable to the medication per se, and investigated variables contributing to AE reporting. Methods: We pooled data from 2 large prospective studies, the Multicenter Study of Early Epilepsy and Single Seizures and the Northern Manhattan Study of incident unprovoked seizures, and compared adverse event profile (AEP) total and factor scores between adult cases prescribed AEDs for new-onset seizures and untreated controls, adjusting for several demographic and clinical variables. Differences in AEP scores were also tested across different AED monotherapies and controls, and between cases and controls grouped by number of seizures. Results: A total of 212 cases and 206 controls were identified. Most cases (94.2%) were taking low AED doses. AEP scores did not differ significantly between the 2 groups. Depression, female gender, symptomatic etiology, younger seizure onset age, >= 2 seizures, and history of febrile seizures were associated with higher AEP scores. There were no significant differences in AEP scores across different monotherapies and controls. AEP scores increased in both cases and controls with increasing number of seizures, the increment being more pronounced in cases. Conclusions: When AED treatment is started at low doses following new-onset seizures, AE reporting does not differ from untreated individuals. Targeting specific factors affecting AE reporting could lead to improved tolerability of epilepsy treatment. Neurology (R) 2011; 76:273-279 C1 [Perucca, P.] Univ Pavia, Inst Neurol IRCCS C Mondino Fdn, I-27100 Pavia, Italy. [Jacoby, A.] Univ Liverpool, Div Publ Hlth, Liverpool L69 3BX, Merseyside, England. [Marson, A. G.; Baker, G. A.] Univ Liverpool, Unit Neurol Sci, Liverpool L69 3BX, Merseyside, England. [Lane, S.] Univ Liverpool, Ctr Med Stat & Hlth Evaluat, Liverpool L69 3BX, Merseyside, England. [Benn, E. K. T.; Hauser, W. A.; Hesdorffer, D. C.] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA. [Thurman, D. J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Hauser, W. A.; Hesdorffer, D. C.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. [Gilliam, F. G.] Geisinger Med Ctr, Dept Neurol, Danville, PA 17822 USA. RP Perucca, P (reprint author), IRCCS Fdn Ist Neurol C Mondino, Via Mondino 2, I-27100 Pavia, Italy. EM piero.perucca@libero.it OI Perucca, Piero/0000-0002-7855-7066 FU Janssen; Eisai Inc.; Pfizer Inc; National Health Service UK (NHS); MRC; Epilepsy Research Foundation; Epilepsy Action; GlaxoSmithKline; sanofi-aventis; UCB; NHS; NIHR; Epilepsy Action UK; Epilepsy Research UK; Leukaemia Research Fund; NIH (NINDS); CDC; Hotchkiss Neurological Institute; AUCD; Maternal and Child Health Bureau; Centers for Disease Control and Prevention [MM-0322]; UK Research Medical Council [G9125317]; NIH (NICHD) FX Dr. Perucca reports no disclosures. Dr. Jacoby has served on scientific advisory boards for Stitchting Epilepsia Instellingen Nederland (SEIN) and Janssen; has received funding for travel or speaker honoraria from Janssen and Eisai Inc.; serves on the editorial boards of Seizure and Epilepsy & Behaviour; receives publishing royalties from Quality of Life in Epilepsy: Beyond Seizure Counts in Assessment and Treatment (Harwood Academic Publishers, 2000); has served as a consultant for Janssen, GlaxoSmithKline, sanofi-aventis, and Eisai Inc.; and receives research support from Pfizer Inc, National Health Service UK (NHS), MRC, Epilepsy Research Foundation, and Epilepsy Action. Dr. Marson has served on a scientific advisory board for UCB; has received funding for travel or speaker honoraria from GlaxoSmithKline, sanofi-aventis, UCB, Eisai Inc., and Janssen; serves on the editorial boards of Epilepsia and Therapeutics Bulletin, and Coordinating Editor for the Cochrane Epilepsy Group; and receives research support from GlaxoSmithKline, UCB, Eisai Inc., NHS, MRC, Epilepsy Research Foundation, NIHR, and Epilepsy Action. Dr. Baker has served on a scientific advisory board for sanofi-aventis; serves on the editorial board of Epilepsy and Behaviour; has received speaker honoraria from Eisai Inc.; has given expert testimony on fetal anticonvulsant syndrome; and has received research support from sanofi-aventis, Pfizer Inc, UCB, Epilepsy Research UK, Medical Research Council, Epilepsy Action UK. Dr. Lane has received research support from the Leukaemia Research Fund and the NIHR. Ms. Benn has received research support from the NIH (NINDS and NICHD). Dr. Thurman reports no disclosures. Dr. Hauser has served on a scientific advisory board for Lundbeck, Inc. Ovation Pharmaceuticals, Inc.; has served as a consultant for Pfizer Inc and Intranasal; serves on the editorial boards of Acta Neurologica Scandinavia, Neuroepidemiology, and Epilepsy Research; and has received research support from the CDC and the NIH/NINDS, and the Hotchkiss Neurological Institute. Dr. Gilliam has served on a scientific advisory board for Cyberonics, Inc.; has received speaker honoraria from Ortho-McNeil-Janssen Pharmaceuticals, Inc.; and serves on the editorial board of Epileptic Disorders. Dr. Hesdorffer has served on a scientific advisory board for Pfizer Inc; has received funding for travel from UCB; serves as an Editor of Epilepsia, Editor of Epilepsy Research, and as a Contributing Editor of Epilepsy Currents; and has received research support from the CDC, the AUCD, the NIH (NINDS, NICHD, and the Maternal and Child Health Bureau).; Supported by the Centers for Disease Control and Prevention (MM-0322) and the UK Research Medical Council (G9125317). NR 38 TC 25 Z9 26 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0028-3878 J9 NEUROLOGY JI Neurology PD JAN 18 PY 2011 VL 76 IS 3 BP 273 EP 279 DI 10.1212/WNL.0b013e318207b073 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA 708OG UT WOS:000286371900016 PM 21242496 ER PT J AU Gee, JE Glass, MB Lackner, G Helsel, LO Daneshvar, M Hollis, DG Jordan, J Morey, R Steigerwalt, A Hertweck, C AF Gee, Jay E. Glass, Mindy B. Lackner, Gerald Helsel, Leta O. Daneshvar, Maryam Hollis, Dannie G. Jordan, Jean Morey, Roger Steigerwalt, Arnold Hertweck, Christian TI Characterization of Burkholderia rhizoxinica and B. endofungorum Isolated from Clinical Specimens SO PLOS ONE LA English DT Article ID FUNGUS RHIZOPUS-MICROSPORUS; BACTERIAL ENDOSYMBIONTS; BAYESIAN-INFERENCE; SP-NOV.; EVOLUTIONARY; RHIZONIN; TOXIN; PSEUDOMALLEI AB Eight isolates submitted to CDC from 1989 to 2006 from clinical specimens were initially identified as members of the genus Burkholderia based on preliminary cellular fatty acid analysis and/or 16S rRNA gene sequencing. With the recent descriptions of the new species B. rhizoxinica and B. endofungorum, which are considered endosymbiotic bacteria in Rhizopus microsporus fungi, we now identify seven of these clinical isolates as B. rhizoxinica and one as B. endofungorum based on biochemical testing, 16s rRNA, and DNA-DNA hybridization results. We also further characterize these isolates by assessing toxin production and/or by multiple locus sequence typing. C1 [Gee, Jay E.; Glass, Mindy B.; Helsel, Leta O.; Daneshvar, Maryam; Hollis, Dannie G.; Jordan, Jean; Morey, Roger; Steigerwalt, Arnold] Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Lackner, Gerald; Hertweck, Christian] Leibniz Inst Nat Prod Res & Infect Biol, Jena, Germany. [Hertweck, Christian] Univ Jena, Jena, Germany. RP Gee, JE (reprint author), Ctr Dis Control & Prevent, Bacterial Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM JGee1@cdc.gov RI Hertweck, Christian/G-1896-2014 OI Hertweck, Christian/0000-0002-0367-337X NR 27 TC 4 Z9 4 U1 0 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 18 PY 2011 VL 6 IS 1 AR e15731 DI 10.1371/journal.pone.0015731 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 710NW UT WOS:000286519500026 PM 21267449 ER PT J AU Shrestha, SS Wallace, GS Meltzer, MI AF Shrestha, Sundar S. Wallace, Gregory S. Meltzer, Martin I. TI Response to letter to editor responding to article by Shrestha SS, Wallace GS, Meltzer MI. Modeling the national pediatric vaccine stockpile: Supply shortages, health impacts and cost consequences [Vaccine 2010; 28:6318-6332] SO VACCINE LA English DT Letter C1 [Shrestha, Sundar S.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30329 USA. [Wallace, Gregory S.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Meltzer, Martin I.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. RP Shrestha, SS (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 1600 Clifton Rd NE,Mailstop K-10, Atlanta, GA 30329 USA. EM SShrestha@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 17 PY 2011 VL 29 IS 4 BP 616 EP 616 DI 10.1016/j.vaccine.2010.10.048 PG 1 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 715AT UT WOS:000286853500003 ER PT J AU Baldwin, SL Fox, CB Pallansch, MA Coler, RN Reed, SG Friede, M AF Baldwin, Susan L. Fox, Christopher B. Pallansch, Mark A. Coler, Rhea N. Reed, Steven G. Friede, Martin TI Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions SO VACCINE LA English DT Article DE IPV; Adjuvant; Oil-in-water ID HEPATITIS-B VACCINE; IMMUNOGENIC ACTIVITY; MACACA MULATTA; INFLUENZA; ERADICATION; SAFETY; POLIOMYELITIS; ADJUVANT; IMMUNIZATION; RESPONSES AB The use of inactivated poliovirus vaccines (IPV) will be required to achieve, world-wide eradication of polio. The current expense of IPV is however prohibitive for, some countries, and therefore efforts to decrease the costs of the vaccine are a high, priority. Our results show that the addition of oil-in-water emulsion adjuvants to an, inactivated trivalent poliovirus vaccine are dose-sparing and are capable of enhancing, neutralizing antibody titers in the rat potency model. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Baldwin, Susan L.; Fox, Christopher B.; Coler, Rhea N.; Reed, Steven G.] Infect Dis Res Inst, Seattle, WA 98104 USA. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Polio & Picornavirus Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Reed, Steven G.] Immune Design Corp, Seattle, WA 98104 USA. [Friede, Martin] World Hlth Org, Initiat Vaccine Res, CH-12211 Geneva 27, Switzerland. RP Baldwin, SL (reprint author), Infect Dis Res Inst, 1124 Columbia St,Suite 400, Seattle, WA 98104 USA. EM sbaldwin@idri.org OI Fox, Christopher/0000-0002-4644-2619 FU World Health Organization FX We are grateful to Tara Evers, Farah Mompoint, Alison Bernard, Narek Shaverdian, John Laurence, Remy Bailer, Winston Wicomb, Susan Lin, Sandra Sivananthan, Barbara Anderson, and Debbie Moore for their excellent technical assistance. This work was supported by funding through the World Health Organization. NR 42 TC 20 Z9 22 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 17 PY 2011 VL 29 IS 4 BP 644 EP 649 DI 10.1016/j.vaccine.2010.11.043 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 715AT UT WOS:000286853500008 PM 21134451 ER PT J AU Tian, LH Satterwhite, CL Braxton, JR Groseclose, SL AF Tian, Lin H. Satterwhite, Catherine Lindsey Braxton, Jim R. Groseclose, Samuel L. TI Application of the Time-Series Approach to Assess the Temporal Trend of Racial Disparity in Chlamydia Prevalence in the US National Job Training Program SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE chlamydia; health status disparities; prevalence; time ID AFRICAN-AMERICAN COMMUNITIES; SEXUALLY-TRANSMITTED-DISEASES; YOUNG FEMALE ENROLLEES; UNITED-STATES; STD DISPARITIES; HEALTH PLANS; WOMEN; EPIDEMIOLOGY; TRACHOMATIS; INFECTION AB The authors applied a time-series approach to assess the temporal trend of racial disparity in chlamydia prevalence between young, socioeconomically disadvantaged blacks and whites entering the US National Job Training Program. Racial disparity was defined as the arithmetic difference between age group-, specimen type-, and region of residence-standardized chlamydia prevalences in blacks and whites. A regression with autoregressive moving average errors model was employed to adjust for serial correlation. Data from 46,849 women (2006-2008) and 136,892 men (2004-2008) were analyzed. Racial disparity significantly decreased among women (by an average of 0.122% per 2-month interval; P < 0.05) but not among men (-0.010%, P = 0.57). Chlamydia prevalence significantly declined for black women (-0.139% per 2-month interval; P = 0.004), black men (-0.045%, P < 0.001), and white men (-0.035%, P = 0.002) but not for white women (-0.028%, P = 0.413). Despite the decreases among black women and black men, the black-white disparities remained high for both sexes; in 2008, the racial disparity was 8.1% (95% confidence interval: 6.8, 9.3) for women and 9.0% (95% confidence interval: 8.4, 9.6) for men. These findings suggest that current chlamydia control efforts may be reaching young black men and women but need to be scaled up or modified to address the excess risk among blacks. C1 [Tian, Lin H.; Satterwhite, Catherine Lindsey; Braxton, Jim R.; Groseclose, Samuel L.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA. RP Tian, LH (reprint author), Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, 1600 Clifton Rd NE,Mailstop E-63, Atlanta, GA 30333 USA. EM ltian@cdc.gov NR 38 TC 1 Z9 1 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JAN 15 PY 2011 VL 173 IS 2 BP 217 EP 224 DI 10.1093/aje/kwq344 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 698XF UT WOS:000285627500011 PM 21071603 ER PT J AU Esposito, DH Tate, JE Kang, G Parashar, UD AF Esposito, Douglas H. Tate, Jacqueline E. Kang, Gagandeep Parashar, Umesh D. TI Projected Impact and Cost-Effectiveness of a Rotavirus Vaccination Program in India, 2008 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID MORTALITY; DIARRHEA; CHILDREN; DISEASE AB Background. To assess the value of rotavirus vaccination in India, we determined the potential impact and cost-effectiveness of a national rotavirus vaccination program. Methods. We compared the national rotavirus disease and cost burden with and without a vaccination program and assessed the cost-effectiveness of vaccination. Model inputs included measures of disease and cost burden, vaccine performance, and vaccination coverage and cost. We measured the annual number of health-related events and treatment costs averted, as well as the cost-effectiveness in US dollars per disability-adjusted life-year (DALY) and cost per death averted. One-way sensitivity analyses were performed by individually varying each model input. Results. With use of a vaccine that has an estimated effectiveness of 50%, a rotavirus vaccination program in India would prevent similar to 44,000 deaths, similar to 293,000 hospitalizations, and similar to 328,000 outpatient visits annually, which would avert $20.6 million in medical treatment costs. Vaccination would be cost-saving at the GAVI Alliance price of $0.15 per dose. At $1.00 per dose, a vaccination program would cost $49.8 million, which would result in an expenditure of $21.41 per DALY averted or $662.94 per life saved. Even at $7.00 per dose, vaccination would be highly cost-effective. In sensitivity analyses, varying efficacy against severe rotavirus disease and vaccine price had the greatest impact on cost-effectiveness. Conclusions. A national rotavirus vaccination program in India would prevent substantial rotavirus morbidity and mortality and would be highly cost-effective at a range of vaccine prices. Public health officials can use this locally derived data to evaluate how this highly cost-effective intervention might fit into India's long-term health care goals. C1 [Esposito, Douglas H.; Tate, Jacqueline E.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Kang, Gagandeep] Christian Med Coll & Hosp, Dept Gastrointestinal Sci, Vellore, Tamil Nadu, India. RP Esposito, DH (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clinton Rd NE,MS A47, Atlanta, GA 30333 USA. EM hgj4@cdc.gov FU Centers for Disease Control and Prevention FX Centers for Disease Control and Prevention. NR 24 TC 33 Z9 34 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2011 VL 52 IS 2 BP 171 EP 177 DI 10.1093/cid/ciq094 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JS UT WOS:000286215300005 PM 21288839 ER PT J AU Jabeen, K Farooqi, J Zafar, A Jamil, B Mahmood, SF Ali, F Saeed, N Barakzai, A Ahmed, A Khan, E Brandt, ME Hasan, R AF Jabeen, Kauser Farooqi, Joveria Zafar, Afia Jamil, Bushra Mahmood, Syed Faisal Ali, Farheen Saeed, Noureen Barakzai, Abrar Ahmed, Arsalan Khan, Erum Brandt, Mary E. Hasan, Rumina TI Rhinocladiella mackenziei as an Emerging Cause of Cerebral Phaeohyphomycosis in Pakistan: A Case Series SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID CENTRAL-NERVOUS-SYSTEM; RAMICHLORIDIUM-MACKENZIEI AB Six cases of Rhinocladiella mackenziei cerebral phaeohyphomycosis are being reported for the first time in Pakistan. Identification was confirmed by DNA sequencing (isolates and fixed tissue). Diabetes, head trauma, immunosuppressive treatment, and postpartum state were present in 4 cases. Two survivals and 3 fatalities occurred, with 1 patient lost to follow-up. C1 [Jabeen, Kauser; Farooqi, Joveria; Zafar, Afia; Saeed, Noureen; Barakzai, Abrar; Ahmed, Arsalan; Khan, Erum; Hasan, Rumina] Aga Khan Hosp, Dept Pathol Microbiol, Karachi, Pakistan. [Jamil, Bushra; Mahmood, Syed Faisal; Ali, Farheen] Aga Khan Hosp, Dept Med, Karachi, Pakistan. [Brandt, Mary E.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. RP Jabeen, K (reprint author), Aga Khan Univ Hosp, Dept Pathol Microbiol, Stadium Rd,POB 3500, Karachi 74800, Pakistan. EM kausar.jabeen@aku.edu RI Hasan, Rumina/F-4420-2015; Jabeen, Kauser/I-8018-2015 NR 12 TC 6 Z9 6 U1 1 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2011 VL 52 IS 2 BP 213 EP 217 DI 10.1093/cid/ciq114 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JS UT WOS:000286215300012 PM 21288846 ER PT J AU Sheth, AN Althoff, KN Brooks, JT AF Sheth, Anandi N. Althoff, Keri N. Brooks, John T. TI Influenza Susceptibility, Severity, and Shedding in HIV-Infected Adults: A Review of the Literature SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; CRITICALLY-ILL PATIENTS; NEW-YORK-CITY; IMMUNOCOMPROMISED PATIENT; A(H1N1) INFECTION; A VIRUS; RESISTANT; VACCINATION; SEASON; HOSPITALIZATIONS AB Influenza is a common cause of respiratory illness in adults infected with human immunodeficiency virus (HIV), but current knowledge about seasonal and 2009 H1N1 pandemic influenza A (H1N1pdm) virus infections in HIV-infected persons is limited. In this paper, we review the existing literature regarding influenza susceptibility, severity, and shedding in HIV-infected adults. Data show HIV infection does not significantly increase susceptibility to influenza. AIDS is associated with greater seasonal influenza-related morbidity and mortality, but the risk associated with HIV infection among those with less immune suppression is largely unknown. Immunologic compromise has been shown to increase the magnitude and duration of influenza virus shedding; however, these studies are limited within HIV-infected populations. With regards to H1N1pdm, data are even more limited. Reports raise concern of increased severity among HIV-infected persons, although this may be driven by other comorbid illnesses. Prospective studies are needed among HIV-infected persons to more definitively investigate influenza susceptibility, severity, and shedding. C1 [Althoff, Keri N.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Sheth, Anandi N.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA. RP Sheth, AN (reprint author), 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA. EM ansheth@emory.edu RI Andrade, Hugo/M-6631-2013 OI Andrade, Hugo/0000-0001-6781-6125 FU NIAID NIH HHS [K01 AI093197] NR 52 TC 27 Z9 27 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2011 VL 52 IS 2 BP 219 EP 227 DI 10.1093/cid/ciq110 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JS UT WOS:000286215300014 PM 21288848 ER PT J AU Delaney, KP Branson, BM Uniyal, A Phillips, S Candal, D Owen, M Kerndt, PR AF Delaney, Kevin P. Branson, Bernard M. Uniyal, Apurva Phillips, Susan Candal, Debra Owen, Michele Kerndt, Peter R. TI Evaluation of the Performance Characteristics of 6 Rapid HIV Antibody Tests SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; UNITED-STATES; INFECTION; DIAGNOSIS; INDIVIDUALS; EXPOSURE; ANTIGEN AB Background. Since 2002, the US Food and Drug Administration has approved 6 rapid human immunodeficiency virus (HIV) tests for use in the United States. To date, there has been no direct comparison of the performance of all 6 tests. Methods. Persons known to be HIV-infected and persons who sought HIV testing at 2 clinical sites in Los Angeles, California, were recruited for evaluation of 6 rapid HIV tests with whole blood, oral fluid, serum, and plasma specimens. Sensitivity and specificity of the rapid tests were compared with viral lysate and immunoglobulin (Ig) M-sensitive peptide HIV enzyme immunoassays (EIAs). Results. A total of 6282 specimens were tested. Sensitivity was >95% and specificity was >99% for all rapid tests. Compared with the IgM-sensitive EIA, rapid tests gave false-negative results with an additional 2-5 specimens. All rapid tests had statistically equivalent performance characteristics, based on overlapping confidence intervals for sensitivity and specificity, compared with either conventional EIA. Conclusions. All 6 rapid tests have high sensitivity and specificity, compared with that of conventional EIAs. Because performance was similar for all tests and specimen types, other characteristics, such as convenience, time to result, shelf life, and cost will likely be determining factors for selection of a rapid HIV screening test for a specific application. C1 [Delaney, Kevin P.; Branson, Bernard M.; Phillips, Susan; Candal, Debra; Owen, Michele] Ctr Dis Control & Prevent, Div HIV AIDS Prevention Surveillance & Epidemiol, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Uniyal, Apurva; Kerndt, Peter R.] Los Angeles Cty Dept Hlth, STD Control Program, Los Angeles, CA USA. RP Delaney, KP (reprint author), CDC, Div HIV AIDS Prevent, Mailstop E46,1600 Clifton Rd, Atlanta, GA 30333 USA. EM kdelaney@cdc.gov NR 39 TC 57 Z9 58 U1 1 U2 7 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2011 VL 52 IS 2 BP 257 EP 263 DI 10.1093/cid/ciq068 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JS UT WOS:000286215300019 PM 21288853 ER PT J AU Wang, CB Zhang, XY Bialek, S Cannon, MJ AF Wang, Chengbin Zhang, Xingyou Bialek, Stephanie Cannon, Michael J. TI Attribution of Congenital Cytomegalovirus Infection to Primary Versus Non-Primary Maternal Infection SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID IMMUNITY AB Congenital cytomegalovirus (CMV) infection is a leading cause of developmental disabilities. In the United States during the period 1988-1994, approximately one-quarter of congenital CMV infections were attributable to primary maternal infection (n = 8772), and three-quarters were attributable to non-primary maternal infection (n = 29,918). Effective prevention strategies need to be developed for both primary and non-primary maternal infections. C1 [Wang, Chengbin; Zhang, Xingyou; Bialek, Stephanie; Cannon, Michael J.] Ctr Dis Control & Prevent, Atlanta, GA 30345 USA. RP Cannon, MJ (reprint author), Ctr Dis Control & Prevent, 1825 Century Ctr Blvd,Mailstop E-86, Atlanta, GA 30345 USA. EM mcannon@cdc.gov RI Cannon, Michael/E-5894-2011 OI Cannon, Michael/0000-0001-5776-5010 NR 10 TC 70 Z9 72 U1 1 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2011 VL 52 IS 2 BP E11 EP E13 DI 10.1093/cid/ciq085 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JS UT WOS:000286215300001 PM 21288834 ER PT J AU Alam, MT de Souza, DK Vinayak, S Griffing, SM Poe, AC Duah, NO Ghansah, A Asamoa, K Slutsker, L Wilson, MD Barnwell, JW Udhayakumar, V Koram, KA AF Alam, Md Tauqeer de Souza, Dziedzom K. Vinayak, Sumiti Griffing, Sean M. Poe, Amanda C. Duah, Nancy O. Ghansah, Anita Asamoa, Kwame Slutsker, Laurence Wilson, Michael D. Barnwell, John W. Udhayakumar, Venkatachalam Koram, Kwadwo A. TI Selective Sweeps and Genetic Lineages of Plasmodium falciparum Drug -Resistant Alleles in Ghana SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID PYRIMETHAMINE-RESISTANCE; SULFADOXINE-PYRIMETHAMINE; UNCOMPLICATED MALARIA; CHLOROQUINE RESISTANCE; MULTIDRUG-RESISTANCE; NORTHERN GHANA; PFMDR1 GENE; IN-VITRO; ANTIMALARIAL-DRUGS; MUTATIONS AB Background. In 2005, Ghana adopted artemisinin-based combination therapy (ACT) for primary treatment of falciparum malaria. A comprehensive study of the drug-resistance-associated mutations and their genetic lineages will lead to a better understanding of the evolution of antimalarial drug resistance in this region. Methods. The pfcrt, pfmdr1, dhps, and dhfr mutations associated with chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) resistance and the microsatellite loci flanking these genes were genotyped in Plasmodium falciparum isolates from Ghana. Results. The prevalence of mutations associated with both CQ and SP resistance was high in Ghana. However, we observed a decrease in prevalence of the pfcrt K76T mutation in northern Ghana after the change in drug policy from CQ to ACT. Analysis of genetic diversity and differentiation at microsatellite loci flanking all 4 genes indicated that they have been under strong selection, because of CQ and SP use. The triple-mutant pfcrt and dhfr alleles in Ghana were derived from Southeast Asia, whereas the double-mutant dhfr, dhps, and pfmdr1 alleles were of African lineage. Conclusion. Because of the possible role of pfmdr1 in amodiaquine and mefloquine resistance, demonstrating selection on pfmdr1 and defining lineages of resistant alleles in an African population holds great importance. C1 [Alam, Md Tauqeer; Vinayak, Sumiti; Griffing, Sean M.; Poe, Amanda C.; Asamoa, Kwame; Slutsker, Laurence; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30329 USA. [Griffing, Sean M.] Emory Univ, Atlanta, GA 30322 USA. [Alam, Md Tauqeer; Vinayak, Sumiti; Griffing, Sean M.; Poe, Amanda C.] Atlanta Res & Educ Fdn, VA Med Ctr, Atlanta, GA USA. [de Souza, Dziedzom K.; Ghansah, Anita; Wilson, Michael D.] Univ Ghana, Noguchi Mem Inst Med Res, Dept Parasitol, Legon, Ghana. [Duah, Nancy O.; Koram, Kwadwo A.] Univ Ghana, Noguchi Mem Inst Med Res, Dept Epidemiol, Legon, Ghana. RP Alam, MT (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE,Mail Stop D-67, Atlanta, GA 30329 USA. EM hsf1@cdc.gov RI Vinayak, Sumiti/F-9395-2013; OI Duah, Nancy/0000-0001-8819-1793 FU Atlanta Research and Education Foundation, VA Medical Center [IAA 09FED911106]; CDC Antimicrobial Resistance Working Group [PID 1227]; Global Fund to Fight AIDS, Tuberculosis and Malaria [GHN-405-G04-M]; International Atomic Energy Agency (IAEA) [RAF 6025]; American Society for Microbiology; Coordinating Center for Infectious Diseases FX This work was supported by the Atlanta Research and Education Foundation, VA Medical Center (IAA 09FED911106); CDC Antimicrobial Resistance Working Group (PID 1227); National Malaria Control Programme of Ghana with funds from the Global Fund to Fight AIDS, Tuberculosis and Malaria (GHN-405-G04-M) and International Atomic Energy Agency (IAEA) (RAF 6025); American Society for Microbiology and the Coordinating Center for Infectious Diseases postdoctoral fellowship (to M.T.A.). The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript. NR 50 TC 36 Z9 37 U1 0 U2 7 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD JAN 15 PY 2011 VL 203 IS 2 BP 220 EP 227 DI 10.1093/infdis/jiq038 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 705XB UT WOS:000286172900013 PM 21288822 ER PT J AU Mathias, DK Ochomo, E Atieli, F Ombok, M Bayoh, MN Olang, G Muhia, D Kamau, L Vulule, JM Hamel, MJ Hawley, WA Walker, ED Gimnig, JE AF Mathias, Derrick K. Ochomo, Eric Atieli, Francis Ombok, Maurice Bayoh, M. Nabie Olang, George Muhia, Damaris Kamau, Luna Vulule, John M. Hamel, Mary J. Hawley, William A. Walker, Edward D. Gimnig, John E. TI Spatial and temporal variation in the kdr allele L1014S in Anopheles gambiae s.s. and phenotypic variability in susceptibility to insecticides in Western Kenya SO MALARIA JOURNAL LA English DT Article ID PERMETHRIN-IMPREGNATED NETS; KNOCKDOWN RESISTANCE KDR; TREATED BED NETS; PYRETHROID INSECTICIDES; MALARIA TRANSMISSION; NORTHERN CAMEROON; MOSQUITOS; BEDNETS; AREA; TOLERANCE AB Background: Malaria vector control in Africa depends upon effective insecticides in bed nets and indoor residual sprays. This study investigated the extent of insecticide resistance in Anopheles gambiae s.l., Anopheles gambiae s.s. and Anopheles arabiensis in western Kenya where ownership of insecticide-treated bed nets has risen steadily from the late 1990s to 2010. Temporal and spatial variation in the frequency of a knock down resistance (kdr) allele in A. gambiae s.s. was quantified, as was variation in phenotypic resistance among geographic populations of A. gambiae s.l. Methods: To investigate temporal variation in kdr frequency, individual specimens of A. gambiae s.s. from two sentinel sites were genotyped using RT-PCR from 1996-2010. Spatial variation in kdr frequency, species composition, and resistance status were investigated in additional populations of A. gambiae s.l. sampled in western Kenya in 2009 and 2010. Specimens were genotyped for kdr as above and identified to species via conventional PCR. Field-collected larvae were reared to adulthood and tested for insecticide resistance using WHO bioassays. Results: Anopheles gambiae s.s. showed a dramatic increase in kdr frequency from 1996 - 2010, coincident with the scale up of insecticide-treated nets. By 2009-2010, the kdr L1014S allele was nearly fixed in the A. gambiae s.s. population, but was absent in A. arabiensis. Near Lake Victoria, A. arabiensis was dominant in samples, while at sites north of the lake A. gambiae s.s was more common but declined relative to A. arabiensis from 2009 to 2010. Bioassays demonstrated that A. gambiae s.s. had moderate phenotypic levels of resistance to DDT, permethrin and deltamethrin while A. arabiensis was susceptible to all insecticides tested. Conclusions: The kdr L1014S allele has approached fixation in A. gambiae s.s. populations of western Kenya, and these same populations exhibit varying degrees of phenotypic resistance to DDT and pyrethroid insecticides. The near absence of A. gambiae s.s. from populations along the lakeshore and the apparent decline in other populations suggest that insecticide-treated nets remain effective against this mosquito despite the increase in kdr allele frequency. The persistence of A. arabiensis, despite little or no detectable insecticide resistance, is likely due to behavioural traits such as outdoor feeding and/or feeding on non-human hosts by which this species avoids interaction with insecticide-treated nets. C1 [Mathias, Derrick K.; Walker, Edward D.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA. [Mathias, Derrick K.; Ochomo, Eric; Atieli, Francis; Ombok, Maurice; Bayoh, M. Nabie; Olang, George; Vulule, John M.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Mathias, Derrick K.; Ochomo, Eric; Atieli, Francis; Ombok, Maurice; Bayoh, M. Nabie; Olang, George; Hamel, Mary J.] Ctr Dis Control & Prevent, Kisumu, Kenya. [Muhia, Damaris; Kamau, Luna] Kenya Govt Med Res Ctr, Ctr Biotechnol Res & Dev, Nairobi, Kenya. [Hamel, Mary J.; Hawley, William A.; Gimnig, John E.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30341 USA. [Mathias, Derrick K.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA. RP Walker, ED (reprint author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA. EM dmathias@jhsph.edu; hzg1@cdc.gov FU Bill and Melinda Gates Foundation; National Science Foundation (NSF) [EF-072377]; US President's Malaria Initiative; American Society for Microbiology FX We gratefully acknowledge the field and laboratory work of Samson Otieno, Ben Oloo, Richard Owera, Richard Nyawalo, Laban Adero, Walter Nyawade, George Masula, Richard Amito, Gideon Nyansikera and Joseph Nduati. We also would like to thank Doug Norris for comments on an earlier version of the manuscript. This study was supported by grants from the Bill and Melinda Gates Foundation and the National Science Foundation (NSF grant EF-072377). Field work was also supported with funding from the US President's Malaria Initiative. DKM was partially supported by a postdoctoral fellowship from the American Society for Microbiology. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. This paper is published with the permission of the director of the Kenya Medical Research Institute. NR 56 TC 47 Z9 48 U1 1 U2 23 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD JAN 14 PY 2011 VL 10 AR 10 DI 10.1186/1475-2875-10-10 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 740QT UT WOS:000288810200003 PM 21235783 ER PT J AU McClave, A Rock, V Thorne, S Malarcher, A AF McClave, A. Rock, V. Thorne, S. Malarcher, A. TI State-Specific Prevalence of Cigarette Smoking and Smokeless Tobacco Use Among Adults-United States, 2009 (Reprinted from MMWR, vol 59, pg 1400-1406, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [McClave, A.; Rock, V.; Thorne, S.; Malarcher, A.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP McClave, A (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. NR 6 TC 2 Z9 2 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 12 PY 2011 VL 305 IS 2 BP 143 EP 146 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA 705BM UT WOS:000286103400011 ER PT J AU Tseng, HF Smith, N Harpaz, R Bialek, SR Sy, LS Jacobsen, SJ AF Tseng, Hung Fu Smith, Ning Harpaz, Rafael Bialek, Stephanie R. Sy, Lina S. Jacobsen, Steven J. TI Herpes Zoster Vaccine in Older Adults and the Risk of Subsequent Herpes Zoster Disease SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID INFLUENZA VACCINE; VARICELLA; EFFICACY; HOSPITALIZATIONS; EPIDEMIOLOGY; OPHTHALMICUS; MANAGEMENT; ACCURACY; CHILDREN; SENIORS AB Context Approximately 1 million episodes of herpes zoster occur annually in the United States. Although prelicensure data provided evidence that herpes zoster vaccine works in a select study population under idealized circumstances, the vaccine needs to be evaluated in field conditions. Objective To evaluate risk of herpes zoster after receipt of herpes zoster vaccine among individuals in general practice settings. Design, Setting, and Participants A retrospective cohort study from January 1, 2007, through December 31, 2009, of individuals enrolled in the Kaiser Permanente Southern California health plan. Participants were immunocompetent community-dwelling adults aged 60 years or older. The 75 761 members in the vaccinated cohort were age matched (1:3) to 227 283 unvaccinated members. Main Outcome Measure Incidence of herpes zoster. Results Herpes zoster vaccine recipients were more likely to be white, women, with more outpatient visits, and fewer chronic diseases. The number of herpes zoster cases among vaccinated individuals was 828 in 130 415 person-years (6.4 per 1000 person-years; 95% confidence interval [CI], 5.9-6.8), and for unvaccinated individuals it was 4606 in 355 659 person-years (13.0 per 1000 person-years; 95% CI, 12.6-13.3). In adjusted analysis, vaccination was associated with a reduced risk of herpes zoster (hazard ratio [HR], 0.45; 95% CI, 0.42-0.48); this reduction occurred in all age strata and among individuals with chronic diseases. Risk of herpes zoster differed by vaccination status to a greater magnitude than the risk of unrelated acute medical conditions, suggesting results for herpes zoster were not due to bias. Ophthalmic herpes zoster (HR, 0.37; 95% CI, 0.23-0.61) and hospitalizations coded as herpes zoster (HR, 0.35; 95% CI, 0.24-0.51) were less likely among vaccine recipients. Conclusions Among immunocompetent community-dwelling adults aged 60 years or older, receipt of the herpes zoster vaccine was associated with a lower incidence of herpes zoster. The risk was reduced among all age strata and among individuals with chronic diseases. JAMA. 2011; 305(2): 160-166 C1 [Tseng, Hung Fu; Smith, Ning; Sy, Lina S.; Jacobsen, Steven J.] So Calif Kaiser Permanente, Dept Res & Evaluat, Pasadena, CA USA. [Harpaz, Rafael; Bialek, Stephanie R.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Tseng, HF (reprint author), Kaiser Permanente, So Calif Med Grp, Dept Res & Evaluat, 100 S Los Robles Ave,2nd Floor, Pasadena, CA 91101 USA. EM Hung-Fu.x.Tseng@kp.org FU Merck FX All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Tseng, Smith, and Jacobsen and Ms Sy report having received research funding from Merck for other vaccine studies. Dr Jacobsen reports having served as an unpaid consultant for Merck Research Laboratories. Drs Harpaz and Bialek report no disclosures. NR 37 TC 89 Z9 91 U1 2 U2 7 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 12 PY 2011 VL 305 IS 2 BP 160 EP 166 DI 10.1001/jama.2010.1983 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 705BM UT WOS:000286103400021 PM 21224457 ER PT J AU Coleman, LA Kieke, B Irving, S Shay, DK Vandermause, M Lindstrom, S Belongia, EA AF Coleman, Laura A. Kieke, Burney Irving, Stephanie Shay, David K. Vandermause, Mary Lindstrom, Stephen Belongia, Edward A. TI Comparison of influenza vaccine effectiveness using different methods of case detection: Clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) SO VACCINE LA English DT Article DE Influenza vaccine effectiveness; Rapid test; Polymerase chain reaction ID DIRECT FLUORESCENT ASSAY; A H1N1 VIRUS; RT-PCR; RESPIRATORY SPECIMENS; 2004-2005 SEASON; PERFORMANCE; INFECTION AB Annual evaluation of influenza vaccine effectiveness (VE) is needed to assess ongoing impact of immunization efforts in the setting of antigenic drift and periodic vaccine reformulation. Optimal methodology for determining VE remains unclear. We compared influenza VE generated from prospective enrollment and rRT-PCR testing (active surveillance group) with VE based on clinician-ordered diagnostic tests (clinical testing group) in a defined population over four seasons. VE was calculated as (1 - adjusted OR) for vaccination in cases vs. test-negative controls. VE based on clinical testing underestimated VE based on active surveillance and testing with rRT-PCR by 5-33% depending on season. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Coleman, Laura A.] Marshfield Clin Fdn Med Res & Educ, Epidemiol Res Ctr, Marshfield, WI 54449 USA. [Shay, David K.; Lindstrom, Stephen] CDC, Influenza Div, Atlanta, GA 30333 USA. RP Coleman, LA (reprint author), Marshfield Clin Fdn Med Res & Educ, Epidemiol Res Ctr, 1000 N Oak Ave,ML2, Marshfield, WI 54449 USA. EM Coleman.laura@mcrf.mfldclin.edu OI Irving, Stephanie/0000-0001-7437-6797; Shay, David/0000-0001-9619-4820 FU Centers for Disease Control and Prevention [1 UO1 CI000192-02, U18IP000183] FX This project was supported by cooperative agreements from the Centers for Disease Control and Prevention (1 UO1 CI000192-02 and U18IP000183). NR 13 TC 9 Z9 9 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 10 PY 2011 VL 29 IS 3 BP 387 EP 390 DI 10.1016/j.vaccine.2010.10.082 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 715AQ UT WOS:000286853200005 PM 21095253 ER PT J AU Sejvar, JJ Kohl, KS Gidudu, J Amato, A Bakshi, N Baxter, R Burwen, DR Cornblath, DR Cleerbout, J Edwards, KM Heininger, U Hughes, R Khuri-Bulos, N Korinthenberg, R Law, BJ Munro, U Maltezou, HC Nell, P Oleske, J Sparks, R Velentgas, P Vermeer, P Wiznitzer, M AF Sejvar, James J. Kohl, Katrin S. Gidudu, Jane Amato, Anthony Bakshi, Nandini Baxter, Roger Burwen, Dale R. Cornblath, David R. Cleerbout, Jan Edwards, Kathryn M. Heininger, Ulrich Hughes, Richard Khuri-Bulos, Najwa Korinthenberg, Rudolf Law, Barbara J. Munro, Ursula Maltezou, Helena C. Nell, Patricia Oleske, James Sparks, Robert Velentgas, Priscilla Vermeer, Patricia Wiznitzer, Max CA Brighton Collaboration GBS Working TI Guillain-Barre syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data SO VACCINE LA English DT Article DE Guillain-Barre syndrome; Neuropathy; Fisher syndrome; Acute inflammatory demyelinating polyradiculoneuropathy; Adverse event; Immunization; Guidelines; Case definition ID MEDIATED NEUROLOGIC DISEASE; MOTOR AXONAL NEUROPATHY; MOLECULAR MIMICRY; INFLUENZA VACCINATION; UNITED-STATES; ELECTRODIAGNOSTIC CRITERIA; CAMPYLOBACTER-JEJUNI; DIAGNOSTIC-CRITERIA; RABIES VACCINATION; EPIDEMIOLOGY C1 [Sejvar, James J.; Kohl, Katrin S.; Gidudu, Jane] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Amato, Anthony] Brigham & Womens Hosp, Dept Neurol, Div Neuromuscular Dis, Boston, MA 02115 USA. [Velentgas, Priscilla] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA. [Bakshi, Nandini; Baxter, Roger] NCK Kaiser Permanente, Oakland, CA USA. [Burwen, Dale R.] US FDA, Rockville, MD 20857 USA. [Cornblath, David R.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Cleerbout, Jan] GlaxoSmithKline Biol, Rixensart, Belgium. [Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Heininger, Ulrich] Univ Childrens Hosp, Basel, Switzerland. [Hughes, Richard] Kings Coll London, Sch Med, London WC2R 2LS, England. [Khuri-Bulos, Najwa] Jordan Univ Hosp, Amman, Jordan. [Korinthenberg, Rudolf] Univ Hosp Freiburg, Freiburg, Germany. [Law, Barbara J.] Publ Hlth Agcy Canada, Ottawa, ON, Canada. [Munro, Ursula] Sanofi Pasteur MSD GmbH, Walldorf, Germany. [Maltezou, Helena C.] Hellen Ctr Dis Control & Prevent, Athens, Greece. [Nell, Patricia] USAF, Airforce Reserve Command, Sturgeon Bay, WI USA. [Oleske, James] Univ Hosp, New Jersey Med Sch, Morris Plains, NJ USA. [Sparks, Robert] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Velentgas, Priscilla] Harvard Pilgrim Hlth Care, Boston, MA USA. [Vermeer, Patricia] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands. [Wiznitzer, Max] Univ Hosp Cleveland, Dept Neurol, Cleveland, OH 44106 USA. RP Sejvar, JJ (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM secretariat@brightoncollaboration.org OI Korinthenberg, Rudolf/0000-0002-4638-3460 FU WHO FX The authors are grateful for the support and helpful comments from members of Brighton Collaboration Steering Committee during the time of the development of this document, who are not already included as authors (Mike Blum, Paul Heath, Hector Izurieta, Brigitte Keller Stanislawski, Katrin Kohl Odile Leroy), and the participants in the Reference Group (Adam Rudiger, Adderson Elisabeth, Aguilar Maria, Aldrovandi Grace, Allen Mary, Bachtiar Novilia Sjafri, Barami A. A. Salim, Baxter Roger, Bettinger Julie, Bilynsky Roman, Blum Michael, Bonhoeffer Jan, Brady Michael, Buettcher Michael, Buttery Jim, Cane Alejandro, Chang Soju, Chatterjee Arani, Chawla Krishan, Cherian Thomas, Cleerbout Jan, Close Philippe, Condit Richard, Cornblath David, Couch Robert B., da Costa Christopher, Davis Larry, de Menezes Martins Reinaldo, de Vries Corinne, Deotti Sandra Maria, Dimitrijevic Dragana, Dong Duo, Evengard Birgitta, Falup-Pecurariu Cristian, Fernandopulle Rohini, Ferreira Germano, Fisher Margaret C, Galama Jochem, Gallegos Karl, Gershman Mark, Gibbs Neville, Gidudu Jane, Gurwith Marc, Halsey Neal, Hanlon Erin, Hitchcock William, Hossain Shah, Huang Wan-Ting, Hunter Deborah, Isaacs David, Jacobson Robert, Johann-Liang Rosemary, Jones Barbara, Jovancevic Milivoj, Kaisar Mahfuzul Islam, Kang Gagandeep, Klug Bettina, Korinthenberg Rudolf, Kulcsar Andrea, Lee Grace, Lievano Fabio, MacDonald Noni, Mahmood Asif, Maltezou Helena, Martin Martin Susana, McIntosh G David, Mentzer Dirk, Meredith Stefanie, Meszner Zsofia, Milstien Julie, Minor Mary, Modlin John, Montgomery Jay, Morse Ann, Munro Ursula, Nalin David, Nell Patricia, Nimmannitya Suchitra, Nisslein Thomas, Nokleby Hanne, Nwosu Kenneth, Oleske James M., Patnaik Badri, Pinheiro Luis, Pourmalek Farshad, Ramasamy Ranjan, Rump Eva-Beate, Samson Heather, Santos Eliane, Schuller Elisabeth, Schultze Viola, Sidhu Maninder K., Sillan Francoise, Sliman Joseph, Soh Bee Leng Sally, Sparks Robert, Sprenger Ralf, Steele Russell, Stoller Rudolf, Storsaeter Jann, Suznjevic Vladimir, Tebaa Amina, Tridente Giuseppe, Trimis Georgios, Uhnoo Ingrid, Van Dinther Kristy, Varricchio Frederick, Ventura Rafael, Vilella Anna, Warden Beverly, Weston William, Wimalaratne Omala, Wong Virginia, Chun-Nei, Zajdowicz Thad, Zaman Khalequz, Zanoni Giovanna, Zielinski Andrzej, and Zuber Patrick and harmonization work by Michael Buettcher, Sabine Faisst, and Jan Bonhoeffer. We are also grateful for the support of WHO and ECDC for creating this document. Finally, we would like to thank the members of the WHO/CIOMS Working Group on Vaccine Pharmacovigilance (http://www.cioms.ch/frame current programme. htm) for the review of, constructive comments on, and endorsement of this document. NR 84 TC 120 Z9 123 U1 3 U2 13 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JAN 10 PY 2011 VL 29 IS 3 BP 599 EP 612 DI 10.1016/j.vaccine.2010.06.003 PG 14 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 715AQ UT WOS:000286853200031 PM 20600491 ER PT J AU Wang, RJ Qi, M Zhu, JJ Sun, D Ning, CS Zhao, JF Zhang, LX Xiao, LH AF Wang, Rongjun Qi, Meng Zhu Jingjing Sun, Dong Ning, Changshen Zhao, Jinfeng Zhang, Longxian Xiao, Lihua TI Prevalence of Cryptosporidium baileyi in ostriches (Struthio camelus) in Zhengzhou, China SO VETERINARY PARASITOLOGY LA English DT Article DE Cryptosporidium; Ostriches; C. baileyi; Cross-transmission; Chickens; Quails ID MOLECULAR CHARACTERIZATION; HOST-SPECIFICITY; CHICKENS; INFECTION; PROLAPSE; PHALLUS; ISOLATE; CLOACA AB Few data are available on the molecular characterization of Cryptosporidium spp. in ostriches. The objective of this study was to determine the prevalence of Cryptosporidium species or genotypes in ostriches. A total of 452 fecal samples from five farms, a zoo, and an animal rescue center in Zhengzhou, Henan Province, China were examined for Cryptosporidium oocysts by microscopy of wet mount of fecal materials concentrated by the Sheather's sugar flotation technique. Fifty-three samples were Cryptosporidium-positive from four farms, with an overall prevalence of 11.7%. The percentage of animals shedding oocysts was 0, 16.2%, 7.2%, and 0 in 1-3 weeks, 4-8 weeks, 3-12 months, and more than 12 months ostriches, respectively (chi(2)=17.74; rho < 0.01). PCR-restriction fragment length polymorphism (RFLP) analysis of the small subunit (SSU) rRNA gene of the 53 Cryptosporidium-positive samples showed the presence of only Cryptosporidium baileyi, which was confirmed by DNA sequencing of the SSU rRNA PCR products from 16 positive samples. Cross-transmission studies demonstrated that the C. baileyi isolate could infect chickens and quails. Thus, ostriches are commonly infected with C. baileyi that is genetically and biologically similar to C. baileyi found in other birds. (C) 2010 Elsevier B.V. All rights reserved. C1 [Wang, Rongjun; Qi, Meng; Zhu Jingjing; Ning, Changshen; Zhao, Jinfeng; Zhang, Longxian] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China. [Sun, Dong] Kaifeng Ctr Dis Control & Prevent, Kaifeng 475000, Peoples R China. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Zhang, LX (reprint author), Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China. EM zhanglx8999@yahoo.com.cn; lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU National Natural Science Foundation of China [30771881, 30871863, 30928019]; Ministry of Health Special Funds of Public Sector Research [200808012] FX This study was supported in part by the National Natural Science Foundation of China (Nos. 30771881, 30871863, and 30928019) and Ministry of Health Special Funds of Public Sector Research (No. 200808012). NR 23 TC 12 Z9 14 U1 2 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-4017 J9 VET PARASITOL JI Vet. Parasitol. PD JAN 10 PY 2011 VL 175 IS 1-2 BP 151 EP 154 DI 10.1016/j.vetpar.2010.10.005 PG 4 WC Parasitology; Veterinary Sciences SC Parasitology; Veterinary Sciences GA 704FR UT WOS:000286037000024 PM 21030152 ER PT J AU Moonan, PK Quitugua, TN Pogoda, JM Woo, G Drewyer, G Sahbazian, B Dunbar, D Jost, KC Wallace, C Weis, SE AF Moonan, Patrick K. Quitugua, Teresa N. Pogoda, Janice M. Woo, Gary Drewyer, Gerry Sahbazian, Behzad Dunbar, Denise Jost, Kenneth C., Jr. Wallace, Charles Weis, Stephen E. TI Does directly observed therapy (DOT) reduce drug resistant tuberculosis? SO BMC PUBLIC HEALTH LA English DT Article ID NEW-YORK-CITY; SHORT-COURSE CHEMOTHERAPY; PULMONARY TUBERCULOSIS; TRANSMISSION; TWICE; EXPERIENCE; PHYSICIANS; RIFAMPIN; HEALTH; TRIAL AB Background: Directly observed therapy (DOT) is a widely recommended and promoted strategy to manage tuberculosis (TB), however, there is still disagreement about the role of DOT in TB control and the impact it has on reducing the acquisition and transmission of drug resistant TB. This study compares the portion of drug resistant genotype clusters, representing recent transmission, within and between communities implementing programs differing only in their directly observed therapy (DOT) practices. Methods: Genotype clusters were defined as 2 or more patient members with matching IS6110 restriction fragment length polymorphism (RFLP) and spoligotype patterns from all culture-positive tuberculosis cases diagnosed between January 1, 1995 and December 31, 2001. Logistic regression was used to compute maximum-likelihood estimates of odds ratios (ORs) and 95% confidence intervals (CIs) comparing cluster members with and without drug resistant isolates. In the universal DOT county, all patients received doses under direct observation of health department staff; whereas in selective DOT county, the majority of received patients doses under direct observation of health department staff, while some were able to self-administer doses. Results: Isolates from 1,706 persons collected during 1,721 episodes of tuberculosis were genotyped. Cluster members from the selective DOT county were more than twice as likely than cluster members from the universal DOT county to have at least one isolate resistant to isoniazid, rifampin, and/or ethambutol (OR = 2.3, 95% CI: 1.7, 3.1). Selective DOT county isolates were nearly 5 times more likely than universal DOT county isolates to belong to clusters with at least 2 resistant isolates having identical resistance patterns (OR = 4.7, 95% CI: 2.9, 7.6). Conclusions: Universal DOT for tuberculosis is associated with a decrease in the acquisition and transmission of resistant tuberculosis. C1 [Moonan, Patrick K.; Pogoda, Janice M.; Drewyer, Gerry; Sahbazian, Behzad; Weis, Stephen E.] Univ N Texas Hlth Sci Ctr Ft Worth, Dept Med, Ft Worth, TX USA. [Moonan, Patrick K.; Drewyer, Gerry; Sahbazian, Behzad; Weis, Stephen E.] Tarrant Cty Hlth Dept, Ft Worth, TX USA. [Quitugua, Teresa N.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA. [Pogoda, Janice M.] Statology, Ventura, CA USA. [Woo, Gary] Dallas Cty Hlth & Human Serv, Dallas, TX USA. [Dunbar, Denise; Jost, Kenneth C., Jr.; Wallace, Charles; Weis, Stephen E.] Texas Dept State Hlth Serv, Austin, TX USA. [Moonan, Patrick K.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Weis, SE (reprint author), Univ N Texas Hlth Sci Ctr Ft Worth, Dept Med, Ft Worth, TX USA. EM sweis@hsc.unt.edu RI Moonan, Patrick/F-4307-2014; OI Moonan, Patrick/0000-0002-3550-2065 FU Robert J. and Helen C. Kleberg Foundation; CDC National Tuberculosis Genotyping and Surveillance Network; Texas Department of State Health Services; CDC Tuberculosis Trials and Epidemiologic Studies Consortium FX The authors acknowledge editorial assistance of Thaddeus Miller and the manuscript review and suggestions by Francesca Sanchez M. D and Peter Barnes M.D. This work was supported in part by the Robert J. and Helen C. Kleberg Foundation, by CDC Tuberculosis Trials and Epidemiologic Studies Consortium and cooperative agreements between the CDC National Tuberculosis Genotyping and Surveillance Network and the Texas Department of State Health Services. NR 40 TC 15 Z9 16 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD JAN 7 PY 2011 VL 11 AR 19 DI 10.1186/1471-2458-11-19 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 714OH UT WOS:000286818400001 PM 21214913 ER PT J AU McMenamin, SB Halpin, HA Ingram, M Rosenthal, A AF McMenamin, S. B. Halpin, H. A. Ingram, M. Rosenthal, A. TI State Medicaid Coverage for Tobacco-Dependence Treatments-United States, 2009 (Reprinted from MMWR, vol 59, pg 1340-1343, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [McMenamin, S. B.; Halpin, H. A.; Ingram, M.] Univ Calif Berkeley, Ctr Hlth & Publ Policy Studies, Berkeley, CA 94720 USA. [Rosenthal, A.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP McMenamin, SB (reprint author), Univ Calif Berkeley, Ctr Hlth & Publ Policy Studies, Berkeley, CA 94720 USA. NR 10 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 5 PY 2011 VL 305 IS 1 BP 34 EP 36 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 702VN UT WOS:000285924100011 ER PT J AU Belongia, EA Shay, DK AF Belongia, Edward A. Shay, David K. TI Comparing Severity and Outcomes for Seasonal and 2009 H1N1 Infections Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Shay, David K.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Belongia, EA (reprint author), Marshfield Clin Res Fdn, Marshfield, WI USA. EM belongia.edward@marshfieldclinic.org NR 1 TC 0 Z9 0 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 5 PY 2011 VL 305 IS 1 BP 40 EP 40 DI 10.1001/jama.2010.1889 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA 702VN UT WOS:000285924100019 ER PT J AU Materna, B Harriman, K Rosenberg, J Shusterman, D Windham, G Atwell, J Beckman, S Mortensen, E Zipprich, J AF Materna, B. Harriman, K. Rosenberg, J. Shusterman, D. Windham, G. Atwell, J. Beckman, S. Mortensen, E. Zipprich, J. TI Occupational Transmission of Neisseria meningitidis-California, 2009 (Reprinted from MMWR, vol 59, pg 1480-1483, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Mortensen, E.; Zipprich, J.] CDC, EIS, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 5 PY 2011 VL 305 IS 1 BP 29 EP + PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 702VN UT WOS:000285924100009 ER PT J AU Fairley, TL Tai, E Townsend, JS Stewart, SL Steele, CB Davis, SP Underwood, JM AF Fairley, T. L. Tai, E. Townsend, J. S. Stewart, S. L. Steele, C. B. Davis, S. P. Underwood, J. M. TI Racial/Ethnic Disparities and Geographic Differences in Lung Cancer Incidence-38 States and the District of Columbia, 1998-2006 (Reprinted from MMWR, vol 59, pg 1433-1438, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Fairley, T. L.; Tai, E.; Townsend, J. S.; Stewart, S. L.; Steele, C. B.] Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA USA. [Davis, S. P.] Natl Ctr Chron Dis Prevent & Hlth Promot, Off Smoking & Hlth, Atlanta, GA USA. [Underwood, J. M.] CDC, EIS, Atlanta, GA 30333 USA. RP Fairley, TL (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 5 PY 2011 VL 305 IS 1 BP 32 EP 34 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 702VN UT WOS:000285924100010 ER PT J AU Thombley, M Ijaz, K Metchock, B LoBue, P AF Thombley, Melisa Ijaz, Kashef Metchock, Beverly LoBue, Philip BE Schlossberg, D TI Role of the Health Department-Legal and Public Health Considerations SO TUBERCULOSIS AND NONTUBERCULOUS MYCOBACTERIAL INFECTIONS, 6TH EDITION LA English DT Article; Book Chapter ID LATENT TUBERCULOSIS INFECTION; UNITED-STATES; CONTACT INVESTIGATIONS; TREATMENT COMPLETION; PROGRAMS; POPULATION; PREVENTION; GUIDELINES; EXPERIENCE; DETENTION C1 [Thombley, Melisa; Ijaz, Kashef; Metchock, Beverly; LoBue, Philip] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. RP Thombley, M (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, Mail Stop E-10,1600 Clifton Rd, Atlanta, GA 30333 USA. NR 60 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-713-8 PY 2011 BP 224 EP 241 PG 18 WC Infectious Diseases SC Infectious Diseases GA BYN83 UT WOS:000299465700014 ER PT J AU Gebhardt, MC McGehee, LA Grindel, CG Testani-Dufour, L AF Gebhardt, Mary Catherine McGehee, Linda A. Grindel, Cecelia Gatson Testani-Dufour, Linda TI Caregiver and Nurse Hopes for Recovery of Patients with Acquired Brain Injury SO REHABILITATION NURSING LA English DT Article DE brain injury; caregiver; hope ID FAMILY CAREGIVERS; DEPRESSIVE SYMPTOMS; HEALTH; PEOPLE; CARE AB From the moment an adolescent with acquired brain injury (ABI) is admitted to the hospital, his or her caregiver develops hopes for the recovery and future of the patient; however, rehabilitation nurses have reported that these hopes are not always congruent with the nurse's observations of the adolescent's progression. The purpose of this study was threefold: (1) explore the caregiver's hope for recovery of his or her family member who has experienced an ABI, (2) compare the nurse's hopes for the patient with ABI to those of the caregiver, and (3) identify what caregivers and nurses do to maintain hope for recovery during the rehabilitation process. This qualitative study validated that in some cases there was a disconnect between caregivers' and nurses' hopes for recovery. Four themes related to the caregiver's maintenance of hope were identified: "the importance of family," "taking one day at a time," " knowing the patient better," and " spiritual strength brings me through." Enhancing the perceptual congruence between nurse and caregiver hope during rehabilitation will ultimately improve patient outcomes. C1 [Gebhardt, Mary Catherine; Grindel, Cecelia Gatson] Georgia State Univ, Atlanta, GA 30303 USA. [McGehee, Linda A.] Ctr Dis Control & Prevent, Natl Fdn, Atlanta, GA USA. [Testani-Dufour, Linda] Shephard Ctr, Post Acute Brain Injury Unit, Atlanta, GA USA. RP Gebhardt, MC (reprint author), Georgia State Univ, Atlanta, GA 30303 USA. EM mgebhardt@gsu.edu FU Rehabilitation Nursing Foundation of the Association of Rehabilitation Nurses; Georgia State University's College of Health and Human Sciences Intramural Grant Program FX This study was partially funded by the Rehabilitation Nursing Foundation of the Association of Rehabilitation Nurses and the Georgia State University's College of Health and Human Sciences Intramural Grant Program. We would like to acknowledge the support of the nurses and staff at the Shepherd Center, and we would like to thank the caregivers who graciously shared their experience with us. NR 13 TC 4 Z9 4 U1 0 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0278-4807 J9 REHABIL NURS JI Rehabil. Nurs. PD JAN-FEB PY 2011 VL 36 IS 1 BP 3 EP 12 DI 10.1002/j.2048-7940.2011.tb00059.x PG 10 WC Nursing; Rehabilitation SC Nursing; Rehabilitation GA 998GA UT WOS:000308224300002 PM 21290959 ER PT J AU Caster, A Shrivastava-Ranjan, P Kahn, R AF Caster, A. Shrivastava-Ranjan, P. Kahn, R. TI Cargos Specify the Site and Identity of Adaptor Recruitment to the Golgi and Recycling Endosomes. SO MOLECULAR BIOLOGY OF THE CELL LA English DT Meeting Abstract CT Annual Meeting of the American-Society-for-Cell-Biology (ASCB) CY DEC 03-07, 2011 CL Denver, CO SP Amer Soc Cell Biol (ASCB) C1 [Caster, A.; Kahn, R.] Emory Univ, Atlanta, GA 30322 USA. [Shrivastava-Ranjan, P.] CDC, Special Pathogens Branch, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CELL BIOLOGY PI BETHESDA PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA SN 1059-1524 J9 MOL BIOL CELL JI Mol. Biol. Cell PY 2011 VL 22 MA 1617 PG 1 WC Cell Biology SC Cell Biology GA 961YM UT WOS:000305505503202 ER PT S AU Hettick, JM Green, BJ Buskirk, AD Slaven, JE Kashon, ML Beezhold, DH AF Hettick, Justin M. Green, Brett J. Buskirk, Amanda D. Slaven, James E. Kashon, Michael L. Beezhold, Donald H. BE Fenselau, C Demirev, P TI Discrimination of Fungi by MALDI-TOF Mass Spectrometry SO RAPID CHARACTERIZATION OF MICROORGANISMS BY MASS SPECTROMETRY SE ACS Symposium Series LA English DT Proceedings Paper CT 238th National Meeting of the American-Chemical-Society (ACS)/American-Chemical-Society (ACS) Symposium on Emerging Contaminants, Pharmaceuticals and Personal Care Products (PPCPs), and Organohalogens in Wastewater and Municipal Biosolids CY AUG 16-20, 2009 CL Washington, DC SP Amer Chem Soc, Div Chem Toxicol, Amer Chem Soc, Env Chem Inc ID LASER-DESORPTION/IONIZATION-TIME; MICROORGANISM IDENTIFICATION; INTACT MICROORGANISMS; RAPID IDENTIFICATION; PROTEIN BIOMARKERS; STRAIN LEVEL; BACTERIA; SPORES; DESORPTION; EXPOSURE AB Traditionally, fungal identification has largely been based on the subjective micro- and macroscopic examination of morphological and culture characteristics. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF MS) was used to generate reproducible mass spectral "fingerprints" for 76 fungal species, particularly from the medically important genera, Penicillium and Aspergillus. The mass spectra contain abundant mass signals and allow unambiguous discrimination between species. Species identification error rates were determined to be 0% and 1.4% using resubstitution and cross-validation methods, respectively. The ability of MALDI TOP MS to differentiate fungal strains was additionally examined for the aflatoxin producing species, Aspergillus flavus. Identification error rates for 40 tested A. flavus cultures from five unique strains were determined to be 0% and 5% using resubstitution and cross-validation methods, respectively. Analysis of dematiaceous (dark-pigmented) fungi has been observed to yield poor MALDI-TOF mass spectra. Results demonstrate this was due to the presence of melanin in the cell wall of fungal spores and hyphae. Strategies to overcome this limitation are presented. These results indicate that MALDI-TOF MS data may be a useful diagnostic tool and alternative to available immunodiagnostic and molecular methods for the objective identification of environmental, industrial and clinically important fungal species. C1 [Hettick, Justin M.; Green, Brett J.; Buskirk, Amanda D.; Slaven, James E.; Kashon, Michael L.; Beezhold, Donald H.] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Hettick, JM (reprint author), NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. EM jhettick@cdc.gov RI Hettick, Justin/E-9955-2010 NR 47 TC 6 Z9 6 U1 0 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 USA SN 0097-6156 BN 978-0-8412-2612-8 J9 ACS SYM SER JI ACS Symp. Ser. PY 2011 VL 1065 BP 35 EP 50 PG 16 WC Chemistry, Analytical; Microbiology SC Chemistry; Microbiology GA BAS36 UT WOS:000305357700003 ER PT S AU Barr, JR Kalb, SR Pirkle, JL AF Barr, John R. Kalb, Suzanne R. Pirkle, James L. BE Fenselau, C Demirev, P TI Detection, Differentiation and Subtyping of Botulinum Neurotoxins in Clinical Samples with Mass Spectrometry SO RAPID CHARACTERIZATION OF MICROORGANISMS BY MASS SPECTROMETRY SE ACS Symposium Series LA English DT Proceedings Paper CT 238th National Meeting of the American-Chemical-Society (ACS)/American-Chemical-Society (ACS) Symposium on Emerging Contaminants, Pharmaceuticals and Personal Care Products (PPCPs), and Organohalogens in Wastewater and Municipal Biosolids CY AUG 16-20, 2009 CL Washington, DC SP Amer Chem Soc, Div Chem Toxicol, Amer Chem Soc, Env Chem Inc ID CLOSTRIDIUM-BOTULINUM; NEUROTRANSMITTER RELEASE; B NEUROTOXIN; PROTEOLYTIC CLEAVAGE; ENDOPEP-MS; SEROTYPE-A; TOXIN; SNAP-25; IDENTIFICATION; TETANUS AB Botulinum neurotoxins (BoNTs) are the most toxic substances known to man and are the etiologic agents responsible for the deadly disease botulism. To provide a means of assessing exposure to BoNTs, we have developed the Endopep-MS method, which can detect and differentiate BoNTs in clinical and food samples. The method involves extracting the toxin with high affinity antibodies that are selective for only one of the BoNT serotypes; cleavage of synthetic peptides according to the specific enzymatic activity for each of the BoNT serotypes; and selectively detecting the toxin-dependent peptides by using high resolution matrix-assisted laserdesorption ionization time-of-flight mass spectrometry. We can achieve limits of detection lower than that of the mouse bioassay, the historic standard, in clinical samples with BoNT/A, /B, /E, and /F, the four serotypes typically associated with human cases of botulism. We discuss the application of the method with two examples: an outbreak of botulism from hot dog chili sauce and botulism in Mississipi catfish. We have also added proteomic analysis to identify BoNT subtypes and strains allowing epidemiologists to quickly assess possible similarities and differences between concurrent botulism outbreaks. C1 [Barr, John R.; Kalb, Suzanne R.; Pirkle, James L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. RP Barr, JR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM jbarr@cdc.gov NR 36 TC 1 Z9 1 U1 0 U2 3 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 SIXTEENTH ST NW, WASHINGTON, DC 20036 USA SN 0097-6156 BN 978-0-8412-2612-8 J9 ACS SYM SER JI ACS Symp. Ser. PY 2011 VL 1065 BP 83 EP 97 PG 15 WC Chemistry, Analytical; Microbiology SC Chemistry; Microbiology GA BAS36 UT WOS:000305357700006 ER PT S AU Bern, C Martin, DL Gilman, RH AF Bern, Caryn Martin, Diana L. Gilman, Robert H. BE Weiss, LM Tanowitz, HB Kirchhoff, LV TI Acute and Congenital Chagas Disease SO ADVANCES IN PARASITOLOGY, VOL 75: CHAGAS DISEASE, PT A SE Advances in Parasitology LA English DT Review; Book Chapter ID TRYPANOSOMA-CRUZI INFECTION; POLYMERASE-CHAIN-REACTION; RAPID IMMUNOCHROMATOGRAPHIC ASSAY; EXCRETED-SECRETED ANTIGENS; ACUTE-PHASE ANTIGEN; UNITED-STATES; ENDEMIC AREA; NONENDEMIC AREA; KINETOPLAST DNA; EARLY-DIAGNOSIS AB The acute phase of Chagas disease lasts 4-8 weeks and is characterized by microscopically detectable parasitaemia. Symptoms are usually mild with severe acute disease occurring in less than 1% of patients. Orally transmitted Trypanosoma cruzi outbreaks can have more severe acute morbidity and higher mortality than vector-borne infection. Congenital T. cruzi infection occurs in 1-10% of infants of infected mothers. Most congenital infections are asymptomatic or cause non-specific signs, requiring laboratory screening for detection. A small proportion of congenital infections cause severe morbidity with hepatosplenomegaly, anaemia, meningoencephalitis and/or respiratory insufficiency, with an associated high mortality. Infected infants are presumed to carry the same 20-30% lifetime risk of cardiac or gastrointestinal disease as other infected individuals. Most control programs in Latin America employ prenatal serological screening followed by microscopic examination of cord blood from infants of seropositive mothers. Recent data confirm that polymerase chain reaction (PCR) is more sensitive and detects congenital infections earlier than conventional techniques. For infants not diagnosed at birth, conventional serology is recommended at at 6 to 9 months of age. In programs that have been evaluated, less than 20% of at risk infants completed all steps of the screening algorithm. A sensitive, specific and practical screening test for newborns is needed to enable Chagas disease to be added to newborn screening programs. C1 [Bern, Caryn; Martin, Diana L.] Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. [Gilman, Robert H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Bern, C (reprint author), Ctr Dis Control & Prevent, Parasit Dis Branch, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. NR 137 TC 28 Z9 28 U1 0 U2 12 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0065-308X BN 978-0-12-385863-4 J9 ADV PARASIT JI Adv.Parasitol. PY 2011 VL 75 BP 19 EP 47 DI 10.1016/B978-0-12-385863-4.00002-2 PG 29 WC Parasitology SC Parasitology GA BZX50 UT WOS:000303216500002 PM 21820550 ER PT J AU De-Regil, LM Jefferds, MED Sylvetsky, AC Dowswell, T AF De-Regil, Luz Maria Jefferds, Maria Elena D. Sylvetsky, Allison C. Dowswell, Therese TI Intermittent iron supplementation for improving nutrition and development in children under 12 years of age SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID FOLIC-ACID SUPPLEMENTATION; MULTIPLE MICRONUTRIENT SUPPLEMENTATION; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; ADOLESCENT GIRLS; BANGLADESHI INFANTS; SCHOOL GIRLS; PRESCHOOL-CHILDREN; WESTERN KENYA; FERRITIN CONCENTRATIONS AB Background Approximately 600 million children of preschool and school age are anaemic worldwide. It is estimated that half of the cases are due to iron deficiency. Consequences of iron deficiency anaemia during childhood include growth retardation, reduced school achievement, impaired motor and cognitive development, and increased morbidity and mortality. The provision of daily iron supplements is a widely used strategy for improving iron status in children but its effectiveness has been limited due to its side effects, which can include nausea, constipation or staining of the teeth. As a consequence, intermittent iron supplementation (one, two or three times a week on nonconsecutive days) has been proposed as an effective and safer alternative to daily supplementation. Objectives To assess the effects of intermittent iron supplementation, alone or in combination with other vitamins and minerals, on nutritional and developmental outcomes in children from birth to 12 years of age compared with a placebo, no intervention or daily supplementation. Search methods We searched the following databases on 24 May 2011: CENTRAL (2011, Issue 2), MEDLINE (1948 to May week 2, 2011), EMBASE (1980 to 2011 Week 20), CINAHL (1937 to current), POPLINE (all available years) and WHO International Clinical Trials Registry Platform (ICTRP). On 29 June 2011 we searched all available years in the following databases: SCIELO, LILACS, IBECS and IMBIOMED. We also contacted relevant organisations (on 3 July 2011) to identify ongoing and unpublished studies. Selection criteria Randomised and quasi-randomised trials with either individual or cluster randomisation. Participants were children under the age of 12 years at the time of intervention with no specific health problems. The intervention assessed was intermittent iron supplementation compared with a placebo, no intervention or daily supplementation. Data collection and analysis Two authors independently assessed the eligibility of studies against the inclusion criteria, extracted data from included studies and assessed the risk of bias of the included studies. Main results We included 33 trials, involving 13,114 children (similar to 49% females) from 20 countries in Latin America, Africa and Asia. The methodological quality of the trials was mixed. Nineteen trials evaluated intermittent iron supplementation versus no intervention or a placebo and 21 studies evaluated intermittent versus daily iron supplementation. Some of these trials contributed data to both comparisons. Iron alone was provided in most of the trials. Fifteen studies included children younger than 60 months; 11 trials included children 60 months and older, and seven studies included children in both age categories. One trial included exclusively females. Seven trials included only anaemic children; three studies assessed only non-anaemic children, and in the rest the baseline prevalence of anaemia ranged from 15% to 90%. In comparison with receiving no intervention or a placebo, children receiving iron supplements intermittently have a lower risk of anaemia (average risk ratio (RR) 0.51, 95% confidence interval (CI) 0.37 to 0.72, ten studies) and iron deficiency (RR 0.24, 95% CI 0.06 to 0.91, three studies) and have higher haemoglobin (mean difference (MD) 5.20 g/L, 95% CI 2.51 to 7.88, 19 studies) and ferritin concentrations (MD 14.17 mu g/L, 95% CI 3.53 to 24.81, five studies). Intermittent supplementation was as effective as daily supplementation in improving haemoglobin (MD -0.60 g/L, 95% CI -1.54 to 0.35, 19 studies) and ferritin concentrations (MD -4.19 mu g/L, 95% CI -9.42 to 1.05, 10 studies), but increased the risk of anaemia in comparison with daily iron supplementation (RR 1.23, 95% CI 1.04 to1.47, six studies). Data on adherence were scarce and it tended to be higher among those children receiving intermittent supplementation, although this result was not statistically significant. We did not identify any differential effect of the type of intermittent supplementation regimen (one, two or three times a week), the total weekly dose of elemental iron, the nutrient composition, whether recipients were male or female or the length of the intervention. Authors' conclusions Intermittent iron supplementation is efficacious to improve haemoglobin concentrations and reduce the risk of having anaemia or iron deficiency in children younger than 12 years of age when compared with a placebo or no intervention, but it is less effective than daily supplementation to prevent or control anaemia. Intermittent supplementation may be a viable public health intervention in settings where daily supplementation has failed or has not been implemented. Information on mortality, morbidity, developmental outcomes and side effects, however, is still lacking. C1 [De-Regil, Luz Maria] WHO, Dept Nutr Hlth & Dev, Micronutrients Unit, CH-1211 Geneva, Switzerland. [Jefferds, Maria Elena D.] Ctr Dis Control & Prevent, Int Micronutrient Malnutr Prevent & Control Progr, Nutr Branch, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Sylvetsky, Allison C.] Emory Univ, Grad Div Biol & Biomed Sci, Atlanta, GA 30322 USA. [Dowswell, Therese] Univ Liverpool, Dept Womens & Childrens Hlth, Cochrane Pregnancy & Childbirth Grp, Liverpool L69 3BX, Merseyside, England. RP De-Regil, LM (reprint author), WHO, Dept Nutr Hlth & Dev, Micronutrients Unit, 20 Ave Appia, CH-1211 Geneva, Switzerland. EM deregillu@who.int FU Government of Luxembourg; Centers for Disease Control and Prevention (CDC), Division of Nutrition, Physical Activity, and Obesity, USA; Micronutrients Unit, Department of Nutrition for Health and Development, World Health Organization, Switzerland; Government of Luxembourg, Luxembourg FX Internal sources; Centers for Disease Control and Prevention (CDC), Division of Nutrition, Physical Activity, and Obesity, USA.; Micronutrients Unit, Department of Nutrition for Health and Development, World Health Organization, Switzerland.; External sources; Government of Luxembourg, Luxembourg.; WHO acknowledges the Government of Luxembourg for their financial support to the Micronutrients Unit for conducting systematic reviews on micronutrient interventions NR 124 TC 16 Z9 16 U1 4 U2 22 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2011 IS 12 AR CD009085 DI 10.1002/14651858.CD009085.pub2 PG 271 WC Medicine, General & Internal SC General & Internal Medicine GA 901BV UT WOS:000300937600085 PM 22161444 ER PT J AU Earl, AM Desjardins, CA Fitzgerald, MG Arachchi, HM Zeng, QD Mehta, T Griggs, A Birren, BW Toney, NC Carr, J Posey, J Butler, WR AF Earl, Ashlee M. Desjardins, Christopher A. Fitzgerald, Michael G. Arachchi, Harindra M. Zeng, Qiandong Mehta, Teena Griggs, Allison Birren, Bruce W. Toney, Nadege C. Carr, Janice Posey, James Butler, W. Ray TI High quality draft genome sequence of Segniliparus rugosus CDC 945(T)= (ATCC BAA-974(T)) SO STANDARDS IN GENOMIC SCIENCES LA English DT Article DE Segniliparaceae; genome sequencing; Human Microbiome Project ID RNA GENES; PROPOSAL; ACTINOBACTERIA; IDENTIFICATION; BACTERIA; PROJECT; UPDATE; SYSTEM; NOV; 16S AB Segniliparus rugosus represents one of two species in the genus Segniliparus, the sole genus in the family Segniliparaceae. A unique and interesting feature of this family is the presence of extremely long carbon-chain length mycolic acids bound in the cell wall. S. rugosus is also a medically important species because it is an opportunistic pathogen associated with mammalian lung disease. This report represents the second species in the genus to have its genome sequenced. The 3,567,567 bp long genome with 3,516 protein-coding and 49 RNA genes is part of the NIH Roadmap for Medical Research, Human Microbiome Project. C1 [Earl, Ashlee M.; Desjardins, Christopher A.; Fitzgerald, Michael G.; Arachchi, Harindra M.; Zeng, Qiandong; Mehta, Teena; Griggs, Allison; Birren, Bruce W.] Broad Inst MIT & Harvard, Genome Sequencing & Anal Program, Cambridge Ctr 7, Cambridge, MA USA. [Posey, James; Butler, W. Ray] Ctr Dis Control & Prevent, Div TB Eliminat, Branch Lab, Atlanta, GA USA. [Toney, Nadege C.; Carr, Janice] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Clin & Environm Microbiol Branch, Atlanta, GA USA. RP Earl, AM (reprint author), Broad Inst MIT & Harvard, Genome Sequencing & Anal Program, Cambridge Ctr 7, Cambridge, MA USA. OI Earl, Ashlee/0000-0001-7857-9145 FU NIH [HHSN272200900017C, U54-HG004969] FX The authors gratefully acknowledge the Broad Genome Sequencing Platform, Lucia Alvarado-Balderrama for data submission and Susanna G. Hamilton for project management. We also acknowledge NIH for funding this project with grants to the Broad Institute (grants HHSN272200900017C and U54-HG004969). NR 30 TC 1 Z9 1 U1 0 U2 5 PU GENOMIC STAND CONSORT PI EAST LANSING PA MICHIGAN STATE UNIV, GEEO GARRITY, DEPT MICROBIOL, 6162 BIOMED & PHYS SCI BLDG, EAST LANSING, MI 48824 USA SN 1944-3277 J9 STAND GENOMIC SCI JI Stand. Genomic Sci. PY 2011 VL 5 IS 3 BP 389 EP 397 DI 10.4056/sigs.2255041 PG 9 WC Genetics & Heredity; Microbiology SC Genetics & Heredity; Microbiology GA 893RR UT WOS:000300373600012 PM 22675588 ER PT J AU Johnson, BJB AF Johnson, Barbara J. B. BE Halperin, JJ TI Laboratory Diagnostic Testing for Borrelia burgdorferi Infection SO LYME DISEASE: AN EVIDENCE-BASED APPROACH SE Advances in Molecular and Cellular Microbiology LA English DT Article; Book Chapter ID EARLY LYME-DISEASE; LINKED-IMMUNOSORBENT-ASSAY; POLYMERASE-CHAIN-REACTION; SPIELMANII SP-NOV; SENSU-LATO; ANTIBODY-RESPONSES; SEROLOGIC TESTS; UNITED-STATES; SERODIAGNOSIS; ARTHRITIS C1 Ctr Dis Control & Prevent CDC, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. RP Johnson, BJB (reprint author), Ctr Dis Control & Prevent CDC, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. NR 66 TC 13 Z9 13 U1 0 U2 0 PU CABI PUBLISHING-C A B INT PI WALLINGFORD PA CABI PUBLISHING, WALLINGFORD 0X10 8DE, OXON, ENGLAND BN 978-1-84593-804-8 J9 ADV M C M PY 2011 IS 20 BP 73 EP 88 D2 10.1079/9781845938048.0000 PG 16 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA BXP04 UT WOS:000296588500005 ER PT J AU Mead, PS AF Mead, Paul S. BE Halperin, JJ TI Global Epidemiology of Borrelia burgdorferi Infections SO LYME DISEASE: AN EVIDENCE-BASED APPROACH SE Advances in Molecular and Cellular Microbiology LA English DT Article; Book Chapter ID LYME-DISEASE SPIROCHETE; SENSU-LATO; RISK-FACTORS; TRANSMISSION; EUROPE C1 Ctr Dis Control & Prevent CDC, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. RP Mead, PS (reprint author), Ctr Dis Control & Prevent CDC, Bacterial Dis Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. NR 32 TC 1 Z9 1 U1 0 U2 0 PU CABI PUBLISHING-C A B INT PI WALLINGFORD PA CABI PUBLISHING, WALLINGFORD 0X10 8DE, OXON, ENGLAND BN 978-1-84593-804-8 J9 ADV M C M PY 2011 IS 20 BP 100 EP 114 D2 10.1079/9781845938048.0000 PG 15 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA BXP04 UT WOS:000296588500007 ER PT J AU Kim, SY England, JL Sharma, JA Njoroge, T AF Kim, Shin Y. England, J. Lucinda Sharma, J. Andrea Njoroge, Terry TI Gestational Diabetes Mellitus and Risk of Childhood Overweight and Obesity in Offspring: A Systematic Review SO EXPERIMENTAL DIABETES RESEARCH LA English DT Review ID BODY-MASS INDEX; MATERNAL OBESITY; PREPREGNANCY OBESITY; BIRTH-WEIGHT; PREGNANCY; PREVALENCE; ASSOCIATION; MOTHERS; HYPERGLYCEMIA; OUTCOMES AB We systematically reviewed research examining the association between gestational diabetes (GDM) and childhood overweight and obesity. We identified studies from three sources: (1) a PubMed search of articles published between January 1990-January 2011, (2) reference lists of publications from the PubMed search, and (3) reference lists of review articles. We included studies that examined GDM separately from pregestational diabetes and childhood overweight or obesity defined as BMI > 85th or 95th percentile. A total of 12 studies were included in the systematic review. Crude odds ratios for the relationship between GDM and childhood overweight or obesity ranged from 0.7 to 6.3; in 8 studies, the associations were not statistically significant. In only 3 studies were results adjusted for any confounders; in the 2 that adjusted for prepregnancy obesity, the GDM and childhood overweight or obesity associations were attenuated and not statistically significant after adjustment. This paper demonstrates inconsistent evidence of an association between GDM and offspring overweight and obesity due to the methodological limitations of existing studies. Recommendations for future research are presented, which address methodological challenges. C1 [Kim, Shin Y.; England, J. Lucinda; Sharma, J. Andrea; Njoroge, Terry] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Kim, SY (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. EM skim1@cdc.gov NR 38 TC 44 Z9 44 U1 1 U2 12 PU HINDAWI PUBLISHING CORPORATION PI NEW YORK PA 410 PARK AVENUE, 15TH FLOOR, #287 PMB, NEW YORK, NY 10022 USA SN 1687-5214 J9 EXP DIABETES RES JI Exp. Diabetes Res. PY 2011 AR 541308 DI 10.1155/2011/541308 PG 9 WC Endocrinology & Metabolism; Medicine, Research & Experimental SC Endocrinology & Metabolism; Research & Experimental Medicine GA 845GG UT WOS:000296810400001 ER PT J AU Wang, D Ho, A Wu, X Hamilton, A Goodman, M Fleming, S Rao, C German, R Owen, J AF Wang, D. Ho, A. Wu, X. Hamilton, A. Goodman, M. Fleming, S. Rao, C. German, R. Owen, J. TI Results of Patterns of Care Study of Patients Treated with External Beam Radiotherapy for Prostate Cancer in 2004 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract C1 [Wang, D.] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA. [Ho, A.; Owen, J.] Amer Coll Radiol, Clin Res Ctr, Philadelphia, PA USA. [Wu, X.] LSU Hlth Sci Ctr, Louisiana Tumor Registry, New Orleans, LA USA. [Hamilton, A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Goodman, M.] Emory Univ, Dept Epidemiol, Rollins Sch Pub Hlth, Atlanta, GA 30322 USA. [Fleming, S.] Univ Kentucky, Coll Publ Hlth, Lexington, KY USA. [Rao, C.] NC Cent Canc Registry, Raleigh, NC USA. [German, R.] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PY 2011 VL 81 IS 2 SU S BP S561 EP S562 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA 840AX UT WOS:000296411701231 ER PT J AU Earley, M Chafin, D Mei, JV Cuthbert, CD AF Earley, M. Chafin, D. Mei, J., V Cuthbert, C. D. TI EVALUATION OF DRIED BLOOD SPOT QUALITY CONTROL MATERIALS FOR CYSTIC FIBROSIS MOLECULAR TESTS SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Earley, M.; Chafin, D.; Mei, J., V; Cuthbert, C. D.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PY 2011 SU 34 BP 363 EP 363 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 835YA UT WOS:000296071800494 ER PT J AU Kharrazi, M Graham, S Lorey, F Cordovado, SK Mueller, P AF Kharrazi, M. Graham, S. Lorey, F. Cordovado, S. K. Mueller, P. TI MORTALITY FROM CYSTIC FIBROSIS (CF) IN THE FIRST 30 MONTHS OF LIFE IN THE PERIOD BEFORE CF NEWBORN SCREENING IN CALIFORNIA SO PEDIATRIC PULMONOLOGY LA English DT Meeting Abstract C1 [Kharrazi, M.; Lorey, F.] Calif Dept Publ Hlth, Genet Dis Screening Program, Richmond, CA USA. [Graham, S.] Sequoia Fdn, La Jolla, CA USA. [Cordovado, S. K.; Mueller, P.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 8755-6863 J9 PEDIATR PULM JI Pediatr. Pulmonol. PY 2011 SU 34 BP 363 EP 363 PG 1 WC Pediatrics; Respiratory System SC Pediatrics; Respiratory System GA 835YA UT WOS:000296071800496 ER PT J AU Harris, LM Baur, C Donaldson, MS Lefebvre, RC Dugan, E Arayasirikul, S AF Harris, Linda M. Baur, Cynthia Donaldson, Molla S. Lefebvre, R. Craig Dugan, Emily Arayasirikul, Sean BE Thompson, TL Parrott, R Nussbaum, JF TI HEALTH COMMUNICATION AND HEALTH INFORMATION TECHNOLOGY Priority Issues, Policy Implications, and Research Opportunities for Healthy People 2020 SO ROUTLEDGE HANDBOOK OF HEALTH COMMUNICATION, 2ND EDITION SE Routledge Communications Series LA English DT Article; Book Chapter C1 [Harris, Linda M.] Off Secretary Hlth & Human Serv, Off Dis Prevent & Hlth Promot, Hlth Commun & E Hlth Team, Rockville, MD 20852 USA. [Harris, Linda M.] Natl Hlth Informat Ctr, Beirut, Lebanon. Concept Five Technol, Salt Lake City, UT USA. [Harris, Linda M.] Natl Business Grp Hlth, Family Hlth Programs, Washington, DC USA. [Baur, Cynthia] Ctr Dis Control & Prevent, Off Associate Director Commun, US Dept HHS, Atlanta, GA USA. [Baur, Cynthia] CDC, Div Hlth Commun & Mkt, Natl Ctr Hlth Mkt, Atlanta, GA 30333 USA. [Baur, Cynthia] Healthy People 2020 Hlth Commun & Hlth Informat T, Washington, DC USA. [Baur, Cynthia] HHS Workgrp Hlth Literacy, Rockville, MD USA. [Donaldson, Molla S.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA. [Donaldson, Molla S.] MSD Healthcare Consulting Group, Chevy Chase, MD USA. [Lefebvre, R. Craig] Publ Hlth Program, New York, NY USA. [Lefebvre, R. Craig] SocialShift, Sarasota, FL USA. [Dugan, Emily] Off Natl Coordinator Hlth Informat Technol, Washington, DC USA. [Arayasirikul, Sean] US Off Dis Prevent & Hlth Promot ODPHP, Rockville, MD USA. [Lefebvre, R. Craig] George Washington Univ, Washington, DC 20052 USA. [Lefebvre, R. Craig] Univ Maryland, College Pk, MD 20742 USA. [Lefebvre, R. Craig] Univ S Florida, Sch Publ Hlth, Tampa, FL 33620 USA. RP Harris, LM (reprint author), Off Secretary Hlth & Human Serv, Off Dis Prevent & Hlth Promot, Hlth Commun & E Hlth Team, Rockville, MD 20852 USA. NR 17 TC 1 Z9 1 U1 0 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-84606-3 J9 ROUTL COMMUN SER PY 2011 BP 482 EP 497 PG 16 WC Communication SC Communication GA BVV31 UT WOS:000292870800033 ER PT J AU De-Regil, LM Suchdev, PS Vist, GE Walleser, S Pena-Rosas, JP AF De-Regil, Luz Maria Suchdev, Parminder S. Vist, Gunn E. Walleser, Silke Pena-Rosas, Juan Pablo TI Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID PLACEBO-CONTROLLED TRIAL; VITAMIN-A SUPPLEMENTATION; CLUSTER-RANDOMIZED TRIAL; COMPLEMENTARY FOODS; YOUNG-CHILDREN; IRON-DEFICIENCY; PRESCHOOL-CHILDREN; CAMBODIAN INFANTS; DOUBLE-BLIND; RURAL HAITI AB Background Vitamin and mineral deficiencies, particularly those of iron, vitamin A and zinc, affect more than two billion people worldwide. Young children are highly vulnerable because of rapid growth and inadequate dietary practices. Micronutrient powders (MNP) are single-dose packets containing multiple vitamins and minerals in powder form that can be sprinkled onto any semi-solid food. The use of MNP for home or point-of-use fortification of complementary foods has been proposed as an intervention for improving micronutrient intake in children under two years of age. Objectives To assess the effects and safety of home (point-of-use) fortification of foods with multiple micronutrient powders on nutritional, health and developmental outcomes in children under two years of age. Search strategy We searched the following databases in February 2011: Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE (1948 to week 2 February 2011), EMBASE (1980 to Week 6 2011), CINAHL (1937 to current), CPCI-S (1990 to 19 February 2011), Science Citation Index (1970 to 19 February 2011), African Index Medicus (searched 23 February 2011), POPLINE (searched 21 February 2011), Clinical Trials.gov (searched 23 February 2011), mRCT (searched 23 February 2011), and World Health Organization International Clinical Trials Registry Platform (ICTRP) (searched 23 February 2011). We also contacted relevant organisations (25 January 2011) for the identification of ongoing and unpublished studies. Selection criteria We included randomised and quasi-randomised trials with either individual or cluster randomisation. Participants were children under the age of two years at the time of intervention, with no specific health problems. The intervention was consumption of food fortified at the point of use with multiple micronutrient powders formulated with at least iron, zinc and vitamin A compared with placebo, no intervention or the use of iron containing supplements, which is the standard practice. Data collection and analysis Two review authors independently assessed the eligibility of studies against the inclusion criteria, extracted data from included studies and assessed the risk of bias of the included studies. Main results We included eight trials (3748 participants) conducted in low income countries in Asia, Africa and the Caribbean, where anaemia is a public health problem. The interventions lasted between two and 12 months and the powder formulations contained between five and 15 nutrients. Six trials compared the use of MNP versus no intervention or a placebo and the other two compared the use of MNP versus daily iron drops. Most of the included trials were assessed as at low risk of bias. Home fortification with MNP reduced anaemia by 31% (six trials, RR 0.69; 95% CI 0.60 to 0.78) and iron deficiency by 51% (four trials, RR 0.49; 95% CI 0.35 to 0.67) in infants and young children when compared with no intervention or placebo, but we did not find an effect on growth. In comparison with daily iron supplementation, the use of MNP produced similar results on anaemia (one trial, RR 0.89; 95% CI 0.58 to 1.39) and haemoglobin concentrations (two trials, MD -2.36 g/L; 95% CI -10.30 to 5.58); however, given the limited amount of data these results should be interpreted cautiously. No deaths were reported in the trials and information on side effects and morbidity, including malaria, was scarce. It seems that the use of MNP is efficacious among infants and young children six to 23 months of age living in settings with different prevalences of anaemia and malaria endemicity, regardless of whether the intervention lasts two, six or 12 months or whether recipients are male or female. Authors' conclusions Home fortification of foods with multiple micronutrient powders is an effective intervention to reduce anaemia and iron deficiency in children six months to 23 months of age. The provision of MNP is better than no intervention or placebo and possibly comparable to commonly used daily iron supplementation. The benefits of this intervention as a child survival strategy or on developmental outcomes are unclear. Data on effects on malaria outcomes are lacking and further investigation of morbidity outcomes is needed. The micronutrient powders containing multiple nutrients are well accepted but adherence is variable and in some cases comparable to that achieved in infants and young children receiving standard iron supplements as drops or syrups. C1 [De-Regil, Luz Maria; Pena-Rosas, Juan Pablo] WHO, Dept Nutr Hlth & Dev, Micronutrients Unit, CH-1211 Geneva, Switzerland. [Suchdev, Parminder S.] Emory Univ, Nutr Branch, Ctr Dis Control & Prevent CDC, Atlanta, GA 30322 USA. [Vist, Gunn E.] Norwegian Knowledge Ctr Hlth Serv, Prevent Hlth Promot & Org Unit, Oslo, Norway. RP De-Regil, LM (reprint author), WHO, Dept Nutr Hlth & Dev, Micronutrients Unit, 20 Ave Appia, CH-1211 Geneva, Switzerland. EM deregillu@who.int RI Suchdev, Parmi/K-4851-2012; OI Pena-Rosas, Juan Pablo/0000-0002-6737-9831 FU editorial office of the Cochrane Developmental, Psychosocial and Learning Problems Group; Emory University, USA; US Centers for Disease Control and Prevention (CDC), Atlanta, GA; Micronutrients Unit, Department of Nutrition for Health and Development, World Health Organization, Switzerland; Micronutrient Initiative (MI), Canada; Micronutrient Initiative (MI); Global Alliance for Improved Nutrition (GAIN), Switzerland; Global Alliance for Improved Nutrition (GAIN) FX We would like to thank the trial authors and organizations who contributed additional data for this review. In addition, we would like to thank the staff at the editorial office of the Cochrane Developmental, Psychosocial and Learning Problems Group for their support in the preparation of this review and, in particular, Geraldine Macdonald and Laura MacDonald, as well as Margaret Anderson who helped with the search strategy.; Internal sources; Emory University, USA.; PS works as Assistant Professor of Pediatrics for Emory University and is partially funded by the US Centers for Disease Control and Prevention (CDC), Atlanta, GA; Micronutrients Unit, Department of Nutrition for Health and Development, World Health Organization, Switzerland.; External sources; Micronutrient Initiative (MI), Canada.; WHO acknowledges Micronutrient Initiative (MI) for their financial support to the Micronutrients Unit for conducting systematic reviews on micronutrients interventions.; Global Alliance for Improved Nutrition (GAIN), Switzerland.; WHO acknowledges the Global Alliance for Improved Nutrition (GAIN) for their financial support to the Micronutrients Unit for conducting systematic reviews on micronutrients interventions. NR 93 TC 31 Z9 33 U1 1 U2 18 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2011 IS 9 AR CD008959 DI 10.1002/14651858.CD008959.pub2 PG 86 WC Medicine, General & Internal SC General & Internal Medicine GA 817AH UT WOS:000294642700054 PM 21901727 ER PT J AU Gallo, MF Lopez, LM Grimes, DA Schulz, KF Helmerhorst, FM AF Gallo, Maria F. Lopez, Laureen M. Grimes, David A. Schulz, Kenneth F. Helmerhorst, Frans M. TI Combination contraceptives: effects on weight SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review DE Administration, Cutaneous; Body Weight [drug effects]; Contraceptive Agents, Female [administration & dosage; adverse effects]; Contraceptives, Oral, Combined [adverse effects]; Contraceptives, Oral, Hormonal [adverse effects]; Randomized Controlled Trials as Topic; Weight Gain; Female; Humans ID DOSE ORAL-CONTRACEPTIVES; 20 MU-G; G ETHINYL ESTRADIOL; RANDOMIZED-CONTROLLED-TRIAL; COMPARATIVE CLINICAL-TRIAL; 3 MG DROSPIRENONE; CYCLE CONTROL; G ETHINYLESTRADIOL; BODY-WEIGHT; VAGINAL RING AB Background Weight gain is often considered a side effect of combination hormonal contraceptives, and many women and clinicians believe that an association exists. Concern about weight gain can limit the use of this highly effective method of contraception by deterring the initiation of its use and causing early discontinuation among users. However, a causal relationship between combination contraceptives and weight gain has not been established. Objectives The aim of the review was to evaluate the potential association between combination contraceptive use and changes in weight. Search strategy We searched the computerized databases CENTRAL (The Cochrane Library), MEDLINE, POPLINE, EMBASE, and LILACS for studies of combination contraceptives, as well as ClinicalTrials.gov and International Clinical Trials Registry Platform (ICTRP). Searches were conducted from January to May 2011. We also wrote to known investigators and manufacturers to request information about other published or unpublished trials not discovered in our search. Selection criteria All English-language, randomized controlled trials were eligible if they had at least three treatment cycles and compared a combination contraceptive to a placebo or to a combination contraceptive that differed in drug, dosage, regimen, or study length. Data collection and analysis All titles and abstracts located in the literature searches were assessed. Data were entered and analyzed with RevMan. A second author verified the data entered. For continuous data, we calculated the mean difference and 95% confidence interval (CI) for the mean change in weight between baseline and post-treatment measurements using a fixed-effect model. For categorical data, such as the proportion of women who gained or lost more than a specified amount of weight, the Peto odds ratio with 95% CI was calculated. Main results We found 49 trials that met our inclusion criteria. The trials included 85 weight change comparisons for 52 distinct contraceptive pairs (or placebos). The four trials with a placebo or no intervention group did not find evidence supporting a causal association between combination oral contraceptives or a combination skin patch and weight change. Most comparisons of different combination contraceptives showed no substantial difference in weight. In addition, discontinuation of combination contraceptives because of weight change did not differ between groups where this was studied. Authors' conclusions Available evidence was insufficient to determine the effect of combination contraceptives on weight, but no large effect was evident. Trials to evaluate the link between combination contraceptives and weight change require a placebo or non-hormonal group to control for other factors, including changes in weight over time. C1 [Gallo, Maria F.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. [Schulz, Kenneth F.] UNC Sch Med, Res Triangle Pk, NC USA. [Helmerhorst, Frans M.] Leiden Univ, Med Ctr, Div Reprod Med, Leiden, Netherlands. [Helmerhorst, Frans M.] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands. RP Lopez, LM (reprint author), FHI 360,POB 13950, Res Triangle Pk, NC 27709 USA. EM llopez@fhi.org FU National Institute of Child Health and Human Development, USA; U.S. Agency for International Development, USA FX National Institute of Child Health and Human Development, USA.; U.S. Agency for International Development, USA. NR 103 TC 16 Z9 16 U1 3 U2 11 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2011 IS 9 AR CD003987 DI 10.1002/14651858.CD003987.pub4 PG 114 WC Medicine, General & Internal SC General & Internal Medicine GA 817AH UT WOS:000294642700014 PM 21901687 ER PT J AU Epping, JN AF Epping, Jacqueline N. BA Johnson, RA Beck, AM McCune, S BF Johnson, RA Beck, AM McCune, S TI Physical activity recommendations and dog walking SO HEALTH BENEFITS OF DOG WALKING FOR PEOPLE AND PETS: EVIDENCE AND CASE STUDIES SE New Directions in the Human-Animal Bond LA English DT Article; Book Chapter ID HEALTH; POPULATION; OWNERSHIP; BEHAVIOR; FITNESS; LIFE C1 Ctr Dis Control & Prevent, Phys Act & Hlth Branch, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. RP Epping, JN (reprint author), Ctr Dis Control & Prevent, Phys Act & Hlth Branch, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. NR 47 TC 2 Z9 2 U1 0 U2 2 PU PURDUE UNIV PRESS PI W LAFAYETTE PA SOUTH CAMPUS COURTS D, W LAFAYETTE, IN 47907 USA BN 978-1-55753-582-5 J9 NEW DIR HUM-ANIM BON PY 2011 BP 7 EP 24 PG 18 WC Public, Environmental & Occupational Health; Veterinary Sciences SC Public, Environmental & Occupational Health; Veterinary Sciences GA BWJ18 UT WOS:000294004000003 ER PT B AU DeGue, S AF DeGue, Sarah BE Blazina, C Boyraz, G ShenMiller, D TI A Triad of Family Violence: Examining Overlap in the Abuse of Children, Partners, and Pets SO PSYCHOLOGY OF THE HUMAN-ANIMAL BOND: A RESOURCE FOR CLINICIANS AND RESEARCHERS LA English DT Article; Book Chapter ID ANIMAL CRUELTY; DOMESTIC VIOLENCE; RISK-FACTORS; CONFLICT; EMPATHY; WOMEN; COOCCURRENCE; ASSOCIATIONS; PREVENTION; CHILDHOOD C1 Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. RP DeGue, S (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. EM sdegue@cdc.gov NR 61 TC 3 Z9 3 U1 1 U2 5 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-1-4419-9760-9 PY 2011 BP 245 EP 262 DI 10.1007/978-1-4419-9761-6_14 D2 10.1007/978-1-4419-9761-6 PG 18 WC Psychology, Clinical; Psychology SC Psychology GA BVX93 UT WOS:000293101000014 ER PT J AU Satcher, D Rachel, SA AF Satcher, David Rachel, Sharon A. BE Parker, R Sommer, M TI Eliminating Global Health Inequities Bridging the Gap SO ROUTLEDGE HANDBOOK OF GLOBAL PUBLIC HEALTH LA English DT Article; Book Chapter ID WOMEN; GIRLS C1 [Satcher, David; Rachel, Sharon A.] Morehouse Sch Med, Satcher Hlth Leadership Inst, Ctr Excellence Sexual Hlth, Atlanta, GA 30310 USA. [Satcher, David] Morehouse Sch Med, Ctr Excellence Hlth Dispar, Atlanta, GA USA. [Satcher, David] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Satcher, D (reprint author), Morehouse Sch Med, Satcher Hlth Leadership Inst, Ctr Excellence Sexual Hlth, Atlanta, GA 30310 USA. NR 23 TC 0 Z9 0 U1 0 U2 1 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-203-83272-1 PY 2011 BP 80 EP 87 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BVZ61 UT WOS:000293213300008 ER PT J AU Angira, F Peters, PJ Polle, N Zeh, C Masaba, R Borkowf, CB Oyaro, B Omolo, P Ogindo, P Ndivo, R Lando, R Fowler, MG Weidle, PJ Thomas, TK AF Angira, F. Peters, P. J. Polle, N. Zeh, C. Masaba, R. Borkowf, C. B. Oyaro, B. Omolo, P. Ogindo, P. Ndivo, R. Lando, R. Fowler, M. G. Weidle, P. J. Thomas, T. K. TI Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya SO ANTIVIRAL THERAPY LA English DT Meeting Abstract C1 [Angira, F.; Polle, N.; Oyaro, B.; Omolo, P.; Ogindo, P.; Ndivo, R.; Lando, R.] Kenya Govt Med Res Ctr, Kisumu, Kenya. [Peters, P. J.; Borkowf, C. B.; Weidle, P. J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Polle, N.] Minist Hlth, Nairobi, Kenya. [Zeh, C.; Masaba, R.; Thomas, T. K.] Ctr Dis Control & Prevent, Kisumu, Kenya. [Fowler, M. G.] Makerere Univ Johns Hopkins Univ Res Collaborat, Kampala, Uganda. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2011 VL 16 SU 2 BP A59 EP A59 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 813OD UT WOS:000294375900067 ER PT J AU Camacho-Gonzalez, AF Tong, T Wheeling, J Nesheim, S Bohannon, B Chakraborty, R Greenbaum, L Emmanuel, P Rivera, D Dominguez, K AF Camacho-Gonzalez, A. F. Tong, T. Wheeling, J. Nesheim, S. Bohannon, B. Chakraborty, R. Greenbaum, L. Emmanuel, P. Rivera, D. Dominguez, K. CA LEGACY Consortium TI Renal disease in HIV-infected children and adolescents participating in the LEGACY cohort, United States, 2001-2006 SO ANTIVIRAL THERAPY LA English DT Meeting Abstract C1 [Camacho-Gonzalez, A. F.; Chakraborty, R.; Greenbaum, L.] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Atlanta, GA USA. [Camacho-Gonzalez, A. F.; Nesheim, S.; Bohannon, B.; Dominguez, K.; LEGACY Consortium] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Epidemiol Branch, Atlanta, GA USA. [Tong, T.; Wheeling, J.] Northrop Grumman Inc, Atlanta, GA USA. [Emmanuel, P.] Univ S Florida, Tampa, FL USA. [Rivera, D.] Univ Miami, Leonard M Miller Sch Med, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2011 VL 16 SU 2 BP A15 EP A16 PG 2 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 813OD UT WOS:000294375900019 ER PT J AU Dobard, C Sharma, S Cong, M Lipscomb, J West, R Holder, A Pau, CP Smith, J Novembre, F Garcia-Lerma, JG Heneine, W AF Dobard, C. Sharma, S. Cong, M. Lipscomb, J. West, R. Holder, A. Pau, C-P Smith, J. Novembre, F. Garcia-Lerma, J. G. Heneine, W. TI Vaginal tenofovir (TFV) gel is effective against transmission of TFV-resistant virus in macaques SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies CY JUN 07-11, 2011 CL Los Cabos, MEXICO C1 [Dobard, C.; Sharma, S.; Cong, M.; Lipscomb, J.; West, R.; Holder, A.; Pau, C-P; Smith, J.; Novembre, F.; Garcia-Lerma, J. G.; Heneine, W.] CDC, Atlanta, GA 30333 USA. [Dobard, C.; Sharma, S.; Cong, M.; Lipscomb, J.; West, R.; Holder, A.; Pau, C-P; Smith, J.; Novembre, F.; Garcia-Lerma, J. G.; Heneine, W.] Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2011 VL 16 IS 4 BP A39 EP A39 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 813OB UT WOS:000294375700055 ER PT J AU Wadonda, N Moyo, K van Oosterhout, JJ Aberle-Grasse, J Warne, T Chilima, B Banda, R Porter, C Weigel, R Kagoli, M Hosseinipour, M Jordan, MR Demby, A Kabuluzi, S Chimbwandira, F Yang, C Bennett, DE AF Wadonda, N. Moyo, K. van Oosterhout, J. J. Aberle-Grasse, J. Warne, T. Chilima, B. Banda, R. Porter, C. Weigel, R. Kagoli, M. Hosseinipour, M. Jordan, M. R. Demby, A. Kabuluzi, S. Chimbwandira, F. Yang, C. Bennett, D. E. TI Prevalence of HIV drug resistance before treatment initiation and at 12 months after treatment initiation in four sites in the Malawi ART programme SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies CY JUN 07-11, 2011 CL Los Cabos, MEXICO C1 [Wadonda, N.; Moyo, K.; Chilima, B.; Kagoli, M.; Kabuluzi, S.; Chimbwandira, F.] Minist Hlth, Lilongwe, Malawi. Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA. [van Oosterhout, J. J.] Coll Med, Blantyre, Malawi. [Banda, R.] World Hlth Org, Geneva, Switzerland. [Aberle-Grasse, J.; Warne, T.; Demby, A.; Yang, C.; Bennett, D. E.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Porter, C.] Howard Univ, Tech Support Project, Washington, DC USA. [Hosseinipour, M.] UNC Project, Lilongwe, Malawi. [Jordan, M. R.] Tufts Univ, Sch Med, Boston, MA 02111 USA. RI Yang, Chunfu/G-6890-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2011 VL 16 IS 4 BP A131 EP A131 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 813OB UT WOS:000294375700126 ER PT J AU Wagner, BG Garcia-Lerma, JG Blower, S AF Wagner, B. G. Garcia-Lerma, J. G. Blower, S. TI HIV drug resistance mutations: identifying variants most likely to generate large transmission clusters SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies CY JUN 07-11, 2011 CL Los Cabos, MEXICO C1 [Wagner, B. G.; Blower, S.] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Biomed Modeling, Los Angeles, CA 90095 USA. [Garcia-Lerma, J. G.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Lab Branch, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2011 VL 16 IS 4 BP A147 EP A147 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 813OB UT WOS:000294375700139 ER PT J AU Wei, X Smith, AJ Forrest, DW Cardenas, GA Beck, DW LaLota, M Metsch, LR Sionean, C Owen, SM Johnson, JA AF Wei, X. Smith, A. J. Forrest, D. W. Cardenas, G. A. Beck, D. W. LaLota, M. Metsch, L. R. Sionean, C. Owen, S. M. Johnson, J. A. TI HIV resistance mutation analysis of dried blood spots collected in a south Florida field study of risk groups, 2007-2009 SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies CY JUN 07-11, 2011 CL Los Cabos, MEXICO C1 [Wei, X.; Smith, A. J.; Sionean, C.; Owen, S. M.; Johnson, J. A.] CDC, Atlanta, GA 30333 USA. [Forrest, D. W.; Metsch, L. R.] U Miami, Miami, FL USA. [Cardenas, G. A.; Beck, D. W.; LaLota, M.] Florida Dept Hlth & Rehabil Serv, Tallahassee, FL 32399 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2011 VL 16 IS 4 BP A153 EP A153 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 813OB UT WOS:000294375700145 ER PT J AU Rosenbluth, B Whitaker, DJ Valle, LA Ball, B AF Rosenbluth, Barri Whitaker, Daniel J. Valle, Linda Anne Ball, Barbara BE Espelage, DL Swearer, SM TI INTEGRATING STRATEGIES FOR BULLYING, SEXUAL HARASSMENT, AND DATING VIOLENCE PREVENTION The Expect Respect Elementary School Project SO BULLYING IN NORTH AMERICAN SCHOOLS, SEOND EDITION LA English DT Article; Book Chapter ID ADOLESCENT GIRLS; WEIGHT CONTROL C1 [Rosenbluth, Barri] SafePl Expect Respect Program, Austin, TX USA. [Whitaker, Daniel J.] Georgia State Univ, Atlanta, GA 30303 USA. [Valle, Linda Anne] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Rosenbluth, B (reprint author), SafePl Expect Respect Program, Austin, TX USA. NR 23 TC 0 Z9 0 U1 3 U2 4 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-415-80654-1 PY 2011 BP 241 EP 251 PG 11 WC Education & Educational Research SC Education & Educational Research GA BUH52 UT WOS:000289288900018 ER PT J AU Covello, VT AF Covello, Vincent T. BE Brenner, GH Bush, DH Moses, J TI Principles of Risk Communication SO CREATING SPIRITUAL AND PSYCHOLOGICAL RESILIENCE: INTEGRATING CARE IN DISASTER RELIEF WORK LA English DT Article; Book Chapter ID PERCEPTION C1 [Covello, Vincent T.] Ctr Risk Commun, New York, NY 10022 USA. [Covello, Vincent T.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Covello, Vincent T.] US EPA, Washington, DC USA. [Covello, Vincent T.] Columbia Univ, Fac Med, New York, NY USA. RP Covello, VT (reprint author), Ctr Risk Commun, New York, NY 10022 USA. NR 37 TC 0 Z9 0 U1 0 U2 2 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-20386-953-6 PY 2011 BP 39 EP 74 PG 36 WC Psychology, Clinical; Social Work; Religion SC Psychology; Social Work; Religion GA BUP96 UT WOS:000290017600006 ER PT J AU Smith, RP Taylor, J Larkin, GL North, CS Ryan, D Holmes, A AF Smith, Rebecca P. Taylor, Julie Larkin, Gregory Luke North, Carol S. Ryan, Diane Holmes, Anastasia BE Brenner, GH Bush, DH Moses, J TI On Reentering the Chapel Models for Collaborations Between Psychiatrists, Communities of Faith, and Faith-Based Providers After Hurricane Katrina SO CREATING SPIRITUAL AND PSYCHOLOGICAL RESILIENCE: INTEGRATING CARE IN DISASTER RELIEF WORK LA English DT Article; Book Chapter C1 [Smith, Rebecca P.] Mt Sinai Med Ctr, New York, NY 10029 USA. [Smith, Rebecca P.] NIMH, Bethesda, MD USA. [North, Carol S.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. [North, Carol S.] VA N Texas Hlth Care Syst, Program Trauma & Disaster, Dallas, TX USA. [Larkin, Gregory Luke] Yale Univ, Sch Med, New Haven, CT 06520 USA. [Larkin, Gregory Luke] CDC, Natl Ctr Injury Control & Prevent, Atlanta, GA 30333 USA. [Larkin, Gregory Luke] CDC, NIMH, Atlanta, GA 30333 USA. [Larkin, Gregory Luke] CDC, SAMHSA, Atlanta, GA 30333 USA. [Larkin, Gregory Luke] Guys & St Thomas NHS Trust, London, England. [Larkin, Gregory Luke] British Council, Guys St Thomas Kings Sch Med, London, England. RP Smith, RP (reprint author), Mt Sinai Med Ctr, New York, NY 10029 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE PI LONDON PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND BN 978-0-20386-953-6 PY 2011 BP 125 EP 132 PG 8 WC Psychology, Clinical; Social Work; Religion SC Psychology; Social Work; Religion GA BUP96 UT WOS:000290017600011 ER PT B AU Mensah, GA Glover, MJ AF Mensah, George A. Glover, Maleeka J. BE Williams, RA TI Epidemiologic Profiles of Racial and Ethnic Disparities in Health and Health Care SO HEALTHCARE DISPARITIES AT THE CROSSROADS WITH HEALTHCARE REFORM LA English DT Article; Book Chapter DE Chronic diseases; Mortality; Life expectancy; Race and ethnicity; Healthy People 2010; Eight Americas Study; Risk factor data; Quality of life ID UNITED-STATES; CARDIOVASCULAR-DISEASE; AFRICAN-AMERICANS; MISCLASSIFICATION; MORTALITY; INDIANS; NATIVES; EQUITY; RACE AB Disparities in health status and healthcare delivery have been documented in the USA throughout most of the last two centuries (Ewbank, Milbank Q 65 (Suppl 1): 100-128, 1987; Krieger, Int J Health Serv 17(2):259-278, 1987; Kochanek et al., Am J Public Health 84(6):938-944, 1994). More recently, the Institute of Medicine (Unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: National Academies Press, 2003) and the Agency for Healthcare Research and Quality (AHRQ) (U.S. Department of Health and Human Services, National Healthcare Disparities Report. http://www.ahrq.gov/ qual/nhdr05/nhdr05.pdf, Accessed on 1 July 2006) have confirmed that disparities are pervasive and that improvements are possible. Eliminating these disparities is one of the two overarching goals of the Healthy People 2010 national public health agenda. In this endeavor, the availability of reliable, population-based indicators of disparities can be crucial for assessing the magnitude, trends, and impact of interventions designed to reduce and eventually eliminate disparities. These indicators can also serve to inform policy and program development, help set priorities, and assist in identifying areas where additional research is needed. In this chapter, we use published data from national health statistics and surveillance reports to present epidemiologic profiles of established disparities in health status and health care for population subgroups defined by race and ethnicity. We first introduce the categories of race and ethnicity and define the concept of disparities in health care. The distribution and demographic changes in the racial and ethnic categories are presented along with current projections to the year 2050. Selected examples of the Healthy People 2010 objectives and targets for elimination of disparities are discussed. Current data and trends on life expectancy, risk factor and chronic disease prevalence, other morbidity, mortality, access to care, and quality of care are then presented. The need for continued refinement of conceptual and methodological issues in the collection of healthcare data by race and ethnicity is also emphasized. The chapter concludes with caveats on the challenges and limitations in the interpretation of racial and ethnic comparisons in the healthcare setting and future opportunities for the development and implementation of programs and strategies to eliminate these disparities in health and health care. C1 [Mensah, George A.] Pepsico Global Res & Dev, Heart Hlth & Global Hlth Policy, Purchase, NY 10755 USA. [Mensah, George A.] CDC, Atlanta, GA 30333 USA. [Mensah, George A.] Natl Ctr Chron Dis Prevent & Hlth Promot, Washington, DC USA. [Glover, Maleeka J.] US PHS, Atlanta, GA USA. [Glover, Maleeka J.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Mensah, GA (reprint author), Pepsico Global Res & Dev, Heart Hlth & Global Hlth Policy, Purchase, NY 10755 USA. EM george.mensah@pepsico.com NR 38 TC 0 Z9 0 U1 1 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-7135-7 PY 2011 BP 23 EP 39 DI 10.1007/978-1-4419-7136-4_3 D2 10.1007/978-1-4419-7136-4 PG 17 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA BUN82 UT WOS:000289865100003 ER PT B AU Lollar, DJ Andresen, EM AF Lollar, Donald J. Andresen, Elena M. BE Lollar, DJ Andresen, EM TI Public Health Perspectives on Disability Epidemiology to Ethics and Beyond Introduction SO PUBLIC HEALTH PERSPECTIVES ON DISABILITY: EPIDEMIOLOGY TO ETHICS AND BEYOND LA English DT Editorial Material; Book Chapter C1 [Lollar, Donald J.] Oregon Hlth & Sci Univ, Div Hlth Serv, Portland, OR 97201 USA. [Lollar, Donald J.] US Ctr Dis Control & Prevent CDC, NCBDDD, Atlanta, GA USA. [Andresen, Elena M.] Univ Florida, Publ Heath & Hlth Profess, Dept Epidemiol & Biostat, Gainesville, FL 32611 USA. RP Lollar, DJ (reprint author), Oregon Hlth & Sci Univ, Div Hlth Serv, Portland, OR 97201 USA. NR 26 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-7340-5 PY 2011 BP 3 EP 12 DI 10.1007/978-1-4419-7341-2_1 D2 10.1007/978-1-4419-7341-2 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BSL54 UT WOS:000284860100003 ER PT B AU Anderson, RN AF Anderson, Robert N. BE Rogers, RG Crimmins, EM TI Coding and Classifying Causes of Death: Trends and International Differences SO INTERNATIONAL HANDBOOK OF ADULT MORTALITY SE International Handbooks of Population LA English DT Article; Book Chapter ID CAUSE-OF-DEATH; DATA-DERIVED ALGORITHMS; MORTALITY STATISTICS; MULTIPLE CAUSES; VERBAL AUTOPSY; UNITED-STATES; CERTIFICATE DIAGNOSIS; PROPER COMPLETION; VITAL-STATISTICS; VALIDATION C1 Ctr Dis Control & Prevent, Mortal Stat Branch, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Anderson, RN (reprint author), Ctr Dis Control & Prevent, Mortal Stat Branch, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM rca7@cdc.gov NR 161 TC 6 Z9 7 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-90-481-9995-2 J9 INT HANDB POPUL PY 2011 VL 2 BP 467 EP 489 DI 10.1007/978-90-481-9996-9_22 D2 10.1007/978-90-481-9996-9 PG 23 WC Demography; Public, Environmental & Occupational Health SC Demography; Public, Environmental & Occupational Health GA BTX20 UT WOS:000288355700022 ER PT B AU Goering, RV Ribot, EM Gerner-Smidt, P AF Goering, Richard V. Ribot, Efrain M. Gerner-Smidt, Peter BE Persing, DH Tenover, FC Tang, YW Nolte, FS Hayden, RT VanBelkum, A TI Pulsed-Field Gel Electrophoresis: Laboratory and Epidemiologic Considerations for Interpretation of Data SO MOLECULAR MICROBIOLOGY: DIAGNOSTIC PRINCIPLES AND PRACTICE, SECOND EDITION LA English DT Article; Book Chapter ID LARGE DNA-MOLECULES; RESISTANT STAPHYLOCOCCUS-AUREUS; COMMERCIAL SOFTWARE PACKAGES; ESCHERICHIA-COLI O157-H7; STANDARDIZED PROTOCOL; TYPING METHODS; PATTERNS; STRAINS; MACRORESTRICTION; SEPARATION C1 [Goering, Richard V.] Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA. [Ribot, Efrain M.; Gerner-Smidt, Peter] Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Natl Ctr Zoonot Vectorborne & Enter Dis, Atlanta, GA 30332 USA. RP Goering, RV (reprint author), Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA. NR 42 TC 9 Z9 9 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-497-7 PY 2011 BP 167 EP 177 PG 11 WC Biochemistry & Molecular Biology; Medical Laboratory Technology; Microbiology SC Biochemistry & Molecular Biology; Medical Laboratory Technology; Microbiology GA BSK39 UT WOS:000284744300010 ER PT J AU Lopez, LM Grimes, DA Schulz, KF Curtis, KM AF Lopez, Laureen M. Grimes, David A. Schulz, Kenneth F. Curtis, Kathryn M. TI Steroidal contraceptives: effect on bone fractures in women SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review DE Bone Density [drug effects]; Bone Remodeling [drug effects]; Contraceptives, Oral, Hormonal [adverse effects; pharmacology]; Estrogens [pharmacology]; Fractures, Bone [chemically induced]; Medroxyprogesterone Acetate [adverse effects; pharmacology]; Premenopause; Progestins [pharmacology]; Randomized Controlled Trials as Topic; Female; Humans ID DEPOT-MEDROXYPROGESTERONE ACETATE; RANDOMIZED CONTROLLED-TRIAL; YOUNG FERTILE WOMEN; 30 MU-G; MINERAL DENSITY; ORAL-CONTRACEPTIVES; HORMONAL CONTRACEPTION; ETHINYL ESTRADIOL; ADOLESCENT GIRLS; DOUBLE-BLIND AB Background Steroidal contraceptive use has been associated with changes in bone mineral density in women. Whether such changes increase the risk of fractures later in life is not clear. Osteoporosis is a major public health concern. Age-related decline in bone mass increases the risk of fracture, especially of the spine, hip, and wrist. Concern about bone health influences the recommendation and use of these effective contraceptives globally. Objectives To evaluate the effect of using hormonal contraceptives before menopause on the risk of fracture in women Search strategy We searched for studies of fracture or bone health and hormonal contraceptives in MEDLINE, POPLINE, CENTRAL, EMBASE, and LILACS, as well as ClinicalTrials.gov and ICTRP. We wrote to investigators to find additional trials. Selection criteria Randomized controlled trials (RCTs) were considered if they examined fractures, bone mineral density (BMD), or bone turnover in women with hormonal contraceptive use prior to menopause. Interventions could include comparing a hormonal contraceptive with a placebo or another hormonal contraceptive or could compare providing a supplement versus a placebo. Data collection and analysis We assessed all titles and abstracts identified through the literature searches. Mean differences were computed using the inverse variance approach. For dichotomous outcomes, the Mantel-Haenszel odds ratio (OR) was calculated. Both included the 95% confidence interval (CI) and used a fixed-effect model. Due to different interventions, no trials could be combined for meta-analysis. Main results Of the 16 RCTs we found, 2 used a placebo and 1 used a non-hormonal method as the comparison, while 13 compared two hormonal contraceptives. No trial had fracture as an outcome. Most measured BMD and several assessed bone turnover. Depot medroxyprogesterone acetate (DMPA) was associated with decreased bone mineral density. The placebo-controlled trials showed BMD increases for DMPA plus estrogen supplement and decreases for DMPA plus placebo. Combination contraceptives did not appear to negatively affect bone health, but none were placebo-controlled. For implants, the single-rod etonogestrel group showed a greater BMD decrease versus the two-rod levonorgestrel group. However, results were not consistent across all implant comparisons. Authors' conclusions Whether steroidal contraceptives influence fracture risk cannot be determined from existing information. Many trials had small numbers of participants and some had large losses to follow up. Health care providers and women should consider the costs and benefits of these effective contraceptives. For example, injectable contraceptives and implants provide effective, long-term birth control yet do not involve a daily regimen. Progestin-only contraceptives are considered appropriate for women who should avoid estrogen due to medical conditions. C1 [Lopez, Laureen M.; Grimes, David A.; Schulz, Kenneth F.] FHI, Res Triangle Pk, NC 27709 USA. [Curtis, Kathryn M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Lopez, LM (reprint author), FHI, POB 13950, Res Triangle Pk, NC 27709 USA. EM llopez@fhi.org FU U.S. Agency for International Development, USA; National Institute of Child Health and Human Development, USA FX External sources; U.S. Agency for International Development, USA.; National Institute of Child Health and Human Development, USA. NR 71 TC 14 Z9 14 U1 1 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2011 IS 7 AR CD006033 DI 10.1002/14651858.CD006033.pub4 PG 73 WC Medicine, General & Internal SC General & Internal Medicine GA 789YB UT WOS:000292554306007 PM 21735401 ER PT S AU Svircev, AM Lehman, SM Sholberg, P Roach, D Castle, AJ AF Svircev, Antonet M. Lehman, Susan M. Sholberg, Peter Roach, Dwayne Castle, Alan J. BE Witzany, G TI Phage Biopesticides and Soil Bacteria: Multi layered and Complex Interactions SO BIOCOMMUNICATION IN SOIL MICROORGANISMS SE Soil Biology LA English DT Article; Book Chapter ID POLYMERASE-CHAIN-REACTION; TRANSMISSION ELECTRON-MICROSCOPY; ERWINIA-AMYLOVORA BACTERIOPHAGE; H-MUTANT BACTERIOPHAGES; ESCHERICHIA-COLI; LISTERIA-MONOCYTOGENES; POPULATION-DYNAMICS; DNA QUANTIFICATION; PCR AMPLIFICATION; HUMIC SUBSTANCES C1 [Svircev, Antonet M.] Agr & Agri Food, Vineland Stn, ON L0R 2G0, Canada. [Lehman, Susan M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Sholberg, Peter] Agr & Agri Food Canada, Pacific Agri Food Res Ctr, Summerland, BC V0H 1Z0, Canada. [Roach, Dwayne; Castle, Alan J.] Brock Univ, Dept Biol Sci, St Catharines, ON L2S 3A1, Canada. RP Svircev, AM (reprint author), Agr & Agri Food, 4902 Victoria Ave N, Vineland Stn, ON L0R 2G0, Canada. NR 117 TC 5 Z9 5 U1 1 U2 3 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 1613-3382 BN 978-3-642-14511-7 J9 SOIL BIOL JI Soil Biol. PY 2011 VL 23 BP 215 EP 235 DI 10.1007/978-3-642-14512-4_8 D2 10.1007/978-3-642-14512-4 PG 21 WC Soil Science SC Agriculture GA BSJ81 UT WOS:000284730500008 ER PT S AU Toms, LML Hearn, L Sjodin, A Mueller, JF AF Toms, Leisa-Maree L. Hearn, Laurence Sjoedin, Andreas Mueller, Jochen F. BE Eljarrat, E Barcelo, D TI Human Exposure to Brominated Flame Retardants SO BROMINATED FLAME RETARDANTS SE Handbook of Environmental Chemistry Series LA English DT Article; Book Chapter DE Adipose tissue; Blood; Body burden; Exposure; Half-lives; Human milk ID POLYBROMINATED DIPHENYL ETHERS; POLYCHLORINATED-BIPHENYLS PCBS; HUMAN ADIPOSE-TISSUE; HUMAN BREAST-MILK; IN-HOUSE DUST; SWEDISH HUMAN-MILK; DIETARY-INTAKE; TEMPORAL TRENDS; UNITED-STATES; ORGANOCHLORINE PESTICIDES AB Human polybrominated diphenyl ether (PBDE) exposure occurs through a range of pathways including: ingestion of dust including hand-to-mouth contact; inhalation (air/particulate matter); and ingestion via food including the unique nutrition sources of human milk and placental transfer. While inhalation has been deemed a minor source of exposure, ingestion of food and dust make greater contributions to overall PBDE body burden with intake via dust reported to be much higher in infants than in adults. PBDEs have been detected in samples of human milk, blood serum, cord blood, and adipose tissue worldwide. Concentrations have been found to be highest in populations from North America, followed by Australia, Europe, and Asia. While factors such as gender and parity may not affect concentrations., occupational exposure and age (infants and children) are associated with higher PBDE concentrations. In contrast to "traditional" persistent organic pollutants, there is an inverse relationship between PBDE body burden and age. Predicted body burden calculated using available information on intake and elimination rates of BFRs appears to underestimate measured human body burden data obtained through analysis of BFRs in blood or human milk. This may be due to unknown exposure or inaccurate elimination data. Further exposure studies should focus on younger age groups and an investigation of human PBDE half-lives. C1 [Toms, Leisa-Maree L.; Hearn, Laurence; Mueller, Jochen F.] Univ Queensland, Natl Res Ctr Environm Toxicol, Coopers Plains, Qld 4108, Australia. [Sjoedin, Andreas] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Mueller, JF (reprint author), Univ Queensland, Natl Res Ctr Environm Toxicol, 39 Kessels Rd, Coopers Plains, Qld 4108, Australia. EM j.mueller@uq.edu.au OI Mueller, Jochen/0000-0002-0000-1973 NR 191 TC 6 Z9 7 U1 0 U2 18 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY SN 1433-6863 BN 978-3-642-19268-5 J9 HANDB ENVIRON CHEM JI Handb. Environ. Chem. PY 2011 VL 16 BP 203 EP 239 DI 10.1007/698_2010_90 D2 10.1007/978-3-642-19269-2 PG 37 WC Chemistry, Applied; Chemistry, Analytical; Environmental Sciences SC Chemistry; Environmental Sciences & Ecology GA BVE65 UT WOS:000291322400008 ER PT J AU Zhu, G Xiao, LH AF Zhu, Guan Xiao, Lihua BE Fratamico, P Liu, Y Kathariou, S TI Cryptosporidium Species SO GENOMES OF FOODBORNE AND WATERBORNE PATHOGENS LA English DT Article; Book Chapter ID FRAGMENT-LENGTH-POLYMORPHISM; RIBOSOMAL-RNA GENE; REDUCTASE-THYMIDYLATE SYNTHASE; ACETYL-COA CARBOXYLASE; HIV-INFECTED PERSONS; FATTY-ACID SYNTHASE; PCR-RFLP ANALYSIS; MOLECULAR CHARACTERIZATION; PARVUM OOCYSTS; DIHYDROFOLATE-REDUCTASE C1 [Zhu, Guan] Texas A&M Univ, Dept Vet Pathobiol, College Stn, TX 77843 USA. [Zhu, Guan] Texas A&M Univ, Fac Genet Program, College Stn, TX 77843 USA. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Vector Borne &, Atlanta, GA 30341 USA. RP Zhu, G (reprint author), Texas A&M Univ, Dept Vet Pathobiol, College Stn, TX 77843 USA. RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 NR 149 TC 1 Z9 1 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-457-1 PY 2011 BP 271 EP 286 PG 16 WC Food Science & Technology; Genetics & Heredity; Microbiology SC Food Science & Technology; Genetics & Heredity; Microbiology GA BTZ28 UT WOS:000288488300020 ER PT J AU Welles, S Ross, M Banik, S Fisher, L McFarlane, M Kachur, R Rietmeijer, C Allensworth-Davies, D AF Welles, Seth Ross, Michael Banik, Swagata Fisher, Leslie McFarlane, Mary Kachur, Rachel Rietmeijer, Cornelis Allensworth-Davies, Donald TI Demographic and Sexual Behavior Comparisons of Indian and US Internet Samples of Men who have Sex with Men SO INTERNATIONAL JOURNAL OF SEXUAL HEALTH LA English DT Article DE Adult sexuality; homosexuality; bisexuality; sexual attitudes and behaviors; Internet ID TRANSMITTED-DISEASES; HIV INTERVENTIONS; RISK BEHAVIORS; ONLINE; PARTNERS; PREVENTION; PREVALENCE; CHENNAI; MSM AB Data were collected via the Internet on sexual behaviors of Indian men who have sex with men (MSM; n = 171); these data were compared to online American MSM (n = 682). Among Indian MSM, 51% had never been tested for HIV, 100% believed themselves to be HIV-uninfected, and 22% (secondary Internet male partners) to 43% (primary male partners) reported not using condoms during last anal intercourse. While U.S. MSM were more likely to not use condoms (42% for secondary Internet partners to 67% for primary male partners), most (88%) had been tested for HIV (.0001 p .002, all comparisons). Low rates of HIV testing, beliefs about being HIV-uninfected, and significant levels of unsafe anal intercourse could fuel the spread of infection among Indian MSM. C1 [Welles, Seth] Drexel Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA 19102 USA. [Ross, Michael] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Banik, Swagata; Fisher, Leslie] Cleveland State Univ, Dept Psychol, Cleveland, OH 44115 USA. [McFarlane, Mary; Kachur, Rachel] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Rietmeijer, Cornelis] Denver Publ Hlth, STD Clin, Denver, CO USA. [Rietmeijer, Cornelis] Denver Publ Hlth, Control Program, Denver, CO USA. [Allensworth-Davies, Donald] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Welles, S (reprint author), Drexel Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 1505 Race St, Philadelphia, PA 19102 USA. EM slw58@drexel.edu NR 46 TC 3 Z9 3 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1931-7611 J9 INT J SEX HEALTH JI Int. J. Sex. Health PY 2011 VL 23 IS 2 BP 90 EP 101 AR PII 938603030 DI 10.1080/19317611.2011.562278 PG 12 WC Psychology, Clinical; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary SC Psychology; Public, Environmental & Occupational Health; Social Sciences - Other Topics GA 780NM UT WOS:000291864500002 ER PT J AU Tharp, ALT Sharp, C Stanford, MS Lake, SL Raine, A Kent, TA AF Tharp, Andra L. Teten Sharp, Carla Stanford, Matthew S. Lake, Sarah L. Raine, Adrian Kent, Thomas A. TI Correspondence of aggressive behavior classifications among young adults using the Impulsive Premeditated Aggression Scale and the Reactive Proactive Questionnaire SO PERSONALITY AND INDIVIDUAL DIFFERENCES LA English DT Article DE Reactive; Proactive; Impulsive; Premeditated; Aggression ID ADOLESCENTS AB The two most studied bimodal classifications of aggressive behavior are impulsive/premeditated and reactive/proactive aggression. Despite differences in the conceptualization of these classifications and the primary use of each in different developmental phases, the two classifications are often used interchangeably. The purpose of the current study was to determine the correspondence of the two classification schemes in a sample of young adults (N = 250) using two validated measures: the Reactive Proactive Questionnaire (Raine et al., 2006) and the Impulsive Premeditated Aggression Scale (Stanford et al., 2003). Convergent and discriminant validity of the scales was partially supported. Clusters derived from each scale corresponded for 38% of the cases. When the scales were used together, six subtype categories were identified, such that low, impulsive, and premeditated components were found for reactive and proactive aggressors. The six categories differed significantly on measures of aggression, anger, and hostility. Thus, the measures, and potentially the classifications, complemented but did not correspond to each other. These results suggest that the two classification systems may not be equivalent and should not be used interchangeably. Published by Elsevier Ltd. C1 [Tharp, Andra L. Teten] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Sharp, Carla] Univ Houston, Houston, TX 77004 USA. [Stanford, Matthew S.; Lake, Sarah L.] Baylor Univ, Waco, TX 76798 USA. [Raine, Adrian] Univ Penn, Philadelphia, PA 19104 USA. [Kent, Thomas A.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA. RP Tharp, ALT (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,MS F-64, Atlanta, GA 30341 USA. EM ateten@cdc.gov OI Kent, Thomas/0000-0002-9877-7584; Sharp, Carla/0000-0001-8349-4701 NR 22 TC 8 Z9 8 U1 2 U2 19 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0191-8869 J9 PERS INDIV DIFFER JI Pers. Individ. Differ. PD JAN PY 2011 VL 50 IS 2 BP 279 EP 285 DI 10.1016/j.paid.2010.10.003 PG 7 WC Psychology, Social SC Psychology GA 693OI UT WOS:000285233000029 ER PT J AU Baker, PRA Francis, DP Soares, J Weightman, AL Foster, C AF Baker, P. R. A. Francis, D. P. Soares, J. Weightman, A. L. Foster, C. TI Community wide interventions for increasing physical activity SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; HEART-HEALTH-PROGRAM; CARDIOVASCULAR-DISEASE PREVENTION; LIFE-STYLE INTERVENTIONS; STANFORD 5-CITY PROJECT; PROMOTING SAFE WALKING; SEDENTARY OLDER-ADULTS; SCHOOL-BASED-PROGRAM; REDUCE RISK-FACTORS; SANTE ST-HENRI AB Background Multi-strategic community wide interventions for physical activity are increasingly popular but their ability to achieve population level improvements is unknown. Objectives To evaluate the effects of community wide, multi-strategic interventions upon population levels of physical activity. Search strategy We searched the Cochrane Public Health Group Specialised Register, The Cochrane Library, MEDLINE, MEDLINE in Process, EMBASE, CINAHL, LILACS, PsycINFO, ASSIA, The British Nursing Index, Chinese CNKI databases, EPPI Centre (DoPHER, TRoPHI), ERIC, HMIC, Sociological Abstracts, SPORTDiscus, Transport Database and Web of Science (Science Citation Index, Social Sciences Citation Index, Conference Proceedings Citation Index). We also scanned websites of the EU Platform on Diet, Physical Activity and Health; Health-Evidence.ca; the International Union for Health Promotion and Education; the NIHR Coordinating Centre for Health Technology (NCCHTA) and NICE and SIGN guidelines. Reference lists of all relevant systematic reviews, guidelines and primary studies were followed up. We contacted experts in the field from the National Obesity Observatory Oxford, Oxford University; Queensland Health, Queensland University of Technology, the University of Central Queensland; the University of Tennessee and Washington University; and handsearched six relevant journals. The searches were last updated to the end of November 2009 and were not restricted by language or publication status. Selection criteria Cluster randomised controlled trials, randomised controlled trials (RCT), quasi-experimental designs which used a control population for comparison, interrupted time-series (ITS) studies, and prospective controlled cohort studies (PCCS) were included. Only studies with a minimum six-month follow up from the start of the intervention to measurement of outcomes were included. Community wide interventions had to comprise at least two broad strategies aimed at physical activity for the whole population. Studies which randomised individuals from the same community were excluded. Data collection and analysis At least two review authors independently extracted the data and assessed the risk of bias of each included study. Non-English language papers were reviewed with the assistance of an epidemiologist interpreter. Each study was assessed for the setting, the number of included components and their intensity. Outcome measures were grouped according to whether they were dichotomous (physically active, physically active during leisure time and sedentary or physically inactive) or continuous (leisure time physical activity, walking, energy expenditure). For dichotomous measures we calculated the unadjusted and adjusted risk difference, and the unadjusted and adjusted relative risk. For continuous measures we calculated net percentage change from baseline, unadjusted and adjusted risk difference, and the unadjusted and adjusted relative risk. Main results After the selection process had been completed 25 studies were included in the review. Of the included studies, 19 were set in high income countries, using the World Bank economic classification, and the remaining six were in low income countries. The interventions varied by the number of strategies included and their intensity. Almost all of the interventions included a component of building partnerships with local governments or non-governmental organisations (NGOs) (22 studies). None of the studies provided results by socio-economic disadvantage or other markers of equity consideration. However of those included studies undertaken in high income countries, 11 studies were described by the authors as being provided to deprived, disadvantaged, or low socio-economic communities. Fifteen studies were identified as having a high risk of bias, 10 studies were unclear, and no studies had a low risk of bias. Selection bias was a major concern with these studies, with only one study using randomisation to allocate communities (Simon 2008). No studies were judged as being at low risk of selection bias although 16 studies were considered to have an unclear risk of bias. Eleven studies had a high risk of detection bias, 10 with an unclear risk and four with no risk. Assessment of detection bias included an assessment of the validity of the measurement tools and quality of outcome measures. The effects reported were inconsistent across the studies and the measures. Some of the better designed studies showed no improvement in measures of physical activity. Publication bias was evident. Authors' conclusions Although numerous studies have been undertaken, there is a noticeable inconsistency of the findings of the available studies and this is confounded by serious methodological issues within the included studies. The body of evidence in this review does not support the hypothesis that multi-component community wide interventions effectively increase population levels of physical activity. There is a clear need for well-designed intervention studies and such studies should focus on the quality of the measurement of physical activity, the frequency of measurement and the allocation to intervention and control communities. C1 [Baker, P. R. A.] Queensland Univ Technol, Sch Publ Hlth, Kelvin Grove, Australia. [Baker, P. R. A.] Queensland Hlth, Cent Reg Serv, Div CHO, Stafford Dc, Qld 4053, Australia. [Francis, D. P.] Queensland Hlth, Populat Hlth Serv, Cent Area Hlth Serv, Stafford Dc, Qld 4053, Australia. [Soares, J.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Weightman, A. L.] Cardiff Univ, SURE, Informat Serv, Cardiff, S Glam, Wales. [Foster, C.] Univ Oxford, BHF Hlth Promot Res Grp, Oxford, England. RP Baker, PRA (reprint author), Queensland Univ Technol, Sch Publ Hlth, Kelvin Grove, Australia. EM drpbaker@optusnet.com.au RI Weightman, Alison/A-4680-2010; Baker, Philip/J-1109-2012 OI Weightman, Alison/0000-0001-5210-3798; FU Queensland Health, Australia; National Institute for Health Research, UK FX Internal sources; Health Practitioner Research Scheme 2009 - 2010: Queensland Health, Australia. $29,000 Australian was provide as a research fellowship supporting the reviewers PB and DF.; External sources; National Institute for Health Research, Cochrane Review Incentive Scheme, UK. 5000 p ounds sterling for publication of the review by a set deadline (4 February 2011) NR 269 TC 40 Z9 40 U1 10 U2 69 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2011 IS 4 AR CD008366 DI 10.1002/14651858.CD008366.pub2 PG 129 WC Medicine, General & Internal SC General & Internal Medicine GA 749SQ UT WOS:000289490200016 PM 21491409 ER PT J AU Halpern, V Lopez, LM Grimes, DA Gallo, MF AF Halpern, Vera Lopez, Laureen M. Grimes, David A. Gallo, Maria F. TI Strategies to improve adherence and acceptability of hormonal methods of contraception SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review DE Patient Compliance [psychology]; Treatment Refusal [psychology]; Contraception [psychology]; Contraceptive Agents, Female [administration & dosage; adverse effects]; Contraceptives, Oral, Hormonal [administration & dosage; adverse effects]; Counseling; Medroxyprogesterone Acetate [administration & dosage; adverse effects]; Randomized Controlled Trials as Topic; Female; Humans ID RANDOMIZED-CONTROLLED-TRIAL; DEPOT-MEDROXYPROGESTERONE ACETATE; FAMILY-PLANNING-SERVICES; LONG-ACTING METHODS; DUAL-METHOD USE; ORAL-CONTRACEPTIVES; DISCONTINUATION RATES; WOMEN; FERTILITY; IMPACT AB Background Worldwide, hormonal contraceptives are among the most popular reversible contraceptives in current use. Despite their high theoretical effectiveness, typical use results in much lower effectiveness. In large part, this disparity reflects difficulties in adherence to the contraceptive regimen and low rates for long-term continuation. Objectives To determine the effectiveness of ancillary techniques to improve adherence to, and continuation rates of, hormonal methods of contraception. Search strategy We searched computerized databases for randomized controlled trials (RCTs) comparing client-provider interventions with standard family planning counseling. Sources included CENTRAL, MEDLINE, EMBASE, POPLINE, LILACS, PsycINFO, ClinicalTrials.gov and ICTRP. Selection criteria We included randomized controlled trials (RCTs) of an intensive counseling technique or client-provider intervention versus routine family planning counseling. Interventions included group motivation; structured, peer, or multi-component counseling; and intensive reminders of appointments or next dosing. Outcome measures were discontinuation, reasons for discontinuation, number of missed pills and on-time injections, and pregnancy. Data collection and analysis The primary author evaluated all titles and abstracts from the searches to determine eligibility. Two authors independently extracted data from the included studies. With RevMan, we calculated the odds ratio for all dichotomous outcomes and the mean difference for continuous data. The studies were so different that we did not conduct a meta-analysis. Main results We found eight RCTs; only one showed a statistically significant benefit of the experimental intervention. In that trial, women who received repeated, structured information about the injectable contraceptive depo-medroxyprogesterone acetate (DMPA) were less likely to have discontinued the method by 12 months (OR 0.27; 95% CI 0.16 to 0.44) than were women who had routine counseling. The intervention group was also less likely to discontinue due to menstrual disturbances (OR 0.20; 95% CI 0.11 to 0.37). In another study, the intervention group was less likely to discontinue due to dissatisfaction with the contraceptive method (OR 0.61; 95% CI 0.38 to 0.98), but overall continuation was not affected. Authors' conclusions Most studies to date have shown no benefit of strategies to improve adherence and continuation. These trials have important limitations, however. Three had small sample sizes, four had high losses to follow up, and the intervention and its intensity varied across the studies. High-quality research is a priority, since adherence and continuation are fundamentally important to the successful use of hormonal contraceptives. C1 [Halpern, Vera; Lopez, Laureen M.; Grimes, David A.] FHI, Res Triangle Pk, NC 27709 USA. [Gallo, Maria F.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Lopez, LM (reprint author), FHI, POB 13950, Res Triangle Pk, NC 27709 USA. EM llopez@fhi.org FU U.S. Agency for International Development, USA; National Institute of Child Health and Human Development, USA FX External sources; U.S. Agency for International Development, USA.; National Institute of Child Health and Human Development, USA. NR 51 TC 27 Z9 27 U1 2 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2011 IS 4 AR CD004317 DI 10.1002/14651858.CD004317.pub3 PG 38 WC Medicine, General & Internal SC General & Internal Medicine GA 749SQ UT WOS:000289490200032 PM 21491389 ER PT J AU de Balogh, K Dominguez, M El-Irdissi, A Otto, P Zingeser, J AF de Balogh, Katinka Dominguez, Morgane El-Irdissi, Ahmed Otto, Patrick Zingeser, James TI Innovative Approaches in Veterinary Public Health by Embracing the One Health Framework SO ECOHEALTH LA English DT Meeting Abstract C1 [de Balogh, Katinka; Dominguez, Morgane; El-Irdissi, Ahmed; Otto, Patrick] FAO, I-00100 Rome, Italy. [Zingeser, James] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1612-9202 J9 ECOHEALTH JI EcoHealth PY 2011 VL 7 SU 1 BP S78 EP S78 PG 1 WC Biodiversity Conservation; Ecology; Environmental Sciences SC Biodiversity & Conservation; Environmental Sciences & Ecology GA 728VB UT WOS:000287901500133 ER PT J AU Saha, S Pattanayak, SK Sills, EO Singha, AK AF Saha, Shubhayu Pattanayak, Subhrendu K. Sills, Erin O. Singha, Ashok K. TI Under-mining health: Environmental justice and mining in India SO HEALTH & PLACE LA English DT Article DE Environmental health; Malaria; Respiratory infections; GIS; Instrumental variable; 2SRI ID GEOGRAPHIC INFORMATION-SYSTEMS; AIR-POLLUTION; PUBLIC-HEALTH; EPIDEMIOLOGY; EXPOSURE; EQUITY; FUTURE; GIS; SUSTAINABILITY; INEQUALITIES AB Despite the potential for economic growth, extractive mineral industries can impose negative health externalities in mining communities. We estimate the size of these externalities by combining household interviews with mine location and estimating statistical functions of respiratory illness and malaria among villagers living along a gradient of proximity to iron-ore mines in rural India. Two-stage regression modeling with cluster corrections suggests that villagers living closer to mines had higher respiratory illness and malaria-related workday loss, but the evidence for mine workers is mixed. These findings contribute to the thin empirical literature on environmental justice and public health in developing countries. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Pattanayak, Subhrendu K.] Duke Univ, Nicholas Sch Environm, Sanford Sch Publ Policy, Durham, NC 27708 USA. [Saha, Shubhayu] Ctr Dis Control, Climate Change Program, Atlanta, GA 30333 USA. [Sills, Erin O.] N Carolina State Univ, Raleigh, NC 27695 USA. RP Pattanayak, SK (reprint author), Duke Univ, Nicholas Sch Environm, Sanford Sch Publ Policy, 126 Rubenstein Hall, Durham, NC 27708 USA. EM subhrendu.pattanayak@duke.edu RI Banks, Tamara/G-3007-2012 NR 81 TC 15 Z9 16 U1 1 U2 19 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1353-8292 J9 HEALTH PLACE JI Health Place PD JAN PY 2011 VL 17 IS 1 BP 140 EP 148 DI 10.1016/j.healthplace.2010.09.007 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 740FH UT WOS:000288776500017 PM 21130678 ER PT J AU Amarasinghe, A Wichmann, O Margolis, HS Mahoney, RT AF Amarasinghe, Ananda Wichmann, Ole Margolis, Harold S. Mahoney, Richard T. TI Comment on "Forecasting dengue vaccine demand in disease endemic and non-endemic countries" Amarasinghe et al. Hum Vaccines 2010; 6:745-53 Reply SO HUMAN VACCINES LA English DT Letter C1 [Amarasinghe, Ananda; Mahoney, Richard T.] Int Vaccine Inst, PDVI, Seoul, South Korea. [Wichmann, Ole] Robert Koch Inst, D-1000 Berlin, Germany. [Margolis, Harold S.] Ctr Dis Control & Prevent, Guam, PR USA. RP Amarasinghe, A (reprint author), Int Vaccine Inst, PDVI, Seoul, South Korea. EM ana.amarasinghe@pdvi.org NR 4 TC 0 Z9 0 U1 0 U2 0 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8600 J9 HUM VACCINES JI Hum. Vaccines PD JAN PY 2011 VL 7 IS 1 BP 131 EP 131 DI 10.4161/hv.7.1.14267 PG 1 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA 743BB UT WOS:000288989300029 ER PT J AU Alonso, PL Atta, HY Drakeley, C Eisele, T Hay, SI Lupez, MHR Meek, S Steketee, R Slutsker, L AF Alonso, Pedro L. Atta, Hoda Youseff Drakeley, Chris Eisele, Thomas Hay, Simon I. Rodriguez Lupez, Mario Henry Meek, Sylvia Steketee, Richard Slutsker, Laurence CA malERA Consultative Grp Monitoring TI A Research Agenda for Malaria Eradication: Monitoring, Evaluation, and Surveillance SO PLOS MEDICINE LA English DT Review ID TRANSMISSION; PROGRESS; STRATEGY AB Monitoring, evaluation, and surveillance measure how well public health programs operate over time and achieve their goals. As countries approach malaria elimination, these activities will need to shift from measuring reductions in morbidity and mortality, to detecting infections (with or without symptoms) and measuring transmission. Thus, the monitoring and evaluation and surveillance research and development agenda needs to develop the tools and strategies that will replace passive surveillance of morbidity with active and prompt detection of infection, including confirmation of interruption of transmission by detecting present and past infections, particularly in mobile populations. The capacity to assess trends and respond without delay will need to be developed, so that surveillance itself becomes an intervention. Research is also needed to develop sensitive field tests that can detect low levels of parasitaemia, together with strategies for their implementation. Other areas to explore include the rigorous evaluation of the utility of more detailed maps of disease and infection incidence and prevalence, the development of new maps to inform programmatic responses and the use of surveillance technologies based on cell phone or real-time internet Web-based reporting. Because any new strategies for monitoring and evaluation and surveillance for eradication have major implications for program implementation, research is also needed to test systems of delivery for acceptability, feasibility, efficiency, cost-effectiveness, and community engagement. Finally, there is a clear need to systematically review the information from past elimination efforts for malaria and other infectious diseases. C1 [Alonso, Pedro L.] Univ Barcelona, Barcelona Ctr Int Hlth Res, Hosp Clin, Barcelona, Spain. [Atta, Hoda Youseff] World Hlth Org EMRO, Cairo, Egypt. [Drakeley, Chris] London Sch Hyg & Trop Med, London WC1, England. [Eisele, Thomas] Tulane Univ, New Orleans, LA 70118 USA. [Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England. [Rodriguez Lupez, Mario Henry] Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico. [Meek, Sylvia] Malaria Consortium, London, England. [Steketee, Richard] PATH MACEPA, Ferney Voltaire, France. [Slutsker, Laurence] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP Alonso, PL (reprint author), Univ Barcelona, Barcelona Ctr Int Hlth Res, Hosp Clin, Barcelona, Spain. RI Hay, Simon/F-8967-2015; Bassat, Quique/P-2341-2016 OI Hay, Simon/0000-0002-0611-7272; Bassat, Quique/0000-0003-0875-7596 FU Bill & Melinda Gates Foundation FX malERA received a grant from the Bill & Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 45 TC 2 Z9 2 U1 1 U2 18 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD JAN PY 2011 VL 8 IS 1 AR e1000400 DI 10.1371/journal.pmed.1000400 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 711LX UT WOS:000286594200015 ER PT J AU Alonso, PL Barnwell, JW Bell, D Hanson, K Mendis, K Moonen, B Newman, RD de Savigny, D Schapira, A Slutsker, L Tanner, M Teuscher, T AF Alonso, Pedro L. Barnwell, John W. Bell, David Hanson, Kara Mendis, Kamini Moonen, Bruno Newman, Robert D. de Savigny, Don Schapira, Allan Slutsker, Laurence Tanner, Marcel Teuscher, Thomas CA malERA Consultative Grp Diagnoses TI A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics SO PLOS MEDICINE LA English DT Review ID MEDIATED ISOTHERMAL AMPLIFICATION; PLASMODIUM-FALCIPARUM DNA; RETROSPECTIVE EXAMINATION; MOSQUITO INFECTION; CLINICAL ALGORITHM; LOW TRANSMISSION; SOLOMON-ISLANDS; VIVAX; AREA; TANZANIA AB Many of malaria's signs and symptoms are indistinguishable from those of other febrile diseases. Detection of the presence of Plasmodium parasites is essential, therefore, to guide case management. Improved diagnostic tools are required to enable targeted treatment of infected individuals. In addition, field-ready diagnostic tools for mass screening and surveillance that can detect asymptomatic infections of very low parasite densities are needed to monitor transmission reduction and ensure elimination. Antibody-based tests for infection and novel methods based on biomarkers need further development and validation, as do methods for the detection and treatment of Plasmodium vivax. Current rapid diagnostic tests targeting P. vivax are generally less effective than those targeting Plasmodium falciparum. Moreover, because current drugs for radical cure may cause serious side effects in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, more information is needed on the distribution of G6PD-deficiency variants as well as tests to identify at-risk individuals. Finally, in an environment of very low or absent malaria transmission, sustaining interest in elimination and maintaining resources will become increasingly important. Thus, research is required into the context in which malaria diagnostic tests are used, into diagnostics for other febrile diseases, and into the integration of these tests into health systems. C1 [Alonso, Pedro L.] Univ Barcelona, Barcelona Ctr Int Hlth Res, Hosp Clin, Barcelona, Spain. [Barnwell, John W.; Slutsker, Laurence] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Bell, David] Fdn Innovat New Diagnost FIND, Geneva, Switzerland. [Hanson, Kara] London Sch Hyg & Trop Med, London WC1, England. [Mendis, Kamini; Newman, Robert D.] World Hlth Org, Geneva, Switzerland. [Moonen, Bruno] Clinton Hlth Access Initiat, Nairobi, Kenya. [de Savigny, Don; Schapira, Allan; Tanner, Marcel] Univ Basel, Basel, Switzerland. [de Savigny, Don; Schapira, Allan; Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Teuscher, Thomas] Roll Back Malaria Partnership, Geneva, Switzerland. RP Alonso, PL (reprint author), Univ Barcelona, Barcelona Ctr Int Hlth Res, Hosp Clin, Barcelona, Spain. RI Bassat, Quique/P-2341-2016 OI Bassat, Quique/0000-0003-0875-7596 FU Bill & Melinda Gates Foundation FX malERA received a grant from the Bill & Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 75 TC 13 Z9 14 U1 1 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD JAN PY 2011 VL 8 IS 1 AR e1000396 DI 10.1371/journal.pmed.1000396 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 711LX UT WOS:000286594200011 ER PT J AU Alonso, PL Besansky, NJ Burkot, TR Collins, FH Hemingway, J James, AA Lengeler, C Lindsay, S Liu, QY Lobo, NF Mnzava, A Tanner, M Zwiebel, L AF Alonso, Pedro L. Besansky, Nora J. Burkot, Thomas R. Collins, Frank H. Hemingway, Janet James, Anthony A. Lengeler, Christian Lindsay, Steven Liu, Qiyong Lobo, Neil F. Mnzava, Abraham Tanner, Marcel Zwiebel, Larry CA maIERA Consultative Grp Vector Con TI A Research Agenda for Malaria Eradication: Vector Control SO PLOS MEDICINE LA English DT Review ID INSECTICIDE RESISTANCE; ANOPHELES-GAMBIAE; FUTURE AB Different challenges are presented by the variety of malaria transmission environments present in the world today. In each setting, improved control for reduction of morbidity is a necessary first step towards the long-range goal of malaria eradication and a priority for regions where the disease burden is high. For many geographic areas where transmission rates are low to moderate, sustained and well-managed application of currently available tools may be sufficient to achieve local elimination. The research needs for these areas will be to sustain and perhaps improve the effectiveness of currently available tools. For other low-to-moderate transmission regions, notably areas where the vectors exhibit behaviours such as outdoor feeding and resting that are not well targeted by current strategies, new interventions that target predictable features of the biology/ecologies of the local vectors will be required. To achieve elimination in areas where high levels of transmission are sustained by very efficient vector species, radically new interventions that significantly reduce the vectorial capacity of wild populations will be needed. Ideally, such interventions should be implemented with a one-time application with a long-lasting impact, such as genetic modification of the vectorial capacity of the wild vector population. C1 [Alonso, Pedro L.] Univ Barcelona, Barcelona Ctr Int Hlth Res, Hosp Clin, Barcelona, Spain. [Besansky, Nora J.; Collins, Frank H.; Lobo, Neil F.] Univ Notre Dame, Notre Dame, IN 46556 USA. [Burkot, Thomas R.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Hemingway, Janet] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [James, Anthony A.] Univ Calif Irvine, Irvine, CA USA. [Lengeler, Christian; Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Lindsay, Steven] London Sch Hyg & Trop Med, London WC1, England. [Liu, Qiyong] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, Beijing, Peoples R China. [Mnzava, Abraham] World Hlth Org, Cairo, Egypt. [Tanner, Marcel] Univ Basel, Basel, Switzerland. [Zwiebel, Larry] Vanderbilt Univ, Nashville, TN USA. RP Alonso, PL (reprint author), Univ Barcelona, Barcelona Ctr Int Hlth Res, Hosp Clin, Barcelona, Spain. RI Burkot, Thomas/C-6838-2013; OI Zwiebel, Laurence/0000-0001-6686-7289; Hemingway, Janet/0000-0002-3200-7173; Chandre, Fabrice/0000-0002-1994-9705 FU Bill & Melinda Gates Foundation FX malERA received a grant from the Bill & Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 15 Z9 15 U1 0 U2 27 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD JAN PY 2011 VL 8 IS 1 AR e1000401 DI 10.1371/journal.pmed.1000401 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 711LX UT WOS:000286594200016 ER PT J AU Alonso, PL Bell, D Hanson, K Mendis, K Newman, RD de Savigny, D Schapira, A Slutsker, L Tanner, M Teuscher, T AF Alonso, Pedro L. Bell, David Hanson, Kara Mendis, Kamini Newman, Robert D. de Savigny, Don Schapira, Allan Slutsker, Laurence Tanner, Marcel Teuscher, Thomas CA malERA Consultative Grp Hlth Syst TI A Research Agenda for Malaria Eradication: Health Systems and Operational Research SO PLOS MEDICINE LA English DT Review ID WORKERS; AFRICA; MANAGEMENT; MEDICINE; DISEASES; NETS; CARE AB Health systems research and development is needed to support the global malaria eradication agenda. In this paper, we (the malERA Consultative Group on Health Systems and Operational Research) focus on the health systems needs of the elimination phase of malaria eradication and consider groupings of countries at different stages along the pathway to elimination. We examine the difference between the last attempt at eradication of malaria and more recent initiatives, and consider the changing health system challenges as countries make progress towards elimination. We review recent technological and theoretical developments related to health systems and the renewed commitment to strengthening health systems for universal access and greater equity. Finally, we identify a number of needs for research and development, including tools for analyzing and improving effective coverage and strengthening decision making and discuss the relevance of these needs at all levels of the health system from the community to the international level. C1 [Alonso, Pedro L.] Univ Barcelona, Barcelona Ctr Int Hlth Res, Hosp Clin, Barcelona, Spain. [Alonso, Pedro L.] Ctr Invest Saude Manhica, Manhica, Mozambique. [Bell, David] Fdn Innovat New Diagnost FIND, Geneva, Switzerland. [Hanson, Kara] London Sch Hyg & Trop Med, London WC1, England. [Mendis, Kamini; Newman, Robert D.] World Hlth Org, Geneva, Switzerland. [de Savigny, Don; Schapira, Allan; Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [de Savigny, Don; Schapira, Allan; Tanner, Marcel] Univ Basel, Basel, Switzerland. [Slutsker, Laurence] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Teuscher, Thomas] Roll Back Malaria Partnership, Geneva, Switzerland. RP Alonso, PL (reprint author), Univ Barcelona, Barcelona Ctr Int Hlth Res, Hosp Clin, Barcelona, Spain. RI Bassat, Quique/P-2341-2016 OI Bassat, Quique/0000-0003-0875-7596 FU Bill & Melinda Gates Foundation FX malERA received a grant from the Bill & Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 5 Z9 5 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD JAN PY 2011 VL 8 IS 1 AR e1000397 DI 10.1371/journal.pmed.1000397 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 711LX UT WOS:000286594200012 ER PT J AU Kirkpatrick, B Fleming, LE Bean, JA Nierenberg, K Backer, LC Cheng, YS Pierce, R Reich, A Naar, J Wanner, A Abraham, WM Zhou, Y Hollenbeck, J Baden, DG AF Kirkpatrick, Barbara Fleming, Lora E. Bean, Judy A. Nierenberg, Kate Backer, Lorraine C. Cheng, Yung Sung Pierce, Richard Reich, Andrew Naar, Jerome Wanner, Adam Abraham, William M. Zhou, Yue Hollenbeck, Julie Baden, Daniel G. TI Aerosolized red tide toxins (brevetoxins) and asthma: Continued health effects after 1 h beach exposure SO HARMFUL ALGAE LA English DT Article DE Coastal; Harmful algal blooms (HABs); Inhalation toxicity; Karenia brevis ID MARINE AEROSOL; FLORIDA; BREVIS AB Blooms of the toxic dinoflagellate. Karenia brevis, produce potent neurotoxins in marine aerosols. Recent studies have demonstrated acute changes in both symptoms and pulmonary function in asthmatics after only 1 h of beach exposure to these aerosols. This study investigated if there were latent and/or sustained effects in asthmatics in the days following the initial beach exposure during periods with and without an active Florida red tide. Symptom data and spirometry data were collected before and after 1 h of beach exposure. Subjects kept daily symptom diaries and measured their peak flow each morning for 5 days following beach exposure. During non-exposure periods, there were no significant changes in symptoms or pulmonary function either acutely or over 5 days of follow-up. After the beach exposure during an active Florida red tide, subjects had elevated mean symptoms which did not return to the pre-exposure baseline for at least 4 days. The peak flow measurements decreased after the initial beach exposure, decreased further within 24 h, and continued to be suppressed even after 5 days. Asthmatics may continue to have increased symptoms and delayed respiratory function suppression for several days after 1 h of exposure to the Florida red tide toxin aerosols. (C) 2010 Elsevier B.V. All rights reserved. C1 [Kirkpatrick, Barbara; Nierenberg, Kate; Pierce, Richard] Mote Marine Lab, Sarasota, FL 34236 USA. [Fleming, Lora E.; Hollenbeck, Julie] Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, NSF, Miami, FL 33149 USA. [Fleming, Lora E.; Hollenbeck, Julie] Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, NIEHS Oceans & Human Hlth Ctr, Miami, FL 33149 USA. [Fleming, Lora E.; Wanner, Adam] Univ Miami, Sch Med, Miami, FL 33136 USA. [Bean, Judy A.] Childrens Hosp Med Ctr, Cincinnati, OH USA. [Bean, Judy A.] Univ Cincinnati, Cincinnati, OH USA. [Backer, Lorraine C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Cheng, Yung Sung] Lovelace Resp Res Inst, Albuquerque, NM 87108 USA. [Reich, Andrew] Florida Dept Hlth, Tallahassee, FL 32399 USA. [Naar, Jerome; Baden, Daniel G.] Univ N Carolina, Ctr Marine Sci, Wilmington, NC 28409 USA. [Abraham, William M.] Mt Sinai Med Ctr, Miami Beach, FL 33140 USA. RP Fleming, LE (reprint author), Publ Hlth Univ Miami, Sch Med, Dept Epidemiol, Clin Res Bldg CRB,10th Floor,1120 NW 14th S, Miami, FL 33136 USA. EM lfleming@med.miami.edu FU National Institute of Environmental Health Sciences (NIEHS) [P01 ES 10594, 1 P50 ES12736]; Centers for Disease Control and Prevention (CDC); Florida Department of Health; Florida Dept of Environmental Protection (FL DEP) Florida Red Tide Control and Mitigation; National Science Foundation (NSF); National Institute of Environmental Health Sciences (NIEHS) Oceans and Human Health Center at the University of Miami Rosenstiel School [NSF] [NSF OCE0432368, NSF OCE0911373] FX This research was supported by the National Institute of Environmental Health Sciences (NIEHS) Aerosolized Florida Red Tide PO1 [P01 ES 10594] with a Minority Supplement, as well as by the Centers for Disease Control and Prevention (CDC), and the Florida Department of Health. Additional support was received from the Florida Dept of Environmental Protection (FL DEP) Florida Red Tide Control and Mitigation; the National Science Foundation (NSF) and the National Institute of Environmental Health Sciences (NIEHS) Oceans and Human Health Center at the University of Miami Rosenstiel School [NSF OCE0432368 and NSF OCE0911373];[NIEHS 1 P50 ES12736].[SS] NR 24 TC 11 Z9 11 U1 0 U2 16 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1568-9883 J9 HARMFUL ALGAE JI Harmful Algae PD JAN PY 2011 VL 10 IS 2 BP 138 EP 143 DI 10.1016/j.hal.2010.08.005 PG 6 WC Marine & Freshwater Biology SC Marine & Freshwater Biology GA 714XP UT WOS:000286845300003 PM 21499552 ER PT J AU Fleming, LE Kirkpatrick, B Backer, LC Walsh, CJ Nierenberg, K Clark, J Reich, A Hollenbeck, J Benson, J Cheng, YS Naar, J Pierce, R Bourdelais, AJ Abraham, WM Kirkpatrick, G Zaias, J Wanner, A Mendes, E Shalat, S Hoagland, P Stephan, W Bean, J Watkins, S Clarke, T Byrne, M Baden, DG AF Fleming, Lora E. Kirkpatrick, Barbara Backer, Lorraine C. Walsh, Cathy J. Nierenberg, Kate Clark, John Reich, Andrew Hollenbeck, Julie Benson, Janet Cheng, Yung Sung Naar, Jerome Pierce, Richard Bourdelais, Andrea J. Abraham, William M. Kirkpatrick, Gary Zaias, Julia Wanner, Adam Mendes, Eliana Shalat, Stuart Hoagland, Porter Stephan, Wendy Bean, Judy Watkins, Sharon Clarke, Tainya Byrne, Margaret Baden, Daniel G. TI Review of Florida red tide and human health effects SO HARMFUL ALGAE LA English DT Review DE Brevetoxins; Florida red tide; Harmful algal bloom (HAB); Karenia brevis; Marine toxin diseases; Neurotoxic fish poisoning; Neurotoxic shellfish poisoning (NSP); Red tide; Respiratory irritation; Shellfish poisoning ID DINOFLAGELLATE KARENIA-BREVIS; HARMFUL ALGAL BLOOM; HUMAN EXPOSURE; AEROSOLIZED BREVETOXINS; TOXINS BREVETOXINS; MARINE AEROSOL; IN-VITRO; INTRATRACHEAL INSTILLATION; INHALATION TOXICITY; CELLULAR-METABOLISM AB This paper reviews the literature describing research performed over the past decade on the known and possible exposures and human health effects associated with Florida red tides. These harmful algal blooms are caused by the dinoflagellate, Karenia brevis, and similar organisms, all of which produce a suite of natural toxins known as brevetoxins. Florida red tide research has benefited from a consistently funded, long-term research program, that has allowed an interdisciplinary team of researchers to focus their attention on this specific environmental issue-one that is critically important to Gulf of Mexico and other coastal communities. This long-term interdisciplinary approach has allowed the team to engage the local community, identify measures to protect public health, take emerging technologies into the field, forge advances in natural products chemistry, and develop a valuable pharmaceutical product. The review includes a brief discussion of the Florida red tide organisms and their toxins, and then focuses on the effects of these toxins on animals and humans, including how these effects predict what we might expect to see in exposed people. (C) 2010 Elsevier B.V. All rights reserved. C1 [Fleming, Lora E.; Clark, John; Clarke, Tainya; Byrne, Margaret] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA. [Fleming, Lora E.; Hollenbeck, Julie; Zaias, Julia] Univ Miami, NSF NIEHS Oceans & Human Hlth Ctr, Miami, FL 33149 USA. [Kirkpatrick, Barbara; Walsh, Cathy J.; Nierenberg, Kate; Pierce, Richard; Kirkpatrick, Gary] Mote Marine Lab, Sarasota, FL 34236 USA. [Backer, Lorraine C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. [Reich, Andrew; Benson, Janet; Cheng, Yung Sung; Watkins, Sharon] Florida Dept Health, Tallahassee, FL 32399 USA. [Reich, Andrew; Benson, Janet; Cheng, Yung Sung; Watkins, Sharon] Lovelace Resp Inst, Albuquerque, NM 87108 USA. [Naar, Jerome; Bourdelais, Andrea J.; Baden, Daniel G.] Univ N Carolina, Ctr Marine Sci, Wilmington, NC 28409 USA. [Abraham, William M.; Wanner, Adam; Mendes, Eliana] Univ Miami, Div Pulm Med, Dept Med, Miller Sch Med, Miami, FL 33136 USA. [Abraham, William M.] Mt Sinai Med Ctr, Dept Res, Miami Beach, FL 33140 USA. [Shalat, Stuart] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, EOHSI, Piscataway, NJ 08854 USA. [Shalat, Stuart] Rutgers State Univ, Piscataway, NJ 08854 USA. [Hoagland, Porter] Woods Hole Oceanog Inst, Marine Policy Ctr, Woods Hole, MA 02543 USA. [Stephan, Wendy] Univ Miami, Dept Pediat, Florida Poison Informat Ctr, Sch Med, Miami, FL 33136 USA. [Bean, Judy] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. RP Fleming, LE (reprint author), Univ Miami, Sch Med, Div Marine Biol & Fisheries, Dept Epidemiol & Publ Hlth, 1120 NW 14th Ave,Clin Res Bldg,10th Floor,Room 10, Miami, FL 33136 USA. EM lfleming@med.miami.edu OI Hoagland, Porter/0000-0003-0744-4184 FU National Institute for Environmental Health Sciences (NIEHS) [P01 ES10594, R21 ES014717, P30 ES005022, R21 ES017413]; Centers for Disease Control and Prevention (CDC); Florida Department of Health; National Science Foundation (NSF)-NIEHS Oceans and Human Health Center at the University of Miami Rosenstiel School of Marine and Atmospheric Sciences [NSF OCE0432368, NSF OCE0911373, NIEHS P50 ES12736]; NSF [1009106] FX This study was funded in part by the National Institute for Environmental Health Sciences (NIEHS) P01 ES10594, NIEHS R21 ES014717, NIEHS P30 ES005022, and NIEHS R21 ES017413; the Centers for Disease Control and Prevention (CDC); the Florida Department of Health; the National Science Foundation (NSF)-NIEHS Oceans and Human Health Center at the University of Miami Rosenstiel School of Marine and Atmospheric Sciences (NSF OCE0432368/OCE0911373; NIEHS P50 ES12736); and NSF 1009106.[SS] NR 132 TC 41 Z9 45 U1 10 U2 79 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1568-9883 EI 1878-1470 J9 HARMFUL ALGAE JI Harmful Algae PD JAN PY 2011 VL 10 IS 2 BP 224 EP 233 DI 10.1016/j.hal.2010.08.006 PG 10 WC Marine & Freshwater Biology SC Marine & Freshwater Biology GA 714XP UT WOS:000286845300013 PM 21218152 ER PT J AU Ragland, M Trivers, K Matthews, B Andrilla, CH Miller, J Lishner, D Goff, B Baldwin, L AF Ragland, M. Trivers, K. Matthews, B. Andrilla, C. H. Miller, J. Lishner, D. Goff, B. Baldwin, L. TI IS PHYSICIAN NON-PROFESSIONAL EXPERIENCE WITH CANCER ASSOCIATED WITH OVARIAN CANCER SCREENING PRACTICES? SO JOURNAL OF INVESTIGATIVE MEDICINE LA English DT Meeting Abstract C1 [Ragland, M.; Matthews, B.; Andrilla, C. H.; Lishner, D.; Goff, B.; Baldwin, L.] Univ Washington, Sch Med, Seattle, WA USA. [Trivers, K.; Miller, J.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1081-5589 J9 J INVEST MED JI J. Invest. Med. PD JAN PY 2011 VL 59 IS 1 MA 438 BP 211 EP 211 PG 1 WC Medicine, General & Internal; Medicine, Research & Experimental SC General & Internal Medicine; Research & Experimental Medicine GA 697TZ UT WOS:000285542500453 ER PT J AU Gallo, MF Nanda, K Grimes, DA Lopez, LM Schulz, KF AF Gallo, Maria F. Nanda, Kavita Grimes, David A. Lopez, Laureen M. Schulz, Kenneth F. TI 20 mu g versus > 20 mu g estrogen combined oral contraceptives for contraception SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review DE Contraceptives; Oral; Combined [administration & dosage; adverse effects]; Contraceptives; Oral; Hormonal [administration & dosage; adverse effects]; Desogestrel [administration & dosage; adverse effects]; Estrogens [administration & dosage; adverse effects]; Ethinyl Estradiol [administration & dosage; adverse effects]; Menstruation Disturbances [chemically induced]; Randomized Controlled Trials as Topic; Female; Humans ID G ETHINYL ESTRADIOL; CYCLE CONTROL; G GESTODENE; G ETHINYLESTRADIOL; BLEEDING PATTERNS; CARBOHYDRATE-METABOLISM; MONOPHASIC GESTODENE; CONTROLLED-TRIALS; RANDOMIZED-TRIAL; G LEVONORGESTREL AB Background Concern about estrogen-related adverse effects has led to progressive reductions in the estrogen dose in combination oral contraceptives (COCs). However, reducing the amount of estrogen to improve safety could result in decreased contraceptive effectiveness and unacceptable changes in bleeding patterns. Objectives To test the hypothesis that COCs containing <= 20 mu g ethinyl estradiol (EE) perform similarly as those containing > 20 mu g in terms of contraceptive effectiveness, bleeding patterns, discontinuation, and side effects. Search strategy We searched CENTRAL, MEDLINE, EMBASE, POPLINE, ClinicalTrials.gov, and ICTRP, and examined references of eligible trials. Initially, we wrote to oral contraceptive manufacturers to identify trials. Selection criteria English-language reports of randomized controlled trials were eligible that compare a COC containing <= 20 mu g EE with a COC containing > 20 mu g EE. We excluded studies where the interventions were designed to be administered for less than three consecutive cycles or to be used primarily as treatment for non-contraceptive conditions. Trials had to report on contraceptive effectiveness, bleeding patterns, trial discontinuation due to bleeding-related reasons or other side effects, or side effects to be included in the review. Data collection and analysis One author evaluated all titles and abstracts from literature searches to determine whether they met the inclusion criteria. Two authors independently extracted data from studies identified for inclusion. We wrote to the researchers when additional information was needed. Data were entered and analyzed with RevMan. Main results No differences were found in contraceptive effectiveness for the 13 COC pairs for which this outcome was reported. Compared to the higher-estrogen pills, several COCs containing 20 mu g EE resulted in higher rates of early trial discontinuation (overall and due to adverse events such as irregular bleeding) as well as increased risk of bleeding disturbances (both amenorrhea or infrequent bleeding and irregular, prolonged, frequent bleeding, or breakthrough bleeding or spotting). Authors' conclusions While COCs containing 20 mu g EE may be theoretically safer, this review did not focus on the rare events required to assess this hypothesis. Data from existing randomized controlled trials are inadequate to detect possible differences in contraceptive effectiveness. Low-dose estrogen COCs resulted in higher rates of bleeding pattern disruptions. However, most trials compared COCs containing different progestin types, and changes in bleeding patterns could be related to progestin type as well as estrogen dose. Higher follow-up rates are essential for meaningful interpretation of results. C1 [Gallo, Maria F.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Nanda, Kavita; Grimes, David A.; Lopez, Laureen M.; Schulz, Kenneth F.] FHI, Res Triangle Pk, NC USA. RP Gallo, MF (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway,Mail Stop K-34, Atlanta, GA 30341 USA. EM mgallo@cdc.gov FU National Institute of Child Health and Human Development, USA; U.S. Agency for International Development, USA FX External sources; National Institute of Child Health and Human Development, USA.; U.S. Agency for International Development, USA. NR 62 TC 10 Z9 10 U1 1 U2 4 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1469-493X J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2011 IS 1 AR CD003989 DI 10.1002/14651858.CD003989.pub4 PG 129 WC Medicine, General & Internal SC General & Internal Medicine GA 708VQ UT WOS:000286392800014 PM 21249657 ER PT J AU Blount, B Silva, L Cardinali, F Ashley, D LaKind, J AF Blount, Ben Silva, Lalith Cardinali, Fred Ashley, David LaKind, Judy TI Levels of Trihalomethanes in Tap Water and Human Blood in a Representative US Population, National Health and Nutrition Examination Survey 1999-2004 SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Blount, Ben; Silva, Lalith; Cardinali, Fred; Ashley, David] Ctr Dis Control & Prevent, Atlanta, GA USA. [LaKind, Judy] LaKind Associates LLC, Catonsville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S155 EP S156 DI 10.1097/01.ede.0000392149.66127.06 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800457 ER PT J AU Blount, B Valentin-Blasini, L Delinsky, A Otero-Santos, S AF Blount, Ben Valentin-Blasini, Liza Delinsky, Amy Otero-Santos, Samaret TI Exposure Assessment of the Developing Fetus and Newborn Infants: Methods to Measure Perchlorate and Related Anions in Maternal and Fetal Matrices SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Blount, Ben; Valentin-Blasini, Liza; Delinsky, Amy; Otero-Santos, Samaret] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S114 EP S114 DI 10.1097/01.ede.0000392019.57130.8d PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800327 ER PT J AU Boehmer, T Flanders, D Yip, F Samat, J AF Boehmer, Tegan Flanders, Dana Yip, Fuyuen Samat, Jeremy TI Air Quality Impacts of Higher Gas Prices in Atlanta, Georgia During 2006-2008 SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Boehmer, Tegan; Flanders, Dana; Yip, Fuyuen; Samat, Jeremy] Ctr Dis Control & Prevent, Atlanta, GA USA. [Flanders, Dana; Samat, Jeremy] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S200 EP S201 DI 10.1097/01.ede.0000392297.33130.35 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800605 ER PT J AU Bradman, A Castorina, R Rosas, LG Fenster, L Marks, A Sjodin, A Harley, K Holland, N Eskenazi, B AF Bradman, Asa Castorina, Rosemary Rosas, Lisa Goldman Fenster, Laura Marks, Amy Sjodin, Andreas Harley, Kim Holland, Nina Eskenazi, Brenda TI Polybrominated Diphenyl Ether (PBDE) Exposure Among Mexican Children and Mexican-American Children in the CHAMACOS Cohort, and NHANES SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Bradman, Asa; Castorina, Rosemary; Marks, Amy; Harley, Kim; Holland, Nina; Eskenazi, Brenda] UC Berkeley, Sch Publ Hlth, Ctr Childrens Environm Hlth Res, Berkeley, CA USA. [Rosas, Lisa Goldman] UCSF, Dept Family & Community Med, Ctr Social Dispar Hlth, San Francisco, CA USA. [Fenster, Laura] Calif Dept Publ Hlth, Div Environm & Occupat Dis Control, Richmond, CA USA. [Sjodin, Andreas] CDC, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RI Sjodin, Andreas/F-2464-2010 NR 0 TC 0 Z9 0 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S148 EP S148 DI 10.1097/01.ede.0000392127.88105.bc PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800435 ER PT J AU Bush, KF Frumkin, H Kotha, SR Dhiman, RC Eisenberg, J Sur, D Rood, R Batterman, S Joseph, A Gronlund, C Agrawal, A Shah, B Hu, H Kapil, V Luber, G Brown, DG Kaur, T Hess, J Wilson, M Balakrishnan, K AF Bush, Kathleen F. Frumkin, Howard Kotha, S. Rani Dhiman, R. C. Eisenberg, Joseph Sur, Dipika Rood, Richard Batterman, Stuart Joseph, Aley Gronlund, Carina Agrawal, Arun Shah, Bela Hu, Howard Kapil, Vilcas Luber, George Brown, Daniel G. Kaur, Tanvir Hess, Jeremy Wilson, Mark Balakrishnan, Kalpana TI The Impact of Climate Change on Public Health in India: Future Research Directions SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Bush, Kathleen F.; Eisenberg, Joseph; Batterman, Stuart; Gronlund, Carina; Hu, Howard] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Bush, Kathleen F.; Kotha, S. Rani; Hu, Howard] Univ Michigan, Ctr Global Hlth, Ann Arbor, MI 48109 USA. [Frumkin, Howard; Kapil, Vilcas; Luber, George; Hess, Jeremy] Ctr Dis Control, Atlanta, GA 30333 USA. [Dhiman, R. C.; Sur, Dipika; Shah, Bela; Kaur, Tanvir] Indian Council Med Res, Delhi, India. [Eisenberg, Joseph; Joseph, Aley; Wilson, Mark] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Rood, Richard] Univ Michigan, Coll Engn, Dept Atmospher Ocean & Space Sci, Ann Arbor, MI 48109 USA. [Agrawal, Arun; Brown, Daniel G.] Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA. [Balakrishnan, Kalpana] Dept Occupat & Environm Hlth, Chennai, Tamil Nadu, India. RI Brown, Daniel/L-8089-2013 OI Brown, Daniel/0000-0001-6023-5950 NR 0 TC 0 Z9 0 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S21 EP S21 DI 10.1097/01.ede.0000391722.16123.9b PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800030 ER PT J AU Castorina, R Bradman, A Fenster, L Sjodin, A Jones, R Eisen, E Harley, K Holland, N Eskenazi, B AF Castorina, Rosemary Bradman, Asa Fenster, Laura Sjodin, Andreas Jones, Richard Eisen, Ellen Harley, Kim Holland, Nina Eskenazi, Brenda TI Predictors of Serum Polybrominated Diphenyl Ether (PBDE) Exposure Among Pregnant Women Living in California, and Comparison of Maternal and Child Levels SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Castorina, Rosemary; Bradman, Asa; Eisen, Ellen; Harley, Kim; Holland, Nina; Eskenazi, Brenda] UC Berkeley Sch Publ Hlth, Ctr Childrens Environm Hlth Res, Berkeley, CA USA. [Fenster, Laura] Calif Dept Publ Hlth, Div Environm & Occupat Dis Control, Richmond, CA USA. [Sjodin, Andreas; Jones, Richard] CDC, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RI Sjodin, Andreas/F-2464-2010 NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S81 EP S81 DI 10.1097/01.ede.0000391911.23952.2f PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800219 ER PT J AU Eftim, S Parker, J Kravets, N Nachman, K Sapkota, A AF Eftim, Sorina Parker, Jenniifer Kravets, Natalyia Nachman, Keeve Sapkota, Amir TI Validation of Traffic Exposure Surrogates Against a Biomarker of Internal Dose Among Nonsmoking US Population SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Eftim, Sorina; Sapkota, Amir] Univ Maryland, College Pk, MD 20742 USA. [Parker, Jenniifer; Kravets, Natalyia] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Nachman, Keeve] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S204 EP S204 DI 10.1097/01.ede.0000392309.01743.93 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800617 ER PT J AU Eskenazi, B Warner, M Fuerst, T Rubinacci, A Sirtori, M Marksm, A Needham, L Brambilla, P Mocarelli, P AF Eskenazi, Brenda Warner, Marcella Fuerst, Thomas Rubinacci, Alessandro Sirtori, Marcella Marksm, Amy Needham, Larry Brambilla, Paolo Mocarelli, Paolo TI Serum Dioxin Concentrations and Bone Mineral Density in the Seveso Women's Health Study SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Eskenazi, Brenda; Warner, Marcella; Marksm, Amy] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Fuerst, Thomas] Synarc Inc, San Francisco, CA USA. [Rubinacci, Alessandro; Sirtori, Marcella] Ist Sci San Raffaele, I-20132 Milan, Italy. [Needham, Larry] Ctr Dis Control & Prevent, Atlanta, GA USA. [Brambilla, Paolo; Mocarelli, Paolo] Univ Milano Bicocca, Desio, Italy. RI Needham, Larry/E-4930-2011 NR 0 TC 0 Z9 0 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S55 EP S55 DI 10.1097/01.ede.0000391830.96342.c5 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800138 ER PT J AU Hoepner, L Whyatt, R Ramirez, J Calafat, A Perera, F Rundle, A AF Hoepner, Lori Whyatt, Robin Ramirez, Judy Calafat, Antonia Perera, Frederica Rundle, Andrew TI The Effect of Prenatal and Early Life Exposure to Bisphenol A on Body Size at Age 7 Years SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Hoepner, Lori; Whyatt, Robin; Ramirez, Judy; Perera, Frederica] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA. [Calafat, Antonia] Ctr Dis Control, Atlanta, GA 30333 USA. [Rundle, Andrew] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S170 EP S171 DI 10.1097/01.ede.0000392198.92951.e5 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800506 ER PT J AU Lewis, L Redwood, Y Kieszak, S Daniel, J McCoy, L Schleicher, R McGeehin, M Breiman, R AF Lewis, Lauren Redwood, Yanique Kieszak, Stephanie Daniel, Johnni McCoy, Les Schleicher, Rosemary McGeehin, Michael Breiman, Robert TI Aflatoxin Exposure in a High Risk Population in Eastern Kenya SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Lewis, Lauren; Redwood, Yanique; Kieszak, Stephanie; Daniel, Johnni; McCoy, Les; Schleicher, Rosemary; McGeehin, Michael; Breiman, Robert] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S114 EP S114 DI 10.1097/01.ede.0000392018.19012.d1 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800326 ER PT J AU Martin, CA Schier, J Chang, A Gurley, E Hossain, MJ Rahman, M Luby, S Haider, MS Alamgir, ASM Homaira, N Husain, MM Wazed, MA Birkholz, D Skinner, C Yard, E Wolkin, A Lewis, L Thomas, J AF Martin, Colleen A. Schier, Joshua Chang, Arthur Gurley, Emily Hossain, M. Jahangir Rahman, Mahmudur Luby, Stephen Haider, M. Sabbir Alamgir, A. S. M. Homaira, Nusrat Husain, M. Mushtuq Wazed, M. A. Birkholz, Detlef Skinner, Carl Yard, Ellen Wolkin, Amy Lewis, Lauren Thomas, Jerry TI Investigation of an Outbreak of Unintentional Acute Pesticide Poisoning: Assessment of Exposure to Carbamate and Organophosphate Insecticides, Rural Bangladesh, 2009 SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Martin, Colleen A.; Schier, Joshua; Chang, Arthur; Skinner, Carl; Yard, Ellen; Wolkin, Amy; Lewis, Lauren; Thomas, Jerry] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gurley, Emily; Hossain, M. Jahangir; Luby, Stephen; Homaira, Nusrat] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Rahman, Mahmudur; Haider, M. Sabbir; Alamgir, A. S. M.; Husain, M. Mushtuq; Wazed, M. A.] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh. [Birkholz, Detlef] ALS Lab Grp, Edmonton, AB, Canada. RI Gurley, Emily/B-7903-2010 OI Gurley, Emily/0000-0002-8648-9403 NR 0 TC 1 Z9 1 U1 3 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S115 EP S115 DI 10.1097/01.ede.0000392020.64753.3c PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800328 ER PT J AU Mehta, S Parker, J Akinbami, L Murtugudde, R Sapkota, A AF Mehta, Suril Parker, Jennifer Akinbami, Lam Murtugudde, Raghu Sapkota, Amir TI Climate Events and Health Outcomes: Data Linkage From 2 Large National Databases SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Mehta, Suril; Parker, Jennifer; Akinbami, Lam] Ctr Dis Control & Prevent, Hyattsville, MD USA. [Murtugudde, Raghu; Sapkota, Amir] Univ Maryland, College Pk, MD 20742 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S25 EP S25 DI 10.1097/01.ede.0000391735.47441.e0 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800043 ER PT J AU Murphy, M Barney, Y Begay, MG Morgan, P Kieszak, S Caldwell, K Chang, A Graham, S McGeehin, M Lewis, L AF Murphy, Matthew Barney, Yolanda Begay, Mae-Gilene Morgan, Philbert Kieszak, Stephanie Caldwell, Kathleen Chang, Art Graham, Shannon McGeehin, Michael Lewis, Lauren TI Investigation of Household Drinking Water Sources and Contaminant Exposures in the Navajo Nation, 2008-2009 SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Murphy, Matthew; Kieszak, Stephanie; Caldwell, Kathleen; Chang, Art; McGeehin, Michael; Lewis, Lauren] Ctr Dis Control & Prevent, Atlanta, GA USA. [Barney, Yolanda; Morgan, Philbert] Navajo Nation Environm Protect Agcy, Window Rock, AZ USA. [Begay, Mae-Gilene] Navajo Nation Div Hlth, Window Rock, AZ USA. [Graham, Shannon] Agcy Tox Subst & Dis Registry, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S114 EP S114 DI 10.1097/01.ede.0000392017.19012.35 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800325 ER PT J AU Philippat, C Mortamais, M Chevrier, C Petit, C Calafat, A Cordier, S Slama, R Manori, S Ye, XY AF Philippat, Claire Mortamais, Marion Chevrier, Cecile Petit, Claire Calafat, Antonia Cordier, Sylvaine Slama, Remy Manori, Silvia Ye Xiaoyun TI Maternal Exposure to Phthalates and Phenols and Fetal Growth Among Male Newborns SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Philippat, Claire; Slama, Remy] Inserm Univ J Fourier Grenoble, INSERM, Avenir Team Environm Epidemiol Appl Fecund & Repr, Joint Res Ctr U823, Grenoble, France. [Mortamais, Marion] INSERM, U888, Montpellier, France. [Chevrier, Cecile; Petit, Claire; Cordier, Sylvaine] INSERM, Rennes, France. [Chevrier, Cecile; Petit, Claire; Cordier, Sylvaine] Univ Rennes 1, Rennes, France. [Calafat, Antonia; Manori, Silvia; Ye Xiaoyun] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RI Philippat, Claire/N-2423-2013; Cordier, Sylvaine/F-7919-2013; Slama, Remy/M-1755-2013; Chevrier, Cecile/J-9170-2015 OI Slama, Remy/0000-0002-8980-8529; NR 0 TC 0 Z9 0 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S127 EP S127 DI 10.1097/01.ede.0000392058.70591.a3 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800366 ER PT J AU Sapkota, A Eftim, S Nachman, K Kravets, N Shenassa, E Akinbami, L Parker, J AF Sapkota, Amir Eftim, Sorina Nachman, Keeve Kravets, Natalyia Shenassa, Edmund Akinbami, Lara Parker, Jenniifer TI Traffic Exposure and Asthma Exacerbation Among a Nationally Representative Sample of the US Population SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Sapkota, Amir; Eftim, Sorina; Shenassa, Edmund] Univ Maryland, College Pk, MD 20742 USA. [Nachman, Keeve] Johns Hopkins Univ, Baltimore, MD USA. [Kravets, Natalyia] NOVA Res Co, Hyattsville, MD USA. [Akinbami, Lara; Parker, Jenniifer] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S64 EP S64 DI 10.1097/01.ede.0000391858.04859.c4 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800166 ER PT J AU Sarnat, JA Greenwald, R Yip, F Bergin, M Kewada, P Gooch, J Boswell, C Boehmer, T AF Sarnat, Jeremy A. Greenwald, Roby Yip, Fuyuen Bergin, Mike Kewada, Priya Gooch, James Boswell, Colin Boehmer, Tegan TI In-vehicle Correlations Among Particle Number, Organic, and Inorganic Species for a Cohort of Car Commuters in Atlanta SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Sarnat, Jeremy A.; Greenwald, Roby; Kewada, Priya; Gooch, James] Emory Univ, Atlanta, GA 30322 USA. [Sarnat, Jeremy A.; Yip, Fuyuen] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bergin, Mike; Boswell, Colin; Boehmer, Tegan] Georgia Inst Technol, Atlanta, GA 30332 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S214 EP S214 DI 10.1097/01.ede.0000392342.77085.7b PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800650 ER PT J AU Teitelbaum, S Calafat, A AF Teitelbaum, Susan Calafat, Antonia TI Assessment Methodology for Newly Emerging Exposures in Environmental Epidemiology SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Teitelbaum, Susan] Mt Sinai Sch Med, New York, NY USA. [Calafat, Antonia] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S132 EP S132 DI 10.1097/01.ede.0000392074.06031.90 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800382 ER PT J AU Warner, M Eskenazi, B Samuels, S Needham, L Brambilla, P Mocarelli, P AF Warner, Marcella Eskenazi, Brenda Samuels, Steven Needham, Larry Brambilla, Paolo Mocarelli, Paolo TI Serum Dioxin Concentrations and Breast Cancer Risk in the Seveso Women SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Warner, Marcella; Eskenazi, Brenda] Univ Calif Berkeley, Berkeley, CA 94720 USA. [Samuels, Steven] SUNY Albany, Albany, NY 12222 USA. [Needham, Larry] Ctr Dis Control & Prevent, Atlanta, GA USA. [Brambilla, Paolo; Mocarelli, Paolo] Univ Milano Bicocca, Desio, Italy. RI Needham, Larry/E-4930-2011 NR 0 TC 1 Z9 1 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S102 EP S102 DI 10.1097/01.ede.0000391980.95316.94 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800288 ER PT J AU Wartenberg, D Parker, J Woodruff, T Rich, DQ AF Wartenberg, Dan Parker, Jennifer Woodruff, Tracey Rich, David Q. TI The ICAPPO Collaboration on Air Pollution and Birth Outcomes: A Meta-analysis of Pilot Data SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Wartenberg, Dan; Rich, David Q.] UMDNJ RobertWood Johnson Med Sch, Piscataway, NJ USA. [Wartenberg, Dan] UMDNJ Sch Publ Hlth, Piscataway, NJ USA. [Parker, Jennifer] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Woodruff, Tracey] Univ Calif San Francisco, San Francisco, CA 94143 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S121 EP S121 DI 10.1097/01.ede.0000392041.23064.58 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800349 ER PT J AU Whyatt, R Arias, F Calafat, A Rauh, V Factor-Litvak, P AF Whyatt, Robin Arias, Franchesca Calafat, Antonia Rauh, Virginia Factor-Litvak, Pam TI Associations Between Maternal Prenatal Phthalate Urinary Metabolite Concentrations and Child Mental and Motor Development at Age 3 Years SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Whyatt, Robin; Arias, Franchesca; Rauh, Virginia] Columbia Univ, Columbia Ctr Childrens Environm Hlth, New York, NY USA. [Whyatt, Robin; Arias, Franchesca] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA. [Calafat, Antonia] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rauh, Virginia] Columbia Univ, Mailman Sch Publ Hlth, Dept Populat & Family Hlth, New York, NY USA. [Calafat, Antonia] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. NR 0 TC 1 Z9 1 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S126 EP S127 DI 10.1097/01.ede.0000392057.32473.08 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800365 ER PT J AU Yard, E Terrell, M Hunt, D Cameron, L Small, C McGeehin, M Marcus, M AF Yard, Ellen Terrell, Metrecia Hunt, Danielle Cameron, Lorraine Small, Chanley McGeehin, Michael Marcus, Michele TI Incidence of Thyroid Disease Following Exposure to Polybrominated Biphenyls and Polychlorinated Biphenyls, Michigan, 1974-2006 SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Yard, Ellen; Hunt, Danielle; McGeehin, Michael; Marcus, Michele] Ctr Dis Control & Prevent, Atlanta, GA USA. [Terrell, Metrecia; Small, Chanley; Marcus, Michele] Rollins Sch Publ Hlth, Atlanta, GA USA. [Cameron, Lorraine] Michigan Dept Community Hlth, Lansing, MI USA. RI Marcus, Michele/J-2746-2015 NR 0 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S55 EP S55 DI 10.1097/01.ede.0000391831.34460.a8 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800139 ER PT J AU Yip, F Samat, J Holguin, F Garbe, P AF Yip, Fuyuen Samat, Jeremy Holguin, Fernando Garbe, Paul TI Impact of Ambient Air Pollution on the Respiratory Health of Children With Sickle Cell Anemia in Atlanta, Georgia SO EPIDEMIOLOGY LA English DT Meeting Abstract CT Joint Conference of International-Society-of-Exposure-Science/International-Society-for-Envi ronmental-Epidemiology CY AUG 28-SEP 01, 2010 CL Seoul, SOUTH KOREA SP Int Soc Exposure Sci, Int Soc Environm Epidemiol C1 [Yip, Fuyuen; Garbe, Paul] Ctr Dis Control & Prevent, Atlanta, GA USA. [Samat, Jeremy] Emory Univ, Atlanta, GA 30322 USA. [Holguin, Fernando] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JAN PY 2011 VL 22 IS 1 SU S BP S66 EP S66 DI 10.1097/01.ede.0000391865.17428.4a PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695VN UT WOS:000285400800173 ER PT J AU Jamison, M Grotegut, C James, A AF Jamison, Margaret Grotegut, Chad James, Andra TI Risk factors, rate and mortality associated with cardiomyopathy in pregnancy SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-for-Maternal-Fetal-Medicine CY FEB 01-06, 2010 CL Chicago, IL SP Soc Maternal Fetal Med C1 [Jamison, Margaret] Natl Ctr Hlth Stat, CDC, Res Triangle Pk, NC USA. [Grotegut, Chad; James, Andra] Duke Univ, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JAN PY 2011 VL 204 SU 1 MA 804 BP S314 EP S315 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 702WV UT WOS:000285927500801 ER PT J AU Wilson, P Davis, K Meyer, P Bukowski, R AF Wilson, Peter Davis, Karen Meyer, Peter Bukowski, Radek TI Delivery of a small for gestational age infant and risk of ischemic heart disease SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Meeting Abstract CT 30th Annual Meeting of the Society-for-Maternal-Fetal-Medicine CY FEB 01-06, 2010 CL Chicago, IL SP Soc Maternal Fetal Med C1 [Wilson, Peter] Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA. [Davis, Karen; Meyer, Peter] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Res Data Ctr, Hyattsville, MD 20782 USA. [Bukowski, Radek] Univ Texas Med Branch, Galveston, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JAN PY 2011 VL 204 SU 1 MA 161 BP S76 EP S76 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 702WV UT WOS:000285927500161 ER PT J AU Schlessinger, S Kokko, K Fratkin, J Butt, F Hawxby, A Todaro, M Henderson, H Seawright, A Parker, C Byers, P Gonzalez-Peralta, R Kayler, L Fauerbach, L Lawrence, R Haafi, A Stanek, D Hammond, R Thoroughman, D Pippen, T Johnson, S Mahle, W Lyon, G Laporte, K Kanter, K Ivey, M Arnold, K Lance, S Navarro-Almario, E Farnon, E Kuehnert, M Shieh, W Paddock, C Zaki, S Drew, C Schmitz, A Sejvar, J Sriram, R Visvesvara, G Beach, M Yoder, J Roy, S Qvarnstrom, Y Bandea, R daSilva, A Bosserman, E Budge, P Lutterloh, E AF Schlessinger, S. Kokko, K. Fratkin, J. Butt, F. Hawxby, A. Todaro, M. Henderson, H. Seawright, A. Parker, C. Byers, P. Gonzalez-Peralta, R. Kayler, L. Fauerbach, L. Lawrence, R. Haafi, A. Stanek, D. Hammond, R. Thoroughman, D. Pippen, T. Johnson, S. Mahle, W. Lyon, G., III Laporte, K. Kanter, K. Ivey, M. Arnold, K. Lance, S. Navarro-Almario, E. Farnon, E. Kuehnert, M. Shieh, W. Paddock, C. Zaki, S. Drew, C. Schmitz, A. Sejvar, J. Sriram, R. Visvesvara, G. Beach, M. Yoder, J. Roy, S. Qvarnstrom, Y. Bandea, R. daSilva, A. Bosserman, E. Budge, P. Lutterloh, E. TI Balamuthia mandrillaris Transmitted Through Organ Transplantation - Mississippi, 2009 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material ID MENINGOENCEPHALITIS; PATIENT C1 [Schlessinger, S.] Mississippi Organ Recovery Agcy, Flowood, MS USA. [Kokko, K.; Fratkin, J.; Butt, F.; Hawxby, A.; Todaro, M.; Henderson, H.; Seawright, A.; Parker, C.] Univ Mississippi, Med Ctr, University, MS 38677 USA. [Gonzalez-Peralta, R.; Kayler, L.; Fauerbach, L.; Lawrence, R.; Haafi, A.] Univ Florida, Shands Hosp, Gainesville, FL 32611 USA. [Mahle, W.; Lyon, G., III; Laporte, K.; Kanter, K.] Emory Univ, Atlanta, GA 30322 USA. [Navarro-Almario, E.] US FDA, Rockville, MD 20857 USA. [Budge, P.; Lutterloh, E.] CDC, Atlanta, GA 30333 USA. RP Schlessinger, S (reprint author), Mississippi Organ Recovery Agcy, Flowood, MS USA. NR 10 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JAN PY 2011 VL 11 IS 1 BP 173 EP 176 DI 10.1111/j.1600-6143.2010.03395_1.x PG 4 WC Surgery; Transplantation SC Surgery; Transplantation GA 700ZG UT WOS:000285783500026 ER PT J AU Mbaeyi, C AF Mbaeyi, C. CA Ctr Global Hlth TI Notes from the Field: Transplant-Transmitted Balamuthia mandrillaris - Arizona, 2010 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material C1 [Mbaeyi, C.] CDC, Atlanta, GA 30333 USA. RP Mbaeyi, C (reprint author), CDC, Atlanta, GA 30333 USA. NR 3 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1600-6135 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JAN PY 2011 VL 11 IS 1 BP 176 EP 176 DI 10.1111/j.1600-6143.2010.03395_2.x PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA 700ZG UT WOS:000285783500027 ER PT J AU Kalasapudi, B Shah, S Leleiko, N Lidofsky, S Bright, R Grabert, S Law, M Moniz, H Bancroft, B Patel, M Harris, A Cole, E Merrick, M Flowers, N Sands, B AF Kalasapudi, B. Shah, S. Leleiko, N. Lidofsky, S. Bright, R. Grabert, S. Law, M. Moniz, H. Bancroft, B. Patel, M. Harris, A. Cole, E. Merrick, M. Flowers, N. Sands, B. TI Medical therapy of IBD in the first year after diagnosis: Preliminary results from the Ocean State Crohn's and Colitis Area Registry (OSCCAR). SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Kalasapudi, B.; Shah, S.; Leleiko, N.; Lidofsky, S.; Bright, R.; Law, M.; Moniz, H.; Bancroft, B.; Patel, M.; Harris, A.] Lifespan, Providence, RI USA. [Kalasapudi, B.; Shah, S.; Leleiko, N.; Lidofsky, S.; Bright, R.; Law, M.; Moniz, H.; Bancroft, B.; Patel, M.; Harris, A.] Brown Univ, Providence, RI 02912 USA. [Grabert, S.; Cole, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Merrick, M.] Crohns & Colitis Fdn Amer, New York, NY USA. [Flowers, N.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sands, B.] Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2011 VL 17 SU 1 BP S8 EP S9 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 693WO UT WOS:000285256300027 ER PT J AU Kalasapudi, B Shah, S Leleiko, N Lidofsky, S Bright, R Grabert, S Law, M Moniz, H Bancroft, B Patel, M Harris, A Cole, E Merrick, M Flowers, N Sands, B AF Kalasapudi, B. Shah, S. Leleiko, N. Lidofsky, S. Bright, R. Grabert, S. Law, M. Moniz, H. Bancroft, B. Patel, M. Harris, A. Cole, E. Merrick, M. Flowers, N. Sands, B. TI Presenting Symptoms at Diagnosis of Crohn's Disease and Ulcerative Colitis: Results from the Ocean State Crohn's and Colitis Area Registry (OSCCAR) SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohn's and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Kalasapudi, B.; Shah, S.; Leleiko, N.; Lidofsky, S.; Bright, R.; Law, M.; Moniz, H.; Bancroft, B.; Patel, M.; Harris, A.] Brown Univ, Providence, RI 02912 USA. [Kalasapudi, B.; Shah, S.; Leleiko, N.; Lidofsky, S.; Bright, R.; Law, M.; Moniz, H.; Bancroft, B.; Patel, M.; Harris, A.] Lifespan, Providence, RI USA. [Law, M.; Cole, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Merrick, M.] Crohns & Colitis Fdn Amer, New York, NY USA. [Flowers, N.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sands, B.] Mt Sinai Sch Med, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2011 VL 17 SU 1 BP S48 EP S48 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 693WO UT WOS:000285256300157 ER PT J AU Sands, B Shah, S Leleiko, N Lidofsky, S Bright, R Grabert, S Law, M Moniz, H Bancroft, B Kalasapudi, B Cole, E Merrick, M Flowers, N Patel, M Harris, A AF Sands, B. Shah, S. Leleiko, N. Lidofsky, S. Bright, R. Grabert, S. Law, M. Moniz, H. Bancroft, B. Kalasapudi, B. Cole, E. Merrick, M. Flowers, N. Patel, M. Harris, A. TI Ocean State Crohn's and Colitis Area Registry (OSCCAR): Incidence of Crohn's disease and ulcerative colitis in a prospective, population-based inception cohort in Rhode Island. SO INFLAMMATORY BOWEL DISEASES LA English DT Meeting Abstract CT Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference CY DEC 09-12, 2010 CL Hollywood, FL C1 [Sands, B.] Mt Sinai Sch Med, New York, NY USA. [Shah, S.; Leleiko, N.; Lidofsky, S.; Bright, R.; Law, M.; Moniz, H.; Bancroft, B.; Kalasapudi, B.; Patel, M.; Harris, A.] Lifespan, Providence, RI USA. [Shah, S.; Leleiko, N.; Lidofsky, S.; Bright, R.; Law, M.; Moniz, H.; Bancroft, B.; Kalasapudi, B.; Patel, M.; Harris, A.] Brown Univ, Providence, RI 02912 USA. [Grabert, S.; Cole, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Merrick, M.] Crohns & Colitis Fdn Amer, New York, NY USA. [Flowers, N.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1078-0998 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2011 VL 17 SU 1 BP S8 EP S8 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 693WO UT WOS:000285256300026 ER PT J AU Chesson, H Markowitz, L AF Chesson, H. Markowitz, L. BE Alary, M TI The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination of Females over Age 12 Years in the United States SO 19TH CONFERENCE OF THE INTERNATIONAL SOCIETY FOR STD RESEARCH (ISSTDR) LA English DT Proceedings Paper CT 19th Conference of the International-Society-for-Sexually-Transmitted-Diseases-Research (ISSTDR) CY JUL 10-13, 2011 CL Quebec, CANADA SP Int Soc Sexually Transmitted Dis Res (ISSTDR) ID HPV; WOMEN AB We used a previously-published, simplified model of HPV transmission to estimate the cost-effectiveness of HPV vaccination strategies for females in the US. Results from our model suggest that catch-up vaccination of females generally becomes less cost-effective as age at vaccination increases, a result which is consistent with previously published models. Vaccination of females becomes less cost-effective in our model as the duration of the catch-up program increases, and also if males are vaccinated. C1 [Chesson, H.; Markowitz, L.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. NR 8 TC 1 Z9 1 U1 0 U2 2 PU MEDIMOND S R L PI 40128 BOLOGNA PA VIA MASERATI 5, 40128 BOLOGNA, 00000, ITALY BN 978-88-7587-629-6 PY 2011 BP 19 EP 22 PG 4 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA BYT83 UT WOS:000300217600004 ER PT J AU Saville, AW Albright, K Nowels, C Barnard, J Daley, MF Stokley, S Irby, K Kempe, A AF Saville, Alison W. Albright, Karen Nowels, Carolyn Barnard, Juliana Daley, Matthew F. Stokley, Shannon Irby, Kimberly Kempe, Allison TI Getting Under the Hood: Exploring Issues That Affect Provider-Based Recall Using an Immunization Information System SO ACADEMIC PEDIATRICS LA English DT Article DE immunization information systems; immunizations; recall and reminder messages ID QUALITATIVE CONTENT-ANALYSIS; UNITED-STATES; INTERVENTIONS; ADOLESCENTS; CHILDREN AB OBJECTIVE: To assess 1) pediatric practices' use of provider-based recall using an immunization information system 8 months after training on the recall process; 2) initiation and sustainability barriers to provider-based recall using an immunization information system; 3) strategies that facilitated recall initiation; and 4) recommendations for alternative approaches for conducting recall. METHODS: In 2008,11 practices received training on the automatic recall function in the Colorado Immunization Information System (CIIS) for both infants and adolescents. The 2-hour computer-based training provided an opportunity for attendees to run real-time recall reports with CIIS staff assistance. Eight months later, key informant interviews were conducted with 24 providers and staff from these practices. RESULTS: Eight months after training, only 4 of 11 practices had implemented recall using CIIS: 3 practices recalled children <= 2 years of age, and I practice recalled adolescent girls for human papillomavirus vaccine. Initiation barriers included lack of awareness of baseline immunization rates, distrust in the accuracy of CHS-generated data, and perceived difficulties recalling adolescents. Having unrealistic expectations about recall effectiveness was a barrier to sustainability. Strategies that facilitated recall included having a dedicated staff person for recall efforts and recalling children <= 2 years of age. Most key informants viewed population-based recall conducted by public health departments or schools as an acceptable alternative to provider-based recall. CONCLUSIONS: Even with a promising tool to assist pediatric offices, implementing provider-based recall is challenging for pediatric practices. Given existing barriers, providers expressed support for alternative recall methods. C1 [Saville, Alison W.; Albright, Karen; Barnard, Juliana; Daley, Matthew F.; Kempe, Allison] Childrens Hosp, Childrens Outcomes Res Program, Denver, CO 80218 USA. [Albright, Karen] Univ Colorado, Colorado Sch Publ Hlth, Dept Community & Behav Hlth, Denver, CO 80202 USA. [Saville, Alison W.; Albright, Karen; Nowels, Carolyn; Barnard, Juliana] Univ Colorado, Colorado Hlth Outcomes Res Program, Denver, CO 80202 USA. [Daley, Matthew F.; Kempe, Allison] Univ Colorado, Dept Pediat, Denver, CO 80202 USA. [Stokley, Shannon] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Irby, Kimberly] Colorado Dept Publ Hlth & Environm, Immunizat Program, Denver, CO USA. RP Saville, AW (reprint author), 12477 E 19th Ave F443, Aurora, CO 80045 USA. EM Alison.saville@ucdenver.edu FU Centers for Disease Control and Prevention [3U01IP000129-02W1] FX This investigation was funded by a grant from the Centers for Disease Control and Prevention 3U01IP000129-02W1 to the University of Colorado Denver. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the US Department of Health and Human Services. NR 18 TC 25 Z9 25 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 J9 ACAD PEDIATR JI Acad. Pediatr. PD JAN-FEB PY 2011 VL 11 IS 1 BP 44 EP 49 DI 10.1016/j.acap.2010.12.009 PG 6 WC Pediatrics SC Pediatrics GA 716YK UT WOS:000287009200009 PM 21272823 ER PT J AU Pankratov, O Shimanskaya, I Pankratov, V Navrotsky, A Ballard, R Unemo, M Domeika, M AF Pankratov, Oleg Shimanskaya, Iryna Pankratov, Valentin Navrotsky, Alexandr Ballard, Ronald Unemo, Magnus Domeika, Marius TI Laboratory Diagnosis of Sexually Transmitted Infections in Belarus SO ACTA DERMATO-VENEREOLOGICA LA English DT Letter ID POLYMERASE-CHAIN-REACTION; NEISSERIA-GONORRHOEAE; 1ST EVALUATION; RUSSIA; QUALITY C1 [Pankratov, Oleg; Shimanskaya, Iryna] Belarusian State Med Acad Postgrad Studies, Minsk, Byelarus. [Pankratov, Valentin; Navrotsky, Alexandr] Belarusian State Med Univ, Minsk, Byelarus. [Ballard, Ronald] Ctr Dis Control & Prevent CDC, Div STD Prevent, Atlanta, GA USA. [Unemo, Magnus] Orebro Univ Hosp, Dept Lab Med, Orebro, Sweden. [Domeika, Marius] Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden. RP Pankratov, O (reprint author), Belarusian State Med Acad Postgrad Studies, Minsk, Byelarus. EM marius.domeika@medsci.uu.se NR 11 TC 2 Z9 2 U1 1 U2 4 PU ACTA DERMATO-VENEREOLOGICA PI UPPSALA PA TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN SN 0001-5555 J9 ACTA DERM-VENEREOL JI Acta Derm.-Venereol. PY 2011 VL 91 IS 1 BP 64 EP 65 DI 10.2340/00015555-0982 PG 2 WC Dermatology SC Dermatology GA 710YV UT WOS:000286553800013 PM 21103829 ER PT J AU Shimanskaya, I Zhurauskaya, L Pankratov, O Unemo, M Ballard, R Domeika, M AF Shimanskaya, Iryna Zhurauskaya, Larisa Pankratov, Oleg Unemo, Magnus Ballard, Ronald Domeika, Marius TI Evaluation of Three Serological Tests Manufactured in Belarus for the Diagnosis of Syphilis SO ACTA DERMATO-VENEREOLOGICA LA English DT Article DE syphilis; serology; laboratory diagnosis; Treponema pallidum passive particle agglutination; rapid plasma reagin; Belarus ID SEXUALLY-TRANSMITTED INFECTIONS; RUSSIAN-FEDERATION; ST-PETERSBURG; PREVALENCE; MOSCOW AB The performance of three serological tests manufactured in Belarus for the diagnosis of syphilis, i.e. a microprecipitation reaction (MPR) and two enzyme-linked immunosorbent assays (ELISAs) were compared with internationally recognized assays, namely the rapid plasma reagin test and the Treponema pallidum passive particle agglutination assay (TPPA). Sera from 392 consecutive patients attending Brest (Belarus) regional dermatovenereological dispensaries were tested. The sensitivity of the MPR test was low (77.3%) compared with the rapid plasma reagin test, while the specificity was high (100%). In contrast, both Belarusian ELISAs performed well when compared with the TPPA (sensitivities of 99.2% and 100%, specificities of 98.7% and 99.0%, respectively). There is a clear need to improve the sensitivity of the existing Belarusian MPR test or to use a more sensitive screening test in order to improve diagnosis of the disease in Belarus. C1 [Domeika, Marius] Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden. [Shimanskaya, Iryna] Belarus Med Acad Postgrad Studies, Dept Dermatovenereol, Minsk, Byelarus. [Zhurauskaya, Larisa] Brest Reg Dermatovenereol Dispensary, Brest, Byelarus. [Pankratov, Oleg] Belarus State Med Univ, Minsk, Byelarus. [Unemo, Magnus] Orebro Univ Hosp, Dept Lab Med, Swedish Reference Lab Pathogen Neisseria, Orebro, Sweden. [Ballard, Ronald] Ctr Dis Control & Prevent CDC, Div STD Prevent, Atlanta, GA USA. [Domeika, Marius] Eastern European Comm Swedish Hlth Care Community, Stockholm, Sweden. RP Domeika, M (reprint author), Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden. EM marius.domeika@medsci.uu.se FU Swedish Developmental Agency (SIDA) via Eastern European Committee of Swedish Health Care Community [6013] FX This study was conducted as an activity of the East European Network for Sexual and Reproductive Health (EE SRH Network), which works towards quality enhancement of STI diagnostic services in the area. Authors wish to thank the laboratory personnel and administration of the Brest Central Skin and Venereal Disease Dispensary for help in organizing the study and running the tests and regional dispensaries for providing with samples. The study was support by the grant provided by Swedish Developmental Agency (SIDA) via Eastern European Committee of Swedish Health Care Community, No 6013. NR 13 TC 1 Z9 1 U1 1 U2 5 PU ACTA DERMATO-VENEREOLOGICA PI UPPSALA PA TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN SN 0001-5555 J9 ACTA DERM-VENEREOL JI Acta Derm.-Venereol. PY 2011 VL 91 IS 3 BP 299 EP 302 DI 10.2340/00015555-1056 PG 4 WC Dermatology SC Dermatology GA 783EB UT WOS:000292063200008 PM 21369683 ER PT J AU Domeika, M Babayan, K Ismailov, R Shimanskaya, I Chudomirova, K Brilene, T Kvlividze, O Deak, J Askarova, G Mamajeva, G Kucinskiene, V Frigo, N Savicheva, A Krasnoselskich, T Mavrov, G Kasymov, O Izvekova, O Unemo, M Ballard, RC AF Domeika, Marius Babayan, Karen Ismailov, Rashad Shimanskaya, Iryna Chudomirova, Krasimira Brilene, Tatjana Kvlividze, Oleg Deak, Judith Askarova, Gulsum Mamajeva, Galina Kucinskiene, Vesta Frigo, Natalia Savicheva, Alevtina Krasnoselskich, Tatiana Mavrov, Gennadiy Kasymov, Olim Izvekova, Olga Unemo, Magnus Ballard, Ronald Campbell TI Survey of Diagnostic Services for Genital Herpes in Fourteen Countries in Eastern Europe SO ACTA DERMATO-VENEREOLOGICA LA English DT Article DE genital herpes infection; diagnosis; Eastern Europe ID SIMPLEX-VIRUS; ULCER DISEASE; INFECTION; ETIOLOGY AB This paper reports survey-based data on the diagnosis and management of genital herpes simplex virus (HSV) infection in 14 countries of the Eastern European Network for Sexual and Reproductive Health (EE SRH). Only 43% of the countries could provide the number of genital HSV cases recorded at national level. Eighty-six percent of countries employed syndromic management in cases of genital ulcer disease. Most countries performed type-specific and/or non-type-specific enzyme immunoassays to detect HSV antibodies. Non-type-specific serology for diagnostic purposes should be actively discouraged. Direct detection methods for HSV, such as PCR, antigen detection and culture, are available in the region, but their usage was extremely low. Their use in Eastern European countries should be actively promoted. The availability of laboratory services must be improved, and countries in the region should implement consensus recommendations for the laboratory diagnosis of genital HSV infections in order to improve clinical practice. C1 [Domeika, Marius] Uppsala Univ, Dept Med Sci, SE-78185 Uppsala, Sweden. [Domeika, Marius] Eastern European Comm Swedish Hlth Care Community, Stockholm, Sweden. [Babayan, Karen] Med Sci Ctr Dermatol, Yerevan, Armenia. [Babayan, Karen] STI, Yerevan, Armenia. [Ismailov, Rashad] Skin & Venereal Dis Dispensary, Baku, Azerbaijan. [Shimanskaya, Iryna] Belarus Med Acad Postgrad Studies, Dept Dermatovenereol, Minsk, Byelarus. [Chudomirova, Krasimira] Plovdiv Med Univ, Dept Dermatovenereol, Plovdiv, Bulgaria. [Brilene, Tatjana] Univ Tartu, Biomed Ctr, EE-50090 Tartu, Estonia. [Kvlividze, Oleg] Tbilisi State Univ, Dept Med, GE-380086 Tbilisi, Rep of Georgia. [Deak, Judith] Univ Szeged, Szeged, Hungary. [Askarova, Gulsum] Res Inst Skin & Venereal Dis Dispensary, Alma Ata, Kazakhstan. [Mamajeva, Galina] Republican Skin & Venereal Dis Dispensary, Bishkek, Kyrgyzstan. [Kucinskiene, Vesta] Kaunas Univ Med, Skin & Venereal Dis Dept, Kaunas, Lithuania. [Frigo, Natalia] Cent Inst Skin & Venereal Dis, Microbiol Lab, Moscow, Russia. [Savicheva, Alevtina] RAMS, DO Ott Inst Obstet & Gynecol, St Petersburg, Russia. [Krasnoselskich, Tatiana] Pavlov State Med Univ, Dept Dermatol & Venereol, St Petersburg, Russia. [Kasymov, Olim] Inst Postgrad Med Educ, Dept Skin & Venereal Dis, Dushanbe, Tajikistan. [Izvekova, Olga] Inst Dermatovenereol, Tashkent, Uzbekistan. [Unemo, Magnus] Orebro Univ Hosp, Dept Lab Med, Swedish Reference Lab Pathogen Neisseria, Orebro, Sweden. [Ballard, Ronald Campbell] Ctr Dis Control & Prevent, Div STD Prevent, CDC, Atlanta, GA USA. RP Domeika, M (reprint author), Uppsala Univ, Dept Med Sci, Dag Hammarskjolds Vag 17, SE-78185 Uppsala, Sweden. EM marius.domeika@medsci.uu.se OI Deak, Judit/0000-0002-5477-0241 FU East Europe Committee of the Swedish Health Care Community, SIDA FX The present study was supported by a grant from the East Europe Committee of the Swedish Health Care Community, SIDA. NR 12 TC 0 Z9 0 U1 0 U2 8 PU ACTA DERMATO-VENEREOLOGICA PI UPPSALA PA TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN SN 0001-5555 J9 ACTA DERM-VENEREOL JI Acta Derm.-Venereol. PY 2011 VL 91 IS 3 BP 333 EP 336 DI 10.2340/00015555-1033 PG 4 WC Dermatology SC Dermatology GA 783EB UT WOS:000292063200014 PM 21369687 ER PT J AU Polson, KA Brogdon, WG Rawlins, SC Chadee, DD AF Polson, Karen A. Brogdon, William G. Rawlins, Samuel C. Chadee, Dave D. TI Characterization of insecticide resistance in Trinidadian strains of Aedes aegypti mosquitoes SO ACTA TROPICA LA English DT Article DE Aedes aegypti; Insecticide resistance; Resistance mechanisms ID SODIUM-CHANNEL GENE; CROSS-RESISTANCE; PROTEIN MICROASSAY; DDT-RESISTANCE; CULICIDAE; ANOPHELES; DIPTERA; ORGANOPHOSPHORUS; POPULATIONS; MECHANISMS AB Bioassays and biochemical assays were conducted on eight Trinidadian strains of Aedes aegypti larvae to determine the involvement of biochemical mechanisms in resistance to insecticides. Larval strains were assayed to dichlorodiphenyltrichloroethane (DDT), bendiocarb, temephos and permethrin, using the Centers for Disease Control and Prevention (CDC) time-mortality bioassay method. A Resistance Threshold (RT) was calculated for each insecticide in relation to the CAREC reference susceptible Ae. aegypti strain and larval strains with <80% mortality were considered to be resistant. Biochemical assays were performed to determine the activities of nonspecific esterases (alpha- and beta-), PNPA-esterases, mixed function oxidases (MFO), glutathione-S-transferases (GST) and acetylcholinesterase (AChE) enzymes which are involved in insecticide resistance in mosquitoes. Enzyme profiles of each strain were compared with those of the CAREC reference susceptible strain by Kruskal-Wallis and Dunn's multiple comparison tests (p < 0.05). The CAREC 99th percentile was calculated for each enzyme and the percentage of individuals with enzyme activities above that of the CAREC 99th percentile was calculated. Activities were classified as unaltered (<50%), incipiently altered (15-50%) or altered (>50%) for each strain. The established RTs for permethrin and bendiocarb were 30 and 75 min, respectively; and 120 min for DDT and temephos. All strains were resistant to DDT (1.00-40.25% mortality) and temephos (11.50-74.50% mortality) while six strains were resistant to bendiocarb (51.50-78.50% mortality) and five to permethrin (6.50-42.50% mortality). Biochemical assays revealed that the median activity levels for all enzymes varied significantly (p < 0.05). The Curepe strain had incipiently altered levels of alpha-esterase while the other seven strains had altered activity with five of them registering 100%. The St Clair strain showed altered activity levels of beta-esterase while three strains had incipiently altered levels. The majority of strains had altered activity of MFO enzymes but only the St Clair strain showed altered activity of GST. PNPA-esterases activity was unaltered in all strains and only the Haleland Park strain showed altered remaining AChE activity in the presence of propoxur. Elevated levels of enzymes (incipiently altered or altered), except in the case of PNPA-esterases, show that biochemical resistance may play an important role in the manifestation of insecticide resistance in Trinidadian populations of Ae. aegypti. It is therefore important for insecticide resistance surveillance to be ongoing as the detection of resistance before it spreads throughout an entire population makes it possible for early intervention. (C) 2010 Elsevier B.V. All rights reserved. C1 [Polson, Karen A.; Chadee, Dave D.] Univ W Indies, St Augustine, Trinid & Tobago. [Brogdon, William G.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Rawlins, Samuel C.] Caribbean Epidemiol Ctr CAREC, Port Of Spain, Trinid & Tobago. RP Chadee, DD (reprint author), Univ W Indies, St Augustine, Trinid & Tobago. EM chadee@tstt.net.tt NR 56 TC 32 Z9 34 U1 1 U2 13 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0001-706X EI 1873-6254 J9 ACTA TROP JI Acta Trop. PD JAN PY 2011 VL 117 IS 1 BP 31 EP 38 DI 10.1016/j.actatropica.2010.09.005 PG 8 WC Parasitology; Tropical Medicine SC Parasitology; Tropical Medicine GA 687NQ UT WOS:000284785600007 PM 20858454 ER PT S AU Smith, TG Wu, XF Franka, R Rupprecht, CE AF Smith, Todd G. Wu, Xianfu Franka, Richard Rupprecht, Charles E. BE Jackson, AC TI Design of Future Rabies Biologics and Antiviral Drugs SO ADVANCES IN VIRUS RESEARCH: RESEARCH ADVANCES IN RABIES, VOL 79 SE Advances in Virus Research LA English DT Review; Book Chapter ID HUMAN MONOCLONAL-ANTIBODY; RECEPTOR-CHANNEL BLOCKERS; CHICK EMBRYO CELLS; POSTEXPOSURE PROPHYLAXIS; VIRUS GLYCOPROTEIN; IMMUNE GLOBULIN; NEUTRALIZING ANTIBODIES; PHOSPHOPROTEIN-P; HUMAN ADENOVIRUS; VACCINE AB In recent years, no major paradigm shifts have occurred in the utilization of new products for the prevention and control of rabies. Development of new cost-effective rabies biologics and antiviral drugs is critical in continuing to prevent and reduce disease. Current rabies vaccines are highly effective but have developed largely based on technical improvements in the vaccine industry. In the future, alternative approaches for improved vaccines, including novel avirulent rabies virus (RABV) vectors, should be pursued, Any rabies vaccine that is effective without the need for rabies immune globulin (RIG) will contribute fundamentally to disease prevention by reducing the cost and complexity of postexposure prophylaxis (PEP). The lack of high quality, affordable RIG is a continuing problem. Virus-specific monoclonal antibodies (mAbs) will soon fulfill the PEP requirement for passive immunity, currently met with RIG. Several relevant strategies for mAb production, including use of transgenic mice, humanization of mouse mAbs, and generation of human immune libraries, are underway. As a result of successful PEP and pre-exposure prophylaxis in developed countries, until recently, no significant focused efforts have been devoted to RABV-specific antiviral agents. To date, combination therapy including broad spectrum antiviral agents has been successful in only one case, and reports of antiviral activity are often conflicting. Current antiviral strategies target either the nucleoprotein or phosphoprotein, but drugs targeting the viral polymerase should be considered. Considering the lag from creation of new concepts to experimental development and clinical trials, many years will likely elapse between today's ideas and tomorrow's practices. C1 [Smith, Todd G.; Wu, Xianfu; Franka, Richard; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA USA. RP Smith, TG (reprint author), Ctr Dis Control & Prevent, Poxvirus & Rabies Branch, Atlanta, GA USA. NR 116 TC 13 Z9 15 U1 0 U2 12 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0065-3527 BN 978-0-12-387040-7 J9 ADV VIRUS RES JI Adv.Virus Res. PY 2011 VL 79 BP 345 EP 363 DI 10.1016/B978-0-12-387040-7.00016-0 PG 19 WC Virology SC Virology GA BVG79 UT WOS:000291501900016 PM 21601054 ER PT J AU Malisa, A Pearce, R Abdullah, S Mutayoba, B Mshinda, H Kachur, P Bloland, P Roper, C AF Malisa, A. Pearce, R. Abdullah, S. Mutayoba, B. Mshinda, H. Kachur, P. Bloland, P. Roper, C. TI Molecular monitoring of resistant dhfr and dhps allelic haplotypes in Morogoro and Mvomero districts in south eastern Tanzania SO AFRICAN HEALTH SCIENCES LA English DT Article DE Plasmodium falciparum infection; Sulfadoxine/Pyrimethamine resistance; Polymerase Chain Reaction; Sequence Specific Oligonucleotide Probing ID INTERMITTENT PREVENTIVE TREATMENT; PLASMODIUM-FALCIPARUM INFECTIONS; PYRIMETHAMINE TREATMENT FAILURE; SULFADOXINE-PYRIMETHAMINE; DIHYDROPTEROATE SYNTHASE; DIHYDROFOLATE-REDUCTASE; TREATMENT POLICY; MALARIA; EFFICACY; MARKERS AB Background: Resistance to the antimalarial drug sulfadoxine-pyrimethamine (SP) emerged in Plasmodium falciparum from Asia in the 1960s and subsequently spread to Africa. In Tanzania, SP use as a national policy began in 1983 as a second line to chloroquine (CQ) for the treatment of uncomplicated malaria, until August 2001 when it was approved to replace CQ as a national first line. Objective: The present study assesses the frequency of resistant dhfr and dhps alleles in Morogoro-Mvomero district in south eastern Tanzania and contrast their rate of change during 17 years of SP second line use against five years of SP first line use. Methodology: Cross sectional surveys of asymptomatic infections were carried out at the end of rainy season during July-September of 2000, when SP was the national second line (CQ was the first line) and 2006 when SP was the national first line antimalarial treatment. Genetic analysis of SP resistance genes was carried out on 1,044 asymptomatic infections and the effect of the two policies on SP evolution compared. Results: The frequency of the most resistant allele, the double dhps-triple dhfr mutant genotype, increased by only 1% during 17 years of SP second line use, but there was a dramatic increase by 45% during five years of SP first line use. Conclusion: We conclude that National policy change from second line to first line SP, brought about an immediate shift in treatment practice and this in turn had a highly significant impact on drug pressure. The use of SP in specific programs only such as intermittent preventive treatment of infants (IPTi) and intermittent preventive treatment of pregnant women (IPTp) will most likely reduce substantially SP selection pressure and the SP resistance alleles alike. C1 [Malisa, A.] SUA, Fac Sci, Dept Biol Sci, Morogoro, Tanzania. [Pearce, R.; Roper, C.] London Sch Hyg & Trop Med, Dept Infect Trop Dis, Pathogen Mol Biol Unit, London WC1, England. [Malisa, A.; Abdullah, S.; Mshinda, H.] Ifakara Hlth Inst IHI Ifakara, Morogoro, Tanzania. [Mutayoba, B.] SUA, Fac Vet Med, Dept Vet Physiol Biochem Pharmacol & Toxicol, Morogoro, Tanzania. [Kachur, P.; Bloland, P.] Ctr Dis Control & Prevent CDC, Malaria Epidemiol Branch, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA USA. RP Malisa, A (reprint author), SUA, Fac Sci, Dept Biol Sci, POB 3038, Morogoro, Tanzania. EM amalisa@suanet.ac.tz RI Roper, Cally/K-2989-2013 OI Roper, Cally/0000-0002-6545-309X FU Interdisciplinary Monitoring Project for Antimalarial Combination Therapy in Tanzania (IMPACT-Tz); United States Agency for International Development (USAID) FX We are grateful to the people of Mvomero and Morogoro districts who participated in the study. We also thank the IMPACT-Tz team members who did the surveys in 2000 and 2006. This study was conducted under the auspices of Interdisciplinary Monitoring Project for Antimalarial Combination Therapy in Tanzania (IMPACT-Tz). IMPACT-Tz is primarily supported financially by the United States Agency for International Development (USAID) NR 26 TC 4 Z9 5 U1 0 U2 0 PU MAKERERE UNIV, FAC MED PI KAMPALA PA PO BOX 7072, KAMPALA, 00000, UGANDA SN 1680-6905 J9 AFR HEALTH SCI JI Afr. Health Sci. PY 2011 VL 11 IS 2 BP 142 EP 150 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 846PX UT WOS:000296916800001 PM 21857842 ER PT J AU Singh, K Buckner, B Tate, J Ndubani, P Kamwanga, J AF Singh, K. Buckner, B. Tate, J. Ndubani, P. Kamwanga, J. TI Age, poverty and alcohol use as HIV risk factors for women in Mongu, Zambia SO AFRICAN HEALTH SCIENCES LA English DT Article DE HIV; poverty; alcohol; young women; Zambia ID SUB-SAHARAN AFRICA; INFECTION AB Background: Age, poverty and alcohol use are seen as risk factors for HIV among women in sub-Saharan Africa. Objective: The objective of this study was to understand the influence of socioeconomic factors (including age and poverty) as well as alcohol use on risky sexual behaviors among women in Mongu, Zambia. Methods: This study examines these factors in the local context of Mongu, Zambia using the Priorities for Local AIDS Control Efforts (PLACE) methodology. This methodology allows for the study of risky behaviors while taking into consideration local factors. The two outcome variable studied were transactional sex in the past year and having two or more sexual partners in the past year. Results: In this study age was not a significant factor, but alcohol use and poverty/desire for economic advancement were significant factors. Conclusion: Programs and policies need to address the influence of alcohol on risky sexual behaviors and also the important but complex influence of poverty. C1 [Singh, K.; Buckner, B.] Univ N Carolina, Chapel Hill, NC 27516 USA. [Tate, J.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Ndubani, P.; Kamwanga, J.] Frontiers Dev & Res Grp, Lusaka, Zambia. RP Singh, K (reprint author), Univ N Carolina, CB 8120, Chapel Hill, NC 27516 USA. FU U.S. Agency for International Development (USAID) [GPO-A-00-03-00003-00] FX This paper is based on work funded by the U.S. Agency for International Development (USAID) under the terms of Cooperative Agreement GPO-A-00-03-00003-00. The authors wish to thank the interviewers and respondents for their participation, efforts and time. They also wish to thank Paul Brodish for his assistance with revising the manuscript. NR 17 TC 1 Z9 1 U1 0 U2 1 PU MAKERERE UNIV, FAC MED PI KAMPALA PA PO BOX 7072, KAMPALA, 00000, UGANDA SN 1680-6905 J9 AFR HEALTH SCI JI Afr. Health Sci. PY 2011 VL 11 IS 2 BP 204 EP 210 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 846PX UT WOS:000296916800011 PM 21857851 ER PT J AU Ybarra, ML Mitchell, KJ Hamburger, M Diener-West, M Leaf, PJ AF Ybarra, Michele L. Mitchell, Kimberly J. Hamburger, Merle Diener-West, Marie Leaf, Philip J. TI X-Rated Material and Perpetration of Sexually Aggressive Behavior Among Children and Adolescents: Is There a Link? SO AGGRESSIVE BEHAVIOR LA English DT Article DE pornography; internet; sexual aggression; youth violence prevention; longitudinal study ID PROTECTIVE FACTORS; INTERNET SAMPLES; PORNOGRAPHY; EXPOSURE; VIOLENCE; PREDICTORS; RISK; VICTIMIZATION; METAANALYSIS; VICTIMS AB Longitudinal linkages between intentional exposure to x-rated material and sexually aggressive behavior were examined among youth 10-15 year olds surveyed nationally in the United States. At Wave 1 in 2006, participants (n=1,588) were queried about these exposures and outcomes in the preceding 12 months. Wave 2 data (n=1,206) were collected approximately 12 months after Wave 1 and Wave 3 data (n=1,159) were collected approximately 24 months after Wave 1. Thus, data for this project represent a 36-month time frame. A marginal model with generalized estimating equations was used to represent the population-average odds of sexually aggressive behavior over the 36 months as a function of exposure to x-rated material over the same time and to account for clustering in the data within person over time. An average of 5% of youth reported perpetrating sexually aggressive behavior and 23% of youth reported intentional exposure to x-rated material. After adjusting for other potentially influential proximal (i.e., sexual aggression victimization) and distal characteristics (e. g., substance use), we found that intentional exposure to violent x-rated material over time predicted an almost 6-fold increase in the odds of self-reported sexually aggressive behavior (aOR: 5.8, 95% CI: 3.2, 10.5), whereas exposure to nonviolent x-rated material was not statistically significantly related (aOR: 1.7, 95% CI: 0.94, 2.9). Associations were similar for boys and girls (boys nonviolent x-rated material aOR=2.0, 95% CI: 0.8, 4.7; violent x-rated material aOR=6.5, 95% CI: 2.7, 15.3; girls nonviolent x-rated material aOR=1.2, 95% CI: 0.5, 3.2; violet x-rated material aOR=6.1, 95% CI: 2.5, 14.8). Aggr. Behav. 37: 1-18, 2011. (C) 2010 Wiley-Liss, Inc. C1 [Ybarra, Michele L.] Internet Solut Kids, Santa Ana, CA 92705 USA. [Mitchell, Kimberly J.] Univ New Hampshire, Durham, NH 03824 USA. [Hamburger, Merle] Ctr Dis Control & Prevent, Atlanta, GA USA. [Diener-West, Marie; Leaf, Philip J.] Johns Hopkins Sch Publ Hlth, Baltimore, MD USA. RP Ybarra, ML (reprint author), Internet Solut Kids, 1820 E Garry Ave 105, Santa Ana, CA 92705 USA. EM Michele@ISolutions4kids.org FU Centers for Disease Control and Prevention (CDC) [U49/CE000206] FX Grant sponsor: Centers for Disease Control and Prevention (CDC); Grant number: U49/CE000206. NR 67 TC 41 Z9 41 U1 2 U2 29 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0096-140X J9 AGGRESSIVE BEHAV JI Aggressive Behav. PD JAN-FEB PY 2011 VL 37 IS 1 BP 1 EP 18 DI 10.1002/ab.20367 PG 18 WC Behavioral Sciences; Psychology, Multidisciplinary SC Behavioral Sciences; Psychology GA 695UM UT WOS:000285398100001 PM 21046607 ER PT J AU Marc, LG Patel-Larson, A Hall, HI Hughes, D Alegria, M Jeantyc, G Eveillard, YS Jean-Louis, E AF Marc, Linda G. Patel-Larson, Alpa Hall, H. Irene Hughes, Denise Alegria, Margarita Jeantyc, Georgette Eveillard, Yanick Sanon Jean-Louis, Eustache CA NHAHA TI HIV among Haitian-born persons in the United States 1985 to 2007 (vol 24, pg 2089, 2010) SO AIDS LA English DT Correction C1 [Marc, Linda G.; Alegria, Margarita] Cambridge Hlth Alliance, Ctr Multicultural Mental Hlth Res, Somerville, MA USA. [Marc, Linda G.; Alegria, Margarita] Harvard Univ, Sch Med, Somerville, MA USA. [Patel-Larson, Alpa; Hall, H. Irene; Hughes, Denise] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Jeantyc, Georgette] Res Inst Behav Sci Int, Boston, MA USA. [Jeantyc, Georgette; Eveillard, Yanick Sanon] NHAHA, New York, NY USA. [Jean-Louis, Eustache] CCHER, Boston, MA USA. RP Marc, LG (reprint author), Cambridge Hlth Alliance, Ctr Multicultural Mental Hlth Res, Somerville, MA USA. NR 1 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD JAN PY 2011 VL 25 IS 2 BP 277 EP 277 DI 10.1097/QAD.0b013e3283436073 PG 1 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 697GT UT WOS:000285501900022 ER PT J AU Gruber, D Campos, P Dutcher, M Safford, L Phillips, K Craw, J Gardner, L AF Gruber, DeAnn Campos, Peter Dutcher, Marcia Safford, Laurie Phillips, Karen Craw, Jason Gardner, Lytt TI Linking recently diagnosed HIV-positive persons to medical care: perspectives of referring providers SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; linking to medical care; referring providers; case management ID ANTIRETROVIRAL TREATMENT ACCESS; HETEROSEXUAL TRANSMISSION; INFECTED PERSONS; UNITED-STATES; VIRAL LOAD; SERVICES; INTERVENTION; ENGAGEMENT; RETENTION; IMPACT AB Background. Quantitative results from clients participating in the Antiretroviral Treatment Access Studies-II (ARTAS-II) intervention have previously been published. The current report provides qualitative data from providers (agency staff who referred clients to ARTAS-II) concerning how the introduction of ARTAS-II case managers affected referrals to HIV care. Methods. Referring providers from agencies that conducted HIV counseling and testing (community organizations, health care clinics, hospitals, and public health agencies) that had been asked to refer recently diagnosed HIV-positive individuals to ARTAS-II participated. Five ARTAS-II sites interviewed a total of 18 providers using a survey instrument of 11 open-ended questions. The questions covered interviewee characteristics (e.g., how long have you been in this position, job title) and questions related to the ARTAS-II project (e.g., before ARTAS-II, how did you link clients? what benefits have come from being part of the ARTAS-II program?) Results. Prior to the ARTAS-II project, the referring providers described the referral process as ranging from uncertain to disorganized and chaotic. Referring providers reported the process improved dramatically following implementation of the project, with the transition from HIV testing to medical care becoming less complicated and less prone to delays. Recommendations from the providers for further improvement included increasing the number of ARTAS-II case managers, having the program staff use direct, face-to-face communication with staff at referring agencies, and increasing system integration by having ARTAS-II program staff be co-located in clinic settings. Conclusion. The introduction of ARTAS-II case managers to receive referrals from HIV counseling and testing programs was widely viewed as a success by referring providers. ARTAS-II case managers were reported to fill a much needed role that strengthened the HIV service delivery system. C1 [Gruber, DeAnn] Louisiana Off Publ Hlth, HIV AIDS Program, New Orleans, LA USA. [Campos, Peter] AIDS Survival Project, Atlanta, GA USA. [Dutcher, Marcia] Kansas City Free Hlth Clin, Kansas City, MO USA. [Safford, Laurie] Virginia Commonwealth Univ, Richmond, VA USA. [Phillips, Karen] Hlth Serv Ctr, Anniston, AL USA. [Craw, Jason] Northrop Grumman Corp, Atlanta, GA USA. [Gardner, Lytt] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Gruber, D (reprint author), Louisiana Off Publ Hlth, HIV AIDS Program, New Orleans, LA USA. EM deann.gruber@la.gov NR 25 TC 7 Z9 7 U1 0 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2011 VL 23 IS 1 BP 16 EP 24 AR PII 931921462 DI 10.1080/09540121.2010.498865 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 714QE UT WOS:000286823300003 PM 21218273 ER PT J AU Pereyra, M Metsch, LR Tomar, S Valverde, E Jeanty, Y Messinger, S Boza, H AF Pereyra, Margaret Metsch, Lisa R. Tomar, Scott Valverde, Eduardo Jeanty, Yves Messinger, Shari Boza, Henry TI Utilization of dental care services among low-income HIV-positive persons receiving primary care in South Florida SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE oral health; HIV; dental health services; primary health care ID ACTIVE ANTIRETROVIRAL THERAPY; BEHAVIORAL-MODEL; MEDICAL-CARE; ORAL-HEALTH; VULNERABLE POPULATIONS; UNMET NEEDS; INFECTION; ACCESS; WOMEN; MANIFESTATIONS AB We investigated the use of dental care services among a population of low-income persons living with HIV/AIDS who had not seen a dental care provider during the 12 months prior to study enrollment. A total of 593 participants were recruited from five HIV primary care clinics in two South Florida counties and interviewed regarding past utilization of dental care services, HIV primary care service utilization, and barriers to care. Multivariate logistic regression analysis was used to determine correlates of oral care utilization within the preceding two years. One-third of respondents reported seeing a dentist in the preceding two years. The odds of having seen a dentist were greater for respondents with stable housing, more than a high school education, and who had received help in getting dental care; black respondents (compared to Hispanics and non-Hispanic whites) were less likely to have seen a dentist in the preceding two years. Despite the availability of dental services for low-income HIV-positive persons, utilization of dental care remains low. This study reinforces the need to provide assistance to HIV-positive persons in obtaining dental care. In particular, it indicates that such assistance should be targeted toward Black Americans, persons with low income and unstable housing situations, and those with limited help to navigate the health care system. C1 [Pereyra, Margaret; Metsch, Lisa R.; Jeanty, Yves; Messinger, Shari; Boza, Henry] Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA. [Tomar, Scott] Univ Florida, Coll Dent, Dept Community Dent & Behav Sci, Gainesville, FL USA. [Valverde, Eduardo] Ctr Dis Control & Prevent, Behav & Clin Surveillance Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Pereyra, M (reprint author), Univ Miami, Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33136 USA. EM mpereyra@med.miami.edu FU NIDCR NIH HHS [R01 DE015523-06, R01 DE015523] NR 37 TC 4 Z9 4 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2011 VL 23 IS 1 BP 98 EP 106 AR PII 931919501 DI 10.1080/09540121.2010.498861 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 714QE UT WOS:000286823300013 PM 21218282 ER PT J AU Barzilay, EJ Aghoghovbia, TS Blanton, EM Akinpelumi, AA Coldiron, ME Akinfolayan, O Adeleye, OA LaTrielle, A Hoekstra, RM Gilpin, U Quick, R AF Barzilay, Ezra J. Aghoghovbia, Titilayo S. Blanton, Elizabeth M. Akinpelumi, Abiodun A. Coldiron, Matthew E. Akinfolayan, Olamide Adeleye, Olufolake A. LaTrielle, Amy Hoekstra, Robert M. Gilpin, Uzoamaka Quick, Robert TI Diarrhea prevention in people living with HIV: an evaluation of a point-of-use water quality intervention in Lagos, Nigeria SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; AIDS; diarrhea; water treatment; PMTCT ID HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; SAFE STORAGE; OPPORTUNISTIC INFECTIONS; DEVELOPING-COUNTRIES; RURAL UGANDA; TUBERCULOSIS; CHLORINATION; DISEASE; METAANALYSIS AB Diarrhea is a leading cause of morbidity and mortality in people living with HIV (PLHIV) in Africa. The impact of a point-of-use water chlorination and storage intervention on diarrheal-disease risk in a population of HIV-infected women in Lagos, Nigeria was evaluated. A baseline survey was performed, followed by six weeks of baseline diarrhea surveillance consisting of weekly home visits, distribution of free water chlorination products and safe storage containers to project participants, and continued weekly home-based diarrhea surveillance for 15 additional weeks. To confirm use of the water chlorination product, during each home visit, stored water was tested for residual chlorine. About 187 women were enrolled. At baseline, 80% of women had access to improved water supplies and 95% had access to sanitation facilities. Following distribution of the intervention, water stored in participants' households was observed to have residual chlorine during 50-80% of home visits, a sign of adherence to recommended water-treatment practices. Diarrhea rates in project participants were 36% lower in the post-intervention period than during the baseline period (p=0.04). Diarrhea rates were 46% lower in the post-intervention period than the baseline period among project participants who were confirmed to have residual chlorine in stored water during 85% or more of home visits (p=0.04); there was no significant difference in diarrhea rates between baseline and post-intervention periods in participants confirmed to have residual chlorine in stored water during less than 85% of home visits. The percent change in diarrhea rates between baseline and post-intervention surveillance periods was statistically significant among non-users of prophylactic antibiotics (-62%, p=0.02) and among persons who used neither prophylactic antibiotics nor antiretroviral treatment (-46%, p=0.04). Point-of-use water treatment was associated with a reduced risk of diarrhea in PLHIV. Regular water treatment was required to achieve health benefits. C1 [Barzilay, Ezra J.; Blanton, Elizabeth M.; Quick, Robert] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA 30333 USA. [Aghoghovbia, Titilayo S.; Akinfolayan, Olamide; Adeleye, Olufolake A.] HOPE Worldwide, Lagos, Nigeria. [Akinpelumi, Abiodun A.; LaTrielle, Amy] Soc Family Hlth, Abuja, Nigeria. [Coldiron, Matthew E.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Hoekstra, Robert M.] Ctr Dis Control & Prevent, Biostat Informat Management Branch, Atlanta, GA USA. [Gilpin, Uzoamaka] Populat Serv Int, Washington, DC USA. RP Barzilay, EJ (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA 30333 USA. EM bwk9@cdc.gov NR 36 TC 13 Z9 13 U1 5 U2 10 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2011 VL 23 IS 3 BP 330 EP 339 AR PII 933807665 DI 10.1080/09540121.2010.507749 PG 10 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 724NZ UT WOS:000287584800009 PM 21347896 ER PT J AU Kyser, M Buchacz, K Bush, TJ Conley, LJ Hammer, J Henry, K Kojic, EM Milam, J Overton, ET Wood, KC Brooks, JT AF Kyser, Melanie Buchacz, Kate Bush, Timothy J. Conley, Lois J. Hammer, John Henry, Keith Kojic, Erna M. Milam, Joel Overton, E. Turner Wood, Kathy C. Brooks, John T. TI Factors associated with non-adherence to antiretroviral therapy in the SUN study SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE adherence; risk factors; cART; HAART ID HIV-INFECTED PATIENTS; LESS-THAN 95-PERCENT; DEPRESSIVE SYMPTOMS; MEDICATION ADHERENCE; GENERAL-POPULATION; PHYSICAL-ACTIVITY; MORTALITY; COHORT; PREDICTORS; PATIENT AB Background. Adherence of 95% or greater to highly active combination antiretroviral therapy is generally considered necessary to achieve optimal virologic suppression in HIV-infected patients. Understanding factors associated with poor adherence is essential to improve patient compliance, maximize virologic suppression, and reduce morbidity and mortality. Methods. We evaluated baseline data from 528 patients taking antiretrovirals, enrolled from March 2004 to June 2006, in a multicenter, longitudinal, prospective cohort study (the SUN study). Using multiple logistic regression, we examined independent risk factors for non-adherence, defined as reporting having missed one or more antiretroviral doses in the past three days on the baseline questionnaire. Results. Of 528 participants (22% female, 28% black, median age 41 years, and median CD4 cell count 486 cells/mm(3)), 85 (16%) were non-adherent. In the final parsimonious multivariate model, factors independently associated with non-adherence included black race (adjusted odds ratio (aOR): 2.08, 95% confidence interval (CI): 1.20-3.60 vs. white race), being unemployed and looking for work (aOR: 2.03, 95% CI: 1.14-3.61 vs. all other employment categories), having been diagnosed with HIV >= 5 years ago (aOR: 1.95, 95% CI: 1.18-3.24 vs. being HIV-diagnosed <5 years ago), drinking three or more drinks per day (aOR: 1.73, 95% CI: 1.02-2.91 vs. drinking <3 drinks per day), and having not engaged in any aerobic exercise in the last 30 days (aOR: 2.13, 95% CI: 1.25-3.57). Conclusion. Although the above factors may not be causally related to non-adherence, they might serve as proxies for identifying HIV-infected patients at greatest risk for non-adherence who may benefit from additional adherence support. C1 [Kyser, Melanie; Buchacz, Kate; Bush, Timothy J.; Conley, Lois J.; Brooks, John T.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis TB & STD Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Hammer, John] Rose Med Ctr, Denver, CO USA. [Henry, Keith] Univ Minnesota, Hennepin Cty Med Ctr, HIV Program, Minneapolis, MN 55415 USA. [Kojic, Erna M.] Brown Univ, Miriam Hosp, Providence, RI USA. [Milam, Joel] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA. [Overton, E. Turner] Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA. [Wood, Kathy C.] Cerner Corp, Vienna, VA USA. RP Brooks, JT (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis TB & STD Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM zud4@cdc.gov NR 44 TC 25 Z9 28 U1 3 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2011 VL 23 IS 5 BP 601 EP 611 DI 10.1080/09540121.2010.525603 PG 11 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 750LM UT WOS:000289548100010 PM 21293992 ER PT J AU Sullivan, PS Juhasz, M McNaghten, AD Frankel, M Bozzette, S Shapiro, M AF Sullivan, Patrick S. Juhasz, Marta McNaghten, A. D. Frankel, Martin Bozzette, Sam Shapiro, Martin TI Time to first annual HIV care visit and associated factors for patients in care for HIV infection in 10 US cities SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV; access to care; viral load; CD4 count ID UNITED-STATES; CLINICAL SURVEILLANCE; SERVICES UTILIZATION; ADULTS; OUTPATIENT; HIV/AIDS; AIDS AB Background. Visiting a medical provider less frequently than clinical circumstances would suggest is appropriate has been reported to be associated with worse clinical outcomes for patients living with HIV infection. Patients with less frequent attendance to HIV care also may be systematically underrepresented in research or surveillance studies that enroll patients sequentially over a specified enrollment period - for example several months. For both reasons, understanding factors associated with time to care visit is important. Methods. We used data from the Adult and Adolescent Spectrum of HIV Disease (ASD) project, a multi-site clinical outcomes surveillance system that enrolled and followed patients in care for HIV prospectively from 1990 to 2004. For this analysis, we used data from all patients observed in ASD at least one time before 1 January 2003, and who had at least one HIV care visit in 2003. We documented time to first annual HIV care visit for each patient, and used Kaplan-Meier plots and proportional hazards regression to describe factors associated with longer time to care visit. Results. A total of 12,135 patients had >= 1 care visit during 2003 and were included in the analysis. Of these, 81%, 88%, and 95% had their first visit within three, four, and six months, respectively. In multivariate analysis, having a delayed (later) care visit was associated with not ever having had an AIDS diagnosis, having an HIV RNA concentration >= 10,000 copies/mL, having a current CD4 count <100 cells/mu L, having no health insurance, and not being currently prescribed antiretroviral therapy. Having a delayed care visit was not associated with race/ethnicity or age. Conclusions. Having a delayed first annual HIV care visit was associated with higher viremia, lower CD4 cell count, and lack of health insurance. Interventions to address these factors are likely to ameliorate some of the consequences of HIV. For studies enrolling patients in care for HIV over a finite time period, an enrollment period of four-six months should sufficiently reflect the patient population seen in a one-year period, including those attending care infrequently. C1 [Sullivan, Patrick S.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Juhasz, Marta] Solor Consulting, Cluj Napoca, Romania. [McNaghten, A. D.] Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA USA. [Frankel, Martin; Bozzette, Sam; Shapiro, Martin] RAND Corp, Santa Monica, CA USA. RP Sullivan, PS (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. EM pssulli@emory.edu OI Sullivan, Patrick/0000-0002-7728-0587 NR 13 TC 3 Z9 3 U1 0 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2011 VL 23 IS 10 BP 1314 EP 1320 DI 10.1080/09540121.2011.555746 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 881JV UT WOS:000299480800014 PM 21939408 ER PT J AU Tripathi, A Gardner, LI Ogbuanu, I Youmans, E Stephens, T Gibson, JJ Duffus, WA AF Tripathi, Avnish Gardner, Lytt I. Ogbuanu, Ikechukwu Youmans, Eren Stephens, Terri Gibson, James J. Duffus, Wayne A. TI Predictors of time to enter medical care after a new HIV diagnosis: a statewide population-based study SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV infections; HIV/AIDS prevention and control; linkage to care; case management; South Carolina HIV surveillance ID ANTIRETROVIRAL TREATMENT ACCESS; INFECTED PERSONS; DELAYED ENTRY; RECOMMENDATIONS; INTERVENTION; ADOLESCENTS; PREVENTION; RETENTION; SOCIETY; HEALTH AB Public health benefits of expanded HIV screening will be adequately realized only if an early diagnosis is followed by prompt linkage to care. We characterized rates and factors associated with failure to enter into medical care within three months of HIV diagnosis and assessed the predictors of time to enter care over a follow-up period of up to 60 months. The study cohort included 3697 South Carolina (SC) residents >= 13 years who were newly HIV-diagnosed in 2004-2008. Date of first laboratory report of CD4(+) T-cell count or viral load (VL) test after 30 days of confirmatory HIV diagnosis was used to define time to linkage to care. Results showed that of the total 3697 persons, 1768 (48%) entered care within three months, 1115 (30%) in four-12 months after diagnosis, and 814 (22%) failed to initiate care within 12 months of HIV diagnosis. At the end of study follow-up period of up to 60 months from the date of HIV diagnosis, 472/3697 (13%) individuals remained out of care. Multivariable Cox proportional hazards analysis showed that compared with hospitals, time to enter care was shorter in those diagnosed at state mental health/correctional facilities (adjusted hazards ratio [aHR] 1.16; 95% confidence interval [CI] 1.02-1.34) and longer in those diagnosed at county health departments (aHR 0.87; 95% CI 0.80-0.96) and at "Other/unknown'' facilities (aHR 0.79; 95% CI 0.70-0.89). Time to entry into care was longer for men (aHR 0.82; 95% CI 0.75-0.89) compared with women, blacks (aHR 0.91; 95% CI 0.83-0.98) compared with whites, and males who have sex with males (MSM) (aHR 0.89; 95% CI 0.80-0.98) compared with heterosexual exposure. Delayed entry into HIV care remains a challenge in controlling HIV transmission in SC. Better integration of testing and care facilities could improve the proportion of newly HIV-diagnosed persons who enter care in a timely manner. C1 [Tripathi, Avnish; Ogbuanu, Ikechukwu; Youmans, Eren] Univ S Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA. [Gardner, Lytt I.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Stephens, Terri; Gibson, James J.; Duffus, Wayne A.] HIV STD Div, Dept Hlth & Environm Control, Columbia, SC USA. [Duffus, Wayne A.] Univ S Carolina, Dept Med, Sch Med, Div Infect Dis, Columbia, SC 29208 USA. RP Tripathi, A (reprint author), Univ S Carolina, Arnold Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA. EM avnish.tripathi@sc.edu NR 23 TC 22 Z9 23 U1 0 U2 12 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2011 VL 23 IS 11 BP 1366 EP 1373 DI 10.1080/09540121.2011.565032 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 881JX UT WOS:000299481100003 PM 22022847 ER PT J AU Kucerova, Z Sokolova, OI Demyanov, AV Kvac, M Sak, B Kvetonova, D Secor, WE AF Kucerova, Z. Sokolova, O. I. Demyanov, A. V. Kvac, M. Sak, B. Kvetonova, D. Secor, W. E. TI Microsporidiosis and Cryptosporidiosis in HIV/AIDS Patients in St. Petersburg, Russia: Serological Identification of Microsporidia and Cryptosporidium parvum in Sera Samples from HIV/AIDS Patients SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID ENCEPHALITOZOON-CUNICULI; INFECTIONS AB To determine seroprevalence of the opportunistic organisms Cryptosporidium parvum and microsporidia (Encephalitozoon cuniculi, E. intestinalis, E. hellem, and Enterocytozoon bieneusi) in Russian HIV/AIDS patients, we evaluated 46 sera from HIV/AIDS patients from the S.P. Botkin Clinical Infectious Diseases Hospital, St. Petersburg, Russia. Five (10.9%) sera were seropositive for E. cuniculi and 19 (41.3%) were positive for C. parvum by ELISA. By IFAT, 6 (13.0%) sera were seropositive for E. bieneusi, 4 (8.7%) for E. intestinalis, and 9 (19.6%) for E. hellem. This study is the first report to estimate the prevalence of infection with Cryptosporidium and microsporidia among Russian HIV/AIDS patients. C1 [Kucerova, Z.; Secor, W. E.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30329 USA. [Kucerova, Z.] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Sokolova, O. I.] St Petersburg State Univ, Dept Med, St Petersburg, Russia. [Demyanov, A. V.] State Inst Highly Pure Biopreparat, Lab Immunopharmacol, St Petersburg, Russia. [Kvac, M.; Sak, B.; Kvetonova, D.] Acad Sci Czech Republic, Ctr Biol, Ceske Budejovice, Czech Republic. [Kvac, M.] Univ S Bohemia, Fac Agr, Ceske Budejovice, Czech Republic. RP Kucerova, Z (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis, 1600 Clifton Rd,MS D65, Atlanta, GA 30329 USA. EM zik0@cdc.gov RI Kvac, Martin/G-7299-2014; Sak, Bohumil/G-9262-2014; Sokolova, Olga/K-1179-2014; Demyanov, Anton/Q-3492-2016 OI Kvac, Martin/0000-0003-0013-6090; Sokolova, Olga/0000-0002-5723-4305; FU Civil Research and Development Foundation (CRDF) [RUB2-002707-SP-05CRDF]; Grant Agency of Academy of Sciences of the Czech Republic [KJB500960701]; EPA-CDC Interagency Agreement [DW-75-92243701] FX This study was supported by Civil Research and Development Foundation (CRDF) cooperative grants program RUB2-002707-SP-05CRDF, by project no. KJB500960701 from the Grant Agency of Academy of Sciences of the Czech Republic, and by EPA-CDC Interagency Agreement DW-75-92243701. NR 15 TC 4 Z9 6 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD JAN PY 2011 VL 27 IS 1 BP 13 EP 15 DI 10.1089/aid.2010.0132 PG 3 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 708JL UT WOS:000286358000003 PM 20929396 ER PT J AU Silbergeld, EK Contreras, EQ Hartung, T Hirsch, C Hogberg, H Jachak, AC Jordan, W Landsiedel, R Morris, J Patri, A Pounds, JG Ruiz, AD Shvedova, A Tanguay, R Tatarazako, N van Vliet, E Walker, NJ Wiesner, M Wilcox, N Zurlo, J AF Silbergeld, Ellen K. Contreras, Elizabeth Q. Hartung, Thomas Hirsch, Cordula Hogberg, Helena Jachak, Ashish C. Jordan, William Landsiedel, Robert Morris, Jeffery Patri, Anil Pounds, Joel G. de Vizcaya Ruiz, Andrea Shvedova, Anna Tanguay, Robert Tatarazako, Norihasa van Vliet, Erwin Walker, Nigel J. Wiesner, Mark Wilcox, Neil Zurlo, Joanne TI Nanotoxicology: "The End of the Beginning" - Signs on the Roadmap to a Strategy for Assuring the Safe Application and Use of Nanomaterials SO ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION LA English DT Article DE nanomaterials; nanotoxicology; alternative methods; 3Rs; Tox-21c AB In October 2010, a group of experts met as part of the transatlantic think tank for toxicology (t(4)) to exchange ideas about the current status and future of safety testing of nanomaterials. At present, there is no widely accepted path forward to assure appropriate and effective hazard identification for engineered nanomaterials. The group discussed needs for characterization of nanomaterials and identified testing protocols that incorporate the use of innovative alternative whole models such as zebrafish or C. elegans, as well as in vitro or alternative methods to examine specific functional pathways and modes of action. The group proposed elements of a potential testing scheme for nanomaterials that works towards an integrated testing strategy, incorporating the goals of the NRC report Toxicity Testing in the 21(st) Century: A Vision and a Strategy by focusing on pathways of toxic response, and utilizing an evidence-based strategy for developing the knowledge base for safety assessment. Finally, the group recommended that a reliable, open, curated database be developed that interfaces with existing databases to enable sharing of information. C1 [Silbergeld, Ellen K.; Jachak, Ashish C.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA. [Contreras, Elizabeth Q.] Rice Univ, Dept Chem, Houston, TX USA. [Hartung, Thomas; Hogberg, Helena; van Vliet, Erwin; Zurlo, Joanne] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Alternat Anim Testing, Baltimore, MD USA. [Hirsch, Cordula] Empa Swiss Fed Labs Mat Sci & Technol, St Gallen, Switzerland. [Jordan, William; Morris, Jeffery] US EPA, Washington, DC 20460 USA. [Landsiedel, Robert] BASF, Ludwigshafen, Germany. [Patri, Anil] NCI, Nanotechnol Characterizat Lab, NIH, Frederick, MD 21701 USA. [Pounds, Joel G.] Pacific NW Natl Lab, Richland, WA 99352 USA. [de Vizcaya Ruiz, Andrea] CINVESTAV, Mexico City 14000, DF, Mexico. [Shvedova, Anna] CDC, Natl Inst Occupat Safety & Hlth, Morgantown, WV USA. [Tanguay, Robert] Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA. [Tatarazako, Norihasa] Natl Inst Environm Sci, Tsukuba, Ibaraki, Japan. [Walker, Nigel J.] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA. [Walker, Nigel J.] NIEHS, Natl Toxicol Program, Res Triangle Pk, NC 27709 USA. [Wiesner, Mark] Duke Univ, Dept Civil & Environm Engn, Durham, NC 27706 USA. [Wilcox, Neil] US FDA, Off Cosmet & Colors, Ctr Food Safety & Appl Nutr, College Pk, MD USA. RP Zurlo, J (reprint author), Johns Hopkins Ctr Alternat Anim Testing, 615 N Wolfe St,W7032, Baltimore, MD 21205 USA. EM jzurlo@jhsph.edu RI Landsiedel, Robert/D-1960-2012; Walker, Nigel/D-6583-2012; Nanotechnology Characterization Lab, NCL/K-8454-2012 OI Landsiedel, Robert/0000-0003-3756-1904; Walker, Nigel/0000-0002-9111-6855; FU Doerenkamp-Zbinden Foundation FX We thank the Doerenkamp-Zbinden Foundation for sponsoring this workshop as part of the t4 activities. NR 5 TC 10 Z9 10 U1 1 U2 11 PU SPEKTRUM AKAD VERLAG PI HEIDELBERG PA SLEVOGTSTRASSE 3-5, D-69126 HEIDELBERG, GERMANY SN 1868-596X J9 ALTEX-ALTERN ANIM EX JI ALTEX-Altern. Anim. Exp. PY 2011 VL 28 IS 3 BP 236 EP 241 PG 6 WC Instruments & Instrumentation; Medicine, Research & Experimental SC Instruments & Instrumentation; Research & Experimental Medicine GA 829IZ UT WOS:000295573100006 PM 21993959 ER PT J AU Chen, Z AF Chen, Zhuo TI INFORMATION, PRICES, AND HEALTHY LIFESTYLE CHOICES OF ADULTS: DISCUSSION SO AMERICAN JOURNAL OF AGRICULTURAL ECONOMICS LA English DT Editorial Material ID OBESITY C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Chen, Z (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. OI Chen, Zhuo/0000-0002-5351-3489 NR 7 TC 0 Z9 0 U1 0 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9092 J9 AM J AGR ECON JI Am. J. Agr. Econ. PD JAN PY 2011 VL 93 IS 2 BP 387 EP 388 DI 10.1093/ajae/aaq101 PG 2 WC Agricultural Economics & Policy; Economics SC Agriculture; Business & Economics GA 789XH UT WOS:000292552000017 ER PT J AU Yeung, LF Cogswell, ME Carriquiry, AL Bailey, LB Pfeiffer, CM Berry, RJ AF Yeung, Lorraine F. Cogswell, Mary E. Carriquiry, Alicia L. Bailey, Lynn B. Pfeiffer, Christine M. Berry, Robert J. TI Contributions of enriched cereal-grain products, ready-to-eat cereals, and supplements to folic acid and vitamin B-12 usual intake and folate and vitamin B-12 status in US children: National Health and Nutrition Examination Survey (NHANES), 2003-2006 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID UNITED-STATES; NUTRIENT INTAKE; PHYSICAL-ACTIVITY; DIETARY-INTAKE; ADOLESCENTS; BREAKFAST; CONSUMPTION; INFANTS; FOODS; CATCH AB Background: US children consume folic acid from multiple sources. These sources may contribute differently to usual intakes above the age-specific tolerable upper intake level (UL) for folic acid and to folate and vitamin B-12 status. Objective: We estimated usual daily folic acid intakes above the UL and adjusted serum and red blood cell folate, serum vitamin B-12, homocysteine, and methylmalonic acid (MMA) concentrations in US children by age group and by the following 3 major folic acid intake sources: enriched cereal-grain products (ECGP), ready-to-eat cereals (RTE), and supplements containing folic acid (SUP). Design: We analyzed data in 4 groups of children aged 1-3, 4-8, 9-13, and 14-18 y from the National Health and Nutrition Examination Survey (NHANES), 2003-2006 (n = 7161). Results: A total of 19-48% of children consumed folic acid from ECGP only. Intakes above the UL varied from 0-0.1% of children who consumed ECGP only to 15-78% of children who consumed ECGP+RTE+SUP. In children aged 1-8 y, 99-100% of those who consumed >= 200 mu g folic acid/d from supplements exceeded their UL. Although <0.5% of children had folate deficiency or low vitamin B-12 status, the consumption of RTE or SUP with folic acid was associated with higher mean folate and vitamin B-12 concentrations and, in some older children, with lower homocysteine and MMA concentrations. Conclusions: Our data suggest that the majority of US children consume more than one source of folic acid. Postfortification, the consumption of RTE or SUP increases usual daily intakes and blood concentrations of folate and vitamin B-12. Am J Clin Nutr 2011;93:172-85. C1 [Yeung, Lorraine F.; Cogswell, Mary E.; Berry, Robert J.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Carriquiry, Alicia L.] Iowa State Univ, Dept Stat, Ames, IA USA. [Bailey, Lynn B.] Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA. RP Yeung, LF (reprint author), Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mailstop E-86, Atlanta, GA 30333 USA. EM lyeung@cdc.gov OI Berry, Robert/0000-0002-7162-5046 FU Centers for Disease Control and Prevention FX Supported by the Centers for Disease Control and Prevention. NR 38 TC 21 Z9 21 U1 1 U2 6 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD JAN PY 2011 VL 93 IS 1 BP 172 EP 185 DI 10.3945/ajcn.2010.30127 PG 14 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 696PJ UT WOS:000285453500022 PM 21084645 ER PT J AU Pfeifer, JD Zehnbauer, B Payton, J AF Pfeifer, John D. Zehnbauer, Barbara Payton, Jacqueline TI The Changing Spectrum of DNA-Based Specimen Provenance Testing in Surgical Pathology SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY LA English DT Article DE Patient safety; Specimen provenance; Molecular diagnostics; Microsatellite analysis; Identity determination ID PARAFFIN-EMBEDDED TISSUE; RADICAL PROSTATECTOMY; PATIENT SAFETY; Q-PROBES; IDENTIFICATION; IDENTITY; CANCER; ERROR; MARKERS; CONTAMINATION AB Short tandem repeat (STR) analysis has emerged as the method of choice for testing to resolve specimen source contamination and identity problems that arise in surgical pathology. We studied a series of consecutive cases referred for STR typing during a 5-year period to document the usefulness of the approach and to describe the broadening scope of testing. The series demonstrates that STR-based typing can be applied in virtually any setting in which specimen source confirmation is requested, that STR-based typing is informative in 92% of eases, but that exceptions occasionally arise that complicate test interpretation. The series also demonstrates that in addition to traditional uses of STR typing, testing is now performed in the absence of any direct indication that a specimen mix-up or contamination may have occurred, namely, when the pathologic findings are unexpected or the clinical setting is atypical. The case series underscores the ability of STR testing to detect errors that cannot be captured by current laboratory protocols, a finding that has important implications for patient safety. C1 [Pfeifer, John D.; Payton, Jacqueline] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA. [Zehnbauer, Barbara] Ctr Dis Control & Prevent, Div Lab Sci & Stand, Atlanta, GA USA. RP Pfeifer, JD (reprint author), Washington Univ, Sch Med, Dept Pathol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA. NR 28 TC 8 Z9 8 U1 0 U2 2 PU AMER SOC CLINICAL PATHOLOGY PI CHICAGO PA 2100 W HARRISON ST, CHICAGO, IL 60612 USA SN 0002-9173 J9 AM J CLIN PATHOL JI Am. J. Clin. Pathol. PD JAN PY 2011 VL 135 IS 1 BP 132 EP 138 DI 10.1309/AJCPLNO4PFVZVA4P PG 7 WC Pathology SC Pathology GA 697TB UT WOS:000285538700017 PM 21173135 ER PT J AU Flegal, KM Graubard, BI Williamson, DF Cooper, RS AF Flegal, Katherine M. Graubard, Barry I. Williamson, David F. Cooper, Richard S. TI Reverse Causation and Illness-related Weight Loss in Observational Studies of Body Weight and Mortality SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Editorial Material DE bias (epidemiology); body mass index; body weight; confounding factors (epidemiology); epidemiologic methods; mortality; selection bias ID BREAST-CANCER DIAGNOSIS; EXCLUDING EARLY DEATHS; ALL-CAUSE MORTALITY; HIP FRACTURE RISK; ACUTE LUNG INJURY; MIDDLE-AGED MEN; MASS INDEX; FOLLOW-UP; PROSPECTIVE COHORT; OLDER WOMEN AB In studies of weight and mortality, the construct of reverse causation has come to be used to imply that the exposure-outcome relation is biased by weight loss due to preexisting illness. Observed weight-mortality associations are sometimes thought to result from this bias. Evidence for the occurrence of such bias is weak and inconsistent, suggesting that either the analytical methods used have been inadequate or else illness-related weight loss is not an important source of bias. Deleting participants has been the most frequent approach to control possible bias. As implemented, this can lead to deletion of almost 90% of all deaths in a sample and to deletion of more overweight and obese participants than participants with normal or below normal weight. Because it has not been demonstrated that the procedures used to adjust for reverse causation increase validity or have large or systematic effects on relative risks, it is premature to consider reverse causation as an important cause of bias. Further research would be useful to elucidate the potential effects and importance of reverse causation or illness-related weight loss as a source of bias in the observed associations between weight and mortality in cohort studies. C1 [Flegal, Katherine M.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Graubard, Barry I.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. [Williamson, David F.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Cooper, Richard S.] Loyola Univ, Sch Med, Dept Prevent Med & Epidemiol, Maywood, IL 60153 USA. RP Flegal, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4336, Hyattsville, MD 20782 USA. EM kmf2@cdc.gov RI Flegal, Katherine/A-4608-2013; OI Flegal, Katherine/0000-0002-0838-469X NR 112 TC 63 Z9 63 U1 1 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JAN 1 PY 2011 VL 173 IS 1 BP 1 EP 9 DI 10.1093/aje/kwq341 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695ZR UT WOS:000285412200001 PM 21059807 ER PT J AU Press, DJ Sullivan-Halley, J Ursin, G Deapen, D McDonald, JA Strom, BL Norman, SA Simon, MS Marchbanks, PA Folger, SG Liff, JM Burkman, RT Malone, KE Weiss, LK Spirtas, R Bernstein, L AF Press, David J. Sullivan-Halley, Jane Ursin, Giske Deapen, Dennis McDonald, Jill A. Strom, Brian L. Norman, Sandra A. Simon, Michael S. Marchbanks, Polly A. Folger, Suzanne G. Liff, Jonathan M. Burkman, Ronald T. Malone, Kathleen E. Weiss, Linda K. Spirtas, Robert Bernstein, Leslie TI Breast Cancer Risk and Ovariectomy, Hysterectomy, and Tubal Sterilization in the Women's Contraceptive and Reproductive Experiences Study SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE breast neoplasms; case-control studies; hysterectomy; ovariectomy; sterilization; tubal ID HORMONE REPLACEMENT THERAPY; FOLLICLE-STIMULATING-HORMONE; OVARIAN-FUNCTION; UNILATERAL OOPHORECTOMY; ABDOMINAL HYSTERECTOMY; RECEPTOR STATUS; FSH-LEVELS; SURGERY; AGE; MENOPAUSE AB Removal or impairment of ovaries before menopause may affect a woman's breast cancer risk by altering her cumulative exposure to ovarian hormones. The Women's Contraceptive and Reproductive Experiences Study, a population-based, multicenter case-control study of incident invasive breast cancer, recruited women aged 35-64 years (4,490 cases and 4,611 controls) who provided data on ovariectomy, hysterectomy, and tubal sterilization during in-person interviews. Controls were frequency-matched to cases by age, race, and study site. Unconditional logistic regression analysis was used. Women who had not undergone premenopausal reproductive surgery were the referent group. Bilateral ovariectomy was associated with reduced breast cancer risk overall (odds ratio (OR) = 0.59, 95% confidence interval (CI): 0.50, 0.69) and among women < 45 years of age (ORs ranged from 0.31 to 0.52), but not among those who were older at surgery. It was also associated with a reduced risk for estrogen and progesterone receptor-positive tumors (OR = 0.63, 95% CI: 0.52, 0.75) but not receptor-negative tumors. Hysterectomy with ovarian conservation (OR = 0.83, 95% CI: 0.72, 0.96) and hysterectomy with partial ovary removal (OR = 0.73, 95% CI: 0.59, 0.91) were also associated with lower risk. No association with breast cancer risk was observed with tubal sterilization only or partial ovariectomy without hysterectomy. Reproductive organ surgeries may alter ovarian hormone levels, thereby affecting breast cancer risk. C1 [Bernstein, Leslie] City Hope Comprehens Canc Ctr, Div Canc Etiol, Dept Populat Sci, Duarte, CA 91010 USA. [Sullivan-Halley, Jane; Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Duarte, CA 91010 USA. [Press, David J.; Ursin, Giske; Deapen, Dennis; Bernstein, Leslie] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Press, David J.; Ursin, Giske; Deapen, Dennis; Bernstein, Leslie] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA. [McDonald, Jill A.; Marchbanks, Polly A.; Folger, Suzanne G.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Strom, Brian L.; Norman, Sandra A.] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA. [Simon, Michael S.] Wayne State Univ, Div Hematol & Oncol, Karmanos Canc Inst, Detroit, MI USA. [Simon, Michael S.] Wayne State Univ, Populat Studies & Prevent Program, Karmanos Canc Inst, Detroit, MI USA. [Liff, Jonathan M.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Burkman, Ronald T.] Tufts Univ, Sch Med, Dept Obstet & Gynecol, Springfield, MA 01199 USA. [Burkman, Ronald T.] Baystate Med Ctr, Springfield, MA USA. [Malone, Kathleen E.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Weiss, Linda K.] NCI, Canc Ctr Branch, Bethesda, MD 20892 USA. [Spirtas, Robert] NICHHD, Contracept & Reprod Hlth Branch, Populat Res Ctr, Bethesda, MD 20892 USA. RP Bernstein, L (reprint author), City Hope Comprehens Canc Ctr, Div Canc Etiol, Dept Populat Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA. EM lbernstein@coh.org FU National Institute of Child Health and Human Development; National Cancer Institute, through Emory University [N01-HD-2-3168]; Fred Hutchinson Cancer Research Center [N01-HD-2-3166]; Karmanos Cancer Institute at Wayne State University [N01-HD-3-3174]; University of Pennsylvania [1-HD-3-3176]; University of Southern California [N01-HD-3-3175]; Centers for Disease Control and Prevention [Y01-HD-7022]; California Department of Health Services FX Data collection for the Women's CARE Study was supported by the National Institute of Child Health and Human Development, with additional support from the National Cancer Institute, through contracts with Emory University (N01-HD-2-3168), the Fred Hutchinson Cancer Research Center (N01-HD-2-3166), the Karmanos Cancer Institute at Wayne State University (N01-HD-3-3174), the University of Pennsylvania (N01-HD-3-3176), and the University of Southern California (N01-HD-3-3175); and through an intraagency agreement with the Centers for Disease Control and Prevention (Y01-HD-7022). Support for use of Surveillance, Epidemiology, and End Results cancer registries for case identification was obtained through contracts N01-PC-67006 (Atlanta), N01-CN-65064 (Detroit), N01-PC-67010 (Los Angeles), and N01-CN-0532 (Seattle). The collection of cancer incidence data in California used in this publication (University of Southern California, Los Angeles County portion of this study) was also supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by the California Health and Safety Code, Section 103885. NR 52 TC 21 Z9 21 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JAN 1 PY 2011 VL 173 IS 1 BP 38 EP 47 DI 10.1093/aje/kwq339 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695ZR UT WOS:000285412200004 PM 21109566 ER PT J AU Waggoner, JK Kullman, GJ Henneberger, PK Umbach, DM Blair, A Alavanja, MCR Kamel, F Lynch, CF Knott, C London, SJ Hines, CJ Thomas, KW Sandler, DP Lubin, JH Freeman, LE Hoppin, JA AF Waggoner, Jenna K. Kullman, Greg J. Henneberger, Paul K. Umbach, David M. Blair, Aaron Alavanja, Michael C. R. Kamel, Freya Lynch, Charles F. Knott, Charles London, Stephanie J. Hines, Cynthia J. Thomas, Kent W. Sandler, Dale P. Lubin, Jay H. Beane Freeman, Laura E. Hoppin, Jane A. TI Mortality in the Agricultural Health Study, 1993-2007 SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE agriculture; healthy worker effect; mortality; neoplasms; pesticides; wounds and injuries ID PESTICIDE APPLICATORS; PROSTATE-CANCER; INJURY MORTALITY; UNITED-STATES; FARMERS; RISK; EXPOSURE; METAANALYSES; COHORT; WIVES AB Comparing agricultural cohorts with the general population is challenging because the general healthiness of farmers may mask potential adverse health effects of farming. Using data from the Agricultural Health Study, a cohort of 89,656 pesticide applicators and their spouses (N = 89, 656) in North Carolina and Iowa, the authors computed standardized mortality ratios (SMRs) comparing deaths from time of the enrollment (1993-1997) through 2007 to state-specific rates. To compensate for the cohort's overall healthiness, relative SMRs were estimated by calculating the SMR for each cause relative to the SMR for all other causes. In 1,198,129 person-years of follow-up, 6,419 deaths were observed. The all-cause mortality rate was less than expected (SMRapplicators = 0.54, 95% confidence interval (CI): 0.52, 0.55; SMRspouses = 0.52, 95% CI: 0.50, 0.55). SMRs for all cancers, heart disease, and diabetes were significantly below 1.0. In contrast, applicators experienced elevated numbers of machine-related deaths (SMR = 4.15, 95% CI: 3.18, 5.31), motor vehicle nontraffic accidents (SMR = 2.80, 95% CI: 1.81, 4.14), and collisions with objects (SMR = 2.12, 95% CI: 1.25, 3.34). In the relative SMR analysis for applicators, the relative mortality ratio was elevated for lymphohematopoietic cancers, melanoma, and digestive system, prostate, kidney, and brain cancers. Among spouses, relative SMRs exceeded 1.0 for lymphohematopoietic cancers and malignancies of the digestive system, brain, breast, and ovary. Unintentional fatal injuries remain an important risk for farmers; mortality ratios from several cancers were elevated relative to other causes. C1 [Waggoner, Jenna K.; Kamel, Freya; London, Stephanie J.; Sandler, Dale P.; Hoppin, Jane A.] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA. [Waggoner, Jenna K.; Kullman, Greg J.; Henneberger, Paul K.] NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA. [Umbach, David M.] NIEHS, Biostat Branch, Res Triangle Pk, NC 27709 USA. [Blair, Aaron; Alavanja, Michael C. R.; Lubin, Jay H.; Beane Freeman, Laura E.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. [Lynch, Charles F.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA. [Knott, Charles] Battelle Mem Inst, Durham, NC USA. [Hines, Cynthia J.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Thomas, Kent W.] US EPA, Natl Exposure Res Lab, Res Triangle Pk, NC 27711 USA. RP Hoppin, JA (reprint author), NIEHS, Epidemiol Branch, MD A3-05,POB 12233, Res Triangle Pk, NC 27709 USA. EM hoppin1@niehs.nih.gov RI Beane Freeman, Laura/C-4468-2015; OI Beane Freeman, Laura/0000-0003-1294-4124; Kamel, Freya/0000-0001-5052-6615; London, Stephanie/0000-0003-4911-5290; Sandler, Dale/0000-0002-6776-0018 FU Association of Schools of Public Health/Centers for Disease Control; National Institute for Occupational Safety and Health; National Institutes of Health; National Institutes of Health, National Institute of Environmental Health Sciences [Z01-ES049030]; National Institutes of Health National Cancer Institute [Z01-CP010119] FX This work was supported by the Association of Schools of Public Health/Centers for Disease Control fellowship program; the National Institute for Occupational Safety and Health; the Intramural Research Program of the National Institutes of Health; and the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (Z01-ES049030) and the National Institutes of Health National Cancer Institute (Z01-CP010119). NR 42 TC 36 Z9 37 U1 0 U2 19 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JAN 1 PY 2011 VL 173 IS 1 BP 71 EP 83 DI 10.1093/aje/kwq323 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 695ZR UT WOS:000285412200008 PM 21084556 ER PT J AU Dubowitz, T Heron, M Basurto-Davila, R Bird, CE Lurie, N Escarce, JJ AF Dubowitz, Tamara Heron, Melonie Basurto-Davila, Ricardo Bird, Chloe E. Lurie, Nicole Escarce, Jose J. TI Racial/Ethnic Differences in US Health Behaviors: A Decomposition Analysis SO AMERICAN JOURNAL OF HEALTH BEHAVIOR LA English DT Article DE race/ethnicity; health behaviors; Oaxaca decomposition; health disparities ID NEIGHBORHOOD SOCIOECONOMIC-STATUS; DISEASE RISK-FACTORS; CARDIOVASCULAR-DISEASE; BLACK-NEIGHBORHOODS; AFRICAN-AMERICANS; NORTH-CAROLINA; UNITED-STATES; NHANES-III; ALCOHOL; ADULTS AB Objective: To quantify contributions of individual sociodemographic factors, neighborhood socioeconomic status (NSES), and unmeasured factors to racial/ethnic differences in health behaviors for non-Hispanic (NH) whites, NH blacks, and Mexican Americans. Methods: We used linear regression and Oaxaca decomposition analyses. Results: Although individual characteristics and NSES contributed to racial/ethnic differences in health behaviors, differential responses by individual characteristics and NSES also played a significant role. Conclusions: There are racial/ethnic differences in the way that individual-level determinants and NSES affect health behaviors. Understanding the mechanisms for differential responses could inform community interventions and public health campaigns that target particular groups. C1 [Dubowitz, Tamara] RAND Corp, Pittsburgh, PA 15213 USA. [Heron, Melonie] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Basurto-Davila, Ricardo; Bird, Chloe E.] RAND Corp, Santa Monica, CA USA. [Lurie, Nicole] US Dept HHS, Washington, DC 20201 USA. [Escarce, Jose J.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Escarce, Jose J.] RAND Corp, Los Angeles, CA USA. RP Dubowitz, T (reprint author), RAND Corp, 4570 5th Ave,Suite 600, Pittsburgh, PA 15213 USA. EM dubowitz@rand.org FU NIEHS NIH HHS [1P50ES012383-01, P50 ES012383-019001, P50 ES012383] NR 57 TC 11 Z9 12 U1 2 U2 11 PU PNG PUBLICATIONS PI OAK RIDGE PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA SN 1087-3244 J9 AM J HEALTH BEHAV JI Am. J. Health Behav. PY 2011 VL 35 IS 3 BP 290 EP 304 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 781MY UT WOS:000291938200004 PM 21683019 ER PT J AU Fang, J Keenan, NL Dai, SF AF Fang, Jing Keenan, Nora L. Dai, Shifan TI Fruit/Vegetable Intake and Physical Activity Among Adults With High Cholesterol SO AMERICAN JOURNAL OF HEALTH BEHAVIOR LA English DT Article DE cholesterol; fruits and vegetables; physical activity; behavioral surveillance ID CORONARY-HEART-DISEASE; TREATMENT PANEL-III; RISK-FACTORS; VEGETABLE CONSUMPTION; BLOOD CHOLESTEROL; UNITED-STATES; HYPERCHOLESTEROLEMIA; DETERMINANTS; PREVALENCE; VALIDITY AB Objectives: To determine whether hypercholesterolemic adults followed healthy eating and appropriate physical activity. Methods: Using the 2007 Behavioral Risk Factor Surveillance System, we measured >= 5 servings of fruits and vegetables/day and Healthy People 2010 recommended physical activity. Results: Of 363,667 adults >= 18 years, 37.3% had hypercholesterolemia. The percentages of healthy eating and physical activity were lower among those with hypercholesterolemia than among those without (23.8% vs 27.9% for healthy eating [P< 0.001], 43.1% vs 51.7% for physical activity [P<0.001]). Conclusion: Hypercholesterolemic adults are less likely to practice healthy eating and to engage in physical activity than are those without hypercholesterolemia. C1 [Fang, Jing; Keenan, Nora L.; Dai, Shifan] Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. RP Fang, J (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. EM jfang@cdc.gov NR 30 TC 2 Z9 2 U1 0 U2 0 PU PNG PUBLICATIONS PI OAK RIDGE PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA SN 1945-7359 J9 AM J HEALTH BEHAV JI Am. J. Health Behav. PY 2011 VL 35 IS 6 BP 689 EP 698 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 909MD UT WOS:000301567700005 PM 22251760 ER PT J AU Grams, ME Plantinga, LC Hedgeman, E Saran, R Myers, GL Williams, DE Powe, NR AF Grams, Morgan E. Plantinga, Laura C. Hedgeman, Elizabeth Saran, Rajiv Myers, Gary L. Williams, Desmond E. Powe, Neil R. CA CDC CKD Surveillance Team TI Validation of CKD and Related Conditions in Existing Data Sets: A Systematic Review SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Chronic kidney disease; prevalence; accuracy; validation ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; CLINICAL-MODIFICATION CODES; ICD-10 ADMINISTRATIVE DATA; HEART-FAILURE; INTERNATIONAL-CLASSIFICATION; CARDIOVASCULAR-DISEASE; COMORBID CONDITIONS; DEATH CERTIFICATES; OUTCOMES RESEARCH AB Background: Accurate classification of individuals with kidney disease is vital to research and public health efforts aimed at improving health outcomes. Our objective is to identify and synthesize published literature evaluating the accuracy of existing data sources related to kidney disease. Study Design: A systematic review of studies seeking to validate the accuracy of the underlying data relevant to kidney disease. Setting & Population: US-based and international studies covering a wide range of both outpatient and inpatient study populations. Selection Criteria for Studies: Any English-language study investigating the prevalence or cause of kidney disease, existence of comorbid conditions, or cause of death in patients with chronic kidney disease (CKD). All definitions and stages of CKD, including end-stage renal disease (ESRD), were accepted. Index Tests: Presence of a kidney disease-related variable in existing data sets, including administrative data sets and disease registries. Reference Tests: Presence of a kidney disease-related variable defined using laboratory criteria or medical record review. Results: 30 studies were identified. Most studies investigated the accuracy of kidney disease reporting, comparing coded renal disease with that defined using estimated glomerular filtration rate. The sensitivity of coded renal disease varied widely (0.08-0.83). Specificity was higher, with all studies reporting values >= 0.90. Studies evaluating the cause of CKD, comorbid conditions, and cause of death in patients with CKD used ESRD or transplant populations exclusively, and accuracy was highly variable compared with ESRD registry data. Limitations: Only English-language studies were evaluated. Conclusions: Given the heterogeneous results of validation studies, a variety of attributes of existing data sources, including the accuracy of individual data items within these sources, should be considered carefully before use in research, quality improvement, and public health efforts. Am J Kidney Dis. 57(1): 44-54. (C) 2010 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved. C1 [Plantinga, Laura C.; Powe, Neil R.] San Francisco Gen Hosp, Dept Med, San Francisco, CA 94110 USA. [Plantinga, Laura C.; Powe, Neil R.] Univ Calif San Francisco, San Francisco, CA 94110 USA. [Grams, Morgan E.] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA. [Hedgeman, Elizabeth; Saran, Rajiv] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Myers, Gary L.; Williams, Desmond E.] Ctr Dis Control & Prevent, Div NHANES, Natl Ctr Hlth Stat, CDC, Atlanta, GA USA. RP Powe, NR (reprint author), San Francisco Gen Hosp, Dept Med, 1001 Potrero Ave,Bldg 5F38, San Francisco, CA 94110 USA. EM npowe@medsfgh.ucsf.edu OI Grams, Morgan/0000-0002-4430-6023 FU CDC through the Association of American Medical Colleges (AAMC) [MM-1143-10/10]; National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD [K24DK02643] FX This project was supported under a cooperative agreement from the CDC through the Association of American Medical Colleges (AAMC), grant no. MM-1143-10/10. Report contents are solely the responsibility of the authors and do not necessarily represent the official views of the AAMC or CDC. Dr Powe is partially supported by grant K24DK02643 from the National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD. NR 47 TC 31 Z9 31 U1 0 U2 6 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JAN PY 2011 VL 57 IS 1 BP 44 EP 54 DI 10.1053/j.ajkd.2010.05.013 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 698VP UT WOS:000285621600009 PM 20692079 ER PT J AU Ackermann, RT Cheng, YLJ Williamson, DF Gregg, EW AF Ackermann, Ronald T. Cheng, Yiling J. Williamson, David F. Gregg, Edward W. TI Identifying Adults at High Risk for Diabetes and Cardiovascular Disease Using Hemoglobin A1c National Health and Nutrition Examination Survey 2005-2006 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID IMPAIRED GLUCOSE-TOLERANCE; SERVICES TASK-FORCE; PREVENTION PROGRAM; LIFE-STYLE; METAANALYSIS; REDUCTION; ASSOCIATION; MORTALITY; METFORMIN; MELLITUS AB Background: The American Diabetes Association (ADA) recently proposed the use of hemoglobin A1c as a practical and valid strategy to identify high-risk people for whom delivery of an intensive lifestyle intervention to prevent type 2 diabetes is likely to be cost effective. Purpose: To estimate composite risks of developing diabetes and cardiovascular disease (CVD) for adults with different hemoglobin A1c test results and to compare those risks with those of adults who met the 2003 ADA definition for prediabetes. Methods: Cross-sectional data from the 2005-2006 National Health and Nutrition Examination Survey were analyzed in 2009. The method of Stern and colleagues was used to estimate the 7.5-year probability of type 2 diabetes, and the Framingham General CVD Risk Engine was used to estimate the 10-year probability of CVD for adults with different A1c results. Sample weights were used to account for sampling probability and to adjust for noncoverage and nonresponse. Results: Among adults meeting the 2003 ADA definition for prediabetes, the probabilities for incident type 2 diabetes (over 7.5 years) and CVD (over 10 years) were 33.5% and 10.7%, respectively. Use of A1c alone, in the range of 5.5% to < 6.5%, would identify a population with comparable risks for diabetes (32.4% [SE = 1.2%]) and CVD (11.4% [SE = 0.6%]). A slightly higher cutoff (>= 5.7%) would identify adults with risks of 41.3% (SE = 1.5%) for diabetes and 13.3% (SE = 0.8%) for CVD risks that are comparable to people enrolled in the Diabetes Prevention Program. Conclusions: A1c-based testing in clinical settings should be considered as a means to identify greater numbers of adults at high risk of developing type 2 diabetes and CVD. (Am J Prev Med 2011; 40(1): 11-17) (C) 2011 American Journal of Preventive Medicine C1 [Ackermann, Ronald T.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA. [Cheng, Yiling J.; Gregg, Edward W.] Emory Univ, Div Diabet Translat, CDC, Atlanta, GA 30322 USA. [Williamson, David F.] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Ackermann, RT (reprint author), Indiana Univ Sch Med, Dept Med, 410 W 10th St,Suite 1140, Indianapolis, IN 46202 USA. EM rtackerm@iupui.edu FU CDC; Robert Wood Johnson Foundation [57398] FX Support for this research was provided by the CDC and the Robert Wood Johnson Foundation Physician Faculty Scholars Program (Grant 57398). The findings and conclusions in this report are those of the authors and do not necessarily represent the official positions of the CDC. NR 28 TC 41 Z9 41 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2011 VL 40 IS 1 BP 11 EP 17 DI 10.1016/j.amepre.2010.09.022 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 692WY UT WOS:000285187800002 PM 21146762 ER PT J AU Bellcross, CA Kolor, K Goddard, KAB Coates, RJ Reyes, M Khoury, MJ AF Bellcross, Cecelia A. Kolor, Katherine Goddard, Katrina A. B. Coates, Ralph J. Reyes, Michele Khoury, Muin J. TI Awareness and Utilization of BRCA1/2 Testing Among US Primary Care Physicians SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID OVARIAN-CANCER SUSCEPTIBILITY; GENETIC RISK-ASSESSMENT; MUTATION CARRIERS; BREAST-CANCER; SALPINGO-OOPHORECTOMY; FAMILY PHYSICIANS; NATIONAL-SURVEY; METAANALYSIS; STATEMENT; KNOWLEDGE AB Background: Testing for mutations in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 (BRCA) has been commercially available since 1996. Purpose: This study sought to determine, among U. S. primary care physicians, the level of awareness and utilization of BRCA testing and the 2005 U. S. Preventive Services Task Force (USPSTF) recommendations. Methods: In 2009, data were analyzed on 1500 physician respondents to the 2007 DocStyles national survey (515 family practitioners, 485 internists, 250 pediatricians, and 250 obstetricians/gynecologists). Results: Overall, 87% of physicians were aware of BRCA testing, and 25% reported having ordered testing for at least one patient in the past year. Ordering tests was most prevalent among obstetricians/gynecologists in practice for more than 10 years, with more affluent patients. Physicians were asked to select indications for BRCA testing from seven different clinical scenarios representing increased (4) or low-risk (3) situations consistent with the USPSTF guidelines. Among ordering physicians (pediatricians excluded), 45% chose at least one low-risk scenario as an indication for BRCA testing. Only 19% correctly selected all of the increased-risk and none of the low-risk scenarios. Conclusions: A substantial majority of primary care physicians are aware of BRCA testing and many report having ordered at least one test within the past year. A minority, however, appear to consistently recognize the family history patterns identified by the USPSTF as appropriate indications for BRCA evaluation. These results suggest the need to improve providers' knowledge about existing recommendations-particularly in this era of increased BRCA direct-to-consumer marketing. (Am J Prev Med 2011; 40(1): 61-66) (C) 2011 American Journal of Preventive Medicine C1 [Bellcross, Cecelia A.; Kolor, Katherine; Coates, Ralph J.; Reyes, Michele; Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, CDC, Atlanta, GA 30333 USA. [Goddard, Katrina A. B.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA. RP Bellcross, CA (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, CDC, 1600 Clifton Rd NE,MS E-61, Atlanta, GA 30333 USA. EM cbellcross@cdc.gov NR 23 TC 60 Z9 60 U1 2 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2011 VL 40 IS 1 BP 61 EP 66 DI 10.1016/j.amepre.2010.09.027 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 692WY UT WOS:000285187800009 PM 21146769 ER PT J AU Schoeni, RF Dow, WH Miller, WD Pamuk, ER AF Schoeni, Robert F. Dow, William H. Miller, Wilhelmine D. Pamuk, Elsie R. TI The Economic Value of Improving the Health of Disadvantaged Americans SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID UNITED-STATES; LIFE AB Background: Higher educational attainment is associated with better health status and longer life. Purpose: This analysis estimates the annual dollar value of the benefits that would accrue to less-educated American adults if they experienced the lower mortality rates and better health of those with a college education. Methods: Using estimates of differences in mortality among adults aged >= 25 years by educational attainment from the National Longitudinal Mortality Survey and of education-based differentials in health status from published studies based on the Medical Expenditure Panel Survey, combined with existing estimates of the economic value of a healthy life year, the economic value of raising the health of individuals with less than a college education to the health of the college educated is estimated. Results: The annual economic value that would accrue to disadvantaged (less-educated) Americans if their health and longevity improved to that of college-educated Americans is $1.02 trillion. Conclusions: This modeling exercise does not fully account for the social costs and benefits of particular policies and programs to reduce health disparities; rather, it provides a sense of the magnitude of the economic value lost in health disparities to compare with other social issues vying for attention. The aggregate economic gains from interventions that improve the health of disadvantaged Americans are potentially large. (Am J Prev Med 2011; 40(1S1): S67-S72) (C) 2011 American Journal of Preventive Medicine C1 [Schoeni, Robert F.] Univ Michigan, Inst Social Res, Ann Arbor, MI 48109 USA. [Dow, William H.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Miller, Wilhelmine D.] Univ Chicago, NORC, Bethesda, MD USA. [Pamuk, Elsie R.] CDC, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Schoeni, RF (reprint author), Univ Michigan, Inst Social Res, 426 Thompson St, Ann Arbor, MI 48109 USA. EM bschoeni@umich.edu OI Dow, William/0000-0002-4080-1668 FU Robert Wood Johnson Foundation; Department of Health Policy, George Washington University School of Public Health and Health Services FX Publication of this article was supported by the Robert Wood Johnson Foundation and the Department of Health Policy, George Washington University School of Public Health and Health Services, as part of a supplement to the American Journal of Preventive Medicine (Am J Prev Med 2011; 40[1S1]). NR 22 TC 14 Z9 14 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2011 VL 40 IS 1 SU 1 BP S67 EP S72 DI 10.1016/j.amepre.2010.09.032 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 692XM UT WOS:000285189200007 PM 21146781 ER PT J AU Brostrom, R Fred, D Heetderks, A Desai, M Song, R Haddad, M Wada, R Bamrah, S AF Brostrom, Richard Fred, Dorina Heetderks, Andy Desai, Mitesh Song, Rinn Haddad, Maryam Wada, Roylinne Bamrah, Sapna TI Islands of Hope: Building Local Capacity to Manage an Outbreak of Multidrug-Resistant Tuberculosis in the Pacific SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Editorial Material AB A single case of multidrug-resistant tuberculosis (MDR-TB) can overwhelm the technical and financial capacity of small TB programs. In May 2008, the island state of Chuuk requested assistance for their first cases of MDR-TB. Second-line drugs and isolation rooms were unavailable, lab capacity was limited, and clinicians lacked experience. Delayed response caused prolonged transmission among household contacts. Several agencies responded with technical assistance and resources. Subsequent evaluations identified 16 additional MDR-TB cases and 124 infected contacts. Within six months, the local TB program gained remarkable capacity to manage MDR-TB cases and contacts, and greatly improve care for all TB patients. The Chuuk outbreak demonstrates the importance of establishing MDR-TB readiness in smaller jurisdictions and maintaining an essential TB control infrastructure. (Am J Public Health. 2011; 101:14-18.doi:10.2105/AJPH. 2009.177170) C1 [Wada, Roylinne] US Dept Interior, Honolulu, HI USA. [Heetderks, Andy; Haddad, Maryam; Bamrah, Sapna] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Brostrom, R (reprint author), Lanakila Hlth Ctr, 1700 Lanakila Ave, Honolulu, HI 96817 USA. EM richard.brostrom@gmail.com NR 9 TC 6 Z9 6 U1 0 U2 3 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 2011 VL 101 IS 1 BP 14 EP 18 DI 10.2105/AJPH.2009.177170 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 699LN UT WOS:000285665000007 PM 21148710 ER PT J AU Manangan, LP Salibay, CJA Wallace, RM Kammerer, S Pratt, R McAllister, L Robison, V AF Manangan, Lila Ponce Salibay, Catheryn Jumao-as Wallace, Ryan MacLaren Kammerer, Steve Pratt, Robert McAllister, Laura Robison, Valerie TI Tuberculosis Among Persons Born in the Philippines and Living in the United States, 2000-2001 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID IMMIGRANTS AB Objectives. We examined demographic, clinical, and treatment outcome characteristics of Filipinos with tuberculosis (TB) in the United States. Methods. We calculated TB case rates from US Census Bureau population estimates and National Tuberculosis Surveillance System data for US-born non-Hispanic Whites and for US residents born in the Philippines, India, China, Cambodia, Vietnam, Pakistan, and Korea countries that are major contributors to the TB burden in the United States. We compared Filipinos with the other groups through univariate and multivariate analyses. Results. Of 45 504 TB patients, 15.5% were Filipinos; 43.0% were other Asian/Pacific Islander groups; and 41.6% were Whites. Per 100000 persons in 2007, the TB rate was 73.5 among Cambodians, 54.0 among Vietnamese, 52.1 among Filipinos, and 0.9 among Whites. Filipinos were more likely than other groups to be employed as health care workers and to have used private health care providers but less likely to be HIV positive and to be offered HIV testing. Conclusions. The relatively high TB rate among Filipinos indicates that TB control strategies should target this population. Providers should be encouraged to offer HIV testing to all TB patients. (Am J Public Health. 2011;101:101-111. doi: 10.2105/AJPH.2009.175331) C1 [Manangan, Lila Ponce; Wallace, Ryan MacLaren; Robison, Valerie] Ctr Dis Control & Prevent CDC, Div TB Eliminat, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Salibay, Catheryn Jumao-as; McAllister, Laura] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Manangan, Lila Ponce] CDC, Div TB Eliminat, Atlanta, GA 30333 USA. RP Manangan, LP (reprint author), CDC, Div TB Eliminat, 1600 Clifton Rd,Mailstop E-10, Atlanta, GA 30333 USA. EM lpm2@cdc.gov NR 31 TC 4 Z9 4 U1 1 U2 6 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 2011 VL 101 IS 1 BP 101 EP 111 DI 10.2105/AJPH.2009.175331 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 699LN UT WOS:000285665000022 PM 20299652 ER PT J AU Oster, AM Dorell, CG Mena, LA Thomas, PE Toledo, CA Heffelfinger, JD AF Oster, Alexandra M. Dorell, Christina G. Mena, Leandro A. Thomas, Peter E. Toledo, Carlos A. Heffelfinger, Jamas D. TI HIV Risk Among Young African American Men Who Have Sex With Men: A Case-Control Study in Mississippi SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; BLACK-MEN; SURVEILLANCE SYSTEM; DEEP SOUTH; INFECTION; PREVALENCE; BEHAVIORS; PREVENTION; PARTNERS; CITIES AB Objectives. We conducted a case control study in the Jackson, Mississippi, area to identify factors associated with HIV infection among young African American men who have sex with men (MSM). Methods. During February to April 2008, we used surveillance records to identify young (16-25 years old) African American MSM diagnosed with HIV between 2006 and 2008 (case participants) and recruited young African American MSM who did not have HIV (controls). Logistic regression analysis was used to assess factors associated with HIV infection. Results. In a multivariable analysis of 25 case participants and 85 controls, having older male partners (adjusted odds ratio [OR]=5.5; 95% confidence interval [CI]=1.8, 17.3), engaging in unprotected anal intercourse with casual male partners (adjusted OR =6.3; 95% CI=1.8, 22.3), and being likely to give in to a partner who wanted to have unprotected sex (adjusted OR = 5.0; 95% CI = 1.2, 20.6) were associated with HIV infection. Conclusions. Given the high prevalence of risk behaviors among the young African American MSM in our study, HIV prevention efforts must begin before or during early adolescence and need to focus on improving negotiation and communication regarding sex. (Am J Public Health. 2011;101:137-143. doi:10.2105/AJPH.2009.185850) C1 [Oster, Alexandra M.; Dorell, Christina G.; Thomas, Peter E.; Toledo, Carlos A.; Heffelfinger, Jamas D.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Oster, Alexandra M.; Dorell, Christina G.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Mena, Leandro A.] Mississippi Dept Hlth, Med Ctr, Jackson, MS USA. [Mena, Leandro A.] Univ Mississippi, Med Ctr, Jackson, MS USA. RP Oster, AM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,Mail Stop E-46, Atlanta, GA 30333 USA. EM aoster@cdc.gov FU Centers for Disease Control and Prevention; Mississippi State Department of Health FX This investigation was supported by the Centers for Disease Control and Prevention and the Mississippi State Department of Health. NR 26 TC 21 Z9 21 U1 0 U2 4 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 2011 VL 101 IS 1 BP 137 EP 143 DI 10.2105/AJPH.2009.185850 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 699LN UT WOS:000285665000026 PM 21088266 ER PT J AU Couch, SR Coles, CJ AF Couch, Stephen R. Coles, Charlton J. TI Community Stress, Psychosocial Hazards, and EPA Decision-Making in Communities Impacted by Chronic Technological Disasters SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID NATURAL DISASTER; BLOOD-PRESSURE; SOCIOECONOMIC-STATUS; VICTIMS SPEAK; MENTAL-HEALTH; OLDER-ADULTS; LEAD LEVELS; HYPERTENSION; CONSERVATION; CONTAMINATION AB Psychosocial stress has emerged as an important consideration in managing environmental health risks. Stress has adverse impacts on health and may interact with environmental hazards to increase health risk. This article's primary objective was to explore psychosocial stress related to environmental contamination. We hypothesized that knowledge about stress should be used in conjunction with chemical risk assessment to inform environmental risk management decisions. Knowledge of psychosocial stress at contaminated sites began by exploring the relationships among social capital, collective efficacy, and contamination at the community level. We discussed stress at the family and individual levels, focusing on stress proliferation, available resources, and coping styles and mechanisms. We then made recommendations on how to improve the use of information on psychosocial stress in environmental decision-making, particularly in communities facing chronic technological disasters. (Am J Public Health. 2011;101:S140-S148. doi:10.2105/AJPH.2010.300039) C1 [Couch, Stephen R.] Penn State Univ, Acad Affairs, Schuylkill Haven, PA 17972 USA. [Coles, Charlton J.] Agcy Toxic Subst & Dis Registry, Ctrs Dis Control, Div Toxicol & Environm Med, Atlanta, GA USA. [Coles, Charlton J.] Agcy Toxic Subst & Dis Registry, Ctrs Dis Control, Environm Med & Educ Serv Branch, Atlanta, GA USA. RP Couch, SR (reprint author), Penn State Univ, Acad Affairs, Schuylkill Campus,200 Univ Dr, Schuylkill Haven, PA 17972 USA. EM src@psu.edu FU Environmental Protection Agency (EPA) [1110-109] FX The contents of this paper were presented at "Strengthening Environmental Justice Research and Decision Making: A Symposium on the Science of Disproportionate Environmental Health Impacts," March 17-19, 2010 in Washington, DC, and supported by Environmental Protection Agency (EPA) Contract 1110-109. The authors of this paper would like thank the following organizations, EPA, CDC, ATSDR, Michael D. Baker, and Drs. Bruce McEwen (Rockefeller University), Pam Tucker (CDC/ATSDR), and Nweke Onyemaechi (EPA), for their guidance and input during the conceptualization and writing of this article. NR 87 TC 12 Z9 12 U1 1 U2 17 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PY 2011 VL 101 SU 1 BP S140 EP S148 DI 10.2105/AJPH.2010.300039 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 849QU UT WOS:000297141000021 PM 21836109 ER PT J AU McEwen, BS Tucker, P AF McEwen, Bruce S. Tucker, Pamela TI Critical Biological Pathways for Chronic Psychosocial Stress and Research Opportunities to Advance the Consideration of Stress in Chemical Risk Assessment SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SUBJECTIVE SOCIAL-STATUS; ACUTE MYOCARDIAL-INFARCTION; PARTICULATE AIR-POLLUTION; CASE-CROSSOVER ANALYSIS; PITUITARY-ADRENAL AXIS; COMBINED MATERNAL LEAD; SOCIOECONOMIC-STATUS; ALLOSTATIC LOAD; BLOOD-PRESSURE; UNITED-STATES AB Emerging evidence suggests that psychosocial stress and toxicants may interact to modify health risks. Stress toxicant interactions could be important in chemical risk assessment, but these interactions are poorly understood and additional research is necessary to advance their application. Environmental health research can increase knowledge of these interactions by exploring hypotheses on allostatic load, which measures the cumulative impacts of stress across multiple physiological pathways, using knowledge about physiological pathways for stress-related health effects, and evidence of common target pathways for both stress and toxicants. In this article, critical physiological pathways for stress-related health effects are discussed, with specific attention to allostatic load and stress toxicant interactions, concluding with research suggestions for potential applications of such research in chemical risk assessment. (Am J Public Health. 2011;101:S131-S139. doi:10.2105/AJPH.2011.300270) C1 [Tucker, Pamela] Agcy Tox Subst & Dis Registry, Div Toxicol & Environm Med MS F62, Atlanta, GA 30333 USA. [McEwen, Bruce S.] Rockefeller Univ, Harold & Margaret Milliken Hatch Lab Neuroendrocr, New York, NY 10021 USA. RP Tucker, P (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Environm Med MS F62, MS F 62,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM pgt0@cdc.gov FU US Environmental Protection Agency's Office of Environmental Justice under GSA [GS-00F-0001S] FX This article was developed with support provided by the US Environmental Protection Agency's Office of Environmental Justice under GSA contract no GS-00F-0001S, Task Order No. 16. NR 122 TC 30 Z9 30 U1 3 U2 16 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PY 2011 VL 101 SU 1 BP S131 EP S139 DI 10.2105/AJPH.2011.300270 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 849QU UT WOS:000297141000020 PM 22021312 ER PT J AU Amarir, F El Mansouri, B Fellah, H Sebti, F Mohammed, L Handali, S Wilkins, P El Idrissi, AL Sadak, A Rhajaoui, M AF Amarir, Fatima El Mansouri, Bouchra Fellah, Hajiba Sebti, Faiza Mohammed, Lakranbi Handali, Sukwan Wilkins, Patricia El Idrissi, Abderrahman Laamrani Sadak, Abderrahim Rhajaoui, Mohamed TI National Serologic Survey of Haematobium Schistosomiasis in Morocco Evidence for Elimination SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ADULT MICROSOMAL ANTIGENS; POLYMERASE-CHAIN-REACTION; MANSONI; ANTIBODIES; COMPONENTS; DNA AB The Moroccan Health Ministry launched a Process of Eliminating Schistosomiasis in 1994 During 2005-2009, the epidemiologic status showed a clear interruption of disease transmission at the national level, only a few residual cases were recorded Our present study is the first systematic serologic survey to evaluate the transmission status in remaining disease endemic foci A study population of 2,382 children born after the date of the last autochthonous cases were selected from provinces with histories of high schistosomiasis transmission (Tata, Chtouka Ait Baha Errachidia El Kelaa Des Sraghna, and Beni Mellal) To identify the presence of disease specific antibodies directed against Schistosoma haematobium adult worm microsomal antigens were detected by using an enzyme-linked immunoelectrotransfer blot assay The results showed an absence of antibodies in all serum samples Consequently, our findings confirm either a low transmission status or an interruption of schistosomiasis transmission within the last disease endemic foci C1 [Amarir, Fatima; El Mansouri, Bouchra; Fellah, Hajiba; Sebti, Faiza; Mohammed, Lakranbi; Rhajaoui, Mohamed] Natl Inst Hyg, Dept Parasitol, Rabat, Morocco. [El Idrissi, Abderrahman Laamrani] Direct Epidemiol & Control Dis, Rabat, Morocco. [Sadak, Abderrahim] Univ Mohammed 5, Dept Biol, Rabat, Morocco. [Handali, Sukwan; Wilkins, Patricia] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. RP Rhajaoui, M (reprint author), Natl Inst Hyg, Dept Parasitol, Ave Ibn Battouta, Rabat, Morocco. FU World Health Organization [2 008/237 0] FX This study was supported by the World Health Organization (Reference no 2 008/237 0) NR 35 TC 12 Z9 12 U1 0 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2011 VL 84 IS 1 BP 15 EP 19 DI 10.4269/ajtmh.2011.10-0378 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 702OK UT WOS:000285903800004 PM 21212195 ER PT J AU Nundy, S Gilman, RH Xiao, LH Cabrera, L Cama, R Ortega, YR Kahn, G Cama, VA AF Nundy, Shantanu Gilman, Robert H. Xiao, Lihua Cabrera, Lilia Cama, Rosa Ortega, Ynes R. Kahn, Geoffrey Cama, Vitaliano A. TI Wealth and Its Associations with Enteric Parasitic Infections in a Low-Income Community in Peru Use of Principal Component Analysis SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID ECONOMIC-STATUS; CHILDREN; DIARRHEA; HEALTH; POOR; SHANTYTOWN; WATER AB The association of wealth and infections with Giardia,Cryptosporidium, Cyclospora, and microsporidia were examined in a longitudinal cohort conducted in Peru from 2001 to 2006 Data from 492 participants were daily clinical manifestations weekly copro parasitological diagnosis, and housing characteristics and assets owned (48 variables), and these data were used to construct a global wealth index using principal component analysis Data were analyzed using continuous and categorical (wealth tertiles) models Participant's mean age was 3 43 years (range = 0-12 years), with average follow-up of 993 days Univariate and multivariate analyses identified significant associations between wealth and infections with Giardia and microsporidia Participants with greater wealth Indexes were associated with protection against Giardia (P < 0 001) and persistent Giardia infections (> 14 days) For microsporidia, greater wealth was protective (P = 0 066 continuous and P = 0 042 by tertiles) Contrarily, infections with Cryptosporidium and Cyclospora were independent of wealth Thus, subtle differences in wealth may affect the frequency of specific parasitic infections within low-income communities C1 Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30329 USA. [Gilman, Robert H.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. Asociac Benef Proyectos Informat Salud Med & Agr, Dept Invest, Lima, Peru. [Ortega, Ynes R.] Univ Georgia, Dept Food Sci & Technol, Ctr Food Safety, Griffin, GA 30223 USA. [Nundy, Shantanu] Univ Chicago, Med Ctr, Dept Internal Med, Chicago, IL 60637 USA. [Xiao, Lihua; Kahn, Geoffrey; Cama, Vitaliano A.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. RP Cama, VA (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd,Bldg 23,Room 10 164 MS 65, Atlanta, GA 30329 USA. RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU Centers for Disease Control and Prevention; NIH NIAID [5P01AI051976, 5R21AI059661]; USDA CSREES [2001 51110 11340] FX This study was funded in part by the Centers for Disease Control and Prevention O C Hubert Fellowship Program NIH NIAID Grants 5P01AI051976 and 5R21AI059661 and USDA CSREES Grant 2001 51110 11340 NR 20 TC 12 Z9 12 U1 2 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2011 VL 84 IS 1 BP 38 EP 42 DI 10.4269/ajtmh.2011.10-0442 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 702OK UT WOS:000285903800007 PM 21212198 ER PT J AU Bowman, NM Kawai, V Gilman, RH Bocangel, C Cardenas, GG Cabrera, L Levy, MZ del Carpio, JGC Delgado, F Rosenthal, L Pinedo-Cancino, VV Steurer, F Seitz, AE Maguire, JH Bern, C AF Bowman, Natalie M. Kawai, Vivian Gilman, Robert H. Bocangel, Cesar Galdos Cardenas, Gerson Cabrera, Lilia Levy, Michael Z. Geny Cornejo del Carpio, Juan Delgado, Freddy Rosenthal, Lauren Pinedo-Cancino, Vivian V. Steurer, Francis Seitz, Amy E. Maguire, James H. Bern, Caryn TI Autonomic Dysfunction and Risk Factors Associated with Trypanosoma cruzi Infection among Children in Arequipa, Peru SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID CHAGAS-DISEASE CONTROL; HOUSEHOLD PREVALENCE; NORTHWEST ARGENTINA; TRIATOMA-INFESTANS; SEROPREVALENCE; PREDICTORS; MORTALITY; COMMUNITY; HUMANS; BRAZIL AB Chagas disease affects an estimated 8 million people in Latin America Infected individuals have 20-30% lifetime risk of developing cardiomyopathy, but more subtle changes in autonomic responses may be more frequent We conducted a matched case control study of children in Arequipa, Peru, where triatomine infestation and Trypanosoma cruzi infection are emerging problems We collected data on home environment, history physical examination, electrocardiogram, and autonomic testing Signs of triatomine infestation and/or animals sleeping in the child's room and household members with Chagas disease were associated with Increased infection risk Electrocardiogram findings did not differ between cases and controls However, compared with control children, infected children had blunted auto nomic responses by three different measures, the Valsalva maneuver, the cold pressor test, and the orthostatic test T cruzi-infected children show autonomic dysfunction, although the prognostic value of this finding is not clear Sustained vector control programs are essential to decreasing future 7 cruzi infections C1 [Bowman, Natalie M.; Gilman, Robert H.; Galdos Cardenas, Gerson] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA. [Bowman, Natalie M.] Univ N Carolina, Div Infect Dis, Chapel Hill, NC USA. [Bowman, Natalie M.] Johns Hopkins Univ Hosp, Dept Internal Med, Baltimore, MD 21287 USA. [Kawai, Vivian; Gilman, Robert H.; Cabrera, Lilia; Pinedo-Cancino, Vivian V.] Asociac Benef PRISMA, Lima, Peru. [Bocangel, Cesar; Galdos Cardenas, Gerson; Geny Cornejo del Carpio, Juan; Delgado, Freddy] Arequipa Minis Hlth, Arequipa, Peru. [Levy, Michael Z.] Univ Penn, Philadelphia, PA 19104 USA. [Levy, Michael Z.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Rosenthal, Lauren] Morgan Stanley Childrens Hosp New York, New York, NY USA. [Steurer, Francis; Bern, Caryn] Ctr Dis Control & Prevent, Atlanta, GA USA. [Seitz, Amy E.] NIAID, NIH, Bethesda, MD 20892 USA. [Maguire, James H.] Harvard Univ, Sch Med, Boston, MA USA. RP Bowman, NM (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, 615 N Wolfe St,Room W5515, Baltimore, MD 21205 USA. FU Fogarty Ellison Fellowship in Global Health and Clinical Research; Centers for Disease Control and Prevention Foundation; O C Hubert Fellowship; National Institutes of Health (NIH) [5T35 AI 007646 03, 1K01AI079162, U19 AI 33061, 5P50AI074285 02] FX N M B was supported by the Fogarty Ellison Fellowship in Global Health and Clinical Research the Centers for Disease Control and Prevention Foundation O C Hubert Fellowship and the National Institutes of Health (NIH) timing Grant 5T35 AI 007646 03 M Z L is supported by Grant 1K01AI079162 This work was funded by a grant from the International Society for Infectious Diseases NIH International Collaborations in Infectious Disease Research Opportunity Grant U19 AI 33061 and NIH Grant 5P50AI074285 02 The funding source had no role in the study design collection, analysis and interpretation of the data preparation of the manuscript or the decision to submit for publication NR 46 TC 8 Z9 8 U1 0 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2011 VL 84 IS 1 BP 85 EP 90 DI 10.4269/ajtmh.2011.10-0303 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 702OK UT WOS:000285903800016 PM 21212207 ER PT J AU Eremeeva, ME Stromdahl, EY AF Eremeeva, Marina E. Stromdahl, Ellen Y. TI Short Report New Spotted Fever Group Rickettsia in a Rhipicephalus turanicus Tick Removed from a Child in Eastern Sicily, Italy SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SANGUINEUS TICKS; MASSILIAE; IDENTIFICATION AB A new genotype of spotted fever group Rickettsia (SFGR) was identified in Rhipicephalus turanicus from eastern Sicily On the basis of current molecular criteria, the genetic characteristics obtained from multiple locus sequence typing satisfy the requirements for Candidatus status of this SFGR Further detection and identification of this SFGR during entomological and clinical surveys will be required to establish the prevalence of this Rickettsia and its potential pathogenicity for humans C1 [Eremeeva, Marina E.] Ctr Dis Control & Prevent, Rickettstal Zoonoses Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Stromdahl, Ellen Y.] USA, Entomol Sci Program, Publ Hlth Command, Aberdeen Proving Ground, MD USA. RP Eremeeva, ME (reprint author), Ctr Dis Control & Prevent, Rickettstal Zoonoses Branch, Natl Ctr Emerging & Zoonot Infect Dis, Mail Stop G13,1600 Clifton Rd NE, Atlanta, GA 30333 USA. NR 15 TC 7 Z9 7 U1 1 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2011 VL 84 IS 1 BP 99 EP 101 DI 10.4269/ajtmh.2011.10-0176 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 702OK UT WOS:000285903800018 PM 21212209 ER PT J AU Canavate, C Herrero, M Nieto, J Cruz, I Chicharro, C Apancio, P Mulugeta, A Argaw, D Blackstock, AJ Alvar, J Bern, C AF Canavate, Carmen Herrero, Merce Nieto, Javier Cruz, Israel Chicharro, Carmen Apancio, Pilar Mulugeta, Abate Argaw, Daniel Blackstock, Anna J. Alvar, Jorge Bern, Caryn TI Evaluation of Two rK39 Dipstick Tests, Direct Agglutination Test, and Indirect Fluorescent Antibody Test for Diagnosis of Visceral Leishmaniasis in a New Epidemic Site in Highland Ethiopia SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; KALA-AZAR; INDIAN SUBCONTINENT; FIELD-EVALUATION; STRIP TEST; DAT; OUTBREAK; SUDAN; ELISA; KATEX AB We assessed the performance characteristics of two rK39 immunochromatographic tests, a direct agglutination test (DAT), and an indirect immunofluorescent antibody test (IFAT) in the site of a new epidemic of visceral leishmaniasis (VL) in northwestern Ethiopia The study population was composed of 179 patients with suspected VL and 67 controls The sensitivities of Kalazar Detect (R), DiaMed IT Leish (R) DAT, and IFAT in 35 polymerase chain reaction con firmed VL cases were 94 3%, 91 4%, 91 4% and 100%, respectively, and the specificities were 98 5%, 94%, 98 5%, and 98 5%, respectively In a Bayesian latent class analysis of all 246 specimens, the estimated sensitivities were 90 5%, 89%, 88 8%, and 96% for Kalazar Detect (R) DiaMed-IT Leish (R), DAT, and IFAT, respectively, DAT showed the highest estimated specificity (97 4%) Both rK39 immunochromatographic tests perform as well as DAT, and are suitable for VL diagnosis in first level health centers in this area of Ethiopia C1 [Canavate, Carmen; Nieto, Javier; Cruz, Israel; Chicharro, Carmen] Inst Salud Carlos III, World Hlth Org Collaborating Ctr Leishmaniasis, Natl Ctr Microbiol, Madrid, Spain. [Apancio, Pilar] Inst Salud Carlos III, Natl Ctr Trop Med, Madrid, Spain. [Herrero, Merce; Mulugeta, Abate; Argaw, Daniel] WHO, Dis Prevent & Control Programmes, Addis Ababa, Ethiopia. [Blackstock, Anna J.; Bern, Caryn] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30341 USA. [Blackstock, Anna J.] Atlanta Res & Educ Fdn, Decatur, GA USA. [Alvar, Jorge] WHO, Dept Control Neglected Trop Dis, Leishmaniasis Control Program, CH-1211 Geneva, Switzerland. [Herrero, Merce] Med Sans Frontieres Ethiopia Operat Ctr Barcelona, Addis Zemen, Ethiopia. RP Bern, C (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, 4770 Buford Highway NE,Mailstop F22, Atlanta, GA 30341 USA. FU Agencia Espanola de Cooperacion Internacional FX We thank Jose Miguel Rubio and Margriet den Boer for helpful comments on the text and the Agencia Espanola de Cooperacion Internacional for supporting this study NR 33 TC 13 Z9 13 U1 0 U2 6 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2011 VL 84 IS 1 BP 102 EP 106 DI 10.4269/ajtmh.2011.10-0229 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 702OK UT WOS:000285903800019 PM 21212210 ER PT J AU Liu, CC Geva, E Mauk, M Qiu, XB Abrams, WR Malamud, D Curtis, K Owen, SM Bau, HH AF Liu, Changchun Geva, Eran Mauk, Michael Qiu, Xianbo Abrams, William R. Malamud, Daniel Curtis, Kelly Owen, S. Michele Bau, Haim H. TI An isothermal amplification reactor with an integrated isolation membrane for point-of-care detection of infectious diseases SO ANALYST LA English DT Article ID REAL-TIME PCR; ON-A-CHIP; REVERSE-TRANSCRIPTION; SAMPLE PREPARATION; RAPID DETECTION; QUANTITATIVE DETECTION; MICROFLUIDIC CASSETTE; CLINICAL DIAGNOSTICS; MULTIPLEX PCR; DNA AB A simple, point of care, inexpensive, disposable cassette for the detection of nucleic acids extracted from pathogens was designed, constructed, and tested. The cassette utilizes a single reaction chamber for isothermal amplification of nucleic acids. The chamber is equipped with an integrated, flow-through, Flinders Technology Associates (Whatman FTA (R)) membrane for the isolation, concentration, and purification of DNA and/or RNA. The nucleic acids captured by the membrane are used directly as templates for amplification without elution, thus simplifying the cassette's flow control. The FTA membrane also serves another critical role-enabling the removal of inhibitors that dramatically reduce detection sensitivity. Thermal control is provided with a thin film heater external to the cassette. The amplification process was monitored in real time with a portable, compact fluorescent reader. The utility of the integrated, single-chamber cassette was demonstrated by detecting the presence of HIV-1 in oral fluids. The HIV RNA was reverse transcribed and subjected to loop-mediated, isothermal amplification (LAMP). A detection limit of less than 10 HIV particles was demonstrated. The cassette is particularly suitable for resource poor regions, where funds and trained personnel are in short supply. The cassette can be readily modified to detect nucleic acids associated with other pathogens borne in saliva, urine, and other body fluids as well as in water and food. C1 [Liu, Changchun; Mauk, Michael; Qiu, Xianbo; Bau, Haim H.] Univ Penn, Dept Mech Engn & Appl Mech, Philadelphia, PA 19104 USA. [Geva, Eran; Abrams, William R.; Malamud, Daniel] NYU, Coll Dent, Dept Basic Sci, New York, NY 10010 USA. [Curtis, Kelly; Owen, S. Michele] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Bau, HH (reprint author), Univ Penn, Dept Mech Engn & Appl Mech, 229 Towne Bldg,220 S 33rd St, Philadelphia, PA 19104 USA. EM bau@seas.upenn.edu RI Abrams, William/A-5782-2008; OI Malamud, Daniel/0000-0002-9094-4122 FU NIH/NIDCR [U01DE017855] FX The work was supported by NIH/NIDCR Grant U01DE017855. The primers for the LAMP process were designed and provided by the Center for Disease Control and Prevention (CDC) through a Material Transfer Agreement with New York University. NR 45 TC 57 Z9 58 U1 5 U2 56 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 0003-2654 J9 ANALYST JI Analyst PY 2011 VL 136 IS 10 BP 2069 EP 2076 DI 10.1039/c1an00007a PG 8 WC Chemistry, Analytical SC Chemistry GA 754ZI UT WOS:000289896000009 PM 21455542 ER PT J AU Fernandez, FM Hostetler, D Powell, K Kaur, H Green, MD Mildenhall, DC Newton, PN AF Fernandez, Facundo M. Hostetler, Dana Powell, Kristen Kaur, Harparkash Green, Michael D. Mildenhall, Dallas C. Newton, Paul N. TI Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countries SO ANALYST LA English DT Article ID DESORPTION ELECTROSPRAY-IONIZATION; COUNTERFEIT ANTIMALARIAL TABLETS; NEAR-INFRARED SPECTROSCOPY; TANDEM MASS-SPECTROMETRY; FAKE ARTESUNATE; SOUTHEAST-ASIA; FALCIPARUM-MALARIA; RAMAN-SPECTROSCOPY; AMBIENT CONDITIONS; REAL-TIME AB Throughout history, poor quality medicines have been a persistent problem, with periodical crises in the supply of antimicrobials, such as fake cinchona bark in the 1600s and fake quinine in the 1800s. Regrettably, this problem seems to have grown in the last decade, especially afflicting unsuspecting patients and those seeking medicines via on-line pharmacies. Here we discuss some of the challenges related to the fight against poor quality drugs, and counterfeits in particular, with an emphasis on the analytical tools available, their relative performance, and the necessary workflows needed for distinguishing between genuine, substandard, degraded and counterfeit medicines. C1 [Fernandez, Facundo M.; Hostetler, Dana; Powell, Kristen] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Kaur, Harparkash] London Sch Hyg & Trop Med, London WC1, England. [Green, Michael D.] US Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Mildenhall, Dallas C.] GNS Sci, Lower Hutt 5040, New Zealand. [Newton, Paul N.] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford, England. [Newton, Paul N.] Mahosot Hosp, Wellcome Trust Mahosot Hosp Oxford Trop Med Colla, Microbiol Lab, Vientiane, Lao Pdr, Thailand. RP Fernandez, FM (reprint author), Georgia Inst Technol, Sch Chem & Biochem, 901 Atlantic Dr NW, Atlanta, GA 30332 USA. EM facundo.fernandez@chemistry.gatech.edu RI Fernandez, Facundo/B-7015-2008 FU Artemisinin Combination Therapy Consortium; Bill and Melinda Gates Foundation; Wellcome Trust of Great Britain; US National Science Foundation [CHE-0645094] FX The authors are grateful to the Artemisinin Combination Therapy Consortium for funding their project through a grant from the Bill and Melinda Gates Foundation to the London school of Hygiene and Tropical Medicine. PNN is supported by the Wellcome Trust of Great Britain. FMF also thanks the US National Science Foundation for financial support though CAREER award #CHE-0645094. NR 59 TC 21 Z9 21 U1 1 U2 31 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 0003-2654 J9 ANALYST JI Analyst PY 2011 VL 136 IS 15 BP 3073 EP 3082 DI 10.1039/c0an00627k PG 10 WC Chemistry, Analytical SC Chemistry GA 795KD UT WOS:000292972200006 PM 21107455 ER PT J AU Ye, XY Zhou, XL Needham, LL Calafat, AM AF Ye, Xiaoyun Zhou, Xiaoliu Needham, Larry L. Calafat, Antonia M. TI In-vitro oxidation of bisphenol A: Is bisphenol A catechol a suitable biomarker for human exposure to bisphenol A? SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE Bisphenol A; Bisphenol A catechol; In-vitro metabolism; In-vivo metabolism; Exposure ID HUMAN URINE; DEVELOPMENTAL TOXICITY; ENVIRONMENTAL PHENOLS; LIQUID-CHROMATOGRAPHY; ESTROGENIC ACTIVITY; METABOLISM; RATS; PARABENS; DNA; BENZOPHENONE-3 AB The extensive use of bisphenol A (BPA) in the manufacture of consumer products results in widespread human exposure to the chemical. In the body, BPA undergoes first-pass metabolism to form BPA glucuronide, considered to be a major BPA byproduct. Concentrations of total (free plus conjugated) urinary species of BPA are used to assess human exposure to BPA. However, because BPA can be present in numerous consumer and household products, potential contamination with parent BPA during collection and handling may pose a challenge when measuring BPA in such biological samples as blood or urine. In this study we investigated the in-vitro phase I metabolism of BPA in rat and human liver microsomes by using on-line solid-phase extraction-high-performance liquid chromatography-tandem mass spectrometry to identify phase I metabolites (e. g., BPA oxidation products) that could be used as potential alternative biomarkers of BPA exposure. We unambiguously identified 5-hydroxy BPA (BPA catechol) as an in-vitro oxidative metabolite of BPA, but human microsomes oxidized only about 10% of BPA to BPA catechol. We evaluated the usefulness of BPA catechol as a potential biomarker of human exposure to BPA by measuring total concentrations of BPA catechol and BPA in 20 urine samples. We detected BPA catechol at much lower concentrations and frequency than those of BPA. Further-more, we found that free BPA catechol was rather unstable in urine, which highlights the importance of sampling techniques to adequate interpretation of biomonitoring data. Together, these findings suggest that BPA catechol may not be a suitable biomarker of environmental exposure to BPA, but could be used to confirm BPA exposure in special populations or in situations when urine specimens were potentially contaminated with BPA. C1 [Ye, Xiaoyun; Zhou, Xiaoliu; Needham, Larry L.; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Ye, XY (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Hwy,Mailstop F53, Atlanta, GA 30341 USA. EM xay5@cdc.gov RI Needham, Larry/E-4930-2011 NR 42 TC 21 Z9 21 U1 0 U2 20 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD JAN PY 2011 VL 399 IS 3 BP 1071 EP 1079 DI 10.1007/s00216-010-4344-x PG 9 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 711NQ UT WOS:000286599100008 PM 21058032 ER PT J AU Stefaniak, AB Virji, MA Day, GA AF Stefaniak, Aleksandr B. Virji, M. Abbas Day, Gregory A. TI Release of Beryllium from Beryllium-Containing Materials in Artificial Skin Surface Film Liquids SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE beryllium sensitization; bioaccessibility; particle dissolution; skin ID PHAGOLYSOSOMAL SIMULANT FLUID; DERMAL EXPOSURE; ALLOY FACILITY; DISEASE; SENSITIZATION; OXIDE; METAL; DISSOLUTION; NICKEL; RISK AB Methods: Dissolution of 11 particulate beryllium materials (hydroxide, metal, oxides and copper-beryllium fume), 3 copper-beryllium alloy reference materials (chips and solid block), and 4 copper-beryllium alloy tools was measured over 7 days in artificial sweat buffered to pH 5.3 and pH 6.5. Results: All test materials released beryllium ions in artificial sweat. Particulate from a reduction furnace that contained both crystalline and amorphous beryllium was the most soluble compound-40% dissolved in 8 h. Rates of beryllium release from all other particulate and reference materials were faster at pH 5.3 than at pH 6.5 (P < 0.05). At pH 5.3, values of the chemical dissolution rate constant, k [g (cm(2) day)(-1)] differed significantly for hydroxide, metal, and oxide -1.7 +/- 0.0 x 10(-7), 1.7 +/- 0.6 x 10(-8), and 1.0 +/- 0.5 x 10(-9), respectively (P < 0.05). Up to 30 mu g of beryllium was released from the alloy tools within 1 h. Dissolution rates in artificial sweat were equal to or faster than values previously determined for these materials in lung models. Conclusions: Poorly soluble beryllium materials undergo dissolution in artificial sweat, suggesting that skin exposure is a biologically plausible pathway for development of sensitization. Skin surface acidity, which is regulated by sweat chemistry and bacterial hydrolysis of sebum lipids varies by anatomical region and may be an exposure-modifying factor for beryllium particle dissolution. C1 [Stefaniak, Aleksandr B.; Virji, M. Abbas; Day, Gregory A.] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Stefaniak, AB (reprint author), NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. EM astefaniak@cdc.gov RI Stefaniak, Aleksandr/I-3616-2012 FU National Institute for Occupational Safety and Health FX National Institute for Occupational Safety and Health. NR 47 TC 6 Z9 6 U1 3 U2 14 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD JAN PY 2011 VL 55 IS 1 BP 57 EP 69 DI 10.1093/annhyg/meq057 PG 13 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 706JN UT WOS:000286214800006 PM 20729394 ER PT J AU Jin, Y Hein, MJ Deddens, JA Hines, CJ AF Jin, Yan Hein, Misty J. Deddens, James A. Hines, Cynthia J. TI Analysis of Lognormally Distributed Exposure Data with Repeated Measures and Values below the Limit of Detection Using SAS SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE censoring; exposure determinants; limit of detection; LOD; NLMIXED; occupational exposure; repeated measures; SAS ID MIXED EFFECTS MODELS; WITHIN-WORKER; CENSORED-DATA; DETERMINANTS; NONDETECTS; COMPONENTS AB Studies of determinants of occupational exposure frequently involve left-censored lognormally distributed data, often with repeated measures. Left censoring occurs when observations are below the analytical limit of detection (LOD); repeated measures data results from taking multiple measurements on the same worker. A common method of dealing with this type of data has been to substitute a value (such as LOD/2) for the censored data followed by statistical analysis using the 'usual' methods. Recently, maximum likelihood estimation (MLE) methods have been employed to reduce bias associated with the substitution method. We compared substitution and MLE methods using simulated lognormally distributed exposure data subjected to varying amounts of censoring using two procedures available in SAS: LIFEREG and NLMIXED. In these simulations, the MLE method resulted in less bias and performed well even for censoring up to 80%, whereas the substitution method resulted in considerable bias. We illustrate the NLMIXED procedure using a dataset of chlorpyrifos air measurements collected from termiticide applicators on consecutive days over a 5-day workweek. We provide sample SAS code for several situations including one and two groups, with and without repeated measures, random slopes, and nested random effects. C1 [Jin, Yan; Hein, Misty J.; Deddens, James A.; Hines, Cynthia J.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Deddens, James A.] Univ Cincinnati, Dept Math Sci, Cincinnati, OH 45221 USA. RP Jin, Y (reprint author), NIOSH, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM hkn9@cdc.gov FU National Institute for Occupational Safety and Health FX This work was supported by intramural research funds from the National Institute for Occupational Safety and Health. NR 32 TC 37 Z9 37 U1 4 U2 20 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD JAN PY 2011 VL 55 IS 1 BP 97 EP 112 DI 10.1093/annhyg/meq061 PG 16 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA 706JN UT WOS:000286214800009 PM 21177260 ER PT S AU Eisen, L Eisen, RJ AF Eisen, Lars Eisen, Rebecca J. BE Berenbaum, MR Carde, RT Robinson, GE TI Using Geographic Information Systems and Decision Support Systems for the Prediction, Prevention, and Control of Vector-Borne Diseases SO ANNUAL REVIEW OF ENTOMOLOGY, VOL 56 SE Annual Review of Entomology LA English DT Review; Book Chapter DE GIS; modeling; risk map; Lyme borreliosis; plague; malaria; dengue; West Nile virus disease ID WEST-NILE-VIRUS; CLIMATE-BASED MODEL; SPACE-TIME ANALYSIS; UNITED-STATES; LYME-DISEASE; SPATIAL-DISTRIBUTION; IXODES-SCAPULARIS; MALARIA TRANSMISSION; HUMAN PLAGUE; SPATIOTEMPORAL PATTERNS AB Emerging and resurging vector-borne diseases cause significant morbidity and mortality, especially in the developing world. We focus on how advances in mapping, Geographic Information System, and Decision Support System technologies, and progress in spatial and space-time modeling, can be harnessed to prevent and control these diseases. Major themes, which are addressed using examples from tick-borne Lyme borreliosis; flea-borne plague; and mosquito-borne dengue, malaria, and West Nile virus disease, include (a) selection of spatial and space-time modeling techniques, (b) importance of using high-quality and biologically or epidemiologically relevant data, (c) incorporation of new technologies into operational vector and disease control programs, (d) transfer of map-based information to stakeholders, and (e) adaptation of technology solutions for use in resource-poor environments. We see great potential for the use of new technologies and approaches to more effectively target limited surveillance, prevention, and control resources and to reduce vector-borne and other infectious diseases. C1 [Eisen, Lars] Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Eisen, Rebecca J.] Ctr Dis Control & Prevent, Coordinating Ctr Infect Dis, Div Vector Borne Infect Dis, Ft Collins, CO 80522 USA. RP Eisen, L (reprint author), Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. EM lars.cisen@colostate.edu; dyn2@cdc.gov FU NIAID NIH HHS [N01-AI-25489] NR 125 TC 50 Z9 52 U1 9 U2 79 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0066-4170 BN 978-0-8243-0156-9 J9 ANNU REV ENTOMOL JI Annu. Rev. Entomol. PY 2011 VL 56 BP 41 EP 61 DI 10.1146/annurev-ento-120709-144847 PG 21 WC Entomology SC Entomology GA BTF65 UT WOS:000286841900003 PM 20868280 ER PT S AU Ford, ES Capewell, S AF Ford, Earl S. Capewell, Simon BE Fielding, JE Brownson, RC Green, LW TI Proportion of the Decline in Cardiovascular Mortality Disease due to Prevention Versus Treatment: Public Health Versus Clinical Care SO ANNUAL REVIEW OF PUBLIC HEALTH, VOL 32 SE Annual Review of Public Health LA English DT Review; Book Chapter DE coronary disease; primary prevention; secondary prevention; risk factors ID CORONARY-HEART-DISEASE; RISK-FACTOR CHANGES; ACUTE MYOCARDIAL-INFARCTION; MONICA PROJECT POPULATIONS; STANFORD 5-CITY PROJECT; PHYSICAL-ACTIVITY; UNITED-STATES; NEW-ZEALAND; US ADULTS; ENVIRONMENTAL INTERVENTIONS AB Mortality rates from coronary heart disease (CHD), which had risen during the twentieth century in many countries, started declining in some countries during the 1960s. Once initial skepticism about the validity of the observed trends dissipated, researchers attempted to generate explanations about the events that had transpired using a variety of techniques, including ecological examinations of the trends in risk factors for CHD and changes in management of CHD, multivariate risk equations, and increasingly sophisticated modeling techniques. Improvements in risk factors as well as changes in cardiac treatments have both contributed to the reductions in CHD mortality, although estimates of their contributions have varied among countries. Models suggest that additional large reductions in CHD mortality are feasible by either improving the distribution of risk factors in the population or raising the percentage of patients receiving evidence-based treatments. C1 [Ford, Earl S.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Capewell, Simon] Univ Liverpool, Div Publ Hlth, Liverpool L69 3GB, Merseyside, England. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. EM eford@cdc.gov; capewell@liverpool.ac.uk FU Medical Research Council [G0900847] NR 134 TC 102 Z9 107 U1 3 U2 31 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0163-7525 BN 978-0-8243-2732-3 J9 ANNU REV PUBL HEALTH JI Annu. Rev. Public Health PY 2011 VL 32 BP 5 EP 22 DI 10.1146/annurev-publhealth-031210-101211 PG 18 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BUZ33 UT WOS:000290776200002 PM 21417752 ER PT S AU Schulte, P Howard, J AF Schulte, Paul Howard, John BE Fielding, JE Brownson, RC Green, LW TI Genetic Susceptibility and the Setting of Occupational Health Standards SO ANNUAL REVIEW OF PUBLIC HEALTH, VOL 32 SE Annual Review of Public Health LA English DT Review; Book Chapter DE genetics; risk assessment; regulation ID DOSE-DEPENDENT TRANSITIONS; GENOME-WIDE ASSOCIATION; CLEAN-AIR ACT; RISK-ASSESSMENT; VARIABILITY; ENVIRONMENT; TOXICITY; EXTRAPOLATION; INFORMATION; MECHANISMS AB As more is learned about genetic susceptibility to occupational and environmental hazards, there will be increasing pressure to use genetic susceptibility information in setting occupational health standards. Historically, this has not been done, but a growing body of research assesses inherited genetic factors as modifiers of the effects of hazardous exposures. Additionally, acquired genetic and epigenetic characteristics could also be used in standard setting. However, for both inherited and acquired genetic characteristics, many scientific, ethical, legal, and social issues could arise. Investigators need to examine the potential role and implications of using genetic information in standard setting. In this review, we focus primarily on inherited genetic factors and their role in occupational health standard setting. C1 [Schulte, Paul] Ctr Dis Control & Prevent, NIOSH, Cincinnati, OH 45226 USA. [Howard, John] Ctr Dis Control & Prevent, NIOSH, Washington, DC 20201 USA. RP Schulte, P (reprint author), Ctr Dis Control & Prevent, NIOSH, Cincinnati, OH 45226 USA. EM pschulte@cdc.gov; jhoward1@cdc.gov NR 52 TC 6 Z9 7 U1 0 U2 1 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0163-7525 BN 978-0-8243-2732-3 J9 ANNU REV PUBL HEALTH JI Annu. Rev. Public Health PY 2011 VL 32 BP 149 EP 159 DI 10.1146/annurev-publhealth-031210-101144 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BUZ33 UT WOS:000290776200009 PM 21128760 ER PT J AU Alam, MT Vinayak, S Congpuong, K Wongsrichanalai, C Satimai, W Slutsker, L Escalante, AA Barnwell, JW Udhayakumar, V AF Alam, Md Tauqeer Vinayak, Sumiti Congpuong, Kanungnit Wongsrichanalai, Chansuda Satimai, Wichai Slutsker, Laurence Escalante, Ananias A. Barnwell, John W. Udhayakumar, Venkatachalam TI Tracking Origins and Spread of Sulfadoxine-Resistant Plasmodium falciparum dhps Alleles in Thailand SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID DIHYDROPTEROATE SYNTHETASE GENES; ANTIMALARIAL-DRUG-RESISTANCE; SINGLE-DOSE THERAPY; PAPUA-NEW-GUINEA; MALARIA PARASITES; DIHYDROFOLATE-REDUCTASE; ARTEMISININ RESISTANCE; CHLOROQUINE-RESISTANCE; POINT MUTATIONS; SOUTHEAST-ASIA AB The emergence and spread of drug-resistant Plasmodium falciparum have been a major impediment for the control of malaria worldwide. Earlier studies have shown that similar to chloroquine (CQ) resistance, high levels of pyrimethamine resistance in P. falciparum originated independently 4 to 5 times globally, including one origin at the Thailand-Cambodia border. In this study we describe the origins and spread of sulfadoxine-resistance-conferring dihydropteroate synthase (dhps) alleles in Thailand. The dhps mutations and flanking microsatellite loci were genotyped for P. falciparum isolates collected from 11 Thai provinces along the Burma, Cambodia, and Malaysia borders. Results indicated that resistant dhps alleles were fixed in Thailand, predominantly being the SGEGA, AGEAA, and SGNGA triple mutants and the AGKAA double mutant (mutated codons are underlined). These alleles had different geographical distributions. The SGEGA alleles were found mostly at the Burma border, while the SGNGA alleles occurred mainly at the Cambodia border and nearby provinces. Microsatellite data suggested that there were two major genetic lineages of the triple mutants in Thailand, one common for SGEGA/SGNGA alleles and another one independent for AGEAA. Importantly, the newly reported SGNGA alleles possibly originated at the Thailand-Cambodia border. All parasites in the Yala province (Malaysia border) had AGKAA alleles with almost identical flanking microsatellites haplotypes. They were also identical at putatively neutral loci on chromosomes 2 and 3, suggesting a clonal nature of the parasite population in Yala. In summary, this study suggests multiple and independent origins of resistant dhps alleles in Thailand. C1 [Alam, Md Tauqeer; Vinayak, Sumiti; Slutsker, Laurence; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30333 USA. [Alam, Md Tauqeer; Vinayak, Sumiti] VAMC, Atlanta Res & Educ Fdn, Atlanta, GA USA. [Congpuong, Kanungnit; Satimai, Wichai] Minist Publ Hlth, Bur Vector Borne Dis, Lab Reference Ctr, Nonthaburi, Thailand. [Escalante, Ananias A.] Arizona State Univ, Sch Life Sci, Tempe, AZ USA. RP Udhayakumar, V (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 1600 Clifton Rd NE,Mail Stop D-67, Atlanta, GA 30333 USA. EM vxu0@cdc.gov RI Vinayak, Sumiti/F-9395-2013 FU American Society for Microbiology (ASM); Coordinating Center for Infectious Diseases (CCID); Atlanta Research and Education Foundation, VAMC, Atlanta, GA; CDC Antimicrobial Resistance Working Group; National Institutes of Health (NIH) [R01GM084320] FX M.T.A. is supported by an American Society for Microbiology (ASM) and Coordinating Center for Infectious Diseases (CCID) post-doctoral fellowship. We acknowledge support from the Atlanta Research and Education Foundation, VAMC, Atlanta, GA, and the CDC Antimicrobial Resistance Working Group. A.A.E. is supported by National Institutes of Health (NIH) grant R01GM084320. The funders had no role in study design, data collection and analysis, preparation of the manuscript, or decision to publish. NR 55 TC 23 Z9 24 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2011 VL 55 IS 1 BP 155 EP 164 DI 10.1128/AAC.00691-10 PG 10 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 698FB UT WOS:000285577400019 PM 20956597 ER PT S AU Vernon, AA AF Vernon, Andrew A. BE Donald, PR VanHelden, PD TI Current Standard Treatment SO ANTITUBERCULOSIS CHEMOTHERAPY SE Progress in Respiratory Research LA English DT Article; Book Chapter ID DIRECTLY OBSERVED THERAPY; RANDOMIZED CONTROLLED-TRIAL; SHORT-COURSE CHEMOTHERAPY; DIAGNOSED PULMONARY TUBERCULOSIS; 6-MONTH COOPERATIVE TUBERCULOSIS; SELF-ADMINISTERED THERAPY; HIV-RELATED TUBERCULOSIS; NEW-YORK-CITY; COST-EFFECTIVENESS; DRUG-RESISTANCE AB Therapy of tuberculosis has been hailed as one of the great achievements of the mid-20th century. The remarkable efficacy of short-course chemotherapy (SCC) as developed by the British Medical Research Council and others is now well established. However, problems of long duration, complexity, toxicity, failure of intermittency to succeed in important subpopulations, and pharmacokinetic variability persist. Some of the evidence for the success of SCC is presented, as are some of the reasons why alternatives are being sought. Copyright (C) 2011 S. Karger AG, Basel C1 Ctr Dis Control & Prevent, Clin Res Branch, Div TB Eliminat, NCHHSTP,OID, Atlanta, GA 30333 USA. RP Vernon, AA (reprint author), Ctr Dis Control & Prevent, Clin Res Branch, Div TB Eliminat, NCHHSTP,OID, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM anv3@cdc.gov NR 82 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1422-2140 BN 978-3-8055-9627-5 J9 PROG RESPIR RES JI Prog. Respir. Res. PY 2011 VL 40 BP 61 EP 72 PG 12 WC Respiratory System SC Respiratory System GA BXA70 UT WOS:000295549400008 ER PT J AU Kouiavskaia, DV Dragunsky, EM Liu, HM Oberste, MS Collett, MS Chumakov, KM AF Kouiavskaia, Diana V. Dragunsky, Eugenia M. Liu, Hong-Mei Oberste, M. Steven Collett, Marc S. Chumakov, Konstantin M. TI Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073 SO ANTIVIRAL THERAPY LA English DT Article AB Background: The National Research Council has recommended development of polio antiviral drugs to assist in management of outbreaks and to mitigate adverse consequences of vaccination. V-073 is a small molecule poliovirus capsid inhibitor that is being developed for these purposes. Antiviral use raises the potential of treatment-emergent resistance. Understanding virological consequences of resistance is important. Methods: Six independent laboratory-derived V-073-resistant poliovirus variants were characterized for their ability to be neutralized by conventional vaccine-induced immune sera, to elicit serum neutralizing antibodies upon CD-1 mouse immunization, and to replicate in and to cause paralysis of TgPVR21 mice. Results: V-073-resistant variants were effectively neutralized by oral perliovirus vaccine and inactivated poliovirus vaccine human immune sera. All variants elicited virus neutralizing antibody titres in CD-1 mice that were comparable to drug-susceptible parental and Sabin vaccine strain viruses. Infection efficiency of TgPVR21 mice by variants was comparable to (1 of 6 variants) or considerably lower than (5 of 6 variants) parental viruses. Drug-resistant variants replicated to levels comparable to (1 of 6 variants) or substantially less than (5 of 6 variants) their drug-susceptible parental viruses and were on average 1.4 log(10) (range 0.3 to >2.8 log(10)) less neurovirulent. Conclusions: Laboratory-derived V-073-resistant variants exhibit clear attenuation of pathogenic properties while maintaining immunological features of drug-susceptible viruses. C1 [Collett, Marc S.] ViroDefense Inc, Rockville, MD USA. [Kouiavskaia, Diana V.; Dragunsky, Eugenia M.; Chumakov, Konstantin M.] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA. [Liu, Hong-Mei; Oberste, M. Steven] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Collett, MS (reprint author), ViroDefense Inc, Rockville, MD USA. EM mscollett@aol.com FU CBER/FDA [224-06-1322 / Y1-AI-6153-01]; NIAID/NIH [224-06-1322 / Y1-AI-6153-01]; Task Force for Global Health, Inc. through WHO; Task Force for Global Health, Inc. through Rotary International; ViroDefense Inc. FX The work was supported by the Interagency Agreement number 224-06-1322 / Y1-AI-6153-01 between CBER/FDA and NIAID/NIH. ViroDefense Inc. received financial support from The Task Force for Global Health, Inc. through grants from the WHO and Rotary International. We thank Dr Walter Dowdle for his continued support.; MSC is a principal of ViroDefense Inc., the corporate sponsor of drug candidate V-073. All other authors declare no competing interests. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of Centers for Diseases Control and Prevention or Food and Drug Administration. NR 11 TC 14 Z9 14 U1 0 U2 2 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2011 VL 16 IS 7 BP 999 EP 1004 DI 10.3851/IMP1838 PG 6 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 846ZO UT WOS:000296941900008 PM 22024515 ER PT J AU Minniear, TD Zeh, C Polle, N Peters, P Oyaro, B Angira, F Akoth, B Ndivo, R Oswago, S Omolo, P Mills, L Thomas, T AF Minniear, T. D. Zeh, C. Polle, N. Peters, P. Oyaro, B. Angira, F. Akoth, B. Ndivo, R. Oswago, S. Omolo, P. Mills, L. Thomas, T. TI Adverse events in Kenyan infants born to HIV-infected mothers receiving triple antiretroviral regimens for prevention of mother-to-child transmission SO ANTIVIRAL THERAPY LA English DT Meeting Abstract C1 [Minniear, T. D.; Peters, P.; Mills, L.; Thomas, T.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Zeh, C.; Polle, N.; Mills, L.] Ctr Dis Control & Prevent, Kisumu, Kenya. [Polle, N.; Oyaro, B.; Angira, F.; Akoth, B.; Ndivo, R.; Oswago, S.; Omolo, P.] Kenya Govt Med Res Ctr, Kisumu, Kenya. Minist Hlth, Nairobi, Kenya. NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2011 VL 16 SU 2 BP A59 EP A60 PG 2 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 813OD UT WOS:000294375900068 ER PT J AU Verreault, D Gendron, L Rousseau, GM Veillette, M Masse, D Lindsley, WG Moineau, S Duchaine, C AF Verreault, Daniel Gendron, Louis Rousseau, Genevieve M. Veillette, Marc Masse, Daniel Lindsley, William G. Moineau, Sylvain Duchaine, Caroline TI Detection of Airborne Lactococcal Bacteriophages in Cheese Manufacturing Plants SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID LACTIC-ACID BACTERIA; DAIRY BACTERIOPHAGES; STARTER CULTURES; MULTIPLEX PCR; PHAGES; IDENTIFICATION; SEQUENCE; MILK; BIODIVERSITY; RESISTANCE AB The dairy industry adds starter bacterial cultures to heat-treated milk to control the fermentation process during the manufacture of many cheeses. These highly concentrated bacterial populations are susceptible to virulent phages that are ubiquitous in cheese factories. In this study, the dissemination of these phages by the airborne route and their presence on working surfaces were investigated in a cheese factory. Several surfaces were swabbed, and five air samplers (polytetrafluoroethylene filter, polycarbonate filter, BioSampler, Coriolis cyclone sampler, and NIOSH two-stage cyclone bioaerosol personal sampler) were tested. Samples were then analyzed for the presence of two Lactococcus lactis phage groups (936 and c2), and quantification was done by quantitative PCR (qPCR). Both lactococcal phage groups were found on most swabbed surfaces, while airborne phages were detected at concentrations of at least 10(3) genomes/m(3) of air. The NIOSH sampler had the highest rate of air samples with detectable levels of lactococcal phages. This study demonstrates that virulent phages can circulate through the air and that they are ubiquitous in cheese manufacturing facilities. C1 [Verreault, Daniel; Gendron, Louis; Veillette, Marc; Duchaine, Caroline] Hop Laval, Ctr Rech, Inst Univ Cardiol & Pneumol, Ste Foy, PQ G1V 4G5, Canada. [Verreault, Daniel; Gendron, Louis; Moineau, Sylvain; Duchaine, Caroline] Univ Laval, Fac Sci & Genie, Dept Biochim Microbiol & Bioinformat, Quebec City, PQ G1V 0A6, Canada. [Rousseau, Genevieve M.; Moineau, Sylvain] Univ Laval, GREB, Fac Med Dent, Quebec City, PQ G1V 0A6, Canada. [Rousseau, Genevieve M.; Moineau, Sylvain] Univ Laval, Felix Herelle Reference Ctr Bacterial Viruses, Fac Med Dent, Quebec City, PQ G1V 0A6, Canada. [Masse, Daniel] Agr & Agri Food Canada, Dairy & Swine Res & Dev Ctr, Sherbrooke, PQ J1M 0C8, Canada. [Lindsley, William G.] Ctr Dis Control & Prevent, Hlth Effects Lab Div, Natl Inst Occupat Safety & Hlth, Morgantown, WV 26505 USA. RP Duchaine, C (reprint author), Hop Laval, Ctr Rech, Inst Univ Cardiol & Pneumol, 2725 Chemin Ste Foy, Ste Foy, PQ G1V 4G5, Canada. EM caroline.duchaine@bcm.ulaval.ca RI Gendron, Louis/I-8113-2012; Moineau, Sylvain/N-3578-2013; OI Lindsley, William/0000-0003-0720-5829 FU Natural Sciences and Engineering Research Council of Canada (NSERC); FRSQ; FQRNT-NOVALAIT-MAPAQ; Agriculture and Agri-Food Canada FX C. Duchaine and S. Moineau received funding from the Natural Sciences and Engineering Research Council of Canada (NSERC). C. Duchaine is also the recipient of an FRSQ Junior 2 scholarship and of a CCHSA time release program and is a member of the FRSQ Respiratory Health Network. This work was funded by a joint grant from FQRNT-NOVALAIT-MAPAQ and Agriculture and Agri-Food Canada. NR 42 TC 29 Z9 30 U1 4 U2 33 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD JAN PY 2011 VL 77 IS 2 BP 491 EP 497 DI 10.1128/AEM.01391-10 PG 7 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 705PB UT WOS:000286147300013 PM 21115712 ER PT J AU Storm, JE Mazor, KA Aldous, KM Blount, BC Brodie, SE Serle, JB AF Storm, Jan E. Mazor, Kimberly A. Aldous, Kenneth M. Blount, Benjamin C. Brodie, Scott E. Serle, Janet B. TI Visual Contrast Sensitivity in Children Exposed to Tetrachloroethylene SO ARCHIVES OF ENVIRONMENTAL & OCCUPATIONAL HEALTH LA English DT Article DE residential indoor air; tetrachloroethylene; VCS; visual contrast sensitivity ID VOLATILE ORGANIC-COMPOUNDS; PER-TRILLION LEVEL; HUMAN BLOOD; WORKERS; SOLVENTS; DYSFUNCTION; AIR; PERCHLOROETHYLENE; RESIDENCES; CHEMICALS AB This study examined relationships between indoor air, breath, and blood tetrachloroethylene (perc) levels and visual contrast sensitivity (VCS) among adult and child residents of buildings with or without a colocated dry cleaner using perc. Decreasing trends in proportions of adults or children with maximum VCS scores indicated decreased VCS at a single spatial frequency (12 cycles per degree [cpd]) among children residing in buildings with colocated dry cleaners when indoor air perc level averaged 336 mu g/m(3); breath perc level averaged 159.5 mu g/m(3); and blood perc level averaged 0.51 mu g/L. Adjusted logistic regression indicated that increases in indoor air, breath, and blood perc levels among all child participants significantly increased the odds for decreased VCS at 12 cpd. Adult VCS was not significantly decreased by increasing indoor air, breath, or blood perc level. These results suggest that elevated residential perc exposures may alter children's VCS, a possible subclinical central nervous system effect. C1 [Storm, Jan E.; Mazor, Kimberly A.] New York State Dept Hlth, Ctr Environm Hlth, Troy, NY 12180 USA. [Aldous, Kenneth M.] New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA. [Blount, Benjamin C.] US Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Brodie, Scott E.; Serle, Janet B.] Mt Sinai Sch Med, Dept Opthalmol, New York, NY USA. RP Storm, JE (reprint author), New York State Dept Hlth, Ctr Environm Hlth, 547 River St, Troy, NY 12180 USA. EM jes19@health.state.ny.us FU US EPA [R827446010] FX Research described in this report has been funded wholly or in part by the US EPA through grant #R827446010 to the NYS DOH. It has not been subject to the Agency's required peer and policy review and therefore does not necessarily reflect the views of the Agency and no official endorsement should be inferred. All parents and children who participated and all staff associated with Northern Manhattan Perinatal Partnership, Inc. are gratefully acknowledged. The authors also thank the eight scientists who commented on a draft report summarizing these findings of the NYC Perc Project. This report incorporates many of these reviewers' comments and suggestions. NR 55 TC 9 Z9 10 U1 0 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1933-8244 J9 ARCH ENVIRON OCCUP H JI Arch. Environ. Occup. Health PY 2011 VL 66 IS 3 BP 166 EP 177 DI 10.1080/19338244.2010.539638 PG 12 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 888HO UT WOS:000299994700005 PM 21864105 ER PT J AU Klein, R Chou, CF Klein, BEK Zhang, XZ Meuer, SM Saaddine, JB AF Klein, Ronald Chou, Chiu-Fang Klein, Barbara E. K. Zhang, Xinzhi Meuer, Stacy M. Saaddine, Jinan B. TI Prevalence of Age-Related Macular Degeneration in the US Population SO ARCHIVES OF OPHTHALMOLOGY LA English DT Article ID NUTRITION EXAMINATION SURVEY; BEAVER DAM EYE; NATIONAL-HEALTH; RACIAL-DIFFERENCES; UNITED-STATES; MACULOPATHY; ATHEROSCLEROSIS; WISCONSIN; ADULTS AB Objective: To examine the prevalence of age-related macular degeneration (AMD) in non-Hispanic white, non-Hispanic black, Mexican American, and other racial/ethnic groups. Design: A US nationally representative, population-based, cross-sectional study involving a total of 5553 persons aged 40 years and older from the 2005-2008 National Health and Nutrition Examination Survey. The main outcome measure was AMD determined by the grading of 45 degrees digital images from both eyes using a standardized protocol. Results: In the civilian, noninstitutionalized, US population aged 40 years and older, the estimated prevalence of any AMD was 6.5% (95% confidence interval, 5.5-7.6) and the estimated prevalence of late AMD was 0.8% (95% confidence interval, 0.5-1.3). Non-Hispanic black persons aged 60 years and older had a statistically significantly lower prevalence of any AMD than non-Hispanic white persons aged 60 years and older (odds ratio=0.37; 95% confidence interval, 0.21-0.67). Conclusions: Overall, the prevalence of any AMD in the 2005-2008 National Health and Nutrition Examination Survey was 6.5%, which is lower than the 9.4% prevalence reported in the 1988-1994 Third National Health and Nutrition Examination Survey. While this finding might be explained in part by possible methodological differences, these estimates are consistent with a decreasing incidence of AMD and suggest important public health care implications. C1 [Klein, Ronald; Klein, Barbara E. K.; Meuer, Stacy M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA. [Chou, Chiu-Fang; Zhang, Xinzhi; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Div Diabet Translat, Vis Hlth Initiat, Atlanta, GA USA. RP Klein, R (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,Room 417 WARF, Madison, WI 53726 USA. EM kleinr@epi.ophth.wisc.edu FU National Health and Nutrition Examination Survey [200-2004-07459]; Research to Prevent Blindness FX This research was supported by National Health and Nutrition Examination Survey contract 200-2004-07459, which provided funding for the entire study including collection and analyses of data. Additional support was provided by Senior Scientific Investigator Awards from Research to Prevent Blindness (Drs R. Klein and B.E.K. Klein). NR 32 TC 197 Z9 203 U1 3 U2 16 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD JAN PY 2011 VL 129 IS 1 BP 75 EP 80 DI 10.1001/archophthalmol.2010.318 PG 6 WC Ophthalmology SC Ophthalmology GA 704MI UT WOS:000286056700010 PM 21220632 ER PT J AU Eaton, DK Foti, K Brener, ND Crosby, AE Flores, G Kann, L AF Eaton, Danice K. Foti, Kathryn Brener, Nancy D. Crosby, Alex E. Flores, Glenn Kann, Laura TI Associations Between Risk Behaviors and Suicidal Ideation and Suicide Attempts: Do Racial/Ethnic Variations in Associations Account for Increased Risk of Suicidal Behaviors Among Hispanic/Latina 9th- to 12th-Grade Female Students? SO ARCHIVES OF SUICIDE RESEARCH LA English DT Article DE adolescents; race; ethnicity; risk behaviors; suicide ID HIGH-SCHOOL-STUDENTS; ADOLESCENT SUICIDE; DATING VIOLENCE; SUBSTANCE USE; DEPRESSION; YOUTH; PREVALENCE; DISPARITIES; ETHNICITY; AMERICAN AB The objective of this study was to identify factors that may account for the disproportionately high prevalence of suicidal behaviors among Hispanic/Latina youth by examining whether associations of health risk behaviors with suicidal ideation and suicide attempts vary by race/ethnicity among female students. Data from the school-based 2007 national Youth Risk Behavior Survey were analyzed. Analyses were conducted among female students in grades 9 through 12 and included 21 risk behaviors related to unintentional injuries and violence; tobacco use; alcohol and other drug use; sexual behaviors that contribute to unintended pregnancy and sexually transmitted infections, including human immunodeficiency virus; physical activity; obesity and weight control; and perceived health status. With the exception of physical activity behaviors and obesity, all risk behaviors examined were associated with suicidal ideation and suicide attempts. Associations of risk behaviors with suicidal ideation varied by race/ethnicity for 5 of 21 behaviors, and for 0 of 21 behaviors for suicide attempts. Stratified analyses provided little insight into factors that may account for the higher prevalence of suicidal behaviors among Hispanic/Latina female students. These results suggest that the increased risk of suicidal behaviors among Hispanic/Latina female students cannot be accounted for by differential associations with these selected risk behaviors. Other factors, such as family characteristics, acculturation, and the socio-cultural environment, should be examined in future research. C1 [Eaton, Danice K.; Foti, Kathryn; Brener, Nancy D.; Kann, Laura] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Crosby, Alex E.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Flores, Glenn] Univ Texas SW Med Ctr Dallas, Dept Pediat, Div Gen Pediat, Dallas, TX 75390 USA. [Flores, Glenn] Childrens Med Ctr, Dallas, TX 75235 USA. RP Eaton, DK (reprint author), 4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM Deaton@cdc.gov NR 43 TC 15 Z9 15 U1 1 U2 10 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1381-1118 J9 ARCH SUICIDE RES JI Arch. Suicide Res. PY 2011 VL 15 IS 2 BP 113 EP 126 AR PII 937134247 DI 10.1080/13811118.2011.565268 PG 14 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 761LY UT WOS:000290400600002 PM 21541858 ER PT J AU Wasilenko, JL Arafa, AM Selim, AA Hassan, MK Aly, MM Ali, A Nassif, S Elebiary, E Balish, A Klimov, A Suarez, DL Swayne, DE Pantin-Jackwood, MJ AF Wasilenko, J. L. Arafa, A. M. Selim, A. A. Hassan, M. K. Aly, M. M. Ali, A. Nassif, S. Elebiary, E. Balish, A. Klimov, A. Suarez, D. L. Swayne, D. E. Pantin-Jackwood, M. J. TI Pathogenicity of two Egyptian H5N1 highly pathogenic avian influenza viruses in domestic ducks SO ARCHIVES OF VIROLOGY LA English DT Article ID SINGLE-AMINO-ACID; A VIRUSES; ANAS-PLATYRHYNCHOS; MOLECULAR CHARACTERIZATION; PHYLOGENETIC ANALYSIS; RECEPTOR SPECIFICITY; SURFACE-PROTEINS; RNA-POLYMERASE; CLADE 2.2; HEMAGGLUTININ AB Domestic ducks have been implicated in the dissemination and evolution of H5N1 highly pathogenic avian influenza (HPAI) viruses. In this study, two H5N1 HPAI viruses belonging to clade 2.2.1 isolated in Egypt in 2007 and 2008 were analyzed for their pathogenicity in domestic Pekin ducks. Both viruses produced clinical signs and mortality, but the 2008 virus was more virulent, inducing early onset of neurological signs and killing all ducks with a mean death time (MDT) of 4.1 days. The 2007 virus killed 3/8 ducks with a MDT of 7 days. Full-genome sequencing and phylogenetic analysis were used to examine differences in the virus genes that might explain the differences observed in pathogenicity. The genomes differed in 49 amino acids, with most of the differences found in the hemagglutinin protein. This increase in pathogenicity in ducks observed with certain H5N1 HPAI viruses has implications for the control of the disease, since vaccinated ducks infected with highly virulent strains shed viruses for longer periods of time, perpetuating the virus in the environment and increasing the possibility of transmission to susceptible birds. C1 [Wasilenko, J. L.; Suarez, D. L.; Swayne, D. E.; Pantin-Jackwood, M. J.] ARS, Exot & Emerging Avian Viral Dis Unit, SE Poultry Res Lab, USDA, Athens, GA 30605 USA. [Arafa, A. M.; Selim, A. A.; Hassan, M. K.; Aly, M. M.] Natl Lab Vet Qual Control Poultry Prod, Giza 12618, Egypt. [Ali, A.; Nassif, S.; Elebiary, E.] CLEVB, Cairo, Egypt. [Balish, A.; Klimov, A.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Pantin-Jackwood, MJ (reprint author), ARS, Exot & Emerging Avian Viral Dis Unit, SE Poultry Res Lab, USDA, 934 Coll Stn Rd, Athens, GA 30605 USA. EM Mary.Pantin-Jackwood@ARS.USDA.gov FU US Department of Agriculture, ARS [6612-32000-048] FX The authors appreciate the assistance provided by Diane Smith, Ronald Graham and Roger Brock in conducting these studies. The authors also thank the SAA sequencing facility at SEPRL and the FSIS histopathology laboratory at Russell Research Center-USDA for technical assistance. They also thank the Naval Medical Research Unit No. 3 (NAMRU3), Egypt, for help providing one of the viruses. Funding was given by the US Department of Agriculture, ARS, Current Research Information System project #6612-32000-048. NR 79 TC 19 Z9 20 U1 1 U2 6 PU SPRINGER WIEN PI WIEN PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA SN 0304-8608 J9 ARCH VIROL JI Arch. Virol. PD JAN PY 2011 VL 156 IS 1 BP 37 EP 51 DI 10.1007/s00705-010-0813-y PG 15 WC Virology SC Virology GA 708KZ UT WOS:000286362000005 PM 20882306 ER PT J AU Kelley, GA Kelley, KS Hootman, JM Jones, DL AF Kelley, George A. Kelley, Kristi S. Hootman, Jennifer M. Jones, Dina L. TI Effects of Community-Deliverable Exercise on Pain and Physical Function in Adults With Arthritis and Other Rheumatic Diseases: A Meta-Analysis SO ARTHRITIS CARE & RESEARCH LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; CLINICAL-PRACTICE GUIDELINES; WATER DECREASES PAIN; QUALITY-OF-LIFE; KNEE OSTEOARTHRITIS; AEROBIC EXERCISE; OLDER-ADULTS; ANKYLOSING-SPONDYLITIS; UNITED-STATES; EMPIRICAL-EVIDENCE AB Objective. To use the meta-analytic approach to determine the effects of community-deliverable exercise on pain and physical function in adults with arthritis and other rheumatic diseases (AORD). Methods. Data sources consisted of 6 electronic databases, cross-referencing from retrieved studies and expert review. Study selection included 1) randomized controlled trials; 2) >= 1 exercise intervention group; 3) community-deliverable exercise interventions >= 4 weeks in duration; 4) control group; 5) adults ages >= 18 years with rheumatoid arthritis, osteoarthritis, fibromyalgia, lupus, gout, or ankylosing spondylitis; 6) published and unpublished studies; 7) studies published in any language between January 1, 1980, and January 1, 2008; and 8) data available for pain and/or physical function. Data abstraction included dual coding by 2 of the authors. Standardized effect sizes (g) and random-effects models were used to pool pain and physical function outcomes. Data were analyzed according to per-protocol and intent-to-treat (ITT) results. The minimally clinically important difference (MCID) and number needed to treat (NNT) were also calculated. Results. Thirty-three studies representing 3,180 men and women (1,857 exercise, 1,323 control) with rheumatoid arthritis, osteoarthritis, and fibromyalgia were included. Statistically significant and clinically important improvements were observed for pain (per-protocol g = -0.37 [95% confidence interval (95% CI) -0.53, -0.21], MCID -18%; ITT g = -0.20 [95% CI -0.33, -0.07], MCID -9%, NNT 9) and physical function (per-protocol g = 0.37 [95% CI 0.21, 0.52], MCID 15%; ITT g = 0.34 [95% CI 0.25, 0.43], MCID 10%, NNT 5). Conclusion. Community-deliverable exercise improves pain and physical function in adults with the types of AORD included in the analysis. Dose-response as well as studies in those with other types of AORD is needed. C1 [Kelley, George A.] W Virginia Univ, Meta Analyt Res Grp, Sch Med,Robert C Byrd Hlth Sci Ctr, Dept Community Med, Morgantown, WV 26506 USA. [Hootman, Jennifer M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Kelley, GA (reprint author), W Virginia Univ, Meta Analyt Res Grp, Sch Med,Robert C Byrd Hlth Sci Ctr, Dept Community Med, POB 9190, Morgantown, WV 26506 USA. EM gkelley@hsc.wvu.edu FU Centers for Disease Control and Prevention through the Association of American Medical Colleges [U36/CCU319276]; Association of American Medical Colleges [MM-0944-06/06] FX Supported by a cooperative agreement from the Centers for Disease Control and Prevention through the Association of American Medical Colleges (grant U36/CCU319276, Association of American Medical Colleges ID MM-0944-06/06). NR 104 TC 38 Z9 38 U1 1 U2 16 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JAN PY 2011 VL 63 IS 1 BP 79 EP 93 DI 10.1002/acr.20347 PG 15 WC Rheumatology SC Rheumatology GA 703AA UT WOS:000285935800010 PM 20824798 ER PT J AU Bolen, J Helmick, CG Sacks, JJ Gizlice, Z Potter, C AF Bolen, Julie Helmick, Charles G. Sacks, Jeffrey J. Gizlice, Ziya Potter, Catima TI Should People Who Have Joint Symptoms, But No Diagnosis of Arthritis From a Doctor, Be Included in Surveillance Efforts? SO ARTHRITIS CARE & RESEARCH LA English DT Article ID UNITED-STATES; PREVALENCE AB Objective. In 2005, 27% of adults reported doctor-diagnosed arthritis, and 14% reported chronic joint symptoms but no doctor-diagnosed arthritis (i.e., possible arthritis). We evaluate the value of including persons classified as having possible arthritis in surveillance of arthritis. Methods. In 2005, Kansas, Oklahoma, North Carolina, and Utah added extra questions to their Behavioral Risk Factor Surveillance System (BRFSS) telephone survey targeted to a subsample of those classified as having possible arthritis. Results. Persons classified as having possible arthritis (n = 2,884) were younger, more often male, and had less activity limitation than persons with doctor-diagnosed arthritis. Of those classified as having possible arthritis, half had seen a doctor for their symptoms, 12.5% reported arthritis, and 61.9% gave other causes. Of the half who had not seen a doctor, most reported mild symptoms (64.8%). Conclusion. Only 6.3% of those classified as having possible arthritis had what we considered to be arthritis. Most who did not see a doctor reported mild symptoms and, therefore, would be unlikely to be amenable to medical and public health interventions for arthritis. Although including possible arthritis would slightly improve the sensitivity of detecting arthritis in the population, it would increase false-positives that would interfere with targeting state intervention efforts and burden estimates. The ability to add back questions to the BRFSS survey allows for the reintroduction of possible arthritis in case national surveillance indicates it necessary or if studies document an increased rate at which possible arthritis turns into arthritis. Currently, possible arthritis does not need to be included in state arthritis surveillance efforts, and limited question space on surveys is better spent on other arthritis issues. C1 [Bolen, Julie; Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Sacks, Jeffrey J.] Sue Binder Consulting, Atlanta, GA USA. [Gizlice, Ziya] Univ N Carolina, Chapel Hill, NC USA. [Potter, Catima] Univ Kansas, Sch Nursing, Kansas City, KS USA. RP Bolen, J (reprint author), 1600 Clifton Rd NE,Mailstop E-88, Atlanta, GA 30341 USA. EM jcr2@cdc.gov OI Potter, Catima/0000-0002-7927-8608 FU Centers for Disease Control and Prevention FX Supported by the Centers for Disease Control and Prevention. NR 10 TC 6 Z9 6 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD JAN PY 2011 VL 63 IS 1 BP 150 EP 154 DI 10.1002/acr.20313 PG 5 WC Rheumatology SC Rheumatology GA 703AA UT WOS:000285935800018 PM 20665738 ER PT J AU Nelson, AE Shi, XYA Schwartz, TA Chen, JC Renner, JB Caldwell, KL Helmick, CG Jordan, JM AF Nelson, Amanda E. Shi, Xiaoyan A. Schwartz, Todd A. Chen, Jiu-Chiuan Renner, Jordan B. Caldwell, Kathleen L. Helmick, Charles G. Jordan, Joanne M. TI Whole blood lead levels are associated with radiographic and symptomatic knee osteoarthritis: a cross-sectional analysis in the Johnston County Osteoarthritis Project SO ARTHRITIS RESEARCH & THERAPY LA English DT Article ID NITRIC-OXIDE; UNITED-STATES; NATIONAL-HEALTH; TRACE-ELEMENTS; BONE LEAD; EXPOSURE; ARTHRITIS; DISEASE; HEMOCHROMATOSIS; EPIDEMIOLOGY AB Introduction: Lead (Pb) is known to affect bone, and recent evidence suggests that it has effects on cartilage as well. As osteoarthritis (OA) is a highly prevalent disease affecting bone and cartilage, we undertook the present analysis to determine whether whole blood Pb levels are associated with radiographic and symptomatic OA (rOA and sxOA, respectively) of the knee. Methods: The analysis was conducted using cross-sectional data from the Johnston County Osteoarthritis Project, a rural, population-based study, including whole blood Pb levels, bilateral posteroanterior weight-bearing knee radiography and knee symptom data. rOA assessment included joint-based presence (Kellgren-Lawrence (K-L) grade 2 or higher) and severity (none, K-L grade 0 or 1; mild, K-L grade 2; moderate or severe, K-L grade 3 or 4), as well as person-based laterality (unilateral or bilateral). SxOA was deemed present (joint-based) in a knee on the basis of K-L grade 2 or higher with symptoms, with symptoms rated based on severity (0, rOA without symptoms; 1, rOA with mild symptoms; 2, rOA with moderate or severe symptoms) and in person-based analyses was either unilateral or bilateral. Generalized logit or proportional odds regression models were used to examine associations between the knee OA status variables and natural log-transformed blood Pb (ln Pb), continuously and in quartiles, controlling for age, race, sex, body mass index (BMI), smoking and alcohol drinking. Results: Those individuals with whole blood Pb data (N = 1,669) had a mean (+/-SD) age of 65.4 (+/-11.0) years and a mean BMI of 31.2 (+/-7.1) kg/m(2), including 66.6% women and 35.4% African-Americans, with a median blood Pb level of 1.8 mu g/dl (range, 0.3 to 42.0 mu g/dl). In joint-based analyses, for every 1-U increase in ln Pb, the odds of prevalent knee rOA were 20% higher (aOR, 1.20; 95% CI, 1.01 to 1.44), while the odds of more severe rOA were 26% higher (aOR, 1.26; 95% CI, 1.05 to 1.50, under proportional odds). In person-based analyses, the odds of bilateral rOA were 32% higher for each 1 U increase in ln Pb (aOR, 1.32; 95% CI, 1.03 to 1.70). Similarly for knee sxOA, for each 1-U increase in ln Pb, the odds of having sxOA were 16% higher, the odds of having more severe symptoms were 17% higher and the odds of having bilateral knee symptoms were 25% higher. Similar findings were obtained with regard to ln Pb in quartiles. Conclusions: Increases in the prevalence and severity measures for both radiographically and symptomatically confirmed knee OA (although statistically significant only for rOA) were observed with increasing levels of blood Pb, suggesting that Pb may be a potentially modifiable environmental risk factor for OA. C1 [Nelson, Amanda E.; Schwartz, Todd A.; Renner, Jordan B.; Jordan, Joanne M.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA. [Shi, Xiaoyan A.; Schwartz, Todd A.] Univ N Carolina, Dept Biostat, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA. [Chen, Jiu-Chiuan] Univ So Calif, Div Environm Hlth, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90089 USA. [Renner, Jordan B.] Univ N Carolina, Dept Radiol, Chapel Hill, NC 27514 USA. [Caldwell, Kathleen L.; Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Nelson, AE (reprint author), Univ N Carolina, Thurston Arthrit Res Ctr, 3300 Thurston Bldg, Chapel Hill, NC 27599 USA. EM aenelson@med.unc.edu RI Schwartz, Todd/D-4995-2012; Chen, JC/I-2261-2016 OI Schwartz, Todd/0000-0002-0232-2543; FU National Institutes of Health (NIH) [1L30 AR056604]; American College of Rheumatology/Research and Education Foundation; John A Hartford Center of Excellence in Geriatrics; NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [AR-07416]; NIH/NIAMS Multipurpose Arthritis and Musculoskeletal Diseases Center [5-P60-AR-30701]; Centers for Disease Control and Prevention through the Association of Schools of Public Health [S043, S3486]; Multidisciplinary Clinical Research Center [5-P60-AR49465] FX The authors thank the Johnston County Osteoarthritis Project staff and participants, without whom this work would not have been possible. This work was funded in part by National Institutes of Health (NIH) Loan repayment 1L30 AR056604, a Clinical Investigator Fellowship Award from the American College of Rheumatology/Research and Education Foundation, fellowship funding from the John A Hartford Center of Excellence in Geriatrics and NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) T-32 training grant AR-07416 (to AEN), NIH/NIAMS Multipurpose Arthritis and Musculoskeletal Diseases Center grant 5-P60-AR-30701, a cooperative agreement from the Centers for Disease Control and Prevention through the Association of Schools of Public Health S043 and S3486 (to JBR and JMJ), and Multidisciplinary Clinical Research Center grant 5-P60-AR49465 (to TAS, JBR and JMJ). The findings and conclusions described in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 56 TC 6 Z9 6 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1478-6354 J9 ARTHRITIS RES THER JI Arthritis Res. Ther. PY 2011 VL 13 IS 2 AR R37 DI 10.1186/ar3270 PG 9 WC Rheumatology SC Rheumatology GA 788MS UT WOS:000292449700002 PM 21362189 ER PT J AU King, BA Dube, SR Ko, JY AF King, Brian A. Dube, Shanta R. Ko, Jean Y. TI Secondhand Smoke Concentrations in Hospitality Venues in the Pacific Basin: Findings from American Samoa, Commonwealth of the Northern Mariana Islands, and Guam SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION LA English DT Article DE Tobacco smoking; secondhand smoke; air pollution; health policy; public smoking bans ID EXPOSURE; QUALITY; AIR AB Introduction: Secondhand smoke (SHS) from burning tobacco products causes disease and premature death among nonsmokers. Although the number of laws prohibiting smoking in indoor public places continues to increase, millions of nonsmokers in the United States (US) and its territories remain exposed to SHS. This study assessed indoor air pollution from SHS in hospitality venues in three US Pacific Basin territories. Methods: Air monitors were used to assess PM2.5, an environmental marker for SHS, in 19 smoke-permitted and 18 smoke-free bars and restaurants in American Samoa, Commonwealth of the Northern Mariana Islands (CNMI), and Guam. Observational logs were used to record smoking and other sources of air pollution. Differences in average PM2.5 concentrations were determined using bivariate statistics. Results: The average PM2.5 level in venues where smoking was always permitted [arithmetic mean (AM)=299.98 mu g/m(3); geometric mean (GM)=200.39 mu g/m(3)] was significantly higher (p<0.001) than smoke-free venues [AM=8.33 mu g/m(3); GM= 6.14 mu g/m(3)]. In venues where smoking was allowed only during certain times, the average level outside these times [AM=42.10 mu g/m(3); GM=41.87 mu g/m(3)] was also significantly higher (p<0.001) than smoke-free venues. Conclusions: Employees and patrons of smoke-permitted bars and restaurants are exposed to dangerous levels of air pollution from SHS, even during periods when active smoking is not occurring. Prohibiting smoking in all public indoor areas, irrespective of the venue type or time of day, is the only way to fully protect nonsmokers from SHS exposure in these environments. C1 [King, Brian A.; Dube, Shanta R.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30333 USA. [King, Brian A.; Ko, Jean Y.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Ko, Jean Y.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP King, BA (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30333 USA. EM baking@cdc.gov FU Intramural CDC HHS [CC999999] NR 22 TC 3 Z9 3 U1 0 U2 2 PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION PI GYEONGGI-DO PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO, ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA SN 1513-7368 J9 ASIAN PAC J CANCER P JI Asian Pac. J. Cancer Prev. PY 2011 VL 12 IS 11 BP 2881 EP 2885 PG 5 WC Oncology SC Oncology GA 915HV UT WOS:000302015800013 PM 22393958 ER PT B AU Kuempel, E Castranova, V AF Kuempel, Eileen Castranova, Vincent BE Ramachandran, G TI Hazard and Risk Assessment of Workplace Exposure to Engineered Nanoparticles: Methods, Issues, and Carbon Nanotube Case Study SO ASSESSING NANOPARTICLE RISKS TO HUMAN HEALTH LA English DT Article; Book Chapter ID CHRONIC INHALATION EXPOSURE; ULTRAFINE TITANIUM-DIOXIDE; PULMONARY RESPONSES; PARTICLE CLEARANCE; INTRATRACHEAL INSTILLATION; SUBCHRONIC INHALATION; LUNG INFLAMMATION; OXIDATIVE STRESS; ALVEOLAR REGION; SURFACE-AREA C1 [Kuempel, Eileen] NIOSH, Cincinnati, OH 45226 USA. [Kuempel, Eileen] NIOSH, Nanoelect Res Ctr, Nanotechnol Res Ctr, Cincinnati, OH 45226 USA. [Castranova, Vincent] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV USA. [Castranova, Vincent] W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA. [Castranova, Vincent] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA. [Castranova, Vincent] NIOSH, Nanotoxicol Program, Morgantown, WV USA. RP Kuempel, E (reprint author), NIOSH, Cincinnati, OH 45226 USA. NR 98 TC 1 Z9 1 U1 0 U2 3 PU WILLIAM ANDREW INC PI NORWICH PA 13 EATON AVE, NORWICH, NY 13815 USA BN 978-1-4377-7864-9 PY 2011 BP 65 EP 97 DI 10.1016/B978-1-4377-7863-2.00003-0 PG 33 WC Public, Environmental & Occupational Health; Nanoscience & Nanotechnology SC Public, Environmental & Occupational Health; Science & Technology - Other Topics GA BFK38 UT WOS:000320229200004 ER PT B AU Mahy, BWJ AF Mahy, Brian W. J. BE Samal, SK TI The Biology of Paramyxoviruses Introduction SO BIOLOGY OF PARAMYXOVIRUSES LA English DT Editorial Material; Book Chapter ID INFLUENZA C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Mahy, BWJ (reprint author), Ctr Dis Control & Prevent, MS61, Atlanta, GA 30333 USA. EM virusjournals@gmail.com NR 9 TC 0 Z9 0 U1 1 U2 2 PU CAISTER ACADEMIC PRESS PI WYMONDHAM PA 32 HEWITTS LANE, WYMONDHAM NR 18 0JA, ENGLAND BN 978-1-904455-85-1 PY 2011 BP 1 EP 3 PG 3 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BVP39 UT WOS:000292216900001 ER PT B AU Lo, MK Coughlin, MM Rota, PA AF Lo, Michael K. Coughlin, Melissa M. Rota, Paul A. BE Samal, SK TI Hendra and Nipah Viruses SO BIOLOGY OF PARAMYXOVIRUSES LA English DT Article; Book Chapter ID INDEPENDENT RIBOSOMAL INITIATION; EQUINE MORBILLIVIRUS PNEUMONIA; EMERGENT DEADLY PARAMYXOVIRUS; RESPIRATORY SYNCYTIAL VIRUS; BATS PTEROPUS-POLIOCEPHALUS; HOMOLOGOUS FUSION PROTEIN; AMINO-ACID SUBSTITUTIONS; TO-PERSON TRANSMISSION; CENTRAL-NERVOUS-SYSTEM; HEXAMER GENOME LENGTH AB Nipah and Hendra viruses comprise the genus Henipavirus and are highly pathogenic paramyxoviruses, which cause fatal encephalitis and respiratory disease in humans. Since their respective initial outbreaks in 1998 and 1994, they have continued to cause sporadic outbreaks resulting in fatal disease. Owing to their designation as biosafety level 4 pathogens, the level of containment required to work with live henipaviruses is available only to select laboratories around the world. This chapter provides an overview of henipaviruses in regards to their diagnosis, clinical features, and epidemiology, while highlighting recent studies which have expanded our knowledge of their molecular biology, pathogenesis, and control with novel antiviral therapeutics. C1 [Lo, Michael K.; Coughlin, Melissa M.; Rota, Paul A.] Ctr Dis Control & Prevent, Div Viral Dis, Measles Mumps Rubella & Herpes Viruses Lab Branch, Atlanta, GA 30333 USA. RP Rota, PA (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Measles Mumps Rubella & Herpes Viruses Lab Branch, Atlanta, GA 30333 USA. EM mlo@cdc.gov; mcoughlin@cdc.gov; prota@cdc.gov NR 254 TC 2 Z9 2 U1 0 U2 3 PU CAISTER ACADEMIC PRESS PI WYMONDHAM PA 32 HEWITTS LANE, WYMONDHAM NR 18 0JA, ENGLAND BN 978-1-904455-85-1 PY 2011 BP 211 EP 243 PG 33 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA BVP39 UT WOS:000292216900007 ER PT J AU Rasmussen, SA Riehle-Colarusso, T Shapira, SK Honein, MA Reefhuis, J AF Rasmussen, Sonja A. Riehle-Colarusso, Tiffany Shapira, Stuart K. Honein, Margaret A. Reefhuis, Jennita CA Natl Birth Defects Prevention Stud TI LETTER TO THE EDITOR: VENTRICULAR SEPTAL DEFECTS AND THE NATIONAL BIRTH DEFECTS PREVENTION STUDY SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Letter C1 [Rasmussen, Sonja A.; Riehle-Colarusso, Tiffany; Shapira, Stuart K.; Honein, Margaret A.; Reefhuis, Jennita; Natl Birth Defects Prevention Stud] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Rasmussen, SA (reprint author), Ctr Dis Control, 1600 Clifton Rd NE,Mail Stop E-86, Atlanta, GA 30333 USA. EM skr9@cdc.gov RI Publications, NBDPS/B-7692-2013 NR 5 TC 2 Z9 2 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JAN PY 2011 VL 91 IS 1 BP 66 EP 66 DI 10.1002/bdra.20750 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA 708ZB UT WOS:000286401700010 PM 21254361 ER PT J AU Olson, JC Cuff, CF Lukomski, S Lukomska, E Canizales, Y Wu, B Crout, RJ Thomas, JG McNeil, DW Weyant, RJ Marazita, ML Paster, BJ Elliott, T AF Olson, Joan C. Cuff, Christopher F. Lukomski, Slawomir Lukomska, Ewa Canizales, Yeremi Wu, Bei Crout, Richard J. Thomas, John G. McNeil, Daniel W. Weyant, Robert J. Marazita, Mary L. Paster, Bruce J. Elliott, Thomas TI Use of 16S ribosomal RNA gene analyses to characterize the bacterial signature associated with poor oral health in West Virginia SO BMC ORAL HEALTH LA English DT Article AB Background: West Virginia has the worst oral health in the United States, but the reasons for this are unclear. This pilot study explored the etiology of this disparity using culture-independent analyses to identify bacterial species associated with oral disease. Methods: Bacteria in subgingival plaque samples from twelve participants in two independent West Virginia dental-related studies were characterized using 16S rRNA gene sequencing and Human Oral Microbe Identification Microarray (HOMIM) analysis. Unifrac analysis was used to characterize phylogenetic differences between bacterial communities obtained from plaque of participants with low or high oral disease, which was further evaluated using clustering and Principal Coordinate Analysis. Results: Statistically different bacterial signatures (P < 0.001) were identified in subgingival plaque of individuals with low or high oral disease in West Virginia based on 16S rRNA gene sequencing. Low disease contained a high frequency of Veillonella and Streptococcus, with a moderate number of Capnocytophaga. High disease exhibited substantially increased bacterial diversity and included a large proportion of Clostridiales cluster bacteria (Selenomonas, Eubacterium, Dialister). Phylogenetic trees constructed using 16S rRNA gene sequencing revealed that Clostridiales were repeated colonizers in plaque associated with high oral disease, providing evidence that the oral environment is somehow influencing the bacterial signature linked to disease. Conclusions: Culture-independent analyses identified an atypical bacterial signature associated with high oral disease in West Virginians and provided evidence that the oral environment influenced this signature. Both findings provide insight into the etiology of the oral disparity in West Virginia. C1 [Olson, Joan C.; Cuff, Christopher F.; Lukomski, Slawomir; Lukomska, Ewa; Elliott, Thomas] W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA. [Lukomska, Ewa] NIOSH, Hlth Effects Lab Div, CDC, Morgantown, WV USA. [Canizales, Yeremi] W Virginia Univ, Sch Dent, Morgantown, WV 26506 USA. [Wu, Bei] Duke Univ, Med Ctr, Sch Nursing, Durham, NC USA. [Crout, Richard J.] W Virginia Univ, Sch Dent, Dept Periodontol, Morgantown, WV 26506 USA. [Thomas, John G.] W Virginia Univ, Dept Pathol, Morgantown, WV 26506 USA. [McNeil, Daniel W.] W Virginia Univ, Dept Clin Psychol, Morgantown, WV 26506 USA. [Weyant, Robert J.] Univ Pittsburgh, Sch Dent Med, Dept Dent Publ Hlth & Informat Management, Pittsburgh, PA USA. [Marazita, Mary L.] Univ Pittsburgh, Sch Dent Med, Dept Oral Biol, Ctr Craniofacial & Dent Genet, Pittsburgh, PA USA. [Marazita, Mary L.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. [Paster, Bruce J.] Forsyth Inst, Dept Mol Genet, Cambridge, MA USA. [Paster, Bruce J.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA. RP Olson, JC (reprint author), W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA. EM jolson@hsc.wvu.edu FU NIH [5P20RR016477]; West Virginia University Health Sciences Center; West Virginia University School of Dentistry; National Institute of Dental and Craniofacial Research (NIDCR) [R01-DE014899]; NIDCR [R21-DE016970] FX We thank Sara Owen, a WVU summer INBRE student, who helped with 16S rRNA gene analyses. Her efforts were supported by NIH grant 5P20RR016477 to the West Virginia IDeA Network for Biomedical Research Excellence. 16S rRNA gene analysis performed in this study was funded by the West Virginia University Health Sciences Center Internal Grants funding program, and the West Virginia University School of Dentistry. The COHRA study was supported by a grant from the National Institute of Dental and Craniofacial Research (NIDCR) (R01-DE014899; MLM, RJC, DWM, RJW). The Cognitive study was supported by a grant from the NIDCR (R21-DE016970; BW, RJC). NR 17 TC 16 Z9 18 U1 0 U2 13 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6831 J9 BMC ORAL HEALTH JI BMC Oral Health PY 2011 VL 11 AR 7 DI 10.1186/1472-6831-11-7 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA V27EP UT WOS:000208596800007 PM 21362199 ER PT J AU Witmer, C Presley, R Kulkarni, R Soucie, JM Manno, CS Raffini, L AF Witmer, Char Presley, Rodney Kulkarni, Roshni Soucie, J. Michael Manno, Catherine S. Raffini, Leslie TI Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE haemophilia; intracranial haemorrhage; prophylaxis; risk factors; head trauma ID RISK-FACTORS; PREVALENCE; EPISODES; DISEASE; DEATH; BOYS AB P>Intracranial haemorrhage (ICH) is the most serious type of bleeding for patients with haemophilia. Prior published reports regarding ICH predate the widespread provision of prophylaxis. Our study objectives were to determine risk factors for ICH and whether prophylaxis reduces ICH occurrence. We performed a nested case-control study of persons with haemophilia, >= 2 years of age enrolled in the Centers for Disease Control and Prevention Universal Data Collection project. Of 10 262 patients 199 (1 center dot 9%) experienced an ICH for an incidence rate of 390/105 patient years. Head trauma was reported in 44% (88/199). ICH mortality was 19 center dot 6% (39/199). Significant risk factors for ICH included a high titre inhibitor [odds ratio (OR) = 4 center dot 01, 95% confidence interval (2 center dot 40-6 center dot 71)], prior ICH [OR = 3 center dot 62 (2 center dot 66-4 center dot 92)] and severe haemophilia [OR = 3 center dot 25 (2 center dot 01-5 center dot 25)]. Prophylaxis was associated with a significant risk reduction for ICH occurrence in patients with severe haemophilia who were negative for human immunodeficiency virus or an inhibitor, with an OR of 0 center dot 52 (0 center dot 34-0 center dot 81) and 0 center dot 50 (0 center dot 32-0 center dot 77) respectively. The most significant risk factors for ICH included the presence of an inhibitor, prior ICH, severity of haemophilia and reported head trauma. This is the first study to demonstrate that prescribed prophylaxis conferred a protective effect against ICH in patients with uncomplicated severe disease. C1 [Witmer, Char; Raffini, Leslie] Univ Penn, Sch Med, Childrens Hosp Philadelphia, Div Hematol,Dept Pediat, Philadelphia, PA 19104 USA. [Presley, Rodney; Kulkarni, Roshni; Soucie, J. Michael] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Kulkarni, Roshni] Michigan State Univ, Dept Pediat & Human Dev, E Lansing, MI 48824 USA. [Manno, Catherine S.] NYU, Sch Med, Dept Pediat, New York, NY USA. [Manno, Catherine S.] NYU, Sch Med, Div Pediat Hematol Oncol, New York, NY USA. RP Witmer, C (reprint author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Div Hematol,Dept Pediat, 3501 Civ Ctr Blvd,CTRB 11th Floor, Philadelphia, PA 19104 USA. EM witmer@email.chop.edu OI Manno, Catherine/0000-0001-8029-0391 NR 18 TC 38 Z9 39 U1 0 U2 3 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0007-1048 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD JAN PY 2011 VL 152 IS 2 BP 211 EP 216 DI 10.1111/j.1365-2141.2010.08469.x PG 6 WC Hematology SC Hematology GA 700OD UT WOS:000285752600009 PM 21114482 ER PT J AU Kalb, SR Baudys, J Smith, TJ Pirkle, JL Barr, JR AF Kalb, Suzanne R. Baudys, Jakub Smith, Theresa J. Pirkle, James L. Barr, John R. BE Stulik, J Toman, R Butaye, P Ulrich, RG TI Subtype and Toxin Variant Identification of Botulinum Neurotoxin Type A Using Proteomics Techniques SO BSL3 AND BSL4 AGENTS: PROTEOMICS, GLYCOMICS, AND ANTIGENICITY LA English DT Article; Book Chapter ID NEUROTRANSMITTER RELEASE; INFANT BOTULISM; SEROTYPE-A; SNAP-25; PROTEIN; CLEAVES; TETANUS; BOND; PROTEOLYSIS; PEPTIDES C1 [Kalb, Suzanne R.; Baudys, Jakub; Pirkle, James L.; Barr, John R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. [Smith, Theresa J.] US Army Med Res, Inst Infect Dis, Ft Detrick, MD 21702 USA. RP Kalb, SR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Hwy NE, Atlanta, GA 30341 USA. OI Kalb, Suzanne/0000-0002-8067-136X NR 29 TC 1 Z9 1 U1 0 U2 0 PU WILEY-V C H VERLAG GMBH PI WEINHEIM PA PAPPELALLEE 3, W-69469 WEINHEIM, GERMANY BN 978-3-527-32780-5 PY 2011 BP 153 EP 165 D2 10.1002/9783527638192 PG 13 WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Genetics & Heredity GA BA9WE UT WOS:000339912800016 ER PT B AU Spiropoulou, CF AF Spiropoulou, Christina F. BE Plyusnin, A Elliott, RM TI Molecular Biology of Hantavirus Infection SO BUNYAVIRIDAE: MOLECULAR AND CELLULAR BIOLOGY LA English DT Article; Book Chapter ID SIN-NOMBRE-VIRUS; TUMOR-NECROSIS-FACTOR; CREEK CANAL VIRUS; VIRAL-RNA PANHANDLE; MOUSE PEROMYSCUS-MANICULATUS; MEMBRANE-ASSOCIATED PROTEIN; INNATE IMMUNE-RESPONSES; G1 CYTOPLASMIC TAIL; COILED-COIL DOMAIN; M-GENOME SEGMENT AB Hantaviruses are mainly rodent-borne human pathogens with a worldwide distribution and mortality rates among infected individuals of up to 40%. Members of the Hantavirus genus can be broadly divided into the Old World hantaviruses, which cause haemorrhagic fever with renal syndrome (HFRS), and the New World hantaviruses, which cause hantavirus pulmonary syndrome (HPS). The virus life cycle with few exceptions is very similar to that of other members of the Bunyaviridae family. What is really unique to hantaviruses is the unusual mechanisms by which they cause severe disease in humans and establish persistence in their rodent reservoir hosts. In this chapter, features of the hantavirus life cycle and the virus host cell interaction are highlighted in an attempt to understand what makes hantaviruses among the most important human pathogens of the family Bunyaviridae. C1 Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Spiropoulou, CF (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM ccs8@cdc.gov NR 139 TC 6 Z9 6 U1 0 U2 2 PU CAISTER ACADEMIC PRESS PI WYMONDHAM PA 32 HEWITTS LANE, WYMONDHAM NR 18 0JA, ENGLAND BN 978-1-904455-90-5 PY 2011 BP 41 EP 60 PG 20 WC Biochemistry & Molecular Biology; Virology SC Biochemistry & Molecular Biology; Virology GA BWV45 UT WOS:000295059200002 ER PT J AU Li, GW Zhang, P Wang, JP An, YL Gong, QH Gregg, E Roglic, G Yang, WY Zhang, B Hu, YH Bennett, PH AF Li, Guangwei Zhang, Ping Wang, Jinping An, Yali Gong, Qiuhong Gregg, Edward Roglic, Gojka Yang, Wenying Zhang, Bo Hu, Yinghua Bennett, Peter H. TI Cardiovascular incidence in an incipient population-based cohort with newly diagnosed diabetes and impaired glucose tolerance in China: The DaQing Diabetes Study SO CARDIOLOGY LA English DT Meeting Abstract C1 [Li, Guangwei; An, Yali; Gong, Qiuhong] CAMS, Fu Wai Hosp, Endocrinol & Cardiovasc Dis Ctr, Beijing 100037, Peoples R China. [Li, Guangwei; An, Yali; Gong, Qiuhong] PUMC, Beijing 100037, Peoples R China. [Li, Guangwei; Yang, Wenying; Zhang, Bo] China Japan Friendship Hosp, Dept Endocrinol, Beijing 10029, Peoples R China. [Zhang, Ping; Gregg, Edward] CDC, Atlanta, GA 30341 USA. [Wang, Jinping; Hu, Yinghua] DaQing First Hosp, Da Qing 163316, Peoples R China. [Bennett, Peter H.] NIDDK, Phoenix, AZ 85014 USA. [Roglic, Gojka] WHO Geneva, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 3 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 J9 CARDIOLOGY JI Cardiology PY 2011 VL 120 SU 1 BP 6 EP 6 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 865IR UT WOS:000298305100009 ER PT J AU Li, GW Zhang, P Wang, JP An, YL Gong, QH Gregg, E Roglic, G Yang, WY Zhang, B Hu, YH Bennett, PH AF Li, Guangwei Zhang, Ping Wang, Jinping An, Yali Gong, Qiuhong Gregg, Edward Roglic, Gojka Yang, Wenying Zhang, Bo Hu, Yinghua Bennett, Peter H. TI Modifiable predictors of cardiovascular disease and mortality in Chinese with impaired glucose tolerance: 23-year follow-up of the Daqing Diabetes Prevention Study SO CARDIOLOGY LA English DT Meeting Abstract C1 [Li, Guangwei; An, Yali; Gong, Qiuhong] CAMS, Fu Wai Hosp, Endocrinol & Cardiovasc Dis Ctr, Beijing 100037, Peoples R China. [Li, Guangwei; An, Yali; Gong, Qiuhong] PUMC, Beijing 100037, Peoples R China. [Li, Guangwei; Yang, Wenying; Zhang, Bo] China Japan Friendship Hosp, Dept Endocrinol, Beijing 10029, Peoples R China. [Zhang, Ping; Gregg, Edward] CDC, Atlanta, GA 30341 USA. [Wang, Jinping; Hu, Yinghua] DaQing First Hosp, Da Qing 163316, Peoples R China. [Bennett, Peter H.] NIDDK, Phoenix, AZ 85014 USA. [Roglic, Gojka] WHO Geneva, Geneva, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 J9 CARDIOLOGY JI Cardiology PY 2011 VL 120 SU 1 BP 15 EP 16 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 865IR UT WOS:000298305100028 ER PT J AU Silva, MJ Furr, J Samandar, E Preau, JL Gray, LE Needham, LL Calafat, AM AF Silva, Manori J. Furr, Johnathan Samandar, Ella Preau, James L., Jr. Gray, L. Earl Needham, Larry L. Calafat, Antonia M. TI Urinary and serum metabolites of di-n-pentyl phthalate in rats SO CHEMOSPHERE LA English DT Article DE Di-n-pentyl phthalate (DPP); Mono-n-pentyl phthalate (MPP); MHPP; Biomarkers; Exposure assessment; Oxidative metabolism ID DEUTERIUM-LABELED DEHP; DI(2-ETHYLHEXYL)PHTHALATE DEHP; OXIDATIVE METABOLITES; MASS-SPECTROMETRY; BUTYL PHTHALATE; OCTYL PHTHALATE; HUMAN EXPOSURE; BIOMARKERS; ESTERS; EXCRETION AB Di-n-pentyl phthalate (DPP) is used mainly as a plasticizer in nitrocellulose. At high doses. DPP acts as a potent testicular toxicant in rats. We administered a single oral dose of 500 mg kg(-1) bw of DPP to adult female Sprague-Dawley rats (N = 9) and collected 24-h urine samples 1 d before and 24- and 48-h after DPP was administered to tentatively identify DPP metabolites that could be used as exposure biomarkers. At necropsy, 48 h after dosing, we also collected serum. The metabolites were extracted from urine or serum, resolved with high performance liquid chromatography, and detected by mass spectrometry. Two DPP metabolites, phthalic acid (PA) and mono(3-carboxypropyl) phthalate (MCPP), were identified by using authentic standards, whereas mono-n-pentyl phthalate (MPP), mono(4-oxopentyl) phthalate (MOPP), mono(4-hydroxypentyl) phthalate (MHPP), mono(4-carboxybutyl) phthalate (MCBP), mono(2-carboxyethyl) phthalate (MCEP), and mono-n-pentenyl phthalate (MPeP) were identified based on their full scan mass spectrometric fragmentation pattern. The omega - 1 oxidation product, MHPP, was the predominant urinary metabolite of DPP. The median urinary concentrations (mu g mL(-1)) of the metabolites in the first 24 h urine collection after DPP administration were 993 (MHPP), 168 (MCBP), 0.2 (MCEP), 222 (MPP), 47 (MOPP), 26 (PA), 16 (MPeP), and 9 (MCPP): the concentrations of metabolites in the second 24 h urine collection after DPP administration were significantly lower than in the first collection. We identified some urinary metabolic products in the serum, but at much lower levels than in urine. Because of the similarities in metabolism of phthalates between rats and humans, based on our results and the fact that MHPP can only be formed from the metabolism of DPP, MHPP would be the most adequate DPP exposure biomarker for human exposure assessment. Nonetheless, based on the urinary levels of MHPP, our preliminary data suggest that human exposure to DPP in the United States is rather limited. Published by Elsevier Ltd. C1 [Silva, Manori J.; Samandar, Ella; Preau, James L., Jr.; Needham, Larry L.; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Furr, Johnathan; Gray, L. Earl] US EPA, Reprod Toxicol Branch, Toxic Assessment Div, Natl Hlth & Environm Effects Res Lab,Off Res & De, Res Triangle Pk, NC 27711 USA. RP Silva, MJ (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,Mailstop F53, Chamblee, GA 30341 USA. EM zca2@cdc.gov RI Needham, Larry/E-4930-2011 NR 29 TC 8 Z9 8 U1 5 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0045-6535 J9 CHEMOSPHERE JI Chemosphere PD JAN PY 2011 VL 82 IS 3 BP 431 EP 436 DI 10.1016/j.chemosphere.2010.09.052 PG 6 WC Environmental Sciences SC Environmental Sciences & Ecology GA 710EN UT WOS:000286493800018 PM 20951405 ER PT J AU Wirth, M Burch, J Violanti, J Burchfiel, C Fekedulegn, D Andrew, M Zhang, HM Miller, DB Hebert, JR Vena, JE AF Wirth, Michael Burch, James Violanti, John Burchfiel, Cecil Fekedulegn, Desta Andrew, Michael Zhang, Hongmei Miller, Diane B. Hebert, James R. Vena, John E. TI Shiftwork Duration and the Awakening Cortisol Response Among Police Officers SO CHRONOBIOLOGY INTERNATIONAL LA English DT Article DE Cortisol awakening response; Police; Shiftwork; Stress ID CHRONIC-FATIGUE-SYNDROME; JOB-RELATED STRESS; SALIVARY CORTISOL; CARDIOVASCULAR-DISEASE; RISK-FACTORS; INTERNAL DESYNCHRONIZATION; PSYCHOLOGICAL STRESS; CIRCADIAN-RHYTHMS; PROSTATE-CANCER; NURSES HEALTH AB Police officers are required to work irregular hours, which induces stress, fatigue, and sleep disruption, and they have higher rates of chronic disease and mortality. Cortisol is a well-known "stress hormone" produced via activation of the hypothalamic-pituitary-adrenal axis. An abnormal secretion pattern has been associated with immune system dysregulation and may serve as an early indicator of disease risk. This study examined the effects of long-and short-term shiftwork on the cortisol awakening response among officers (n = 68) in the Buffalo Cardio-Metabolic Occupational Police Stress (BCOPS) pilot study (2001-2003). The time each officer spent on day (start time: 04: 0011: 59 h), afternoon (12:00-19:59 h), or night (20:00-03:59 h) shifts was summarized from 1994 to examination date to characterize long-term (mean: 14 +/- 9 yrs) and short-term (3, 5, 7, or 14 days prior to participation) shiftwork exposures. The cortisol awakening response was characterized by summarizing the area under the curve (AUC) for samples collected on first awakening, and at 15-, 30-, and 45-min intervals after waking. Data were collected on a scheduled training or off day. The cortisol AUC with respect to ground (AUC(G)) summarized total cortisol output after waking, and the cortisol AUC with respect to increase (AUC(I)) characterized the waking cortisol response. Officers also completed the Center for Epidemiologic Studies Depression scale. Waking cortisol AUC values were lower among officers working short-term night or afternoon shifts than day shifts, with maximal differences occurring after 5 days of shiftwork. The duration of long-term shiftwork was not associated with the cortisol awakening response, although values were attenuated among officers with more career shift changes. (Author correspondence: burch@mailbox.sc.edu) C1 [Burch, James] Univ S Carolina, Canc Prevent & Control Program, Dept Epidemiol & Biostat, Columbia, SC 29208 USA. [Wirth, Michael; Burch, James; Zhang, Hongmei; Hebert, James R.] Univ S Carolina, S Carolina Statewide Canc Prevent & Control Progr, Columbia, SC 29208 USA. [Burch, James] Vet Affairs Med Ctr, Dorn Dept, Columbia, SC USA. [Violanti, John] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA. [Burchfiel, Cecil; Fekedulegn, Desta; Andrew, Michael] NIOSH, Biostat & Epidemiol Branch, Ctr Dis Control & Prevent, Morgantown, WV USA. [Miller, Diane B.] NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA. [Vena, John E.] Univ Georgia, Coll Publ Hlth, Dept Epidemiol & Biostat, Athens, GA 30602 USA. RP Burch, J (reprint author), Univ S Carolina, Canc Prevent & Control Program, Dept Epidemiol & Biostat, 915 Greene St,Room 228, Columbia, SC 29208 USA. EM burch@mailbox.sc.edu RI Wirth, Michael/C-6330-2013 FU Biostatistics and Epidemiology Branch of the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgan-town, West Virginia [212-2008-M-24052]; Cancer Training Branch of the National Cancer Institute [K05 CA136975]; National Institute of General Medical Sciences [T32-5R18CE001240] FX This project was supported by Contract No. 212-2008-M-24052 from the Biostatistics and Epidemiology Branch of the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgan-town, West Virginia. Dr. Hebert is supported by an Established Investigator Award in Cancer Prevention and Control from the Cancer Training Branch of the National Cancer Institute (K05 CA136975). Michael Wirth's participation in this research was supported by the University of South Carolina's Behavioral-Biomedical Interface Program, which is funded in part by training grant T32-5R18CE001240 from the National Institute of General Medical Sciences. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 99 TC 18 Z9 19 U1 2 U2 30 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0742-0528 EI 1525-6073 J9 CHRONOBIOL INT JI Chronobiol. Int. PY 2011 VL 28 IS 5 BP 446 EP 457 DI 10.3109/07420528.2011.573112 PG 12 WC Biology; Physiology SC Life Sciences & Biomedicine - Other Topics; Physiology GA 786OW UT WOS:000292318800008 PM 21721860 ER PT J AU Dillner, J Arbyn, M Unger, E Dillner, L AF Dillner, J. Arbyn, M. Unger, E. Dillner, L. TI Monitoring of human papillomavirus vaccination SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY LA English DT Review DE cancer prevention; effectiveness; genotyping; surveillance ID VIRUS-LIKE PARTICLES; CERVICAL INTRAEPITHELIAL NEOPLASIA; RANDOMIZED CONTROLLED-TRIAL; MINOR CAPSID PROTEIN; NONVACCINE HPV TYPES; AGED 16-26 YEARS; YOUNG-WOMEN; FOLLOW-UP; NATURAL-HISTORY; NEUTRALIZING EPITOPES AB P>Persistent infection with oncogenic human papillomavirus (HPV) is a necessary causal factor in the development of cervical cancer. Moreover, HPV, predominately type 16 and to a lesser degree type 18, is linked causally to varying proportions of other anogenital cancers (vulva, vagina, penis, anus) as well as cancers elsewhere in the body (oropharynx, larynx, conjunctiva). HPV types 6 and 11 cause most of genital warts and recurrent respiratory papillomatosis. Effective prophylactic vaccines have been developed. In this review, we address briefly the immunological aspects of HPV infection and the results of HPV vaccination trials. Internationally standardized monitoring and evaluation of prophylactic HPV vaccination programmes will be essential for arriving at the most cost-effective strategies for cancer control. C1 [Dillner, J.] Univ Hosp, Dept Clin Microbiol, WHO HPV LabNet Global Reference Lab, Lab Med Skane, SE-20502 Malmo, Sweden. [Arbyn, M.] Sci Inst Publ Hlth, Canc Epidemiol Unit, Brussels, Belgium. [Unger, E.] Ctr Dis Control, WHO HPV LabNet Global Reference Lab, Atlanta, GA 30333 USA. RP Dillner, J (reprint author), Univ Hosp, Dept Clin Microbiol, WHO HPV LabNet Global Reference Lab, Lab Med Skane, Entrance 78, SE-20502 Malmo, Sweden. EM joakim.dillner@med.lu.se OI Unger, Elizabeth/0000-0002-2925-5635 NR 96 TC 18 Z9 18 U1 0 U2 4 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0009-9104 J9 CLIN EXP IMMUNOL JI Clin. Exp. Immunol. PD JAN PY 2011 VL 163 IS 1 BP 17 EP 25 DI 10.1111/j.1365-2249.2010.04268.x PG 9 WC Immunology SC Immunology GA 688LW UT WOS:000284851800003 PM 21062269 ER PT J AU Latner, DR McGrew, M Williams, N Lowe, L Werman, R Warnock, E Gallagher, K Doyle, P Smole, S Lett, S Cocoros, N DeMaria, A Konomi, R Brown, CJ Rota, PA Bellini, WJ Hickman, CJ AF Latner, Donald R. McGrew, Marcia Williams, Nobia Lowe, Luis Werman, Roniel Warnock, Eli Gallagher, Kathleen Doyle, Peter Smole, Sandra Lett, Susan Cocoros, Noelle DeMaria, Alfred Konomi, Raimond Brown, Cedric J. Rota, Paul A. Bellini, William J. Hickman, Carole J. TI Enzyme-Linked Immunospot Assay Detection of Mumps-Specific Antibody-Secreting B Cells as an Alternative Method of Laboratory Diagnosis SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID ACUTE VIRAL-INFECTION; JANUARY 1-MAY 2; UNITED-STATES; MULTISTATE OUTBREAK; RECURRENT PAROTITIS; MEASLES ELIMINATION; CLINICAL SPECIMENS; ELISPOT ASSAY; BONE-MARROW; VIRUS AB Although high measles, mumps, and rubella (MMR) vaccination coverage has been successful in dramatically reducing mumps disease in the United States, mumps (re) infections occasionally occur in individuals who have been either previously vaccinated or naturally infected. Standard diagnostics that detect virus or virus-specific antibody are dependable for confirming primary mumps infection in immunologically naive persons, but these methods perform inconsistently for individuals with prior immune exposure. We hypothesized that detection of activated mumps-specific antibody-secreting B cells (ASCs) by enzyme-linked immunospot (ELISPOT) assay could be used as a more reliable diagnostic. To test this, a time course of virus-specific ASC responses was measured by ELISPOT assay following MMR vaccination of 16 previously vaccinated or naturally exposed adult volunteers. Mumps-specific ASCs were detectable in 68% of these individuals at some point during the first 3 weeks following revaccination. In addition, mumps-specific ASCs were detected in 7/7 previously vaccinated individuals who recently had been infected as part of a confirmed mumps outbreak. These data suggest that ELISPOT detection of mumps-specific ASCs has the potential for use as an alternative method of diagnosis when suspect cases cannot be confirmed by detection of IgM or virus. In addition, it was determined that mumps-specific memory B cells are detected at a much lower frequency than measles- or rubella-specific cells, suggesting that mumps infection may not generate robust B-cell memory. C1 [Latner, Donald R.] Ctr Dis Control & Prevent, MMRHLB, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Werman, Roniel; Warnock, Eli] Ctr Dis Control & Prevent, Off Chief Operating Officer, Off Hlth & Safety, Atlanta, GA 30333 USA. [Doyle, Peter] Northeastern Univ, Univ Hlth & Counseling Serv, Boston, MA 02115 USA. [Smole, Sandra; Lett, Susan; Cocoros, Noelle; DeMaria, Alfred; Konomi, Raimond] Massachusetts Dept Publ Hlth, Jamaica Plain, MA 02130 USA. RP Latner, DR (reprint author), Ctr Dis Control & Prevent, MMRHLB, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,MS-G18, Atlanta, GA 30333 USA. EM dlatner@cdc.gov NR 48 TC 12 Z9 13 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD JAN PY 2011 VL 18 IS 1 BP 35 EP 42 DI 10.1128/CVI.00284-10 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 702BK UT WOS:000285869400002 PM 21047998 ER PT J AU Rose, CE Romero-Steiner, S Burton, RL Carlone, GM Goldblatt, D Nahm, MH Ashton, L Haston, M Ekstrom, N Haikala, R Kayhty, H Henckaerts, I Durant, N Poolman, JT Fernsten, P Yu, XH Hu, BT Jansen, KU Blake, M Simonetti, ER Hermans, PWM Plikaytis, BD AF Rose, Charles E. Romero-Steiner, Sandra Burton, Robert L. Carlone, George M. Goldblatt, David Nahm, Moon H. Ashton, Lindsey Haston, Mitch Ekstrom, Nina Haikala, Raili Kayhty, Helena Henckaerts, Isabelle Durant, Nathalie Poolman, Jan T. Fernsten, Phil Yu, Xinhong Hu, Branda T. Jansen, Kathrin U. Blake, Milan Simonetti, Elles R. Hermans, Peter W. M. Plikaytis, Brian D. TI Multilaboratory Comparison of Streptococcus pneumoniae Opsonophagocytic Killing Assays and Their Level of Agreement for the Determination of Functional Antibody Activity in Human Reference Sera SO CLINICAL AND VACCINE IMMUNOLOGY LA English DT Article ID PNEUMOCOCCAL ANTIBODIES AB Antibody-mediated killing of Streptococcus pneumoniae (pneumococcus) by phagocytes is an important mechanism of protection of the human host against pneumococcal infections. Measurement of opsonophagocytic antibodies by use of a standardized opsonophagocytic assay (OPA) is important for the evaluation of candidate vaccines and required for the licensure of new pneumococcal conjugate vaccine formulations. We assessed agreement among six laboratories that used their own optimized OPAs on a panel of 16 human reference sera for 13 pneumococcal serotypes. Consensus titers, estimated using an analysis-of-variance (ANOVA) mixed-effects model, provided a common reference for assessing agreement among these laboratories. Agreement was evaluated in terms of assay accuracy, reproducibility, repeatability, precision, and bias. We also reviewed four acceptance criterion intervals for assessing the comparability of protocols when assaying the same reference sera. The precision, accuracy, and concordance results among laboratories and the consensus titers revealed acceptable agreement. The results of this study indicate that the bioassays evaluated in this study are robust, and the resultant OPA values are reproducible for the determination of functional antibody titers specific to 13 pneumococcal serotypes when performed by laboratories using highly standardized but not identical assays. The statistical methodologies employed in this study may serve as a template for evaluating future multilaboratory studies. C1 [Rose, Charles E.; Plikaytis, Brian D.] Ctr Dis Control & Prevent, Biostat Off, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Romero-Steiner, Sandra; Carlone, George M.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Burton, Robert L.; Nahm, Moon H.] Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA. [Goldblatt, David; Ashton, Lindsey; Haston, Mitch] UCL, Immunobiol Unit, Inst Child Hlth, London, England. [Ekstrom, Nina; Haikala, Raili; Kayhty, Helena] Natl Inst Hlth & Welf, Dept Vaccinat & Immune Protect, Helsinki, Finland. [Henckaerts, Isabelle; Durant, Nathalie; Poolman, Jan T.] GlaxoSmithKline Biol, Bacterial Vaccines Program, R&D, B-1330 Rixensart, Belgium. [Fernsten, Phil; Yu, Xinhong; Hu, Branda T.; Jansen, Kathrin U.] Pfizer Vaccine Res, Pearl River, NY 10965 USA. [Blake, Milan] US FDA, Div Bacterial Parasit & Allergenic Prod, Ctr Biol Evaluat & Res, Rockville, MD 20851 USA. [Simonetti, Elles R.; Hermans, Peter W. M.] Radboud Univ Nijmegen, Med Ctr, Dept Pediat, NL-6525 ED Nijmegen, Netherlands. RP Rose, CE (reprint author), Ctr Dis Control & Prevent, Biostat Off, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Bldg 1,Room 5044,MS C-09,1600 Clifton Rd, Atlanta, GA 30333 USA. EM CRose@cdc.gov RI Goldblatt, David/C-5972-2008; Hermans, Peter/H-8042-2014; Simonetti, Elles/N-2966-2016; OI Goldblatt, David/0000-0002-0769-5242; Romero-Steiner, Sandra/0000-0003-4128-7768; Nahm, Moon/0000-0002-6922-1042 FU NIH [AI-30021 (NIH/NIAID/DMID)] FX This project was funded in part by NIH contract AI-30021 (NIH/NIAID/DMID) to the University of Alabama at Birmingham (M.H.N.). NR 25 TC 24 Z9 27 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 1556-6811 J9 CLIN VACCINE IMMUNOL JI Clin. Vaccine Immunol. PD JAN PY 2011 VL 18 IS 1 BP 135 EP 142 DI 10.1128/CVI.00370-10 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 702BK UT WOS:000285869400015 PM 21084458 ER PT J AU Armstrong, GL Brammer, L Finelli, L AF Armstrong, Gregory L. Brammer, Lynnette Finelli, Lyn TI Timely Assessment of the Severity of the 2009 H1N1 Influenza Pandemic SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; UNITED-STATES; MORTALITY AB During the 2009 influenza pandemic, weekly mortality data were analyzed to estimate excess mortality above a seasonally adjusted baseline modeled from prior years' data. Between the 1962-1963 and 2008-2009 seasons, among persons >= 25 years old, excess mortality had been substantially higher during influenza A(H3N2)-dominant years than during A(H1N1)-dominant years. Among persons >= 15 years of age, excess mortality was higher in the 1968-1969 influenza pandemic season than during any other season. During the 2009-2010 pandemic, among all age groups < 65 years old, excess mortality increased earlier than during any of the previous 47 seasons, eventually exceeding mortality in any prior non-pandemic season. In the >= 65-year-old age group, excess mortality remained relatively low, at rates typical of seasonal influenza A(H1N1) seasons. The model provided a timely assessment of severity during the 2009-2010 influenza pandemic, showing that, compared with prior seasons, mortality was relatively high among persons < 65 years old and relatively low among those >= 65 years old. C1 [Armstrong, Gregory L.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Brammer, Lynnette; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Armstrong, GL (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Mailstop A-47,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM garmstrong@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 12 TC 9 Z9 9 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S83 EP S89 DI 10.1093/cid/ciq013 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500012 PM 21342905 ER PT J AU Bhattarai, A Villanueva, J Palekar, RS Fagan, R Sessions, W Winter, J Berman, L Lute, J Leap, R Marchbanks, T Sodha, SV Moll, M Xu, XY Fry, A Fiore, A Ostroff, S Swerdlow, DL AF Bhattarai, Achuyt Villanueva, Julie Palekar, Rakhee S. Fagan, Ryan Sessions, Wendy Winter, Joern Berman, LaShondra Lute, James Leap, Rebecca Marchbanks, Tiffany Sodha, Samir V. Moll, Maria Xu, Xiyan Fry, Alicia Fiore, Anthony Ostroff, Stephen Swerdlow, David L. CA Penn Working Grp TI Viral Shedding Duration of Pandemic Influenza A H1N1 Virus during an Elementary School Outbreak-Pennsylvania, May-June 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID INFECTION AB We report shedding duration of 2009 pandemic influenza A (pH1N1) virus from a school-associated outbreak in Pennsylvania during May through June 2009. Outbreak-associated students or household contacts with influenza-like illness (ILI) onset within 7 days of interview were recruited. Nasopharyngeal specimens, collected every 48 hours until 2 consecutive nonpositive tests, underwent real-time reverse transcriptase polymerase chain reaction (rRT-PCR) and culture for pH1N1 virus. Culture-positive specimens underwent virus titrations. Twenty-six (median age, 8 years) rRT-PCR-positive persons, for pH1N1 virus, were included in analysis. Median shedding duration from fever onset by rRT-PCR was 6 days (range, 1-13) and 5 days (range, 1-7) by culture. Following fever resolution virus was isolated for a median of 2 days (range, 0-5). Highest and lowest virus titers detected, 2 and 5 days following fever onset, were 3.2 and 1.2 log(10) TCID(50)/mL respectively. Overall, shedding duration in children and adults were similar to seasonal influenza viruses. C1 [Bhattarai, Achuyt; Villanueva, Julie; Palekar, Rakhee S.; Fagan, Ryan; Sessions, Wendy; Winter, Joern; Berman, LaShondra; Leap, Rebecca; Sodha, Samir V.; Xu, Xiyan; Fry, Alicia; Fiore, Anthony; Swerdlow, David L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Villanueva, Julie] Battelle Mem Inst, Atlanta, GA USA. [Lute, James; Marchbanks, Tiffany; Moll, Maria; Ostroff, Stephen] Penn Dept Hlth, Harrisburg, PA 17108 USA. RP Bhattarai, A (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop A38, Atlanta, GA 30333 USA. EM abhattarai@cdc.gov RI Bhattarai, Achuyt/B-8760-2008 OI Bhattarai, Achuyt/0000-0002-0514-4850 FU Centers for Disease Control and Prevention (CDC) [U60/CCU007277]; Centers for Disease Control and Prevention FX This investigation was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE) and funded by the Centers for Disease Control and Prevention (CDC) Co-operative Agreement U60/CCU007277.; Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 15 TC 19 Z9 19 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S102 EP S108 DI 10.1093/cid/ciq026 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500015 PM 21342880 ER PT J AU Borse, RH Behravesh, CB Dumanovsky, T Zucker, JR Swerdlow, D Edelson, P Choe-Castillo, J Meltzer, MI AF Borse, Rebekah H. Behravesh, Casey Barton Dumanovsky, Tamara Zucker, Jane R. Swerdlow, David Edelson, Paul Choe-Castillo, Julia Meltzer, Martin I. TI Closing Schools in Response to the 2009 Pandemic Influenza A H1N1 Virus in New York City: Economic Impact on Households SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; CLOSURE; CHILDREN; TRANSMISSION; SPREAD AB Understanding the effectiveness of a school closure in limiting social interaction and the economic impact of school closure on households is critical when developing guidelines to prevent spread of pandemic influenza. A New York City survey conducted in June 2009 in 554 households affected by the 2009 pandemic influenza H1N1-related school closures showed that, during closure, 30% of students visited at least 1 locale outside their homes. If all the adults in the home were employed, an ill child was less likely to leave home. In 17% of the households, at least 1 adult missed some work because of the closure. If all adults in the home were employed, someone was more likely to take time off work. If other children were in the household, it was less likely that an adult took time off work. The findings of our study will be important when developing future pandemic school-closure guidance. C1 [Borse, Rebekah H.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Dumanovsky, Tamara; Zucker, Jane R.; Choe-Castillo, Julia] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Choe-Castillo, Julia] Dept Educ, Off Sch Hlth, New York, NY USA. RP Borse, RH (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd NE,MS D59, Atlanta, GA 30333 USA. EM rborse@cdc.gov FU CDC; Centers for Disease Control and Prevention FX This information was collected and paid for by CDC; it was cleared by the human subjects' board as a public health, non-research study to assess an existing public health intervention in response to an immediate public health threat.; Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 28 TC 11 Z9 13 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S168 EP S172 DI 10.1093/cid/ciq033 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500024 PM 21342890 ER PT J AU Brammer, L Blanton, L Epperson, S Mustaquim, D Bishop, A Kniss, K Dhara, R Nowell, M Kamimoto, L Finelli, L AF Brammer, Lynnette Blanton, Lenee Epperson, Scott Mustaquim, Desiree Bishop, Amber Kniss, Krista Dhara, Rosaline Nowell, Mackenzie Kamimoto, Laurie Finelli, Lyn TI Surveillance for Influenza during the 2009 Influenza A (H1N1) Pandemic-United States, April 2009-March 2010 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID VIRUS; CHILDREN AB The emergence in April 2009 and subsequent spread of the 2009 pandemic influenza A (H1N1) virus resulted in the first pandemic of the 21st century. This historic event was associated with unusual patterns of influenza activity in terms of the timing and persons affected in the United States throughout the summer and fall months of 2009 and the winter of 2010. The US Influenza Surveillance System identified 2 distinct waves of pandemic influenza H1N1 activity-the first peaking in June 2009, followed by a second peak in October 2009. All influenza surveillance components showed levels of influenza activity above that typically seen during late summer and early fall. During this period, influenza activity reached its highest level during the week ending 24 October 2009. This report summarizes US influenza surveillance data from 12 April 2009 through 27 March 2010. C1 [Brammer, Lynnette; Blanton, Lenee; Epperson, Scott; Mustaquim, Desiree; Bishop, Amber; Kniss, Krista; Dhara, Rosaline; Nowell, Mackenzie; Kamimoto, Laurie; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Brammer, L (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30333 USA. EM lsb1@cdc.gov FU National Center for Immunization and Respiratory Diseases; Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention Emerging Infections Program and the National Center for Immunization and Respiratory Diseases.; Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 10 TC 32 Z9 36 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S27 EP S35 DI 10.1093/cid/ciq009 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500005 PM 21342896 ER PT J AU Cox, CM Blanton, L Dhara, R Brammer, L Finelli, L AF Cox, Chad M. Blanton, Lenee Dhara, Rosaline Brammer, Lynnette Finelli, Lyn TI 2009 Pandemic Influenza A (H1N1) Deaths among Children-United States, 2009-2010 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID INFECTION; VIRUS; MORTALITY; MEXICO AB The 2009 pandemic influenza A (H1N1) (pH1N1) virus emerged in the United States in April 2009 (1) and has since caused significant morbidity and mortality worldwide (2-6). We compared pandemic influenza A (H1N1) (pH1N1)-associated deaths occurring from 15 April 2009 through 23 January 2010 with seasonal influenza-associated deaths occurring from 1 October 2007 through 14 April 2009, a period during which data collected were most comparable. Among 317 children who died of pH1N1-associated illness, 301 (95%) had a reported medical history. Of those 301, 205 (68%) had a medical condition associated with an increased risk of severe illness from influenza. Children who died of pH1N1-associated illness had a higher median age (9.4 vs 6.2 years; P <.01) and longer time from onset of symptoms to death (7 vs 5 days, P <.01) compared with children who died of seasonal influenza-associated illness. The majority of pediatric deaths from pH1N1 were in older children with high-risk medical conditions. Vaccination continues to be critical for all children, especially those at increased risk of influenza-related complications. C1 [Cox, Chad M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Influenza Div, Atlanta, GA USA. RP Cox, CM (reprint author), 1600 Clifton Rd,MS-A32, Atlanta, GA 30333 USA. EM cyv5@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 22 TC 57 Z9 59 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S69 EP S74 DI 10.1093/cid/ciq011 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500010 PM 21342902 ER PT J AU Donnelly, CA Finelli, L Cauchemez, S Olsen, SJ Doshi, S Jackson, ML Kennedy, ED Kamimoto, L Marchbanks, TL Morgan, OW Patel, M Swerdlow, DL Ferguson, NM AF Donnelly, Christl A. Finelli, Lyn Cauchemez, Simon Olsen, Sonja J. Doshi, Saumil Jackson, Michael L. Kennedy, Erin D. Kamimoto, Laurie Marchbanks, Tiffany L. Morgan, Oliver W. Patel, Minal Swerdlow, David L. Ferguson, Neil M. CA pH1N1 Household Invest Working Grp TI Serial Intervals and the Temporal Distribution of Secondary Infections within Households of 2009 Pandemic Influenza A (H1N1): Implications for Influenza Control Recommendations SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID NEW-YORK-CITY; VIRUS; OUTBREAK; TRANSMISSION; CHILDREN; DISEASE; SCHOOL AB A critical issue during the 2009 influenza A (H1N1) pandemic was determining the appropriate duration of time individuals with influenza-like illness (ILI) should remain isolated to reduce onward transmission while limiting societal disruption. Ideally this is based on knowledge of the relative infectiousness of ill individuals at each point during the course of the infection. Data on 261 clinically apparent pH1N1 infector-infectee pairs in households, from 7 epidemiological studies conducted in the United States early in 2009, were analyzed to estimate the distribution of times from symptom onset in an infector to symptom onset in the household contacts they infect (mean, 2.9 days, not correcting for tertiary transmission). Only 5% of transmission events were estimated to take place > 3 days after the onset of clinical symptoms among those ill with pH1N1 virus. These results will inform future recommendations on duration of isolation of individuals with ILI. C1 [Donnelly, Christl A.; Cauchemez, Simon; Ferguson, Neil M.] Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, London W2 1PG, England. [Doshi, Saumil; Jackson, Michael L.; Swerdlow, David L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Olsen, Sonja J.; Morgan, Oliver W.] Ctr Dis Control & Prevent, Div Emerging Infect & Surveillance Serv, Atlanta, GA USA. [Doshi, Saumil; Jackson, Michael L.; Kennedy, Erin D.; Patel, Minal] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. [Finelli, Lyn; Kennedy, Erin D.; Kamimoto, Laurie] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Atlanta, GA USA. [Marchbanks, Tiffany L.] Ctr Dis Control & Prevent, CDC CSTE Appl Epidemiol Fellowship Program, Atlanta, GA USA. [Patel, Minal] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Bacterial & Mycot Dis, Atlanta, GA USA. [Marchbanks, Tiffany L.] Penn Dept Hlth, Div Infect Dis Epidemiol, Harrisburg, PA 17108 USA. RP Donnelly, CA (reprint author), Univ London Imperial Coll Sci Technol & Med, MRC Ctr Outbreak Anal & Modelling, Dept Infect Dis Epidemiol, St Marys Campus,Norfolk Pl, London W2 1PG, England. EM c.donnelly@im-perial.ac.uk RI Ferguson, Neil/B-8578-2008; Bhattarai, Achuyt/B-8760-2008; OI Ferguson, Neil/0000-0002-1154-8093; Bhattarai, Achuyt/0000-0002-0514-4850; Donnelly, Christl/0000-0002-0195-2463 FU Medical Research Council; Bill and Melinda Gates Foundation [49276]; National Institute of General Medical Sciences (NIGMS) Models of Infectious Disease Agent Study (MIDAS) initiative [1U54GM088491-01]; European Community [201601]; Research Councils UK; Applied Epidemiology; CDC [U60/CCU007277]; Centers for Disease Control and Prevention; Sanofi Pasteur FX This study was supported by the Medical Research Council (N. M. F., C. A. D., S. C.), the Bill and Melinda Gates Foundation (49276 to N. M. F.), the National Institute of General Medical Sciences (NIGMS) Models of Infectious Disease Agent Study (MIDAS) initiative (1U54GM088491-01 to N. M. F., C. A. D., and S. C.), the European Community's Seventh Framework Programme (201601 to N. M. F.), the Research Councils UK (to S. C.), an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (to T. L. M.), and the CDC Cooperative Agreement (U60/CCU007277 to T. L. M.). Funders took no part in the design or interpretation of the study. The content of this article is solely the responsibility of the authors and does not necessarily represent the views of the funding sources.; Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention.; S.C. has received consulting fees from Sanofi Pasteur for advising them on modelling the spread of varicella and varicella herpes zoster. All other authors: no conflicts. NR 29 TC 33 Z9 33 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S123 EP S130 DI 10.1093/cid/ciq028 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500018 PM 21342883 ER PT J AU Fowlkes, AL Arguin, P Biggerstaff, MS Gindler, J Blau, D Jain, S Dhara, R McLaughlin, J Turnipseed, E Meyer, JJ Louie, JK Siniscalchi, A Hamilton, JJ Reeves, A Park, SY Richter, D Ritchey, MD Cocoros, NM Blythe, D Peters, S Lynfield, R Peterson, L Anderson, J Moore, Z Williams, R McHugh, L Cruz, C Waters, CL Page, SL McDonald, CK Vandermeer, M Waller, K Bandy, U Jones, TF Bullion, L Vernon, V Lofy, KH Haupt, T Finelli, L AF Fowlkes, Ashley L. Arguin, Paul Biggerstaff, Matthew S. Gindler, Jacqueline Blau, Dianna Jain, Seema Dhara, Roseline McLaughlin, Joe Turnipseed, Elizabeth Meyer, John J. Louie, Janice K. Siniscalchi, Alan Hamilton, Janet J. Reeves, Ariane Park, Sarah Y. Richter, Deborah Ritchey, Matthew D. Cocoros, Noelle M. Blythe, David Peters, Susan Lynfield, Ruth Peterson, Lesha Anderson, Jannifer Moore, Zack Williams, Robin McHugh, Lisa Cruz, Carmen Waters, Christine L. Page, Shannon L. McDonald, Christie K. Vandermeer, Meredith Waller, Kirsten Bandy, Utpala Jones, Timothy F. Bullion, Lesley Vernon, Valoree Lofy, Kathryn H. Haupt, Thomas Finelli, Lyn TI Epidemiology of 2009 Pandemic Influenza A (H1N1) Deaths in the United States, April-July 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID VIRUS; HUMANS AB During the spring of 2009, pandemic influenza A (H1N1) virus (pH1N1) was recognized and rapidly spread worldwide. To describe the geographic distribution and patient characteristics of pH1N1-associated deaths in the United States, the Centers for Disease Control and Prevention requested information from health departments on all laboratory-confirmed pH1N1 deaths reported from 17 April through 23 July 2009. Data were collected using medical charts, medical examiner reports, and death certificates. A total of 377 pH1N1-associated deaths were identified, for a mortality rate of .12 deaths per 100 000 population. Activity was geographically localized, with the highest mortality rates in Hawaii, New York, and Utah. Seventy-six percent of deaths occurred in persons aged 18-65 years, and 9% occurred in persons aged >= 65 years. Underlying medical conditions were reported for 78% of deaths: chronic lung disease among adults (39%) and neurologic disease among children (54%). Overall mortality associated with pH1N1 was low; however, the majority of deaths occurred in persons aged < 65 years with underlying medical conditions. C1 [Fowlkes, Ashley L.; Biggerstaff, Matthew S.; Jain, Seema; Dhara, Roseline; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. [Arguin, Paul] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Zoonot & Vector Borne Dis, Atlanta, GA 30329 USA. [Gindler, Jacqueline] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. [Blau, Dianna] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Zoonot & Vector Borne Dis, Atlanta, GA 30329 USA. [McLaughlin, Joe] Alaska Dept Hlth & Social Serv, Anchorage, AK USA. [Turnipseed, Elizabeth] Alabama Dept Publ Hlth, Montgomery, AL 36102 USA. [Meyer, John J.] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. [Louie, Janice K.] Calif Dept Hlth Serv, Richmond, CA USA. [Siniscalchi, Alan] Connecticut Dept Publ Hlth, Hartford, CT USA. [Hamilton, Janet J.] Florida Dept Hlth, Tallahassee, FL USA. [Reeves, Ariane] Georgia Div Publ Hlth, Atlanta, GA USA. [Park, Sarah Y.] Hawaii State Dept Hlth, Honolulu, HI USA. [Richter, Deborah] Illinois Dept Publ Hlth, Springfield, IL 62761 USA. [Ritchey, Matthew D.] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. [Cocoros, Noelle M.] Massachusetts Dept Publ Hlth, Boston, MA USA. [Blythe, David] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Peters, Susan] Michigan Dept Community Hlth, Lansing, MI USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Peterson, Lesha] Missouri Dept Hlth & Senior Serv, Jefferson City, MO USA. [Anderson, Jannifer] Mississippi Dept Hlth, Jackson, MS USA. [Moore, Zack] N Carolina Dept Hlth & Human Serv, Raleigh, NC USA. [Williams, Robin] Nebraska Dept Hlth & Human Serv, Lincoln, NE USA. [McHugh, Lisa] New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA. [Cruz, Carmen] Nevada Dept Hlth & Human Serv, Carson City, NV USA. [Waters, Christine L.] New York State Dept Hlth, Albany, NY USA. [Page, Shannon L.] Ohio Dept Hlth, Columbus, OH 43266 USA. [McDonald, Christie K.] Oklahoma Dept Hlth, Oklahoma City, OK USA. [Vandermeer, Meredith] Oregon Publ Hlth Div, Portland, OR USA. [Waller, Kirsten] Penn Dept Hlth, Harrisburg, PA 17108 USA. [Bandy, Utpala] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Jones, Timothy F.] Tennessee Dept Hlth, Nashville, TN USA. [Bullion, Lesley] Texas Dept State Hlth Serv, Austin, TX USA. [Vernon, Valoree] Utah Dept Hlth, Salt Lake City, UT 84116 USA. [Lofy, Kathryn H.] Washington State Dept Hlth, Shoreline, WA USA. [Haupt, Thomas] Wisconsin Dept Hlth Serv, Madison, WI USA. RP Fowlkes, AL (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A32, Atlanta, GA 30329 USA. EM afowlkes@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," which was sponsored by the Centers for Disease Control and Prevention. NR 25 TC 38 Z9 40 U1 0 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S60 EP S68 DI 10.1093/cid/ciq022 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500009 PM 21342901 ER PT J AU Gindler, J Grohskopf, LA Biggerstaff, M Finelli, L AF Gindler, Jacqueline Grohskopf, Lisa A. Biggerstaff, Matthew Finelli, Lyn TI A Model Survey for Assessing 2009 Pandemic Influenza A (H1N1) Virus Disease Burden in the Workplace SO CLINICAL INFECTIOUS DISEASES LA English DT Article AB Emergence of 2009 pandemic influenza A (H1N1) (pH1N1) virus in 2009 raised concern about the potential impact of widespread or severe disease on the nation's workforce. The Centers for Disease Control and Prevention recommended that employers develop flexible pandemic response plans. We used the Behavioral Risk Factor Surveillance System's influenza module as a model for a brief workplace survey to ascertain the influenza-like illness (ILI) burden on epidemiology staff in Centers for Disease Control and Prevention Emergency Operations Center. Fifty-seven (78%) of 73 recipients completed the survey. Ten (18%) met the ILI case definition. The 10 respondent ILI cases missed 24 total work days, although none sought medical care. Eleven (14%) of 77 household contacts also had ILI, but no ILI case was hospitalized. This survey enabled us to rapidly obtain information about our workforce ILI burden and evaluate the potential need for additional resources because of employee absence. C1 [Gindler, Jacqueline] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Grohskopf, Lisa A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Atlanta, GA 30333 USA. [Biggerstaff, Matthew; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Gindler, J (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM jgindler@cdc.gov FU Centers for Disease Control and 370 Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and 370 Prevention. NR 9 TC 0 Z9 0 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S173 EP S176 DI 10.1093/cid/ciq034 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500025 PM 21342891 ER PT J AU Guh, A Reed, C Gould, LH Kutty, P Iuliano, D Mitchell, T Dee, D Desai, M Siebold, J Silverman, P Massoudi, M Lynch, M Sotir, M Armstrong, G Swerdlow, D AF Guh, Alice Reed, Carrie Gould, L. Hannah Kutty, Preeta Iuliano, Danielle Mitchell, Tarissa Dee, Deborah Desai, Mitesh Siebold, Joseph Silverman, Paul Massoudi, Mehran Lynch, Michael Sotir, Mark Armstrong, Gregory Swerdlow, David TI Transmission of 2009 Pandemic Influenza A (H1N1) at a Public University-Delaware, April-May 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID VIRUS-INFECTION; COLLEGE; A-USSR-77; ILLNESSES; OUTBREAK; STUDENTS; CAMPUS; RISK AB We investigated the first documented university outbreak of the 2009 pandemic influenza A(H1N1) to identify factors associated with disease transmission. An online student survey was administered to assess risk factors for influenza-like illness (ILI), defined as fever with cough or sore throat. Of 6049 survey respondents, 567 (9%) experienced ILI during 27 March to 9 May 2009. Studying with an ill contact (adjusted risk ratios [aRR], 1.29; 95% confidence intervals [CI], 1.01-1.65) and caring for an ill contact (aRR, 1.51; CI, 1.14-2.01) any time during 27 March to 9 May were predictors for ILI. Respondents reported that 680 (6%) of 11,411 housemates were ill; living with an ill housemate was a predictor for ILI (RR, 1.38; CI, 1.04-1.83). Close contact or prolonged exposures to ill persons were likely associated with experiencing ILI. Self-protective measures should be promoted in university populations to mitigate transmission. C1 [Guh, Alice; Reed, Carrie; Iuliano, Danielle; Mitchell, Tarissa; Dee, Deborah; Desai, Mitesh] Ctr Dis Control & Prevent CDC, Epidem Intelligence Off, Atlanta, GA USA. [Guh, Alice; Reed, Carrie; Iuliano, Danielle; Mitchell, Tarissa; Dee, Deborah; Desai, Mitesh; Massoudi, Mehran] Ctr Dis Control & Prevent CDC, Sci Educ & Profess Dev Program Off Proposed, Atlanta, GA USA. [Guh, Alice] Connecticut State Dept Publ Hlth, Hartford, CT USA. [Reed, Carrie] CDC, Influenza Div, Atlanta, GA 30333 USA. [Gould, L. Hannah; Sotir, Mark; Swerdlow, David] CDC, Div Foodborne Bacterial & Mycot Dis, Atlanta, GA 30333 USA. [Kutty, Preeta; Armstrong, Gregory] CDC, Div Viral Dis, Atlanta, GA 30333 USA. [Iuliano, Danielle] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Mitchell, Tarissa] CDC, Div Global Migrat & Quarantine, Atlanta, GA 30333 USA. [Dee, Deborah] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Desai, Mitesh] CDC, Div TB Eliminat, Atlanta, GA 30333 USA. [Siebold, Joseph] Univ Delaware, Student Hlth Serv, Newark, DE USA. [Silverman, Paul] Delaware Hlth & Social Serv, Div Publ Hlth, Dover, DE USA. [Lynch, Michael] Ctr Dis Control & Prevent CDC, Div Parasit Dis, Atlanta, GA USA. RP Guh, A (reprint author), 1600 Clifton Rd NE,MS A-31, Atlanta, GA 30329 USA. EM ggt4@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 27 TC 6 Z9 7 U1 1 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S131 EP S137 DI 10.1093/cid/ciq029 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500019 PM 21342885 ER PT J AU Iuliano, AD Dawood, FS Silk, BJ Bhattarai, A Copeland, D Doshi, S France, AM Jackson, ML Kennedy, E Loustalot, F Marchbanks, T Mitchell, T Averhoff, F Olsen, SJ Swerdlow, DL Finelli, L AF Iuliano, A. Danielle Dawood, Fatimah S. Silk, Benjamin J. Bhattarai, Achuyt Copeland, Daphne Doshi, Saumil France, Anne Marie Jackson, Michael L. Kennedy, Erin Loustalot, Fleetwood Marchbanks, Tiffany Mitchell, Tarissa Averhoff, Francisco Olsen, Sonja J. Swerdlow, David L. Finelli, Lyn TI Investigating 2009 Pandemic Influenza A (H1N1) in US Schools: What Have We Learned? SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HOUSEHOLD; OUTBREAK; VIRUS; TRANSMISSION; FAMILIES AB US investigations of school-based outbreaks of 2009 pandemic influenza A (H1N1) virus infection characterized influenza-like illness (ILI) attack rates, transmission risk factors, and adherence to nonpharmaceutical interventions. We summarize seven school-based investigations conducted during April-June 2009 to determine what questions might be answered by future investigations. Surveys were administered 5-28 days after identification of the outbreaks, and participation rates varied among households (39-86%) and individuals (24-49%). Compared with adults (4%-10%) and children aged < 4 years (2%-7%), elementary through university students had higher ILI attack rates (4%-32%). Large gatherings or close contact with sick persons were identified as transmission risk factors. More participants reported adherence to hygiene measures, but fewer reported adherence to isolation measures. Challenges included low participation and delays in survey initiation that potentially introduced bias. Although school-based investigations can increase our understanding of epidemiology and prevention strategy effectiveness, investigators should decide which objectives are most feasible, given timing and design constraints. C1 [Iuliano, A. Danielle] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Silk, Benjamin J.; Jackson, Michael L.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. [Dawood, Fatimah S.; Doshi, Saumil; Kennedy, Erin] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Bhattarai, Achuyt] Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Atlanta, GA USA. [Copeland, Daphne; Mitchell, Tarissa; Averhoff, Francisco] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA USA. [Loustalot, Fleetwood] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Marchbanks, Tiffany] Ctr Dis Control & Prevent, Penn Dept Hlth, Atlanta, GA USA. [Olsen, Sonja J.] Ctr Dis Control & Prevent, Div Emerging Infect & Surveillance Serv, Atlanta, GA USA. [Swerdlow, David L.; Finelli, Lyn] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Iuliano, A. Danielle; Dawood, Fatimah S.; Silk, Benjamin J.; Bhattarai, Achuyt; Doshi, Saumil; France, Anne Marie; Jackson, Michael L.; Kennedy, Erin; Loustalot, Fleetwood; Mitchell, Tarissa] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. [Marchbanks, Tiffany] Ctr Dis Control & Prevent, Council State & Territorial Epidemiologist Appl E, Atlanta, GA USA. RP Iuliano, AD (reprint author), 1600 Clifton Rd,MS A-32, Atlanta, GA 30329 USA. EM aiuliano@cdc.gov RI Bhattarai, Achuyt/B-8760-2008 OI Bhattarai, Achuyt/0000-0002-0514-4850 FU CDC Foundation; Centers for Disease Control and Prevention [U60/CCU007277] FX We thank our colleagues in state and local health departments, as well as school administrators, faculty and staff, and students and families from participating schools and communities. We also specifically thank the San Diego County Health and Human Services Agency (HHSA), San Diego Unified School District, Delaware Department of Health and Social Services, University of Delaware, NYC Swine Flu Investigation Team at the New York City Department of Health and Mental Hygiene, the Conrad Weiser Area School District, Pennsylvania Department of Health, Texas Department of State Health Services, Dallas County Department of Health and Human Services, Tarrant County Public Health, Office of Surveillance and Public Health Preparedness at the Houston Department of Health and Human Services, Houston Independent School District, and the Schertz-Cibolo-Universal City Independent School District. Numerous other staff and volunteers at the Centers for Disease Control and Prevention and the CDC Foundation supported and participated in these investigations.; This work was supported by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists and funded by the Centers for Disease Control and Prevention (Cooperative Agreement U60/CCU007277).; Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 20 TC 9 Z9 9 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S161 EP S167 DI 10.1093/cid/ciq032 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500023 PM 21342889 ER PT J AU Janusz, KB Cortes, JE Serdarevic, F Jones, RC Jones, JD Ritger, KA Morita, JY Gerber, SI Gallagher, L Biggerstaff, BJ Hicks, LA Swerdlow, DL Fischer, M Staples, JE AF Janusz, Kristen B. Cortes, Jennifer E. Serdarevic, Fadila Jones, Roderick C. Jones, Joshua D. Ritger, Kathleen A. Morita, Julie Y. Gerber, Susan I. Gallagher, L. Biggerstaff, Brad J. Hicks, Lauri A. Swerdlow, David L. Fischer, Marc Staples, J. Erin CA Chicago H1N1 Epidemiology Team TI Influenza-Like Illness in a Community Surrounding a School-Based Outbreak of 2009 Pandemic Influenza A (H1N1) Virus-Chicago, Illinois, 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID SEASONAL INFLUENZA; TRANSMISSION; IMPACT; CLOSURE AB In April 2009, following the first school closure due to 2009 pandemic influenza A (H1N1) (pH1N1) in Chicago, Illinois, area hospitals were inundated with patients presenting with influenza-like illness (ILI). The extent of disease spread into the surrounding community was unclear. We performed a household survey to estimate the ILI attack rate among community residents and compared reported ILI with confirmed pH1N1 cases and ILI surveillance data (ie, hospital ILI visits, influenza testing, and school absenteeism). The estimated ILI attack rate was 4.6% (95% confidence interval, 2.8%-7.4%), with cases distributed throughout the 5-week study period. In contrast, 36 (84%) of 43 confirmed pH1N1 cases were identified the week of the school closure. Trends in surveillance data peaked during the same week and rapidly decreased to near baseline. Public awareness and health care practices impact standard ILI surveillance data. Community-based surveys are a valuable tool to help assess the burden of ILI in a community. C1 [Janusz, Kristen B.; Biggerstaff, Brad J.; Fischer, Marc; Staples, J. Erin] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Cortes, Jennifer E.; Serdarevic, Fadila; Hicks, Lauri A.; Swerdlow, David L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Serdarevic, Fadila; Jones, Roderick C.; Jones, Joshua D.; Ritger, Kathleen A.; Morita, Julie Y.; Gerber, Susan I.] Chicago Dept Publ Hlth, Chicago, IL USA. [Gallagher, L.] Illinois Dept Publ Hlth, Springfield, IL 62761 USA. [Gerber, Susan I.] Cook Cty Dept Publ Hlth, Oak Pk, IL USA. RP Staples, JE (reprint author), CDC, 3150 Rampart Rd,MS P-02, Ft Collins, CO 80521 USA. EM estaples@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 15 TC 6 Z9 6 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S94 EP S101 DI 10.1093/cid/ciq025 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500014 PM 21342907 ER PT J AU Jernigan, DB Lindstrom, SL Johnson, JR Miller, JD Hoelscher, M Humes, R Shively, R Brammer, L Burke, SA Villanueva, JM Balish, A Uyeki, T Mustaquim, D Bishop, A Handsfield, JH Astles, R Xu, X Klimov, AI Cox, NJ Shaw, MW AF Jernigan, D. B. Lindstrom, S. L. Johnson, J. R. Miller, J. D. Hoelscher, M. Humes, R. Shively, R. Brammer, L. Burke, S. A. Villanueva, J. M. Balish, A. Uyeki, T. Mustaquim, D. Bishop, A. Handsfield, J. H. Astles, R. Xu, X. Klimov, A. I. Cox, N. J. Shaw, M. W. TI Detecting 2009 Pandemic Influenza A (H1N1) Virus Infection: Availability of Diagnostic Testing Led to Rapid Pandemic Response SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; HUMANS; SENSITIVITY; PERFORMANCE; CALIFORNIA AB Diagnostic tests for detecting emerging influenza virus strains with pandemic potential are critical for directing global influenza prevention and control activities. In 2008, the Centers for Disease Control and Prevention received US Food and Drug Administration approval for a highly sensitive influenza polymerase chain reaction (PCR) assay. Devices were deployed to public health laboratories in the United States and globally. Within 2 weeks of the first recognition of 2009 pandemic influenza H1N1, the Centers for Disease Control and Prevention developed and began distributing a new approved pandemic influenza H1N1 PCR assay, which used the previously deployed device platform to meet a > 8-fold increase in specimen submissions. Rapid antigen tests were widely used by clinicians at the point of care; however, test sensitivity was low (40%-69%). Many clinical laboratories developed their own pandemic influenza H1N1 PCR assays to meet clinician demand. Future planning efforts should identify ways to improve availability of reliable testing to manage patient care and approaches for optimal use of molecular testing for detecting and controlling emerging influenza virus strains. C1 [Jernigan, D. B.; Lindstrom, S. L.; Miller, J. D.; Hoelscher, M.; Brammer, L.; Balish, A.; Uyeki, T.; Mustaquim, D.; Bishop, A.; Xu, X.; Klimov, A. I.; Cox, N. J.; Shaw, M. W.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Handsfield, J. H.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Enter Zoonot & Infect Dis, Atlanta, GA 30333 USA. [Astles, R.] Ctr Dis Control & Prevent, Div Lab Sci & Stand, Off Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. [Johnson, J. R.; Burke, S. A.; Villanueva, J. M.] Battelle CDC Operat, Atlanta, GA USA. [Humes, R.] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Shively, R.] US Dept HHS, Biomed Adv Res & Dev Author, Washington, DC 20201 USA. RP Jernigan, DB (reprint author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Mailstop A-20,1600 Clifton Rd, Atlanta, GA 30333 USA. EM dbj0@cdc.gov FU Centers for Disease Controla and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," which was sponsored by the Centers for Disease Controla and Prevention. NR 39 TC 42 Z9 43 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S36 EP S43 DI 10.1093/cid/ciq020 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500006 PM 21342897 ER PT J AU Jhung, MA Swerdlow, D Olsen, SJ Jernigan, D Biggerstaff, M Kamimoto, L Kniss, K Reed, C Fry, A Brammer, L Gindler, J Gregg, WJ Bresee, J Finelli, L AF Jhung, Michael A. Swerdlow, David Olsen, Sonja J. Jernigan, Daniel Biggerstaff, Matthew Kamimoto, Laurie Kniss, Krista Reed, Carrie Fry, Alicia Brammer, Lynnette Gindler, Jacqueline Gregg, William J. Bresee, Joseph Finelli, Lyn TI Epidemiology of 2009 Pandemic Influenza A (H1N1) in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID NEW-YORK-CITY; CRITICALLY-ILL PATIENTS; APRIL-MAY 2009; PREGNANT-WOMEN; VIRUS-INFECTIONS; HOUSEHOLD TRANSMISSION; HOSPITALIZED-PATIENTS; RESPIRATORY ILLNESS; SEASONAL INFLUENZA; POSTPARTUM WOMEN AB In April 2009, the Centers for Disease Control and Prevention confirmed 2 cases of 2009 pandemic influenza A (H1N1) virus infection in children from southern California, marking the beginning of what would be the first influenza pandemic of the twenty-first century. This report describes the epidemiology of the 2009 H1N1 pandemic in the United States, including characterization of cases, fluctuations of disease burden over the course of a year, the age distribution of illness and severe outcomes, and estimation of the overall burden of disease. C1 [Jhung, Michael A.; Jernigan, Daniel; Biggerstaff, Matthew; Kamimoto, Laurie; Kniss, Krista; Reed, Carrie; Fry, Alicia; Brammer, Lynnette; Gregg, William J.; Bresee, Joseph; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Swerdlow, David] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Off Director, Atlanta, GA USA. [Olsen, Sonja J.] Ctr Dis Control & Prevent, Div Emerging Infect & Surveillance Serv, Atlanta, GA USA. RP Jhung, MA (reprint author), 1600 Clifton Rd,MS-A32, Atlanta, GA 30333 USA. EM mjhung@cdc.gov RI Chiang, Vincent, Ming-Hsien/D-4312-2016 OI Chiang, Vincent, Ming-Hsien/0000-0002-2029-7863 FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 79 TC 72 Z9 72 U1 0 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S13 EP S26 DI 10.1093/cid/ciq008 PG 14 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500004 PM 21342884 ER PT J AU Kasowski, EJ Garten, RJ Bridges, CB AF Kasowski, Eric J. Garten, Rebecca J. Bridges, Carolyn B. TI Influenza Pandemic Epidemiologic and Virologic Diversity: Reminding Ourselves of the Possibilities SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HONG-KONG INFLUENZA; A H1N1 INFECTION; UNITED-STATES; ASIAN INFLUENZA; VIRUS; SWINE; MORTALITY; EVOLUTION; IMMUNITY; ORIGIN AB The 2009 influenza A (H1N1) pandemic serves as a stark reminder of the inherently unpredictable nature of influenza virus. Although most planning centered on the potential emergence of a wholly new influenza A subtype of avian origin causing the next pandemic, a very different scenario occurred: a mammalian-adapted reassortant drift variant of a familiar subtype caused the first pandemic of the 21st Century. This pandemic also reminds us of the variability possible with respect to the epidemiology of pandemic influenza, the effects of population immunity to novel influenza strains on age-specific morbidity and mortality, and the potential importance of domestic animals in the ecology of influenza and the formation of new virus strains with pandemic potential. Future pandemic preparedness planning should include addressing gaps in influenza surveillance among nonhuman mammalian species at the animal human interface as part of pandemic risk assessment. C1 [Kasowski, Eric J.; Garten, Rebecca J.; Bridges, Carolyn B.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Kasowski, EJ (reprint author), 1600 Clifton Rd,MS-A20, Atlanta, GA 30333 USA. EM isg2@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 45 TC 25 Z9 25 U1 0 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S44 EP S49 DI 10.1093/cid/ciq010 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500007 PM 21342899 ER PT J AU Loustalot, F Silk, BJ Gaither, A Shim, T Lamias, M Dawood, F Morgan, OW Fishbein, D Guerra, S Verani, JR Carlson, SA Fonseca, VP Olsen, SJ AF Loustalot, Fleetwood Silk, Benjamin J. Gaither, Amber Shim, Trudi Lamias, Mark Dawood, Fatimah Morgan, Oliver W. Fishbein, Daniel Guerra, Sandra Verani, Jennifer R. Carlson, Susan A. Fonseca, Vincent P. Olsen, Sonja J. TI Household Transmission of 2009 Pandemic Influenza A (H1N1) and Nonpharmaceutical Interventions among Households of High School Students in San Antonio, Texas SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID VIRUS; AGE AB San Antonio, Texas, was one of the first metropolitan areas where 2009 pandemic influenza A (H1N1) virus (pH1N1) was detected. Identification of laboratory-confirmed pH1N1 in 2 students led to a preemptive 8-day closure of their high school. We assessed transmission of pH1N1 and changes in adoption of nonpharmaceutical interventions (NPIs) within households of students attending the affected school. Household secondary attack rates were 3.7% overall and 9.1% among those 0-4 years of age. Widespread adoption of NPIs was reported among household members. Respondents who viewed pH1N1 as very serious were more likely to adopt certain NPIs than were respondents who viewed pH1N1 as not very serious. NPIs may complement influenza vaccine prevention programs or be the only line of defense when pandemic vaccine is unavailable. The 2009 pandemic provided a unique opportunity to study NPIs, and these real-world experiences provide much-needed data to inform pandemic response policy. C1 [Loustalot, Fleetwood; Silk, Benjamin J.; Dawood, Fatimah] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30341 USA. [Loustalot, Fleetwood; Carlson, Susan A.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Silk, Benjamin J.; Verani, Jennifer R.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA 30341 USA. [Gaither, Amber] Ctr Dis Control & Prevent, James A Ferguson Emerging Infect Dis Fellowship, Atlanta, GA 30341 USA. [Lamias, Mark] Ctr Dis Control & Prevent, Natl Ctr Preparedness Detect & Control Infect Dis, Atlanta, GA 30341 USA. [Dawood, Fatimah] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30341 USA. [Morgan, Oliver W.; Olsen, Sonja J.] Ctr Dis Control & Prevent, Div Emerging Infect & Surveillance Serv, Atlanta, GA 30341 USA. [Fishbein, Daniel] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30341 USA. [Shim, Trudi; Guerra, Sandra] Dept State Hlth Serv, San Antonio, TX USA. [Fonseca, Vincent P.] Dept State Hlth Serv, Austin, TX USA. RP Loustalot, F (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, 4770 Buford Hwy NE,MS K-47, Atlanta, GA 30341 USA. EM floustalot@cdc.gov RI Valle, Ruben/A-7512-2013 FU San Antonio community; Centers for Disease Control and Prevention FX We thank the local and state public health and school officials as well as the San Antonio community for their support of this project. The technical expertise of John Stamper and Angela Austin during the development of the internet questionnaire is greatly appreciated. We also thank Dr. Fernando Guerra and Dr. Bryan Alsip of the San Antonio Metropolitan Health Department for their support. The project was possible only through the responsiveness of volunteer interviewers, including Yusra K. Ahmad, Karen Arrowood, Charisma Y. Atkins, A. Elizabeth Barrera, Mary E. Bartlett, Shareeta M. Carter-Garrett, Sue Casteel, Georgina D. Castro, Blanche C. Collins, Helene M. Doleyres, Geneva M. Edwards, Jameelah Franklin, Patricia Hall, Kathy D. Hemphill, Sulma J. Herrera, Reyna L. Jones, Heather A. Joseph, Laura Kearns, Kimberly Miller, Cedric V. Lane, James Lee, Allison J. Lentz, Brittany L. Littlejohn, Christine Mitchell, Helen Perry, Vincent Radke, Joanna Regan, Cerise D. Robinson, Michelle A. Rose, Nicholas Schaad, Meera V. Sreenivasan, Karrie-Ann Toews, Twanda Wadlington, Frankie H. White, and Wendy Worthington.; Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 17 TC 15 Z9 15 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S146 EP S153 DI 10.1093/cid/ciq057 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500021 PM 21342887 ER PT J AU Lucas, PM Morgan, OW Gibbons, TF Guerrero, AC Maupin, GM Butler, JL Canas, LC Fonseca, VP Olsen, SJ MacIntosh, VH AF Lucas, Pauline M. Morgan, Oliver W. Gibbons, Thomas F. Guerrero, Alicia C. Maupin, Genny M. Butler, Jenny L. Canas, Linda C. Fonseca, Vincent P. Olsen, Sonja J. MacIntosh, Victor H. TI Diagnosis of 2009 Pandemic Influenza A (pH1N1) and Seasonal Influenza Using Rapid Influenza Antigen Tests, San Antonio, Texas, April-June 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; H1N1 VIRUS; B VIRUSES; SURVEILLANCE; SENSITIVITY; CULTURE AB Clinicians frequently use influenza rapid antigen tests for diagnostic testing. We tested nasal wash samples from 1 April to 7 June 2009 from 1538 patients using the QuickVue Influenza A+B (Quidel) rapid influenza antigen test and compared the results with real-time reverse transcription polymerase chain reaction (rRT-PCR) assay (gold standard). The prevalence of 2009 pandemic influenza A (pH1N1) was 1.98%, seasonal influenza type A .87%, and seasonal influenza type B 2.07%. The sensitivity and specificity of the rapid test for pH1N1 was 20% (95% CI, 8-39) and 99% (95% CI, 98-99), for seasonal influenza type A 15% (95% CI, 2-45) and 99% (95% CI, 98-99), and for influenza type B was 31% (95% CI, 9-61) and 99% (95% CI, 98-99.7). Rapid influenza antigen tests were of limited use at a time when the prevalence of pH1N1 and seasonal influenza in the United States was low. Clinicians should instead rely on clinical impression and laboratory diagnosis by rRT-PCR. C1 [MacIntosh, Victor H.] USAF, Sch Aerosp Med, Epidemiol Consult Serv, Dept Def Global Lab Based Influenza Surveillance, Brooks City Base, TX 78235 USA. [Morgan, Oliver W.; Olsen, Sonja J.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Atlanta, GA USA. [Fonseca, Vincent P.] Texas Dept State Hlth Serv, Austin, TX USA. [Guerrero, Alicia C.; Butler, Jenny L.] Conceptual Mind Works, San Antonio, TX USA. [Maupin, Genny M.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP MacIntosh, VH (reprint author), USAF, Sch Aerosp Med, Epidemiol Consult Serv, Dept Def Global Lab Based Influenza Surveillance, 2513 Kennedy Cir,Bldg 180, Brooks City Base, TX 78235 USA. EM omorgan@cdc.gov; victor.macintosh@us.af.mil FU Unites States Air Force School of Aerospace Medicine; Global Emerging Infections Surveillance and Response System; Armed Forces Health Surveillance Center; Centers for Disease Control and Prevention FX Unites States Air Force School of Aerospace Medicine; Global Emerging Infections Surveillance and Response System; Armed Forces Health Surveillance Center.; Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 27 TC 19 Z9 19 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S116 EP S122 DI 10.1093/cid/ciq027 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500017 PM 21342882 ER PT J AU Marchbanks, TL Bhattarai, A Fagan, RP Ostroff, S Sodha, SV Moll, ME Lee, BY Chang, CCH Ennis, B Britz, P Fiore, A Nguyen, M Palekar, R Archer, WR Gift, TL Leap, R Nygren, BL Cauchemez, S Angulo, FJ Swerdlow, D AF Marchbanks, Tiffany L. Bhattarai, Achuyt Fagan, Ryan P. Ostroff, Stephen Sodha, Samir V. Moll, Maria E. Lee, Bruce Y. Chang, Chung-Chou H. Ennis, Brent Britz, Phyllis Fiore, Anthony Nguyen, Michael Palekar, Rakhee Archer, W. Roodly Gift, Thomas L. Leap, Rebecca Nygren, Benjamin L. Cauchemez, Simon Angulo, Frederick J. Swerdlow, David CA Penn Working Grp TI An Outbreak of 2009 Pandemic Influenza A (H1N1) Virus Infection in an Elementary School in Pennsylvania SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID TRANSMISSION; VACCINE AB In May 2009, one of the earliest outbreaks of 2009 pandemic influenza A virus (pH1N1) infection resulted in the closure of a semi-rural Pennsylvania elementary school. Two sequential telephone surveys were administered to 1345 students (85% of the students enrolled in the school) and household members in 313 households to collect data on influenza-like illness (ILI). A total of 167 persons (12.4%) among those in the surveyed households, including 93 (24.0%) of the School A students, reported ILI. Students were 3.1 times more likely than were other household members to develop ILI (95% confidence interval [CI], 2.3-4.1). Fourth-grade students were more likely to be affected than were students in other grades (relative risk, 2.2; 95% CI, 1.2-3.9). pH1N1 was confirmed in 26 (72.2%) of the individuals tested by real-time reverse-transcriptase polymerase chain reaction. The outbreak did not resume upon the reopening of the school after the 7-day closure. This investigation found that pH1N1 outbreaks at schools can have substantial attack rates; however, grades and classrooms are affected variably. Additioanl study is warranted to determine the effectiveness of school closure during outbreaks. C1 [Marchbanks, Tiffany L.] Ctr Dis Control & Prevent, Council State & Territorial Epidemiologists Appl, Penn Dept Hlth, Harrisburg, PA 17108 USA. [Bhattarai, Achuyt; Fagan, Ryan P.; Sodha, Samir V.; Fiore, Anthony; Nguyen, Michael; Palekar, Rakhee; Archer, W. Roodly; Gift, Thomas L.; Leap, Rebecca; Nygren, Benjamin L.; Angulo, Frederick J.; Swerdlow, David] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lee, Bruce Y.; Chang, Chung-Chou H.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA. [Lee, Bruce Y.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Lee, Bruce Y.] Univ Pittsburgh, Dept Biomed Informat, Pittsburgh, PA USA. [Chang, Chung-Chou H.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Cauchemez, Simon] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, Ctr Outbreak Anal & Modelling, London, England. RP Marchbanks, TL (reprint author), St Louis Cty Dept Hlth, Div Communicable Dis Control, 111 S Meramec Ave, Clayton, MO 63105 USA. EM tmarchbanks@stlouisco.com RI Bhattarai, Achuyt/B-8760-2008; OI Bhattarai, Achuyt/0000-0002-0514-4850; Ayers, Tracy/0000-0003-4140-3263 FU Applied Epidemiology; Centers for Disease Control and Prevention (CDC) [U60/CCU007277]; Centers for Disease Control and Prevention; Sanofi Pasteur FX Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists and funded by the Centers for Disease Control and Prevention (CDC) Cooperative Agreement U60/CCU007277 (to T.L.M.).; Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention.; S.C. has received consulting fees from Sanofi Pasteur for advising them on modelling the spread of varicella and varicella herpes zoster. All other authors: no conflicts. NR 21 TC 12 Z9 13 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S154 EP S160 DI 10.1093/cid/ciq058 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500022 PM 21342888 ER PT J AU Mitchell, T Dee, DL Phares, CR Lipman, HB Gould, LH Kutty, P Desai, M Guh, A Iuliano, AD Silverman, P Siebold, J Armstrong, GL Swerdlow, DL Massoudi, MS Fishbein, DB AF Mitchell, Tarissa Dee, Deborah L. Phares, Christina R. Lipman, Harvey B. Gould, L. Hannah Kutty, Preeta Desai, Mitesh Guh, Alice Iuliano, A. Danielle Silverman, Paul Siebold, Joseph Armstrong, Gregory L. Swerdlow, David L. Massoudi, Mehran S. Fishbein, Daniel B. TI Non-Pharmaceutical Interventions during an Outbreak of 2009 Pandemic Influenza A (H1N1) Virus Infection at a Large Public University, April-May 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID COMMUNICATION; TRANSMISSION AB Nonpharmaceutical interventions (NPIs), such as home isolation, social distancing, and infection control measures, are recommended by public health agencies as strategies to mitigate transmission during influenza pandemics. However, NPI implementation has rarely been studied in large populations. During an outbreak of 2009 Pandemic Influenza A (H1N1) virus infection at a large public university in April 2009, an online survey was conducted among students, faculty, and staff to assess knowledge of and adherence to university-recommended NPI. Although 3924 (65%) of 6049 student respondents and 1057 (74%) of 1401 faculty respondents reported increased use of self-protective NPI, such as hand washing, only 27 (6.4%) of 423 students and 5 (8.6%) of 58 faculty with acute respiratory infection (ARI) reported staying home while ill. Nearly one-half (46%) of student respondents, including 44.7% of those with ARI, attended social events. Results indicate a need for efforts to increase compliance with home isolation and social distancing measures. C1 [Mitchell, Tarissa] Ctr Dis Control & Prevent, Immigrant Refugee & Migrant Hlth Branch, Atlanta, GA 30329 USA. [Siebold, Joseph] Univ Delaware, Student Hlth Serv, Newark, DE 19716 USA. [Silverman, Paul] Delaware Hlth & Social Serv, Div Publ Hlth, Dover, DE USA. RP Mitchell, T (reprint author), Ctr Dis Control & Prevent, Immigrant Refugee & Migrant Hlth Branch, 1600 Clifton Rd NE,Mailstop E-03, Atlanta, GA 30329 USA. EM tmitchell1@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 18 TC 19 Z9 19 U1 1 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S138 EP S145 DI 10.1093/cid/ciq056 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500020 PM 21342886 ER PT J AU Peters, PJ Skarbinski, J Louie, JK Jain, S Roland, M Jani, SG Finelli, L Brooks, JT AF Peters, Philip J. Skarbinski, Jacek Louie, Janice K. Jain, Seema Roland, Michelle Jani, Shilpa G. Finelli, Lyn Brooks, John T. CA New York City Dept Hlth TI HIV-Infected Hospitalized Patients with 2009 Pandemic Influenza A (pH1N1)-United States, Spring and Summer 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMMUNIZATION PRACTICES ACIP; ADVISORY-COMMITTEE; UNITED-STATES; RECOMMENDATIONS; A(H1N1); WOMEN; VACCINATION; PREVENTION; MORTALITY AB We describe the clinical findings of HIV-infected patients hospitalized with 2009 pandemic influenza A (pH1N1). Data were derived from 3 separate case series in the United States. Among 911 adults hospitalized with pH1N1 influenza, 31 (3.4%) were HIV infected compared with an HIV prevalence of 0.45% in the general US adult population. HIV-infected influenza patients experienced similar rates of intensive care unit admission (29% vs 34%) and death (13% vs 13%) compared with non-HIV-infected patients. Among HIV-infected patients with available data, 14 (50%) of 28 patients had a CD4 cell count < 200 cells/mu L, which was not associated with an increased risk of an intensive care unit admission or death. Overall, 25 (81%) HIV-infected patients received influenza antiviral therapy, but treatment was initiated within 48 h of illness onset in only 33% of cases. Clinicians should consider early empiric influenza antiviral treatment in HIV-infected patients presenting with suspected influenza. C1 [Peters, Philip J.; Skarbinski, Jacek; Jain, Seema; Finelli, Lyn; Brooks, John T.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Louie, Janice K.; Jani, Shilpa G.] Calif Dept Publ Hlth, Richmond, CA USA. [New York City Dept Hlth] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Roland, Michelle] Calif Dept Publ Hlth, Sacramento, CA USA. RP Peters, PJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E-45, Atlanta, GA 30333 USA. EM pjpeters@cdc.gov RI Andrade, Hugo/M-6631-2013 OI Andrade, Hugo/0000-0001-6781-6125 FU California Department of Public Health; New York City Department of Health; CDC; Centers for Disease Control and Prevention FX This publication was made possible by support from the California Department of Public Health, the New York City Department of Health, and the CDC.; Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 30 TC 12 Z9 12 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S183 EP S188 DI 10.1093/cid/ciq036 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500027 PM 21342893 ER PT J AU Reed, C Angulo, FJ Biggerstaff, M Swerdlow, D Finelli, L AF Reed, Carrie Angulo, Frederick J. Biggerstaff, Matthew Swerdlow, David Finelli, Lyn TI Influenza-Like Illness in the Community during the Emergence of 2009 Pandemic Influenza A(H1N1) - Survey of 10 States, April 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID TELEPHONE SURVEY; UNITED-STATES AB Following the emergence of 2009 pandemic influenza A(H1N1) virus (pH1N1) in the United States, the incidence of pH1N1 in the community was unclear, because not all persons with influenza come to medical attention. To better estimate the incidence of pH1N1 in the community early in the pandemic, a telephone survey was conducted in 10 states. The community incidence of influenza-like illness in April 2009 was 4.7 per 100 adults (95% confidence interval: 2.8-6.6); half of adults reported seeking medical care for their illness. Such surveys may be important tools for assessing the level of illness in the general population, including those who do not seek medical care and are thus not captured using traditional surveillance methods. C1 [Reed, Carrie; Biggerstaff, Matthew; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Angulo, Frederick J.; Swerdlow, David] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Reed, C (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. EM creed1@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 11 TC 9 Z9 10 U1 1 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S90 EP S93 DI 10.1093/cid/ciq024 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500013 PM 21342906 ER PT J AU Schuchat, A Bell, BP Redd, SC AF Schuchat, Anne Bell, Beth P. Redd, Stephen C. TI The Science behind Preparing and Responding to Pandemic Influenza: The Lessons and Limits of Science SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID A H1N1 VIRUS; UNITED-STATES; MF59-ADJUVANTED VACCINE; JUNE 2009; CALIFORNIA; A(H1N1); HEALTH; TRIAL; H5N1 AB A strong evidence base provides the foundation for planning and response strategies. Investments in pandemic preparedness included support for research that aided early detection, response, and control of the 2009 influenza A (H1N1) (pH1N1) pandemic. Scientific investigations conducted during the pandemic guided understanding of the virus, disease severity, and epidemiologic risk factors. Field investigations also produced information that strengthened guidance for the use of antivirals, identification of target populations for monovalent pH1N1 vaccine, and refinement of recommendations for social distancing measures. Communication of this evolving evidence base was important to sustaining credibility of public health. Areas where substantial controversy emerged, such as the optimal approach to respiratory protection of healthcare workers, often suffered from gaps in the evidence base. Many aspects of the 2009-2010 pandemic influenza experience provide ongoing opportunities for additional study, which will strengthen plans for future pandemic response as well as control of seasonal influenza. C1 [Schuchat, Anne; Bell, Beth P.; Redd, Stephen C.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Schuchat, A (reprint author), 1600 Clifton Rd,Mailstop E-05, Atlanta, GA 30333 USA. EM aschuchat@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 32 TC 17 Z9 17 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S8 EP S12 DI 10.1093/cid/ciq007 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500003 PM 21342904 ER PT J AU Shrestha, SS Swerdlow, DL Borse, RH Prabhu, VS Finelli, L Atkins, CY Owusu-Edusei, K Bell, B Mead, PS Biggerstaff, M Brammer, L Davidson, H Jernigan, D Jhung, MA Kamimoto, LA Merlin, TL Nowell, M Redd, SC Reed, C Schuchat, A Meltzer, MI AF Shrestha, Sundar S. Swerdlow, David L. Borse, Rebekah H. Prabhu, Vimalanand S. Finelli, Lyn Atkins, Charisma Y. Owusu-Edusei, Kwame Bell, Beth Mead, Paul S. Biggerstaff, Matthew Brammer, Lynnette Davidson, Heidi Jernigan, Daniel Jhung, Michael A. Kamimoto, Laurie A. Merlin, Toby L. Nowell, Mackenzie Redd, Stephen C. Reed, Carrie Schuchat, Anne Meltzer, Martin I. TI Estimating the Burden of 2009 Pandemic Influenza A (H1N1) in the United States (April 2009-April 2010) SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID VIRUS AB To calculate the burden of 2009 pandemic influenza A (pH1N1) in the United States, we extrapolated from the Centers for Disease Control and Prevention's Emerging Infections Program laboratory-confirmed hospitalizations across the entire United States, and then corrected for underreporting. From 12 April 2009 to 10 April 2010, we estimate that approximately 60.8 million cases (range: 43.3-89.3 million), 274 304 hospitalizations (195 086-402 719), and 12 469 deaths (8868-18 306) occurred in the United States due to pH1N1. Eighty-seven percent of deaths occurred in those under 65 years of age with children and working adults having risks of hospitalization and death 4 to 7 times and 8 to 12 times greater, respectively, than estimates of impact due to seasonal influenza covering the years 1976-2001. In our study, adults 65 years of age or older were found to have rates of hospitalization and death that were up to 75% and 81%, respectively, lower than seasonal influenza. These results confirm the necessity of a concerted public health response to pH1N1. C1 [Shrestha, Sundar S.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Swerdlow, David L.; Bell, Beth; Schuchat, Anne] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Off Director, Atlanta, GA USA. [Borse, Rebekah H.; Atkins, Charisma Y.; Meltzer, Martin I.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Atlanta, GA USA. [Prabhu, Vimalanand S.] Ctr Dis Control & Prevent, Div Global HIV AIDs, Atlanta, GA USA. [Finelli, Lyn; Biggerstaff, Matthew; Brammer, Lynnette; Davidson, Heidi; Jernigan, Daniel; Jhung, Michael A.; Kamimoto, Laurie A.; Nowell, Mackenzie; Reed, Carrie] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Owusu-Edusei, Kwame] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. [Mead, Paul S.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Atlanta, GA USA. [Merlin, Toby L.; Redd, Stephen C.] Ctr Dis Control & Prevent, Off Infect Dis, Atlanta, GA USA. RP Meltzer, MI (reprint author), Ctr Dis Control & Prevent CDC, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM qzm4@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 11 TC 138 Z9 138 U1 1 U2 10 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S75 EP S82 DI 10.1093/cid/ciq012 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500011 PM 21342903 ER PT J AU Skarbinski, J Jain, S Bramley, A Lee, EJ Huang, JA Kirschke, D Stone, A Wedlake, T Richards, SM Page, S Ragan, P Bullion, L Neises, D Williams, RM Petruccelli, BP Vandermeer, M Lofy, KH Gindler, J Finelli, L AF Skarbinski, Jacek Jain, Seema Bramley, Anna Lee, Esther J. Huang, Jean Kirschke, David Stone, Allison Wedlake, Tiffany Richards, Shawn M. Page, Shannon Ragan, Patti Bullion, Lesley Neises, Daniel Williams, Robin M. Petruccelli, Bruno P. Vandermeer, Meredith Lofy, Kathryn H. Gindler, Jacqueline Finelli, Lyn CA 2009 Pandemic Influenza A H1N1 Virus Fall Hosp Invest Team TI Hospitalized Patients with 2009 Pandemic Influenza A (H1N1) Virus Infection in the United States-September-October 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID PREGNANT-WOMEN; SEASONAL INFLUENZA; CHILDREN; COMPLICATIONS; SURVEILLANCE; ADMISSIONS; CALIFORNIA; EMERGENCE; DEATHS; HUMANS AB Given the potential worsening clinical severity of 2009 pandemic influenza A (H1N1) virus (pH1N1) infection from spring to fall 2009, we conducted a clinical case series among patients hospitalized with pH1N1 infection from September through October 2009. A case patient was defined as a hospitalized person who had test results positive for pH1N1 virus by real-time reverse-transcription polymerase chain reaction. Among 255 hospitalized patients, 34% were admitted to an intensive care unit and 8% died. Thirty-four percent of patients were children < 18 years of age, 8% were adults >= 65 years of age, and 67% had an underlying medical condition. Chest radiographs obtained at hospital admission that had findings that were consistent with pneumonia were noted in 103 (46%) of 255 patients. Among 255 hospitalized patients, 208 (82%) received neuraminidase inhibitors, but only 47% had treatment started < 2 days after illness onset. Overall, characteristics of hospitalized patients with pH1N1 infection in fall 2009 were similar to characteristics of patients hospitalized with pH1N1 infection in spring 2009, which suggests that clinical severity did not change substantially over this period. C1 [Skarbinski, Jacek; Gindler, Jacqueline] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Skarbinski, Jacek] Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA USA. [Jain, Seema; Bramley, Anna; Lee, Esther J.; Huang, Jean; 2009 Pandemic Influenza A H1N1 Virus Fall Hosp Invest Team] Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA. [Gindler, Jacqueline] Div Birth Defects & Dev Disabil, Atlanta, GA USA. [Kirschke, David] Tennessee Dept Hlth, Nashville, TN USA. [Stone, Allison] Calif Dept Publ Hlth, Richmond, CA USA. [Wedlake, Tiffany] Univ N Carolina, Dept Social Med, Chapel Hill, NC USA. [Richards, Shawn M.] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. [Page, Shannon] Ohio Dept Hlth, Columbus, OH 43266 USA. [Ragan, Patti] Florida Dept Hlth Bur Epidemiol, Tallahassee, FL USA. [Bullion, Lesley] Texas Dept State Hlth Serv, Austin, TX USA. [Neises, Daniel] Kansas Dept Hlth & Environm, Topeka, KS USA. [Williams, Robin M.] Nebraska Dept Hlth & Human Serv, Lincoln, NE USA. [Petruccelli, Bruno P.] Penn Dept Hlth, Harrisburg, PA 17108 USA. [Vandermeer, Meredith] Oregon Publ Hlth Div, Portland, OR USA. [Lofy, Kathryn H.] Washington State Dept Hlth, Shoreline, WA USA. RP Skarbinski, J (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS-F22, Atlanta, GA 30341 USA. EM jskarbinski@cdc.gov FU Influenza Division at the Centers for Disease Control; Centers for Disease Control and Prevention FX The Influenza Division at the Centers for Disease Control.; Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 45 TC 49 Z9 50 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S50 EP S59 DI 10.1093/cid/ciq021 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500008 PM 21342900 ER PT J AU Sugerman, D Nadeau, KH Lafond, K Cameron, W Soetebier, K Jhung, M Isakov, A Greenwald, I Neil, K Schrag, S Fry, A AF Sugerman, David Nadeau, Kelly H. Lafond, Kathryn Cameron, Wendy Soetebier, Karl Jhung, Michael Isakov, Alexander Greenwald, Ian Neil, Karen Schrag, Stephanie Fry, Alicia TI A Survey of Emergency Department 2009 Pandemic Influenza A (H1N1) Surge Preparedness-Atlanta, Georgia, July-October 2009 SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID LENGTH-OF-STAY; DISASTER PREPAREDNESS; LOS-ANGELES; CAPACITY AB During August through September 2009, a surge in emergency department (ED) visits for 2009 pandemic influenza A (pH1N1) illness occurred in Georgia, particularly among children. To understand surge preparedness and capacity, we obtained influenza-like illness (ILI) ED visit data from the Georgia State Electronic Notifiable Disease Surveillance System (SendSS) and conducted a retrospective, Internet-based survey among all 26 metro Atlanta ED managers with reference to the period 1 July-1 October 2009. SendSS detected a marked and progressive increase in mean monthly ILI visits from 1 July-1 October 2009, which more than tripled (from 399 to 2196) for the 2 participating EDs that cared for pediatric patients during this time. ED managers reported patient volume surges, resulting in space and supply limitations, especially at pediatric EDs. Most (92%) of the facilities had current pandemic influenza plans. Pandemic planning can help to ensure preparedness for natural and man-made disasters and for future influenza pandemics. C1 [Sugerman, David] Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Lafond, Kathryn; Jhung, Michael; Fry, Alicia] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Neil, Karen] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Soetebier, Karl; Schrag, Stephanie] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Nadeau, Kelly H.] Emory Univ, Georgia Dept Community Hlth, Div Emergency Preparedness & Response, Atlanta, GA 30322 USA. [Cameron, Wendy] Emory Univ, Hlth Informat Syst Sect, Off Epidemiol Evaluat & Hlth Informat, Div Publ Hlth,Georgia Dept Human Resources, Atlanta, GA 30322 USA. [Isakov, Alexander] Emory Univ, Off Crit Event Preparedness & Response, Atlanta, GA 30322 USA. [Greenwald, Ian] Duke Preparedness & Response Ctr, Durham, NC USA. RP Sugerman, D (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop E-05, Atlanta, GA 30333 USA. EM ggi4@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 22 TC 6 Z9 6 U1 1 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S177 EP S182 DI 10.1093/cid/ciq035 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500026 PM 21342892 ER PT J AU Suryaprasad, A Morgan, OW Peebles, P Warner, A Kerin, TK Esona, MD Bowen, MD Sessions, W Xu, XY Cromeans, T Dawood, F Shim, T Menon, M Verani, JR Erdman, D Lindstrom, S Fonseca, VP Fry, AM Olsen, SJ AF Suryaprasad, Anil Morgan, Oliver W. Peebles, Patrick Warner, Agnes Kerin, Tara K. Esona, Mathew D. Bowen, Michael D. Sessions, Wendy Xu, Xiyan Cromeans, Theresa Dawood, Fatimah Shim, Trudi Menon, Manoj Verani, Jennifer R. Erdman, Dean Lindstrom, Stephen Fonseca, Vincent P. Fry, Alicia M. Olsen, Sonja J. TI Virus Detection and Duration of Illness Among Patients With 2009 Pandemic Influenza A (H1N1) Virus Infection in Texas SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID NEURAMINIDASE INHIBITOR OSELTAMIVIR; RANDOMIZED CONTROLLED-TRIAL; ZANAMIVIR; EFFICACY; SAFETY; TRANSMISSION; CHILDREN AB Knowledge from early outbreaks is limited regarding the virus detection and illness duration of the 2009 pandemic influenza A (H1N1) infections. During the period from April to May 2009 in Texas, we collected serial nasopharyngeal (NP) and stool specimens from 35 participants, testing by real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) and culture. The participants were aged 2 months to 71 years; 25 (71%) were under 18. The median duration of measured fever was 3.0 days and of virus detection in NP specimens was 4.2 days; however, few specimens were collected between days 5-9. The duration of virus detection (4.2 days) was similar to the duration of fever (3.5 days) (RR, 1.14; 95% CI, .66-1.95; P = .8), but was shorter than the duration of cough (11.0 days) (RR, .41; 95% CI, .24-.68; P < .001). We detected viral RNA in two participants' stools. All cultures were negative. This investigation suggests that the duration of virus detection was likely similar to the seasonal influenza virus. C1 [Suryaprasad, Anil; Morgan, Oliver W.; Dawood, Fatimah] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off Proposed, Atlanta, GA 30333 USA. [Suryaprasad, Anil] Indian Hlth Serv, Div Epidemiol & Dis Prevent, Albuquerque, NM USA. [Morgan, Oliver W.; Olsen, Sonja J.] Ctr Dis Control & Prevent, Div Emerging Infect & Surveillance Serv, Natl Ctr Emerging & Zoonot Infect Dis Proposed, Atlanta, GA 30333 USA. [Peebles, Patrick; Bowen, Michael D.; Sessions, Wendy; Dawood, Fatimah; Lindstrom, Stephen; Fry, Alicia M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. [Warner, Agnes; Verani, Jennifer R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Atlanta, GA 30333 USA. [Kerin, Tara K.; Esona, Mathew D.; Xu, Xiyan; Cromeans, Theresa; Erdman, Dean] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Shim, Trudi; Fonseca, Vincent P.] Texas State Dept Hlth Serv, Austin, TX USA. [Menon, Manoj] Ctr Dis Control & Prevent, Natl Ctr Global Hlth Proposed, Div Parasit Dis, Atlanta, GA 30333 USA. RP Suryaprasad, A (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off Proposed, 1600 Clifton Rd,MS G-37, Atlanta, GA 30333 USA. EM asuryaprasad@cdc.gov FU Centers for Disease Control and Prevention; 395 Texas State Department of Health Services, San Antonio Metropolitan Health District FX The Centers for Disease Control and Prevention, 395 Texas State Department of Health Services, San Antonio Metropolitan Health District.; Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 27 TC 9 Z9 9 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S109 EP S115 DI 10.1093/cid/ciq014 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500016 PM 21342881 ER PT J AU Swerdlow, DL Finelli, L Bridges, CB AF Swerdlow, David L. Finelli, Lyn Bridges, Carolyn B. TI 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations in the United States at the Start of the First Pandemic of the 21(st) Century SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HUMANS; VIRUS AB In April, 2009, CDC identified a novel influenza A virus detected from 2 children with febrile respiratory illness in southern California. The virus quickly emerged and spread globally and by 5 May, confirmed cases had been reported from 41 US states and 21 countries worldwide. Since the virus had never been identified before, little was known about the characteristics of the virus and how the pandemic would progress-would it be severe, how efficient would viral transmission be, would transmission be sustainable, what would the spectrum of illness, factors associated with severe disease, and causes of death be, and what risk groups would be most affected? Field investigations and epidemiologic studies in the United States and elsewhere were critical in helping answer these questions and characterizing the virus and the pandemic. This supplement will report results from field and epidemiologic investigations conducted in the United States since April 2009. C1 [Finelli, Lyn; Bridges, Carolyn B.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Swerdlow, DL (reprint author), 1600 Clifton Rd,MS-A20, Atlanta, GA 30333 USA. EM dswerdlow@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 4 TC 16 Z9 16 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S1 EP S3 DI 10.1093/cid/ciq005 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500001 PM 21342879 ER PT J AU Wenger, JD Castrodale, LJ Bruden, DL Keck, JW Zulz, T Bruce, MG Fearey, DA McLaughlin, J Hurlburt, D Hummel, KB Kitka, S Bentley, S Thomas, TK Singleton, R Redd, JT Layne, L Cheek, JE Hennessy, TW AF Wenger, Jay D. Castrodale, Louisa J. Bruden, Dana L. Keck, James W. Zulz, Tammy Bruce, Michael G. Fearey, Donna A. McLaughlin, Joe Hurlburt, Debby Hummel, Kim Boyd Kitka, Sassa Bentley, Steve Thomas, Timothy K. Singleton, Rosalyn Redd, John T. Layne, Larry Cheek, James E. Hennessy, Thomas W. TI 2009 Pandemic Influenza A H1N1 in Alaska: Temporal and Geographic Characteristics of Spread and Increased Risk of Hospitalization among Alaska Native and Asian/Pacific Islander People SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; CHILDREN; INFECTION; ILLNESS AB Alaska Native people have suffered disproportionately from previous influenza pandemics. We evaluated 3 separate syndromic data sources to determine temporal and geographic patterns of spread of 2009 pandemic influenza A H1N1 (pH1N1) in Alaska, and reviewed records from persons hospitalized with pH1N1 disease in 3 areas in Alaska to characterize clinical and epidemiologic features of disease in Alaskans. A wave of pH1N1 disease swept through Alaska beginning in most areas in August or early September. In rural regions, where Alaska Native people comprise a substantial proportion of the population, disease occurred earlier than in other regions. Alaska Native people and Asian/Pacific Islanders (A/PI) were 2-4 times more likely to be hospitalized than whites. Alaska Native people and other minorities remain at high risk for early and substantial morbidity from pandemic influenza episodes. These findings should be integrated into plans for distribution and use of vaccine and antiviral agents. C1 [Wenger, Jay D.; Bruden, Dana L.; Keck, James W.; Zulz, Tammy; Bruce, Michael G.; Hurlburt, Debby; Hummel, Kim Boyd; Kitka, Sassa; Thomas, Timothy K.; Hennessy, Thomas W.] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK 99508 USA. [Castrodale, Louisa J.; Fearey, Donna A.; McLaughlin, Joe] Alaska Dept Hlth & Social Serv, Epidemiol Sect, Anchorage, AK USA. [Singleton, Rosalyn] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Keck, James W.; Bentley, Steve] Ctr Dis Control & Prevent, Off Workforce & Career Dev, Atlanta, GA USA. [Redd, John T.; Layne, Larry; Cheek, James E.] Indian Hlth Serv, Div Epidemiol & Dis Prevent, Albuquerque, NM USA. RP Wenger, JD (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM jdw2@cdc.gov FU Centers for Disease Control and Prevention FX Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 14 TC 10 Z9 10 U1 0 U2 1 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S189 EP S197 DI 10.1093/cid/ciq037 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500028 PM 21342894 ER PT J AU Wise, ME De Perio, M Halpin, J Jhung, M Magill, S Black, SR Gerber, SI Harriman, K Rosenberg, J Borlaug, G Finelli, L Olsen, SJ Swerdlow, DL Kallen, AJ AF Wise, Matthew E. De Perio, Marie Halpin, John Jhung, Michael Magill, Shelley Black, Stephanie R. Gerber, Susan I. Harriman, Kathleen Rosenberg, Jon Borlaug, Gwen Finelli, Lyn Olsen, Sonja J. Swerdlow, David L. Kallen, Alexander J. TI Transmission of Pandemic (H1N1) 2009 Influenza to Healthcare Personnel in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID PROTECTIVE EQUIPMENT; NOSOCOMIAL OUTBREAK; VIRUS; INFECTION AB After identification of pandemic 2009 influenza (pH1N1) in the United States, the Centers for Disease Control and Prevention (CDC) worked with state and local health officials to characterize infections among healthcare personnel (HCP). Detailed information, including likely routes of exposure, was reported for 70 HCP from 22 states. Thirty-five cases (50%) were classified as being infected in healthcare settings, 18 cases (26%) were considered to have been infected in community settings, and no definitive source was identified for 17 cases (24%). Of the 23 HCP infected by ill patients, only 20% reported using an N95 respirator or surgical mask during all encounters and more than half worked in outpatient clinics. In addition to community transmission, likely patient-to-HCP and HCP-to-HCP transmission were identified in healthcare settings, highlighting the need for comprehensive infection control strategies including administration of influenza vaccine, appropriate management of ill HCP, and adherence to infection control precautions. C1 [Wise, Matthew E.; Magill, Shelley; Kallen, Alexander J.] Ctr Dis Control & Prevent CDC, Div Healthcare Qual Promot, Atlanta, GA USA. [Halpin, John] Ctr Dis Control & Prevent CDC, Natl Inst Occupat Safety & Hlth, Atlanta, GA USA. [Jhung, Michael; Finelli, Lyn] Ctr Dis Control & Prevent CDC, Influenza Div, Atlanta, GA USA. [Olsen, Sonja J.] Ctr Dis Control & Prevent CDC, Div Emerging Infect & Surveillance Serv, Atlanta, GA USA. [Swerdlow, David L.] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [De Perio, Marie] CDC, Natl Inst Occupat Safety & Hlth, Cincinnati, OH USA. [Black, Stephanie R.; Gerber, Susan I.] Chicago Dept Publ Hlth, Chicago, IL USA. [Harriman, Kathleen; Rosenberg, Jon] Calif Dept Publ Hlth, Richmond, CA USA. [Borlaug, Gwen] Wisconsin Div Publ Hlth, Madison, WI USA. RP Wise, ME (reprint author), CDC, Div Healthcare Qual Promot, 1600 Clifton Rd,MS A-35, Atlanta, GA 30333 USA. EM cxx4@cdc.gov FU Centers for Disease Control and Prevention FX Supplement sponsorship. Published as part of a supplement entitled "The 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations," sponsored by the Centers for Disease Control and Prevention. NR 21 TC 25 Z9 25 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 1 PY 2011 VL 52 SU 1 BP S198 EP S204 DI 10.1093/cid/ciq038 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 706JK UT WOS:000286214500029 PM 21342895 ER PT J AU Feng, YY Xiao, LH AF Feng, Yaoyu Xiao, Lihua TI Zoonotic Potential and Molecular Epidemiology of Giardia Species and Giardiasis SO CLINICAL MICROBIOLOGY REVIEWS LA English DT Review ID FRAGMENT-LENGTH-POLYMORPHISM; POLYMERASE-CHAIN-REACTION; REAL-TIME PCR; INTESTINAL PROTOZOAN INFECTIONS; GLUTAMATE-DEHYDROGENASE GENE; PHOSPHATE ISOMERASE GENE; PRIMARY-SCHOOL CHILDREN; WEANED DAIRY CALVES; DAY-CARE-CENTERS; SAO-PAULO STATE AB Molecular diagnostic tools have been used recently in assessing the taxonomy, zoonotic potential, and transmission of Giardia species and giardiasis in humans and animals. The results of these studies have firmly established giardiasis as a zoonotic disease, although host adaptation at the genotype and subtype levels has reduced the likelihood of zoonotic transmission. These studies have also identified variations in the distribution of Giardia duodenalis genotypes among geographic areas and between domestic and wild ruminants and differences in clinical manifestations and outbreak potentials of assemblages A and B. Nevertheless, our efforts in characterizing the molecular epidemiology of giardiasis and the roles of various animals in the transmission of human giardiasis are compromised by the lack of case-control and longitudinal cohort studies and the sampling and testing of humans and animals living in the same community, the frequent occurrence of infections with mixed genotypes and subtypes, and the apparent heterozygosity at some genetic loci for some G. duodenalis genotypes. With the increased usage of multilocus genotyping tools, the development of next-generation subtyping tools, the integration of molecular analysis in epidemiological studies, and an improved understanding of the population genetics of G. duodenalis in humans and animals, we should soon have a better appreciation of the molecular epidemiology of giardiasis, the disease burden of zoonotic transmission, the taxonomy status and virulences of various G. duodenalis genotypes, and the ecology of environmental contamination. C1 [Feng, Yaoyu] E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Resource & Environm Engn, Shanghai 200237, Peoples R China. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA. RP Feng, YY (reprint author), E China Univ Sci & Technol, State Key Lab Bioreactor Engn, Sch Resource & Environm Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn; lxiao@cdc.gov RI Gough, Ethan/B-8633-2012; Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [30771881, 30928019, 81041078]; fundamental research funds for the Central Universities, China [WB0914044]; Shanghai Science and Technology Committee [09540704400]; State Key Laboratory of Veterinary Etiological Biology at the Lanzhou Veterinary Research Institute FX This work was supported in part by the National Natural Science Foundation of China (grant no. 30771881, 30928019, and 81041078); fundamental research funds for the Central Universities, China (grant no. WB0914044); the Shanghai Science and Technology Committee (grant no. 09540704400); and the State Key Laboratory of Veterinary Etiological Biology at the Lanzhou Veterinary Research Institute. NR 317 TC 266 Z9 283 U1 7 U2 54 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0893-8512 EI 1098-6618 J9 CLIN MICROBIOL REV JI Clin. Microbiol. Rev. PD JAN PY 2011 VL 24 IS 1 BP 110 EP 140 DI 10.1128/CMR.00033-10 PG 31 WC Microbiology SC Microbiology GA 705ZA UT WOS:000286178300004 PM 21233509 ER PT B AU Curtis, KM Tepper, NK Marchbanks, PA AF Curtis, Kathryn M. Tepper, Naomi K. Marchbanks, Polly A. BE Shoupe, D TI Contraceptive Use: Guidelines and Effectiveness SO CONTRACEPTION SE Gynecology in Practice LA English DT Article; Book Chapter ID CLINICAL-PRACTICE GUIDELINES; RATES C1 [Curtis, Kathryn M.; Tepper, Naomi K.; Marchbanks, Polly A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. RP Curtis, KM (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30333 USA. NR 19 TC 5 Z9 5 U1 1 U2 1 PU WILEY-BLACKWELL PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER, WEST SUSSEX PO19 8SQ, ENGLAND BN 978-1-4443-3351-0; 978-1-4443-4262-8 J9 GYNECOL PRACT PY 2011 BP 3 EP 12 PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA BA7DB UT WOS:000337466300003 ER PT J AU Logan, JE Crosby, AE Hamburger, ME AF Logan, J. E. Crosby, A. E. Hamburger, M. E. TI Suicidal Ideation, Friendships with Delinquents, Social and Parental Connectedness, and Differential Associations by Sex Findings Among High-Risk Pre/Early Adolescent Population SO CRISIS-THE JOURNAL OF CRISIS INTERVENTION AND SUICIDE PREVENTION LA English DT Article DE suicidal ideation; connectedness; gender differences; delinquent friends; parenting style ID PROTECTIVE-FACTORS; VIOLENCE PREVENTION; GENDER-DIFFERENCES; YOUTH; BEHAVIOR; STUDENTS; ATTEMPTERS; ABUSE; CARE AB Background: The association between suicidal ideation, friendships with delinquents, and social/parental connectedness among pre/early adolescents who reside in high-risk communities is poorly understood. Aims: This study examined among high-risk youths: (1) the association between suicidal ideation and having delinquent friends, school connectedness, social support, and different parenting styles (i.e., caring only, supervision only, caring with supervision); and, (2) the differential associations by sex. Methods: The associations were assessed among 2,598 pre/early adolescents using logistic regression. The analyses were adjusted for demographic, mental distress, illicit substance use, and peer/date violence victimization factors. The interaction terms determined differences by sex. Results: After adjusting for demographic factors and mental distress, suicidal ideation was positively associated with having delinquent friends; however, after factoring in illicit substance use and violence victimization, this association was negative for males. After adjusting for all factors, suicidal ideation was negatively associated with school connectedness and all parenting styles; however, the association between suicidal ideation and having parental caring with supervision was stronger for females. Conclusions: The results suggest the potential benefits of increasing school connectedness and improving parent-child interactions, particularly among females, and the potential benefits of violence and substance-abuse prevention strategies for youths, particularly males, connected with delinquent peers. C1 [Logan, J. E.; Crosby, A. E.; Hamburger, M. E.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Etiol & Surveillance Branch, Atlanta, GA 30341 USA. RP Logan, JE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Violence Prevent, Etiol & Surveillance Branch, 4770 Buford Highway,MS-F63, Atlanta, GA 30341 USA. EM ffa3@cdc.gov NR 32 TC 15 Z9 15 U1 2 U2 8 PU HOGREFE & HUBER PUBLISHERS PI GOTTINGEN PA ROHNSWEG 25, D-37085 GOTTINGEN, GERMANY SN 0227-5910 J9 CRISIS JI Crisis PY 2011 VL 32 IS 6 BP 299 EP 309 DI 10.1027/0227-5910/a000091 PG 11 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA 866FU UT WOS:000298366700002 PM 21940255 ER PT B AU Park, BJ Lockhart, SR Brandt, ME Chiller, TM AF Park, Benjamin J. Lockhart, Shawn R. Brandt, Mary E. Chiller, Tom M. BE Heitman, J Kozel, TR KwonChung, KJ Perfect, JR Casadevall, A TI Public Health Importance of Cryptococcal Disease: Epidemiology, Burden, and Control SO CRYPTOCOCCUS: FROM HUMAN PATHOGEN TO MODEL YEAST LA English DT Article; Book Chapter ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED PATIENTS; CHI-MINH-CITY; OPPORTUNISTIC INFECTIONS; FUNGAL-INFECTIONS; AIDS PATIENTS; ANTIFUNGAL SUSCEPTIBILITY; NATURAL-HISTORY; CLINICAL PRESENTATION C1 [Park, Benjamin J.; Lockhart, Shawn R.; Brandt, Mary E.; Chiller, Tom M.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. RP Park, BJ (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA 30333 USA. NR 72 TC 2 Z9 2 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N STREET NW, WASHINGTON, DC 20036-2904 USA BN 978-1-55581-501-1 PY 2011 BP 585 EP 593 PG 9 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA BSJ71 UT WOS:000284727500043 ER PT J AU Katz, LS Humphrey, JC Conley, AB Nelakuditi, V Kislyuk, AO Agrawal, S Jayaraman, P Harcourt, BH Olsen-Rasmussen, MA Frace, M Sharma, NV Mayer, LW Jordan, IK AF Katz, Lee S. Humphrey, Jay C. Conley, Andrew B. Nelakuditi, Viswateja Kislyuk, Andrey O. Agrawal, Sonia Jayaraman, Pushkala Harcourt, Brian H. Olsen-Rasmussen, Melissa A. Frace, Michael Sharma, Nitya V. Mayer, Leonard W. Jordan, I. King TI Neisseria Base: a comparative genomics database for Neisseria meningitidis SO DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION LA English DT Article ID MULTIPLE SEQUENCE ALIGNMENT; MENINGOCOCCAL DISEASE; SEROGROUP; VIRULENCE; RESOURCE; STRAIN; COMMUNITY; CARRIAGE; BROWSER; TOOLS AB Neisseria meningitidis is an important pathogen, causing life-threatening diseases including meningitis, septicemia and in some cases pneumonia. Genomic studies hold great promise for N. meningitidis research, but substantial database resources are needed to deal with the wealth of information that comes with completely sequenced and annotated genomes. To address this need, we developed Neisseria Base (NBase), a comparative genomics database and genome browser that houses and displays publicly available N. meningitidis genomes. In addition to existing N. meningitidis genome sequences, we sequenced and annotated 19 new genomes using 454 pyrosequencing and the CG-Pipeline genome analysis tool. In total, NBase hosts 27 complete N. meningitidis genome sequences along with their associated annotations. The NBase platform is designed to be scalable, via the underlying database schema and modular code architecture, such that it can readily incorporate new genomes and their associated annotations. The front page of NBase provides user access to these genomes through searching, browsing and downloading. NBase search utility includes BLAST-based sequence similarity searches along with a variety of semantic search options. All genomes can be browsed using a modified version of the GBrowse platform, and a plethora of information on each gene can be viewed using a customized details page. NBase also has a whole-genome comparison tool that yields single-nucleotide polymorphism differences between two user-defined groups of genomes. Using the virulent ST-11 lineage as an example, we demonstrate how this comparative genomics utility can be used to identify novel genomic markers for molecular profiling of N. meningitidis. Database URL: http://nbase.biology.gatech.edu C1 [Katz, Lee S.; Humphrey, Jay C.; Conley, Andrew B.; Nelakuditi, Viswateja; Kislyuk, Andrey O.; Agrawal, Sonia; Jayaraman, Pushkala; Sharma, Nitya V.; Jordan, I. King] Georgia Inst Technol, Sch Biol, Atlanta, GA 30333 USA. [Katz, Lee S.; Harcourt, Brian H.; Mayer, Leonard W.] Ctr Dis Control & Prevent CDC, Meningitis & Vaccine Preventable Dis Branch, Atlanta, GA 30333 USA. [Olsen-Rasmussen, Melissa A.; Frace, Michael] CDC, Biotechnol Core Facil Branch, Div Sci Resources, NCPDCID, Atlanta, GA 30333 USA. [Jordan, I. King] PanAmer Bioinformat Inst, Santa Marta, Magdalena, Colombia. RP Jordan, IK (reprint author), Georgia Inst Technol, Sch Biol, Atlanta, GA 30333 USA. EM king.jordan@biology.gatech.edu FU Centers for Disease Control and Prevention [1 R36 GD000075-1]; Alfred P. Sloan Research Fellowship in Computational and Evolutionary Molecular Biology [BR-4839]; Georgia Research Alliance [GRA.VAC09.O]; Georgia Institute of Technology; Defense Advanced Research Projects Agency [HR0011-05-1-0057] FX Centers for Disease Control and Prevention (1 R36 GD000075-1 to L. S. K.); Alfred P. Sloan Research Fellowship in Computational and Evolutionary Molecular Biology (BR-4839 to I.K.J.); Georgia Research Alliance (GRA.VAC09.O to I.K.J., B. H. H., L. W. M. and L. S. K.]; Bioinformatics program, Georgia Institute of Technology [ to J.C.H., P.J., N.V.S., V.N.); Defense Advanced Research Projects Agency (HR0011-05-1-0057 to A.O.K.). Funding for open access charge: Bioinformatics program, Georgia Institute of Technology. NR 42 TC 5 Z9 5 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1758-0463 J9 DATABASE-OXFORD JI Database PY 2011 AR bar035 DI 10.1093/database/bar035 PG 8 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA 883JQ UT WOS:000299630600037 ER PT B AU Taylor, A Johns, G Williams, G Steenkamp, M AF Taylor, Andrew Johns, Gary Williams, Gregory Steenkamp, Malinda BE Carson, D Rasmussen, RO Ensign, P Huskey, L Taylor, A TI The 'Problem' of Indigenous Migration in the Globalised State SO DEMOGRAPHY AT THE EDGE: REMOTE HUMAN POPULATIONS IN DEVELOPED NATIONS SE International Population Studies LA English DT Article; Book Chapter ID URBAN; AUSTRALIA; DIVIDE; WOMEN; BIRTH C1 [Taylor, Andrew] Charles Darwin Univ, Sch Social Policy & Res, Darwin, NT 0909, Australia. [Johns, Gary] Australian Catholic Univ, Publ Policy Inst, Sydney, NSW 2059, Australia. [Johns, Gary] Georgetown Univ, Washington, DC USA. [Johns, Gary] Inst Publ Affairs, Melbourne, Vic, Australia. [Williams, Gregory] US Bur Census, FSCPE, Washington, DC USA. [Steenkamp, Malinda] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Steenkamp, Malinda] Univ Sydney, Sydney, NSW 2006, Australia. OI Taylor, Andrew/0000-0002-3677-3270 NR 79 TC 4 Z9 4 U1 0 U2 0 PU ASHGATE PUBLISHING LTD PI ALDERSHOT PA GOWER HOUSE, CROFT ROAD, ALDERSHOT GU11 3HR, ENGLAND BN 978-0-7546-9915-6; 978-0-7546-7962-2 J9 INT POP STUD PY 2011 BP 163 EP 188 PG 26 WC Demography SC Demography GA BC6EE UT WOS:000353829300010 ER PT J AU Selvin, E Steffes, MW Gregg, E Brancati, FL Coresh, J AF Selvin, Elizabeth Steffes, Michael W. Gregg, Edward Brancati, Frederick L. Coresh, Josef TI Performance of A1C for the Classification and Prediction of Diabetes SO DIABETES CARE LA English DT Article ID SHORT-TERM VARIABILITY; GLYCATED HEMOGLOBIN; POPULATION; MELLITUS; ADULTS; RISK; US AB OBJECTIVE- Although A1C is now recommended to diagnose diabetes, its test performance for diagnosis and prognosis is uncertain. Our objective was to assess the test performance of A1C against single and repeat glucose measurements for diagnosis of prevalent diabetes and for prediction of incident diabetes. RESEARCH DESIGN AND METHODS- We conducted population-based analyses of 12,485 participants in the Atherosclerosis Risk in Communities (ARIC) study and a subpopulation of 691 participants in the Third National Health and Nutrition Examination Survey (NHANES III) with repeat test results. RESULTS- Against a single fasting glucose >= 126 mg/dl, the sensitivity and specificity of A1C >= 6.5% for detection of prevalent diabetes were 47 and 98%, respectively (area under the curve 0.892). Against repeated fasting glucose (3 years apart) >= 126 mg/dl, sensitivity improved to 67% and specificity remained high (97%) (AUC 0.936). Similar results were obtained in NHANES III against repeated fasting glucose 2 weeks apart. The accuracy of A1C was consistent across age, BMI, and race groups. For individuals with fasting glucose >= 126 mg/dl and A1C >= 6.5% at baseline, the 10-year risk of diagnosed diabetes was 88% compared with 55% among those individuals with fasting glucose >= 126 mg/dl and A1C 5.7-<6.5%. CONCLUSIONS- A1C performs well as a diagnostic tool when diabetes definitions that most closely resemble those used in clinical practice are used as the "gold standard." The high risk of diabetes among individuals with both elevated fasting glucose and A1C suggests a dual role for fasting glucose and A1C for prediction of diabetes. C1 [Selvin, Elizabeth; Brancati, Frederick L.; Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Selvin, Elizabeth; Brancati, Frederick L.; Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA. [Selvin, Elizabeth; Brancati, Frederick L.; Coresh, Josef] Johns Hopkins Univ, Dept Med, Div Gen Internal Med, Baltimore, MD USA. [Steffes, Michael W.] Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Gregg, Edward] Ctr Dis Control & Prevent, Atlanta, GA USA. [Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA. RP Selvin, E (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. EM lselvin@jhsph.edu FU National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R21-DK-080294, K01-DK-076595, K24-DK-62222]; National Heart, Lung, and Blood Institute [N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022]; Johns Hopkins Diabetes Research and Training Center (NIDDK) [P60-DK-079637] FX This research was supported by National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (grants R21-DK-080294 and K01-DK-076595 to E.S.). The ARIC study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute (contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022). F.L.B. was supported by the NIH NIDDK (grant K24-DK-62222) and by the Johns Hopkins Diabetes Research and Training Center (NIDDK grant P60-DK-079637). NR 21 TC 64 Z9 64 U1 1 U2 9 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2011 VL 34 IS 1 BP 84 EP 89 DI 10.2337/dc10-1235 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 710FT UT WOS:000286497000018 PM 20855549 ER PT J AU Funnell, MM Brown, TL Childs, BP Haas, LB Hosey, GM Jensen, B Maryniuk, M Peyrot, M Piette, JD Reader, D Siminerio, LM Weinger, K Weiss, MA AF Funnell, Martha M. Brown, Tammy L. Childs, Belinda P. Haas, Linda B. Hosey, Gwen M. Jensen, Brian Maryniuk, Melinda Peyrot, Mark Piette, John D. Reader, Diane Siminerio, Linda M. Weinger, Katie Weiss, Michael A. TI National Standards for Diabetes Self-Management Education SO DIABETES CARE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; CHRONIC DISEASE MANAGEMENT; IMPROVE GLYCEMIC CONTROL; PRIMARY-CARE PATIENTS; HEALTH-CARE; COMMUNITY-HEALTH; COMPLICATIONS TRIAL; PATIENT EDUCATION; AFRICAN-AMERICAN; CHRONIC ILLNESS C1 [Funnell, Martha M.] Univ Michigan, Dept Med Educ, Diabet Res & Training Ctr, Ann Arbor, MI 48109 USA. [Brown, Tammy L.] Indian Hlth Serv, Albuquerque, NM USA. [Childs, Belinda P.] MidAmer Diabet Associates, Wichita, KS USA. [Haas, Linda B.] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Hosey, Gwen M.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Jensen, Brian] Lakeshore Apothacare, Two Rivers, WI USA. [Maryniuk, Melinda; Weinger, Katie] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA. [Peyrot, Mark] Loyola Coll, Baltimore, MD 21210 USA. [Piette, John D.] VA Ann Arbor Hlth Care Syst, Ann Arbor, MI USA. [Piette, John D.] Univ Michigan, Dept Internal Med, Diabet Res & Training Ctr, Ann Arbor, MI 48109 USA. [Reader, Diane] Int Diabet Ctr, Minneapolis, MN USA. [Siminerio, Linda M.] Univ Pittsburgh, Med Ctr, Inst Diabet, Pittsburgh, PA USA. [Weiss, Michael A.] Patient Centered Solut, Pittsburgh, PA USA. RP Funnell, MM (reprint author), Univ Michigan, Dept Med Educ, Diabet Res & Training Ctr, Ann Arbor, MI 48109 USA. EM mfunnell@umich.edu FU National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [NIH5P60 DK20572, 1 R18 0K062323] FX Work on this article was supported in part by grant nos. NIH5P60 DK20572 and 1 R18 0K062323 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. NR 164 TC 59 Z9 63 U1 3 U2 7 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JAN PY 2011 VL 34 SU 1 BP S89 EP S96 DI 10.2337/dc11-S089 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 710FU UT WOS:000286497100008 PM 21193633 ER PT S AU Powers, AM Roehrig, JT AF Powers, A. M. Roehrig, John T. BE Stephenson, JR Warnes, A TI Alphaviruses SO DIAGNOSTIC VIROLOGY PROTOCOLS, SECOND EDITION SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Alphavirus; Nucleic acid amplification test; ELISA; Monoclonal antibodies ID EQUINE ENCEPHALITIS-VIRUS; MONOCLONAL-ANTIBODIES; INDIRECT IMMUNOFLUORESCENCE; IDENTIFICATION; EPITOPES AB Alphaviruses remain important emerging mosquito-borne, zoonotic pathogens that cause both localized human outbreaks and epizootics (e.g., Venezuelan equine encephalitis) and large human epidemics (e.g., Chikungunya). Alphaviruses are globally dispersed, and each continent has humans at risk from one or more of these arthropod-borne viruses (arboviruses). Symptoms of human alphaviral disease range from frank, severe encephalitis (e.g., eastern and western equine encephalitis) to polyarthritis (e.g., Ross River). Diagnostic techniques to identify human alphaviral infections have changed dramatically with the development and implementation of standardized nucleic acid amplification tests (NAAT). The NAAT is rapidly replacing virus isolation and typing using indirect fluorescent antibody (IFA) assay with monoclonal antibodies (MAbs) as the preferred method of virus identification. The older techniques still have value, however, since alphaviral growth in cell culture is rapid, and I FA with MAbs is inexpensive. This chapter provides detailed, standardized protocols for the identification of alphaviruses from clinical specimens and the serological characterization of human infection-immune sera. Both laboratory approaches are needed to identify and confirm human infections with these agents. C1 [Powers, A. M.; Roehrig, John T.] Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Infect Dis, US Dept HHS,Publ Hlth Serv, Ft Collins, CO USA. RP Powers, AM (reprint author), Ctr Dis Control & Prevent, Arboviral Dis Branch, Div Vector Borne Infect Dis, US Dept HHS,Publ Hlth Serv, Ft Collins, CO USA. OI Roehrig, John/0000-0001-7581-0479 NR 19 TC 10 Z9 11 U1 0 U2 3 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-60761-816-4 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2011 VL 665 BP 17 EP 38 DI 10.1007/978-1-60761-817-1_2 D2 10.1007/978-1-60761-817-1 PG 22 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Virology SC Biochemistry & Molecular Biology; Virology GA BSU95 UT WOS:000285850300002 PM 21116793 ER PT J AU Rein, DB Wittenborn, JS Weinbaum, CM Sabin, M Smith, BD Lesesne, SB AF Rein, David B. Wittenborn, John S. Weinbaum, Cindy M. Sabin, Miriam Smith, Bryce D. Lesesne, Sarah B. TI Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States SO DIGESTIVE AND LIVER DISEASE LA English DT Article DE Decompensated cirrhosis; Hepatocellular carcinoma; Liver failure; Simulation ID INJECTION-DRUG USERS; LIVER FIBROSIS PROGRESSION; VIRUS-INFECTION; ECONOMIC-EVALUATION; NATURAL-HISTORY; THERAPY; BURDEN; SURVIVAL; ALPHA-2A; BENEFITS AB Background: Without diagnosis and antiviral therapy, many patients with chronic hepatitis C infections will develop end-stage liver disease and die from complications. Aims: To evaluate the future impacts of preventive interventions and treatment advances, this paper forecasts a baseline estimate of the future morbidity and mortality of prevalent hepatitis C when left untreated. Methods: We simulated the future disease progression and death for all Americans with prevalent hepatitis C in 2005. To validate the model, we used past seroprevalence to forecast contemporary outcomes. We used the validated model to forecast future cases of end-stage liver disease, transplants, and deaths from 2010 to 2060, and we estimated credible intervals using Monte Carlo simulation. Results: When programmed with past data, our model predicted current levels of hepatitis C outcomes with accuracy between +/- 1% and 13%. Morbidity and mortality from hepatitis C will rise from 2010 to a peak between the years 2030 and 2035. We forecasted a peak of 38,600 incident cases of end-stage liver disease; 3200 referrals for transplant; and 36,100 deaths. Conclusions: Because current rates of screening and treatment are low, future morbidity and mortality from hepatitis C are likely to increase substantially without public health interventions to increase treatment. (C) 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved. C1 [Rein, David B.; Lesesne, Sarah B.] RTI Int, Atlanta, GA 30306 USA. [Wittenborn, John S.] RTI Int, Res Triangle Pk, NC USA. [Weinbaum, Cindy M.; Sabin, Miriam; Smith, Bryce D.] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral Hepatitis, Atlanta, GA USA. RP Rein, DB (reprint author), RTI Int, 2951 Flowers Rd,Suite 119, Atlanta, GA 30306 USA. EM drein@rti.org FU Centers for Disease Control and Prevention's Division of Viral Hepatitis [200-2003-02489-0007] FX This research was funded by the Centers for Disease Control and Prevention's Division of Viral Hepatitis through contract number 200-2003-02489-0007. NR 47 TC 113 Z9 114 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1590-8658 J9 DIGEST LIVER DIS JI Dig. Liver Dis. PD JAN PY 2011 VL 43 IS 1 BP 66 EP 72 DI 10.1016/j.dld.2010.05.006 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 752AZ UT WOS:000289661300010 PM 20739252 ER PT J AU Krahn, G Campbell, VA AF Krahn, Gloria Campbell, Vincent A. TI Evolving views of disability and public health: The roles of advocacy and public health SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Disability; Public health; Disability and health; Advocacy; Models; Future directions; Disparities; Determinants of health ID ENVIRONMENTAL-FACTORS; UNITED-STATES; MOBILITY LIMITATIONS; OUTCOMES RESEARCH; OBESITY; ADULTS; PARTICIPATION; DISPARITIES; PREVALENCE; PROGRAM AB Promoting health, quality of life, and participation of persons with disabilities is a relatively recent development in public health. Its brief history reflects three distinct public health perspectives toward disability-a traditional approach that focuses on preventing disability, a contemporary approach that regards disability as a minority group experiencing disparities relative to people without disabilities, and an emerging perspective where disability status is considered one of multiple determinants of health. The field of disability and health has been influenced by the interaction of disability advocacy with the public health process of surveillance, epidemiology research, and intervention. Advocacy draws on political and legal arguments to press for action on issues such as health care access, control of services, and choice of residence. Public health uses surveillance to document magnitude of problems; epidemiology to identify specific groups, develop measures, and apply rigorous research methods; and intervention to improve health behaviors and health outcomes. The field of disability and public health, however, has lagged in addressing the role of environmental factors in the disabling process, in moving to societal participation as an outcome, and in implementing population scale interventions. (C) 2011 Published by Elsevier Inc. C1 [Krahn, Gloria; Campbell, Vincent A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Krahn, G (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM gfk2@cdc.gov NR 72 TC 15 Z9 15 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 J9 DISABIL HEALTH J JI Disabil. Health J. PD JAN PY 2011 VL 4 IS 1 BP 12 EP 18 DI 10.1016/j.dhjo.2010.05.005 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA 710WG UT WOS:000286547100003 PM 21168802 ER PT B AU Cochi, SL Dowdle, WR AF Cochi, Stephen L. Dowdle, Walter R. BE Cochi, SL Dowdle, WR TI The Eradication of Infectious Diseases Understanding the Lessons and Advancing Experience SO DISEASE ERADICATION IN THE 21ST CENTURY: IMPLICATIONS FOR GLOBAL HEALTH SE Strungmann Forum Reports LA English DT Proceedings Paper CT Ernst-Strungmann Forum on Disease Eradication in the 21st Century CY AUG 29-SEP 03, 2010 CL Frankfurt am Main, GERMANY SP German Sci Fdn ID NEGLECTED TROPICAL DISEASES; GLOBAL HEALTH INITIATIVES; ELIMINATE LYMPHATIC FILARIASIS; ORAL POLIOVIRUS VACCINE; DEVELOPING-COUNTRIES; IMMUNIZATION PROGRAMS; TUBERCULOSIS-CONTROL; COST-EFFECTIVENESS; ECONOMIC-ANALYSIS; NORTHERN NIGERIA C1 [Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. NR 398 TC 4 Z9 4 U1 0 U2 5 PU MIT PRESS PI CAMBRIDGE PA FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA BN 978-0-262-29988-6; 978-0-262-01673-5 J9 STRUNGMANN FORUM REP PY 2011 BP 1 EP + PG 31 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BB1GL UT WOS:000341116400001 ER PT J AU Lucchi, NW Jain, V Wilson, NO Singh, N Udhayakumar, V Stiles, JK AF Lucchi, Naomi W. Jain, Vidhan Wilson, Nana O. Singh, Neeru Udhayakumar, Venkatachalam Stiles, Jonathan K. TI Potential serological biomarkers of cerebral malaria SO DISEASE MARKERS LA English DT Review DE Biomarkers; cerebral malaria; severe malaria; malaria ID SEVERE FALCIPARUM-MALARIA; PLASMODIUM-VIVAX MALARIA; UNCOMPLICATED MALARIA; COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; NEURONAL APOPTOSIS; AFRICAN CHILDREN; HIGH PREVALENCE; RISK-FACTORS; ERYTHROPOIETIN AB Biomarkers have been used to diagnose and prognosticate the progress and outcome of many chronic diseases such as neoplastic and non communicable diseases. However, only recently did the field of malaria research move in the direction of actively identifying biomarkers that can accurately discriminate the severe forms of malaria. Malaria continues to be a deadly disease, killing close to a million people (mostly children) every year. One life-threatening complication of malaria is cerebral malaria (CM). Studies carried out in Africa have demonstrated that even with the best treatment, as high as 15-30% of CM patients die and about 10-24% of CM survivors suffer short-or long-term neurological impairment. The transition from mild malaria to CM can be sudden and requires immediate intervention. Currently, there is no biological test available to confirm the diagnosis of CM and its complications. It is hoped that development of biomarkers to identify CM patients and potential risk for adverse outcomes would greatly enhance better intervention and clinical management to improve the outcomes. We review here what is currently known regarding biomarkers for CM outcomes. A Pub Med literature search was performed using the following search terms: "malaria," "cerebral malaria," "biomarkers," "mortality" and " neurological sequelae." This search revealed a paucity of usable biomarkers for CM management. We propose three main areas in which researchers can attempt to identify CM biomarkers: 1) early biomarkers, 2) diagnostic biomarkers and 3) prognostic biomarkers. C1 [Stiles, Jonathan K.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. [Lucchi, Naomi W.; Udhayakumar, Venkatachalam] Atlanta Res & Educ Fdn, Decatur, GA USA. [Lucchi, Naomi W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Jain, Vidhan; Singh, Neeru] Reg Med Res Ctr Tribals, Natl Inst Malaria Res, Jabalpur, India. RP Stiles, JK (reprint author), Morehouse Sch Med, Dept Microbiol Biochem & Immunol, BMSB Room 349D,720 Westview Dr SW, Atlanta, GA 30310 USA. EM jstiles@msm.edu FU WHO/UNDP/TDR [A00 524]; National Institutes of Health [NIH-FIC (R21TW006804-01), NIH-RCMI (RR03034), NIH-NIGM-MBRS (SO6GM08248)]; Atlanta Research and Education Foundation FX This investigation received financial support from WHO/UNDP/TDR Collaborative Research Grant (A00 524) and National Institutes of Health grant numbers NIH-FIC (R21TW006804-01), NIH-RCMI (RR03034) and NIH-NIGM-MBRS (SO6GM08248). NWL is supported by Atlanta Research and Education Foundation. NR 61 TC 12 Z9 12 U1 1 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0278-0240 J9 DIS MARKERS JI Dis. Markers PY 2011 VL 31 IS 6 BP 327 EP 335 DI 10.3233/DMA-2011-0854 PG 9 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology GA 866JA UT WOS:000298375400001 PM 22182805 ER PT J AU Wilson, NO Jain, V Roberts, CE Lucchi, N Joel, PK Singh, MP Nagpal, AC Dash, AP Udhayakumar, V Singh, N Stiles, JK AF Wilson, Nana O. Jain, Vidhan Roberts, Christina E. Lucchi, Naomi Joel, Pradeep K. Singh, Mrigendra P. Nagpal, Avinash C. Dash, Aditya P. Udhayakumar, Venkatachalam Singh, Neeru Stiles, Jonathan K. TI CXCL4 and CXCL10 predict risk of fatal cerebral malaria SO DISEASE MARKERS LA English DT Article DE CXCL4; CXCL10; PF4; IP-10; malaria; cerebral malaria; Plasmodium falciparum; ROC curve ID CELL ALPHA-CHEMOATTRACTANT; GAMMA-INDUCIBLE PROTEIN-10; FALCIPARUM-INFECTED ERYTHROCYTES; CHEMOKINE RECEPTOR CXCR3; NILE-VIRUS ENCEPHALITIS; BLOOD-BRAIN-BARRIER; PLATELET FACTOR-IV; PLASMODIUM-FALCIPARUM; INTERFERON-GAMMA; CEREBROSPINAL-FLUID AB Plasmodium falciparum in a subset of patients can lead to a diffuse encephalopathy known as cerebral malaria (CM). Despite treatment, mortality caused by CM can be as high as 30% while 10% of survivors of the disease may experience short- and long-term neurological complications. The pathogenesis of CM involves alterations in cytokine and chemokine expression, local inflammation, vascular injury and repair processes. These diverse factors have limited the rate of discovery of prognostic predictors of fatal CM. Identification of reliable early predictors of CM severity will enable clinicians to adjust this risk with appropriate management of CM. Recent studies revealed that elevated levels of CXCL10 expression in cerebrospinal fluid and peripheral blood plasma independently predicted severe and fatal CM. CXCR3, a promiscuous receptor of CXCL10, plays an important role in pathogenesis of mouse model of CM. In this study the role of corresponding CXCR3 ligands (CXCL11, CXCL10, CXCL9 & CXCL4) in fatal or severe CM was evaluated by comparing their levels in 16 healthy control (HC), 26 mild malaria (MM), 26 cerebral malaria survivors (CMS) and 12 non-survivors (CMNS) using enzyme linked immunosorbent assay (ELISA). Levels of CXCL4 and CXCL10 were significantly elevated in CMNS patients (p < 0.05) when compared with HC, MM and CMS. Elevated plasma levels of CXCL10 and CXCL4 were tightly associated with CM mortality. Receiver Operating Characteristic (ROC) curve analysis revealed that CXCL4 and CXCL10 can discriminate CMNS from MM (p < 0.0001) and CMS (p < 0.0001) with an area under the curve (AUC) = 1. These results suggest that CXCL4 and CXCL10 play a prominent role in pathogenesis of CM associated death and may be used as functional or surrogate biomarkers for predicting CM severity. C1 [Wilson, Nana O.; Stiles, Jonathan K.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. [Jain, Vidhan; Singh, Mrigendra P.; Singh, Neeru] Natl Inst Malaria Res Field Unit ICMR, Jabalpur, Madhya Pradesh, India. [Roberts, Christina E.] Spelman Coll, Dept Biol, Atlanta, GA 30314 USA. [Lucchi, Naomi; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, CDC, Atlanta, GA USA. [Joel, Pradeep K.; Nagpal, Avinash C.] Nethaji Subhash Chandra Bose Med Coll Hosp, Jabalpur, Madhya Pradesh, India. [Dash, Aditya P.] Natl Inst Malaria Res ICMR, New Delhi, India. [Singh, Neeru] Reg Med Res Ctr Tribals ICMR, Jabalpur, Madhya Pradesh, India. RP Stiles, JK (reprint author), Morehouse Sch Med, Dept Microbiol Biochem & Immunol, BMSB Room 349D,720 Westview Dr SW, Atlanta, GA 30310 USA. EM jstiles@msm.edu FU WHO/UNDP/TDR [A00 524]; National Institutes of Health [NIH-FIC (R21TW006804-01), NIH-RCMI (RR03034), NIH-NIGM-MBRS (SO6GM08248)]; Center for Disease Diagnosis and Research (CDDR) in Ghana FX This investigation received financial support from WHO/UNDP/TDR Collaborative Research Grant (A00 524) and National Institutes of Health grant numbers NIH-FIC (R21TW006804-01), NIH-RCMI (RR03034) and NIH-NIGM-MBRS (SO6GM08248).; We thank the former Director General, Indian Council of Medical Research (ICMR), Dr. N.K. Ganguly and other ICMR Headquarters staff for their support. The authors acknowledge the patients, CM victims and their guardians for providing permission to use their samples. The authors are grateful to the staff of Nethaji Subash Chandra Bose (NSCB) Hospital (Jabalpur) and Civil Hospital (Maihar) and the support of the Center for Disease Diagnosis and Research (CDDR) in Ghana. NR 83 TC 32 Z9 32 U1 0 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0278-0240 J9 DIS MARKERS JI Dis. Markers PY 2011 VL 30 IS 1 BP 39 EP 49 DI 10.3233/DMA-2011-0763 PG 11 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology GA 768TO UT WOS:000290961500005 PM 21508508 ER PT J AU Sorvillo, F Wilkins, P Shafir, S Eberhard, M AF Sorvillo, Frank Wilkins, Patricia Shafir, Shira Eberhard, Mark TI Public Health Implications of Cysticercosis Acquired in the United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID LOS-ANGELES-COUNTY; TAENIA-SOLIUM CYSTICERCOSIS; CEREBRAL CYSTICERCOSIS; NEUROCYSTICERCOSIS; TRAVEL; INFECTIONS; OUTBREAK; CHILDREN; HISTORY C1 [Sorvillo, Frank] Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90095 USA. [Sorvillo, Frank] Touro Univ Int, Coll Hlth Sci, Cypress, CA USA. [Sorvillo, Frank] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. [Wilkins, Patricia; Eberhard, Mark] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Sorvillo, F (reprint author), Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Box 951772, Los Angeles, CA 90095 USA. EM fsorvill@ucla.edu NR 39 TC 44 Z9 45 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2011 VL 17 IS 1 BP 1 EP 6 DI 10.3201/eid1701.101210 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 702OS UT WOS:000285904600001 PM 21192847 ER PT J AU Scallan, E Hoekstra, RM Angulo, FJ Tauxe, RV Widdowson, MA Roy, SL Jones, JL Griffin, PM AF Scallan, Elaine Hoekstra, Robert M. Angulo, Frederick J. Tauxe, Robert V. Widdowson, Marc-Alain Roy, Sharon L. Jones, Jeffery L. Griffin, Patricia M. TI Foodborne Illness Acquired in the United States-Major Pathogens SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFECTIOUS INTESTINAL DISEASE; ESCHERICHIA-COLI O157-H7; GASTROINTESTINAL SYMPTOMS; ACUTE GASTROENTERITIS; LABORATORY PRACTICES; BURDEN; OUTBREAK; FOOD; SURVEILLANCE; COMMUNITY AB Estimates of foodborne illness can be used to direct food safety policy and interventions. We used data from active and passive surveillance and other sources to estimate that each year 31 major pathogens acquired in the United States caused 9.4 million episodes of foodborne illness (90% credible interval [Crl] 6.6-12.7 million), 55,961 hospitalizations (90% Crl 39,534-75,741), and 1,351 deaths (90% Crl 712-2,268). Most (58%) illnesses were caused by norovirus, followed by nontyphoidal Salmonella spp. (11%), Clostridium perfringens (10%), and Campylobacter spp. (9%). Leading causes of hospitalization were nontyphoidal Salmonella spp. (35%), norovirus (26%), Campylobacter spp. (15%), and Toxoplasma gondii (8%). Leading causes of death were nontyphoidal Salmonella spp. (28%), T gondii (24%), Listeria monocytogenes (19%), and norovirus (11%). These estimates cannot be compared with prior (1999) estimates to assess trends because different methods were used. Additional data and more refined methods can improve future estimates. C1 [Scallan, Elaine; Hoekstra, Robert M.; Angulo, Frederick J.; Tauxe, Robert V.; Widdowson, Marc-Alain; Roy, Sharon L.; Jones, Jeffery L.; Griffin, Patricia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Scallan, E (reprint author), Colorado Sch Publ Hlth, Dept Epidemiol, Mailstop B119,Rm W3146,UCD AMC Bldg 500,13001 E 1, Aurora, CO 80045 USA. EM elainc.scallan@ucdenver.edu NR 37 TC 2165 Z9 2227 U1 70 U2 568 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2011 VL 17 IS 1 BP 7 EP 15 DI 10.3201/eid1701.P11101 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 702OS UT WOS:000285904600002 PM 21192848 ER PT J AU Scallan, E Griffin, PM Angulo, FJ Tauxe, RV Hoekstra, RM AF Scallan, Elaine Griffin, Patricia M. Angulo, Frederick J. Tauxe, Robert V. Hoekstra, Robert M. TI Foodborne Illness Acquired in the United States-Unspecified Agents SO EMERGING INFECTIOUS DISEASES LA English DT Article ID ESCHERICHIA-COLI; DISEASE; GASTROENTERITIS; TRENDS; BURDEN AB Each year, 31 major known pathogens acquired in the United States caused an estimated 9.4 million episodes of foodborne illness. Additional episodes of illness were caused by unspecified agents, including known agents with insufficient data to estimate agent-specific illness, known agents not yet recognized as causing foodborne illness, substances known to be in food but of unproven pathogenicity, and unknown agents. To estimate these additional illnesses, we used data from surveys, hospital records, and death certificates to estimate illnesses, hospitalizations, and deaths from acute gastroenteritis and subtracted illnesses caused by known gastroenteritis pathogens. If the proportions acquired by domestic foodborne transmission were similar to those for known gastroenteritis pathogens, then an estimated 38.4 million (90% credible interval [Crl] 19.8-61.2 million) episodes of domestically acquired foodborne illness were caused by unspecified agents, resulting in 71,878 hospitalizations (90% Crl 9,924-157,340) and 1,686 deaths (90% Crl 369-3,338). C1 [Scallan, Elaine; Griffin, Patricia M.; Angulo, Frederick J.; Tauxe, Robert V.; Hoekstra, Robert M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Scallan, E (reprint author), Colorado Sch Publ Hlth, Dept Epidemiol, Mailstop B119,Rm W3146,UCD AMC Bldg 500,13001 E 1, Aurora, CO 80045 USA. EM elaine.scallan@ucdenver.edu NR 30 TC 320 Z9 332 U1 4 U2 44 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2011 VL 17 IS 1 BP 16 EP 22 DI 10.3201/eid1701.P21101 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 702OS UT WOS:000285904600003 PM 21192849 ER PT J AU McElroy, KL Santiago, GA Lennon, NJ Birren, BW Henn, MR Munoz-Jordan, JL AF McElroy, Kate L. Santiago, Gilberto A. Lennon, Niall J. Birren, Bruce W. Henn, Matthew R. Munoz-Jordan, Jorge L. TI Endurance, Refuge, and Reemergence of Dengue Virus Type 2, Puerto Rico, 1986-2007 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MOLECULAR EVOLUTION; SELECTION; EPIDEMIC; REPLACEMENT; PHYLOGENY; SEROTYPES; ENVELOPE; AMERICA AB To study the evolution of dengue virus (DENV) serotype 2 in Puerto Rico, we examined the genetic composition and diversity of 160 DENV-2 genomes obtained through 22 consecutive years of sampling. A clade replacement took place in 1994-1997 during a period of high incidence of autochthonous DENV-2 and frequent, short-lived reintroductions of foreign DENV-2. This unique clade replacement was complete just before DENV-3 emerged. By temporally and geographically defining DENV-2 lineages, we describe a refuge of this virus through 4 years of low genome diversity. Our analyses may explain the long-term endurance of DENV-2 despite great epidemiologic changes in disease incidence and serotype distribution. C1 [McElroy, Kate L.; Santiago, Gilberto A.; Munoz-Jordan, Jorge L.] Ctr Dis Control & Prevent, San Juan, PR 00920 USA. [Lennon, Niall J.; Birren, Bruce W.; Henn, Matthew R.] Broad Inst MIT & Harvard, Cambridge, MA USA. [McElroy, Kate L.] CDC, Dengue Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Munoz-Jordan, JL (reprint author), Ctr Dis Control & Prevent, 1324 Calle Canada, San Juan, PR 00920 USA. EM jmunoz@cdc.gov FU National Institutes of Health [HHSN266200400001C] FX This project was funded in part by the National Institutes of Health, contract HHSN266200400001C (B.W.B.). NR 32 TC 28 Z9 28 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2011 VL 17 IS 1 BP 64 EP 71 DI 10.3201/eid1701.100961 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 702OS UT WOS:000285904600010 PM 21192856 ER PT J AU Sjolund-Kairlsson, M Howie, R Krueger, A Rickert, R Pecic, G Lupoli, K Folster, JP Whichard, JM AF Sjoelund-Kairlsson, Maria Howie, Rebecca Krueger, Amy Rickert, Regan Pecic, Gary Lupoli, Kathryn Folster, Jason P. Whichard, Jean M. TI CTX-M-producing Non-Typhi Salmonella spp. Isolated from Humans, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SPECTRUM BETA-LACTAMASES; ESCHERICHIA-COLI; ENTEROBACTERIACEAE; EMERGENCE; ANIMALS AB CTX-M-type beta-lactamases are increasing among US Enterobacteriaceae isolates. Of 2,165 non-Typhi Salmonella isolates submitted in 2007 to the National Antimicrobial Resistance Monitoring System, 100 (4.6%) displayed elevated MICs (>= 2 mg/L) of ceftriaxone or ceftiofur. Three isolates (serotypes Typhimurium, Concord, and 1 4,5,12:i:-) contained b/a(CTX-M-5), b/a(CTX-M-15), and b/a(CTX-M-55/57), respectively. C1 [Sjoelund-Kairlsson, Maria; Whichard, Jean M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Howie, Rebecca; Krueger, Amy; Rickert, Regan; Pecic, Gary; Lupoli, Kathryn; Folster, Jason P.] Atlanta Res & Educ Fdn, Decatur, GA USA. [Sjoelund-Kairlsson, Maria] CDC, Natl Antimicrobial Resistance Surveillance Team, Atlanta, GA 30333 USA. RP Sjolund-Kairlsson, M (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop G29, Atlanta, GA 30333 USA. EM fwt4@cdc.gov FU CDC; Food and Drug Administration Center for Veterinary Medicine FX This work was supported by an interagency agreement between CDC and the Food and Drug Administration Center for Veterinary Medicine. NR 15 TC 25 Z9 25 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2011 VL 17 IS 1 BP 97 EP 99 DI 10.3201/eid1701.100511 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 702OS UT WOS:000285904600018 PM 21192864 ER PT J AU Potter, P AF Potter, Polyxeni TI Manna to Gall SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM PMP1@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JAN PY 2011 VL 17 IS 1 BP 160 EP 161 DI 10.3201/eid1701.AC1701 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 702OS UT WOS:000285904600045 PM 21192892 ER PT J AU Mehdi, MR Kim, M Seong, JC Arsalan, MH AF Mehdi, Mohammed Raza Kim, Minho Seong, Jeong Chang Arsalan, Mudassar Hassan TI Spatio-temporal patterns of road traffic noise pollution in Karachi, Pakistan SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Spatio-temporal noise pattern; Road traffic noise pollution; Noise exposure; Noise and health; Karachi ID MYOCARDIAL-INFARCTION; URBAN-ENVIRONMENT; COMMUNITY NOISE; EXPOSURE; HEALTH; ANNOYANCE; TRANSPORTATION; HYPERTENSION; SLEEP; WORLD AB We studied the spatial and temporal patterns of noise exposure due to road traffic in Karachi City, Pakistan, and found that levels of noise were generally higher during mornings and evenings because of the commuting pattern of Karachi residents. This study found the average value of noise levels to be over 66 dB, which could cause serious annoyance according to the World Health Organization (WHO) outdoor noise guidelines. Maximum peak noise was over 101 dB, which is close to 110 dB, the level that can cause possible hearing impairment according to the WHO guidelines. We found that noise pollution is not an environmental problem reserved for developed countries, but occurs in developing countries as well. For this reason, steps might be required to reduce noise levels caused by road traffic. Published by Elsevier Ltd. C1 [Kim, Minho] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA 30341 USA. [Mehdi, Mohammed Raza; Seong, Jeong Chang] Univ W Georgia, Dept Geosci, Carrollton, GA USA. [Mehdi, Mohammed Raza] NED Univ Engn & Technol, Karachi 75270, Pakistan. [Arsalan, Mudassar Hassan] Univ Karachi, Dept Geog, Karachi 75270, Pakistan. RP Kim, M (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, 4770 Buford Hwy NE,MS K-67, Atlanta, GA 30341 USA. EM htjO@cdc.gov FU Higher Education Commission (HEC), Government of Pakistan FX The leading author would like to thank Dr. Jamil H. Kazmi for his intellectual guidance and Dr. Birjees T. Wasi, Department of Geography, University of Karachi, for her encouraging support. The leading author is highly indebted to the Higher Education Commission (HEC), Government of Pakistan, which awarded him the post-doctoral fellowship at the University of West Georgia, Georgia, USA. We acknowledge that the findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the United States Centers for Disease Control and Prevention. NR 48 TC 32 Z9 33 U1 1 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 J9 ENVIRON INT JI Environ. Int. PD JAN PY 2011 VL 37 IS 1 BP 97 EP 104 DI 10.1016/j.envint.2010.08.003 PG 8 WC Environmental Sciences SC Environmental Sciences & Ecology GA 699KP UT WOS:000285662600014 PM 20851468 ER PT J AU Christensen, KY Maisonet, M Rubin, C Holmes, A Calafat, AM Kato, K Flanders, WD Heron, J McGeehin, MA Marcus, M AF Christensen, Krista Yorita Maisonet, Mildred Rubin, Carol Holmes, Adrianne Calafat, Antonia M. Kato, Kayoko Flanders, W. Dana Heron, Jon McGeehin, Michael A. Marcus, Michele TI Exposure to polyfluoroalkyl chemicals during pregnancy is not associated with offspring age at menarche in a contemporary British cohort SO ENVIRONMENT INTERNATIONAL LA English DT Article DE ALSPAC; Polyfluoroalkyl chemicals; Menarche ID NUTRITION EXAMINATION SURVEY; MINNOWS GOBIOCYPRIS-RARUS; LEYDIG-CELL FUNCTION; PERFLUOROOCTANOIC ACID; NATIONAL-HEALTH; AMMONIUM PERFLUOROOCTANOATE; PEROXISOME PROLIFERATORS; PERFLUORINATED CHEMICALS; ENVIRONMENTAL-FACTORS; PUBERTAL MATURATION AB Introduction: Polyfluoroalkyl chemicals (PFCs) are commercially synthesized chemicals used in consumer products. Exposure to certain PFCs is widespread, and some PFCs may act as endocrine disruptors. We used data from the Avon Longitudinal Study of Parents and Children (ALSPAC) in the United Kingdom to conduct a nested case-control study examining the association between age at menarche, and exposure to PFCs during pregnancy. Methods: Cases were selected from female offspring in the ALSPAC who reported menarche before the age of 11.5 years (n = 218), and controls were a random sample of remaining girls (n = 230). Serum samples taken from the girls' mothers during pregnancy (1991-1992) were analyzed using on-line solid-phase extraction coupled to isotope dilution high-performance liquid chromatography-tandem mass spectrometry for 8 PFCs. Logistic regression was used to determine association between maternal serum PFC concentrations, and odds of earlier age at menarche. Results: PFOS and PFOA were the predominant PFCs (median serum concentrations of 19.8 ng/mL and 3.7 ng/mL). All but one PFC were detectable in most samples. Total PFC concentration varied by number of births (inverse association with birth order; p-value < 0.0001) and race of the child (higher among whites; p-value = 0.03). The serum concentrations of carboxylates were associated with increased odds of earlier age at menarche; concentrations of perfluorooctane sulfonamide, the sulfonamide esters and sulfonates were all associated with decreased odds of earlier age at menarche. However, all confidence intervals included the null value of 1.0. Conclusions: ALSPAC study participants had nearly ubiquitous exposure to most PFCs examined, but PFC exposure did not appear to be associated with altered age at menarche of their offspring. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Christensen, Krista Yorita; Maisonet, Mildred; Flanders, W. Dana; Marcus, Michele] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Maisonet, Mildred; Rubin, Carol; Holmes, Adrianne; Calafat, Antonia M.; Kato, Kayoko; Flanders, W. Dana; McGeehin, Michael A.; Marcus, Michele] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Heron, Jon] Univ Bristol, Dept Social Med, Bristol BS8 2PS, Avon, England. RP Marcus, M (reprint author), Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM mmarcus@emory.edu RI Marcus, Michele/J-2746-2015; Heron, Jon/D-5884-2011; OI Heron, Jon/0000-0001-6199-5644; Maisonet, Mildred/0000-0003-3561-2632 FU Centers for Disease Control and Prevention FX This work was supported by the Centers for Disease Control and Prevention. The UK Medical Research Council; the Wellcome Trust; and the University of Bristol provide core support for ALSPAC. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 47 TC 18 Z9 18 U1 1 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 J9 ENVIRON INT JI Environ. Int. PD JAN PY 2011 VL 37 IS 1 BP 129 EP 135 DI 10.1016/j.envint.2010.08.007 PG 7 WC Environmental Sciences SC Environmental Sciences & Ecology GA 699KP UT WOS:000285662600017 PM 20843552 ER PT J AU Berman, T Hochner-Celnikier, D Barr, DB Needham, LL Amitai, Y Wormser, U Richter, E AF Berman, Tamar Hochner-Celnikier, Drorit Barr, Dana Boyd Needham, Larry L. Amitai, Yona Wormser, Uri Richter, Elihu TI Pesticide exposure among pregnant women in Jerusalem, Israel: Results of a pilot study SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Biomonitoring; Exposure; Pesticides; Organophosphates; Pregnancy; Urinary metabolites ID DIALKYL PHOSPHATE METABOLITES; CONTEMPORARY-USE PESTICIDES; ORGANOPHOSPHORUS PESTICIDES; MASS-SPECTROMETRY; COHORT; NEURODEVELOPMENT; QUANTIFICATION; POPULATION; CHILDREN; DELIVERY AB Background: Pesticides have been shown to disrupt neurodevelopment in laboratory animals and in human populations. To date, there have been no studies on exposure to pesticides in pregnant women in Israel, despite reports of widespread exposure in other populations of pregnant women and the importance of evaluating exposure in this susceptible sub-population. Methods: We measured urinary concentrations of organophosphorus (OP) insecticide metabolites and plasma concentrations of OP and other pesticides in 20 pregnant women, recruited in Jerusalem, Israel in 2006, and collected questionnaire data on demographic factors and consumer habits from these women. We compared geometric mean concentrations in subgroups using the Mann-Whitney U-test for independent samples. We compared creatinine-adjusted OP pesticide metabolite concentrations, as well as plasma pesticide concentrations, with other populations of pregnant women. Results: Creatinine-adjusted total dimethyl (DM) metabolite concentrations were between 4 and 6 times higher in this population compared to other populations of pregnant women in the United States while total diethyl (DE) metabolite concentrations were lower. Dimethylphosphate (DMP) was detected in 74% of the urine samples whereas dimethylthiophosphate (DMTP) was detected in 90% of the urine samples. The carbamate bendiocarb was detected in 89% of the plasma samples, while the OP insecticide chlorpyrifos was detected in 42% of the samples. Mean plasma concentrations of bendiocarb and chlorpyrifos in our sample were 4.4 and 3.9 times higher, respectively, than that of an urban minority cohort from New York City. Twelve women (63%) reported using some form of household pest control during their pregnancy and five (26%) reported using household pest control during the past month. Women with a graduate degree had significantly higher geometric mean concentrations of total urinary DM metabolite concentrations compared to other women (P = 0.006). Finally, one woman in the study had exceptionally high concentrations of DMP. DMTP, DMDTP compared to the other women in the study, despite reporting no current occupational exposure to OP pesticides and no other significant exposure sources. Conclusions: Pregnant women in the Jerusalem area are exposed to OP pesticides and to the carbamate pesticide bendiocarb. It is unclear why total DM metabolites concentrations were much higher in this population compared to other populations of pregnant women in the United States and Netherlands. Finally, the finding of very high DM metabolite concentrations in one woman who reported being moved from her regular laboratory work to administrative work upon becoming pregnant, raises questions about the adequacy of measures to protect pregnant women from pesticide exposures during pregnancy. (C) 2010 Elsevier Ltd. All rights reserved. C1 [Berman, Tamar; Wormser, Uri] Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Inst Drug Res, IL-91120 Jerusalem, Israel. [Hochner-Celnikier, Drorit] Hadassah Hebrew Univ Hosp, Dept Obstet & Gynecol, Jerusalem, Israel. [Barr, Dana Boyd] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Needham, Larry L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Amitai, Yona; Richter, Elihu] Hadassah Sch Publ Hlth & Community Med, Jerusalem, Israel. RP Berman, T (reprint author), Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Inst Drug Res, IL-91120 Jerusalem, Israel. EM tamar.berman@moh.health.gov.il RI Needham, Larry/E-4930-2011; Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013 NR 33 TC 25 Z9 29 U1 0 U2 13 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 J9 ENVIRON INT JI Environ. Int. PD JAN PY 2011 VL 37 IS 1 BP 198 EP 203 DI 10.1016/j.envint.2010.09.002 PG 6 WC Environmental Sciences SC Environmental Sciences & Ecology GA 699KP UT WOS:000285662600026 PM 20952069 ER PT J AU Calafat, AM Wong, LY Silva, MJ Samandar, E Preau, JL Jia, LT Needham, LL AF Calafat, Antonia M. Wong, Lee-Yang Silva, Manori J. Samandar, Ella Preau, James L., Jr. Jia, Lily T. Needham, Larry L. TI Selecting Adequate Exposure Biomarkers of Diisononyl and Diisodecyl Phthalates: Data from the 2005-2006 National Health and Nutrition Examination Survey SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE biomonitoring; DIDP; DINP; exposure; human; NHANES; urine ID DI-ISONONYL PHTHALATE; ISO-NONYLPHTHALATE DINP; EXPERT PANEL REPORT; N-BUTYL PHTHALATE; ENVIRONMENTAL CHEMICALS; DEVELOPMENTAL TOXICITY; ISODECYL PHTHALATE; HUMAN-REPRODUCTION; HUMAN URINE; NTP CENTER AB BACKGROUND: High-molecular-weight phthalates, such as diisononyl phthalate (DINP) and diisodecyl phthalate (DIDP), are used primarily as polyvinyl chloride plasticizers. OBJECTIVES: We assessed exposure to DINP and DIDP in a representative sample of persons >= 6 years of age in the U.S. general population from the 2005-2006 National Health and Nutrition Examination Survey (NHANES). METHODS: We analyzed 2,548 urine samples by using online solid-phase extraction coupled to isotope dilution high-performance liquid chromatography-tandem mass spectrometry. RESULTS: We detected monocarboxyisooctyl phthalate (MCOP), a metabolite of DINP, and monocarboxyisononyl phthalate (MCNP), a metabolite of DIDP, in 95.2% and 89.9% of the samples, respectively. We detected monoisononyl phthalate (MNP), a minor metabolite of DINP, much less frequently (12.9%) and at concentration ranges (> 0.8 mu g/L-148.1 mu g/L) much lower than MCOP (> 0.7 mu g/L-4,961 mu g/L). Adjusted geometric mean concentrations of MCOP and MCNP were significantly higher (p < 0.01) among children than among adolescents and adults. CONCLUSIONS: The general U.S. population, including children, was exposed to DINP and DIDP. In previous NHANES cycles, the occurrence of human exposure to DINP by using MNP as the sole urinary biomarker has been underestimated, thus illustrating the importance of selecting the most adequate biomarkers for exposure assessment. C1 [Calafat, Antonia M.; Wong, Lee-Yang; Silva, Manori J.; Samandar, Ella; Preau, James L., Jr.; Jia, Lily T.; Needham, Larry L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. RP Calafat, AM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, 4770 Buford Hwy,NE,Mailstop F53, Atlanta, GA 30341 USA. EM Acalafat@cdc.gov RI Needham, Larry/E-4930-2011 NR 50 TC 27 Z9 27 U1 1 U2 14 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD JAN PY 2011 VL 119 IS 1 BP 50 EP 55 DI 10.1289/ehp.1002316 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 701BI UT WOS:000285788900023 PM 20870567 ER PT J AU Braun, JM Kalkbrenner, AE Calafat, AM Bernert, JT Ye, XY Silva, MJ Barr, DB Sathyanarayana, S Lanphear, BP AF Braun, Joe M. Kalkbrenner, Amy E. Calafat, Antonia M. Bernert, John T. Ye, Xiaoyun Silva, Manori J. Barr, Dana Boyd Sathyanarayana, Sheela Lanphear, Bruce P. TI Variability and Predictors of Urinary Bisphenol A Concentrations during Pregnancy SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE bisphenol A; dietary; occupational; predictors; pregnancy; prenatal; variability ID PHTHALATE METABOLITES; TEMPORAL VARIABILITY; CHILDHOOD BEHAVIOR; TOBACCO-SMOKE; UNITED-STATES; CANNED FOODS; EXPOSURE; WOMEN; CHILDREN; HEALTH AB Background: Prenatal bisphenol A (BPA) exposure may be associated with developmental toxicity, but few studies have examined the variability and predictors of urinary BPA concentrations during pregnancy. Objective: Our goal was to estimate the variability and predictors of serial urinary BPA concentrations taken during pregnancy. Methods: We measured BPA concentrations during pregnancy and at birth in three spot urine samples from 389 women. We calculated the intraclass correlation coefficient (ICC) to assess BPA variability and estimated associations between log(10)-transformed urinary BPA concentrations and demographic, occupational, dietary, and environmental factors, using mixed models. Results: Geometric mean (GM) creatinine-standardized concentrations (micrograms per gram) were 1.7 (16 weeks), 2.0 (26 weeks), and 2.0 (birth). Creatinine-standardized BPA concentrations exhibited low reproducibility (ICC = 0.11). By occupation, cashiers had the highest BPA concentrations (GM: 2.8 mu g/g). Consuming canned vegetables at least once a day was associated with higher BPA concentrations (GM = 2.3 mu g/g) compared with those consuming no canned vegetables (GM = 1.6 mu g/g). BPA concentrations did not vary by consumption of fresh fruits and vegetables, canned fruit, or store-bought fresh and frozen fish. Urinary high-molecular-weight phthalate and serum tobacco smoke metabolite concentrations were positively associated with BPA concentrations. Conclusions: These results suggest numerous sources of BPA exposure during pregnancy. Etiological studies may need to measure urinary BPA concentrations more than once during pregnancy and adjust for phthalates and tobacco smoke exposures. C1 [Braun, Joe M.] Harvard Univ, Dept Environm Hlth, Boston, MA USA. [Kalkbrenner, Amy E.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Calafat, Antonia M.; Bernert, John T.; Ye, Xiaoyun; Silva, Manori J.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Barr, Dana Boyd] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Sathyanarayana, Sheela] Univ Washington, Dept Pediat, Seattle Childrens Hosp, Seattle, WA 98195 USA. [Lanphear, Bruce P.] Cincinnati Childrens Hosp, Div Gen & Community Pediat, Dept Pediat, Med Ctr, Cincinnati, OH USA. [Lanphear, Bruce P.] Simon Fraser Univ, Vancouver, BC, Canada. RP Braun, JM (reprint author), 401 Pk Dr,3rd Floor E, Boston, MA 02215 USA. EM jbraun@hsph.harvard.edu RI Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013; Braun, Joseph/H-8649-2014 FU National Institute of Environmental Health Sciences (NIEHS) [P30ES10126, T32 ES007018]; U.S. Environmental Protection Agency [PO1 ES11261]; National Institute of Child Health and Human Development [T32-HD052468-01]; University of Washington [K-12] FX This study was funded by a grant from the National Institute of Environmental Health Sciences (NIEHS) and the U.S. Environmental Protection Agency (PO1 ES11261). Additional support came from National Institute of Child Health and Human Development training grant T32-HD052468-01, NIEHS grant P30ES10126, the University of Washington K-12 Male Reproductive Health Research Training Grant, and NIEHS Training Grant T32 ES007018. NR 45 TC 162 Z9 168 U1 8 U2 54 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD JAN PY 2011 VL 119 IS 1 BP 131 EP 137 DI 10.1289/ehp.1002366 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 701BI UT WOS:000285788900035 PM 21205581 ER PT J AU Brown, MJ Raymond, J Homa, D Kennedy, C Sinks, T AF Brown, Mary Jean Raymond, Jaime Homa, David Kennedy, Chinaro Sinks, Thomas TI Association between children's blood lead levels, lead service lines, and water disinfection, Washington, DC, 1998-2006 SO ENVIRONMENTAL RESEARCH LA English DT Article DE Lead; Lead service line; Childhood lead poisoning; Drinking water; Blood lead level; Elevated blood lead levels ID 10 MU-G/DL; DRINKING-WATER; US CHILDREN; INTELLECTUAL IMPAIRMENT; EXPOSURES; HEALTH AB Objective: Evaluate the effect of changes in the water disinfection process, and presence of lead service lines (LSLs), on children's blood lead levels (BLLs) in Washington, DC. Methods: Three cross-sectional analyses examined the relationship of LSL and changes in water disinfectant with BLLs in children <6 years of age. The study population was derived from the DC Childhood Lead Poisoning Prevention Program blood lead surveillance system of children who were tested and whose blood lead test results were reported to the DC Health Department. The Washington, DC Water and Sewer Authority (WASA) provided information on LSLs. The final study population consisted of 63,854 children with validated addresses. Results: Controlling for age of housing, LSL was an independent risk factor for BLLs >= 10 mu g/dL, and >= 5 mu g/dL even during time periods when water levels met the US Environmental Protection Agency (EPA) action level of 15 parts per billion (ppb). When chloramine alone was used to disinfect water, the risk for BLL in the highest quartile among children in homes with LSL was greater than when either chlorine or chloramine with orthophosphate was used. For children tested after LSLs in their houses were replaced, those with partially replaced LSL were > 3 times as likely to have BLLs >= 10 mu g/dL versus children who never had LSLs. Conclusions: LSLs were a risk factor for elevated BLLs even when WASA met the EPA water action level. Changes in water disinfection can enhance the effect of LSLs and increase lead exposure. Partially replacing LSLs may not decrease the risk of elevated BLLs associated with LSL exposure. Published by Elsevier Inc. C1 [Brown, Mary Jean; Raymond, Jaime; Homa, David; Kennedy, Chinaro] Ctr Dis Control & Prevent, Lead Poisoning Prevent Branch, Natl Ctr Environm Hlth, Atlanta, GA 30348 USA. [Sinks, Thomas] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Agcy Tox Subst & Dis Registry, Atlanta, GA 30348 USA. RP Brown, MJ (reprint author), Ctr Dis Control & Prevent, Lead Poisoning Prevent Branch, Natl Ctr Environm Hlth, 4770 Buford Highway NE, Atlanta, GA 30348 USA. EM mjb5@cdc.gov NR 36 TC 28 Z9 28 U1 3 U2 18 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 J9 ENVIRON RES JI Environ. Res. PD JAN PY 2011 VL 111 IS 1 BP 67 EP 74 DI 10.1016/j.envres.2010.10.003 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 713DN UT WOS:000286715300010 PM 21112052 ER PT S AU Mariners, JC Pfeiffer, DU Knopf, L Bloland, P Chibeu, D Parmley, J Musenero, M Pisang, C Okuthe, S Zingeser, J Costard, S Jost, CC Hendrickx, S Mehta, P AF Mariners, J. C. Pfeiffer, D. U. Knopf, L. Bloland, P. Chibeu, D. Parmley, J. Musenero, M. Pisang, C. Okuthe, S. Zingeser, J. Costard, S. Jost, C. C. Hendrickx, S. Mehta, P. GP AEEMA TI Institutional Analysis to Enhance Performance of Surveillance Systems SO EPIDEMIOLOGIE ET SANTE ANIMALE, NO 59-60 SE Revue Epidemiologie et Sante Animale LA English DT Proceedings Paper CT 1st International Conference on Animal Health Surveillance (ICAHS) CY MAY 17-20, 2011 CL Lyon, FRANCE SP OECD Co-Operat Res Programme Biol Resource Management Sustainable Agr Syst DE Surveillance; Institutions; Institutional change; Participatory; Epidemiology AB Surveillance systems are social institutions that bring together a diverse range of stakeholders whose interactions are governed by both formal and informal rules. By informal rules, one refers to the customs, expectations, values and attitudes that shape the behavior of surveillance system participants. Institutional analysis can lead to a fuller understanding of the complexity of surveillance institutions and aid in assessing and enhancing surveillance systems through more explicit recognition of their component parts and the processes that mediate system results. This process can assist leaders to craft more inclusive visions for the future of health surveillance that can help drive change. C1 [Mariners, J. C.; Jost, C. C.; Hendrickx, S.; Mehta, P.] Int Livestock Res Inst, POB 30709, Nairobi 00100, Kenya. [Pfeiffer, D. U.; Costard, S.] Univ London, Royal Vet Coll, London, England. [Knopf, L.] World Org Anim Hlth, Paris, France. [Bloland, P.; Zingeser, J.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Chibeu, D.] African Union Interafrican Bur Anim Resources, Atlanta, GA USA. [Parmley, J.] Vet Sans Frontieres, Toronto, ON, Canada. [Musenero, M.] African Epidemiol Network, Toronto, ON, Canada. [Pisang, C.] Vet Sans Frontieres, Brussels, Belgium. [Okuthe, S.] UN Food & Agr Org, Rome, Italy. RP Mariners, JC (reprint author), Int Livestock Res Inst, POB 30709, Nairobi 00100, Kenya. NR 6 TC 0 Z9 0 U1 0 U2 2 PU AEEMA-ASSOC L ETUDE L EPIDEMIOLOGIE MALADIES ANIMALES PI MAISONS-ALFORT CEDEX PA ECOLE NATL VETERINAIRE D ALFORT, 7 AVENUE DU GENERAL DE GAULLE, MAISONS-ALFORT CEDEX, 94704, FRANCE SN 0754-2186 BN 978-2-84039-077-0 J9 REV EPID SAN ANIM PY 2011 VL 59-60 BP 269 EP 271 PG 3 GA BH0FR UT WOS:000394827200093 ER PT J AU Doyle, TJ Hopkins, RS AF Doyle, T. J. Hopkins, R. S. CA Transmission Invest Team TI Low secondary transmission of 2009 pandemic influenza A (H1N1) in households following an outbreak at a summer camp: relationship to timing of exposure SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Influenza; transmission ID SEATTLE FAMILIES; VIRUS INFECTIONS; AGE AB Following an outbreak of 2009 pandemic influenza A (H1N1) at a residential summer camp for boys aged 10-16 years, we assessed secondary household transmission of the novel virus after their return home. Of 212 study participants who attended camp, 49 had confirmed or probable influenza for a primary attack rate of 23%. Of 87 exposed household contacts who did not attend camp, only three instances of probable transmission were observed, for a household secondary attack rate of 3.5%. All secondary cases occurred in households where the ill camp attendee returned home 1 day after onset of illness, with an attack rate of 14.3% in household contacts in this category. Returning home after peak infectivity to others and advanced warning prior to reintegration of sick individuals into the household probably contributed to the overall low secondary attack rate observed. C1 [Doyle, T. J.] Florida Dept Hlth, Miami, FL USA. [Hopkins, R. S.] Florida Dept Hlth & Rehabil Serv, Tallahassee, FL 32399 USA. [Doyle, T. J.] Ctr Dis Control & Prevent, CDC, Miami, FL USA. RP Doyle, TJ (reprint author), 4052 Bald Cypress Way,Bin A-12, Tallahassee, FL 32399 USA. EM tdoyle@cdc.gov NR 9 TC 5 Z9 5 U1 0 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD JAN PY 2011 VL 139 IS 1 BP 45 EP 51 DI 10.1017/S095026881000141X PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 696UT UT WOS:000285467600006 PM 20561391 ER PT J AU Podewils, LJ Holtz, T Riekstina, V Skripconoka, V Zarovska, E Kirvelaite, G Kreigere, E Leimane, V AF Podewils, L. J. Holtz, T. Riekstina, V. Skripconoka, V. Zarovska, E. Kirvelaite, G. Kreigere, E. Leimane, V. TI Impact of malnutrition on clinical presentation, clinical course, and mortality in MDR-TB patients SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Antibiotic resistance; epidemiology; infectious disease; tuberculosis (TB) ID PULMONARY TUBERCULOSIS; SOUTH-INDIA; RISK AB Despite the adoption of strategies to prevent and treat multidrug-resistant tuberculosis (MDR-TB) over the past decade, Latvia continues to have one of the highest rates of MDR-TB in the world. It is important to identify modifiable factors that may impact on MDR-TB patient outcomes. A study was conducted to elucidate the association between nutritional status and clinical presentation, clinical course, and mortality in 995 adult patients treated for MDR-TB from 2000 to 2004. Twenty percent of patients were underweight, defined as a body mass index <18.5, at the time of diagnosis. These patients were significantly more likely to have clinical evidence of advanced disease, and had a greater risk of experiencing >= 3 side-effects [ adjusted odds ratio 1.5, 95% confidence interval (CI) 1.1-2.1] and death (adjusted hazard ratio 1.9, 95% CI 1.1-3.5) compared to patients who were normal or overweight. Interventions aimed at these high-risk patients, including nutritional supplementation as an adjunct to anti-TB therapy, should be considered and evaluated by TB programmes. C1 [Podewils, L. J.] Ctr Dis Control & Prevent, Int Res & Programs Branch, Div TB Eliminat, Atlanta, GA 30333 USA. [Riekstina, V.; Skripconoka, V.; Zarovska, E.; Kirvelaite, G.; Kreigere, E.; Leimane, V.] State Agcy TB & Lung Dis, Riga, Latvia. RP Podewils, LJ (reprint author), Ctr Dis Control & Prevent, Int Res & Programs Branch, Div TB Eliminat, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30333 USA. EM lpp8@cdc.gov FU Latvian Ministry of Health FX Funding for this study was provided by the Latvian Ministry of Health. A small amount was contributed by the U.S. Agency for International Development to support technical assistance to the project, but they had no role in the conduct of the study. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of U.S. CDC. NR 15 TC 13 Z9 13 U1 0 U2 3 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD JAN PY 2011 VL 139 IS 1 BP 113 EP 120 DI 10.1017/S0950268810000907 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 696UT UT WOS:000285467600014 PM 20429966 ER PT S AU Ogden, CL Gorber, SC Dommarco, JAR Carroll, M Shields, M Flegal, K AF Ogden, Cynthia L. Gorber, Sarah Connor Rivera Dommarco, Juan A. Carroll, Margaret Shields, Margot Flegal, Katherine BE Moreno, LA Pigeot, I Ahrens, W TI The Epidemiology of Childhood Obesity in Canada, Mexico and the United States SO EPIDEMIOLOGY OF OBESITY IN CHILDREN AND ADOLESCENTS: PREVALENCE AND ETIOLOGY SE Springer Series on Epidemiology and Health LA English DT Article; Book Chapter ID BODY-MASS-INDEX; EXPERT COMMITTEE; GROWTH REFERENCE; YOUNG ADULTHOOD; US CHILDREN; OVERWEIGHT; ADOLESCENTS; WEIGHT; HEIGHT; TRENDS C1 [Ogden, Cynthia L.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, CDC NCHS, Hyattsville, MD 20782 USA. [Gorber, Sarah Connor] Agence Sante Publ Canada, Publ Hlth Agcy Canada, Ottawa, ON K1A 0K9, Canada. [Rivera Dommarco, Juan A.] Ctr Invest Nutr & Salud, Inst Nacl Salud Publ, Cuernavaca 62563, Morelos, Mexico. RP Ogden, CL (reprint author), Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, CDC NCHS, 3311 Toledo Rd,Room 4414, Hyattsville, MD 20782 USA. EM cogden@cdc.gov; sarah.connor.gorber@phac-aspc.gc.ca; jrivera@correo.insp.mx; Mcarroll@cdc.gov; Margot.Shields@statcan.gc.ca; Kflegal@cdc.gov OI connor gorber, sarah/0000-0001-9240-7294 NR 42 TC 4 Z9 4 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1869-7933 BN 978-1-4419-6038-2 J9 SPRINGER SER EPIDEMI PY 2011 BP 69 EP 93 DI 10.1007/978-1-4419-6039-9_5 D2 10.1007/978-1-4419-6039-9 PG 25 WC Public, Environmental & Occupational Health; Pediatrics SC Public, Environmental & Occupational Health; Pediatrics GA BTJ11 UT WOS:000287050900005 ER PT J AU Hinton, CF Grant, AM Grosse, SD AF Hinton, Cynthia F. Grant, Althea M. Grosse, Scott D. TI Ethical implications and practical considerations of ethnically targeted screening for genetic disorders: the case of hemoglobinopathy screening SO ETHNICITY & HEALTH LA English DT Article DE hemoglobinopathies; newborn screening; prenatal carrier testing; ethics; ethnicity ID SICKLE-CELL-DISEASE; ETHNICITY; UNIVERSAL; ANCESTRY; RACE; PERSPECTIVE; ENGLAND; FRANCE; STATE AB The prevalence of hemoglobinopathies differs among populations due to genetic differences and due to the protective effects of the heterozygote (carrier) state against malaria. Because of the difference in genetic distribution, public health programs have weighed the ethical versus practical implications of ethnically targeted versus universal newborn, and where applicable, prenatal screening. We examine newborn and prenatal screening for hemoglobinopathies in relation to the use of 'race' and ethnicity to assess risk for genetic conditions. First, categories of race/ethnicity are social constructs, therefore, observed or self-identified broad racial/ethnic categories are correlated but not necessarily reliable indicators of geographic ancestry or genetic risk. Second, targeting based on ethnicity poses serious issues of logistics and equity for public health programs and clinical services. In the past, newborn screening for hemoglobinopathies in the United States and United Kingdom was often selective, targeted to women of certain ethnic groups or areas with large concentrations of ethnic minority groups. Presently, newborn screening for hemoglobinopathies is universal in both countries and programs emphasize that individuals of all ethnic backgrounds are at risk for carrying a hemoglobin genetic variant. Reported race/ethnicity is still used as a criterion for offering prenatal carrier testing in the United States, where it is not a public health responsibility. In the United Kingdom, prenatal screening under the National Health Service is universal in high-prevalence areas and in low-prevalence areas is targeted based on reported ancestry. The continued use of targeted prenatal screening in both countries reflects the different purposes and modes of laboratory testing in newborn and prenatal screening. The ethical imperative to identify as many affected infants with life-threatening conditions as possible in newborn screening programs is not applicable to prenatal carrier testing. Because newborn screening dried blood spot specimens are tested for multiple disorders, targeted screening poses serious logistical challenges which is not the case in prenatal screening. C1 [Hinton, Cynthia F.; Grant, Althea M.; Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Hinton, CF (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM CHinton@cdc.gov NR 42 TC 6 Z9 6 U1 0 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1355-7858 J9 ETHNIC HEALTH JI Ethn. Health PY 2011 VL 16 IS 4-5 SI SI BP 377 EP 388 DI 10.1080/13557858.2010.541902 PG 12 WC Ethnic Studies; Public, Environmental & Occupational Health SC Ethnic Studies; Public, Environmental & Occupational Health GA 878AX UT WOS:000299224900006 PM 21797724 ER PT J AU Wang, RJ Zhang, XS Zhu, HL Zhang, LX Feng, YY Jian, FC Ning, CS Qi, M Zhou, Y Fu, KD Wang, YQ Sun, YR Wang, QA Xiao, LH AF Wang, Rongjun Zhang, Xiaosan Zhu, Huili Zhang, Longxian Feng, Yaoyu Jian, Fuchun Ning, Changshen Qi, Meng Zhou, Yang Fu, Kanda Wang, Yaqiang Sun, Yanru Wang, Qiang Xiao, Lihua TI Genetic characterizations of Cryptosporidium spp. and Giardia duodenalis in humans in Henan, China SO EXPERIMENTAL PARASITOLOGY LA English DT Article DE Cryptosporidium; Giardia duodenalis; Humans; Genotyping; Subtyping; Cryptosporidium hominis; Assemblage A; Assemblage B ID MOLECULAR CHARACTERIZATION; ZOONOTIC TRANSMISSION; PUBLIC-HEALTH; CHILDREN; INFECTIONS; CATTLE; IDENTIFICATION; EPIDEMIOLOGY; PREVALENCE; RUMINANTS AB Cryptosporidium and Giardia infections are common causes of diarrhea worldwide. To better understand the transmission of human cryptosporidiosis and giardiasis in Henan, China, 10 Oyprosporidium-positive specimens and 18 Giardia-positive specimens were characterized at the species/genotype and subtype levels. Cryptosporidium specimens were analyzed by DNA sequencing of the small subunit rRNA and 60 kDa glycoprotein genes. Among those genotyped, nine belonged to C hominis and one C fells, with the former belonging to three subtype families: Ia, Ib, and Id. The three Ib subtypes identified, IbA16G2, IbA9G2, and IbA20G2, were very different from the two common Ib subtypes (IbA9G3 and IbA10G2) found in other areas of the world. The distribution of Giardia duodenalis genotypes and subtypes was assessed by sequence analysis of the triosephosphate isomerase (tpi) gene. The assemblages A (eight belonging to A-I and four A-II) and B (belonging to six new subtypes) were found in 12 and six specimens, respectively. More systematic studies are needed to understand the transmission of Cryptosporidium and G. duodenalis in humans in China. Published by Elsevier Inc. C1 [Wang, Rongjun; Zhang, Xiaosan; Zhu, Huili; Zhang, Longxian; Jian, Fuchun; Ning, Changshen; Qi, Meng; Zhou, Yang; Sun, Yanru; Wang, Qiang] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China. [Zhang, Longxian] Atlanta Res & Educ Fdn, Decatur, GA 30033 USA. [Zhang, Longxian; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Feng, Yaoyu] E China Univ Sci & Technol, Sch Resource & Environm Engn, Shanghai 200237, Peoples R China. [Fu, Kanda; Wang, Yaqiang] Henan Univ, Inspect Div Huaihe Hospital, Kaifeng 475000, Peoples R China. RP Zhang, LX (reprint author), Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China. EM zhanglx8999@yahoo.com.cn; lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU Key National Science & Technology Special Projects [2008ZX10004-011]; State Key Laboratory of Veterinary Etiological Biology, Ministry of Health [200808012]; National Natural Science Foundation of China [30928019] FX This study was supported in part by Key National Science & Technology Special Projects (No. 2008ZX10004-011), the State Key Laboratory of Veterinary Etiological Biology, Ministry of Health Special Funds of Public Sector Research (No. 200808012), and the National Natural Science Foundation of China (No. 30928019). NR 37 TC 32 Z9 40 U1 1 U2 10 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4894 J9 EXP PARASITOL JI Exp. Parasitol. PD JAN PY 2011 VL 127 IS 1 BP 42 EP 45 DI 10.1016/j.exppara.2010.06.034 PG 4 WC Parasitology SC Parasitology GA 710BV UT WOS:000286486800008 PM 20599984 ER PT J AU Feng, YY Lal, AA Li, N Xiao, LH AF Feng, Yaoyu Lal, Ashima A. Li, Na Xiao, Lihua TI Subtypes of Cryptosporidium spp. in mice and other small mammals SO EXPERIMENTAL PARASITOLOGY LA English DT Article DE Cryptosporidium; Cryptosporidiosis; Genotyping; Subtyping; Mouse; Zoonosis; Epidemiology ID CLINICAL-MANIFESTATIONS; CHILDREN; EPIDEMIOLOGY; GENOTYPES; HOMINIS; SPAIN AB DNA sequence analysis of the 60 kDa glycoprotein (gp60) gene has been used extensively in subtyping Cryptosporidium hominis in humans and Cryptosporidium parvum in humans and ruminants. In this study, nucleotide sequences of the gp60 gene were obtained from seven Cryptosporidium species and genotypes related to the two species. Altogether, seven subtype families were detected, including four new subtype families. These data should be useful in studies of the transmission and zoonotic potential of cryptosporidiosis in mice and small wild mammals. Published by Elsevier Inc. C1 [Feng, Yaoyu] E China Univ Sci & Technol, Sch Resource & Environm Engn, Shanghai 200237, Peoples R China. [Lal, Ashima A.; Li, Na; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Li, Na] Tongji Univ, Sch Life Sci & Technol, Shanghai 200295, Peoples R China. RP Feng, YY (reprint author), E China Univ Sci & Technol, Sch Resource & Environm Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn; lxiao@cdc.gov RI Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [30771881, 30928019]; Shanghai Science and Technology Committee [09540704400]; Fundamental Research Funds for the Central Universities, China [WB0914044] FX This study was supported in part by National Natural Science Foundation of China (Nos.: 30771881 and 30928019), Shanghai Science and Technology Committee (Nos. : 09540704400), and the Fundamental Research Funds for the Central Universities, China (WB0914044). NR 21 TC 20 Z9 21 U1 2 U2 8 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4894 J9 EXP PARASITOL JI Exp. Parasitol. PD JAN PY 2011 VL 127 IS 1 BP 238 EP 242 DI 10.1016/j.exppara.2010.08.002 PG 5 WC Parasitology SC Parasitology GA 710BV UT WOS:000286486800037 PM 20692256 ER PT J AU Deyde, VM Sampath, R Gubareva, LV AF Deyde, Varough M. Sampath, Rangarajan Gubareva, Larisa V. TI RT-PCR/electrospray ionization mass spectrometry approach in detection and characterization of influenza viruses SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS LA English DT Review DE core genes; H1N1 pandemic; mass spectrometry; PLEX-ID; reverse-transcription PCR/electrospray ionization mass spectrometry; seasonal influenza; T5000 ID ADAMANTANE RESISTANCE; RAPID IDENTIFICATION; A(H1N1) VIRUS; H3N2 VIRUSES; AVIAN H5N1; A VIRUSES; H1N1; PCR; REASSORTMENT; HEMAGGLUTININ AB Reverse-transcription PCR (RT-PCR) coupled with electrospray ionization mass spectrometry (ESI-MS) is a high-throughput nucleic acid-based technology that relies on the accurate measurement of the molecular weight of PCR amplicons that can be used to deduce the base counts (number of As, Gs, Cs and Ts) of DNA. These amplicons represent highly variable regions with information-rich sequences, which are flanked by broad-range primers designed based on highly conserved loci. This technology was first introduced in 2005 for microbial identification and subtyping, and was later applied to influenza virus detection and identification. The influenza RT-PCR/ESI-MS assay allows analysis of approximately 300 samples per 24 h, and aids in the characterization of influenza viruses based on their 'core' gene signatures. Notably, this assay was used to identify one of the first cases of the 2009 H1N1 pandemic viruses. One of the main advantages of the RT-PCR/ESI-MS technology is its universality and adaptability for pathogen characterization. Efforts are being made to customize the currently used influenza surveillance assay for use in the diagnosis of the H1N1 pandemic virus. In this article, we provide a summary of known applications of the RT-PCR/ESI-MS assay in the field of influenza. C1 [Deyde, Varough M.; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Sampath, Rangarajan] Ibis Biosci Inc, Carlsbad, CA USA. RP Gubareva, LV (reprint author), Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM lqg3@cdc.gov FU Centers for Disease Control and Prevention FX Rangarajan Sampath is an employee of the Ibis/Abbott Company that developed the Influenza reverse-transcription PCR/electrospray ionization mass spectrometty assay. This statement is made in the interest of full disclosure and not because the authors consider this to be a conflict of interest. The study was funded by the Centers for Disease Control and Prevention. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The manuscript was cleared for submission to the journal following the CDC's standard operating procedures. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 47 TC 25 Z9 26 U1 0 U2 8 PU EXPERT REVIEWS PI LONDON PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND SN 1473-7159 J9 EXPERT REV MOL DIAGN JI Expert Rev. Mol. Diagn. PD JAN PY 2011 VL 11 IS 1 BP 41 EP 52 DI 10.1586/ERM.10.107 PG 12 WC Pathology SC Pathology GA 742IL UT WOS:000288935300007 PM 21171920 ER PT J AU Buckner-Brown, J AF Buckner-Brown, Joyce TI Racial and Ethnic Approaches to Community Health (REACH) Translating Processes of Change and Attributing Improved Health Outcomes to Social Determinants of Health Programs Introduction SO FAMILY & COMMUNITY HEALTH LA English DT Editorial Material C1 Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Atlanta, GA 30333 USA. RP Buckner-Brown, J (reprint author), Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Atlanta, GA 30333 USA. NR 4 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-6379 J9 FAM COMMUNITY HEALTH JI Fam. Community Health PD JAN-MAR PY 2011 VL 34 IS 1 SU 1 BP S7 EP S8 PG 2 WC Family Studies; Public, Environmental & Occupational Health SC Family Studies; Public, Environmental & Occupational Health GA 700IW UT WOS:000285733000003 PM 21160333 ER PT J AU Buckner-Brown, J Tucker, P Rivera, M Cosgrove, S Coleman, JL Penson, A Bang, D AF Buckner-Brown, Joyce Tucker, Pattie Rivera, Mark Cosgrove, Shannon Coleman, James L. Penson, Aisha Bang, David TI Racial and Ethnic Approaches to Community Health Reducing Health Disparities by Addressing Social Determinants of Health SO FAMILY & COMMUNITY HEALTH LA English DT Article DE health disparities; health equity racial and ethnic approaches to community health; social determinants of health ID CHRONIC HEPATITIS-B; SOUTHERN CALIFORNIA; CANCER; AMERICANS; ACCESS; BREAST AB Poor people and people of color are more likely to live shorter and sicker lives and are less likely to survive a host of chronic illnesses Policies and organizational practices that improve the environments in which people live work, learn and play can reduce these disparities Using the World Health Organization s Call to Action" principles as a discussion framework, we highlight the Centers for Disease Control and Prevention s Racial and Ethnic Approaches to Community Health programs that have developed and applied such strategies to address chronic illnesses Several m turn foster health equity C1 [Buckner-Brown, Joyce] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Atlanta, GA 30341 USA. [Penson, Aisha] Northrop Grumman, Atlanta, GA USA. [Coleman, James L.] Wateree Community Act Inc, Sumter, SC USA. RP Buckner-Brown, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, 4770 Buford Hwy NE,Mailstop K30, Atlanta, GA 30341 USA. NR 36 TC 9 Z9 9 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-6379 J9 FAM COMMUNITY HEALTH JI Fam. Community Health PD JAN-MAR PY 2011 VL 34 IS 1 SU 1 BP S12 EP S22 PG 11 WC Family Studies; Public, Environmental & Occupational Health SC Family Studies; Public, Environmental & Occupational Health GA 700IW UT WOS:000285733000005 PM 21160327 ER PT J AU Jenkins, C Myers, P Heidari, K Kelechi, TJ Buckner-Brown, J AF Jenkins, Carolyn Myers, Patsy Heidari, Khosrow Kelechi, Teresa J. Buckner-Brown, Joyce TI Efforts to Decrease Diabetes-Related Amputations in African Americans by the Racial and Ethnic Approaches to Community Health Charleston and Georgetown Diabetes Coalition SO FAMILY & COMMUNITY HEALTH LA English DT Article DE coalitions; community based participatory actions; diabetes; disparities ID PEOPLE AB Diabetes is the leading cause of amputation of the lower limbs Yet, half of these amputations might be prevented through simple but effective foot care practices This article describes the progress made in the reduction of lower extremity amputations in people with diabetes by the Racial and Ethnic Approaches to Community Health Charleston and Georgetown Diabetes Coalition The coalition s community action plan and interventions were based on an expanded Chronic Care Model that spawned changes in policies, health and education systems, and other community systems for people with diabetes and their support systems C1 [Jenkins, Carolyn; Kelechi, Teresa J.] Med Univ S Carolina, Coll Nursing, Charleston, SC 29425 USA. [Myers, Patsy; Heidari, Khosrow] S Carolina Dept Hlth & Environm Control, Off Chron Dis Epidemiol & Evaluat, Bur Community Hlth & Environm Control, Columbia, SC 29201 USA. [Buckner-Brown, Joyce] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Jenkins, C (reprint author), Med Univ S Carolina, Coll Nursing, 99 Jonathan Lucas,MSC 160, Charleston, SC 29425 USA. FU NCCDPHP CDC HHS [1U58DP001015]; PHS HHS [U50/CCU422184] NR 20 TC 10 Z9 10 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-6379 J9 FAM COMMUNITY HEALTH JI Fam. Community Health PD JAN-MAR PY 2011 VL 34 IS 1 SU 1 BP S63 EP S78 PG 16 WC Family Studies; Public, Environmental & Occupational Health SC Family Studies; Public, Environmental & Occupational Health GA 700IW UT WOS:000285733000009 PM 21160332 ER PT J AU Lamb, AK Ervice, J Lorenzen, K Prentice, B White, S AF Lamb, Anne Kelsey Ervice, Joel Lorenzen, Kathryn Prentice, Bob White, Shannon TI Reducing Asthma Disparities by Addressing Environmental Inequities A Case Study of Regional Asthma Management and Prevention's Advocacy Efforts SO FAMILY & COMMUNITY HEALTH LA English DT Article DE asthma; air quality disparities inequities social determinants of health AB Regional Asthma Management and Prevention describes its collaborative approach to address a social determinant of health-air quality-and the associated inequities that have led to asthma disparities impacting African American and Latino communities in the San Francisco Bay Area The strategies aimed at decreasing diesel pollution in disproportionately impacted communities, span the levels of the socioecological model, with an emphasis on policy outcomes Regional Asthma Management and Prevention describes how this work fits within a larger comprehensive approach to address asthma disparities encompassing several components ranging from clinical management to environmental protection C1 [Lamb, Anne Kelsey; Ervice, Joel; Lorenzen, Kathryn; Prentice, Bob] Reg Asthma Management & Prevent Publ Hlth Inst, Oakland, CA 94607 USA. [White, Shannon] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Lamb, AK (reprint author), Reg Asthma Management & Prevent Publ Hlth Inst, 555 12th St, Oakland, CA 94607 USA. NR 27 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-6379 J9 FAM COMMUNITY HEALTH JI Fam. Community Health PD JAN-MAR PY 2011 VL 34 IS 1 SU 1 BP S54 EP S62 PG 9 WC Family Studies; Public, Environmental & Occupational Health SC Family Studies; Public, Environmental & Occupational Health GA 700IW UT WOS:000285733000008 PM 21160331 ER PT J AU Lewis, LB Galloway-Gilliam, L Flynn, G Nomachi, J Keener, LC Sloane, DC AF Lewis, LaVonna Blair Galloway-Gilliam, Lark Flynn, Gwendolyn Nomachi, Jonathan Keener, LaTonya Chavis Sloane, David C. TI Transforming the Urban Food Desert From the Grassroots Up A Model for Community Change SO FAMILY & COMMUNITY HEALTH LA English DT Article DE African Americans; community change models; food desert; public policy ID HEALTH DISPARITIES; INTERVENTIONS; ENVIRONMENTS; RESTAURANTS AB Confronted by continuing health disparities m vulnerable communities, Community Health Councils (CHC), a nonprofit community based organization in South Los Angeles worked with the African Americans Building a Legacy of Health Coalition and research partners to develop a community change model to address the root causes of health disparities within the community s African American population This article discusses how the CHC Model s development and application led to public policy interventions in a food desert " The CHC Model provided a systematic approach to engaging impacted communities in support of societal level reforms, with the goal to influence health outcomes C1 [Lewis, LaVonna Blair; Sloane, David C.] Univ So Calif, Sch Policy Planning & Dev, Los Angeles, CA 90089 USA. [Galloway-Gilliam, Lark; Flynn, Gwendolyn; Nomachi, Jonathan] Community Hlth Council, Los Angeles, CA USA. [Keener, LaTonya Chavis] Ctr Dis Control & Prevent, Columbus Technol & Serv Inc, REHDAI, Atlanta, GA USA. RP Lewis, LB (reprint author), Univ So Calif, Sch Policy Planning & Dev, 650 Childs Way, Los Angeles, CA 90089 USA. NR 30 TC 7 Z9 7 U1 7 U2 27 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-6379 J9 FAM COMMUNITY HEALTH JI Fam. Community Health PD JAN-MAR PY 2011 VL 34 IS 1 SU 1 BP S92 EP S101 PG 10 WC Family Studies; Public, Environmental & Occupational Health SC Family Studies; Public, Environmental & Occupational Health GA 700IW UT WOS:000285733000011 PM 21160336 ER PT J AU Liburd, LC AF Liburd, Leandris C. TI REACH U S in Action Inspiring Hope, Rewarding Courage Foreword SO FAMILY & COMMUNITY HEALTH LA English DT Editorial Material ID COMMUNITY-HEALTH WORKERS; SOCIAL DETERMINANTS; CULTURE; JUSTICE; CARE C1 CDC, Community Hlth & & Equ Branch, Atlanta, GA 30333 USA. RP Liburd, LC (reprint author), CDC, Community Hlth & & Equ Branch, Atlanta, GA 30333 USA. NR 24 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-6379 J9 FAM COMMUNITY HEALTH JI Fam. Community Health PD JAN-MAR PY 2011 VL 34 IS 1 SU 1 BP S2 EP S6 PG 5 WC Family Studies; Public, Environmental & Occupational Health SC Family Studies; Public, Environmental & Occupational Health GA 700IW UT WOS:000285733000002 PM 21160328 ER PT J AU Wynn, TA Taylor-Jones, MM Johnson, RE Bostick, PB Fouad, M AF Wynn, Theresa A. Taylor-Jones, Monica M. Johnson, Rhoda E. Bostick, Pamela B. Fouad, Mona TI Using Community-Based Participatory Approaches to Mobilize Communities for Policy Change SO FAMILY & COMMUNITY HEALTH LA English DT Article DE advocacy community mobilization community based participatory research direct action organizing; policy change; REACH 2010; socioecological model ID ACTION PLAN; DISPARITIES; HEALTH; BREAST AB The Racial and Ethnic Approaches to Community Health (REACH) Alabama Breast and Cervical Cancer Coalition used community based participatory research principles to address breast and cervical cancer disparities among Alabama s most vulnerable African American communities With funding from the Centers for Disease Control and Prevention the Alabama Breast and Cervical Cancer Coalition implemented a multilevel action plan, which entailed disseminating evidence based strategies to community organizations interested in addressing cancer and other health disparities Based on the Alabama Breast and Cervical Cancer Coalition s technical assistance on advocacy, an independent, community led coalition was formed This article uses a case study approach to document the steps taken by this empowered coalition to mobilize their community to impact cancer disparities using community based participatory research principles as a tool to change tobacco and breast and cervical cancer legislation C1 [Wynn, Theresa A.; Fouad, Mona] Univ Alabama, Sch Med, Div Prevent Med, Birmingham, AL 35294 USA. [Taylor-Jones, Monica M.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Bostick, Pamela B.] Amer Canc Soc, Mid S Div, Atlanta, GA 30329 USA. RP Wynn, TA (reprint author), Univ Alabama, Sch Med, Div Prevent Med, Med Towers Bldg 1717,11th Ave S,Ste 516A, Birmingham, AL 35294 USA. RI Wynn, Thomas/C-2797-2011 NR 19 TC 3 Z9 4 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0160-6379 J9 FAM COMMUNITY HEALTH JI Fam. Community Health PD JAN-MAR PY 2011 VL 34 IS 1 SU 1 BP S102 EP S114 PG 13 WC Family Studies; Public, Environmental & Occupational Health SC Family Studies; Public, Environmental & Occupational Health GA 700IW UT WOS:000285733000012 PM 21160326 ER PT J AU Schmit, VL Patton, TG Gilmore, RD AF Schmit, Virginia L. Patton, Toni G. Gilmore, Robert D., Jr. TI Analysis of Borrelia burgdorferi surface proteins as determinants in establishing host cell interactions SO FRONTIERS IN MICROBIOLOGY LA English DT Article DE Borrelia burgdorferi; cell attachment; gene expression AB Borrelia burgdorfefi infection causes Lyme borreliosis in humans, a condition which can involve a systemic spread of the organism to colonize various tissues and organs. If the infection is left untreated by antimicrobials, it can lead to manifestations including, arthritis, carditis, and/or neurological problems. Identification and characterization of B. burgdorfefi outer membrane proteins that facilitate cellular attachment and invasion to establish infection continue to be investigated. In this study, we sought to further define putative cell binding properties of surface-exposed B. burgdorfefi proteins by observing whether cellular adherence could be blocked by antibodies. B. burgdorfefi mixed separately with monoclonal antibodies (mAbs) against outer surface protein (Osp) A, OspC, decorin-binding protein (Dbp) A, BBA64, and RevA antigens were incubated with human umbilical vein endothelial cells (HUVEC) and human neuroglial cells (H4). B. burgdorferi treated with anti-OspA, -DbpA, and -BBA64 mAbs showed a significant decrease in cellular association compared to controls, whereas B. burgdorfefi treated with anti-OspC and anti-RevA showed no reduction in cellular attachment. Additionally, temporal transcriptional analyses revealed upregulated expression of bba64, ospA, and dbpA during coincubation with cells. Together, the data provide evidence that OspA, DbpA, and BBA64 function in host cell adherence and infection mechanisms. C1 [Schmit, Virginia L.; Patton, Toni G.; Gilmore, Robert D., Jr.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO 80521 USA. RP Gilmore, RD (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM rbg9@cdc.gov NR 51 TC 12 Z9 12 U1 0 U2 1 PU FRONTIERS RESEARCH FOUNDATION PI LAUSANNE PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND SN 1664-302X J9 FRONT MICROBIOL JI Front. Microbiol. PY 2011 VL 2 AR 141 DI 10.3389/fmicb.2011.00141 PG 8 WC Microbiology SC Microbiology GA V31DE UT WOS:000208863500151 PM 21747816 ER PT B AU Green, BJ Schmechel, D Summerbell, RC AF Green, Brett J. Schmechel, Detlef Summerbell, Richard C. BE Adan, OCG Samson, RA TI Aerosolized fungal fragments SO FUNDAMENTALS OF MOLD GROWTH IN INDOOR ENVIRONMENTS AND STRATEGIES FOR HEALTHY LIVING LA English DT Article; Book Chapter ID SCANNING-ELECTRON-MICROSCOPY; DOUBLE-IMMUNOSTAINING TECHNIQUE; NEW-SOUTH-WALES; IN-HOUSE DUST; HYPERSENSITIVITY PNEUMONITIS; STACHYBOTRYS-CHARTARUM; PARTICULATE MATTER; BUILDING-MATERIALS; THIELAVIOPSIS-BASICOLA; ALTERNARIA-ALTERNATA C1 [Green, Brett J.; Schmechel, Detlef] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Hlth Effects Lab Div, Allergy & Clin Immunol Branch, Morgantown, WV 26505 USA. [Summerbell, Richard C.] Sporometrics Inc, Toronto, ON M6K 1Y9, Canada. RP Green, BJ (reprint author), Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Hlth Effects Lab Div, Allergy & Clin Immunol Branch, 1095 Willowdale Rd, Morgantown, WV 26505 USA. NR 158 TC 12 Z9 12 U1 0 U2 0 PU WAGENINGEN ACAD PUBL PI WAGENINGEN PA POSTBUS 220, 6700 AE WAGENINGEN, NETHERLANDS BN 978-90-8686-722-6; 978-90-8686-135-4 PY 2011 BP 211 EP 243 D2 10.3921/978-90-8686-722-6 PG 33 WC Construction & Building Technology; Public, Environmental & Occupational Health; Mycology SC Construction & Building Technology; Public, Environmental & Occupational Health; Mycology GA BHT11 UT WOS:000326602100009 ER PT J AU Auffray, C Caulfield, T Khoury, MJ Lupski, JR Schwab, M Veenstra, T AF Auffray, Charles Caulfield, Timothy Khoury, Muin J. Lupski, James R. Schwab, Matthias Veenstra, Timothy TI Genome Medicine: past, present and future SO GENOME MEDICINE LA English DT Editorial Material C1 [Auffray, Charles] CNRS Inst Biol Sci, F-94801 Villejuif, France. [Caulfield, Timothy] Univ Alberta, Fac Law, Edmonton, AB T6G 2T4, Canada. [Caulfield, Timothy] Univ Alberta, Sch Publ Hlth, Edmonton, AB T6G 2T4, Canada. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Lupski, James R.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. [Lupski, James R.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Lupski, James R.] Texas Childrens Hosp, Houston, TX 77030 USA. [Schwab, Matthias] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70367 Stuttgart, Germany. [Schwab, Matthias] Univ Hosp, Dept Clin Pharmacol, Inst Expt & Clin Pharmacol & Toxicol, D-72076 Tubingen, Germany. [Veenstra, Timothy] NCI, Lab Prote & Analyt Technol, Frederick, MD 21702 USA. RP Auffray, C (reprint author), CNRS Inst Biol Sci, F-94801 Villejuif, France. FU NCRR NIH HHS [M01 RR000188]; NINDS NIH HHS [R01 NS058529] NR 32 TC 10 Z9 11 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-994X J9 GENOME MED JI Genome Med. PY 2011 VL 3 AR 6 DI 10.1186/gm220 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA V27QJ UT WOS:000208627400006 PM 21345269 ER PT J AU Crider, KS Bailey, LB AF Crider, Krista S. Bailey, Lynn B. TI Defying birth defects through diet? SO GENOME MEDICINE LA English DT Article AB The risk of certain birth defects can be modified by maternal diet. A high-fat maternal mouse diet has recently been reported to substantially increase the penetrance of birth defects known to be associated with a deficiency of transcription factor Cited2 as well as induce cleft palate. These effects were associated with a more than twofold reduction in embryonic expression of Pitx2c. This investigation suggests the need to further explore this provocative gene-diet interaction in human studies. C1 [Crider, Krista S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Bailey, Lynn B.] Univ Florida, Food Sci & Human Nutr Dept, Gainesville, FL 32611 USA. RP Bailey, LB (reprint author), Univ Florida, Food Sci & Human Nutr Dept, POB 110370, Gainesville, FL 32611 USA. EM folate@ufl.edu NR 10 TC 3 Z9 3 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-994X J9 GENOME MED JI Genome Med. PY 2011 VL 3 AR 9 DI 10.1186/gm223 PG 3 WC Genetics & Heredity SC Genetics & Heredity GA V27QJ UT WOS:000208627400009 PM 21345254 ER PT J AU Janssens, ACJW Ioannidis, JPA van Duijn, CM Little, J Khoury, MJ AF Janssens, A. Cecile J. W. Ioannidis, John P. A. van Duijn, Cornelia M. Little, Julian Khoury, Muin J. CA GRIPS Grp TI Strengthening the reporting of genetic risk prediction studies: the GRIPS statement SO GENOME MEDICINE LA English DT Article AB The rapid and continuing progress in gene discovery for complex diseases is fueling interest in the potential application of genetic risk models for clinical and public health practice. The number of studies assessing the predictive ability is steadily increasing, but the quality and completeness of reporting varies. A multidisciplinary workshop sponsored by the Human Genome Epidemiology Network developed a checklist of 25 items recommended for strengthening the reporting of genetic risk prediction studies (the GRIPS statement), building on the principles established by prior reporting guidelines. These recommendations aim to enhance the transparency of study reporting, and thereby to improve the synthesis and application of information from multiple studies that might differ in design, conduct, or analysis. A detailed Explanation and Elaboration document is published at http://www.plosmedicine.org. C1 [Janssens, A. Cecile J. W.; van Duijn, Cornelia M.] Erasmus Univ, Dept Epidemiol, Med Ctr, NL-3000 CA Rotterdam, Netherlands. [Ioannidis, John P. A.] Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, GR-45110 Ioannina, Greece. [Ioannidis, John P. A.] Fdn Res & Technol Hellas, Biomed Res Inst, Ioannina 45110, Greece. [Ioannidis, John P. A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA. [Ioannidis, John P. A.] Tufts Med Ctr, Ctr Genet Epidemiol & Modeling & Tufts CTSI, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA. [Ioannidis, John P. A.] Stanford Univ, Stanford Prevent Res Ctr, Sch Med, Stanford, CA 94305 USA. [Little, Julian] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1H 8M5, Canada. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. RP Janssens, ACJW (reprint author), Erasmus Univ, Dept Epidemiol, Med Ctr, POB 2040, NL-3000 CA Rotterdam, Netherlands. EM a.janssens@erasmusmc.nl RI Ioannidis, John/G-9836-2011; janssens, cecile/L-1075-2015; OI Janssens, A Cecile/0000-0002-6153-4976 FU Centers for Disease Control and Prevention on behalf of the Human Genome Epidemiology Network (HuGENet); Erasmus University Medical Center Rotterdam; Center for Medical Systems Biology; VIDI grant of the Netherlands Organisation for Scientific Research (NWO); National Institutes of Health/National Center for Research Resources [UL1 RR025752] FX The members of the GRIPS group are: A Cecile JW Janssens, John PA Ioannidis, Sara Bedrosian, Paolo Boffetta, Siobhan M Dolan, Nicole Dowling, Isabel Fortier, Andrew N Freedman, Jeremy M Grimshaw, Jeffrey Gulcher, Marta Gwinn, Mark A Hlatky, Holly Janes, Peter Kraft, Stephanie Melillo, Christopher J O'Donnell, Michael J Pencina, David Ransohoff, Sheri D Schully, Daniela Seminara, Deborah M Winn, Caroline F Wright, Cornelia M van Duijn, Julian Little, and Muin J Khoury. Funding: the workshop was sponsored by the Centers for Disease Control and Prevention on behalf of the Human Genome Epidemiology Network (HuGENet). The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the Department of Health and Human Services. A Cecile JW Janssens is financially supported by grants from the Erasmus University Medical Center Rotterdam, the Center for Medical Systems Biology in the framework of the Netherlands Genomics Initiative (NGI) and the VIDI grant of the Netherlands Organisation for Scientific Research (NWO). John PA Ioannidis: Tufts CTSI is supported by the National Institutes of Health/National Center for Research Resources (UL1 RR025752). Opinions in this paper are those of the authors and do not necessarily represent the official position or policies of the Tufts CTSI. Julian Little holds a Canada Research Chair in Human Genome Epidemiology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 26 TC 2 Z9 2 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-994X J9 GENOME MED JI Genome Med. PY 2011 VL 3 AR 16 DI 10.1186/gm230 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA V27QJ UT WOS:000208627400016 PM 21410995 ER PT J AU Mihaescu, R Moonesinghe, R Khoury, MJ Janssens, ACJW AF Mihaescu, Raluca Moonesinghe, Ramal Khoury, Muin J. Janssens, A. Cecile J. W. TI Predictive genetic testing for the identification of high-risk groups: a simulation study on the impact of predictive ability SO GENOME MEDICINE LA English DT Article ID CORONARY-HEART-DISEASE; GENOME-BASED PREDICTION; CARDIOVASCULAR EVENTS; SCORE; HEALTH; POLYMORPHISMS; ASSOCIATION; PROFILES; UTILITY; COHORT AB Background: Genetic risk models could potentially be useful in identifying high-risk groups for the prevention of complex diseases. We investigated the performance of this risk stratification strategy by examining epidemiological parameters that impact the predictive ability of risk models. Methods: We assessed sensitivity, specificity, and positive and negative predictive value for all possible risk thresholds that can define high-risk groups and investigated how these measures depend on the frequency of disease in the population, the frequency of the high-risk group, and the discriminative accuracy of the risk model, as assessed by the area under the receiver-operating characteristic curve (AUC). In a simulation study, we modeled genetic risk scores of 50 genes with equal odds ratios and genotype frequencies, and varied the odds ratios and the disease frequency across scenarios. We also performed a simulation of age-related macular degeneration risk prediction based on published odds ratios and frequencies for six genetic risk variants. Results: We show that when the frequency of the high-risk group was lower than the disease frequency, positive predictive value increased with the AUC but sensitivity remained low. When the frequency of the high-risk group was higher than the disease frequency, sensitivity was high but positive predictive value remained low. When both frequencies were equal, both positive predictive value and sensitivity increased with increasing AUC, but higher AUC was needed to maximize both measures. Conclusions: The performance of risk stratification is strongly determined by the frequency of the high-risk group relative to the frequency of disease in the population. The identification of high-risk groups with appreciable combinations of sensitivity and positive predictive value requires higher AUC. C1 [Mihaescu, Raluca; Janssens, A. Cecile J. W.] Erasmus Univ, Med Ctr, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands. [Moonesinghe, Ramal] Ctr Dis Control & Prevent, Off Minor Hlth & Hlth Dispar, Atlanta, GA 30341 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30341 USA. RP Janssens, ACJW (reprint author), Erasmus Univ, Med Ctr, Dept Epidemiol, POB 2040, NL-3000 CA Rotterdam, Netherlands. EM a.janssens@erasmusmc.nl RI janssens, cecile/L-1075-2015; OI Janssens, A Cecile/0000-0002-6153-4976 FU Centre for Medical Systems Biology (CMSB); VIDI grant of the Netherlands Organization for Scientific Research (NWO) FX This study was supported by the Centre for Medical Systems Biology (CMSB) in the framework of the Netherlands Genomics Initiative (NGI). Furthermore, this project was sponsored by the VIDI grant of the Netherlands Organization for Scientific Research (NWO). NR 30 TC 4 Z9 4 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-994X J9 GENOME MED JI Genome Med. PY 2011 VL 3 AR 51 DI 10.1186/gm267 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA V27QJ UT WOS:000208627400051 PM 21797996 ER PT B AU Theis, KA Lubar, DR Brady, TJ AF Theis, Kristina A. Lubar, Debra R. Brady, Teresa J. BE Nakasato, Y Yung, RL TI Health Policy, Public Health, and Arthritis Among Older Adults SO GERIATRIC RHEUMATOLOGY: A COMPREHENSIVE APPROACH LA English DT Article; Book Chapter DE Health policy; Public health; Aging; Interventions; Legislation; Advocacy; Population ID PHYSICAL-ACTIVITY; NATIONAL ARTHRITIS; PRIMARY-CARE; PLAN AB This chapter is designed to review the basics of public health, to highlight its relevance to health-care professionals, and to outline opportunities for the use of health policy in improving and protecting the health of older adults with arthritis. Many public health interventions intersect with the medical system at the level of the individual patient and complement clinical care efforts. Health policies are often designed to have broad effects at the community and population level and to help achieve national public health goals. The unprecedented pace of aging in the US population at the start of the twenty-first century offers a unique challenge and exceptional opportunity to combine the efforts of public health, the health-care system, and health policy to combat the toll arthritis takes on our communities, patients, and country. Health policies, in concert with public health and medical interventions, can be powerful tools to reduce the burden and impact of arthritis. C1 [Theis, Kristina A.; Brady, Teresa J.] US Ctr Dis Control & Prevent, Arthrit Program, Atlanta, GA 30341 USA. [Lubar, Debra R.] US Ctr Dis Control & Prevent, Arthrit Epilepsy & Qual Life Branch, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Theis, KA (reprint author), US Ctr Dis Control & Prevent, Arthrit Program, 4770 Buford Hwy NE,MS K-51, Atlanta, GA 30341 USA. EM ktheis@cdc.gov NR 31 TC 0 Z9 0 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-1-4419-5791-7 PY 2011 BP 93 EP 100 DI 10.1007/978-1-4419-5792-4_11 D2 10.1007/978-1-4419-5792-4 PG 8 WC Geriatrics & Gerontology; Rheumatology SC Geriatrics & Gerontology; Rheumatology GA BVN40 UT WOS:000291957300011 ER PT J AU Freedman, DS Ogden, CL Cusick, SE AF Freedman, David S. Ogden, Cynthia L. Cusick, Sarah E. BE Bagchi, D TI The Measurement and Epidemiology of Child Obesity SO GLOBAL PERSPECTIVES ON CHILDHOOD OBESITY: CURRENT STATUS, CONSEQUENCES AND PREVENTION LA English DT Article; Book Chapter ID BODY-MASS INDEX; X-RAY ABSORPTIOMETRY; CARDIOVASCULAR RISK-FACTORS; FOR-DISEASE-CONTROL; CORONARY-HEART-DISEASE; BIOELECTRICAL-IMPEDANCE; UNITED-STATES; ADOLESCENT OVERWEIGHT; SKINFOLD THICKNESS; GROWTH CHARTS C1 [Freedman, David S.] Ctr Dis Control & Prevent K26, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Ogden, Cynthia L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Cusick, Sarah E.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. RP Freedman, DS (reprint author), Ctr Dis Control & Prevent K26, Div Nutr Phys Act & Obes, Atlanta, GA USA. NR 86 TC 0 Z9 0 U1 2 U2 3 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-08-096172-9 PY 2011 BP 31 EP 42 DI 10.1016/B978-0-12-374995-6.10004-0 PG 12 WC Nutrition & Dietetics SC Nutrition & Dietetics GA BFX37 UT WOS:000321760800005 ER PT J AU Aidoo, M AF Aidoo, Michael TI Divining without seeds: The case for strengthening laboratory medicine in Africa SO GLOBAL PUBLIC HEALTH LA English DT Book Review C1 [Aidoo, Michael] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Aidoo, M (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM maidoo@cdc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1744-1692 J9 GLOB PUBLIC HEALTH JI Glob. Public Health PY 2011 VL 6 IS 8 BP 917 EP 919 DI 10.1080/17441692.2011.605796 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 854RH UT WOS:000297511400010 ER PT J AU Miller, CH Philipp, CS Stein, SF Kouides, PA Lukes, AS Heit, JA Byams, VR Dowling, NF Kulkarni, R AF Miller, C. H. Philipp, C. S. Stein, S. F. Kouides, P. A. Lukes, A. S. Heit, J. A. Byams, V. R. Dowling, N. F. Kulkarni, R. TI The spectrum of haemostatic characteristics of women with unexplained menorrhagia SO HAEMOPHILIA LA English DT Article DE bleeding disorders; menorrhagia; platelet function disorders; von Willebrand disease ID VON-WILLEBRAND-DISEASE; BLEEDING DISORDERS; DEFICIENCY; MANAGEMENT; DIAGNOSIS; DEFECTS AB While an estimated 13% of women with unexplained menorrhagia have von Willebrand disease (VWD), the frequency of other potential bleeding disorders has been uncertain. This study describes the relatively wide range of laboratory characteristics of women with unexplained menorrhagia and presents issues affecting diagnosis in this population. Women with pictorial blood assessment chart (PBAC) score > 100 were identified at six U. S. sites and asked to remain drug free for 10 days prior to testing. Blood was collected on one of the first four menstrual cycle days and tested at a central laboratory for procoagulant factors, VWD and fibrinolytic factors. Platelet function testing by PFA-100 (R) (PFA) and platelet aggregation with ATP release (PAGG/ATPR) were performed locally using standardized methods. Among 232 subjects, a laboratory abnormality was found in 170 (73.3%), including 124 of 182 White (68.1%) and 34 of 37 Black (91.9%) subjects; 6.0% had VWD, 56.0% had abnormal PAGG/ATPR, 4.7% had a non-VWD coagulation defect (NVCD) and 6.5% had an abnormal PFA only. AGG/ATPR was reduced in 58.9% of subjects, with multiple agonists in 28.6%, a single agonist in 6.1% and ristocetin alone in 24.2%. Frequencies of PAGG/ATPR defects varied by study site and race; frequencies of VWD and NVCD were similar. Laboratory abnormalities of haemostasis, especially platelet function defects, were common among women with unexplained menorrhagia across multiple U. S. sites. To what degree these abnormalities are clinically significant requires further study. C1 [Miller, C. H.; Byams, V. R.; Dowling, N. F.; Kulkarni, R.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Philipp, C. S.] UMDNJ Robert Wood Johnson Med Sch, New Brunswick, NJ USA. [Stein, S. F.] Emory Univ, Sch Med, Atlanta, GA USA. [Kouides, P. A.] Univ Rochester, Rochester, NY USA. [Lukes, A. S.] Duke Univ, Durham, NC USA. [Heit, J. A.] Mayo Clin, Rochester, MN USA. [Kulkarni, R.] Michigan State Univ, E Lansing, MI 48824 USA. RP Miller, CH (reprint author), Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS D-02, Atlanta, GA 30333 USA. EM cmiller2@cdc.gov OI Miller, Connie H/0000-0002-3989-7973 FU Association of Teachers of Preventive Medicine; Centers for Disease Control and Prevention FX The authors acknowledge the excellent haemostasis laboratory support centrally at the CDC: Jean Platt, Anne Rice, Elizabeth Haff, and Peggy Rawlins, and at the participating sites: Mary Ann Tara, New York; Chona Baquiran, New Jersey; Sherri LaFrance, Michigan; Randall S. Miller, Minnesota; Keith Klemp, North Carolina. The authors wish to thank Chrono-log Corporation for loan of lumi-aggregometers to two sites. This study was supported by the Association of Teachers of Preventive Medicine and the Centers for Disease Control and Prevention. NR 23 TC 19 Z9 19 U1 0 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1351-8216 J9 HAEMOPHILIA JI Haemophilia PD JAN PY 2011 VL 17 IS 1 BP E223 EP E229 DI 10.1111/j.1365-2516.2010.02382.x PG 7 WC Hematology SC Hematology GA 700RV UT WOS:000285762900045 PM 21040234 ER PT J AU Sleet, DA Dellinger, AM Naumann, RB AF Sleet, David A. Dellinger, Ann M. Naumann, Rebecca B. BE Porter, BE TI The Intersection of Road Traffic Safety and Public Health SO HANDBOOK OF TRAFFIC PSYCHOLOGY LA English DT Article; Book Chapter ID PREVENTION; PROMOTION; INJURY C1 [Sleet, David A.; Dellinger, Ann M.; Naumann, Rebecca B.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Sleet, DA (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 76 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-381985-7 PY 2011 BP 457 EP 470 DI 10.1016/B978-0-12-381984-0.10032-3 PG 14 WC Psychology, Applied; Transportation SC Psychology; Transportation GA BFX84 UT WOS:000321824600033 ER PT J AU Feng, ZJ Li, WK Varma, JK AF Feng, Zijian Li, Wenkai Varma, Jay K. TI Gaps Remain In China's Ability To Detect Emerging Infectious Diseases Despite Advances Since The Onset Of SARS And Avian Flu SO HEALTH AFFAIRS LA English DT Article ID HEALTH SYSTEM; UNITED-STATES; MOLECULAR EPIDEMIOLOGY; RECOGNITION; EMERGENCE; PULSENET; CHILDREN AB Early detection of emerging infections in China is critical to the health of the 1.3 billion Chinese people and to the world. China's surveillance system for endemic infectious diseases has improved greatly since 2003, but the country's ability to conduct surveillance for laboratory-confirmed infections remains underdeveloped. This is dangerous for China, the world's most populous country, which has been the focus of global attention since outbreaks of severe acute respiratory syndrome (SARS) and avian influenza. We describe China's public health advances since the 2003 SARS outbreak and conclude that China must now invest far more in pathogen-based surveillance. An enhanced disease-detection system in China will help prevent and contain outbreaks before they cause substantial illness and death in China and other countries. C1 [Feng, Zijian] Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing, Peoples R China. [Li, Wenkai] US CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Atlanta, GA USA. [Varma, Jay K.] US Ctr Dis Control & Prevent US CDCs, Int Emerging Infect Program, Beijing, Peoples R China. RP Feng, ZJ (reprint author), Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing, Peoples R China. EM jvarma@cdc.gov FU US Centers for Disease Control and Prevention FX The authors acknowledge the support of the Global Disease Detection Program of the US Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention. NR 36 TC 9 Z9 11 U1 1 U2 5 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JAN PY 2011 VL 30 IS 1 BP 127 EP 135 DI 10.1377/hlthaff.2010.0606 PG 9 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 702VK UT WOS:000285923800018 PM 21209448 ER EF